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PREFACE 
After Bologna, Stockholm and Vienna, it seems only yesterday that the Fourth Meeting was 
organized in Helsinki in 2000. The Fifth Meeting is to be held in Budapest, the capital of a new 
member of the European Union, Hungary. 
The scene of this meeting is the Congress Centre of the Faculty of Science of Eötvös 
Loránd University, founded in 1635 by Cardinal Péter Pázmány. In 1950 the University was re-
named after Baron Loránd Eötvös (1848-1919), a professor of physics with an extremely high 
international reputation (he produced, for instance, experimental evidence of the equivalence of 
gravitational and inertial mass); he was also an eminent statesman. 
The idea of the Board of the Society to organize the 5th Meeting of the European Society 
for Chlamydia Research in Budapest was, to make this meeting as accessible as possible for 
researchers from Central and Eastern European countries too. This wish seems to have been 
achieved. It is a further great pleasure for us that there are nearly four hundred participants from all 
five continents. 
The main topics of the 5th Meeting include conventional topics, such as taxonomy, biology, 
diagnostics, immunology and pathogenesis, clinical diseases, epidemiology, animal models, 
chlamydia and cardiovascular diseases, chlamydia of veterinary interest, trachoma, treatment, 
prevention and future prospects. The topics may be conventional, but the contents of the 
presentations are original and deeply interesting, in some cases surveying the recent research 
results and in other cases reporting exciting new knowledge. 
The abstracts have been revised by the Research Committee. Because of the generally high 
standard of the submitted articles, it has been necessary for numerous excellent abstracts to be 
transferred to the Poster Session this year. Our thanks are due to the Research Committee for their 
careful, high-level work. 
This Meeting is only a „passing moment" in time. Knowledge in the field of chlamydiology 
is growing exponentially. This is naturally due to the activity of the contributors, for which we are 
extremely grateful. Let us all take advantage of this meeting to take part in fruitful discussions, to 
agree on new cooperations, and to make new friends. Fresh challenges are waiting for us. 
On behalf of the Organizing Committee, may I wish you all a pleasant and memorable stay in 
Budapest and Hungary. 
Szeged, August 2004 
Judith Deák 
Chair of the Organizing Committee 
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SUBVERSION OF THE EUKARYOTIC HOST CELL BY SECRETED 
CHLAMYDIAL EFFECTOR PROTEINS 
Ted Hackstadt 
Host-Parasite Interactions Section, Laboratory of Intracellular Parasites, National Institutes of 
Health, National Institute of Allergy and Infectious Diseases, Hamilton, MT, USA 
Chlamydiae occupy a unique vacuolar 
niche within the host cell. The chlamydial 
inclusion, unlike vacuoles containing other 
intracellular pathogens, is not interactive with 
endocytic vesicular trafficking pathways but is 
instead fusogenic with an incompletely 
understood exocytic pathway which otherwise 
delivers sphingomyelin and cholesterol from 
the Golgi apparatus to the plasma membrane. 
Entry into this pathway is an active process on 
the part of the chlamydiae as both de novo 
transcription and translation are required. As 
obligate intracellular pathogens intimately 
dependent upon the eukaryotic host cell, 
chlamydiae clearly communicate with the host 
cell in many ways to promote pathogen 
survival and replication. Many Gram-negative 
pathogens modify cellular functions through a 
targeted type m secretion apparatus that 
delivers bacterial effector proteins directly into 
the cytoplasm of the host cell [1], Analysis of 
the chlamydial genome has revealed the 
capacity to encode a complete type m 
secretion system [2-5]. Proteomic analyses 
have indicated a functional type EI secretion 
apparatus on EBs [6]. Secretion of type IH 
effector proteins are now recognized as 
potential controlling elements for many 
significant events during the chlamydial 
developmental cycle. Some of the major 
questions remaining in chlamydial biology are 
dependent upon when the secretion apparatus 
is active and the functions of the secreted 
effectors. 
Many of the changes in the interactions 
of the nascent inclusion require chlamydial 
protein synthesis and are specific and localized 
to the inclusion. This specificity strongly 
suggests modification of the exposed inclusion 
membrane. Examples of chlamydial proteins 
controlling localized events could include the 
recruitment of actin to promote entry [7-10]. 
Other examples of cis-acting modifications to 
the nascent inclusion membrane may include: 
evasion of lysosomal fusion [11-15], 
interactions with microtubules to deliver the 
nascent inclusion to the peri-Golgi region and 
microtubule organizing center [16-18], 
initiation of fusion with exocytic vesicular 
traffic from the Golgi apparatus [14, 19-21], 
and recruitment of, but not fusion with, 
recycling endosomes containing transferrin and 
its receptor [15, 22-24], Examples-of-more 
trans-acting chlamydial control of host cell 
functions include inhibition of apoptosis [25-
29], activation of caspase-1 [30], down-
regulation of MHC class I and II expression 
[31, 32], activation of the 
Raf/MEK/ERK/cPLA2 signaling pathway 
[33], and alterations of host transcriptional 
profiles [34, 35], 
Attachment of chlamydiae to host cells 
and initiation of the entry process has been one 
of the more controversial and interesting areas 
of chlamydial pathogenesis. A large number of 
chlamydial ligands and host receptors have 
been proposed to play a role in this essential 
process [36]. Recent studies with chemically 
mutagenized CHO cells have distinguished 
two distinct stages in the chlamydial entry 
process [37, 38] Heparin sulfate like 
proteoglycans are believed to play a role in an 
initial, electrostatic and reversible interaction 
that precedes an irreversible step leading to 
internalization [39, 40]. The host gene mutated 
to block the secondary, irreversible step has 
not been identified. The host responses and 
requirements for chlamydial entry are, 
however, beginning to be described. One of the 
first overt responses of the host cell is the 
recruitment of actin to the site of EB 
attachment [8]. This results in the formation of 
BIOLOGY - 5 
a pedestal-like structure with the EB at the 
apex. This recruitment of actin occurs rapidly 
and culminates in the internalization of the EB. 
Host signaling molecules known to be 
recruited and required include the RAC 
GTPase [9], WAVE2, and the Arp2/3 
complex. A chlamydial type EH secreted 
effector has been proposed to play an 
important role in the initiation of this process 
[10]. The protein, named Tarp for Translocated 
Actin Recruiting Phosphoprotein, is pre-
existing in an unphosphorylated form in EBs 
and tyrosine phosphorylated within minutes of 
attachment to susceptible host cells. Although 
the molecular mechanisms triggering cell 
signaling pathways remain to be defined, Tarp 
appears to be translocated to the cytoplasmic 
face of the plasma membrane and tyrosine 
phosphorylated while the EBs are still 
extracellular. Whether this protein actually 
serves as a receptor aiding chlamydial 
attachment to the host cell or is simply a 
signaling molecule remains to be determined. 
The entire process of cell signaling, 
actin recruitment, and internalization of EBs is 
transient and over within minutes [9]. 
Endocytosed EBs are then found within a 
plasma membrane derived vesicle that is 
effectively dissociated from all cellular 
processes and displays no known cellular 
markers [15]. This vacuole remains non-
interactive until chlamydial protein synthesis is 
initiated. Once chlamydial protein synthesis 
has begun, the interactions with the host cell 
change dramatically. 
While the chlamydial inclusion has 
been known to be non-lysosomal in character 
for some time now [41], the properties of the 
vacuole and relative contributions of the host 
and parasite to its establishment are only 
recently beginning to be deciphered. Surveys 
of early and late endosomal markers, 
lysosomal markers, fluid phase, and plasma 
membrane markers demonstrate no interaction 
of the endocytic pathway with the inclusion 
membrane of viable chlamydiae [13, 42], 
Instead, the chlamydial inclusion acquires 
sphingomyelin and cholesterol directly from 
the Golgi apparatus from what appears to be an 
exocytic pathway which normally delivers 
these lipids to the plasma membrane. Delivery 
of sphingomyelin and cholesterol is time, 
temperature, and energy dependent and is 
blocked by inhibitors of anterograde Golgi 
trafficking, such as brefeldin A, or of 
microtubule function, such as nocadazole [19-
21]. Recognition of this pathway has provided 
many insights into the cellular interactions of 
the chlamydial inclusion. 
All species of chlamydia interact 
similarly with this pathway to acquire 
sphingomyelin [19, 43, 44]. The molecular 
mechanisms employed by chlamydiae to 
subvert cellular trafficking pathways to the 
advantage of the parasite remain largely 
unknown although they almost certainly 
involve specific modification of the inclusion 
membrane. Most Golgi functions, such as 
glycosylation and transport of proteins, are not 
measurably disrupted in C. trachomatis-
infected cells [22], Indeed, even in chlamydia-
infected cells co-infected with Coxiella 
burnetii, sphingomyelin is delivered only to 
the chlamydial inclusion and not to the C. 
burnetii parasitophorous vacuole [13]. The 
chlamydial inclusion is therefore specifically 
recognized as a target by the cellular 
machinery controlling sphingomyelin 
trafficking. Initiation of fusion with 
sphingomyelin-containing vesicles is initiated 
within about 2 hr following internalization of 
C. trachomatis. In the presence of inhibitors of 
bacterial transcription or translation, 
endocytosed EBs do not attain the ability to 
acquire sphingomyelin and remain within 
vesicles that are effectively non-fusogenic with 
any cellular organelles [14], The collective 
interpretation of these observations is that 
chlamydiae display two distinct mechanisms 
for evasion of lysosomal fusion. One, which 
until recently had been considered passive or 
mediated by structural components of EB, does 
not require chlamydial protein synthesis and 
has been proposed to confer a survival 
advantage upon EBs until such time as they 
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initiate protein synthesis. A more active 
evasion of lysosomal fusion involves 
chlamydial modification of the inclusion 
membrane and is characterized by the ability to 
incorporate sphingomyelin. It has been 
proposed that once the properties of the 
inclusion have been established, the 
chlamydiae are essentially sequestered in a 
vesicle whose fusion properties are 
incompatible with the endosomal/lysosomal 
pathway thus providing a favorable 
intracellular site for their replication. 
The molecular mechanisms underlying 
chlamydial redirection of vesicular fusion 
remain unclear although the requirement for 
chlamydial protein synthesis and the specific 
alteration of only the inclusion membrane 
suggests that chlamydiae modify the 
cytoplasmic face of the inclusion, likely by the 
insertion of chlamydial protein. Concomitant 
with the change in fusogenicity is a 
microtubule-dependent trafficking of the 
nascent inclusion to a perinuclear region in 
close proximity to the Golgi apparatus [16-18]. 
Also during this early time frame, nascent 
inclusions begin to recruit early endosomes 
recycling transferrin and its receptor into very 
close apposition with the inclusion membrane 
although there is no fusion with these vesicles 
[14, 15, 23, 24]. Each of these processes 
require chlamydial protein synthesis and 
specific modification of the cytoplasmic face 
of the inclusion membrane although none of 
the chlamydial proteins controlling these 
events have been identified and it is not clear 
whether they are mediated by the same or 
different proteins. 
An entire class of chlamydial proteins 
modifying the inclusion membrane is now 
recognized. It is clear that chlamydiae modify 
the inclusion membrane extensively with a 
large number of inclusion membrane proteins, 
collectively referred to as Incs . At least forty 
inclusion membrane proteins have been 
described in C. trachomatis with about twenty 
confirmed by immunofluorescence with 
specific antibodies. The Inc protein family 
shares little primary sequence similarity among 
members but is characterized by a long, 40 
amino acids or more, predicted hydrophobic 
domain [45-49]. Exposure of a number of Incs 
on the cytoplasmic face of the inclusion has 
been demonstrated by microinjection of 
specific antibodies although the function(s) of 
the Inc proteins are largely unknown [50]. The 
majority of Incs are expressed early in the 
developmental cycle which is consistent with 
possible roles as mediators of vesicle fusion. 
All Inc proteins thus far tested in heterologous 
secretion systems are secreted via type IH 
secretion [6, 51]. One would suspect that 
chlamydial proteins controlling interactions 
with the host cell would be highly similar, 
however, there is surprisingly little 
conservation of Incs between chlamydial 
species despite all interacting with the same 
host vesicular trafficking pathways. Either 
there are unrecognized conserved small 
domains that control these interactions or 
other, possibly more peripherally associated, 
proteins function in there capacities. 
Chlamydial Tarp and the Inc proteins 
identify at least two distinct stages in 
chlamydial development where secreted 
effectors may play important roles in defining 
the outcome of infection. Certainly there are 
many other levels of communication between 
chlamydiae and the eukaryotic host cell. 
Identifying the remaining secreted effector 
molecules and their functions may be 
challenging but will continue to provide 
insights into the many adaptations chlamydiae 
utilize as successful parasites. 
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THE GENERATION TIME OF CHLAMYDIA TRACHOMATIS 
I. Miyairi1'2*, O.S. Mahdi3, S.P.Ouellette3, R. Beiland3, G.I. Byrne3 
Departments of 'infectious Diseases, St. Jude Children's Research Hospital, Lauderdale, Memphis 
TN and department of Pediatrics,3 Molecular Sciences, U. Tennessee Health Science Center, 
Memphis, TN USA 
The generation time of chlamydia has 
previously been estimated from results of 
quantitative gene expression assays1'2, however 
this may not represent the rate of actual cell 
division. We sought to determine the 
generation time of Chlamydia trachomatis by 
arresting cell division sequentially with 
addition of penicillin and enumerating aberrant 
RBs within an inclusion under light 
microscopy3. A one step growth curve for 
elemental bodies was created for comparison. 
HeLa 229 epithelial cells were grown 
on 8 well chamber/slides and infected with C. 
trachomatis serovar D (MOI 0.3). 50 
microgram/ml of penicillin was added to 
quadruplicate samples at 0, 6, 12, 15, 18, 19.5, 
21, 24, or 30 hours post infection (hpi). SPG 
was added as a control at 0 hpi. C. trachomatis 
and infected cells were fixed with methanol, 
stained with Giemsa fluid at 42 hpi and 
examined by oil immersion light microscopy. 
The number of large aberrant RBs in each 
inclusion was counted and averaged for 200 
inclusions per sample. A one step growth 
curve was also produced by determining the 
number of inclusion forming units in replicate 
samples. HeLa 229 cells were grown on 24 
well plates, infected with C. trachomatis 
serovar D (MOI 0.3) in triplicates and 
collected at 6,12, 15, 18, 21, 24, 30, 39, 42 hpi. 
Cell suspensions were homogenized for IFU 
assay. 
The average number of RBs (standard 
deviation) at 6, 12, 15, 18, 19.5 hpi was 
1.1(0.3), 1.5(1.2), 3.8(3.8), 8.1(6.2), 
14.0(10.0), respectively. We were unable to -
enumerate beyond 21 hpi because of 
overcrowding. The lag phase was observed to 
be approximately 12 hours and the generation 
time was 2.4 hours, for the initial four rounds 
of replication. No infectivity was demonstrable 
for the first 21 hpi, and at 24, 30, 39, 42 hpi 
was 1.0(0.3) xl0*5, 1.6(0.3) xl0*6, 1.4(0.2) 
xl0*7, and 1.5(0.2) xl0*7 respectively. 16S 
rRNA transcript levels also will be measured 
to create a corresponding genomic generation 
curve for comparison. 
The generation time of C. trachomatis 
averaged 2.4 hours corresponding well to 
previous estimates by quantitative gene 
expression assays1'2. There was a large 
distribution of the number of RB per inclusion, 
suggesting replication occurs asynchronously. 
The lag phase was estimated to be about 12 
hours but may be up to 18 hours in significant 
population of organisms. This extended lag 
phase has not been previously noted. 
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A TYPE THREE SECRETION/CONTACT-DEPENDENT MODEL OF 
CHLAMYDIAL INTRACELLULAR DEVELOPMENT 
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Late in development, Chlamydia's 
replicative form, the reticulate body (RB), 
differentiates into the infectious form, the 
elementary body (EB). The signal(s) that 
trigger this crucial physiological change are 
unknown. 
We present a hypothesis for the 
modulation of chlamydial late developmental 
events involving the contact-dependent type HI 
secretion (TTS) system. In this model, TTS 
surface projections mediate intimate contact 
between the RB and the inclusion membrane. 
Below a threshold number of projections, 
detachment of the RB provides a signal for late 
differentiation of RB into EB. 
We use published data and our own 
observations to develop a mathematical model 
investigating this hypothesis. If the hypothesis 
proves to be accurate, then increasing the 
number of inclusions per host cell will increase 
the number of infectious progeny EB. 
Conversely, TTS down-regulation 
resulting in a reduction of the number of 
projections on the surface of the RB or TTS 
selective inactivation will significantly reduce 
the burst size of infectious chlamydial 
particles. The full implications of the 
hypothesis as predicted by the model provide a 
ground for experimental verification. 
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DECIPHERING CHLAMYDIAL GENE REGULATION BY IN SILICO PREDICTION 
OF PROMOTER SEQUENCES 
Peter Timms1, Brian Grech1 and Sarah A Mathews1 
'School of Life Sciences, Queensland University of Technology, Brisbane, Australia 
Even though Chlamydia has a relatively 
small genome, remarkably little is known about 
gene regulation in this important human and 
animal pathogen. The three chlamydial sigma 
factors, sigma 66, sigma 28 and the alternate sigma 
factor, sigma 54 are differentially expressed during 
the chlamydial developmental cycle, suggesting an 
involvement in stage-specific regulation of the 
chlamydial transcriptome. Prior to 1998, only 22 
chlamydial promoters had been studied at the level 
of transcript start site mapping or by using in vitro 
transcription assays. With the full genome 
sequence of over eight chlamydial strains now 
available, bioinformatic approaches can be utilized 
effectively to predict chlamydial promoters. We 
have applied advanced bioinformatics approaches 
to searching the whole chlamydial genomes to 
predict promoters. 
We developed an in silico whole genome 
analysis approach to search for promoters in the 
chalmydial genome. This involved the construction 
of a percentile weighted matrix to represent the -35 
and -10 promoter hexamers for both C. 
trachomatis and C. pneumoniae. We searched the 
whole chlamydial genomes using these weighted 
matrices and selected motif hits with scores above 
a threshold. We then reduced the number of 
predictions by phylogenetic footprinting between 
C. trachomatis and C. pneumoniae. We confirmed 
our in silico outputs by mapping the transcript start 
sites of selected genes. 
When the whole C. trachomatis genome 
was screened with the sigma 70 promoter weighted 
matrix (based on E. coli sigma 70 data), 1000's of 
potential sigma 66-type promoters were predicted, 
many of which were clearly false positives. 
Phylogenetic footprinting of the in silico predicted 
promoters between the available chlamydial 
genome sequences reduced the number to 36 
highly conserved promoters, sigma 66-type 
chlamydial promoters. We then analysed 14 of 
these promoters via transcript start site mapping of 
the relevant gene and were able to confirm that our 
in silico prediction was correct in 7% of cases. 
This in silico approach is slightly biased, as it uses 
the E.coli sigma 70 data as the basis of the matrix. 
Nevertheless, the consensus in silico chlamydial 
sigma 66 promoter TTGATT TATAAT (bold 
indicates high base preference) does show some 
variations when compared to the E. coli sigma 70 
consensus of TTGACA TATAAT. Interestingly, 
the chlamydial in silico consensus also varies 
compared to the consensus produced by the 36 
currently mapped chlamydial promoters 
TTGAXX TATAAT. 
In silico prediction of promoters in whole 
chlamydial genomes can be a useful means to 
predict new promoters and should play an 
important role in unraveling our understanding of 
the subtle and potentially complex gene regulatory 
networks that enable this unique pathogen to be so 
successful. Our in silico approach was strongly 
biased towards the E. coli sigma 70 type promoter 
consensus, however it did predict slight variations 
in the chalmydial genomes analysed. Our 
prediction success rate of over 70% is extremely 
good for predicting further novel promoters in 
Chlamydia. 
Interestingly, a significant number of biologically 
confirmed promoters in one chlamydial species did 
not readily footprint across into the other 
chlamydial species. It is unknown why so many 
promoters are different between the chlamydial 
species, but this may suggest significantly different 
mechanisms of regulating key genes between the 
species. Other interesting features emerging from 
chlamydial genome analysis are that several genes 
appear to have multiple promoters, often from two 
different sigma factor classes and some genes have 
promoters located within the coding region of the 
upstream gene. This suggests that multiple levels 
of gene regulation exist for some different classes 
of genes. Overall, in silico prediction of promoter 
hexamers and other transcription factor binding 
sites should play an important role in defining the 
mechanisms of gene regulation used by this unique 
intracellular parasite. 
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THE (^-GLUTAMINE S-ADENOSYL-L-METHIONINE DEPENDENT 
METHYL-TRANSFERASE PRMC/HEMK IN CHLAMYDIA TRACHOMATIS 
METHYLATES CLASS 1 RELEASE FACTORS 
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Methylation of DNA and protein 
plays an important role in gene expression 
and activity of enzymes. Methylation is 
catalyzed by methyltransferases (MTases) 
using S-adenosyl- L-methionine (AdoMet) as 
methyl donor. The role of methylation in the 
regulation of gene expression and protein 
activity of the obligate intracellular pathogen 
Chlamydia trachomatis is unknown. 
Genomes of Chlamydia spp. apparently lack 
the homologues of genes encoding well 
characterized DNA MTases, as well as the 
gene enabling the synthesis of AdoMet. This 
raises the question whether methylation 
events in Chlamydia spp. do occur. Recently, 
PrmC has been demonstrated to act in E. coli 
as an /V5-Glutamine AdoMet dependent 
MTase of class I peptide release factors 
(RFs), thereby making PrmC the first N5-
Glutamine MTase identified (Heurgue-
Hamard et al EMBO J 2002 (4): 769-78). We 
used a genetic approach to identify and 
analyze the putative prmC homologue of C. 
trachomatis. 
CT024 (prmQ and chlamydial RFs 
(prfA and prfB) of C. trachomatis strain L2 
were PCR amplified and cloned into the 
expression vector pQEL-80 thereby creating 
His-tagged fusion proteins. Next, the genes of 
prfA and prfB as well as the DNA encoding 
the His tag were subcloned into the low copy 
number pWSK129. pWSK129 is compatible 
with pQEL-80. Methylation of RFs was 
analyzed by MALDI-TOF mass spectrometry. 
Neither RF1 nor RF2 is methylated in 
E. coli prmC knock outs, leading to global 
deficiency in termination of translation and 
hence a deliberated growth. Overexpression 
of K12 RF2, thereby overwhelming PrmC, 
also leads to impaired growth. Taking 
advantage of these phenotypes, potential 
PrmC function of CT024 was assessed in the 
genetic background of E. coli. 
Expression of CT024 in a E. coli prmC knock 
out demonstrated that CT024 restores the 
growth defect of this strain, suggesting an 
interaction of CT024 with RFs of E. coli. 
This was substantiated by the observation 
that overexpression of CT024 suppressed the 
toxic effect of overexpression of K12 E. coli 
RF2 and strongly suggested that CT024 
methylates RFs. Indeed, in vivo methylation 
assays carried out with recombinant CT024 
and RFs of chlamydial origin demonstrated 
that CT024 methylates RFs within the tryptic 
fragment containing the universally 
conserved domain Gly-Gly-Gln. This is 
Completely consistent with the enzymatic 
properties of PrmC of E. coli origin. 
We conclude that CT024 encodes a 
functional chlamydial PrmC, acting as an N5-
Glutamine AdoMet dependent MTase of RFs. 
This makes PrmC the first MTase of C. 
trachomatis demonstrated to be involved in 
the basic biological process of translation 
termination. 
Studies are now underway to identify the 
putative chlamydial AdoMet permease. 
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ANALYSIS OF CHLAMYDIA CAVIAE ENTRY SITES AND INVOLVEMENT 
OF CDC42 AND RAC ACTIVITY 
Benjamin Wyplosz*1, Agathe Subtil1, Maria Eugenia Balañát and Alice Dautry-Varsat 
Unité de Biologie des Interactions Cellulaires, Institut Pasteur, Paris, France 
In epithelial cells, endocytic activity is 
mostly dedicated to nutrient and 
macromolecule uptake. To invade these cells, 
Chlamydiaceae, like other pathogens, have 
evolved strategies that utilize the existing 
endocytic machineries and signalling 
pathways, but little is known regarding the 
host cell molecules implicated. 
In this report, we show that within five 
minutes of infection of HeLa cells by 
Chlamydia caviae GPIC strain several events 
take place in the immediate vicinity of invasive 
bacteria: GM1-containing microdomains 
cluster, tyrosine-phosphorylated proteins 
accumulate, and intense actin polymerization 
occurs. 
We show that actin polymerization is 
controlled by the small GTPases Cdc42 and 
Rac, which become activated upon infection. 
Expression of dominant negative forms of 
these GTPases inhibits C. caviae entry and 
leads to abnormal actin polymerization. In 
contrast, the small GTPase Rho does not seem 
essential for bacteria entry. Finally, PI 3-kinase 
activity is also required for internalization of 
C. caviae, probably downstream of the other 
molecular events reported here. 
We present the first scheme of the 
events occurring at the sites of invasion of 
epithelial cells by a member of the 
Chlamydiaceae family. 
^These authors contributed equally to this work 
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INFECTIVITY OF CHLAMYDIA PNEUMONIAE AND CHLAMYDIA 
TRACHOMATIS IS ABOLISHED BY N-GLYCANASE TREATMENT 
Cho-chou Kuo*, Amy Lee, and Lee Ann Campbell 
Department of Pathobiology, University of Washington, Seattle, WA, USA 
Several mechanisms by which chlamdyiae 
attach and enter mammalian host cells have been 
proposed. The most plausible mechanisms are 
attachment mediated by the glycosaminoglycan 
[1,2], the mannose-oligosaccharide [3,4], and the 
estrogen receptor (in endometrial cells) [5], We 
have previously ' shown that the major outer 
membrane (MOMP) of Chlamydia trachomatis is 
glycosylated and the predominant carbohydrate is 
a N-linked high mannose type oligosaccharide [3]. 
It was further shown that the attachment and 
infectivity of C. trachomatis (L2), C. pneumoniae 
(AR-39) and C. psittaci (6BC) in HeLa cells were 
inhibited by high mannose oligosaccharides from 
other sources [3]. These findings suggested that 
chlamydiae may use the high mannose 
oligosaccharide as a ligand for attachment and 
infectivity of mammalian host cells. This 
hypothesis was further tested by determining the 
effect of enzymatic removal of the glycan from 
chlamydiae on infectivity of host cells. 
Linear gradient purified elementary bodies 
of C. pneumoniae AR-39, C. trachomatis E/UW-
5/Cx and L2/434/Bu, and C. psittaci 6BC were 
treated with 30 units of N-glycanase at room 
temperature for 3 hrs before inoculation into 
epithelial cells (HL cells) and endothelial cells 
(HMEC-1 cells). Treatment with O-glycanase was 
used as a negative control. The first passage, 
which measures infectivity, was assayed by 
inclusion counts following a direct fluorescent 
antibody stain. The intracellular growth of 
chlamydia (second passage) was assayed by 
passage of the harvests of the first passage into HL 
cells. 
Treatment with N-glycanase, but not O-
glycanase, reduced the infectivity of C. 
pneumoniae, C. trachomatis, and C. psittaci for 
both HL and HMEC-1 cells. Both the first and 
second passages were affected. However, the 
susceptibility to N-glycanase treatment varied 
among strains tested. In HL cells, the infectivity of 
C. pneumoniae AR39 and C. trachomatis serovar 
L2 was inhibited 97% in the first passage and 
100% in the second passage for both strains. The 
infectivity of C. trachomatis serovar E and C. 
psittaci 6BC was also inhibited by N-glycanase 
treatment, but to a lesser extent. Specifically, 
serovar E was inhibited 52% and 63% in the first 
and second passage, respectively. 6BC was 
inhibited 42% and 69% in the first and second 
passage, respectively. Similar patterns were 
observed in endothelial cells. In HMEC-1 cells, the 
infectivity of AR-39 and serovar L2 was inhibited 
76% and 85% in the first passage and 80% and 
90% in the second passage, respectively. The 
infectivity of serovar E and 6BC was inhibited 
49% and 46% in the first passage and 75% and 
63% in the second passage, respectively. The 
reductions in infectivity were all statistically 
significant at p-values less than 0.05. 
These findings suggest that C. 
pneumoniae, C. trachomatis and C. psittaci may 
use the N-linked high mannose type 
oligosaccharide as ligand for binding to the 
mannose receptor for attachment and infectivity of 
epithelial and endothelial cells and that the 
utilization of this ligand may vary among strains 
and cell types. 
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POLY(ADP-RIBOSE) POLYMERASE-1 PLAYS A ROLE ON CHLAMYDIAL 
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Chlamydiaceae are intracellular 
bacteria that cause a variety of infections in 
humans and animals. Most of the damage due 
to chlamydial infection may not be due to the 
infection itself but to the exacerbated 
inflammatory response induced by infection. It 
has been demonstrated that mice deficient in 
PARP-1 have a defective inflammatory 
immune response, showing abnormalities in 
the expression of NF-icB-dependent genes such 
as TNF-a and IFN-y, conferring to this mouse 
model an advantage in different conditions 
associated with severe inflammation. The aim 
of the present study is to know if PARP-1 
could plays a role in the response to 
chlamydial infection. 
We infected PARP-1-deficient mice 
and their littermates PARP-1+/+ with a 
sublethal dose of Chlamydophyla abortus, 
strain AB7. At 4 and 10 days post- infection, 
mice were killed and the livers were collected 
to carry out bacteriological and 
histopathological analysis. In addition, spleen 
cell cultures and serum samples for IFN-y 
quantification and a TUNEL assay for 
apoptosis detection was performed. In order to 
confirm the in vivo results, we infected with C. 
abortus cultures of PARP- V1' and PARP-1+/+ 
fibroblasts as well as PARP-1"7" fibroblasts in 
which the PARP-1 expresión was restaured by 
stable transfection with the pcDNA-PARP-1-
Zeo plasmid. Additionally, pharmacological 
inhibition of PARP enzymes was performed in 
C. abortus infected McCoy cell line, which is 
very suceptible to chlamydial infection. 
The chlamydial infection was less 
efficient in PARP-1"7" than in PARP+/+ mice. 
However, the inflammatory response was 
similar in both strains, suggesting a potential 
role for PARP-1 in the cross-talking between 
chlamydiae and the host cells. These results 
were confirmed by cell culture, since PARP-L 
7" fibroblasts showed a ten-fold lower rate of 
chlamydiae production than PARP-1+/+ 
fibroblasts or PARP-l"7" fibroblasts in which 
the PARP-1 expression had been restored by 
stable transfection. Moreover, a strong 
inhibition of bacterial production was also 
observed after pharmacological inhibition of 
PARP-1 activity in McCoy cells, indicating 
that this process is dependent on the catalytic 
activity of PARP-1. Likewise, PARP 
inhibition induced a higher level of cell death 
of infected cells, suggesting that PARP-1 
deficiency can contribute to the early release of 
chlamydiae from infected cells, interfering 
with the normal cell cycle. 
We showed that the genetic and 
pharmacological inhibition of PARP-1 
counteracts the development life cycle of 
chlamydiae. Therefore, PARP-1, appear as a 
new potential therapeutic target molecule in 
chlamydial infection which seems to be 
necessary for maintaining the integrity of host 
cells. 
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HIDE-AND-SEEK: HOST-CELL RESPONSES IN MODELS OF PERSISTENT 
CHLAMYDA PNEUMONIAE INFECTION 
Jan Peters, Simone Heß, Katja Endlich, Jessica Thalmann, Gerda Bartling, Andreas 
Klos 
Medical Microbiology, Med. School Hanover (MHH), Hannover, Germany 
Chlamydia pneumoniae causes 
respiratory diseases. Elementary bodies (EB) 
infect epithelial cells where they develop to 
reticular bodies. A third, persistent form seems 
to participate in chronic diseases such as 
arteriosclerosis or asthma. We have recently 
shown for the productive infection that 
intracellular chlamydia induce in their host-
cells drastic changes in the gene expression 
pattern. Here, we compared different models 
of persistence in cell-culture analyzing a subset 
of human genes and proteins. 
HeLa-cells were infected (MOI 30) 
with C. pneumoniae CWL029 in the presence 
of Penicillin G (PenG) at 500 U/ml, IFN-y at 
100 U/ml or the iron chelator DAM at 250 
microM. Over 7 days the persistently infected 
host-cells were investigated, compared to 
mock-infected cells: On each day, supernatant 
was harvested. Total RNA was isolated on day 
1, 4 and 7 post infection. Additionally, 
reactivation was induced after 4 days of 
persistence. Moreover, human monocytes were 
analyzed as cells where persistence naturally 
occurs. The induced expression of various 
host-cell genes with key functions, in 
particular cytokines/growth factors and 
transcription factors was analyzed by real-time 
RT-PCR and by ELISA. 
During persistence induced by PenG, 
DAM or IFN-y less than 0.2 % of infectious 
EBs could be recovered compared to a 
productive infection. When the inducers were 
replaced reactivation of the persistent 
chlamydia occurred - proofing that the 
bacteria were viable during the complete 
course of the experiment. 
One day post infection, chlamydia caused in 
the three models of persistence essentially the 
same strong host cell-responses as in 
productive infection. 
However, intriguingly, two different patterns 
emerged during the later phase of persistent 
infection: In the DAM model, the intracellular 
bacterium caused a long-lasting up-regulation 
of most of the investigated genes and proteins. 
In contrast, in the IFN-y and the PenG models 
of persistence, chlamydia-induced gene 
regulation and cytokine release were almost 
absent. Data on monocytes with UV-
inactivated chlamydia suggested that bacterial 
cell-wall components such as heat shock 
proteins or LPS cause a strong but only 
transient up-regulation of certain genes, 
whereas other factors of viable chlamydia can 
cause a long-lasting response in these cells. 
Depending on cell-type and mode of 
induction, C. pneumoniae can lead to two 
different states of persistence: 1) in one type, 
chlamydia stimulate permanently their host-
cell causing responses such as the release of 
inflammatory mediators, which might be 
responsible for tissue damage. 2) In the other 
type of reaction, persistent C. pneumoniae 
seem to silence most host responses which 
could otherwise indicate their presence to the 
immune system - a prerequisite of prolonged 
survival in the infected organism. Here, tissue 
damage would mainly be caused by activation 
of host cells which might occur during 
bacterial reactivation. 
Thus, this study reveals the ability of 
C. pneumoniae to participate in two putative 
pathomechanisms of persistent infection. 
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CHLAMYDIAPHAGE (CHP2) RECEPTOR PROTEINS 
J.S. Everson,* P.R. Lambden and I.N. Clarke 
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Medicine, Southampton General Hospital, Southampton, UK 
Several bacteriophages have been 
isolated from chlamydiae, and all belong to the 
Microviridae. The host range for 
chlamydiaphage infection is restricted to 
certain species within the genus 
Chlamydophila. Preliminary studies showed 
that the chlamydiaphage tropism was 
determined by the presence of a receptor 
protein. This is unusual for microviruses as the 
receptor for the prototype bacteriophage 
0X174 has been shown to be LPS. 
The aim of this study was to identify the 
chlamydial surface protein(s) which act as 
receptors for the binding of chlamydiaphage 
Chp2. 
Radiolabelling: Purified EBs of C. 
abortus S26 were surface- labelled in 
suspension with 125Iodine and Iodo-Beads® for 
15 minutes at room temperature. The 
suspension was removed from the beads to 
terminate the reaction. Labelled EBs were 
washed twice by centrifugation to remove 
unincorporated iodine, then solubilised in 1% 
dodecyl-p-D-maltoside (DDM) in PBS for lhr 
at 37°C. The extract was pelleted at 20,000g 
and the soluble fraction dialysed against PBS 
to remove excess detergent. The Iodine125 
radiolabeled DDM soluble fraction was used 
in immunoassays. 
Immuno-assays: ELISA: Antigen was 
bound to immunoassay trays overnight. Chp2 
was added to wells and bound phage detected 
using the phage specific monoclonal antibody 
55 (Mab 55). RIP A: Antigen was mixed with 
Chp2 in PBS for lhr at 37°C, followed by 
incubation with Mab 55. Control samples were 
set up in parallel without the addition of phage. 
Goat anti-mouse beaded agarose was added to 
adsorb immune complexes. Beads were 
washed extensively and then derivatised in 
sample dissociating buffer and separated by 
10% SDS-PAGE. Gels were stained and 
exposed for autoradiography. 
Previous studies have shown that 
treating C. abortus EBs with proteinase K 
eliminates phage binding, strongly suggesting 
that the phage receptor is a protein (1). The 
phage specific Mab 55 recognises the coat 
protein VP1 of Chp2 (1). Phage could be 
detected bound to the DDM solubilised 
membrane fraction with Mab 55 in the ELISA 
assay, confirming that the chlamydial phage 
receptor had remained active through the 
radiolabelling and detergent extraction 
procedures. RIPA analysis revealed two bands, 
which were only seen when both phage and 
EBs were present in the reaction mixture. 
These studies show that host cell 
recognition by the chlamydiaphages involves 
protein-protein interactions. 
The chlamydiaphages are closely related 
sharing over 90% genome identity, yet they 
have different but overlapping cell tropisms 
(2). This indicates that there are differences in 
the receptor recognition sites. 
We have shown that Chp2 recognises two 
surface proteins, which act as phage receptors 
in C. abortus S26. 
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EXPRESSION OF NON-STRUCTURAL PROTEINS DURING CHP2 
REPLICATION 
S. A. Garner*, J. S. Everson , P. R. Lambden and I. N. Clarke 
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Medicine, Southampton General Hospital, Southampton, UK 
Chlamydia phage 2 (Chp2) is a chlamydial 
bacteriophage that was isolated from C. abortus1. 
The Chp2 genome encodes 8 major ORFs. ORFs 
1 -3 encode structural proteins 2 but it is not known 
whether the computer-predicted ORFs 4-8 are 
expressed. The aim of this investigation was to 
develop specific immunological reagents to allow 
the detection of the proteins encoded by ORFs 4-8 
and to determine which are expressed during Chp2 
replication. 
Production of polyclonal antisera ORF4 
and ORF5 proteins were expressed as recombinant 
proteins in E. coli and purified by metal affinity 
chromatography using a six-histidine tag that was 
incorporated by the N-terminal fusion peptide 
(XPRESS System™. Invitrogen life technologies). 
As the proteins encoded by ORF6, ORF7 and 
ORF8 are predicted to be small they were 
expressed as larger fusion proteins in E. coli and 
purified by affinity chromatography specific for 
the carrier protein (MBP, NEBL [ORF6 protein] or 
GST, Amersham Pharmacia Biotech [ORF7/ORF8 
protein]). To raise polyclonal antisera five 
subcutaneous injections of approximately (Xg of 
each protein were carried out at ten-day intervals 
in wistar rats [ORF4 protein, ORF5 protein] or 
mice [ORF6 protein, ORF7 protein, ORF8 
protein]. 
Immunofluorescence BGMK were grown on 
13mm coverslips in 24 - well trays. Cells were 
infected with C. abortus containing Chp2. At 72h 
post infection, the culture medium was removed, 
monolayers washed twice in PBS and fixed in ice 
cold methanol for 15 min. Each antiserum was 
incubated with fixed cells for 40 min at 37°C and 
washed three times in PBS. Bound antibody was 
detected with an anti -rat (ORF4-5) or an anti -
mouse (ORF6-8) fluorescein conjugated antibody 
(ISL, Paignton, UK) diluted in 0.0025% Evans 
Blue dye in PBS. 
Western blot The proteins present in partially-
purified Chp2 particles were separated by SDS-
PAGE then transferred to nitrocellulose and 
screened with each polyclonal antiserum. Bound 
antibody was detected with anti -rat or anti mouse 
AP conjugate antibody (Sigma). 
To identify which of the Chp2 ORFs 
encode proteins that are expressed during infection 
the immuno-specific reagents produced to each 
putative protein were used to screen Chp2 infected 
C. abortus inclusions by immunofluorescence and 
also to probe partially-purified Chp2 particles by 
Western blot. It was shown that ORF5 protein and 
ORF7 protein are expressed. The expression of 
ORF4 protein was shown by Western blot analysis 
of partially-purified Chp2 particles. The 
expression of ORF6 protein and ORF8 protein 
could not be demonstrated with the antisera 
produced possibly because the peptides encoded 
by ORFs 6 and 8 failed to elicit a significant 
immune response. There are no proteins with 
significant sequence similarity to ORF6 protein in 
other microviruses therefore it is possible that this 
ORF is not expressed or that expression of this 
ORF and ORF8 maybe below the sensitivity of the 
immunofluorescence assay. 
It has been shown during this study that 
the Chp2 ORF4, ORF5 and ORF7 are expressed 
during Chp2 infection. 
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CANNOT DO WITHOUT - CD71 (TRANSFERRIN RECEPTOR) IS 
NECESSARY TO COMPLETE THE CYCLE OF DEVELOPMENT BY 
CHLAMYDIA TRACHOMATIS L2 
Dagmar Heuer*, Volker Brinkmann, Agnes J. Szczepek, Thomas F. Meyer 
Max-Planck Institute for Infection Biology, Dept. Molecular Biology, Berlin, Germany 
Transferrin receptor (TfR) and its 
ligand transferrin (Tf) are important 
components of the cellular iron delivery 
system. After binding of iron-loaded Tf to TfR, 
both are taken up by clathrin dependend 
endocytosis. The iron is then released from the 
Tf and the Tf/TfR complex is recycled to the 
plasma membrane. In C. trachomatis and C. 
pneumoniae infected cells we and others 
detected Tf/TfR vesicles accumulating around 
the chlamydial inclusions [1, 2, 3]. 
Additionally, depletion of iron from infected 
cell cultures using the iron chelator 
deferoxamine, produced striking effect on 
chlamydial development by inhibition of the 
developmental cycle and an induction of 
persistent form. These chlamydial infections 
could be rescued by addition of iron-loaded Tf 
[4, 5]. To further elucidate the role of TfR in 
chlamydial biology, we used siRNA to silence 
TfR expression and then followed the 
chlamydial developmental cycle. 
The TfR expression was silenced by 
transfection of HEp-2 cells with a specific 
siRNA molecule using the TransMessenger Kit 
(Qiagen). As a control we used an inactive 
siRNA. Two days after transfection, both cells 
populations were infected with C. trachomatis 
L2 (M.O.I. = 1). One day p.i. we determined 
the size of the inclusions and compared 
chlamydial Hsp60 and chlamydial Hsp70 
levels in both cell populations. In addition, 
infectivity studies and electron microscopy 
studies were performed 2 d p.i. 
Using RNAi technology, we were able 
to nearly completely silence the TfR 
expression in C. trachomatis L2 infected HEp-
2 cells. This transient knock down had a 
dramatic effect on the infectivity of chlamydial 
progeny whereas no effect on the size of the 
inclusion or the bacterial protein content was 
seen. Electron microscopy revealed that the 
number of bacteria were unchanged as 
compared to the control. However, in the TfR 
knock down cells, unlike in the control cells, 
we observed predominantly RB, very few EB 
and no aberrant forms, suggestive of inability 
of C. trachomatis to complete its 
developmental cycle. 
Our results suggest the dependency of 
chlamydial developmental cycle on the 
presence of TfR in the host cell. This may 
reflect the chlamydial requirement for iron 
delivery by TfR-dependent pathway and may 
indirectly evidence the interaction of 
endocytotic vesicles with the chlamydial 
inclusions. 
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SELECTIVE COX INHIBITORS 
PNEUMONIAE IN HOST CELLS 
Ying Yan*, Eeva-Liisa Heikkinen, M 
Saikku 
Department of Medical Microbiology, University 
Finland 
Atherosclerosis is nowadays considered as 
an inflammatory disease. Cyclooxygenase (COX) 
plays a key role in inflammation as the rate-
limiting enzyme in the conversion of arachidonic 
acid to prostaglandins. COX exists as 2 isoforms. 
COX-1 is constitutively expressed by most tissues 
and mediates normal physiological functions, 
whereas COX-2 is rapidly induced at sites of 
inflammation. Recent studies have shown that 
COX-2 is expressed by endothelial cells, smooth 
muscle cells, and macrophages in human 
atherosclerotic lesions (1). Coronary heart disease 
and atherosclerosis have been shown to be 
associated with Chlamydia pneumoniae infection, 
which can promote the atherosclerotic process. 
Unselective COX inhibitor, acetosalisylic acid, has 
been shown to inhibit the growth of C. 
pneumoniae (2) but the effect of COX selective 
inhibitors is not known. In this study, the effects of 
selective COX-1 and COX-2 inhibitors on C. 
pneumoniae infection were examined in cell 
culture. 
C. pneumoniae Kajaani 7 isolate (300 + 
100 IFUs/well) were inoculated into confluent HL 
cell monolayers on glass coverslips in the presence 
of 0.01 - 20 pg/ml of selective COX-1 inhibitor, 
SC-560, or COX-2 inhibitor, PTPBS, or without 
drugs. After infection, the cells were washed and 
cultured in the culture medium supplemented with 
0.5 pg/ml of cycloheximide and respective drug 
concentrations and refreshed every 24 h, for 72 h 
at 35°C and 5% C02. In separate experiments, after 
72 hours the cultures were either continued or 
repassaged to fresh HL cells by centrifugation and 
cultured for another 72 h in the medium with or 
without COX inhibitors. The infected cells were 
stained with fluorescein isothiocyanate conjugated 
chlamydial antibody for the presence of inclusions 
and Hoechst staining for apoptosis and studied by 
a fluorescent microscope. Statistical analysis was 
performed with the SPSS software. 
The infectivity of chlamydiae was totally 
inhibited when the concentration of SC-560 was 
lOpg/ml and that of PTPBS 18 pg/ml. The 
inhibition was concentration-dependent within 4-9 
pg/ml of SC-560 and 2-16 pg/ml of PTPBS. The 
drugs lost their effects when concentrations were 
INHIBIT THE GROWTH OF CHLAMYDIA 
ija Leinonen1, Sylvi Silvennoinen-Kassinen, Pekka 
Oulu, and 'National Public Health Institute, Oulu, 
less than 0.01 pg /ml of SC-560 or 0.05 pg/ml of 
PTPBS. 
The inclusion sizes in untreated control 
infections were 0 11.5 + 1.3 pm (n=ll), but they 
were extremely small, 0 1.9 ± 0.7 pm (n=13) 
(p<0.001), and disintegrated in the presence of 9 
pg/ml of SC-560 and 16 pg/ml of PTPBS. With 
the concentrations less than 4 pg/ml of SC-560 and 
2 pg/ml of PTPBS, the inclusion sizes were the 
same as in controls. 
In continued cultures without the drugs the 
numbers of the inclusion increased significantly 
(24 vs. 113, p<0.01). After repassaging or 
extending the infection in the medium without 
COX inhibitors, a few inclusions were found even 
in the cells treated with the highest concentration 
of drugs during the first 72 h culture (p<0.001) and 
the inclusions had normal sizes. After continued 
culture with same drug concentrations as in the 
first 72 h culture, the sizes of the inclusions were 
as small as in the first culture but the number of 
mini-inclusions increased 2-3 fold (4 vs. 12, or 28 
vs. 73, p<0.01). 
The percentages of apoptotic cells in 
infected and uninfected cell cultures with or 
without drugs were similar when the concentration 
were 4 pg/ml of SC-560 and 8 pg/ml of PTPBS 
(p>0.05). No apoptosis was found in the cells with 
C. pneumoniae inclusion. 
Selective COX inhibitors, SC-560 and 
PTPBS, inhibit the growth of C. pneumoniae in 
cell cultures. The inhibitory effect was seen as 
decreased numbers of inclusions and very small 
inclusion sizes, even when the culture time was 
extended for another 72 h. However, after removal 
of the drugs from the culture medium the inclusion 
sizes turned normal and the numbers of inclusion 
increased again. These findings suggest that COX 
inhibitors are chlamydiostatic. C. pneumoniae 
retained its antiapoptotic activity. 
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ENVIRONMENTAL CHLAMYDIAE - DIVERSITY, MEDICAL RELEVANCE, 
AND GENOMICS 
Matthias Horn*, Astrid Collingro, Stephan Schmitz-Esser, Michael Wagner 
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Vienna, Vienna, Austria 
Chlamydiae as we knew them 
Chlamydiae are perhaps the most successful 
obligate intracellular bacterial pathogens, 
representing the world's major cause of 
preventable blindness and sexually transmitted 
disease (1). Until about a decade ago 
chlamydiae were considered a small group of 
few closely related bacteria deeply branching 
within the domain Bacteria, characterized by a 
unique developmental cycle, and thus being 
well separated - both, biologically and 
phylogenetically - from all other known 
bacteria. 
The unexpected diversity of chlamydiae 
The discovery of chlamydiae as symbionts of 
free-living amoebae or insects, as pathogens of 
crustaceans, as contaminants of a laboratory 
cell culture, and in an aborted bovine fetus 
radically changed our perception of chlamydial 
diversity and their distribution in nature (2-7). 
These findings resulted in the description of 
three novel families within the phylum 
Chlamydiae: Parachlamydiaceae, 
Simkaniaceae, and Waddliaceae (4, 8). 
Moreover, molecular data suggest the 
existence of an additional, untold diversity of 
chlamydiae in the environment (9-11). The 
extent of the diversity of environmental 
chlamydiae thus by far exceeds the diversity of 
previously recognized pathogenic chlamydiae. 
"How do you know it's chlamydia?" 
Environmental chlamydiae naturally occur 
within phylogenetically different hosts 
(amoebae vs. humans) than pathogenic 
chlamydiae. However, it seems convincing that 
their designation as "chlamydiae" is well 
justified. Environmental chlamydiae show the 
same obligate intracellular life style as 
pathogenic chlamydiae, and the morphology of 
their developmental stages is highly similar in 
ultrastructure to the elementary and reticulate 
bodies of pathogenic chlamydiae. Most 
importantly, environmental chlamydiae are 
more closely related to pathogenic chlamydiae 
than to any other bacteria, thus representing the 
closest living relatives of pathogenic 
chlamydiae. It is therefore likely that a more 
detailed analysis of the only recently identified 
environmental chlamydiae will reveal further 
similarities with pathogenic chlamydiae, 
making environmental chlamydiae a suitable 
model system to study chlamydial biology. 
Implications for public health 
The increasing awareness of the diversity of 
chlamydiae and their distribution in the 
environment also deserves attention from a 
public health point of view. Several lines of 
evidence indicate a possible association of the 
only recently recognized environmental 
chlamydiae with respiratory disease of humans 
(12). First, elevated antibody titers against 
Simkania or Parachlamydia were detected in 
patients with respiratory disease of unknown 
cause. Second, 16S rRNA genes that are more 
similar to rRNA genes of environmental 
chlamydiae than to rRNA genes of pathogenic 
chlamydiae were found in clinical specimen 
from respiratory disease patients. Third, 
parachlamydiae, which naturally thrive within 
amoebae, have been demonstrated to be able to 
enter and multiply in human cells including 
macrophages and epithelial cells (13, 14). 
Taken together, it seems conceivable that 
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environmental chlamydiae have simply been 
overlooked as possible cause for respiratory 
disease. Therefore, additional studies and the 
inclusion of environmental chlamydiae in 
diagnostic assays are necessary to elucidate the 
role of environmental chlamydiae as potential 
emerging pathogens. 
Environmental chlamydia genomics 
We have recently determined the complete 
genome sequence of a representative of 
environmental chlamydiae, the 
Parachlamydia-related strain UWE25, which 
is in the process of being validly described as 
Protochlamydia amoebophila (15). 
The genome of this Acanthamoeba symbiont is 
about twice as large as the genomes of all 
pathogenic chlamydiae sequenced to date and 
thus represents the second largest genome of 
obligate intracellular bacteria. Nevertheless, 
many essential metabolic pathways are 
truncated in the UWE25 genome. Similar to 
pathogenic chlamydiae, these environmental 
chlamydiae thus depend on the availability of 
host-derived metabolites that are imported into 
the chlamydial cell by a variety of transporters. 
Like their pathogenic counterparts, 
environmental chlamydiae are able to live as 
energy parasites by importing ATP from their 
host cell in exchange for ADP (16). Since they 
are not able to synthesize nucleotides and 
NAD de-novo, they also employ specialized 
transporters for those compounds. 
Environmental chlamydiae are thus the first 
bacteria that have been shown to be able to 
import intact NAD from their host cells (see 
conference abstract by S. Schmitz-Esser et al.). 
Taken together, these findings provide a 
rationale for the observed obligate intracellular 
life style of environmental chlamydiae and 
reveal striking similarities in the biology of 
environmental and pathogenic chlamydiae. 
However, environmental chlamydiae seem to 
be more independent from their host cells than 
pathogenic chlamydiae, since they possess a 
complete TCA cycle and a more versatile 
respiratory chain. In addition, there seem to be 
notable differences in cell wall composition 
between environmental and pathogenic 
chlamydiae, as genomic analysis failed to 
identify homologues of the major outer 
membrane protein or polymorphic outer 
membrane proteins in UWE25. 
Interestingly however, the environmental 
chlamydia strain UWE25 encodes several 
proteins that have been associated with 
virulence of pathogenic chlamydiae, including 
a type three secretion system, the chlamydial 
protease-like activity factor, and putative 
inclusion proteins. Although UWE25 
additionally possesses a type four secretion 
system (that is absent in pathogenic 
chlamydiae), this suggests that in principle the 
interaction of environmental chlamydiae with 
their amoeba hosts resembles the interaction 
between pathogenic chlamydiae and animal or 
human cells (also see conference abstract by 
Collingro et al.). 
A comprehensive online database containing 
the complete annotation and a variety of pre-
calculated analyses, prediction results and 
sequence analysis tools is available at 
http ://mips. gsf. de/services/genomes/u we25/. 
The environmental chlamydia genome 
database also allows any user to add and 
improve the existing annotation. Since this 
database is easily extendable to include 
additional chlamydial genomes, it might 
eventually serve as a community platform for 
comparative chlamydia genomics. 
Reconstructing the evolutionary history of 
chlamydiae 
A major focus of our comparative genome 
sequence analysis of environmental and 
pathogenic chlamydiae was the evolution of 
chlamydiae and the inference of gene 
phylogenies. In this context, the high number 
of plant homologues in the UWE25 genome 
seemed intriguing and confirmed the 
previously hypothesized ancient relationship 
between chlamydiae, cyanobacteria and 
plastids (17). Phylogenetic reconstructions 
suggested that this relationship was rather 
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complex and involved multiple lateral gene 
transfer events between these groups. 
Consistent with the obligate intracellular life 
style of environmental and pathogenic 
chlamydiae, no traces of significant recent 
gene acquisition were detectable in the 
UWE25 genome. The genome of this amoebal 
symbiont thus opens a window on the genetic 
make-up of ancestral chlamydiae. Comparative 
and phylogenetic genome analysis revealed 
that the last common ancestor of both 
pathogenic and environmental chlamydiae, 
which lived around 700 million years ago, was 
already adapted to intracellular survival in 
early eukaryotes. Several virulence factors, like 
the type three secretion system, required for 
interaction of pathogenic chlamydiae with their 
hosts, evolved from genes of the last common 
chlamydial ancestor. Early members of the 
chlamydial evolutionary lineage were therefore 
major inventors of mechanisms for 
exploitation of eukaryotic cells as an 
ecological niche. Their analysis shed new light 
on the evolution of intracellular bacterial 
pathogens. 
What 's next? 
The discovery of environmental chlamydiae 
opened a new possibility to investigate 
chlamydiae using a comparative approach. 
This approach already revealed novel insights 
into the biology and evolution of chlamydiae, 
which will be supplemented by future 
application of functional genomics, including 
global transcription and proteome analysis of 
environmental chlamydiae. 
The ChlamydiaTaxogeriomic project, currently 
underway at TIGR and aiming at complete 
genome sequencing of all remaining species 
within the phylum Chlamydiae (see conference 
abstract by G. Myers et al.), will clearly lift 
comparative genome analysis of chlamydiae to 
the next level. Furthermore, genome 
sequencing of a representative of the natural 
hosts of environmental chlamydiae, 
Acanthamoeba castellanii, is in progress. The 
availability of this genome sequence will 
enable a more advanced and sophisticated 
comparison of the interaction of environmental 
and pathogenic chlamydiae with their 
respective host cells. 
A better understanding of the interaction of 
chlamydiae with their natural hosts and the 
evolution of this interaction will eventually 
help to find and select novel targets for 
vaccines or anti-chlamydia therapy. 
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BIOLOGY OF ENVIRONMENTAL CHLAMYDIAE REVEALED BY 
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Werner Mewes2, Michael Wagner1, and Matthias Horn1 
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Vienna, Vienna, Austria; department of Genome Oriented Bioinformatics, Technical University 
Munich, Freising, Germany 
A still growing number of 
environmental chlamydiae belonging to the 
order Chlamydiales and comprising the closest 
relatives of the medically important pathogenic 
chlamydiae has been discovered from various 
sources during the past years. Comparative 
analysis of the genome of one representative of 
environmental chlamydia, the acanthamoebae 
symbiont UWE25, should therefore reveal new 
insights into the biology of environmental 
chlamydiae and their pathogenic relatives. 
Due to its relatively large genome (2.4 
Mb), the environmental chlamydia UWE25 
has retained many capabilities, which have 
been lost by pathogenic chlamydiae during 
their adaptation to higher eukaryotes. 
Considering its metabolic competence, 
UWE25 is less dependent on its host cell than 
pathogenic chlamydiae. This is most obvious 
for energy metabolism in UWE25, which 
encodes additional components for glycolysis, 
the tricarboxylic acid cycle and oxidative 
phosphorylation. Compared to pathogenic 
chlamydiae, additional genes for amino acid 
metabolism and a complete menaquinone 
biosynthesis pathway could be identified in the 
UWE25 genome. Nevertheless, UWE25, like 
all obligate intracellular bacteria, shows 
reduced metabolic capabilities and exhibits a 
dependence on host-derived metabolites, like 
nucleotides, many amino acids, cofactors and 
vitamins. Interestingly, the cell envelope of 
UWE25 resembles the unique cell envelope of 
pathogenic chlamydiae to a certain extent. Like 
pathogenic chlamydiae, UWE25 possesses an 
outer membrane with cysteine rich proteins, 
and a 3-deoxy-D-manno-octulosonic acid 
(KDO) transferase, which accounts for the 
chlamydia-specific lipopolysaccharide. In 
addition, also several virulence-associated 
genes of pathogenic chlamydiae are encoded in 
the UWE25 genome. These include putative 
inclusion proteins, a type IH secretion system, 
the chlamydial protease-like activity factor 
(CPAF), and three homologues of the heat 
shock protein GroEL. Genes present in 
UWE25, but absent from pathogenic 
chlamydiae include among others a type TV 
secretion system. 
Taken together, environmental chlamydiae 
seem to be more versatile concerning their 
biology than their pathogenic relatives, 
although they show many characteristics of the 
typical chlamydial biology. This greater 
biological independence correlates with the 
changing conditions environmental chlamydiae 
experience in their amoebic host cells. These 
investigations and further research on the 
biology of environmental chlamydiae will help 
to understand the unique biology of 
chlamydiae and even how its evolution. 
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CHARACTERIZATION OF THE CELL ENVELOPE OF THE 
ENVIRONMENTAL CHLAMYDIA UWE25 
Eva Heinz*, Stephan Schmitz-Esser, Astrid Collingro, Michael Wagner, 
and Matthias Horn 
Department of Microbial Ecology, University of Vienna, Vienna, Austria 
Chlamydiae have long been considered 
a unique, coherent bacterial group comprising 
only few closely related species all of which 
are important pathogens of animals and 
humans. The recent finding of chlamydia-
related bacteria in the environment 
dramatically changed our view on chlamydial 
diversity. The so-called environmental 
chlamydiae thrive within ubiquitous, free-
living amoebae and were classified into the 
new family Parachlamydiaceae. All 
recognized chlamydiae possess a unique and 
unusual cell envelope that is most important 
for interaction with their eukaryotic host cells. 
Genome sequencing of the 
Parachlamydia-related environmental 
chlamydia strain UWE25 revealed the 
presence of two major components of the 
chlamydial outer membrane complex, the 
cysteine-rich proteins OmcA and OmcB, while 
no homologue of the major outer membrane 
protein (MOMP) could be detected. In 
addition, no homologues, or respective motifs 
of polymorphic outer membrane proteins of 
Chlamydiaceae could be identified. In order to 
further characterize the major components of 
the UWE25 cell envelope, membrane fractions 
are currently being analyzed using SDS-PAGE 
and MALDI-TOF. 
Comparative analysis of the cell 
envelope composition of environmental 
chlamydiae and Chlamydiaceae will provide 
further insights into their adaptation to their 
respective host cells and into determinants 
required for virulence in higher eukaryotes. 
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CHARACTERIZATION OF NUCLEOTIDE TRANSPORT PROTEINS OF THE 
ENVIRONMENTAL CHLAMYDIA UWE25 
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Urbany2, Michael Wagner1, H. Ekkehard Neuhaus2, and Matthias Horn1 
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Recently an ATP/ADP translocase 
(NTT1) has been identified in the 
Parachlamydia-related endosymbiont UWE25 
£>f Acanthamoeba sp. by an arbitrary PCR 
approach, suggesting that environmental 
chlamydiae use similar strategies to interact 
with their host cells as pathogenic chlamydiae. 
ATP/ADP translocases catalyze the highly 
specific transport of ATP across a membrane 
in an exchange mode with ADP. Such unique 
transport proteins are employed by plant 
plastids and have among the prokaryotes so far 
only been identified in few obligate 
intracellular bacteria belonging to the 
Chlamydiales and the Rickettsiales. 
Analysis of the complete genome 
sequence of UWE25 revealed four additional 
genes coding for putative nucleotide transport 
proteins (NTT2-5). Comparative sequence 
analysis, heterologous gene expression and 
transcriptional analyses were performed in 
order to elucidate the role and function of these 
putative membrane carriers. We demonstrate 
that, like its pathogenic counterparts, UWE25 
possesses a nucleotide triphosphate/H+ 
symporter (NTT2) in addition to an ATP/ADP 
translocase (NTT1). Furthermore, biochemical 
characterization revealed NTT4 to be the first 
known specific NAD+ transport protein found 
among bacteria and eukaryotes, importing 
NAD+ in exchange with ADP. All five ntt 
genes are transcribed during intracellular 
growth of UWE25 in its amoeba host. 
Our findings revealed a unique adaptation of 
UWE25 to intracellular life. Since nucleotide 
transport proteins are unique to few obligate 
intracellular bacteria and plant plastids, these 
-proteins could be well suited as target for the 
development of new antibiotics or herbicides. 
BIOLOGY - 27 
INTERACTION OF CHLAMYDIA TRACHOMATIS WITH THE HOST CELL 
TRAFFICKING PATHWAYS -STUDIES WITH USE OF RNA INTERFERENCE 
(SIRNA-APPROACH) 
Anette Rejman Lipinski*, Dagmar Heuer, Thomas F. Meyer, Agnes J. Szczepek 
Max-Planck-Institute for Infection Biology, Berlin, Germany 
Chlamydiae are obligate intracellular 
bacterial pathogens that survive in a 
membrane-bound vacuole termed inclusion. It 
was shown, that sphingomyelin and cholesterol 
are transported to the chlamydial inclusion [1, 
2], The host and chlamydial pathways 
regulating trafficking to the inclusion have not 
been identified yet. RabGTPases are key 
regulators of host membrane trafficking. Over 
60 members of RabGTPases were identified in 
human genome. Rab's cycle between a 
cytoplasmic, GDP-bound inactive state and a 
membrane-associated, GTP-bound active state. 
They regulate membrane trafficking at 
multiple steps: budding of vesicles, transport, 
docking and fusion with the target membrane 
[3]. 
We hypothesized, that Chlamydia trachomatis 
intercepts host vesicular pathways for the 
maintenance of the inclusion membrane. To 
singularize which of the host proteins and 
consequently, which of the host vesicular 
compartments interacts with the chlamydial 
inclusion, we used RNA interference. 
We have designed and validated 
siRNA, which targeted several Rab-proteins. 
Next, we transfected HeLa cells with the 
synthetic siRNA and estimated possible toxic 
effects using metabolic viability test WST-1. 
The siRNA's selected this way were next used 
in the infection experiments. HeLa cells were 
transfected with siRNA and 48h later cells 
were infected with Chlamydia trachomatis 
serovar L2. One day after infection, phenotype 
of chlamydial inclusions was determined. 
Additionally, we are presently estimating 
levels of chlamydial proteins using 
immunoblotting and determining infectivity of 
the chlamydial progeny grown in siRNA-
treated cells. 
Of all siRNA tested so far, we observed 
obvious phenotypic changes in the chlamydial 
inclusions, which developed in cells depleted 
of RabllA. These inclusions appeared 
enlarged and deformed in comparison with 
inclusions developed in cells treated with a 
non-functional siRNA (Luciferase). A further 
characterization of this different phenotypes is 
being performed. 
Our data show that some of the Rab 
GTPases could be essential for the 
development of Chlamydia trachomatis within 
the host cell. This suggests that Rab's may play 
an important role in trafficking or fusogenic 
properties of the inclusion. 
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CHLAMYDIAL INTERACTION WITH THE HOST AUTOPHAGIC 
PATHWAY 
Hesham M. Al-Younes,1* Volker Brinkmann,2 and Thomas F. Meyer1 
Department of Molecular Biology,1 and Central Microscopy Unit,2 Max Planck Institute for 
Infection Biology, Berlin, Germany 
Chlamydiae are obligate intracellular 
pathogens that replicate within a membrane-
bound compartment, called an inclusion. 
We have examined the interaction of 
the host autophagic pathway with Chlamydia 
trachomatis serovar L2 using the specific 
autophagosomal stain monodansylcadaverine, 
antibodies against autophagosome-associated 
markers and autophagic inhibitors, particularly 
3-methyladenine and certain single amino 
acids. 
The chlamydial inclusion did not 
sequester monodansylcadaverine, suggesting 
absence of fusion with autophagosomes. 
Interestingly, exposure of cultures infected for 
19 h to 3-methyladenine or amino acids until 
the end of infection (44 h) caused varying 
degrees of abnormalities in the inclusion 
maturation and in the progeny infectivity. 
Incubation of host cells with chemicals 
throughout the entire period of infection 
modulated the growth of Chlamydia even more 
dramatically. Further, autophagosomal markers 
MAP-LC3 and calreticulin were found in close 
proximity to the inclusion. 
Collectively, The present data indicate the lack 
of autophagosomal fusion with the inclusion, 
as it was devoid of monodansylcadaverine. 
However, high sensitivity of Chlamydia to 
conditions that inhibit autophagy and the close 
association of MAP-LC3 and calreticulin with 
the inclusion membrane, suggest a potential 
role of host autophagy in the pathogenesis of 
Chlamydia. 
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EUO: A POTENTIAL MARKER FOR PERSISTENT CHLAMYDIA 
TRACHOMATIS AND CHLAMYDIA PNEUMONIAE INFECTIONS 
S. P. Ouellette*, A. L. Douglas, G. I. Byrne, and T. P. Hatch 
Dept Molecular Sciences, Univ of Tennessee Health Science Center, Memphis, USA 
To investigate EUO gene transcription 
and protein levels in C. pneumoniae AR39 
0Cpn\ both) and C. trachomatis L2 (Ct; protein 
only) in tissue culture models of persistence. 
EUO is a prototypic early gene product 
in that it is transcribed soon after infection of 
the host cell; its function is unknown. It binds 
to AT-rich DNA in vitro and appears to be a 
quantitatively minor protein even at maximal 
times of expression (1). In IFN-y induced 
abnormal Ct infections, EUO is the only 
known DNA binding protein the transcription 
of which is highly up-regulated (2), implying 
that EUO may be a global regulator of 
persistent infection. However, little is known 
about the protein levels of EUO in persistent 
Ct infections and about the transcript and 
protein levels in Cpn infections. 
Total RNA was isolated from Cpn 
infected cells at 48hrs post-infection (pi) by the 
Trizol method and purified according to the 
scheme of Belland et al. (3). Total DNA was 
isolated from parallel cultures using the 
Qiagen DNeasy Tissue kit. Primer probe sets 
were designed for Cpn euo, ompA, and omcB 
with Primer Express and validated using 
genomic DNA. Quantitative RT-PCR was 
performed on samples using the ABI 7000 
sequence detection system. Data were 
normalized to the number of chlamydial 
genomes. 
Infected cells were fixed at various times pi 
with methanol and stained with anti-EUO, 
anti-MOMP, and/or anti-OmcB for 
immunofluorescence (IFA). 
By qRT-PCR, we found that euo 
transcripts increased approximately 21-fold in 
IFNy-treated HEp-2 cells infected with Cpn 
but did not increase in cells treated with 
penicillin. Conversely, ompA transcripts 
decreased in IFN-y but not penicillin-treated 
samples. omcB transcripts were decreased in 
both samples indicating a persistent phenotype 
had been achieved. 
EUO protein was absent in Ct and Cpn 
EBs but present within infected cells before 
full conversion to RBs. Most intense staining 
was seen early in the RB replication phase for 
both species. CY-infected HeLa cells treated 
with IFNy or penicillin or starved for 
tryptophan reacted with anti-EUO Ab to a 
much greater degree at 24-48hrs pi than 
normal inclusions in untreated cells. Anti-EUO 
Ab reacted with I F N - Y A N D penicillin-induced 
abnormal forms of Cpn from 24-72hrs pi, 
times at which EUO was barely detectable in 
normal inclusions. MOMP staining was less 
intense in persistent cultures as compared to 
normal, untreated cells whereas OmcB was 
completely absent. 
Our results indicate that EUO is present 
in greatest amounts at early times pi in normal 
infections and remains at late times pi in 
persistently infected cells. The binding of EUO 
to the promoter region of the late stage 
cysteine rich operon (omcAB) in vitro (1) 
suggests that EUO may function to repress late 
gene transcription early in normal infections 
and at all times during persistent infections. 
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THE PRESENCE OF SIGMA FACTORS AND SIGMA REGULATORS 
DURING THE DEVELOPMENTAL CYCLE OF CHLAMYDIA TRACHOMATIS 
L2 
T. P. Hatch* and A. L. Douglas 
University of Tennessee, Health Sciences Center, Memphis, Tennessee, U.S.A. 
The genomes of all chlamydial strains 
sequenced to date encode a major sigma factor, 
Sig66, and two alternative sigmas, Sig28 and 
Sig54. The genomes also encode putative 
regulators of Sig28 activity (Anti-sigma factor 
RsbW; Anti-anti-sigma factors RsbVl, V2; 
Sigma regulator phosphatase RsbU). Our 
objective was to detect the presence of the 
three sigma factors and the Sig28 regulators 
and thus their potential to regulate gene 
expression during the developmental cycle. 
We generated rabbit polyclonal 
antibodies to recombinant C. trachomatis L2 
sigma factors and sigma regulators and 
detected the presence of the native proteins in 
EBs and RBs by immunofluorescence assay 
(IFA). An advantage of the IFA assay is its 
ability to detect antigen at early hours 
postinfection (hpi) in individually infected 
cells when the total number of chlamydiae 
represents a negligible biomass within in the 
infected cell population. 
We detected MOMP, OmcB (a 
prototypic late gene product found in EBs), 
Sig66, Sig54, and EUO (a prototypic early 
gene product not present in EBs) and, to a 
lesser degree, RsbVl, at 4 hpi by IFA, when 
most EBs had not completed their 
reorganization to dividing RBs. Sig66, 
MOMP, EUO, and residual OmcB (from 
infecting EBs) were prominent by 10 hpi in 
inclusions containing 4-to-10 large, dividing 
RBs. Sig28, Sig54, RsbVl, V2, W, and U were 
also detected, but barely above background 
levels. As the infection progressed from 16 to 
24 hpi, the three sigma factors, the Sig28 
regulators, and OmcB became more prominent 
relative to EUO, which steadily declined but 
was still detected at 24 hpi. The intensity of IF 
staining declined for Sig66, Sig28, and the 
Sig28 regulators between 30 and 48 hpi but 
remained high for Sig54 through the terminal 
stage of the cycle. Only Sig54 and MOMP 
were consistently detected in isolated EBs. 
To increase the accessibility of antibodies to 
the cytoplasm of EBs, the disulfide-crosslinked 
EB cell envelopes were treated with reducing 
agents in 0.05% Nonidet-P40 nonionic 
detergent. This treatment greatly enhanced 
reaction of the Sig66, OmcB, and RsbVl 
antisera with isolated EBs; Sig28, RsbW, V2 
and U remained undetectable. 
The three chlamydial sigma factors and the 
Sig28 regulators were detected in dividing RBs 
early in the replicative phase through at least 
early in the late phase of the cycle; thus, all 
three sigma factors have the potential to 
regulate gene expression at these times. The 
apparent absence of Sig28 in EBs and during 
the first few hours of infection suggests Sig28 
does not direct gene transcription at the two 
extreme time points in the developmental 
cycle. In contrast, Sig66 and Sig54, in addition 
to being detected during the replicative phase, 
were detected in isolated EBs and intracellular 
EBs before they had converted to RBs. The 
presence of Sig66 and Sig54 in EBs suggests 
that they possess the potential to initiate gene 
transcription either very early or very late in 
the cycle, or at both times. 
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FUNCTIONAL IDENTIFICATION OF o28-REGULATED GENES IN 
CHLAMYDIA 
Yu, Hilda H.Y.1*, Lee, Sean3, Kibler, Dennis3, and Tan, Ming1'2 
1 2 3 
Departments of Microbiology and Molecular Genetics, Medicine, and Information and 
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Chlamydia is predicted to regulate gene 
expression with two alternative forms of RNA 
polymerase in addition to the major RNA 
polymerase. We have previously demonstrated 
that an alternative RNA polymerase containing 
a28 is active in Chlamydia, and transcribes a 
developmentally regulated gene, hctB. As hctB 
28 
is only expressed at late time points, o RNA 
polymerase appears to have a role in the 
transcription of late genes. 
To identify additional o28-regulated 
genes, we have developed a computer 
algorithm that generates a weighted probability 
28 N matrix based on known a promoter 
sequences in other bacteria. 
Using this algorithm, we have 
identified candidate a28 promoters in C. 
28 
trachomatis and tested them with our a in 
vitro transcription assay. 4 out of 10 promoters 
tested were transcriptionally active, and (In-
dependence was shown by specific inhibition 
with anti-G28 antibodies. We also identified an 
active <5 promoter with an overlapping o 
promoter that was also active, demonstrating 
for the first time that a chlamydial gene can be 
regulated by tandem promoters transcribed by 
different forms of RNA polymerase. 
This approach, which utilized a 
bioinformatics analysis and a functional assay, 
has allowed us to identify o28-regulated genes 
and to begin to define the role of cr28 RNA 
polymerase in regulating gene expression in 
Chlamydia. 
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THE INTERACTION OF ANTI-SIGMA RSBW WITH SIG28 AND ANTI-ANTI-
SIGMAS RSBV1 AND RSBV2 
A. L. Douglas* and T. P. Hatch 
University of Tennessee Health Sciences Center, Memphis, Tennessee, US 
Objective: To determine the interaction of the 
putative C. trachomatis anti-sigma factor 
RsbW with chlamydial RsbV proteins and 
Sig28. 
The genome of C. trachomatis L2 
contains genes for the expression of three 
sigma factors, Sig66, Sig28, and Sig54, and for 
four putative regulators of sigma factor 
activity, RsbW, VI, V2, and U. In B. subtilis, 
the anti-sigma factor RsbW binds to a cognate 
sigma factor and keeps it from binding to 
promoters. RsbW also is able to bind to non-
phosphorylated anti-anti-sigma RsbV in B. 
subtilis, freeing the sigma factor to initiate 
transcription. In addition, RsbW is a kinase, 
which phophorylates RsbV upon binding to it, 
resulting in the release of W from V. RsbU is a 
phosphatase, which returns RsbV to the non-
phosphorylated state capable of binding to 
RsbW. The purpose of our study was to 
demonstrate that C. trachomatis RsbW 
interacts with chlamydial RsbV proteins and 
with chlamydial Sig28 and thus is likely to be 
an anti-sigma factor. 
Sig28 and the sigma regulator genes 
were overexpressed as His-tag and GST-
fusions. Antibodies were generated in rabbits 
with the His-tag proteins as antigens. GST 
pulldowns were performed by combining a 
GST-fusion with other proteins, the bound 
complexes were incubated with glutathione 
Sepharose beads, the beads were washed, and 
the complexes were analyzed by Western blot. 
For kinase reactions, recombinant proteins 
were incubated with 32P-y-ATP, separated on 
SDS-PAGE gels, and the gels were dried and 
analyzed by autoradiography. 
RsbW-GST bound to His-Sig28, as 
determined by pulldown assay. Binding was 
most efficient at 37°C and was undetectable at 
4°C. His-Sig28 did not associate with beads in 
the absence of RsbW-GST, indicating that the 
interaction of Sig28 with RsbW was specific. 
RsbW-GST-beads also pulled down His-
RsbVl and His-RsbV2, when incubated with 
these proteins. Reciprocal experiments were 
also performed. Both Sig28-GST and RsbVl-
GST were found to bind to recombinant His-
RsbW. However, for unknown reasons, 
RsbV2-GST failed to interact with His-RsbW. 
His-tag and RsbW-GST were found to possess 
kinase activity by demonstrating the transfer of 
the terminal phosphate of 32P-y-ATP to 
recombinant RsbVl and V2. Sig28 was not 
similarly phosphorylated, indicating that Sig28 
is not a substrate for the kinase activity of 
RsbW. The addition of 32P-y-ATP to extracts 
of C. trachomatis RBs resulted in the labeling 
of several proteins on SDS-PAGE gels, 
including proteins that co-migrated with 
RsbVl and RsbV2. The intensity of labeling of 
these bands was increased upon the addition of 
recombinant RsbW to extracts, suggesting that 
RsbW can phosphorylate native forms of VI 
and V2 and that the native forms may not be 
phosphorylated or are only partially 
phosphorylated in RBs. 
Our in vitro binding and enzyme assays 
suggest that C. trachomatis RsbW is an anti-
sigma factor and RsbVl and RsbV2 are anti-
anti-sigma factors for the Sig28. 
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INTERFERON y PRODUCTION BY HUMAN NATURAL KILLER CELLS IN 
RESPONSE TO CHLAMYDIA TRACHOMATIS INFECTION 
Natasha Telyatnikova*, Malgosia K Matyszak, Jane C Goodall, and JS Hill Gaston 
Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's 
Hospital, Cambridge, UK 
Interferon y plays a crucial role in the 
control of Chlamydia trachomatis (CT) 
infections in both mice and humans. It can 
directly inhibit chlamydial replication via 
multiple mechanisms as well as direct the 
development of the Thl response. It has 
previously been demonstrated that natural 
killer (NK) cells are an important early source 
of this cytokine during bacterial infections, 
including intravaginal infection of mice with 
Chlamydia muridarum. However, the role of 
NK cells during human chlamydial infections 
has not been fully elucidated. The objective of 
this study is to investigate interferon y 
production by human NK cells in response to 
infection with CT. 
Peripheral blood mononuclear cells 
(PBMC) were isolated from the blood of 
healthy donors using density centrifugation 
over Ficoll-Paque. A highly purified 
population of NK cells was isolated by 
negative selection using magnetic cell 
separation system (Miltenyi Biotec). Dendritic 
cells (DCs) were generated from CD14+ 
monocytes by differentiation in vitro with IL-4 
and GM-CSF. Interferon y production was 
measured by ELISA of culture supernatants 
and intracellular staining using flow cytometry. 
Infection was carried out with the optimal 
concentration of Chlamydia trachomatis 
serovar L2 elementary bodies (EBs). 
Our initial observations showed that 
infection of PBMC with CT EBs resulted in 
production of high levels (33ng/ml) of 
interferon y as early as 14 hours post-infection. 
Further analysis by flow cytometry revealed 
that the major cellular source of this cytokine 
was CD3" CD56+ NK cells. We were able to 
demonstrate consistently that overnight 
stimulation with chlamydia EBs leads to 
interferon y production by 10-30% of CD56+ 
NK cells. Moreover, depletion of CD3+ cells 
from co-culture of PBMC with chlamydia did 
not alter the levels of interferon y production 
by NK cells thus confirming that the CD3+ 
cells are not the crucial players during early 
cytokine response to chlamydia. On the other 
hand, depletion of CD14+ monocytes resulted 
in complete abrogation of NK cell interferon y 
production. This suggests that infection of 
antigen presenting cells is required. To further 
characterize the recognition of chlamydia 
infection by NK cells, we used DCs infected 
with live chlamydia and co-cultured with 
purified NK cells. CT-infected DCs were 
indeed able to stimulate interferon y 
production by NK cells albeit at a lower 
frequency. The role of macrophage-derived IL-
15 and IL-18 in the higher levels of interferon 
y production by NK cells in PBMC stimulated 
with EBs is currently under investigation. 
Control DCs activated with LPS did not 
stimulate interferon y production by NK cells 
above background levels. Therefore, the high 
levels of interferon y production by NK cells 
were not solely due to chlamydial LPS 
activation of DCs. Preliminary studies with a 
blocking antibody to the NKG2D receptor 
suggest that it may be involved in the 
activation of NK cells by chlamydia-infected 
DCs. 
Human NK cells are able to recognize 
chlamydia-infected macrophages and dendritic 
cells leading to early production of interferon 
Y-
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CHLAMYDIAL HSP60 AUTO-REGULATES ITS OWN EXPRESSION 
THROUGH INTERACTIONS WITH THE HRCA REPRESSOR PROTEIN 
Adam Wilson* and Ming Tan 
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Sciences, Irvine, USA 
A key factor in the development of 
chlamydial disease is the chlamydial heat 
shock protein GroEL (Hsp60), a ubiquitously 
expressed protein whose expression is up-
regulated in response to cellular stress. The 
host immune response to the chlamydial heat 
shock proteins has been implicated in 
chlamydial pathogenesis, and antibodies to 
GroEL have been associated with the long-
term morbidity of chlamydial infections 
We have defined a mechanism of heat 
shock gene regulation in chlamydia that entails 
transcriptional repression through a repressor 
protein, HrcA that binds to a cis-acting DNA 
element called CIRCE. Recombinant C. 
trachomatis HrcA binds to CIRCE elements 
upstream of the dnaK and groE promoters and 
represses transcription of both these heat shock 
promoters. We have determined that HrcA-
mediated repression is modulated by GroEL, 
indicating heat shock gene regulation by 
negative feedback. 
Native HrcA purified by DNA affinity 
chromatography co-purified with additional 
chlamydial proteins, among these co-purifying 
proteins was GroEL. Native HrcA also 
produced a different gel mobility shift 
compared to recombinant HrcA, and 
chlamydial GroEL was a component of this 
lower mobility complex. Chlamydia contains 
three GroEL paralogs, but only recombinant 
GroEL 1 stimulated HrcA function as shown by 
increased binding of HrcA to CIRCE and 
repression of in vitro transcription. Neither 
GroEL2 nor GroEL3 had an effect on HrcA 
activity. 
From these results, we propose that 
GroEL 1 autoregulates its own transcription by 
promoting the interaction between HrcA and 
CIRCE and providing a mechanism for the 
regulation of heat shock genes in chlamydia. 
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EFFECT OF PLASMID CURING AGENTS ON CHLAMYDIA TRACHOMATIS 
M. A. Pickett*, J. S. Everson, P. J. Pead, N. S. Thomas and I. N. Clarke 
Molecular Microbiology Group, Division of Infection, Inflammation and Repair, 
School of Medicine, University of Southampton, UK 
To determine the effect of plasmid 
curing agents on Chlamydia trachomatis, by 
using quantitative PCR to assay for plasmid 
and chromosomal markers. 
Curing agents are toxic to both 
prokaryotic and eukaryotic cells. The 
minimum inhibitory concentration (MIC) of 
each curing agent for uninfected BGMK cells 
was determined by culture in the presence of 
increasing amounts of the chemical. The MIC 
was defined as the lowest concentration of 
agent causing detectable cell rounding and 
detachment from the monolayer. 
Cultured BGMK cells were then infected with 
C. trachomatis L1/440/LN and passaged 
several times in tissue culture medium 
containing plasmid curing agent at levels 
below the MIC. Acridine orange and ethidium 
bromide were used alone, but novobiocin and 
imipramine were combined. 
Samples were heated with ammonia solution 
(2M) at 96°C for lhr in an open tube to release 
bacterial DNA with subsequent neutralization 
by evaporation of the alkali. Quantitative PCR 
was performed using TaqMan chemistry in an 
ABI PRISM 7700 Sequence Detection System. 
Primers and probes matching the chlamydial 
omcB gene, which maps to the bacterial 
chromosome, and chlamydial plasmid 
(pLGV440) were used. Purified recombinant 
plasmids containing the omcB gene or the 
chlamydial plasmid were used as assay 
standards. Chlamydial plasmid copy number is 
defined as the ratio plasmid /omcB. 
The MICs for cultured BGMK cells 
were as follows: novobiocin (25pg/ml), 
imipramine (25pg/ml), ethidium bromide 
(250pg/ml) and acridine orange (25pg/ml). 
Concentrations of curing agent up to 80% of 
these values were used in the chlamydial 
infection experiments. 
When chlamydiae were grown in the absence 
of curing agent, the ratio plasmid/omcB, 
i.e. plasmid copy number, was calculated as 
4.1 plasmid copies per bacterial chromosome. 
When a combination of novobiocin (20pg/ml) 
and imipramine (20pg/ml) was added to the 
tissue culture medium, the plasmid copy 
number increased to 6.5. When acridine orange 
(20|ig/ml) or ethidium bromide (200pg/ml) 
was added, the plasmid copy number increased 
to 12.5 and 31.1 respectively. 
Although light microscopy indicated that 
BGMK cells were unaffected by curing agent 
at concentrations up to the MIC, chlamydial 
growth was inhibited. OmcB yields were 
reduced up to 10-fold by acridine orange and 
100 fold by ethidium bromide. 
The quantitative PCR assay results were 
unaffected by the addition of exogenous 
acridine orange or ethidium bromide. The 
sensitivity of the assay was unaffected by the 
degree of supercoiling in plasmid templates. 
As there have been several reports of 
naturally-occurring isolates of C. trachomatis 
lacking the cryptic plasmid, we decided to 
investigate the effect of plasmid curing agents 
on this species. The agents used in this work 
have been used previously, with variable 
success, to cure both gram-positive and gram-
negative bacteria of their plasmids. Plasmid 
curing in obligate intracellular organisms has 
not been reported. Nevertheless, transport of 
curing agent to the inclusion is suggested by 
the inhibition of chlamydial growth. This 
quantitative PCR assay has enabled the 
detection of small changes in average plasmid 
copy number. The apparent increase in 
plasmid copy number was unexpected but may 
suggest the induction of a chlamydial SOS-like 
response by these chemical agents. 
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LONG-TERM EFFECTS OF ELEVATED CONCENTRATIONS OF AMINO 
ACIDS ON CHLAMYDIA INFECTION IN VITRO 
Joscha Gussmann*, Hesham M. Al-Younes and Thomas F. Meyer 
Max Planck Institute for Infection Biology, Department of Molecular Biology, Berlin, Germany 
We recently found that the amino acids 
leucine, isoleucine, methionine, serine and 
phenylalanine markedly modulated acute in 
vitro chlamydial infection. Exposure of host 
cells to excess individual amino acids arrested 
the inclusion maturation and inhibited the 
progeny infectivity. In the present study, we 
investigated the long-term effects of these 
amino acids on Chlamydia infection in vitro. 
longer than 5 days led to total prevention of 
infectivity restoration by amino acid removal. 
Viability of bacteria in prolonged exposure 
experiments is currently investigated by RT-
PCR. 
A cell culture was infected with 
Chlamydia and subsequently treated with 
excess amounts of leucine, isoleucine, 
methionine, phenylalanine or serine. Influence 
of amino acids on bacterial development was 
examined for up to 10 days post-infection 
using microscopic techniques and infectivity 
assays. 
Infected cell monolayers exposed to 
individual amino acids remained intact and 
negligibly detached during the whole period of 
experiments, unlike untreated infected cells, 
which detached almost completely within 4 
days after infection. Treatment with leucine, 
isoleucine or methionine generated very small 
aberrant inclusions that did not increase in size 
over time. Moreover, these amino acids totally 
inhibited the production of infectious progeny, 
whereas phenylalanine and serine were less 
effective in inhibiting the infectivity. 
Ultrastructural analysis revealed the presence 
of morphologically atypical reticulate bodies 
that were sometimes distorted. Infectivity was 
partially recovered when excess amino acids 
were withdrawn within the first 4 days of 
exposure but not later. 
The data confirms the efficiency of 
certain amino acids to suppress the chlamydial 
development. Prolonged treatments for periods 
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THE EFFECTS OF NITRIC OXIDE ON CHLAMYDIAE INFECTION IN 
SMOOTH MUSCLE CELLS 
Tsun-Mei Lin1*, Yi-Ling Chen1, Hock-Liew Eng2 
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Cheng Kung University, Tainan, Taiwan, Department of Pathology, Chang Gung University and 
Memorial Hospital, Kaohsiung Medical Center, Kaohsiung, Taiwan, Republic of China 
The pathogenicity of intracellular 
bacteria of the genus Chlamydia has been 
corrected with its ability to survive and 
develop within cells. Altered production of 
nitric oxide (NO), a known bactericidal and 
anti-inflammatory agent represents possible 
mechanistic links to persistent infection, 
restricting complete chlamydial development 
during infection. Smooth muscle cells (SMC) 
may be important targets of C. pneumoniae 
infection for airway remodeling in chronic 
asthma, bronchial inflammation, and 
atherogenesis. In this study we want to 
evaluate the NO effect on Chlamydia infection 
in SMC. 
The quality of NO production was 
evaluated by chemical assay and 
immunohistochemical stain in murine smooth 
muscle cells, A7r5 infection of C. pneumoniae 
strain TW183. NO donor, SNP (sodium 
nitroprusside), and NOS inhibitor, L-NAME 
treatment were used to determine the important 
role of NO on Chlamydia infection in SMC. 
Decreased production of NO in the 
early phase (< 24 h postinfection), but 
increased in the late phase. SNP pretreatment 
can reduce chlamydial inclusion-forming units 
by 2 loglO units compared with control values. 
In contrast, adding L-NAME enhanced the 
chlamydial growth. The NO effect is more 
specific important in the early phase of 
chlamydial development. 
These results identified the important 
role of NO in restricting C. pneumoniae 
survival and development in SMC at early 
phase, indicating that NO is a necessary 
effecter molecule of SMC involved in the 
mechanisms that regulates whether there is a 
pathogenic or protective response to 
chlamydial infection. 
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CHLAMYDIA PROTEOMICS 
Gunna Christiansen, Svend Birkelund and Brian BS Vandahl 
Institute of Medical Microbiology and Immunology, University of Aarhus, Aarhus, Denmark 
The objective of the present presentation is to 
review results obtained by chlamydial 
proteomics. 
The task of proteomics is a direct investigation 
of proteins in their post-translationally 
modified and processed form present in a 
given biological compartment at a specific 
time and in a defined environment. Proteomics 
is used to describe the investigation of proteins 
and can be approached in various ways but in 
principle it involves two steps: separation of 
the proteins in a sample followed by 
identification of the proteins. 
At present the most used method is separation 
of proteins by two-dimensional polyacrylamide 
gel electrophoresis (2-D PAGE) followed by 
identification of individual protein spots by 
mass spectrometry. 
In the first dimension the sample is loaded 
onto an acrylamide gel-strip with an 
immobilized pH gradient (IPG) [Bjellquist et 
al. 1982], Focusing of the proteins at the pH 
where they carry no net charge (their pi) is 
obtained by the application of a high voltage 
over the strip. Samples are loaded onto the IPG 
strip either by rehydration of a dried IPG strip 
or during focusing by point application onto a 
rehydrated IPG. Loading by rehydration with a 
low voltage improves the recovery of high 
molecular weight proteins and hydrophobic 
proteins [Zuo and Speicher, 2000]. In the 
second dimension the strip with the isoelectric 
focused proteins is placed on top of a 
polyacrylamide gel in which the proteins can 
be separated according to their molecular size 
by SDS gel electrophoresis. The proteins can 
be visualized by a variety of staining pro-
cedures or by autoradiography if the sample is 
radiolabeled. Sample preparation is crucial in 
2-D PAGE as the proteins must be denatured, 
reduced and solubilized throughout electro-
phoresis without change in pi. It is the aim to 
obtain the best possible coverage of the protein 
content of the investigated organism, but no 
single solubilization procedure or sample 
buffer will be optimal for every protein in a 
sample. The standard 2-D sample buffer is 
based on urea and contains detergent, reducing 
agent and carrier ampholytes that helps 
keeping proteins soluble during the isoelectric 
focusing. Limited solubility of highly 
hydrophobic proteins has been a problem in 2-
D PAGE but the introduction of thiourea to the 
buffer has markedly improved the results 
[Rabilloud et al. 1998]. An additional benefit 
of thiourea of importance for bacteria is that it 
inhibits proteases released from the 
periplasmic space that would be active in 
buffers containing urea [Castellanos-Serra and 
Paz-Lago, 2002], Another problem in 2-D 
PAGE is the relatively low recovery of basic 
proteins where incorrect focusing time may 
cause streaking. 
By mass spectrometry (MS) the masses of 
molecules are converted to gas phase ions that 
can be measured with an accuracy of 10-30 
ppm [Jensen et al. 1997]. MS identification of 
proteins is based on the comparison of peptide 
- or peptide fragment masses to corresponding 
masses calculated from translated gene 
database sequences. 
Mass spectrometers have three essential 
components: an ion source, a mass analyzer 
and a detector. The two most widespread 
techniques for ionization are matrix-assisted 
laser desorption/ionization (MALDI) [Karas 
and Hillenkamp, 1988] and electrospray 
ionization (ESI) [Fenn etal. 1989]. 
In MALDI, the analytes are deposited onto a 
target together with matrix molecules that 
absorb energy at the wavelength of the MS 
laser. By firing the laser at the mixture, the 
analyte is brought into the gas phase in an 
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ionized form [Gevaert and Vandekerckhove, 
2000], MALDI is coupled to a time of flight 
(TOF) device for measurement of the masses. 
The ionized peptides are accelerated by the 
application of an electrical field and the time 
of flight until they reach a detector is used to 
calculate their mass/charge ratio. 
In ESI the analyte in solution is sprayed from a 
very thin needle to which a potential is applied 
and upon evaporation of the solvent the analyte 
becomes charged. Thus, ESI can be coupled 
directly to liquid capillary (LC) separation 
equipment. This is known as LC-MS. 
To identify a protein from a gel the gel spot is 
excised and (in-gel) digested with an enzyme, 
most commonly trypsin, which cleaves after 
the basic residues lysine (K) and arginine (R). 
The peptides originating from the enzymatic 
digestion are eluted from the gel and purified 
using reversed phase material. Peptide masses 
are determined by MALDI-TOF. The obtained 
masses of the peptides constitutes the so-called 
peptide mass fingerprint (PMF), which can be 
used to search a protein database such as 
sequenced Chlamydia genomes translated into 
proteins and theoretically digested with the 
same enzyme as the protein [Mann et al. 
1993]. The quality score of the protein 
identification is based on the number of 
matching peptides relative to the size of the 
identified protein and the number of proteins 
in the searched database. In addition, the 
correspondence between observed and 
calculated molecular weight and isoelectric 
point should be evaluated. 
The genome sequence reveals the coding 
capacity of the genome and thus what proteins 
theoretically can be produced. The first 
sequenced Chlamydia genome was that of C. 
trachomatis D [Stephens et al. 1998] followed 
by C. pneumoniae CWL029 [Kalman et al. 
1999], both of which were results of the 
Chlamydia Genome Project (CGP) 
[http://chlamydia-www.berkeley.edu:4231/]. 
Later, also the genome sequence of C. 
muridarium [Read et al. 2000], two other 
isolates of C. pneumoniae [Read et al. 2000, 
Shirai et al. 2000] and recently that of C. 
caviae [Read et al. 2003] were published. The 
coding capacity is informative, but does not 
reveal information about when, where and in 
what quantities the genes are transcribed and 
whether the resulting proteins are modified or 
secreted. The high number of sequenced 
chlamydial genomes provides an excellent 
basis for comparative proteome analyses. 
It is not possible to use transformation to study 
chlamydial gene function but use of 
proteomics has been demonstrated valuable. 
During its intracellular growth host cell protein 
synthesis can be arrested by addition of 
cycloheximide to the culture medium, and thus 
labeling with [35S] methionine/cysteine will 
preferentially go into chlamydial proteins. 
Using this technique the chlamydial protein 
content, tum-over, regulation, cleavage and 
localization can be studied during the 
intracellular growth (see results). 
Reference maps 
The first proteome map of Chlamydia in the 
post genomic area was that of C. pneumoniae 
[Vandahl et al. 2001]. IPG strips were used in 
first dimension. To obtain the best possible 
recovery of hydrophobic proteins thiourea was 
present in the 2-DE buffer. By MS 263 protein 
spots representing 167 different genes were 
identified. The identifications are published on 
the internet at http://www.gram.au.dk in a 
searchable form and in the bacterial proteome 
database at the Max Planck Institute for 
Infection Biology [http://www.mphb-
berlin.mpg.de/2D-PAGE/], This proteome map 
can therefore serve as a global reference for 
further 2-D PAGE studies. In the acidic region 
there was good agreement between predicted 
and observed numbers of proteins, whereas 
recovery in the basic region was poor. The use 
of basic strips (pH 6-11) did not significantly 
improve the number of resolved protein spots 
but gave a better spatial distribution, which is 
important for analysis of the excised spots. 
Radiolabeling was chosen rather than staining 
to avoid purification of the chlamydiae. To 
cover the highest possible number of expressed 
proteins in one gel, two-hour labeling with 
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[35S] methionine/cysteine was done through-
out the developmental cycle. The samples were 
pooled [Vandahl et al. 2001] and thereby 
proteins synthesized at different stages during 
the developmental cycle were represented. As 
a consequence of this the actual protein 
amount in elementary bodies (EBs) was not 
necessarily reflected by the spot volumes. 
In addition to providing a reference map the 
study by Vandahl et al. [2001] showed 
expression of eight polymorphic membrane 
proteins (Pmps), presence of type HI secretion 
proteins in EBs (rendering probable that this 
secretion system is functional in EBs), 
presence of a high number of energy 
metabolizing proteins and proteins involved in 
transcription and translation. Furthermore, a 
number of "hypothetical" proteins were 
identified (31 out of 167) and many of these 
were abundant. One of the most abundant 
hypothetical proteins was Cpn0808 the gene of 
which is located close to the type HI secretion 
protein lcrHl on the genome. It was therefore 
speculated that this protein was loaded in EBs 
ready for secretion by type HI secretion upon 
contact with a future host cell [Vandahl et al. 
2001]. This hypothesis was further 
strengthened by the recent finding of Cpn0809 
in the cytoplasm of C. pneumoniae infected 
cells [Lugert et al. 2003], 
2-D reference maps were made for C. 
trachomatis A, D and L2 EBs [Shaw et al. 
2002a]. The maps showed the serovars to be 
very similar but there was also similarity to the 
C. pneumoniae proteome. As for the C. 
pneumoniae proteome the indentified proteins 
were the known outer membrane proteins, 
hypothetical proteins, type m secretion 
proteins, abundant Pmps and many proteins 
involved in transcription, translation and 
energy metabolism. Protein products from 134, 
133 and 127 different genes were identified in 
the three serovars, respectively, thereby 
providing well covered reference maps for 
further studies. Of the 144 protein species 
identified in all serovars, 55 migrated 
differently in serovars D and L2, 52 differed 
between A and L2 whereas only 26 differed 
between A and D. This reflects the similarity 
of the trachoma serovars A and D and that the 
LGV serovar L2 differs more from the 
trachoma serovars A and D. Most of the 
differences were small, probably caused by 
amino acid substitutions with no or limited 
biological implications. Some proteins with 
identical sequences were found to migrate 
differently (i.e. GroES migrated more basic in 
serovar D than in L2) indicating difference in 
their posttranslational modification. Fumarate 
hydratase (FumC) is absent in L2. In vitro 
translation of the gene from L2 confirmed a 30 
kDa truncation. Malate dehydrogenase (MdhC) 
was remarkably more abundant in C. 
trachomatis L2 than in C. trachomatis A and 
D. MdhC is metabolically downstream of 
FumC in the tricarboxylic acid cycle and the 
two observations may therefore be linked, so 
that C. trachomatis 12 increases the MdhC 
activity for a more efficient utilization of 
malate obtained from the host cell to 
compensate for the FumC impairment [Shaw 
et al. 2002a]. 
Comparative proteomics 
Due to the unique biphasic developmental 
cycle it is of interest to identify proteins 
associated primarily with the intracellular stage 
of the chlamydial development. Shaw et al. 
[2002b] compared proteome profiles of whole 
cell lysates of infected cells (WLIC) with that 
of purified RB/EB and estimated the turnover 
of proteins. Thereby it was possible to identify 
proteins which were specific for the 
intracellular stage of chlamydial development. 
The 7 kDa reticulate body protein (Rbp_7) is 
an example of such a protein. Using 
comparative proteomics a protein secreted into 
the host cell cytoplasm was found. This protein 
was present in WLIC but absent from purified 
chlamydiae and was identified as CT858 of C. 
trachomatis and Cpnl016 of C. pneumoniae 
[Shaw et al. 2002c], These proteins were 
orthologs and known as the Chlamydia 
protease or proteasome like activity factor 
(CPAF) [Zhong et al. 2001], CPAF was 
originally identified by its property to down-
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regulate host cell transcription factors required 
for MHC class I and II presentation and 
subsequently confirmed to be secreted [Zhong 
et al. 2001]. The expression characteristics of 
CPAF in C. trachomatis A, D, L2 and in C. 
pneumoniae were characterized by 2-D PAGE 
[Shaw et al. 2002c]. In the host cell cytoplasm 
CPAF is present as two fragments and none of 
these could be detected after treatment with the 
protease inhibitor TPCK. Therefore, it was 
speculated that cleavage was required for the 
secretion of CPAF [Shaw et al. 2002c], The 
study by Shaw et al. [2002c] demonstrates how 
comparison of proteomes from different 
biological compartments (WLIC, RB, EB) can 
lead to the identification of potentially 
important pathogenicity factors. CPAF was 
predicted to be an outer membrane protein 
based on computer analysis [Stephens and 
Lammel, 2001]. The lack of specific molecular 
characteristics of secreted proteins illustrates 
the importance of supplementing genome 
analysis with additional investigations. 
Growth conditions 
Effects of variation in growth conditions on 
protein synthesis were studied by proteome 
analysis by Shaw et al. [1999 and 2000] who 
analyzed the effect of IFN-y treatment on 
different C. trachomatis serovars. IFN-y is a 
potent immunoregulator involved in the 
control of chlamydial infections and it may 
also be implicated in the development of 
chronic infections. Presence of IFN-y in the 
growth medium inhibits growth of chlamydiae 
and the developmental cycle is arrested with 
appearance of large atypical forms of RB 
especially in the trachoma serovars A-C. To 
visualize differences in proteome profiles 
caused by IFN-y treatment, HeLa cells infected 
with C. trachomatis A, D or L2 were 
cultivated in the presence or absence of IFN-y 
and [35S]-labeled 22-24 hours post infection. 
To reveal proteins that were up- or down-
regulated in response to IFN-
y, autoradiographs of the 2D-PAGE separated 
proteins were compared. Several proteins 
besides the major outer membrane protein 
(MOMP) were down-regulated compared to 
steady levels of GroEL. The down-regulation 
seemed to be rather general and not restricted 
to immunogens [Shaw et al. 1999]. 
Both TrpA and TrpB were found to be 
upregulated in serovars A, D and L2, but in 
serovar A, TrpA was identified at a lower 
molecular weight than expected and 
sequencing the gene revealed the protein to be 
truncated. Also in serovar C TrpA was found 
to be truncated while in serovar B it was 
impossible to amplify the gene by PCR 
indicating that the gene is missing from this 
serovar. Addition of tryptophan to the growth 
medium restored normal growth. As all ocular 
serovars have impaired trpA genes it was 
suggested that these proteins may be of 
importance for the pathogenicity of these 
serovars [Shaw et al. 2000], 
Proteomics of the chlamydial outer 
membrane complex 
Upon extraction of EBs with Sarkosyl (sodium 
lauroyl sarcosinate) an insoluble fraction is 
achieved which in electron microscopy appear 
as empty but apparently intact outer 
membranes of EBs. This fraction is termed the 
Chlamydia outer membrane complex (COMC) 
[Caldwell et al. 1981]. In all Chlamydia 
species, the most abundant protein in the 
COMC is MOMP. Besides MOMP, the 
cysteine rich proteins Omp2 and Omp3 were 
for many years thought to be the only structural 
components of the outer membrane and these 
were the only proteins detected in early 2-D 
PAGE studies of COMC [Caldwell et al. 1981, 
Moroni et al. 1996], In a model of the COMC 
of C. caviae Omp2 was placed in the 
periplasmic space disulfide cross linked to 
Omp3 which was suggested to be anchored in 
the outer membrane by its lipid moiety 
[Everett and Hatch, 1995]. 
1-D PAGE studies revealed that also proteins 
of approximately 98 kDa were present in C. 
pneumoniae COMC and recognized by 
immune sera [Melgosa et al. 1993]. PmplO 
and Pmpll , which migrate at 97-99 kDa, were 
later identified as outer membrane proteins of 
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C. pneumoniae and indicated to be surface 
exposed [Knudsen et al. 1999]. In addition to 
PmplO and Pmpll , Pmp2, 6, 7, 8 and 20 were 
identified in C. pneumoniae COMC by 2-D 
PAGE and MS [Vandahl et al. 2002] and in a 
more recent study also Pmp21 was found to 
besurface localized [Wehrl et al. 2004], Three 
of the Pmp proteins, Pmp6, 20 and 21 were in 
the reference map shown to be cleaved 
[Vandahl et al. 2001], 
Spikes protruding from the outer membrane of 
Chlamydia [Matsumoto, 1982a and b] 
including C. pneumoniae [Miyashita et al. 
1993] have been interpreted as part of a type 
HI secretion apparatus [Bavoil and Hsia, 1998, 
Hatch, 1998]. This interpretation was 
strengthened by the finding of the predicted 
outer membrane component of the type IH 
secretion system, YscC, in COMC [Vandahl et 
al. 2002], 
Proteomics as a complement for genomics 
A computer predicted translation start site in 
mRNA does not always correspond to the first 
amino acid in bacterial proteins and 
posttranslational processing may result in a 
mature protein very different from the one that 
can be predicted from the genome. Thus, in 
many cases, the correct N-terminal sequence 
must be determined experimentally. Examples 
of cleaved chlamydial proteins are the C. 
pneimoniae Pmp 6, 20 and 21 [Vandahl et al. 
2001] and CPAF in both C. pneumoniae and 
C. trachomatis [Shaw et al. 2002c]. 
In large genome sequencing projects, a 
molecular weight threshold for protein 
annotation is often used to avoid annotation of 
many false ORFs. Therefore genes encoding 
such small proteins may be overseen. Such a 
novel ORF (Rbp_7) not annotated in the C. 
trachomatis D genome was identified by Shaw 
et al. (2002b). 
Two-dimensional gel electrophoresis 
databases 
Ordered database systems are available for 
DNA sequences (EBI/NCBI) and for protein 
data (SwissProt). Analysis is facilitated by use 
of ExPASy (Expert Protein Analysis System), 
a www server dedicated to molecular biology 
[Hoogland et al. 1999]. The server provides 
access to proteomics databases, tools and 
services. When "clicking on a spot" in one of 
the 2-D maps, the information on the protein 
(isoelectric point, molecular weight, accession 
number and link to SwissProt) and all 2-D 
maps where the protein is identified are 
displayed. Furthermore, in SwissProt protein 
entries there are links to the 2D-databases of 
identified proteins. The Make 2D-DB package 
13 is developed to help build federated 2-DE. 
databases on one's own web site (Mostaguir et 
al. 2003). An overview of all 2-D PAGE 
databases and services can be seen 
http://www.expasy.org. 
The 2-D PAGE system in combination with 
MS remains an excellent choice for the global 
study of protein expression and protein 
processing. Combined with genomics and 
transcriptomics it will be possible in the future 
to study gene expression globally both in cell 
culture systems, in anamal models and in 
human infections. 
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The chlamydial developmental cycle may 
involve both an acute and a chronic or persistent 
phase. Persistence may lead to frequent re-
infection or develop into long-term sequelae of 
chlamydial disease. In vitro, the persistent phase 
can be induced by various means, including IFN 
(interferon)-y, other cytokines (e.g. TNF-a, TNF-
P, IL-1 p, IL-6), antibiotics or nutrient deprivation. 
C. pneumoniae has been strongly linked with 
atherogenesis, which includes a host of 
proinflammatory cytokines. Despite the potential 
importance of chlamydial persistence, very little is 
known about it at the molecular level. The aim of 
this study was to determine the effects of IFN-y 
and other cytokines on the persistence of C. 
pneumoniae by analyzing alterations in protein 
expression profiles. 
HEp-2 cell monolayers were infected with 
purified C. pneumoniae EBs (MOI 100:1) and 
treated with IFN-y (10, 50 and 100 U/ml), TNF-a 
(50 ng/ml), TNF-p (100 ng/ml), IL-lp (300 pg/ml) 
and IL-6 (100 ng/ml) respectively. At 48 hours 
post-infection, C. pneumoniae titers of inclusion 
forming units per ml were determined. To detect 
chlamydial protein expression, infected HEp-2 
cells were pulse-labeled for 2 h in 
methionine/cysteine-free RPMI 1640 medium 
containing 100 jaCi of [35S] methionine/cysteine 
per ml and 500 jag of cycloheximide per ml in the 
presence or absence of IFN-y or other cytokines. 
Radio-labeled protein extracts were loaded onto 
IPG strips [pH 4-7, 6-11 or 3-10] and iso-
electrofocused. The second dimension was 
resolved with SDS-polyacrylamide gel 
electrophoresis. Vacuum dried gels were exposed 
to high density phospho-imaging screens. Images 
were scanned in Molecular Imager® FX Pro Plus™ 
system. Protein spots were analyzed and quantified 
for differential expression patterns between gels 
treated with and without IFN-y and other cytokines 
using PDQuest™ software. 
Infected monolayers treated with IFN-y 
showed a 4-log decrease in final growth when 
compared to the untreated monolayers. Treatment 
with the other cytokines alone showed no 
significant effect on C. pneumoniae replication 
when compared to the untreated samples, whereas 
combination of the respective cytokine with IFN-y 
exhibited a synergistic effect, especially with TNF-
a + IFN-y (6-fold decrease) and IL-ip + IFN-y (5-
fold decrease). We analyzed the expression 
profiles of 38 C. pneumoniae proteins by advanced 
proteomic tools (PDQuest™ vs. 7.1) under normal 
and cytokine-induced persistence conditions. 
Twenty percent of the C. pneumoniae proteins 
(e.g. GspD, Pyk) remained unchanged under 
persistence conditions. However, 50% (e.g. 
GroEL, DnaK) showed significant up-regulation 
and 30% (e.g. Ndk, Efpl) showed significant 
down-regulation. 
In addition to IFN-y, other inflammatory 
cytokines, including synergistic effects of 
cytokines (e.g. TNF-a + IFN-y, IL-ip + IFN-y) 
may play an important role in mediating C. 
pneumoniae persistence, in vivo. This may be 
important in considering the host inflammatory 
and cellular immune response to infection, as a 
complex milieu of host factors would exist within 
a developing atheroma. These data may lead to the 
identification of pathways affected during 
persistence, which in-turn may allow an 
understanding of mechanism by which C. 
pneumoniae may evade the host immune system to 
establish a chronic infection. 
46 - BIOLOGY 
PROTEOMIC COMPARISON OF CHLAMYDOPHILA ABORTUS PROTEINS 
GROWN IN NORMAL AND IRON-RESTRICTED MCCOY CELLS 
Konstantina S. Kyriakopoulou and Evangelia Vretou 
Hellenic Pasteur Institute, Athens, Greece 
It is now well documented that the 
outcome of chlamydial infection depends on 
iron availability. Little is known about the 
mechanisms used by the bacteria to scavenge, 
transport and assimilate the important ion. 
However, the chlamydial genomes indicate the 
existence of a series of proteins involved in 
iron capture and metabolism. In many gram-
negative bacteria the acquisition of iron is 
regulated by the protein Fur. Fur represses the 
synthesis of iron transport systems when iron 
is available and derepresses it in iron 
depletion. In order to identify proteins 
expressed under conditions of low 
concentrations of iron in C. abortus, we used 
the proteomic approach that includes high-
resolution 2-D gel electrophoresis, 
computational analysis of the gel images, and 
genome data analysis. 
C. abortus strain 577 was grown in 
cycloheximide-treated McCoy cells in the 
presence and absence of lOOpM 
desferrioxamine (Desferal). The bacteria were 
either purified by gastrografin centrifugation or 
were metabolically labelled with 35 S 
methionine/cysteine. Protein analysis was 
performed using a high-resolution non-linear 
3.5-10 immobilized pH gradient (IPG) with 
optimal resolution between pH 4.5-7.5 for the 
separation in the first dimension. The second 
dimension was 10% or 12% SDS-PAGE. The 
autoradiographs and the silver stained gels 
were scanned and processed with the software 
Melanie 3. Molecular mass (Mr) and pi values 
were determined only for those protein spots 
that showed consistent differential expression 
in 8 gels at least (4 gels of normal- and 4 gels 
of low-iron-concentration). The experimentally 
determined values (±20% for Mr and ± 0.5 for 
the pi value) were compared to theoretical 
values for predicted open reading frames (orfs) 
in the Chlamydophila abortus genome 
sequence: 
http://pedant.mips.biochem.mpg.de. 
When chlamydiae were grown in a low-
iron environment we observed altered 
expression in 31 protein spots. Increase of the 
signals was in 19 protein spots and reduction 
in 12. Some of the spots corresponded to 
known proteins, identified by Western 
Blotting, such as the heat shock protein hsp60 
and the major outer membrane protein. The 
coordinates (pi/Mr) of several others matched 
to those of orfs with possible functional 
annotation as proteins involved in iron uptake, 
transport and metabolism. Of particular 
interest was a protein (6.18/15 400) that was 
close to the theoretical values of orf 310 
(6.2/17 893). Orf 310 encodes for a protein 
that is highly similar (51% identity and 68% 
homology) to the divalent-cation-dependent-
regulator A (dcrA, orf CT 296) described as 
functionally related to the ferric regulator Fur 
in C. trachomatis (Willie & Raulston, Mol 
Microbiol. 2001, 40 ,1027-36). 
It is therefore very likely that the C. abortus 
dcrA-analog, orf 310, has similar functional 
characteristics to Fur as shown for the dcrA 
protein. 
Results presented suggest the existence of a 
large number of iron-regulated proteins in C. 
abortus and indicate the presence of a Fur-like, 
dcrA homologue that might act as a regulator. 
These proteins need to be identified by 
sequencing and Western Blotting. 
Investigation of the iron metabolism is not 
only important for understanding chlamydial 
pathogenesis but also for the development of 
vaccines targeted at iron receptors. 
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TRANSCRIPTIONAL REGULATION IN CHLAMYDIA 
Peter Timms1 and Sarah A Mathews1 
1 School of Life Sciences, Queensland University of Technology, Brisbane, Australia 
Eventhough Chlamydia has a relatively small 
genome compared to other eubacteria (870 genes 
in C. trachomatis to around 1020 genes in C. 
pneumoniae) it exists effectively as an obligate 
intracellular bacterium by having an intricate 
developmental cycle and a two-way interaction 
with its host. To achieve this, Chlamydia needs to 
carefully regulate multi-level responses to internal 
and external cues from its environment. While 
translational and post-translational control are 
important, clear evidence exists that Chlamydia 
uses transcriptional control as a significant 
mechanism for gene regulation. 
Investigations into chlamydial transcriptional 
regulation continue to be severely hindered by the 
lack of a genetic system which would allow the 
creation of mutations and subsequent 
complementation studies. Nevertheless, the 
increasingly significant studies into transcriptional 
regulation and interpretation of the whole gene 
composition plus microarray analysis show that 
Chlamydia uses the range of transcriptional 
regulatory mechanisms found in other prokaryotes. 
These include, a) promoter sequence, b) multiple 
promoters, c) alternate sigma factors, d) cis-acting 
DNA elements, e) transcription factors (activators 
or repressors), f) promoters in upstream coding 
regions, g) phosphorylation cascades, and h) 
messenger RNA stability and half-life. 
Most of the molecular investigations of chlamydial 
transcriptional regulation have been performed 
using the easy to grow strains such as C. 
trachomatis L2, C. trachomatis (C.muridarium) 
MoPn and C. psittaci 6BC. Although it is easy to 
categorise all species of chlamydiae into the same 
regulatory analysis it is important to take into 
account the differences which occur due to 
adaption of a specific chlamydiae to a specific host 
system. Comparative genomic analysis, made 
possible by the increasing number of complete 
genome sequences, has unveiled some of these 
differences. This short overview summarises what 
is currently know about the various mechanisms 
used by Chlamydia to regulate the expression of its 
relatively small genome at the level of 
transcription. 
The major components of the chlamydial 
transcriptional machinery 
RNA polymerase is a multi-subunit enzyme 
involved in transcription which is well defined in 
eubacteria and conserved in Chlamydia. The core 
RNA polymerase comprises two a subunits plus 
single P and P' subunits and is responsible for 
elongation of the RNA. The addition of a o factor 
to the 0C2PP' complex results in formation of the 
RNA polymerase holoenzyme which is involved in 
promoter recognition and transcription initiation. 
In eubacteria there are three types of a factors, (a) 
the major a 70-like a factor responsible for the 
majority of transcription initiation, (b) the minor a 
factor responsible for the coordinated expression 
of different sets of genes, and (c) the alternate o 
factor class, a54, which requires activation by a 
response regulator phosphorylated by a sensor 
kinase. The use of different o factors confers 
promoter specificity to the RNA polymerase and 
hence the coordinated expression of the different c 
factors provides a mechanism of transcription 
regulation. 
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Figure 1. Comparative structure of E. coli and C. trachomatis a70-like, 
a28 and a54 showing functional domains. 
Chlamydia contains three a factors, a66 the o70-like 
homolog, cr8 a minor a factor and the alternative 
a14. The amino acid sequence of the a factors 
shows conservation of most of the structural 
components compared to other eubacteria. There 
are a few differences when you compare the C. 
trachomatis a factor amino acid sequences to 
those of E. coli (figure 1). ah6 has additional amino 
acids at both the amino- and carboxyl- termini 
where a28 has deletions at each termini, cr54 is 
missing most of region II, an absence in other 
bacteria affects independent binding to the 
promoter (Southern and Merrick, 2000) plus the 
chlamydial cr'4 contains additional amino acids at 
the carboxyl- termini. These differences between 
the chlamydial sigma factor proteins compared to 
the typical eubacterial counterparts could indicate 
structural and functional differences in the 
chlamydial molecules. 
The key role of promoter sequences in gene 
regulation 
Promoters are sequence-specific elements found 
upstream of the start of the transcriptional unit 
(single gene or operon) which are recognised by a 
a factor. Each a factor has a cognate promoter 
consensus sequence which is conserved across 
eubacteria. In general, the closer the promoter 
sequence resembles the consensus the stronger the 
promoter. The major and minor a factors have two 
promoter elements spaced at -35 and -10 from the 
transcript start site (+1), whereas the alternate c 
factor cr'4 has highly conserved GG and GC at -24 
and -12 from the +1, respectively (figure 2). 
In Chlamydia, promoters have been predicted for 
each of the a factors based on the presence of a 
consensus-like sequence upstream of a gene where 
the mapping of the 5' end of the transcript 
coincides with the promoter. Additional functional 
evidence of eleven cMl promoters and one a28 
promoter using in vitro transcription and 
mutational analysis has more clearly defined these 
promoters (summarised in Hatch, 1999; 
Schaumburg and Tan, 2003; Yu and Tan, 2003). 
Nearly 30 chlamydial promoters have been 
published and comparative analysis reveals five 
distinct classes of promoters. Firstly, highly 
conserved (only one mismatch in each hexamer) 
o °-like -35 and -10 hexamers are defined for the 
dnaK PI, PCT, tuf P3, spc and ORF8 promoters. 
The second class of promoters predicted to be 
recognised by 066 (rRNA PI, ompA PI, groE, 
omcB PI and P2, rsl, ltuA, ltuB, hctA and tuf PI), 
show a less conserved homology to the consensus, 
particularly in the -35 hexamer. Within the two 
classes of a6h promoters 12 of 15 contain a spacer 
A/T sequence directly downstream of the -35 
hexamer. Using the sequences from these a66 
promoters a consensus sequence can be derived 
(figure 2) which is nearly identical to that of the 
c70-like consensus. 
Two published cr'4 promoters (CT652.1 and 
CT683) represent the third class of chlamydial 
promoter where both have highly conserved a'4 
sequence (figure 2). The first a28 promoter was 
identified upstream of hctB following re-analysis 
of the sequence upstream of the mapped transcript 
start site (Yu and Tan, 2003). An additional a28 
promoter has been predicted upstream of fliA 
(Shen et al., 2004) and representation of these 
sequences is shown in figure 2. 
The final class of chlamydial promoters cannot be 
clearly defined. Although the 5' end of the 
transcripts have mapped to the corresponding 
upstream region, they do not contain sequences 
resembling the a7", a28 or a54 promoters. It is 
possible that some mapped transcripts are the 
result of RNA processing and not transcription 
initiation, hence the importance of using assays 
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such as in vitro transcription to verify the 
promoter. 
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Figure 2. Comparison of the eubacterial consensus promoters 
compared to published chlamydial promoters. 
Pre-genome investigations of promoters in 
Chlamydia assumed that all promoters would be 
recognised by a66 since various attempts to 
identify additional a factors had been 
unsuccessful. This led to the observation that the 
sequence requirements for the chlamydial 07() 
homology were less stringent than observed for the 
major o factor. This generated a paradox since 
chlamydial a66 contains the exact amino acids 
required for interaction with the consensus 
promoter nucleotides defined by mutational 
analysis in E. coli (Stephens, 1990). The presence 
of additional amino acids at the amino- and 
carboxyl termini of <rh6 have been proposed to have 
a role in altering the promoter recognition 
(Mathews and Stephens, 1999). In addition the 
presence of a spacer A/T immediately downstream 
of the -35 hexamer, known as a positive cis-acting 
element, has been shown to increase promoter 
activity and is often found to be part of a66 
promoters with lower homology to the consensus 
(Schaumburg and Tan, 2000). Finally, the DNA 
superhelical state and the DNA context 
surrounding the promoters (eg A/T-tracts or 
inverted repeats) are thought to modulate 
transcription initiation at a66 promoters (Mathews 
and Stephens, 1999). 
The availability of whole chlamydial genome 
sequences has allowed the in silico prediction of 
chlamydial promoters. The first two cf4 promoters 
were predicted using a sequence-string based on 
the highly conserved nature of eubacterial cr 
promoters. Predicting cf6 and cr8 promoters has 
proven more difficult due to the allowable 
variation at any base position of the consensus. 
When simple string-searches are applied there are 
thousands of hits in the genome when allowing for 
mismatches to the consensus. A combined 
percentage weight matrix (generated from the 
population of known eubacterial promoters) 
combined with a phylogenetic comparative 
approach has been more successful in predicting a 
population of cf6 promoters (Grech, Mathews and 
Timms, unpublished data). In this work, 
approximately 2190 potential C. trachomatis 
promoters were initially predicted in the first stage 
of the in silico analysis. Phylogenetic foot-
printing, which assumes that biologically relevant 
sequences, such as promoters, will be conserved to 
a greater degree between phylogenetic groups such 
as species, than non-relevant sequences, was then 
used to refine these predictions. This reduced the 
number of promoter predictions nearly 100-fold 
and resulted in the prediction of 36 high scoring 
o66 promoters in C. trachomatis, which all showed 
a strong phylogenetic footprint in C. pneumoniae. 
Interestingly, only four of these 36 in silico 
predicted promoters had been identified previously 
by other methods and all four in silico predictions 
were correct since they were confirmed by the 
previous +1 mapping. Combined bioinformatic and 
transcript analysis approaches can potentially add 
significant new information about chlamydial 
promoters and other regulatory factors. 
Multiple promoters have been identified upstream 
of several chlamydial genes (eg 16S rRNA, ompA, 
tuf, omcB, fliA) and in silico predictions are 
revealing that this may be a general theme of 
transcriptional regulation in Chlamydia. It is 
tempting to hypothesise that the presence of 
multiple promoters, sometimes for different a 
factors (eg fliA) is mechanism Chlamydia utilize 
to coordinately control the precise levels of gene 
expression during development. 
The highly compact nature of the chlamydial 
genome suggests that it conserves genome space 
by limiting its intergenic regions. When compared 
with E. coli (11.3%), C. trachomatis has only 9.0% 
non-coding sequence. It is of interest therefore to 
know if the reduced intergenic space results in 
promoters being located in the upstream gene. 
Recent work indicates that in fact Chlamydia does 
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have promoters located within the upstream coding 
regions of several genes; htrA, acpS, yhfO, lpxA, 
CT404, malQ and CT292 (Mathews et al., 
unpublished observations). Of these predicted 
intragenic promoters, only two ORFs have enough 
non-coding sequence upstream to potentially 
contain a promoter and for the others, the 
intergenic distance ranged from -3 to +5 base 
pairs. The observation that Chlamydia has 
promoters in upstream ORFs is perhaps not that 
surprising as this phenomenon has also been 
reported in several other bacteria and the general 
theme in these other bacteria is that they are 
required for increased expression during stage-
specific events. It is likely to be similar for 
Chlamydia given its unique developmental cycle. 
Transcriptional regulators in Chlamydia 
Chlamydia has a complex developmental cycle and 
the use of northern blots, RT-PCR and micro-array 
analysis have shown that transcripts appear in a 
developmental-stage specific manner. It is 
apparent that Chlamydia can effectively regulate 
the expression of its genome for the completion of 
its complex developmental cycle. At the crude 
level, there are at least three patterns of gene 
expression patterns during development. "Early 
genes" such as euo and groES are transcribed 
within the first two hours post-infection and must 
be required for the transformation from EB to RB. 
Transcripts for "mid-cycle" genes are detected 
from 6 hours post-infection, corresponding to the 
RB multiplication phase. Late genes, such as hctA, 
ltuA and omcB, are only expressed after 12 hours 
post-infection and are presumably required for RB 
to EB conversion and possibly for early EB events. 
Since the commencement expression for each of 
the RNA polymerase a factors differs (Mathews 
and Timms, 1999) it seems that Chlamydia uses its 
a factors to control temporal expression. 
In addition to the evidence for temporal control of 
gene expression, there is also striking evidence for 
transcription control in relation to external stimuli 
such as heat shock, glucose deprivation, 
tryptophan limitation (via y-IFN treatment) and 
iron limitation. Transcriptional regulators involved 
in these responses exert both positive and negative 
effects. 
HrcA repression: HrcA is a repressor that 
negatively regulates a32 expression from the 
promoter of the heat shock genes groE and dnaK 
by binding to a sequence-specific inverted repeat 
known as CIRCE (Narberhaus, 1999). The 
chlamydial genome failed to reveal a or32 homolog, 
however, a hrcA homolog was found and the 
identity of the heat shock genes dnaK, groE, 
groEL2 and groEL3 were already known. CIRCE 
sequences were found upstream of the chlamydial 
dnaK and groE promoters (Schmiel et al., 1994; 
Tan et al., 1996). By adding HrcA to an in vitro 
transcription reaction it was demonstrated that 
HrcA binds to the predicted CIRCE element 
upstream of the dnaK and groE promoters and 
represses transcription. 
DcrA repression and the iron response genes: 
Early in vitro culture experiments showed that 
when iron was limiting, Chlamydia expressed an 
altered set of proteins. The transcriptional 
mechanisms involved however had to wait until 
the chlamydial genome was sequenced. This 
indicated a homolog present in the chlamydial 
genome to the Fur protein, which is known in 
E.coli to be involved in iron-regulated 
transcriptional control. In E.coli this control is via 
the Fur protein binding to the Fur box, or operator 
DNA sequence, upstream of iron-regulated genes. 
The Fur equivalent in Chlamydia was cloned and 
expressed and shown to be able to complement an 
E.coli Fur mutant strain (Wylie et al., 2001). In 
Chlamydia, the repressor (renamed DcrA) 
presumably also binds to a specific chlamydial Fur 
box region of DNA, and divalent metal cations, 
such as Mn2+ and Zn2+ but possibly not Fe2+, are 
required for this activity. Work is continuing on 
how and why Chlamydia uses divalent cation 
concentrations to negatively regulate a sub-set of 
its genome. 
Global regulation via DNA-binding proteins 
Hcl and Hc2 and IHF: In addition to the specific 
regulation of sub-sets of genes by transcription 
factors such as DcrA, Chlamydia also uses global 
regulation of its genome via DNA secondary and 
tertiary structure. Chlamydia contains two 
eukaryote histone-like proteins, termed Hcl and 
Hc2. These transcription factors bind to DNA and 
cause it to condense with the result that gene 
transcription is repressed (Barry et al., 1993; 
Pedersen et al., 1996). This mechanism is used late 
in the developmental cycle (Hcl and Hc2 are 
themselves only produced late in the 
developmental cycle) to mediate condensation of 
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the chlamydial chromosome and trigger the RB to 
EB conversion process. 
Another chlamydial protein that mediates its 
transcription regulation via secondary and tertiary 
DNA structure is IHF, integration host factor. IHF 
reportedly bends DNA upstream of the promoter 
hexamers, which is important in bringing key 
proteins together for effective gene transcription. 
Relatively few genes have been shown to have 
their transcription mediated by IHF binding 
(omcAB is one of the best characterized) however 
the chlamydial genome does apparently have other 
IHF binding sites that might indicate that other 
genes are potentially also controlled by this DNA-
bending transcription factor. 
The role of phosphorylation cascades: Cell 
signaling via reversible phosphorylation is an 
important mechanism of transcriptional control in 
all bacteria, including Chlamydia. A 
bioinformatics analysis of the chlamydial genome 
suggests that Chlamydia has at least 36 proteins 
involved in cell signaling, based on their similarity 
to cell signaling genes from other prokaryotes and 
eukaryotes. The only two-component regulatory 
system in Chlamydia involves ctcB and ctcC 
which are central to the regulation of a54 RNA 
polymerase transcribed genes. CtcC is the 
predicted response regulator which is 
phosphorylated by the putative sensor kinase, CtcB 
and interestingly both genes seem to be 
developmentally regulated suggesting that they are 
essential to late gene events. a28 is thought to be 
regulated by a partner-switching mechanism that 
involves the anti-sigma factor, RsbW. RsbW is a 
type of repressor as when it binds to a28 it 
sequesters a28 from the core enzyme, thereby 
preventing the transcription of CJ28 regulated genes. 
RsbW is in turn regulated by the anti-anti-sigma 
factor RsbV, whose activity is determined by its 
phosphorylation state. While these transcriptional 
control mechanisms are clearly important in 
Chlamydia, we still do not know what the triggers 
are for them. 
Several additional novel cell signaling genes also 
exist in the chlamydial genome, including; (a) two 
phosphohydrolases (yael and icc), (b) a chlamydial 
phosphoprotein (Cpn0877), (c) proteins of 
unknown function (yceA) and (d) several other 
genes of unknown function that are predicted to be 
cell signaling candidates because they contain 
tetratrico peptide repeats, which are involved in 
protein-protein interactions and have been 
identified in proteins involved in a large number of 
regulatory processes (IcrHl, lcrH2, Cpn0693, 
Cpn0840 and Cpn0877). The role that these 
proteins play in controlling chlamydial 
transcription is likewise yet to be elucidated. 
How is transcription linked to translation in 
Chlamydia 
In other bacteria, there are multiple levels of gene 
expression control including; (a) promoter 
strength, (b) repressors and activators of 
transcription, (c) messenger RNA stability and 
half-life, (d) codon usage, (e) protein stability, (f) 
phosphorylation, and (g) glycosylation. One 
important question for Chlamydia is how much 
emphasis does this organism place on regulation at 
the level of transcription versus at the level of 
translation or even post-translation. While the 
stage is too early for a complete answer, some data 
is beginning to emerge which indicates, not 
surprisingly, that Chlamydia uses all levels of 
regulation. Timms, Summersgill, et al. 
(unpublished observations) have analysed the co-
ordinated regulation of 36 genes/proteins by using 
quantitative RT-PCR analysis (to measure 
transcription) and semi-quantitative 2-D proteomic 
gels to compare the relative regulation of 
genes/proteins at 24 hours versus 48 hours in 
C.pneumoniae cultures. Perhaps surprisingly, only 
20% of the genes studied showed the same pattern 
change (ie both up or both down regulated between 
24 and 48 hours) for both RNA and protein. 
Approximately 60% of the genes showed 
constitutive RNA expression levels between 24 
and 48 hrs but significant increases in protein 
levels between these times. The other 20% showed 
varying patterns. This might suggest two major 
mechanisms for Chlamydia; (a) a significant 
component of the genome (at least 20%) is 
primarily regulated at the level of transcription, 
with constitutive transcription combined with 
linked translation, (b) a larger component of the 
genome (perhaps greater than 50%) is significantly 
regulated at the translation and post-translation 
levels (as evidenced by translation changes not 
directly correlating with transcriptional changes). 
It also suggests that the other genes/proteins are 
using other potentially more complex, mechanisms 
of regulation. These observations begin to show us 
the level of complexity that this relatively "simple" 
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organism uses to control the expression of its 
genome. 
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CDNA ARRAY ANALYSIS OF HOST CELL TRANSCRIPTIONAL 
RESPONSES IN ACUTE AND PERSISTENT C. PNEUMONIAE INFECTION 
Mannonen L.1, Haveri A.2, Nikula T.3, Vuola J.M.2, Lahesmaa R.3, Puolakkainen M.1 
Department of Virology, Haartman Institute and Helsinki University Central Hospital, 
University of Helsinki, National Public Health Institute, Helsinki, Turku Center for 
Biothechnology, Turku, Finland 
Chlamydia pneumoniae is strongly 
associated with chronic conditions such as 
atherosclerosis and asthma. In cell culture, 
interferon gamma (IFN-Y) induced persistent 
infection is characterized by ongoing DNA 
replication whereas cell division and 
maturation of the reticulate bodies (RB) are 
totally or partially inhibited. 
Little is known about interactions of the host 
cell and C. pneumoniae during persistency. 
Our aim was to compare host cell responses 
during acute and IFN-Y induced persistent C. 
pneumoniae infection in cell culture. 
The following samples were prepared 
for microarray analysis: 1. Epithelial cells (HL) 
infected with C. pneumoniae Kajaani 6 isolate 
(MOI 0.5; acute infection), 2. HL cells treated 
with 10 U/ml of IFN-Y and infected with C. 
pneumoniae Kajaani 6 isolate (MOI 0.5; 
persistent infection), 3. HL cells treated with 
IFN-Y. To study kinetics of the host cell gene 
regulation, cells were collected 6, 24, 48 and 
150 hours post inoculation. A HL cell pool 
was used as a hybridization control. 
The isolated total RNA was transcribed into 
cDNA and labeled during the RT-reaction with 
Cy3 (HL cell pool) or Cy5 (samples). 
Competitive hybridization of samples versus 
control cell pool was performed on a Can-1 
cDNA array that contains 4000 human genes 
(Turku Center for Biotechnology, Turku, 
Finland). A change in the host cell gene 
expression levels was defined as follows: 
Mean of log2 (sample/control) of the three 
replicate hybridizations greater than 1 
(upregulation) or smaller than -1 
(downregulation), with CV less than 0.25. 
To confirm DNA microarray findings, samples 
are being analyzed with Applied Biosystems 
Real Time RT-PCR Assay On Demand™ 
products. 
We observed changes in several human 
genes after Chlamydia pneumoniae infection: 
At any time point, altered expression profile 
was observed for 86 genes in cells infected 
with C. pneumoniae, and for 203 genes in cells 
infected with C. pneumoniae in the presence of 
IFN-Y. IFN-Y alone changed expression of 134 
of the 4000 genes studied. Expression of 49 
genes was altered in response to either C. 
pneumoniae or IFN-Y. However, no induction 
of IFN-Y was detected by RT-PCR in HL cells 
infected with C. pneumoniae. C. pneumoniae 
together with IFN-y treatment seemed to elicit 
greater changes in the expression levels of 
several genes than IFN-y alone or C. 
pneumoniae alone. Furthermore, some changes 
in gene expression induced by C. pneumoniae 
infection or IFN-Y treatment were absent in 
persistent infection. 
Generally, upregulation of host cell genes was 
more often observed than downregulation. 
However, the late time point (150 hours post 
inoculation) in IFN-Y treated cells was an 
exception. At that time point when altered, the 
host cell gene expression was mostly 
downregulated. 
Several host cell genes were 
specifically regulated during IFN-Y induced 
persistent infection with C. pneumoniae. 
Validation of the findings by RT-PCR is in 
progress. The results provide basis for the 
elucidation of selected genes and pathways for 
the host response in productive and persistent 
C. pneumoniae infection. 
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INDUCTION OF EARLY MRNA SYNTHESIS AND PROTEIN-
PHOSPHOR YLATION IN CHLAMYDIA-INFECTED HELA CELLS 
D. Virok*, D. Nelson, D. Crane, W. Whitmire, H. D. Caldwell 
Laboratory of Intracellular Parasites, Rocky Mountain Laboratories, National Institute of Allergy 
and Infectious Diseases, NIH, Hamilton, Montana, USA 
Chlamydia infection impacts host cell 
cytoskeletal dynamics, cell-signaling 
pathways, and cell-mediated defenses within a 
few hours of infection. In an attempt to better 
understand the underlying biological basis of 
this pathogen-host interaction we have 
analyzed both the host transcriptome and 
signal transduction (ST) responses during the 
early infection period. 
Host cell transcriptional profiles were 
determined using Affymetrix Hu95Av2 DNA-
arrays and ST responses were analyzed by 
probing western blots with P-Tyrosine specific 
mAb 4G10. These analyses were done in 
parallel using inhibitors of chlamydial 
transcription and host protein synthesis at 30 
min and 1 h post-infection. ST studies were 
performed on cells infected with chlamydiae 
representing a wide-range of strains that vary 
in host infection tropism, tissue tropism, and 
disease outcome. These included Chlamydia 
trachomatis serovars A-H, LI, L2, L3; 
Chlamydia pneumoniae, Chlamydophila 
caviae (GPIC strain) and Chlamydia 
muridarum. 
Host cells were transcriptionally silent 
at 30 min following infection with viable or 
transcriptionally inactive chlamydiae, 
demonstrating that attachment and entry occurs 
independently of de novo host transcription 
and protein synthesis. In contrast, a marked up-
regulation in the transcription of a subset of 
host genes with diverse biological function 
was observed at 1 h post-infection. These 
included ST pathways, mediators of 
endocytosis, transcriptional regulators, and 
both pro- and anti-apoptotic genes. This effect 
was dependent on chlamydial transcription, 
implicating an early chlamydial gene 
function(s) in the induction of this response. 
On the other hand, a rapid host and chlamydial 
protein synthesis independent tyrosine 
phosphorylation ST cascade was induced 
during the first 10 min of infection. The ST 
pattern sorted the chlamydial strains into four 
distinct groups: 1) C. trachomatis mucosal (A-
H, trachoma biovar), and 2) non-mucosal 
serovars (L1-L2-L3, LGV biovar), 3) C. 
muridarum, 4) C. pneumoniae and C. caviae. 
Our findings show that chlamydial 
attachment and entry occur independently of 
new host or chlamydial protein synthesis, but 
demonstrate a role for early chlamydial genes 
in the subsequent initiation of host 
transcriptional responses; the function of 
which remains unknown. The process of 
attachment and entry did however stimulate ST 
responses that interestingly separated 
chlamydial strains according to well-
characterized biological and infection 
properties, suggesting a potential relationship 
in chlamydial induced ST events and the 
pathogenesis of infection. 
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COMPARATIVE ANALYSIS OF CHLAMYDOPHILA PNEUMONIAE 
TRANSCRIPTOME DURING ACUTE AND PERSISTENT INFECTION OF 
HUMAN EPITHELIAL CELLS. DEVELOPMENT OF CHLAMYDIAL DNA 
MICROARRAY 
Andre Maurer*, Joerg Angermann, Hans J. Mollenkopf, ThomasF. Meyer, Agnes J. 
Szczepek 
Max Planck Institute for Infection Biology, Department of Molecular Biology, Berlin, Germany 
The issue of chlamydial persistency in 
vitro and in vivo is complex and still poorly 
understood. During persistent stages, 
chlamydial replication is halted but the protein 
synthesis is still active, suggesting a selective 
switch in gene expression. This hypothesis has 
also been supported by a number of 
publications (Hogan et al, 2003; Nicholson et 
al, 2003; Belland et al, 2003). To determine 
which of the chlamydial genes are active 
during an acute and which during a persistent 
infection is of great medical importance. The 
goal of this project was to analyze the 
transcriptome of Chlaymdophila pneumoniae 
during an acute and persistent infection using 
the global approach of the DNA microarray 
technology. 
We have developed a C. pneumoniae-
specific oligonucleotide-based DNA 
microarray. Additionally, we improved and 
optimized RNA extraction methods for the 
needs of a microarray. RNA was purified from 
the epithelial cells infected with C. 
pneumoniae at different time point during an 
acute and persistent (iron depletion - induced) 
infections. Next, labeled cDNA was hybridized 
on the arrays, the arrays were washed, scanned 
and the results were then analyzed. The 
expression of various genes was confirmed by 
quantitative real-time RT-PCR. 
First we investigated the temporal 
changes in the chlamydial transcriptome 
during an acute infection at 18h, 24h, 48h and 
72h p.i. Transcriptional changes in the acute 
infection occurred at all timepoints. At 24 h 
p.i. vs. 48 h p.i. we observed 295 upregulated 
and 367 downregulated genes and at 48 h p.i. 
vs. 72 h p.i. 145 genes were downregulated 
and 210 upregulated with a smaller scattering 
and less genes being regulated more than + 2 
fold compared to the former. 
Next, we performed comparative 
analyses of the acute versus persistent (iron-
depletion induced) chlamydial transcriptome. 
Infected Hep-2 cells were depleted of iron and 
the transcriptome was compared to the 
respective samples of the acute infection at 24h 
p.i., 48h p.i. and 72h p.i. At 24h p.i., 110 genes 
were up- and 143 downregulated, 48h p.i. 350 
were up- and 316 downregulated and at 72h 
p.i. 305 were up- and 327 downregulated. Of 
these, 187 genes were regulated more than ± 
2fold at least at one time point. 
We were able to show that the 
chlamydial transcriptome differs during iron-
depletion produced persistence induced by 
deferoxamine (DAM) as compared to the acute 
infection. The effect of DAM on the 
transcriptome may also be give hints on 
essential proteins that play a role in 
maintaining persistent infection. 
Determination of the potential novel gene 
functions in persistence might have application 
in the development of new anti-chlamydial 
drugs in managing persistent chlamydial 
infections. 
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CHARACTERISATION OF THE ROLE OF CHLAMYDIAL CELL 
SIGNALING GENES IN CHLAMYDIAL PERSISTENCE 
Adam Polkinghorne*1'2, Enrico Brugnera2, James Summersgill3, Andreas Pospischil2, 
Lloyd Vaughan2 and Peter Timms1 
'infectious Diseases Program, School of Life Sciences, Queensland University of Technology, 
Brisbane, Australia' 2Institute of Veterinary Pathology, University of Zurich, Zurich, Switzerland, 
3Division of Infectious Diseases, Department of Medicine, University of Louisville, Louisville, 
Kentucky, USA 
To determine the role of candidate 
chlamydial cell signaling genes in the generation 
of interferon gamma-induced chlamydial 
persistence. 
Initially, a multi-level approach was used 
to predict putative cell signaling genes in 
Chlamydia. This involved the inspection of the C. 
pneumoniae CWL029 genome sequence 
annotation followed by performing PSI-BLAST 
searches for chlamydial homologs to other 
prokaryotic cell signaling genes. 
Differential mRNA expression of these predicted 
chlamydial cell signaling genes was determined 
using real-time RT-PCR in an in vitro model for 
normal acute C. pneumoniae A-03 infections and 
persistent infections induced by gamma interferon 
(IFN-y) treatment and sampled at 24 h and 48 h 
post infection (PI). The average transcript copy 
numbers determined from independent 
experiments were divided by the average 16S 
rRNA copy number to normalize for the number of 
chlamydial bodies present in each sample. The 
untreated control at 48 h PI was used as a 
calibrator for expression comparisons between 
untreated and IFN-y-treated samples, and for 
comparisons with the 24 h PI untreated sample. 
At least 36 chlamydial ORFs were 
predicted to encode cell signaling genes in the C. 
pneumoniae CWL029 genome (1). The majority of 
these genes were previously identified as being 
involved in signal transduction and regulatory 
functions when the chlamydial genome sequence 
was originally completed. Interestingly, however, 
eight additional candidate genes including 
phosphohydrolases (yael and icc) and genes of 
unknown function that contain tetratrieo peptide 
repeats (IcrHl, lcrH2, Cpn0693, Cpn0840 and 
Cpn0877), which are involved in protein-protein 
interactions (2), were also identified. 
When the expression patterns of these cell 
signalling genes was examined in the in vitro 
gamma interferon model, surprisingly, 31 of these 
putative cell signaling genes were differentially 
expressed (ie. greater than two fold differences in 
expression) in the presence of IFN-y at 48 h PI. 
Upregulated cell signaling genes include predicted 
stress response genes (htrA, surE, lytB and hrcA) 
whilst a predicted GTP binding protein gene 
associated with the cell cycle in other bacteria 
(hflX) was downregulated. Differential expression 
of hflX and other predicted chlamydial P-loop 
GTPases (ychF, yhbZ and yphC) suggests that 
regulation of ribosome activity is important in 
chlamydial persistence. 'Blockage' of late 
chlamydial development in the IFN-y-treated 
infection revealed information on the temporal 
expression of a number of candidate genes (IcrHl, 
ctcB, ctcC and pkn5). Downregulation of ftsK, 
amongst other control genes, was used to validate 
our expression results again other chlamydial 
persistence studies (3). 
These results support the proposal of a 
chlamydial response stimulon for regulation of 
persistent chlamydial growth (4). Furthermore, 
differential expression of putative stress response 
genes suggest that the persistent phenotype 
generated in response to extracellular stressors 
such as IFN-y is a chlamydial survival response. 
Detailed characterisation of a subset of these 
important persistence regulators including analysis 
of protein expression (via proteomics and confocal 
microscopy) and direct expression of recombinant 
chlamydial signaling proteins is underway. 
References 
1) Kalman et al. (1999). Nat. Genet. 21:385-389. 
2) Goebl and Yanagida (1991). Trends Biochem. 
Sci. 16:173-177. 
3) Byrne et al. (2001). Infect. Immun. 69:5423-
5429 
4) Belland et al. (2003). Proc. Natl. Acad. Sci. 
USA 100: 15971-15976. 
BIOLOGY - 57 
DIFFERENCES IN THE TRANSCRIPTION OF CHLAMYDIA PNEUMONIAE 
CELL DIVISION AND PEPTIDOGLYCAN-RELATED GENES IN IFNy VS. 
PENICILLIN-TREATMENT HIGHLIGHTS AN EVOLVED 
TRANSCRIPTIONAL RESPONSE TO HOST-MEDIATED STRESS 
S. P. Ouellette*, G. I. Byrne, and R. J. Belland 
Department of Molecular Sciences, University of Tennessee Health Science Center, Memphis, 
USA 
To assess the transcriptional profile of 
cell division and peptidoglycan (PG) related 
genes in C. pneumoniae (Cpn) infected cells 
treated with either IFNy or penicillin. 
Cpn causes acute respiratory diseases 
and has been associated with other chronic 
conditions such as atherosclerosis and asthma. 
Chronic sequelae from chlamydial infections 
are generally thought to be caused by a viable 
but non-culturable form of the organism 
characterized by abnormal RBs. A number of 
conditions can induce non-productive growth 
of Cpn in vitro, and we sought to determine if 
Cpn responds to these stresses in the same 
manner. 
HEp-2 cells in 162 cm2 flasks were 
infected with Cpn AR39 at an MOI of 2 for 2 
hours. Following infection, media with or 
without IFNy or penicillin was added to the 
infected cells. At 48hrs post-infection (pi), 
total RNA was isolated by the Trizol method 
and chlamydial RNA was purified according to 
the scheme of Belland et al (PNAS 100: 8478-
83, 2003). Total DNA was collected from 
duplicate samples using Qiagen's DNeasy 
Tissue kit. In a subset of samples, the IFNy- or 
penicillin-containing medium was removed 
and fresh medium added to reactivate 
chlamydial growth. Total RNA and DNA 
samples were collected 96 or 120hrs pi. 
Control flasks were maintained to monitor the 
infection via immunofluorescence (IFA). 
Primer probe sets were designed using 
Primer Express and validated with genomic 
DNA. Transcripts for each set were assessed in 
the RNA samples and quantified to a genomic 
DNA standard. Total genomes were similarly 
quantified from the DNA samples. Transcript 
copy number was normalized to the number of 
genomes and/or 16S rRNA. 
Transcription of the EB-associated late 
gene product omcB was markedly decreased in 
both IFNy- and penicillin-treated samples, 
indicating a non-productive growth state had 
been achieved. This is further verified by the 
lack of infectious EBs collected from these 
samples. Viability was maintained in these 
cultures as indicated by the ability to recover 
infectious organisms after removal of the 
IFNy- or penicillin-containing medium. 
Control flasks stained with anti-MOMP Ab for 
IFA showed aberrant organisms in the treated 
cultures but normal organisms in the untreated 
cultures. 
By examining transcription of cell 
division and PG-related genes, it is apparent 
that under IFNy treatment, Cpn responds by 
down-regulating the transcription of the 
penicillin binding proteins and their associated 
chaperones, the putative PG amidases, and ftsK 
and mreB whereas under penicillin treatment, 
on\y fis K showed a significant decrease. 
Cpn appears to coordinately regulate 
gene expression in response to IFNy-mediated 
persistence but not to persistence induced with 
penicillin. These results suggest the pathogen 
may have evolved a programmed response to 
host-mediated stresses and that any gene 
expression changes to penicillin are likely 
secondary to the effect of penicillin itself and 
not directly "persistence-inducing." 
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DIAGNOSIS OF GENITAL CHLAMYDIAL INFECTIONS IN THE ERA OF 
AMPLIFICATION TECHNOLOGIES 
A. Stary 
Outpatients'Center for Diagnosis of Infectious Venerodermatological Diseases, Vienna, Austria 
Diagnostic procedures making use of 
amplification of specific nucleic acid 
sequences have provided laboratories with 
powerful tools with particular impact on the 
detection of bacterial genital infections such as 
Chlamydia trachomatis and Neisseria 
gonorrhoeae. 
Compared with cell culture 
methodologies nucleic acid amplification 
(NAA) assays such as polymerase chain 
reaction (PCR), ligase chain reaction (LCR), 
strand displacement amplification (SDA), and 
transcription mediated amplification (TMA) 
have shown to be highly sensitive and specific 
for the detection of genital chlamydial 
infections in symptomatic and asymptomatic 
men and women, detecting up to one third 
more infected individuals. NAA technologies 
have already replaced other diagnostic 
methods for routine diagnosis of genital 
chlamydial infections although the commonest 
test still used in many countries is the enzyme 
immunosorbent assay (EIA) and only a 
minority of diagnostic centres use DNA 
amplification methods for daily routine. In 
several studies antigen detection methods 
available on the market have shown to perform 
with a remarkable lower sensitivity on invasive 
genital samples than NAA techniques on the 
noninvasive specimen type of first voided 
urine (FVU) in both, men and women and have 
been even declared as unethical in respect of 
the patient. 
The high sensitivity of NAA techniques 
enables the detection of amplified chlamydia 
specific DNA or RNA even in specimens 
contaminated with microorganisms such as 
FVU and introital vulvovaginal specimen types 
with similar sensitivities when compared to 
cervical and urethral specimens in both, men 
and women. This offers screening possibilities 
for the detection of a low number of organisms 
present in asymptomatic patients and their 
contact persons without signs of inflammation. 
Screening abilities are even increased by using 
self administered vulvovaginal samples for the 
diagnosis of both, N. gonorrhoeae and C. 
trachomatis which permits testing without a 
speculum examination and even without 
clinical inspection. Community-based urine 
testing by using NAA assays successfully 
identified chlamydial infections in different 
risk groups and was well accepted by 
community-members. Studies have been 
performed in female and male military recruits, 
in asymptomatic men and women, in high 
school students, in pregnant women, and in 
other population groups of special relevance 
for chlamydial diagnosis. It has been shown 
that screening for C. trachomatis can 
significantly impact STD epidemiology by 
facilitating early detection, treatment, and 
interruption of transmission. 
The amplification tests focusing on the 
diagnosis of lower genital tract infection have 
long been restricted to two commercially 
available techniques, the Amplicor PCR, a 
DNA target amplification test for the diagnosis 
of C. trachomatis, and the ligase chain reaction 
LCx, a DNA probe amplification assay for the 
diagnosis of both, C. trachomatis and N. 
gonorrhoeae. In 1996, the Amplicor PCR for 
C. trachomatis was compared with other 
diagnostic methods such as culture and Gen 
Probe by testing cervical and urine samples 
and showed a sensitivity similar but not higher 
than chlamydial culture. Since then, the 
performance procedure and handling 
recommendations of Amplicor PCR were 
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improved e.g. by changing the transport 
medium and by including an internal control 
for the amplification procedure used in the 
COB AS Amplicor. Since 2003, the LCR has 
been retracted from the market and is not 
available but will be replaced by another 
amplification technique in the near future. 
The Gen-Probe APTIMA Combo 2 
assay is a relatively new second generation of 
NAA technology after the AMP CT test and 
combines the technologies of target capture, 
transcription mediated amplification (TMA) 
and Dual Kinetic Assay. It is the only NAA 
which is already FDA approved for the use of 
vaginal specimen types in women. According 
to the results of a study in men, even penile 
specimens were recommended as alternative 
noninvasive sample types for men in addition 
to FVU for chlamydial and gonococcal 
coamplification when tested "by the APTIMA 
Combo 2 assay. 
The strand displacement amplification 
technique ProbeTec, is based on the 
simultaneous amplification and detection of 
target DNA by the use of amplification primers 
along with a fluorescein-labelled detector 
probe and offers real-time amplification and 
detection. It has been approved for practical 
use for the diagnosis of chlamydial as well as 
gonococcal infections in genital und urine 
specimens for both, men and women and is 
widely used for routine diagnosis. 
Disadvantages of NAA assays may still 
be the high costs of the performance in 
laboratories. Furthermore, problems with 
inhibition of amplification and contamination 
under certain conditions may lead to reduced 
reproducibility of positive and negative results. 
Problems of reproducibility were reported for 
both, Amplicor PCR Chlamydia trachomatis 
and for LCR. In a study on cervical specimens 
tested by Amplicor PCR a broad variation for 
discrepant or equivocal PCR results could be 
observed on several repeat testing in both ways 
with false positive or negative results and wide 
variations in the OD values. As possible causes 
of nonreproducibility false-positive-
hybridisation during the detection assay, 
nonspecific priming in the amplification phase, 
amplicon contamination, inhibition of the 
amplification, or a very low concentration of 
chlamydia were discussed. It has to be 
considered, that the study has been performed 
before the internal control for inhibition was 
available. Reproducibility problems were also 
reported for the performance of the LCR and 
occur also for the SDA. They have raised the 
question whether the confirmation of positive 
results should be demanded for routine 
diagnosis which is controversially valued. 
Comparison studies with different 
NAA assays and specimen types have 
demostrated that certain substances in clinical 
specimens may inhibit amplification in a 
certain extense. For PCR Amplicor, inhibitors 
were observed in 19% of cervical specimens, 
and could be reduced by heat treatment at 
95 °C, freeze-thawing, by a 10-fold dilution of 
the samples, and at a higher degree by 
combined methods. Genital samples tested by 
NAA assays have more often a higher 
sensitivity than urine samples for detection of 
C. trachomatis as well as N. gonorrhoeae. 
Although this may be partly due to the lower 
number of target nucleic acids, it has been 
shown that inhibition occurs more often in 
urine than in genital samples. Urinary 
substances associated with inhibition and 
removal of inhibitory activity were described 
in pregnant and nonpregnant women in 
different NAA assays due to different chemical 
substances. The complete removal of urine in 
the sediment decreases also the number of 
inhibition. It seems that the frequency of 
inhibition for NAA assays in urine specimens 
varies among different populations, among 
individuals in the same area at different times, 
and among different NAA assays with 
variations between 3 and 20% and is more 
often observed in chlamydia negative 
individuals. 
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Despite some limitations the NAA 
assays offer an important approach for 
chlamydia diagnosis in men and women at STI 
risk and in the general population acting as an 
unrecognized large reservoir of chlamydia 
infected persons, capable to transmit the 
microorganism to their partner or to newborns 
during perinatal exposure. 
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COMPUTATIONAL ANALYSIS OF INCA STRUCTURE FOR THE 
RATIONAL DESIGN OF NOVEL ANTIBODY-BASED CHLAMYDIA 
IMMUNODIAGNOSTICS 
Larcombe, LD„ 2Karim, K„ Goodman, AC. 
t 9 
Cranfield Biomedical Centre & Cranfield Centre for Supramolecular Technology, Cranfield 
University, Silsoe UK 
This work set out to apply 
computational analytical tools and biophysics 
principles to facilitate the development 
towards a novel chlamydia-specific 
immunodiagnostic. It aims to demonstrate a 
systematic approach to enable the rational 
design of antibodies from annotated genome 
database sequences, which would be relevant 
to a wider application in diagnostic 
development. 
The amino acid sequence of IncA, 
translated from genomic data, was analysed 
using secondary structure prediction 
algorithms, and the results combined to 
identify target regions suitable for the 
preparation of synthetic haptens. 
An initial Kyte-Doolittle hydropathy plot was 
carried out to establish the presence of 
transmembrane helices. Subsequent analysis 
with nnPredict, and the Sybyl™ 
Qian/Sejnowski, Maxfield/Scheraga and 
Garnier/Osguthorpe/Robson algorithms from 
the Tripos Inc. software package was used to 
identify non-transmembrane helical domains. 
Transmambrane domains shown by KD plot 
were corroborated by use of the PHDhtm 
algorithm. 
Non-helical regions were then divided into 
peptide sequences of suitable length for use as 
hepten for generating antibodies. Each 15mer 
peptide was then analysed for net charge, 
hydrophobicity, and other sequence-specific 
characteristics in order to select the most 
suitable peptide. A candidate was chosen from 
each non-helical domain, and subjected to 
BLAST searches to identify homology with 
other proteins likely to be present in any 
clinical samples. 
Finally the most suitable peptide was 
synthesised and used to raise a polyclonal 
antibody. 
After amalgamation of data from the 
structure prediction algorithms, a 
representation of the secondary helical 
structure of IncA was produced sufficient to 
identify three candidate non-helical regions. 
35 single amino acid frame-shifted sequences 
were analysed resulting in a 15mer peptide 
from the cytoplasmic terminal end of the 
protein being chosen. 
The peptide had suitable net charge for 
aqueous solubility, appropriately distributed 
charged, uncharged and hydrophobic residues 
for synthesis, and a minimal probability of 
homology with any relevant alternative 
proteins. 
It has been demonstrated that specific 
antibodies can be produced which could be 
used for diagnostic development solely based 
on data from genomic databases. 
Sufficient tools and theoretical knowledge can 
now be applied so that with only minimal 
experimental evidence of protein expression, 
structure and function, useful diagnostics could 
be developed by identifying relevant genomic 
candidates. 
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ARRAYTUBE™ MICROARRAY HYBRIDISATION ASSAY FOR 
IDENTIFICATION AND DETECTION OF ALL CHLAMYDIAL SPECIES 
Konrad Sachse1*, Helmut Hotzel1, Peter Slickers2, Thomas Ellinger2, and Ralf Ehricht2 
'Federal Research Centre for Virus Diseases of Animals (BFAV), Institute of Bacterial Infections 
and Zoonoses, Jena, 2Clondiag Chip Technologies GmbH, Jena, Germany 
To design, produce and test both in situ 
synthesized and spotted microarrays to 
differentiate among all species of 
Chlamydiaceae. 
In silico analysis of a multiple sequence 
alignment of chlamydial ribosomal rRNA 
genes by the "most variable window approach" 
resulted in the identification of a highly 
discriminatory region for all species of the 
family Chlamydiaceae in domain I of the 23 S 
rRNA gene. This led us to design in situ 
synthesized microarrays carrying 512 distinct, 
but sequence-related 26-nt oligonucleotides in 
two-fold redundancy. Spot size was 32x32 pm. 
For low-density spotted microarrays, species-
specific probes from the most variable window 
were spotted as 3'-amino-modified 26-nt oligos 
(9-fold redundancy, spot size 80 pm). 
Internally biotinylated products of a consensus 
PCR amplifying a 1-kbp segment comprising 
the 3'-end of the 16S rRNA gene, the 
intergenic spacer and the 5'-terminal region of 
the 23 S rRNA gene were hybridized to the 
microarrays using the ArrayTube™ system 
(Clondiag Chip Technologies, Jena, Germany). 
The hybridization reaction was monitored in 
the ATR-01 array tube reader at 25 °C for 40 
min, recording 41 images. Signal amplification 
was achieved by enzyme-catalyzed silver 
precipitation, and signal intensity data with 
local background correction were obtained for 
each spot using the Iconoclust software, 
version 2.2 (Clondiag Chip Technologies). 
Hybridization of all consensus PCR 
products of chlamydial strains to in situ 
synthesized combinatorial microarrays 
revealed clearly distinct hybridization patterns 
for all nine chlamydial species. The high 
stringency of hybridization conditions ensured 
that target strands annealed only to probes 
having the exactly matching complementary 
sequence, whereas no hybridization signals at 
all were seen on derived non-matching but 
sequence-related probes, even including those 
with a single-base variation, unless at the 3'-
end. Likewise, unambiguous differentiation 
among the species Chlamydia (C.) 
trachomatis, C. suis, C. muridarum, 
Chlamydophila (Cp.) pneumoniae, Cp. 
psittaci, Cp. abortus, Cp. felis, Cp. caviae, and 
Cp. pecorum was achieved on spotted arrays as 
well. To assess the suitability of the present 
system for clinical specimens, a series of 
porcine lung tissue samples, two milk samples 
and spiked cell culture were examined. The 
results were in agreement with those from 
diagnostic PCR. 
The present ArrayTube™ platform, 
which involves plastic tube-integrated 
microchips, is comparatively inexpensive and 
easy to handle. The finding that PCR-amplified 
bacterial DNA could be detected and identified 
by the present microarray assay directly from 
clinical material clearly illustrates its potential 
and opens up interesting possibilities for chip-
based genotyping of chlamydiae in the absence 
of cultural isolates. 
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CHARACTERISTICS OF A NEW ABBOTT M2000 AUTOMATED MAGNETIC 
SAMPLER COMBINED WITH MULTIPLEX HOMOGENOUS REAL TIME PCR AND 
THE ABILITY TO DETECT CHLAMYDIA TRACHOMATIS IN RESIDUAL CLINICAL 
SWAB SAMPLES 
Chernesky MA1*, Jang D1, Marshall R2, Yu J2, Howell-Adams B2, Ho S2, Welk J2, Lai-Zhang 
J2, Brashear R2, Diedrich B2, Otis K2 and Webb E2 
McMaster University St. Joseph's Healthcare, Hamilton, Ontario, Canada1, Abbott Laboratories, Abbott 
Park, IL, USA2 
Although nucleic acid amplification 
(NAA) tests are sensitive and specific for detection 
of Chlamydia trachomatis and Neisseria 
gonorrhoeae, most are sensitive to amplification 
inhibitors and lack sufficient throughput. The 
second generation NAA assay from Abbott 
Molecular Diagnostics is comprised of a rapid 
automated magnetic sample prep system to be used 
in combination with homogeneous Real Time PCR 
(HRT-PCR) DNA amplification. The objectives 
were to determine various operating parameters of 
the HRT-PCR and M2000 including throughput, 
analytical sensitivity and target specificity. This 
prototype assay was then used to detect Chlamydia 
DNA in residual swab samples, which had been 
collected and tested by the LCx LCR test (Abbott), 
the Amplicor PCR assay (Roche) or the ProbeTec 
ET multiplex strand displacement amplification 
assay (Becton Dickinson). 
The Abbott M2000 magnetic sample prep 
technology removes both inhibitors and 
fluorophores. The DNA is captured generically 
using a silica based magnetic particle, washed, and 
eluted with water. The HRT-PCR amplification 
and detection method uses DNA amplification 
primers with fluorescence-quenched DNA 
detection probes. The homogeneous assay format 
allows for detection of Chlamydia trachomatis, 
Neisseria gonorrhoeae and internal control 
without the necessity of opening the reaction 
vessel. The system will provide for automation of 
primary barcoded tubes with caps that are 
pierceable by the pipetting system. Both the 
purified DNA and the PCR mastermix are 
automatically added to the PCR tray. Serial 
dilutions of DNA were tested to determine the 
analytical sensitivity of the new test and a panel of 
58 different organisms were used to test 
specificity. A time study was conducted to 
determine throughput for varying numbers of 
clinical samples. Swab samples processed in the 
LCx (n=64) ProbeTec (n=496) and Amplicor 
(n=67) collection systems and assay kits were 
stored up to 12 weeks at -20°C. Residual material 
containing the swab was processed into the HRT-
PCR assay via the M2000. Positive, negative and 
overall concordance was calculated comparing the 
results from the new assay to the FDA-cleared 
tests. 
The dilution experiments demonstrated 
uniform curve separation from 107 to 20 genome 
equivalents of C. trachomatis. None of the 
organisms in the specificity panel organisms were 
positive in the HRT-PCR test when tested at 
biologically normal concentrations. The 
throughput studies showed the following: 96 
samples yielded 192 results in 4.5 hours; 192 gave 
384 results in 7 hours and 288 provided 576 results 
in 9.5 hours. For clinical samples already tested for 
C. trachomatis in 3 first generation NAA tests, the 
concordance of M2000 prepared samples and 
Abbott HRT-PCR with the ProbeTec Chlamydia 
test was 99.1% (325/328) for positives, 98.2% 
(165/168) for negatives and 988% (490/496) 
overall; with the Amplicor Chlamydia results the 
values were 96.3 % (26/27) for positives, 100% 
(40/40) for negatives and 98.5% (66/67) overall; 
with the LCx assay the values were 100% (32/32), 
100% (32/32) and 100% (64/64) overall. 
The M2000 magnetic sample preparation 
combined with homogeneous PCR technology 
provides a rapid, sensitive, and specific 
methodology for detection of C. trachomatis with 
negligible risk of PCR product contamination. The 
ability of the HRT-PCR to detect positives and 
negatives from residual samples collected into a 
variety of collection systems suggests versatility 
and robustness for testing clinical specimens. 
66 - DIAGNOSTICS 
USING PATIENT- & CLINICIAN-COLLECTED VAGINAL SWABS IN THE 
APTIMA® CT ASSAY FOR CHLAMYDIA TRACHOMATIS & APTIMA® GC 
ASSAY FOR NEISSERIA GONORRHOEAE 
Schachter J1, Chernesky M2, Willis D3, Fine P4, Hook EW5, Martin DH6, Fuller D7, 
Jordan J8, Janda W9 
'University of California, San Francisco, SF, CA, 2St. Joseph's Health Care Regional Virology and 
Chlamydiology Laboratory, Hamilton Ontario, Canada, 3Florida State Department of Health, 
Jacksonville, FL, 4Planned Parenthood of Houston and Southeast Texas, Houston, TX, 5University 
of Alabama, Birmingham, AL, 6Louisiana State University Medical Center, New Orleans, LA, 
7Wishard Memorial Hospital, Indianapolis, IN, 8MGees Women's Research Institute, Pittsburgh, 
PA, 9University of Illinois, Chicago, IL 
The literature suggests vaginal swabs 
(VS) may be useful specimens for diagnosing 
genital infections. A kit for the collection of 
VS for screening for Chlamydia trachomatis 
(CT) and Neisseria gonorrhoeae (GC) using 
Gen-Probe Incorporated's commercially 
available APTIMA Combo 2 Assay (AC2)has 
recently received FDA clearance. We assessed 
the performance of the APTIMA CT Assay 
(ACT) and APTIMA GC Assay (AGC) using 
patient- and clinician-collected vaginal swab 
(PVS and CVS) specimens. ACT and AGC 
target rRNA sequences different from those 
used in AC2. but the three assays use the same 
procedures. 
Females were enrolled at eight 
geographically diverse, high and low 
prevalence sites. First catch urine (FCU), one 
PVS, one CVS, and two endocervical swabs 
(ES) were collected from each subject. ACT 
and AGC were done on PVS, CVS, FCU, and 
one ES. AC2 was done on the same FCU and 
ES tested by ACT and AGC. The second ES 
and the FCU were tested using BDProbeTec 
(Becton Dickinson and Company) for CT and 
GC. Subjects were defined as infected if two 
FDA-cleared tests on FCU or ES were 
positive. 
There were 180 CT and 78 GC infected 
subjects among the 1,464 subjects (respective 
prevalences of 12.5% and 5.4%). ACT Assay 
sensitivities and specificities were 98.3% 
(175/178) and 96.5% (1,202/1,245) for PVS 
and 97.2% (175/180) and 95.2% (1,208/1,269) 
for CVS. AGC Assay sensitivities and 
specificities were 96.1% (74/77) and 99.3% 
(1,336/1,345) for PVS and 96.2% (75/78) and 
99.3% (1,359/1,368) for CVS. The ACT Assay 
VS results were in >95% agreement with FCU 
and ES results. With the AGC Assay, 
agreement was >98%. Further testing was 
performed to determine whether the apparent 
false positives (FP) were true positives (TP). 
Previous evaluations of the ACT Assay have 
found that its exquisite sensitivity results in 
apparent FPs that are shown to be TPs by 
repeat testing. That was the case here as with 
CVS 57% (24/42) of the apparent ACT FP, 
and67% (6/9) of apparent AGC FP were 
positive by AC2. 
The ACT Assay and the AGC Assay 
using VS are sensitive and specific for the 
detection of both CT and GC. Patients are are 
equally adept as clinicians in collecting VS. 
VS are well suited for screening for CT and 
GC with the APTIMA CT and GC assays. 
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SCREENING FOR CHLAMYDIA TRACHOMATIS USING SELF-COLLECTED 
SPECIMENS: PERFORMANCE, EASE OF COLLECTION AND PREFERENCE 
Max A. Chernesky* 
McMaster University and St. Joseph's Healthcare. Hamilton, Ontario, Canada 
With high rates of asymptomatic infection, 
Chlamydia trachomatis is easily transmitted. To 
prevent complications of upper genital tract 
infection, screening programs are needed to 
facilitate screening, non-invasive samples (NIS) 
such as first catch urine (FCU) and patient 
collected vaginal swabs (PVS) will need to be easy 
to collect and preferred. Assays used to test NIS 
will have to be as accurate as testing traditional 
cervical swabs (CS). The objective was to review 
studies examining preference and/or ease of 
collection of NIS from different female 
populations and to present the results of a recent 
study in North America examining questions 
regarding self-sampling. 
Four recently published papers were 
selected for review and examined for evidence of 
women's preference, ease of collection and 
performance characteristics on FCU and PVS 
compared to CS in nucleic acid amplification 
(NAA) assays. In an unpublished study, women 
from 8 North American cities collected a PVS and 
FCU which were compared to a clinician-collected 
vaginal swab and CS by the APTEMA® Combo 2 
assay (Gen-Probe Inc.). The CS and FCU were 
also tested in the ProbeTec i ET assay (BD 
Biosciences) to determine infected patients. A total 
of 1090 women completed a questionnaire for ease 
of collection and preference for a PVS or FCU 
compared to the CS. Illustrated instructions 
concerning handling the swab and tube and 
collecting the sample were provided. 
A study of California adolescents1 showed 
that an FCU was ranked slightly higher than PVS 
as a preferred NIS. Non-participation was due to a 
lack of trust for collection and feeling that a 
doctor's expertise was required. Female prisoners2 
and army recruits3 were studied in Baltimore. Most 
of the prisoners found both samples easy to collect 
and preferred a PVS over CS. The army recruits 
found the FCU easier and preferred it slightly over 
PVS. They would prefer to use a PVS at home and 
FCU in the field. Young women in Hamilton4 
preferred self-collection over physician collection 
unanimously in student health, family doctor, birth 
control, STD and street health settings. Greatest 
preference for PVS was shown in student health 
and street health clinics. When testing was done in 
these studies the PVS detected as many or more 
infected women as FCU and CS, using the LCx 
(Abbott) assay. In the current study, using the 
APTIMA® Combo 2 assay for C. trachomatis, the 
PVS and CS detected 95.5%, and the FCU 91.6%, 
of the infected women. Across all of the testing 
sites, 90.4% of the women found that a PVS was 
very easy to collect and virtually none found it 
difficult. The ease of collection was not affected 
by race, age, education, tampon or diaphragm use, 
or STD experience. Almost 80% preferred a PVS 
over a pelvic examination and 60% over an FCU. 
Over 90% would get tested more often if a PVS 
was available. 
When tested in an effective NAA assay 
PVS can identify most women infected with C. 
trachomatis, so they can be treated to prevent 
further transmission and ascending genital 
infection. PVS and FCU are easy to collect and 
preferred over CS. Preferences may be influenced 
by instructions provided to enable easy self-
collection. Findings from these studies should be 
applied to female screening programs for C. 
trachomatis. 
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Collection Methods for Testing for C. trachomatis 
and N. gonorrhoeae Infection. Sex. Transm. Dis. 
2003;30:306-309. 
3. Hsieh et al. Preferences Among Female Army 
Recruits for Use of Self-Administrated Vaginal 
Swabs or Urine to Screen for C. trachomatis 
Genital Infections. Sex. Transm. Dis. 2003;30:769-
773. 
4. Richardson et al. Prevalence of C. trachomatis 
Infections and Specimen Collection Preference 
Among Women, Using Self-Collected Vaginal 
Swabs in Community Settings. Sex Transm. Dis. 
2003;30:880-885. 
68 - DIAGNOSTICS 
DETECTION OF CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE 
INFECTIONS IN MEN BY TESTING FIRST CATCH URINE IN NEW APTIMA® CT 
AND APTIMA GC ASSAYS 
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To compare the APTIMA CT (ACT) 
Assay for Chlamydia trachomatis and APTIMA 
GC (AGC) Assay for Neisseria gonorrhoeae to the 
APTIMA Combo 2 (AC2) Assay (Gen-Probe 
Incorporated) and the BD ProbeTec® (PT) energy 
transfer (ET) amplified DNA assays for CT and 
GC (Becton Dickinson Bioscience, Sparks, Md.) 
performed on urethral swabs (US) and first catch 
urine (FCU) from men. 
From October 2002 to January 2003, we 
enrolled 1,322 men between 15 and 77 years of 
age (mean 28.5) from 6 sites in North America. 
Subjects were classified as symptomatic if 
discharge or dysuria were reported by the subject. 
Two US and one FCU specimen were collected 
from each patient. One of the swabs and an aliquot 
of FCU was tested by ACT, AGC and AC2. The 
other US and an aliquot of FCU were tested by the 
PT assay. For ACT and AGC, swab or urine 
specimens were transferred into AC2 Assay 
transport media. The transport solutions in these 
tubes released the rRNA targets and protected 
them from degradation during storage. The target 
rRNA molecules were isolated from the urine or 
swab samples by the use of a target capture 
method using capture oligomers on magnetic 
microparticles. The ACT and AGC use 
oligonucleotides that target rRNA sequences 
different from those of the commercially available 
AC2. The procedures for the three assays, which 
include target capture, transcription mediated 
amplification (TMA) and a hybridization 
protection assay (HPA) detection technique, are 
the same. The AC2 and PT assay protocols were 
followed from their package inserts. ACT and 
AGC assay results from US and FCU were 
compared to infected patient status (IPS) for 
determining sensitivity, specificity and predictive 
values with 95% confidence intervals. A patient 
was considered infected if both of the specimen 
types were positive in at least one of the FDA-
cleared tests (AC2 or PT) or if at least one of the 2 
specimen types was positive in both AC2 and PT. 
A total of 236 patients were infected with 
CT and 183 with GC according to the IPS 
algorithm. Symptoms were reported in 59.7% 
(141/236) of infected and 40% (435/1086) of 
uninfected men. There were 236 men with CT 
(prevalence 17.9%) and 183 men with GC 
(prevalence 13.9%) infections. Hamilton and San 
Francisco were low prevalence sites for CT and 
GC. The other sites were of high prevalence, 
except for Pittsburgh where the number of subjects 
enrolled was too small to allow meaningful 
calculations. The ACT and AGC assays performed 
similarly as sensitivity and specificity ranges were 
similar across sites and from one specimen type to 
the other in symptomatic and asymptomatic 
patients. The respective ACT and AGC 
sensitivities were 96.2% and 98.9% for FCU and 
97.5% and 99.5% for US. Specificities ranged 
from 96.9% to 99.3% for both assays and 
specimen types. An equal or higher percent was 
achieved in asymptomatic patients infected with 
CT by testing US or FCU. In patients infected with 
GC, the FCU specimen appeared to be more 
effective in symptomatic men. Positive and 
negative agreements between the assays and for 
both specimen types ranged from 94.3% to 100% 
and 93.9% to 99.3%, respectively. These ranges 
were not significantly different. When the data 
were stratified by symptoms, the agreements 
remained similar for CT but GC positive 
agreement was 10% less between AGC and PT in 
asymptomatic subjects 
The ACT and AGC assays demonstrated 
excellent sensitivity and specificity to identify 
infected men using US and FCU when compared 
to the FDA-cleared assays, AC2 and PT. This high 
performance on a non-invasive specimen such as 
FCU from asymptomatic men indicated that these 
tests could be used for screening urine from men. 
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THE NEW POPULATION-BASED EPIDEMIOLOGY OF CHLAMYDIA 
TRACHOMATIS USING NUCLEIC ACID AMPLIFICATION TESTS AND NON-
INVASIVE SPECIMENS: OUTREACH BEYOND THE CLINIC 
Gaydos, Charlotte A.1 
'Johns Hopkins University, Baltimore, MD, USA 
Use of nucleic acid amplification tests 
(NAATs) facilitates non-invasive screening for 
Chlamydia. Use of urines and self-
administered vaginal swabs for NAAT testing 
has been shown to facilitate screening large 
numbers women and men not attending a 
clinic in outreach venues. 
To demonstrate how non-invasive 
samples for chlamydia testing have been used 
to define the epidemiology of chlamydia in 
large population based studies. To review how 
self-sampling methods have been used to 
screen non-traditional patients and venues for 
chlamydia. To discuss how self collected 
samples and use of the mail might make a 
difference in reaching those most at risk. 
Literature review and presentation of 
results of epidemiological studies using non-
invasive samples and NAAT screening will be 
presented. Studies of non-traditional 
population groups that include the military, 
schools, detention centers, household surveys, 
and emergency department patients will be 
discussed. Studies reporting special transport 
of home-collected samples such as the mail for 
nonclinic specimens will be included. 
Epidemiological studies indicated that 
in all of the large population based studies, 
young age was a significant risk factor for 
being chlamydia positive. In female military 
recruits, being from the South, being Black, 
and having new or multiple partners were also 
significantly associated with having chlamydia. 
In male military recruits, being age 20-24 had a 
higher O.R. (3.5) than being <20 years (O.R. 
2.2). Other significant predictors in the male 
recruits were being of non-white race and 
having multiple partners. Re-infection with 
chlamydia was common in many studies that 
followed patients prospectively. Multiple 
studies indicate that 10% (range 7-13%) of 
women are diagnosed with chlamydia again in 
4 months. In detention centers age 30 years 
could be used as a screening criteria for males, 
while for women in detention age <25 years 
was a highly significant predictor of chlamydia 
positivity. In emergency departments, 
screening urine from patients not reporting 
with genital complaints has proven to yield 
high prevalences (13.6%) of chlamydia and/or 
gonorrhea, especially in ages 21-23 years. In an 
inner city probability sample of households, 
3% of those age 18-35 years were estimated to 
have an untreated chlamydia infection, with 
the estimated prevalence being substantially 
higher among Black women. Large population 
studies, which use non-invasive samples and 
NAATs can also make possible geo-mapping 
of those who are infected in order to discern 
where to concentrate control efforts. Use of 
self-administered vaginal swabs as non-
invasive specimens is becoming more wide 
spread for large population studies. They are 
easier to mail to testing sites when samples are 
collected at home and appear to highly 
acceptable to women. Opportunistic NAAT 
screening using a self-administered vaginal 
swab in a study of large general practices 
yielded a prevalence of 5.0%, with 
determinants of infection being age 18-27 
years, >1 partner, no contraceptive use, post 
coital bleeding, symptomatic partner, painful 
micturation, and living in the inner city. 
Large epidemiological studies of non-
traditional patients and out reach programs, 
which extend and supplement regular testing 
programs can be of great value in identifying 
populations at highest risk for chlamydia 
infections. Using these new tools of NAATS 
and non-invasive sample types can lead to the 
detection and treatment of more cases of 
chlamydia, and the prevention of chlamydia 
associated sequelae in the future. 
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NUCLEIC ACID AMPLIFICATION TESTS AND SCREENING FOR 
CHLAMYDIA TRACHOMATIS 
Schachter J. 
University of California, San Francisco, USA 
The ways in which nucleic acid amplification 
tests (NAATs) are used are evolving. NAATs 
can be used with non-invasively collected 
specimens (first-catch urine [FCU] from men 
or women and vaginal swabs [VS] from 
women). This allows the use of NAATs in 
screening the asymptomatic individuals who 
represent the bulk of prevalent infections. 
Literature review and presentation of results of 
clinical trials will describe the most recent 
evaluations of NAAT sensitivity and 
specificity and the results obtained with both 
invasive (urethral/cervical swabs) and 
noninvasive specimens (FCU/VS). Other 
specimen options will be discussed. 
Present and discuss data on evaluation of 
NAATs; their performance with different 
specimens; and approaches toward confirming 
positive NAAT screening results. The second 
generation NAATs from Gen-Probe 
Incorporated (the APTIMA® assays) seem to 
be more sensitive than earlier tests for 
diagnosing genital chlamydial infection. 
NAATs are the most sensitive diagnostic tests 
we have ever had for detecting Chlamydia 
trachomatis infection. We will see increased 
use of VS as a specimen. We are correctly 
identifying more infected individuals than we 
ever could in the past. The way we use NAATs 
has been complicated by CDC screening 
guidelines recommending confirmation of 
positive results when the predictive value is 
<90%. With some NAATs the data suggest 
that confirmation is not necessary. 
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EVALUATION OF THE GEN-PROBE APTIMA COMBO 2 ASSAY FOR THE 
DETECTION OF CHLAMYDIA TRACHOMATIS AND NEISSERIA 
GONORRHOEAE IN MALE AND FEMALE URINE SAMPLES 
Lowe, Peter1*, O'Loughlin, Peter1, White, Michael2 
'Queensland Medical Laboratory, 2PanBio, Queensland, Australia 
To compare the Gen-Probe APTIMA 
Combo 2 (AC2) assay with the Roche Amplicor 
(CT/NG) assay in terms of assay performance, 
ease of use and workflow. To review the validity 
of current testing algorithms in light of NPAAC 
and CDC testing guidelines. Our current testing 
protocol does not allow testing for both 
pathogens unless specifically requested. We 
wanted to evaluate the possibility of additional 
Neisseria gonorrhoeae detection using AC2 
assay. 
An aliquot of urine from samples 
received into the laboratory for Chlamydia 
trachomatis and / or Neisseria gonorrhoeae 
testing by CT/NG PCR was transferred to an 
APTIMA Urine Specimen Transport Tube. A 
total of 1976 male and female urine samples 
were tested. Concordant negative results were 
not evaluated further. Positive CT/NG results 
were further evaluated according to our routine 
protocol. Discordant results were repeated in 
both assays and further evaluated using Gen-
Probe Aptima Chlamydia trachomatis (ACT) or 
Neisseria gonorrhoeae (AGC) assays as 
appropriate. 
Chlamydia trachomatis: After initial 
testing, 150 and 176 results were reported as 
positive by the CT/NG and AC2 assays 
respectively. Six samples had unusual result 
profiles or had insufficient sample to allow 
repeat testing and were excluded from further 
analysis leaving 147 and 172 positive results for 
the CT/NG and AC2 assays. Resolution of 
results using NPAAC / CDC guidelines 
indicated 166 positive and 1804 negative 
samples. Prevalence in this population was 
8.43%. Six samples were positive in the AC2 
assay whilst negative in both the ACT and 
CT/NG assays. No samples were positive in the 
CT/NG assay alone. Calculated sensitivity, 
specificity, PPV and NPV were 88.55%, 100%, 
100% and 98.97% for the Roche CT/NG assay 
and 100%. 99.67%, 96.51% and 100% for the 
Aptima AC2 assay. Neisseria gonorrhoeae: 
After initial testing, 13 and 18 positive results 
were reported by the CT/NG and AC2 assays 
respectively. Resolution of results using NPAAC 
/ CDC guidelines indicated 18 positive and 1958 
negative samples. Prevalence in this population 
was 0.91%. Calculated sensitivity, specificity, 
PPV and NPV were 72.22%, 100%, 100% and 
99.75% for the Roche CT/NG assay and 100%. 
100%, 100% and 100% for the Aptima AC2 
assay. Two additional patients were detected that 
did not have requests for CT/NG PCR. Of note, 
one patient was culture positive, AC2 and AGC 
positive, but repeatably CT/NG negative. This 
sample was not inhibitory. 
The Gen-Probe APTIMA Combo 2 assay 
was shown to be a robust sensitive and specific 
assay in this initial evaluation. Workflow was 
found to be good although not as "hands-off' as 
initially indicated. The AC2 assay showed 
greater sensitivity for Chlamydia trachomatis 
than the CT/NG assay. Further clinical 
evaluation of the 6 patients with results positive 
only in the AC2 assay suggested symptoms and / 
or history consistent with infection. This may 
indicate sensitivity differences between the 
assays or sampling issues from the urine 
specimen. No false positive CT/NG results for 
Neisseria gonorrhoeae were detected in this 
evaluation. This was not expected and may be 
due to the low prevalence in our patient 
population. A second phase evaluation 
incorporating samples from a population with a 
high prevalence of Neisseria gonorrhoeae will 
be undertaken. A review of our current testing 
and re-testing algorithms may be warranted. 
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PERFORMANCE CHARACTERISTICS OF THE ROCHE COBAS TAQMAN 
CHLAMYDIA TRACHOMATIS TEST 
Mark Krevolin, Jian Qing Yang, Jim Pane, Art Sunhachawee, Nitta Lee-Lundy, David 
Hardy, Elizabeth Cervantes 
Roche Molecular Systems, Inc., Pleasanton, CA, USA 
To evaluate the performance 
characteristics of the COBAS TaqMan 
Chlamydia trachomatis (CTM CT) Test for the 
detection of Chlamydia trachomatis (CT) in 
urine and M4 transport media (M4RT). 
The limit of detection (LOD) was 
evaluated by testing 48 replicates of cultured 
CT diluted in urine at concentrations of 60 of 
10 IFU/mL and M4RT at concentrations of 
300 to 30 IFU/mL. Results were compared to 
CT negative urine. For genotype inclusivity, 14 
different genotypes of cultured CT cells diluted 
in M4RT were tested (22 replicates at 80 
IFU/mL of each genotype). Assay 
reproducibility was measured using cultured 
cells of CT serotype H tested at three 
concentrations in either M4RT (40, 80 and 120 
IFU/mL) or urine (10, 20 and 40 IFU/mL) by 2 
operators for 15 days (180 replicates each). 
The positivity rate was calculated to determine 
the reproducibility of the test. Assay specificity 
was determined by testing -1000 clinical 
samples (-500 endocervical swabs and -500 
urines) that previously tested negative by the 
COBAS Amplicor (CA) CT/NG Test. 
Specimens were tested by both the CTM CT 
Test and the CA CT/NG Test. For any 
specimen with an inhibitory result or with 
discrepant results, retesting by both assays was 
performed. Further correlation studies to the 
CA CT/NG assay will be shown. 
The LOD for all genotypes was at or 
below 10 IFU/mL in urine and at or below 30 
IFU/mL in M4RT. The reproducibility analysis 
showed a 100% positivity rate at all three 
concentrations in both urine and M4RT and 
100% negativity rate for CT negative urine. 
Clinical specimen CTM CT Test results 
correlated well with the CA CT/NG Test 
results and showed >99% specificity for 
negative specimens. 
The CTM CT Test is highly sensitive 
and specific with excellent reproducibility and 
genotype inclusivity. The CTM CT Test 
correlates well with the CA CT/NG Test and is 
suitable for the detection of CT in urine and 
swab specimens. 
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EFFECT OF DNA ISOLATION AND POOLING OF URINES ON THE 
SENSITIVITY OF PCR DETECTION OF CHLAMYDIA TRACHOMATIS IN 
ASYMPTOMATIC PREGNANT WOMEN 
G.I.J.G. Rours1, R. Verkooyen2, E.A.E. van der Zwaan2, H.F.M. Willemse2, R. de 
Groot1, H.A. Verbrugh2, J.M. Ossewaarde2* 
Departments of 'Paediatrics and 2Medical Microbiology and Infectious Diseases, Erasmus Medical 
Center, Rotterdam, The Netherlands 
C. trachomatis infections remain a 
major public health problem. A substantial risk 
of chlamydial infection is transmission within 
the community by asymptomatic carriers, but 
also the impact of chlamydial infection on 
pregnant women and their offspring. The ob-
jective of this study was to develop sensitive 
methods for large scale screening of asympto-
matic pregnant women. 
Urines were collected anonymously 
from pregnant women before 24 weeks of 
gestational age. For PCR amplification the 
automated Cobas Amplicor (Roche 
Diagnostics) system was used. Individual 
urines were processed by standard methods. 
These results were considered the reference for 
comparison with the results of the other 
procedures. The first procedure consisted of 
pools of five urines that were further processed 
as single urines by standard methods. When a 
pool tested positive, the results of the indi-
vidual urines were used to resolve the pool re-
sult. In the second procedure, DNA was iso-
lated from a pool of five urines using the DNA 
Isolation Kit III and the automated MagNA 
Pure LC (Roche Diagnostics). When a pool 
tested positive, DNA was isolated from each of 
the five urines individually and tested. 
Finally, 750 urines were included in 
this evaluation. Standard testing of the 
individual urines yielded 31 positive test 
results resulting in an estimated prevalence for 
C. trachomatis of 4.1%. Testing the pooled 
urines resulted in 15 positive pools of which 
20 individual urines had a positive result. By 
this procedure the prevalence was estimated to 
be 2.7%. Eleven specimens would have been 
reported falsely negative using pooled urines 
alone (11 / 750 = 1.5%), which proves the 
sensitivity of standard processing of pooled 
urines to be 64.5% compared to testing of indi-
vidual urines. 
After DNA isolation 34 pools tested positive. 
These pools yielded 44 positive urines in the 
individual test after DNA isolation (prevalence 
of 5.9%). Two pools were positive after DNA 
isolation, but could not be confirmed by indi-
vidual testing of the urines. Another five pools 
were positive after DNA isolation, of which 6 
urines were negative when tested individually 
after DNA isolation, but were positive when 
tested in the standard assay. These positive 
urines would have been misdiagnosed if only 
one test would have been used. Altogether, 50 
urines were positive for C. trachomatis after 
individual testing with or without prior DNA 
isolation revealing a true prevalence of C. tra-
chomatis infection of 6.7% in these apparently 
healthy pregnant women. When considering 
combined individual testing (standard single 
urine and after DNA isolation) as the gold 
standard for infected status, standard individ-
ual testing of urines with the Cobas Amplicor 
yielded a sensitivity of 62%. This sensitivity 
dropped to 40% with the use of pooled urines 
and standard Cobas Amplicor testing. How-
ever, using pooled urines after DNA isolation 
and verification of positive pools by testing the 
individual urines after DNA isolation, the sen-
sitivity proved to be 88%. 
The prevalence of C. trachomatis 
infections in asymptomatic pregnant women 
was significantly higher (5.9%) using DNA 
isolation than using the standard method 
(4.1%). Therefore, DNA isolation is required, 
particularly when pooled urines are used in 
asymptomatic populations. 
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DEVELOPMENT OF REAL-TIME PCR FOR CHLAMYDIA TRACHOMATIS : 
QUANTIFICATION OF PLASMID AND ELEMENTARY BODIES 
Maithe Clerc*, A. NGandjio, C. Bebear, B. de Barbeyrac 
Laboratoire de Bactériologie, Centre National de 
Université de Bordeaux 2. Bordeaux, France 
Most of nucleic acid amplification 
techniques use the multicopy cryptic plasmid 
as target for Chlamydia trachomatis (Ct) 
detection. Furthermore, some studies suggest 
that epidemiological factors are related to the 
quantity of Ct. This present study develops a 
real-time PCR assay on the ABI Prism 7000 
(Applied Biosystems) using Sybr Green, 
1) to evaluate the amount of plasmid in 
strains of various serovars, 
2) to quantify, in some strains, the number of 
elementary bodies (EBs) by inclusion 
3) to detect and quantify Ct in clinical 
specimens. 
Two sets of primers were chosen, the first 
in the single copy gene omp\ (1), the second in 
the multicopy cryptic plasmid (2). For each 
target, specific amplified fragment was cloned 
in pGEMT vector. Both recombinant plasmids 
obtained were measured for their concentration 
and ten fold serial dilutions were used as 
standards in quantitative experiments. Ct 
serovars were grown in McCoy cell monolayer 
cultures. Inclusions were revealed using a Ct 
monoclonal antibody and quantified by serial 
dilutions. Infected cells were disrupted before 
purification of EBs by centrifugation. EBs 
were finally suspended in Tris-HCl pH 7.5. 
EBs infected cells or clinical samples were 
lysed with pK before PCR. 
The number of plasmid by EB was obtained by 
dividing the quantification obtained with 
cryptic plasmid primers by the one obtained 
with omp 1 primers. 
The sensitivity of the assay was 
determined with dilutions of the two 
recombinant plasmids tested in triplicate. The 
limit of detection was two copies/vial (400 
Référence des Infections à Chlamydia 
copies/ml). The triplicate assays showed a 
good reproducibility (standard deviation <0.3). 
The cryptic plasmid number varied from two 
to fifteen according to the serovar in the 
following order: 15 plasmids (serovar L2), 7 
(serovars D, F), 4 (serovars K, Ba), 2 (serovars 
H, G). From titrated cell culture, the EBs could 
be estimated for one inclusion. An important 
variation exists between serovars, 104 
EBs/inclusion (serovars B, J) to 106 
EBs/inclusion (serovars L2, D). Concerning 
clinical specimens, culture positive samples 
showed EB numbers ranging from 104/ml to 
109/ml, while for culture negative samples, EB 
numbers were <104/ml. 
This real-time PCR assay is a highly 
sensitive method since it detects as low as 2 
copies/vial (400 copies/ml). The cryptic 
plasmid is often chosen as PCR target, because 
it is present in multicopies in strains. However, 
the number of plasmid varies among serovars. 
This difference can explain the variable 
sensitivity of detection tests according to 
involved strains. Furthermore, the variable 
number of EBs according to serovar, can 
explain the various size of inclusions observed 
in cell culture examined by microscopy. It can 
also influence the detection sensitivity. The 
low number of EBs in some biological samples 
could be an other reason to explain the relative 
low sensitivity of tissue culture method. Thus, 
our results show that a number of EBs>104/ml 
is necessary to obtain a positive culture. 
References: 
1 B. Dutilh: Res Microbiol,1989,140, 7-16. 
2 M.J. Loeffelholz: J. Clin. Microbiol, 1992, 
30, 2847-2850. 
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CONFIRMATION OF POSITIVE CHLAMYDIA TRACHOMATIS AND 
NEISSERIA GONORRHOEAE SPECIMENS DETECTED BY THE GEN-PROBE 
APTIMA COMBO 2® ASSAY 
Jeanne Moncada*, David Brooks and Julius Schachter 
University of California, San Francisco; Chlamydia Laboratory, Department of Laboratory 
Medicine, San Francisco, CA, USA 
The 2002 CDC guidelines recommend show that confirmatory testing may not be 
confirmatory testing for positive C. warranted for the AC2 assay. 
trachomatis (CT) and N. gonorrhoeae (NG) 
nucleic acid amplified tests if positive 
predictive values are <90%. Approaches for 
confirming a positive test include repeating the 
original test on the original specimen, and 
testing the original specimen with a different 
test/target. We evaluated both strategies on 
positive APTIMA Combo 2 (AC2, Gen-Probe 
Incorporated) specimens. 
Swabs and first catch urine specimens 
from symptomatic and asymptomatic men and 
women were tested by AC2, which detects 
both CT and NG in a single test. The original 
positive CT and NG specimens were repeat 
tested by AC2. Then, the original specimens 
were tested by APTIMA CT Assay (ACT), 
which detects CT or the APTIMA GC Assay 
(AGC), which detects NG. Each of these tests 
targets rRNA sequences different from AC2. 
Of 213 original CT positives in AC2, 
208 (97.7%) confirmed by repeat AC2 testing 
(4/5 that failed had low rlu readings 
(<500,000). ACT confirmed 211 (99.1%). 
Using both methods, 212 (99.5%) of the CT 
positives were confirmed. Of 220 original NG 
positives in AC2, 215 (97.7%) confirmed by 
repeat AC2 testing (1/5 that failed had low rlu 
readings (<500,000). AGC confirmed 214 
(97.3%). Using both methods, 215 (97.7%) of 
the NG positives were confirmed. 
CT and NG positives obtained from the 
AC2 assays are confirmed to a high degree by 
either repeat testing or use of the Gen-Probe 
alternate amp assays. Our preliminary results 
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EVALUATION OF THE RAPID BIOSTAR OIA ASSAY FOR DETECTION OF 
CHLAMYDIA TRACHOMATIS IN ADOLESCENT WOMEN 
C.I. Bandea, E. H. Koumans,2 M.K. Sawyer,3 J. R. Papp,1 E. Unger,1 J. Braxton,2 L.E. 
Markowitz2 and C. M. Black1 
National Center for Infectious Diseases and 2National Center for HIV, STD, and TB Prevention, 
Centers for Disease Control and Prevention, and Department of Pediatrics, Emory University 
School of Medicine, Atlanta, GA, USA 
Evaluate the performance of the Biostar 
Chlamydia OIA, a rapid optical immunoassay 
for the detection of C. trachomatis, in an inner 
city adolescent female population. 
Two hundred and sixty eight 
symptomatic or asymptomatic female 
adolescent patients (12-19 years old) enrolled 
in a larger multi-objective longitudinal STD 
study at a public pediatric clinic in Atlanta, 
Georgia were included in the study. Sexually 
active, HIV negative, non-pregnant adolescent 
females who did not receive antibiotics within 
the previous 30 days, were enrolled after 
consent or, if the adolescent was < 1 8 years, 
after the consent of a parent or guardian. Endo-
cervical swab specimens for the Biostar 
Chlamydia OIA test, culture, EIA and nucleic 
acid amplification tests (NAATs) were 
collected by clinicians during pelvic 
examination. The culture was performed at our 
CDC reference laboratory. The Biostar 
Chlamydia OIA, EIA test and the NAATs 
(PCR, LCR and TMA) were performed 
according to the manufacturer's protocol and 
specifications. The results of the Biostar 
Chlamydia OIA test were compared with those 
of culture and its relative sensitivity and 
specificity were calculated using a reference 
standard based on the results of LCR and 
TMA: a participant was considered infected if 
both NAATs were positive. 
Forty-five (16.8 %) out of 268 
participants enrolled in the study were positive 
by Biostar Chlamydia OIA test compared to 59 
participants (22 %) who tested positive for C. 
trachomatis by culture. Thirty nine (14.6 %) 
patients were positive for C. trachomatis by 
both Chlamydia OIA and culture, six (2.2 %) 
were positive by Chlamydia OLA test but 
negative by culture and 20 (7.5 %) were 
positive by culture and negative by the 
Chlamydia OLA test. The sensitivity and 
specificity of the Chlamydia OLA using culture 
as the reference standard were 66.2 % and 
95.2%, respectively. Our results are 
significantly different compared to the only 
other published results using culture as the 
reference standard, in which the sensitivity and 
specificity of Chlamydia OLA test for the 
detection of C. trachomatis in ocular 
specimens were 94.2 % and 97 %, 
respectively. Most likely, this difference was 
due to different culture methodologies, rather 
than to differential performance of the Biostar 
Chlamydia OLA. Alternatively, this 
discrepancy may be attributable to differences 
in the specimens (ocular vs. genital) or in the 
populations (newborns vs. adolescents). When 
using an independent NAATs reference 
standard, the sensitivity and specificity of the 
Biostar OLA were 59% and 96.5% and those of 
culture were 77.5% and 98%, respectively. By 
comparison, the sensitivity of the EIA and the 
PCR was 78.9% and 92.8% and their 
specificity was 94.9% and 97.5%, respectively. 
Using an improved reference standard 
we have shown that the sensitivity of Biostar 
OLA for the detection of C. trachomatis in 
cervical specimens collected from adolescent 
women is approximately 60%, which is lower 
that that reported in previous studies. 
However, despite its relative low sensitivity, 
the use of Biostar Chlamydia OLA should be 
considered in populations with low rates of 
return for treatment. 
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INTERNET BASED CHLAMYDIA SCREENING USING VAGINAL SWABS: 
WHAT YOUNG WOMEN SAY ABOUT HOME SAMPLING AND THE 
INTERNET 
C.A. Gaydos1, P.A. Rizzo1, M. Barnes1, K. Burnard2, B.J. Wood1, T. Hogan1 
'Johns Hopkins University, Baltimore, MD, 2Thomas Jefferson University, Philadelphia, PA., 
USA 7 
To ascertain the opinions, concerns, 
and perceptions of sexually active women 
regarding the use of the Internet as a tool to 
facilitate home screening for chlamydia using 
self-administered vaginal swabs and the U.S. 
Postal Service. To obtain guidance on how to 
design an effective web-based out-reach 
chlamydia screening program that would be 
used by women. 
Four focus group interview sessions 
were conducted with 26 young women, ages 
18-49 yr. in small groups of 5-9 participants, 
who were recruited from schools of higher 
education. Formal training was conducted with 
female facilitators of comparable ages, who 
then conducted and recorded the sessions. The 
main outcome measures were obtained using 
structured discussions with open-ended 
questions and observation of the groups. 
Participants were asked to express opinions 
about access to chlamydia testing, how and 
where they wished to be tested, their 
perception and willingness to use self-
administered home sampling swabs and use of 
the mail to send in specimens for testing. 
Focus group members were queried about 
specific program activities such as 
advertisements, questionnaires, obtaining 
results, treatment options, and perceptions 
about confidentiality and safety. 
All participants had difficulty 
responding to risk behavior and level of risk 
questions in the first person. Questions were 
repeated and varied to elicit personal 
expression of needs and opinions regarding 
risk. Conversely, participants responded in the 
first person more easily to pictures of 
advertising flyers and drawings of sampling 
diagrams. The women stated that they liked the 
idea of picking up free kits from various 
locations within their community and generally 
approved of the concept of home sampling. 
These women indicated that convenient 
locations included pharmacies, schools, 
recreational centers, and convenience stores. 
Concerns associated with obtaining kits 
included: embarrassment about asking, 
maintaining confidentiality, and simplicity of 
packaging. Participants indicated that they 
would be confident in collecting a self-
administered vaginal swab in the privacy of 
their homes. Women posed concerns about the 
safety and sterility of the swab, stating that 
they wanted to be sure it was sealed before 
using. The option of using a preaddressed 
package to mail the kit to the laboratory for 
testing was viewed positively by all. Many 
changes were suggested about the 
advertisements and questionnaires, as well as 
the kit instructions. The option of taking the 
questionnaire on the Internet was viewed 
favorably by most. Participants described 
many improvements to the kit instructions, to 
include simplification of instructions and 
color-coding of forms to promote proper use of 
the kit. Focus group members were pleased 
with the idea of calling a free 800 number to 
obtain their results. The groups valued 
availability of free and confidential treatment. 
For obtaining results, they expressed that a 
method was needed to be sure that no one else 
would know the nature of their call. 
The information obtained from the 
focus groups supported the concept of a web 
site that could address women's concerns, 
educate, allow for self-assessment of level of 
risk, and assist with access to chlamydia 
screening using home sampling. Valuable 
information was gained regarding the need to 
be sensitive to confidentiality and the need for 
secure packaging of collection kits. 
Implementation of this study must include 
ongoing assessment, including focus group 
feedback. 
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CHLAMYDIAL AND GONOCOCCAL CO-INFECTION AMONG MALE AND 
FEMALE ATTENDEES AT A STD CLINIC 
Azevedo J *, Santo I, Gomes JP, Borrego MJ 
Consulta de Doengas Sexualmente Transmissíveis do Centro de Saúde da Lapa, Lisboa, Portugal 
To determine the frequency of 
Chlamydia trachomatis (CT) genital associated 
with gonococcal (GC) infection among 
attenders at the STD Clinic in Lisbon. 
All female subjects attending the STD 
Clinic, for the first time or seeking care for a 
new problem, male patients attending the 
clinic for STI screening (with or without 
urethral symptoms), and sexual partners of 
patients diagnosed with CT/GC infection, were 
tested for gonorrhoea and Chlamydia 
trachomatis genital infection. 
Co-infection with CT was more likely to be 
diagnosed among females, in younger 
individuals and in individuals of black African 
ethnic group. 
The rate of chamydial and gonococcal 
co-infection was 20.2%. 
The high proportion of cases of gonorrhoea 
that also had chlamydia justifies the policy of 
epidemiological treatment for chlamydia 
carried out in the STD Clinic of Lisbon. 
Patients with diagnosed GC infection were 
identified in the four-year period of 2000 -
2003 at the STD Clinic in Lisbon. All of these 
patients had GC positive cultures and their 
urine samples have been tested for CT, using 
PCR-Amplicor (Roche™) in the Bacteriology 
Department of National Institute of Health. 
Demographic, behavior and clinical data 
(including history of STI and presence of other 
STIs) were analyzed. Data from patients with 
GC and those co-infected with CT were 
compared. 
Treatment was successfully provided to all 
persons with positive results. 
104 episodes of gonorrhoea (83 men 
and 21 women) were identified. Information 
on CT infection was available for all these GC 
cases, of whom 21 (20.2%) were found to be 
co-infected with CT. 
Over half of the cases were caucasian, 25% 
were black African. Median age was 30.5 
(range 16-72) years. 9 male and 7 female 
patients were previously known HIV positive. 
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SCREENING FOR GENITAL CHLAMYDIA TRACHOMATIS INFECTIONS IN 
MEN WITH URETHRITIS IN ISTANBUL 
Ali Agacfidan*, Mustafa Onel*, Hayati Beka*, Ates Kadioglu**, Taner Lama* 
Istanbul Faculty of Medicine, Departments of * Microbiology and Clinical Microbiology, &** 
Urology, Istanbul, Turkey 
Istanbul with its close areas is the 
biggest city in Turkey with covering about 12 
million population is almost one fourth of the 
total population of the country. In recent years, 
increasing migration of sex-workers across 
European borders into Turkey has resulted in 
increased unregistred sex-workers and men 
infected with sexually transmitted diseases 
(STDs) owing to sexual exposure with these 
women. Several studies have also reported the 
increase in prostitution along national border 
as well as associated increases in STDs 
including C. trachomatis. 
For this purpose, symptomatic men 
were screened for C. trachomatis by a nucleic 
acid amplification assay known as the Gen-
Probe Amplified C. trachomatis assay (AMP 
CT) (Gen-Probe Inc. San Diego, CA). From 
January 2002 to February 2004, 1112 
consecutive men with sign or symptoms 
urethritis were enrolled in this study. All 
patients were screened for C. trachomatis and 
questioned on their recent within 1 month 
sexual exposure with a sex-worker. The 
clinician also asked whether they used 
condoms during previous sexual exposures. 
Urethral swabs were collected and processed 
according to the manufacturer's instructions. 
Patients with C. trachomatis were treated with 
a single oral dose of azithromycin. 
The prevalence of C. trachomatis, as 
determined by AMP CT was 15.3 % 
(170/1112). The average age was 33.2 ± 6.3. 
Most of C. trachomatis was found in lower age 
range. All Chlamydia positive patients 
reported exposure with a foreign sex worker 
within 1 month. None of the screened men had 
stated sexual exposure with Turkish sex-
workers. These men also denied condom use 
during their previous sexual exposures. 
C. trachomatis is frequently detected in 
men with urethritis in Istanbul. The lack of 
condom use among these men is also risk 
behaviour for STDs. Screening programs and 
education about condom use in these men and 
sex-workers could help in the overall reduction 
of Chlamydia and other STDs. 
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LIGASE CHAIN REACTION AS A TOOL FOR THE DETECTION OF 
OCCULT CHLAMYDIAL PROSTATIC INFECTION 
1 ^ ¡ b O A 
I.Ostaszewska-Puchalska, B.Zdrodowska-Stefanow , R.Bielecki , M.Baltaziak , 
M.Skawronska2, R.Kozlowski2, M.Wilkowska-Trojniel2 
Center for STD Research and Diagnostics, Bialystok, Medical Academy, Bialystok, Department of 
Dermatology and Venerology, Department of General Pathology, Department of Forensic 
Medicine; Department of Urology, The J. Sniadecki Memorial Integrated Hospital, Bialystok, 
Poland 
Chronic Prostatitis-Chronic Pelvic Pain 
Syndrome (CP-CPPS) is a common urological 
problem that causes substantial patient 
morbidity and significant costs for the health 
care system. It accounts for approximately 25 
% of outpatient visits for genitourinary 
complaints. Unlike BPH and prostate cancer, 
which are predominantly diseases of older 
men, prostatitis affects men of all ages. The 
overall prevalence of rate of prostatitis was 9 
%, similar to the rate of ischemic heart disease 
and diabetes. 
Chlamydia trachomatis (C. trachomatis) is one 
of the most frequent pathogens in sexually 
transmitted diseases. Although there is no 
consensus among investigators on the actual 
role of chlamydial infection in the 
pathogenesis of chronic prostatitis, some 
reports indicate that C. trachomatis might be 
responsible for 30 to 56% of cases. The main 
reasons responsible for underestimation of the 
rate of chlamydial infection are difficulties 
with C. trachomatis culturing and 
identification. 
The aim of this study was to investigate 
the incidence of occult chlamydial infection in 
category m prostatitis among sexually active 
men referred for prostate biopsy. 
Between January and March 2003 86 men 
age 55-78(mean age 65) were refereed to our 
department for prostate cancer check-up 
because of elevated PSA level and/or abnormal 
digital rectal examination. Study was 
performed on 30 patients age 55-78 (mean age 
63) in whom prostate cancer was ruled out and 
the diagnosis of category m, chronic 
nonbacterial prostatitis, was raised on the basis 
of the following findings: 
Pathological evidence of prostatic 
inflammation on histology preparations of 
prostate biopsy specimens. 
- Positive history including NEH-Chronic 
Prostatitis Symptom Index (CPSI). 
- Significant number of white blood cells in 
expressed prostatic secretion (EPS) or 
postprostatic massage urine specimen. 
- Category n, chronic bacterial prostatitis, was 
excluded on the basis of negative cultures. 
- None of the patients received antibiotics for 
at least 3 months before sampling. 
Sera samples were sought for specific anti-
chlamydial IgG and anti-chlamydial IgA 
antibodies by commercial enzyme 
immunoassays. 
Urethral smears and biopsy tissue specimens 
were tested for chlamydial DNA by means of 
ligase chain reaction (LCR). 
Two out of 30 patients enrolled in the 
study had positive results of LCR for 
chlamydial DNA in prostatic tissue samples. 
They were 60 and 68 years of age respectively. 
Both were sexually active. Tissue samples 
obtained from both patients revealed mild to 
moderate signs of prostatitis on histology 
preparations. None of those patients had 
positive history for prostatitis. Sera and EPS 
samples were negative for IgA and IgG anti-
chlamydial antibodies. No leukocytes were 
seen in EPS samples. 
C. trachomatis may cause 
asymptomatic prostatitis. LCR is an easy and 
helpful method for diagnosing urinary tract 
chlamydial infections. 
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EVALUATION OF DIAGNOSTIC PERFORMANCE OF DIFFERENT ASSAYS 
FOR DETECTION OF CHLAMYDIA TRACHOMATIS IN PATIENTS WITH 
RECURRENT UROGENITAL INFECTION 
Hala Badawi1*, Maisa Omar1, Aisha Abu-Aitta1, Mahmoud Romeih2, Essam Riad3 and 
Mohamed Ali Saber2 
Microbiology1, Biochemistry2 Urosurgery3 Departments of Theodor Bilharz Research Institute, 
Imbaba, Giza, Egypt 
Chlamydia trachomatis (CT) urogenital 
infection is a major cause of morbidity in 
sexually active individuals worldwide. It has 
serious sequelae if undiagnosed and 
consequently untreated. 
This study was designed to assess the 
role of CT in the etiopathogenesis of recurrent 
urogenital infection (RUGI) in male patients 
with or without urinary schistosomiasis. The 
performance characteristics of urine-based 
detection of CT using direct fluorescent 
antibody (DFA), enzyme immunoassay (EIA) 
and PCR for plasmid DNA amplification were 
evaluated. IgM seroprevalence for diagnosis of 
active CT infection was investigated using 
micro-immunofluorescent (MIF) assay. 
Three groups were enrolled in the 
study. Two patients' Groups, 40 male patients 
each, with RUGI and with (Group I)or without 
(Group EI) urinary schistosomiasis. Group IH, 
20 male healthy control subjects. Patients and 
controls were subjected to complete clinical 
and laboratory assessment. First voided urine 
(FVU) samples were collected and investigated 
for CT antigen using DFA and EIA and CT 
plasmid DNA using PCR. Blood samples were 
collected and sera were investigated for the 
presence of species-specific IgM antibodies by 
the MIF test. 
The results of the four assays were 
analysed against an expanded reference 
standard in which a specimen was considered 
true positive if it was positive by at least two 
independent tests. The overall prevalence of 
CT infection in our patients was 37.5%. The 
frequency of infection was significantly higher 
in schistosomal (47.5%) versus non-
schistosomal (27.5%) patients. DFA and PCR 
showed better performance than EIA and MIF 
assays. Sensitivity, specificity, positive and 
negative predictive values were 100%, 98%, 
96.8% and 100% for DFA, 93.3%, 100%, 
100% and 96.2% for PCR versus 70%, 100%, 
100% and 84.7% for EIA, 43.3%, 86%, 65% 
and 71.7% for MIF respectively. DFA and 
PCR assays identified correctly 98.7% and 
97.5% of the tested individuals respectively. 
EIA sensitivity increased to 90% after 
verification of negative grey zone (NGZ) 
samples. The results of all assays were 
negative in the control subjects. 
CT was found to be an important cause 
of RUGI particularly in patients with urinary 
schistosomiasis. DFA and PCR are very 
accurate assays and are superior than EIA and 
MIF. Both tests are recommended in 
laboratories where facilities for their 
performance are available. EIA can be an 
alternative cost effective approach with 
reasonable sensitivity if NGZ samples are 
confirmed with DFA or PCR. Although MIF-
IgM is unreliable test with bad diagnostic 
performance, yet it documents a considerable 
number of active infection. Awareness of the 
extent of CT urogenital infection with its 
serious sequelae together with early diagnosis 
and prompt treatment would control the spread 
of infection in our institute. 
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DIAGNOSIS OF LYMPHOGRANULOMA VENEREUM USING 16S RRNA-
BASED FLUORESCENT IN SITU HYBRIDIZATION (FISH) 
Andreas Essig*, Judith Rampf, Cord Sunderkötter and Sven Poppert 
Department of Medical Microbiology and 
Allergology, University of Ulm, Germany 
In this paper, we report the case of a 
young man with Lymphogranuloma venereum 
(LGV) that inspired us to develop a FISH-
based method for identification of 
C. trachomatis biovar LGV. 
In June 2003, a 19 year-old 
immunocompetent homosexual man presented 
with genital ulcer and painfully enlarged 
inguinal lymph nodes in the outpatient clinic 
for dermatology of our university hospital. A 
serum sample was taken for detection of 
antibodies against Treponema pallidum, herpes 
simplex virus, and Chlamydia trachomatis. 
Urethral and ulcer swabs were taken for PCR 
detection and tissue culture of C. trachomatis. 
DNA was extracted from infected HeLa 229 
cell cultures and PCR amplification of the 
ompA gene was performed The sequence of the 
PCR product was determined using an ABI 
PRISM 310 Genetic Analyzer (Applied 
Biosystems). 
In a previous study, we demonstrated the 
usefulness of FISH using rRNA targeted 
oligonucleotide probes for detection and 
differentiation of Chlamydiae. Therefore, a 
16S rRNA-based oligonucleotide probe set 
was developed as a new diagnostic tool for 
identification of C. trachomatis biovar LGV 
strains. 
PCR testing for C. trachomatis using 
the automated Cobas Amplicor PCR system 
was positive from an ulcer swab and tissue 
culture yielded typical inclusion bodies that 
were identified by using a monoclonal 
antibody against the MOMP of C. trachomatis. 
Genotyping of the isolate revealed a sequence 
homology of 99.2% to C. trachomatis serovar 
L2. Antibody testing using a commercially 
Hygiene, and Department of Dermatology and 
available microimmunofluorescence test (MIF) 
revealed IgM antibodies of 1:16 and IgG 
antibodies of 1:512 against C. trachomatis. A 
16S rRNA-based oligonucleotide probe set 
was complemented with a specific probe 
against C. trachomatis biovar LGV. We could 
demonstrate that the newly designed probe 
specifically hybridized with the patients's 
isolate and the target organisms including C. 
trachomatis biovar LI, L2, and L3. The LGV-
specific probe did not give positive signals 
with the tested nontarget organisms including 
C. trachomatis strains of the trachoma biovar 
and C. pneumoniae. 
In respect to the international contacts 
of the patients, sporadic cases and outbreaks of 
LGV may also occur in countries where the 
agent is not endemic. Therefore, clinicians 
should be aware of the typical clinical picture 
of LGV. Rapid diagnosis and adequate therapy 
prevents development of complications as well 
as further spread of the organisms. We could 
demonstrate that FISH using 16S rRNA 
targeted oligonucleotide probes enables rapid 
and easy identification of culture grown strains 
of C. trachomatis biovar LGV. Further studies 
are needed to demonstrate its usefulness for 
direct detection of the organisms from ulcer 
swabs and bubo pus. 
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EIA VS SDA - ARE WE REALLY MISSING OUT? 
Margaret Sillis*, Sue Skidmore 
Norfolk & Norwich University Hospital*, Norwich, Princess Royal Hospital, Apley Castle, 
Telford, UK 
Various initiatives, used to investigate 
the best approach for Chlamydia trachomatis 
screening, have generally concentrated on 
women. However, if a significant impact on 
levels of infection is to be made then men must 
also be included. It is accepted that screening 
samples should be non invasive and that urine 
is a useful candidate. It is debatable which is 
the best test to use and, whilst it has generally 
been found that a nucleic acid amplification 
test (NAAT) should be used for female urines, 
there have been reports which suggest that dual 
amplification enzyme immunoassay (EIA) may 
be acceptable for male samples. This study 
looks at comparing male urines using EIA and 
SDA at 2 testing sites - one (A) where EIA is 
the primary test and site B where SDA is the 
primary test. 
Specimens from males attending a 
GUM clinic at Site A were submitted as 
2x20ml aliquots of urine, where the first void 
aliquot was tested by EIA and, if positive, 
confirmed by SDA. The second void was 
tested only by SDA. Specimens at Site B were 
submitted as a 40ml aliquot and tested by EIA 
and SDA. IDEIA PCE EIA (Dako) and BD 
ProbeTec SDA (Becton-Dickinson) were 
carried out according to the manufacturers' 
instructions. Samples found initially reactive in 
the NAAT were repeated. Negative grey 
zone(50%)EIA testing was used. This strategy 
is defined as the confirmation of a positive GZ 
EIA result by SDA. 
986 male urine samples collected for 
routine diagnostic testing were tested. Site A 
tested 386 samples. 339 samples were negative 
in both assays and a total of 47 were 
considered to be positive (12.1%). 44 were 
positive in both assays with 2 in the grey zone 
(GZ - ie value within 0.025 absorbance units 
below that of the calculated cut-off) and 3 
were positive by SDA but negative by EIA. 
The sensitivity of the EIA compared to NAAT 
was therefore 89.3% increasing to 93.6% if 
negative grey zone testing was used. Site B 
tested 600 samples. 490 were negative and 110 
(18.3%) were positive. 80 were positive in 
both assays including 3 GZ and 30 were 
positive by SDA but negative by EIA. The 
sensitivity was therefore 70.6% or 73.3% with 
negative GZ testing. 
The relative performance of the two 
tests suggested that site-specific factors_were 
involved -this may be related to technical 
performance of the assays, the nature of the 
patient population tested or to the specimen 
quality and impact of a potential dilution effect 
in specimens from Site B. At Site A GUM the 
policy of holding urine for 2h prior to 
specimen collection is strictly adhered to, 
hence the quality of the first void is likely to be 
high. Further tests are in progress to ascertain 
what impact the difference in specimen 
collection procedure and dilution effect may 
have had. Initial findings suggest that the 
impact on the EIA results will be more 
markedly affected than for SDA, as explained 
by reduced antigen load. A number of reports 
in the literature from Japan, Canada and the 
UK have demonstrated sensitivities >91% and 
specificities >99% when comparing the DAKO 
PCE assay with NAATs using various 
specimen types from 'high risk' populations. 
This is in agreement with results from Site A. 
Conversely, the UK CLASS study results were 
similar to those found at Site B. These findings 
will be discussed fully later. 
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CHLAMYDIA TRACHOMATIS AND HUMAN PAPILLOMA VIRUS IN PAP 
SMEAR RESULTS 
Elena T. Dokic*, M. Petrovska, T. Grdanovska, N. Panovski 
Institut of Microbiology, Medical Faculty, Vodnjanska, Skopje, R. Macedonia 
Chlamydia trachomatis (C. 
trachomatis) and Human papilloma virus 
(HPV) are important causes of sexually 
transmitted diseases worldwide. Many cervical 
infections caused by both of them are 
asymptomatic or associated with mild, 
nonspecific symptoms. Consequently, accurate 
laboratory diagnosis of C. trachomatis and 
HPV is necessary to direct real treatment and 
to elucidate the epidemiology of infection. 
The aim of our study was to examine 
whether the cervical C. trachomatis and HPV 
infections are common in women with 
abnormal Pap smears in relation to women 
with correct Pap smears. 
A total of 70 women (age between 20 -
50 years) who applied to Gynecology clinic 
within two months were enrolled to this study. 
In all women was done cytological 
examination by Papanicolou method. In their 
cervical swabs was examined the presence of 
C. trachomatis and HPV by polymerase chain 
reaction (PCR). 
C. trachomatis and HPV screening tests 
were positive in 5 (7,1%) and 15 (21,4%) of 70 
cases. C. trachomatis was positive in two 
women with Displasio cervicis. In the same 
patients were detected HPV type 58 as well. In 
three cases C. trachomatis was found in 
women with correct Pap smear results. HPV 
infection was determined in 8 (53,3%) cases 
with CIN m, in 5 (33,3%) cases with CIN E 
and in 2 (13,3%) cases with Displasio cervicis. 
All HPV's detected in patients with CIN IE 
belonged to type 16. Three HPV's detected in 
women with CIN E were type 16 and two of 
them were type 58 like the two HPV's detected 
in patients with Displasio cervicis. 
This study revealed that cervical 
infection could be caused by C. trachomatis 
and HPV at the same time, and that women 
with cervical HPV infection are much more 
likely to have cytological abnormality of 
cervical epithelia than women with C. 
trachomatis infection. 
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EXPANDED CHLAMYDIA TRACHOMATIS SEROLOGY: CHSP60 IGG AND 
ITS ASSOCIATION WITH TUBAL OCCLUSION 
Clad A1*, Petersen E E1, and Böttcher M2 
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Chlamydia trachomatis infection is the 
most prevalent sexually transmitted bacterial 
disease worldwide and the primary single 
cause of female infertility and ectopic 
pregnancy. About 20-30% of all women who 
undergo in vitro fertilisation have tubal factor 
infertility and more than 80% of tubal 
occlusion is due to ascending genital 
chlamydial infection, which remains 
asymptomatic in most cases. Direct detections, 
e.g. by DNA amplification, of C. trachomatis 
in cervical swabs or first-void urine prove 
current genital chlamydial infection, but 
provide no information about the risk of tubal 
damage. Antibodies against chlamydial heat 
shock protein 60 (cHSP60) have been found to 
be significantly associated with tubal occlusion 
(Eckert LO et al., JID 1997) in women with 
laparoscopically verified PID possibly by 
autoimmune crossreactions with the human 
heat shock protein. The aim of this study was 
to investigate whether the positive predictive 
value for tubal occlusion can be improved by 
combined detection of anti-C. trachomatis 
MOMP and anti-cHSP60 antibodies (expanded 
C. trachomatis serology). Antibodies against 
cHSP60 were measured by using the first 
commercially available cHSP60-IgG test. 
126 women who underwent 
laparoscopy for different reasons, e.g. myoma, 
endometriosis, lower abdominal pain, 
infertility, were investigated by C. 
trachomatis-IgG-pELISA medac (C. 
trachomatis specific MOMP antibodies) and 
cHSP60-IgG-ELISA medac (medac, Hamburg, 
Germany). 24 of these 126 women had 
bilateral tubal occlusion, 102 had 
macroscopically normal fallopian tubes and 
showed no obstruction in the 
chromopertubation tests. 
18% (18/102) of the women with 
normal fallopian tubes were positive for anti-
MOMP IgG in pELISA, while 88% (21/24) of 
the women with occluded tubes were positive. 
The positive predictive value of anti-MOMP 
IgG for tubal occlusion was 53.8%, the 
negative predictive value was 96.6%. 
Reactivity for both anti-MOMP IgG and anti-
cHSP60 IgG was found in 11% (11/102) of the 
women with open tubes and in 79% (19/24) of 
the women with bilaterally occluded tubes. 
The positive predictive value for tubal 
occlusion of the expanded C. trachomatis 
serology was 63.3% compared with 53.8% for 
anti-MOMP IgG alone. The negative 
predictive value for tubal occlusion was 94.8% 
(expanded serology) compared with 96.6% 
(anti-MOMP IgG). 
Positive cHSP60-IgG in women with 
positive C. trachomatis MOMP-IgG 
(expanded C. trachomatis serology) indicates a 
higher risk of tubal damage compared with 
patients with negative cHSP60-IgG. In women 
with current genital chlamydial infection 
(positive direct detection test) a positive 
cHSP60-IgG may indicate ascending infection 
and warrant a longer antibiotic treatment, e.g. 
20 days instead of 10 days. Chlamydial tubal 
infection often remains clinically 
asymptomatic unless superinfection by vaginal 
bacteria occurs, e.g. in women with bacterial 
vaginosis. Expanded C. trachomatis serology 
including cHSP60-IgG in asymptomatic 
women with current chlamydial infection and 
positive MOMP-IgG appears to be the only 
marker associated with a higher risk of tubal 
damage. Studies are needed to determine the 
relative risk of tubal damage in cHSP60-IgG 
positive compared with cHSP60-IgG negative 
women with current genital chlamydial 
infection. 
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CHSP60-IGG-ELISA MEDAC: EVALUATION OF A NEW RESEARCH ASSAY 
FOR DETECTION OF IGG ANTIBODIES TO CHLAMYDIAL HEAT SHOCK 
PROTEIN 60 
Dreesbach K1*, König T1, Christiansen G2, Pedersen AS3, Birkelund S2'3, and Franke D1 
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The role of chlamydial heat shock 
protein 60 (cHSP60) in immunopathogenesis 
of chlamydial disease, especially with regard to 
the female reproductive tract, has been dis-
cussed controversially because of various dis-
crepant findings. They may be due to the use 
of non-standardized in-house tests without a 
clearly defined cut-off. A commercial assay 
suited for routine use should improve the com-
parability of results obtained in different labo-
ratories. We evaluated the new, commercially 
available cHSP60-IgG-ELISA medac with 
regard to precision, suitability for automation 
and quantitation and assessed the possibility to 
discriminate between cHSP60 antibody 
prevalence in healthy individuals and various 
patient cohorts. 
The cHSP60-IgG-ELISA medac uses 
recombinant full-length HSP60 from 
Chlamydia trachomatis and has a defined cut-
off. For evaluation of precision data, each 22-
fold determinations of six sera of different re-
activity were performed for intra-assay vari-
ance, and each 11 independent test runs of 
seven sera for interassay variance. For assess-
ment of the accuracy of end-titer calculation 
twelve sera were titrated. Automation suitabil-
ity was investigated using the DIAS in parallel 
to manually performed test runs. Intra-assay 
(10-fold determination) and interassay variance 
(11 independent test runs) as well as 31 
different sera from the cohorts below were 
measured. Furthermore, 12 sera were tested 
manually and on the BEP IE in parallel. In a 
small pilot investigation antibody prevalence 
was determined in the following cohorts: 100 
blood donors, 37 children, 68 female infertility 
patients (secondary sterility or laparoscopically 
diagnosed TFI), and 44 patients with reactive 
arthritis. 
cHSP60-IgG-ELISA medac demon-
strated a good reproducibility concerning 
intra-assay and interassay variance (<10.5%) 
for both manually and automatically performed 
investigations. Moreover, a good correlation 
between manually and automatically per-
formed test runs was found (r2=0.98). Finally, 
reliable end-titers can be calculated from a 
single OD measurement. The comparison of 
antibody prevalence in blood donors and chil-
dren with various patient groups revealed dis-
tinct differences between blood donors and 
children (14% and 8%) and the infertility 
group as well as the patients with reactive ar-
thritis (60% and 64%). 
The technical performance of cHSP60-
IgG-ELISA medac revealed the possibility to 
obtain future comparable results in various 
laboratories, which could not be obtained with 
the current in-house tests. First prevalence data 
obtained with the cHSP60-IgG-ELISA medac, 
particularly in patients with sequelae due to 
chlamydial upper genital tract infections, seem 
to be promising concerning the diagnostic 
usefulness of this assay. Further studies in 
larger cohorts have to be performed in order to 
work out the diagnostic value of cHSP60 
antibody determination in such diseases. 
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THE COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES FOR 
DETECTION OF CHLAMYDIA TRACHOMATIS 
K. Shalepo, T. Khusnutdinova, O. Misyurina*, E. Shipitsyna, O. Budilovskaya, A. 
Savicheva 
The D.O. Ott Research Institute of Obstetrics and Gynecology, St. Petersburg, *Research Institute 
of Physico-Chemical Medicine, Moscow, Russia 
Objective: Comparison of commercial antibody. C. trachomatis serotype E was the 
tests-systems available in Russia for detection most prevalent in St. Petersburg, 
of Chlamydia trachomatis by direct 
immunofluorescent (DIF) assay. 
A total of 870 sexually active men and 
women were examined with the aim of 
detection of C. trachomatis. Urethral and 
cervical swabs from men and women, 
respectively, were cultured in cycloheximide-
treated McCoy cells with subsequent 
visualization of chlamydial inclusions using 
Chlamydia Direct IF (ID) (bio-Merieux, 
France). C. trachomatis were detected in 20 
(2.3%) patients. After that all samples were 
cultured in parallel and stained with two 
antibodies, one of which was directed against 
the major outer membrane protein (MOMP) 
and the other against the lipopolysaccharide 
(LPS). 
All samples were culture positive by 
the anti-LPS antibody (Russia), whereas only 
11 were positive by the anti-MOMP antibody 
(Russia). In the rest 9 samples stained with the 
anti-MOMP antibody the fluorescence 
intensity was very low, so that the samples 
could not be interpreted as positive. When the 
anti-LPS antibody was used, the fluorescence 
intensity was high both for EB and RB. All 
positive samples were typed. The following 
serotypes were found: E (40%), G (30%), K 
(15%), B, D, I (5%). The anti-MOMP antibody 
failed to detect C. trachomatis serotypes G and 
K. 
Monoclonal anti-LPS antibody was 
shown to be more sensitive for C. trachomatis 
detection in cell culture than anti-MOMP 
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SEROLOGIC MARKERS OF CHRONIC C. TRACHOMATIS INFECTIONS IN 
SUBFERTILE WOMEN 
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Measuring IgG antibodies to C. 
trachomatis (Ctr) is a standard screening test 
for distal tubal pathology (DTP) in subfertile 
women. It has been assumed that chronic 
infections increase the extent of DTP. The 
aims of this study were to evaluate the 
prevalence of serologic markers of chronic Ctr 
infections in subfertile women with and 
without DTP, and to determine the clinical 
relevance of these tests, in addition to the 
standard screening test, in predicting the risk 
of DTP. 
We included 313 subfertile women, 
who underwent a laparoscopy with tubal 
testing to assess the grade of DTP. DTP was 
defined as extensive periadnexal adhesions 
and/or distal occlusion of at least one tube. Our 
standard screening test for the detection of 
serum IgG antibodies to Ctr (AniLabsysterns, 
Finland) was performed, as well as three tests 
for serologic markers of chronicity: IgA 
antibodies to Ctr (AniLabsystems, Finland), 
IgG antibodies to Ctr-HSP (Medac, Germany) 
and an in-house highly sensitive CRP-test. A 
ROC-curve was constructed to determine the 
optimum cut-off level for CRP (1.16 pg/ml). 
For the other tests, cut-off levels were used 
according to the manufacturers' instructions. 
The test results were correlated to the presence 
of DTP. The chi-square test was used to 
compare the prevalence of positive tests in 
women with and without DTP. Positive and 
negative predictive value (PPV and NPV) and 
odds ratio (OR) were calculated. The bootstrap 
technique was used to test the differences 
between OR. P < 0.05 was considered 
statistically significant. 
DTP was found in 59 women (19%), 
whereas 254 women (81%) had no DTP. The 
prevalence of IgG to Ctr was 54% in women 
with DTP,'and 8% in women without DTP (P 
< 0.05). The prevalence of IgA to Ctr was 44% 
in women with DTP, and 13% in women 
without DTP (P < 0.05). The prevalence of 
IgG to Or-HSP was 54% in women with DTP, 
and 20% in women without DTP (P < 0.05). 
The prevalence of a positive CRP was 51% in 
women with DTP, and 37% in women without 
DTP. In 52 women, IgG to Ctr was detectable. 
This -test had a PPV of 62%, a NPV of 90% 
and an OR of 13.9. In 34 women, both IgG and 
IgA to Ctr were detectable. This test 
combination had a PPV of 62%, a NPV of 
86% and an OR of 10.2. In 47 women, both 
IgG to Ctr and CYr-HSP were detectable. This 
test combination had a PPV of 62%, a NPV of 
89% and an OR of 12.7. In 19 women, both 
IgG to Ctr and a positive CRP were detectable. 
This test combination had a PPV of 84%, a 
NPV of 85% and an OR of 31.1. This increase 
in OR, as compared to measuring IgG to Ctr 
only (OR 13.9), was not statistically 
significant. 
The prevalence of the serologic 
markers of chronicity evaluated, is higher in 
subfertile women with DTP as compared to 
those without DTP. Chronic Ctr infections 
seem to be an important risk factor for the 
development of DTP. The PPV and OR of the 
currently used screening test (IgG to Ctr) can 
only be improved by adding CRP. However, 
the increase in OR is not statistically 
significant. The clinical relevance of this test 
combination in predicting the risk of DTP is 
limited, since it can only identify 16 out of 59 
(27%) subfertile women with DTP. 
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IDENTIFICATION OF CHLAMYDOPHILA PNEUMONIAE ANTIGENS BY 
PHAGE DISPLAY TECHNOLOGY 
Markus Mueller, Sebastian Bunk, Stefan Michelfelder, Thomas Härtung, Corinna 
Hermann* 
Biochemical Pharmacology, University of Konstanz, Konstanz, Germany 
The microimmunofluorescence test, the 
current gold standard in Chlamydophila 
pneumoniae serodiagnosis, is based on whole 
elementary bodies as antigen and only reliable 
if performed by an experienced reader. 
Partially automated ELISAs are more objective 
but often lack sensitivity and specificity, since 
they are based on C. pneumoniae-lysates or 
few extracted proteins. The aim of this project 
was to identify specific C. pneumoniae 
antigens by means of the phage surface 
display. The antigens shall be recombinantly or 
synthetically produced and used to improve C. 
pneumoniae serodiagnosis. 
A C. pneumoniae expression library 
was constructed by cloning C. pneumoniae 
TWAR-183 DNA into the pJuFo vector. The 
primary clone size of this library was 7.2 * 105. 
Next the inserted fragments were cloned into 
all three reading frames and both reading 
orientations which resulted in a library with a 
complexity of 8.2 * 106 independent clones. 
Two different serum pools were used for 
biopanning: The selection pools consisted of 
sera from eight atherosclerosis patients and of 
20 sera from healthy volunteers. The antibody 
titers for C. pneumoniae IgG were determined 
by ELISA (SeroCP Quant, Savyon Diagnostic) 
and MIF (SeroFIA MIF, Savyon Diagnostic). 
All sera were positive for C. pneumoniae and 
had an antibody titer >1:512. Five rounds of 
affinity selection were performed. The 
enrichment of phage was monitored by 
titration of the number of colony forming units 
after each cycle of selection and growth. PCR 
analyses of selected clones obtained after the 
fifth round of affinity selection were performed 
in order to identify and characterize the 
enriched genes. 
A random phage surface displayed 
genomic library of C. pneumoniae TW 183 
with a complexity of of 8.2 * 106 was 
established. The diversity of the library, tested 
by PCR analysis and gel electrophoresis of 70 
clones, was high with less than 5% empty 
vectors. After affinity selection six clones 
showing different insert sizes between 300bp 
and 600bp were obtained. Restriction analysis 
and sequencing of affinity enriched clones 
revealed 9 different sequences. Four of them 
coded for chlamydial proteins, while five were 
inserted in the wrong direction. No differences 
were seen between the two sera pools. The 
sequence for the porphobilinogen deaminase 
was present in -12% and for the protein 
deoxyribunuclease V beta in 9% of the 
enriched clones. Furthermore, open reading 
frames encoding an integral membrane protein 
and an enoyl-acyl-carrier protein were found at 
lower frequencies. Reverse transcription PCR 
analysis showed that all enriched sequences 
were indeed transcribed during infection of 
HEp-2 cells. Currently, on the basis of relative 
hydrophobicity blots, predicting B-cell 
epitopes, peptides are synthesized, which shall 
be further evaluated for C. pneumoniae 
serodiagnosis. 
Phage display technology represents a 
powerful method to identify novel antigens by 
their affinity to patients' anibodies from 
genomic libraries. Here, the method was 
applied for the first time to C. pneumoniae. 
The suitability of these proteins as diagnostics 
or as vaccine requires further evaluation. 
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RAPID CHLAMYDIA PNEUMONIAE QUANTIFICATION IN CLINICAL 
SAMPLES BY LIGHTCYCLER REAL-TIME PCR 
R. Sessa*, G. Schiavoni, A. Petrucca1, M. Di Pietro, S. Fallucca, C. Zagaglia, P. 
Cipriani, C.R. Noval2, M. del Piano 
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In recent years, many clinical and 
experimental studies have focused their 
interest on the growing evidence for a strong 
link between Chlamydia pneumoniae and 
pathogenesis of atherosclerosis. 
The aim of our study was to evaluate the 
presence of C. pneumoniae DNA in peripheral 
blood mononuclear cells (PBMC) and in 
atheromatous plaques obtained from patients 
undergoing carotid endarterectomy by a novel 
FRET LightCycler assay (Ciervo A et al., 
2003) and to compare results with nested 
touchdown ompA-based PCR. The latter PCR 
assay has been recommended as C. 
pneumoniae-PCR standard method by the 
Centers for Disease Control and Prevention 
(USA) and Laboratory Centre for Disease 
Control (Canada) (Dowell SF, et al 2001) 
Furthermore, the performance in terms 
of sensitivity and reproducibility of real-time 
PCR assay was also evaluated. 
Until now, 30 consecutive patients 
undergoing carotid endarterectomy were 
enrolled in this study. Atheromatous carotid 
plaques and PBMC specimens were obtained 
from each patient during surgery. 
DNA was extracted from all clinical specimens 
with a Qiagen QIAamp DNA kit according to 
the manufacturer's instructions. 
Detection and quantitation of C. pneumoniae 
DNA in atheromatous carotid plaques and in 
PBMC specimens was performed by real-time 
PCR based on FRET LightCycler probes 
hybridizing an internal, 128 bp region of Pstl 
species-specific fragment. Moreover, all DNA 
extracted from clinical specimens were also 
analyzed by nested touchdown ompA-based 
PCR. DNA from clinical samples were tested 
in triplicate in each PCR assay performed in 
this study. 
In our hands, LightCycler real-time 
PCR based on C. pneumoniae Pstl species-
specific fragment was highly sensitive (from 
106 to 25 C. pneumoniae genomic equivalent) 
and reproducible. 
Overall, 60 tissue specimens (30 carotid 
plaques, 30 PBMC) were examined for 
presence of C. pneumoniae DNA. 
All PCR assays were able to detect C. 
pneumoniae DNA in clinical sample but 
LightCycler real-time PCR revealed a higher 
number of positive samples than nested 
touchdown ompA-based PCR and showed no 
inhibitor tendency, furthermore a higher 
number of genomic equivalent of C. 
pneumoniae was found by real-time PCR in 
PBMC specimens than in atheromatous carotid 
plaques. 
In this study we present evidence that 
PBMC-based real-time PCR may be a useful 
tool for identifying subjects earring C. 
pneumoniae, even at a low concentration, in 
the circulation or in the vascular wall as well. 
It will be a specific indicator of current 
infection and will be used as a marker for 
assessing the microbiological efficacy of 
antichlamydial therapy in clinical intervention 
trials. Moreover, PCR amplification assay by 
LightCycler typically lasted 50-60 min while 
amplification by nested PCR and agarose gel 
detection are associated with a more complex 
workflow and a high risk of carry-over 
contamination and typically lasted 5-6 h for 
completion and accurate reading. 
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DETECTION OF CHLAMYDIA TRACHOMATIS IN DIFFERENT SPECIMEN 
TYPES USING REAL-TIME PCR 
Meike Eickhoff* (1), Sven Thamm (2), Gerd Michel (2) 
(1) artus GmbH, Hamburg, Germany (2) Abbott GmbH & Co. KG, Delkenheim, Germany 
The diagnostic testing for genital 
chlamydia infection has changed in the past 
few years. Until recently, the gold standard for 
identifying C. trachomatis has been culture 
methods. Although specific, this procedure is 
time consuming, laborious and is unfit for the 
routine screening of clinical specimens. 
We evaluated the performance of the 
Real Art™ C. trachomatis TM PCR Kit (artus, 
Germany) on the ABI PRISM™ 7000 SDS 
(Applied Biosystems, USA) with swab, urine 
and sperm specimens to determine our ability 
to detect chlamydia infections as well as in 
invasive as in non-invasive specimens. 
The RealArt™ assay combines 
sequence-specific primers and a dual labeled 
fluorogenic probe. In addition, it contains a 
second amplification system (internal control) 
to identify possible PCR inhibition and to 
control the isolation procedure. Swab 
specimens were purified using the QIAamp 
DNA Mini Kit, urine and sperm specimens by 
the QIAamp Viral RNA Mini Kit (QIAGEN, 
Germany). 
The evaluation of the assay was performed 
with 448 retrospective swab specimens (236 
eye, 4 Douglas, 82 urethral, 65 cervical, 1 
penis and 60 vaginal swabs), 100 retrospective 
urine specimens (50 male and 50 female) and 
80 retrospective sperm specimens. The results 
of the RealArt™ C. trachomatis TM PCR Kit 
for 150 swab specimens (50 urethral, 50 
cervical and 50 vaginal swabs) as well as for 
the 100 urine specimens were compared to 
those of Gen-Probe's transcription mediated 
amplification (APTIMA® Combo 2™ assay). 
The results for the remaining swab specimens 
(236 eye, 4 Douglas, 32 urethral, 15 cervical, 1 
penis and 10 vaginal swabs) and for the 80 
sperm specimens were compared either to an 
in-house Nested PCR or to Bio-Rad's 
Chlamydia Microplate EIA. 
The diagnostic sensitivity of the 
RealArt™ C. trachomatis Kit for 448 swab 
specimens was 97.7 %. Two out of 86 
previously positive tested swab specimens (one 
eye and one vulva swab) could not be detected 
with the RealArt™ Kit, one due to inhibition 
and one apparently because of DNA 
degradation due to longer storage at -20°C. 
For urine and sperm specimens the diagnostic 
sensitivity was 100 %. The positive rate for 
sperm specimens was 2.5 %. One out of the 
two positive results was confirmed by parallel 
testing of a urine sample of the same person. 
The positive rate for urine specimens was 
50 %. The total diagnostic sensitivity was 
98.6 %. The inhibition rate for all analysed 
specimens was 0.2 % (appearing on one eye 
swab). The total diagnostic specificity was 
99.6 %. 
In comparison to the APTIMA® Combo 2™ 
assay the RealArt™ Kit showed a correlation 
of 98.8 %. One out of 50 previously with the 
APTIMA® assay positive tested vulva swabs 
could not be detected apparently because of 
DNA degradation and two female urine 
samples were only positive with the RealArt™ 
assay. Therefore in this comparison study the 
RealArt™ Kit showed a diagnostic sensitivity 
of 99.2% and a specificity of 98.4 % for 
retrospective swab and urine specimens. 
Our results showed that the new 
RealArt™ assay provides a sensitive and 
specific way to detect C. trachomatis not only 
in invasive but also in non-invasive specimens. 
Non-invasive collection methods are more 
acceptable to patients and allow testing outside 
traditional clinic settings. This increases the 
access to care for high-risk groups and enables 
fast screening of this important target group. 
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TIMELY DIAGNOSIS OF ACUTE CHLAMYDIA PNEUMONIAE (CPN) 
INFECTION USING "REAL-TIME" POLYMERASE CHAIN REACTION 
(PCR) TESTING 
D.L. Hahn*,1 J.D. Hester2 
'Dean Medical Center and Dept. Family Medicine, U. Wisconsin Medical School, Madison, WI, 
IBT Reference Laboratory, Lenexa, KS, USA 
Acute Cpn infection accounts for 10% of 
community-acquired pneumonia, 5% of acute 
bronchitis and an unknown proportion of chronic 
sequelae of acute respiratory illness (ARI). ^  
Because clinical manifestations are 
indistinguishable from viral infections, definitive 
diagnosis depends on microbiologic methods that 
are not yet widely available to practicing 
2 
clinicians. We explored the sensitivity of 
different specimens for real-time PCR as a 
diagnostic modality for ARI in a primary care 
setting. Herein we report the identification of a 
family outbreak of acute Cpn respiratory illness 
that would have gone undetected and untreated in 
the absence of timely PCR testing. 
The primary care physician obtained 3 
specimens for PCR testing on patients with ARI: 
(1) a dry throat swab, (2) a throat swab immersed 
in M4 media and (3) 20 mL gargled (distilled) 
water specimen (GWS). Genomic DNA was 
isolated using the Qiagen DNA Mini Kit and 
Taqman real-time PCR was performed targeting a 
121 bp region within the 16S rRNA Cpn gene 
using an ABI-Prism 5700 system. For most 
patients, a single semm specimen was tested (IgM 
and IgG-sELISA, Medac, GmbH, Hamburg, 
Germany) according to the manufacturer's 
instructions. 
Four of 17 patients tested positive for Cpn 
by PCR. All samples obtained during an acute 
illness in 3 patients were PCR+ but quantitative 
yields were consistently best for dry swab, 
intermediate for wet swab and least for GWS. All 
4 met serologic criteria for recent infection (3 
IgM+, 1 IgG+) and were part of a family outbreak. 
Index Case: 48 yo husband was tested 2 weeks 
after onset of an acute biphasic illness (severe sore 
throat followed by bronchitis) and received 7 days 
of doxycycline 100 mg bid before PCR+ test 
results were available. A post-doxycycline GWS 
was PCR- despite persisting symptoms that 
resolved after azithromycin 500 mg/d x 3d, then 
750 mg/wk x 2wk. Wife: Two weeks after her 
husband's illness onset, the 50 yo spouse 
developed a non-specific ARI (nasal congestion, 
moderate sore throat, mild cough). Because of his 
positive results, she was also tested, PCR+ results 
were quickly reported, she was treated with the 
same azithomycin regimen, and symptoms 
resolved completely. Older daughter: At about the 
same time as her mother became ill, the 18 yo 
daughter developed a non-specific ARI (moderate 
sore throat and hoarseness followed by a 
productive cough and nasal congestion). She tested 
PCR+ and symptoms resolved completely after the 
same azithromycin treatment. Younger daughter: 
One month before illness onset in her father, the 
14 yo daughter developed a severe cough and nasal 
congestion that completely resolved after 4 weeks, 
without treatment. Dry throat swab and GWS 
obtained 2 months after illness onset (one month 
after all symptoms had resolved) were PCR+. 
Dry swabs were the most sensitive 
specimen for PCR diagnosis of Cpn ARI. 
Diagnosing the index case led to testing, 
identification and timely treatment of Cpn 
infections in 2 family members with non-specific 
ARI. Persistent PCR positivity was noted one 
month after spontaneous symptom resolution in 
another family member. Real-time PCR provided 
specific microbiologic diagnosis for ARI in "real 
time." Whether identification of Cpn infection will 
be important in the management of chronic 
sequelae of ARI requires further research. 
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CHLAMYDIA PNEUMONIAE IN PBMC: REPRODUCIBILITY OF THE OMPA 
NESTED PCR TOUCHDOWN 
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Department of Public Health Sciences, "La Sapienza" University, Rome, 'S. Andrea Hospital, 
Rome-Italy; 2Hospital de Madrid, Spain 
Several studies have suggested that 
Chlamydia pneumoniae DNA in peripheral 
blood mononuclear cells (PBMC) may be a 
reliable non invasive alternative to identify 
individual risk for endovascular chlamydial 
infection. 
However, no standardized PCR assays are 
available and the prevalence of C. pneumoniae 
in PBMC is susceptible of a great variability 
mainly caused by PCR methods, DNA 
extraction procedures and low concentration of 
C. pneumoniae. The latter may be overcome by 
testing multiple aliquots of DNA extracted of 
the same sample. 
Therefore we evaluated whether the replicate 
PCR testing may provide more accurate 
estimates of DNA prevalence in PBMC of 
patients with atherosclerotic cardiovascular 
disease. Clinical sensitivity and reproducibility 
of ompA nested PCR touchdown also was 
performed. 
Thirty whole-blood specimens were 
obtained from patients undergoing carotid 
endarterectomy and processed to isolate 
PBMC accordance with a method previously 
described (Condos et al., 1996). 
In addition, C. pneumoniae negative PBMC 
specimens from a healthy subject were spiked 
with a serial dilutions of semipurified C. 
pneumoniae elementary bodies (from 8 to 
0.002 IFU/ml final concentration). 
DNA from clinical and spiked PBMC 
specimens were extracted by Qiagen QIAamp 
DNA mini-kit according to the manufacturer's 
instructions. 
In order assess the presence of possible PCR-
inhibitors human P-globin gene was amplified 
from all PBMC DNA samples. Detection of C. 
pneumoniae DNA was performed by ompA 
nested PCR touchdown (Tong and Sillis, 
1993). 
Each clinical and spiked PBMC DNA samples 
were analyzed in replicates of 1,3,5 and 10. 
Clinical PBMC specimen was considered 
positive if one or more of the replicates 
examined were positive. 
PCR-positive PBMC clinical specimens were 
also amplified in triplicate by non-nested PCR, 
targeting the C. pneumoniae Pstl fragment 
(Campbell et al., 1992). 
C. pneumoniae DNA was detected in 
14 of the 30 (46.7%) PBMC clinical specimens 
examined when 10 replicates were tested. All 
14 PCR-positive PBMC samples successfully 
amplified the C. pneumoniae Pstl fragment 
also. For what it concern the remaining 16 
PBMC clinical specimens no positives were 
detected in any of 10 replicates. 
When we analyzed 1, 3, and 5 replicates, 4 
(13.3%), 7 (23.3%), 12 (40%) of the 30 PBMC 
specimens were positive, respectively. 
The limit of detection of ompA nested PCR 
touchdown was 0.008 IFU/ml when 10 
replicates were tested. 
The ompA nested PCR had reproducibility 
scores of 10 for 10 for 8 IFU/ml concentration, 
but scores decreased for smaller numbers of 
IFU/ml. 
Our results showed that replicate C. 
pneumoniae PCR increased clinical sensitivity 
as well as the reproducibility of the ompA 
nested PCR touchdown. 
Therefore we conclude that replicate PCR 
testing may provide a cumbersome but reliable 
tool for estimate of C. pneumoniae DNA 
prevalence in PBMC. 
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COMPARISON OF DIFFERENT PCR METHODS DEVELOPED FOR THE 
DETECTION OF CHLAMYDOPHILA (CHLAMYDIA) PNEUMONIAE IN 
CLINICAL SPECIMENS 
Adrian Mehlitz*, Thomas F. Meyer and Agnes J. Szczepek 
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There is still no gold standard for the 
PCR detection of Chlamydophila (Chlamydia) 
pneumoniae (C. pneumoniaenevertheless 
there are numerous methods available for 
DNA isolation2,3 and PCR detection4"8 of the 
organism. 
It is obvious from the literature that the 
detection of C. pneumoniae in different 
clinical samples varies from high to low 
numbers or even negativity of the samples 
based on the method used9"12. We intended to 
evaluate if there are differences in the 
sensitivity of the most often used PCR 
assays5'6'13. 
We compared the sensitivity of the 
most often used PCR assays, which are 
OmpA-based nested touchdown PCR assay13, 
16S RNA single step6 and PstI restriction 
fragment based single step5. In addition, we 
compared the sensitivity of these assays with 
our own nested PCR CPAF-based assay and an 
OmpA-based real" time PCR assay14. In order 
to compare all the assays, we used our standard 
laboratory strain of C. pneumoniae VR1310, 
standard reagents and column based DNA 
isolation method. 
Using the DNA from the infected cell 
culture, we found that there are differences in 
the sensitivity of pathogen detection. We were 
able to show that the 16S RNA-based assay is 
tenfold less sensitive than the Pstl-based assay, 
which itself is tenfold less sensitive than the 
OmpA based assay. The nested PCR assay is 
able to detect one copy of Cpn DNA. The real 
time OmpA assay is also tenfold less sensitive 
than the nested PCR assay. Using our own 
nested CPAF PCR assay we were able to 
detect one copy of Cpn DNA. 
We demonstrated significant 
differences in the detection limits of the PCR 
assays compared and showed that the nested 
PCR assays are the most sensitive, thus 
recommended for the detection of pathogen in 
clinical specimens. 
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INTERFERENCE AND TOXICITY OF THROAT SPECIMENS FOR 
ISOLATION OF CHLAMYDIA PNEUMONIAE 
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Hammerschlag 
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The optimum specimen for isolation of C. 
pneumoniae from the respiratory tract remains 
controversial. As part of a multicenter study 
evaluating a multiplexed nucleic acid amplification 
test for detection of C. pneumoniae, Mycoplasma 
pneumoniae and Legionella in a single throat 
specimen, in patients with pneumonia, duplicate 
throat swabs (TS) were also collected for isolation 
of C. pneumoniae in tissue culture. The isolation 
rate of C. pneumoniae from TS was only 0.5% 
compared with >5% in prior studies from our 
laboratory using nasopharyngeal (NP) swab speci-
mens. It was also noted that many of the TS con-
tained fluorescing artifacts, or had heavy bacterial 
contamination making them difficult to read. The 
aim of this study was to compare TS to NP 
specimens for recovery of C. pneumoniae in tissue 
culture using a mock infection system to simulate 
the handling of specimens in the laboratory. 
Patients: TS and NP swabs were obtained 
from healthy adult volunteers using Dacron-tipped, 
wire-shafted swabs and placed in transport media. 
After collection, the specimens were split into 3-4 
aliquots, one was immediately inoculated and 
cultured, the remaining were spiked with 10 to 100 
ifu/ml C. pneumoniae CM-1 and processed as 
described below. 
Culture of C. pneumoniae was performed in 
cycloheximide-treated HEp-2 cells grown in 96-
well microtiter plates. 
Mock infected aliquots were either: 1) im-
mediately frozen at -70 C for 72 hrs, then 
defrosted, kept at room temperature (RT) for 2 hrs, 
then inoculated 2) frozen immediately at -70 C for 
72 hrs. 3) kept at RT for 2 hrs, then 4 C overnight, 
then frozen at -70 C for 72 hrs. 3) kept at RT for 2 
hrs or 4) kept at 4 C for 2 hrs, then frozen at -70 C 
for 72 hrs. After 72 hrs, specimens were quickly 
defrosted and inoculated. Cultures were incubated 
at 35 C for 72 hrs, then fixed and stained. Results 
were expressed as ifu/ml. 
TS and NP swabs were collected from 61 
healthy volunteers. None of the specimens were 
positive for C. pneumoniae on initial culture. 
There was no difference in the mean ifu/ml 
between TS and NP of C. pneumoniae in the 
spiked specimens that were frozen immediately at 
-70 C then cultured after 72 hrs. There was a 
significant difference between TS and NP 
specimens frozen, then defrosted and kept at RT, 
40 v. 10.5 ifu/ml (p <0.001 paired t-test). 7 
(17.9%) of the TS specimens contained no 
inclusions and 17 (44%) had <5 ifu/ml. 11 
specimens held at RT, then 4 C overnight before 
being frozen also demonstrated significantly lower 
ifu/ml in the TS compared to NP specimens, 10.4 
v. 35.5 ifu/ml (p=0.004), or kept at RT or 4 C for 2 
hrs, then frozen. 8.6 v 26.8 ifu/ml (p=0.0035) and 
14.7 v. 26.1 ifu/ml (p=0.002), respectively. 10% of 
TS specimens had heavy bacterial contamination 
and/or destruction of the cell monolayer. 
In 1995, as part of a pediatric pneumonia 
treatment study, duplicate TS and NP specimens 
were obtained from 50 of the children enrolled, C. 
pneumoniae was isolated from the NP of 14, but 
only 7 had positive TS. If TS had been used alone, 
Vi of the culture positive patients would have been 
missed. Using conditions simulating the handling 
of specimens for C. pneumoniae culture, we 
demonstrated that TS specimens are less effective 
than NP swabs for isolation C. pneumoniae, 
especially if the specimens are held at RT or 4 C 
for up to 2 hrs before being frozen. Freezing at -70 
C for up to 72 hrs did not have an adverse effect 
on recovery of C. pneumoniae from TS specimens. 
TS were more likely to be contaminated or actually 
toxic to the HEp-2 cell monolayer. This was not 
seen with NP specimens. These results may 
explain the low rates of C. pneumoniae isolation 
reported in some studies. These data suggest that 
the NP should be the preferred site for respiratory 
specimens for C. pneumoniae culture. 
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EVALUATION OF SELECTED RECOMBINANT CHLAMYDIAL ANTIGENS 
FOR SEROLOGICAL DIAGNOSIS OF CHLAMYDIA TRACHOMATIS AND 
CHLAMYDIA PNEUMONIAE INFECTION 
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Essig, A.2 
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To improve the serological diagnosis of 
chlamydial infections, the humoral immune 
response to C. pneumoniae and C. trachomatis 
was analyzed using selected chlamydial 
recombinant antigens and sera from patients 
with acute and chronic chlamydial infection. 
Reactivity of recombinant antigens with 
human sera was analysed by detection of IgG, 
Ig A and IgM antibodies. The band patterns of 
sera from infected patients were compared 
with those of control patients to define the 
diagnostic usefulness of recombinant antigens. 
The antigens PGP3, MOMPIV (the 
variable domain IV of the MOMP protein), 
MIP, MOMP, HSP60, OMP2 of Chlamydia 
trachomatis, MOMP, 53kD, OMP2, OMP4, 
OMP5, OMP11 of Chlamydia pneumoniae and 
MOMP of Chlamydia psittaci were produced 
as recombinant antigens in E.coli and lined on 
nitrocellulose membranes after purification. 
Antigen strips were incubated with about 150 
clinically and microbiologically well-
characterized serum samples. Serum samples 
were taken from i) patients with PCR and/or 
culture proven C. trachomatis-infection, ii) 
patients with clinical signs of chronic C. 
trachomatis infection and elevated C. 
trachomatis-specific MIF antibodies, iii) 
patients with clinical signs of C. pneumoniae-
infection and elevated C. pneumoniae-specific 
MIF antibodies, iv) patients without clinical 
signs of chlamydial infection and MIF serology 
suggestive for past C. pneumoniae infection 
and v) patients without clinical and serological 
signs of chlamydial infection. 
The recombinant Chlamydia 
trachomatis antigens PGP3, MOMPIV, MIP, 
MOMP, HSP60, OMP2 were highly reactive 
with sera of patients suffering from chronic C. 
trachomatis infection. As expected, cross-
reactivities of minor importance were observed 
especially with the MOMP and OMP 2 of C. 
pneumoniae. Sera from patients with C. 
pneumoniae infection revealed strong 
reactivities with the recombinant MOMP, 
OMP5 and 53kD-antigen of Chlamydia 
pneumoniae, while cross-reactions with 
recombinant antigens of Chlamydia 
trachomatis were hardly observed. Cross-
reactivity was also hardly seen with the 
recombinant MOMP antigen of Chlamydia 
psittaci by using serum samples of patients 
with Chlamydia trachomatis or Chlamydia 
pneumoniae infection. 
The combination of selected 
recombinant chlamydial antigens in the 
presented Line assay format was useful for 
serological diagnosis of C. pneumoniae and 
chronic C. trachomatis infections. The 
combination of antigens from Chlamydia 
trachomatis, Chlamydia pneumoniae and of 
Chlamydia psittaci in a single serological 
assay enables detection of defined species as 
well as genus specific antibodies and could 
therefore be an important improvement in 
serodiagnosis of chlamydial infections. 
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CHLAMYDIA PNEUMONIAE IGG AND IGA ANTIBODIES IN MIDDLE AGED, 
DYSLIPIDEMIC MEN MEASURED BY MICROIMMUNOFLUORESCENCE 
(MIF) TECHNIQUE AND ENZYME IMMUNOASSAY (EIA) 
Mika Paldanius1, Tiina Sävykoski1, Leena Tenkanen3, Hanna Virkkunen3, Maija 
Leinonen1 and Pekka Saikku2 
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The lack of specific criteria for the 
identification of chronic Chlamydia 
pneumoniae infections has led to the common 
use of commercial EIA tests instead of gold 
standard microimmunofluorescence (MIF) 
technique in the measurement of C. 
pneumoniae antibodies. Our purpose was to 
compare EIA and MIF results in middle aged, 
dyslipidemic Finnish men. 
Helsinki Heart Study was a placebo-
controlled, coronary primary prevention trial to 
study the efficacy of gemfibrozil. Sera were 
obtained from the population of white, middle-
aged, dyslipidemic Finnish men during 8.5-
year follow-up time. The sera obtained at 
baseline, after 2 years, 0 to 3 months before 
coronary event and after the event, if available, 
from 239 cases and corresponding serum 
samples from controls matched for age, time 
point, locality and treatment were included in 
the study. C. pneumoniae species-specific IgG 
and IgA antibodies were measured by our in-
house MIF and commercial EIA test 
(Labsystems, Helsinki1, Finland). MIF was the 
reference test and the variables were 
categorised by quartiles. 
In MIF, 77 % of the sera were positive 
for IgG and 43 % for IgA antibodies. When the 
highest MIF quartile in IgG (titer of > 256) and 
in IgA (titer of >40) were compared to the 
highest EIA quartiles (IgG: >180 enzyme 
immunounits, EIUs and IgA: >38 EIUs), EIA 
and MIF detected equally 80 % of IgG and 77 
% of IgA samples. 32 % of known MIF IgG 
negative and 57 % of MIF IgA negative 
samples were positive by EIA. The strength of 
an agreement measured as K- values between 
C. pneumoniae specific MIF and EIA tests was 
fair for IgG (0.39) and moderate for IgA 
(0.51). Only the highest MIF IgA quartile at 
the baseline level predicted future coronary 
events with (OR) 1.69 and confidence intervals 
95 % CI (1.05-2.74) without adjustment. 
Conclusions: Especially MIF negative sera 
gave conflicting results in EIA the levels 
varying from negative to strong positive. IgA 
EIA levels did not either predict future 
coronary events. Eighty % of the titers in the 
highest MIF quartiles were also in the highest 
EIA quartile. Originally, Labsystems' IgG and 
IgA kits have been developed for the diagnosis 
of acute infections, therefore further studies are 
needed to validate these kits in the diagnosis of 
chronic infections using MIF test as a gold 
standard. 
Currently Ani Labsystems Ltd. Oy, Helsinki, 
Finland 
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EVALUATION OF COMMERCIAL TESTS FOR SERODIAGNOSIS OF 
CHLAMYDOPHILA PNEUMONIAE IN CLINICAL SAMPLES 
Corinna Hermann*, Katja Gueinzius, Albrecht Oehme1, Sonja v. Aulock, Eberhard 
Straube2 and Thomas Härtung 
Biochemical Pharmacology, University of Konstanz, Konstanz, Microbiology, University of 
Halle, Halle, Microbiology, University of Jena, Jena, Germany 
The - reliability of Chlamydophila 
pneumoniae serodiagnosis is crucial for 
treatment decisions and clinical and sero-
epidemiological studies. Recently, we have 
evaluated eleven different microimmuno-
fluorescence test (MIF) and ELISA/EIA for C. 
pneumoniae IgG-serodiagnosis using sera from 
80 healthy donors (Hermann et al., J Clin 
Microbiol 2002:1603-9). We found huge 
variations in sensitivity ranging from 40-
100%. We have now extended this study to 
sera from pneumoniae patients and have 
focused on the most promising ELISAs 
(SeroCP and SeroCP Quant) identified in our 
previous study and included a new ELISA 
(sELISA). 
Anti-C. pneumoniae antibodies were 
determined in the SeroCP ELISA for IgG and 
IgA and the SeroCP Quant ELISA for IgG and 
IgA (Savyon Diagnostic) and in the Chlamydia 
sELISA and Chlamydia-IgG-rELISA both for 
IgG (medac). The SeroFIA MIFs for IgG and 
IgA (Savyon Diagnostic), the Chlamydia 
pneumoniae IgG MIF (MRL Diagnostics) and 
an in house IgG-MIF performed at the National 
Consultative Laboratory for Chlamydia 
(Institute of Medical Microbiology, University 
of Jena, Germany) were used as reference MIF. 
The sensitivity, specificity and correlation of 
the assay results were determined using 80 sera 
from adult patients with acute pneumonia, 50 
sera from adult patients including 15 cases of 
COPD, 29 of pneumonia and 6 of upper 
respiratory tract infection. 80 sera obtained 
from children aged 18 months to 14 years with 
adenoid vegetations tested negative in MIF and 
PCR, served as negative control sera. 
The concordance between the SeroFIA 
MIF with the in-house MIF and the MIF from 
MRL was 94% and 96%, respectively. The 
agreement of all IgG ELISAs with the 
reference IgG MIF (SeroFIA) was >90% in the 
collective of 80 patients. The positive 
predictive values were all >93%. The negative 
predictive values ranged from 68%-83%. 
False-negative results were obtained only in 
samples that had low titers in the MIF. The 
correlation of the IgG antibody titers 
determined by MIF and SeroCP Quant was 
high (rsp=0.9). For IgA analysis, the positive 
predictive values were >96% and the negative 
predictive values ranged from 65%-86%. Since 
the semi-quantitative SeroCP and quantitative 
SeroCP Quant ELISA achieved the best 
sensitivities, they were evaluated further using 
a second batch of sera from 50 patients with 
predominantly medium and low antibody titers 
in MIF and a control collective of sera from 80 
children with negative MIF results. Again, the 
tests showed high concordance with the MIF 
results (96%) and the antibody titers of SeroCP 
Quant and MIF correlated well (rsp= 0.8). The 
specificities determined with the negative 
control sera were >99% for SeroCP Quant and 
86% for SeroCP. 
These results show that ELISAs that 
are fast and objective achieve seroprevalences, 
sensitivities and specificities very similar to 
MIF. 
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SPECIFIC ENZYME IMMUNO ASSAY (EIA) FOR THE MEASUREMENT OF 
CHLAMYDIAL LIPOPOLYSACCHARIDE (LPS) FROM HUMAN SERUM 
Tiirola T1*, Jaakkola A2, Sinisalo J3, Nieminen M3, Jauhiainen M1, Saikku P4, Bloigu A2 
and Leinonen M2 
National Public Health Institute, 2Oulu and 'Helsinki, 3University Central Hospital, Helsinki, 
4University of Oulu, Finland 
Chlamydia pneumoniae (Cpn) infection 
has been associated with atherosclerosis in 
numerous studies. These associations have been 
verified by means of seroepidemiological studies 
and by direct demonstration of the agent with 
different methods, including culture, 
immunocytochemistry, nucleic acid amplification 
and electron microscopy of atherosclerotic lesions. 
Both animal and human studies have suggested 
that antibiotic treatment of Cpn infection may 
affect the progression of atherosclerosis. At 
present there are no optimal methods to find 
persons with chronic active Cpn infection who 
would benefit of antibiotic treatment. The samples 
from advanced atherosclerotic lesions for the 
demonstration of Cpn are difficult to obtain, and 
thus, there is a need for surrogate markers for 
proper and reliable diagnosis. 
Lipopolysaccharide (LPS) is an essential structural 
component of chlamydial outer membrane and 
during the growth cycle, LPS has been suggested 
to be overproduced and released from inclusions to 
the surface of infected cells. Lipopolysaccharide 
binding protein (LBP) binds circulating LPS and 
transfers it to neutralizing HDL or to CD 14 on 
membranes of blood monocytes. In the present 
study, we describe a simple EIA method based on 
the use of LBP as a capture molecule for 
quantification of circulating chlamydial LPS as a 
possible surrogate marker for vascular Cpn 
infection. 
LPS-concentrations were measured in 102 
sera obtained from patients with acute myocardial 
infarction (AMI) and in 102 sera obtained from 
age- and sex-matched healthy blood donors. LPS 
for standardization was purified from Cpn K6 
isolate by using modified phenol/water extraction 
method. LPS concentrations were determined by 
KDO-assay. 
Microtiter plates were coated with monoclonal 
anti-LPS antibody (0.5|Xg in PBS/ well) by 
incubating at 20°C overnight. Plates were washed 
4 times with 250pl PBS containing 0.05% Tween 
20. Unspecific binding sites were blocked with 
PBS containing 0.2% milk powder (200jxl/well) 
for 1 hr at +37°C. Serum samples were diluted 
1/50 and LPS standard was serially diluted (1/400 
- 1/25600) in PBS containing 0.1% octylglucoside. 
Both serum/standard and LBP solution (lpg/ml in 
0.1% Tween 20-PBS) were added to the wells and 
the mixture was incubated for 1.5 hr at 37°C in a 
shaker (400 rpm). After washing plates 4 times, 
100|fi of the polyclonal anti-LBP, diluted 1/500 in 
0.1% Tween 20-PBS was added to the wells and 
incubated covered for 1 hr at 37°C. After the 
washing step, peroxidase-labeled goat anti-rabbit 
antibody diluted 10000-fold in Tween 20-PBS 
(containing 10% fetal bovine serum), was added to 
the wells (1 OOpl/well) and incubated for 1 hr at 
37°C. After washing, HRP-substrate, o-
phenylenediamide (OPD8, 0.4 mg/ml, prepared in 
0.012% hydrogen peroxide, 0.05M di-sodium 
hydrogen phosphate-dihydrate and 0.025M citric 
acid-1-hydrate) was added (100pl/well) and 
incubated for 1 hr at 20°C in the dark place. 
Enzyme-reaction was stopped by adding 50|ll of 3 
M H2S04 and the absorbance was measured 
immediately at 490 nm by a microplate reader. 
LPS was present in 87.3% of sera obtained 
from AMI patients and in 77.5% of control sera 
(p=0.066) and the geometric mean concentrations 
were 1.917 and 0.728 (ig/ml (p<0.001), 
respectively. 
In the present study we have developed 
EIA method for quantification of chlamydial LPS 
from human serum and found significantly higher 
LPS concentration in the sera of AMI patients than 
in healthy controls. Measurement of chlamydial 
LPS using this new specific method enables us to 
estimate the presence and activity of chronic 
chlamydial infections and the effect of treatment in 
these diseases. 
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THE RESULTS OF CHLAMYDIAL SEROLOGY FROM LABORATORY 
POINT OF VIEW 
Hana Kabickova*, Olga Slamborova 
KlinLab s.r.o., Prague, Czech Republic 
The diagnostic of chlamydial infections 
by the detection of antibodies is very 
widespread in our country even in cases when 
non-invasive sampling for the direct detection 
is possible. Therefore the significance of 
different chlamydial antigens for serodiagnosis 
was evaluated. 
Serological testing was carried out by 
ELISA (medac, Hamburg, Germany) kits: 
rELISA IgG/IgA (Chlamydia genus specific 
LPS), pELISA IgG/IgA (C. trachomatis 
species specific peptide antigen), sELISA 
IgG/IgA (C. pneumoniae species specific 
antigen), ELISA IgG cHSP 60. 
We included into the study the patients who 
were positive at least in one of the 7 tests 
mentioned above. 
All the tests positive were detected in 
3,7% of the 218 patients involved into the 
study. 15% of anti LPS IgG+/IgA+ patients 
had no detectable species-specific antibodies. 
5% of anti LPS IgG+/IgA+ patients had 
species specific IgA + for C. trachomatis only 
and 21.5% of anti LPS IgG+/IgA+ patients had 
species specific IgA + for C. pneumoniae only. 
Many other combinations of +/- of the 7 tests 
were observed. 
- Practically no rise of antibodies was detected 
in cases of successful treatment of acute 
infections. 
- Anti cHSP antibodies can serve as the first 
serological indication of active infection - as 
can be demonstrated on examples with the 
parallel direct detection of C. trachomatis 
infection. 
- The detection of anti cHSP IgG antibodies 
may be helpful as the other marker of the on-
going infection in patients without production 
of IgA antibodies. 
- The determination of anti cHSP IgG 
antibodies enables also the detection of 
persistent infections characterized by the 
development of atypical chlamydial forms with 
dominant cHSP antigen. In group of patients 
with antibodies anti LPS IgA+ persisting more 
than 2 years we found antibodies anti cHSP 
IgG+ more frequently in connection with the 
diagnosis: pelvic inflammatory disease, 
inflammation of vulva and vagina, non 
specified diseases of liver, pain of lower part 
of back. 
- The determination of anti cHSP IgG 
antibodies can be helpful in serodiagnosis of 
chlamydial infections; however further studies 
are required - the study continues. 
Antibodies against the antigens used in 
our study were detected independently each 
other. There was no correlation between the 
level of antibodies in tests anti LPS IgG/anti 
cHSP IgG and anti LPS IgA/anti cHSP IgG 
respectively. Antigen cHSP originated in C. 
trachomatis cross-reacted with antibodies in C. 
pneumoniae infections. 
Our study of long term followed up patients 
indicates: 
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ANTIBIOTIC TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR 
DISEASE 
J. Thomas Grayston 
University of Washington, Department of Epidemiology, Seattle, WA, 98198, USA 
Following demonstration of an association 
between C. pneumoniae and atherosclerosis 
(especially finding C. pneumoniae in arterial 
lesions) there have been many types of 
investigations to determine the etiologic 
significance of C. pneumoniae in 
atherosclerosis. One type of study has been 
antibiotic treatment trials for prevention of 
coronary heart disease events. This paper will 
review 11 prospective trials M 1 . Another group 
of antibiotic treatment trials have attempted to 
restrict progression of atherosclerosis in 
carotid, stented coronary and femoral/popletial 
arteries and the aorta. Five such trials will be 
reviewed 12~16. 
Why a human clinical trial 
A trial with an antibiotic effective against C. 
pneumoniae will not give direct evidence of C. 
pneumoniae in the etiology of atherosclerosis. 
The cause of myocardial infarction is more 
related to plaque instability than further 
obstruction of the coronary artery. Clinical 
trials with an adequate number of subjects and 
observed for several years, is very expensive 
and time consuming. 
The major reason to undertake a secondary 
prevention antibiotic treatment trial of 
coronary heart disease (CHD) is the magnitude 
of the potential public health importance. CHD 
is the number one cause of mortality in the 
developed world and will soon be the most 
important cause worldwide. Even if a trial 
would have only a modest chance for success, 
it would be worthwhile doing because a new 
effective non-surgical treatment for CHD 
could provide an enormous benefit. 
A human trial is the only method to obtain 
evidence on the role of C. pneumoniae in late 
complications of atherosclerotic disease. The 
effect of C. pneumoniae on the early stages of 
atherosclerosis can be studied in animal 
models but not the late complications seen in 
humans. 
Another stimulus for properly powered trials is 
the fact that antibiotic therapy is being given to 
patients with CHD without proof of 
effectiveness. This is based on over-
interpretation of the observational studies. 
Safety 
A human antibiotic treatment trial would 
clearly be speculative and would only be worth 
considering if it was safe for the participants. 
Prior studies of both short and long term 
administration of Macrolide and azalide 
antibiotics have shown few adverse reactions. 
These antibiotics have been given daily to 
patients with AIDS for 1 to 3 years with 
minimal side effects. 
There is appropriate concern about increased 
antibiotic resistance from prolonged therapy. 
While Chlamydia have not developed 
resistance against macrolide antibiotics, long-
term antibiotic therapy could contribute to 
resistance in other organisms. Experience 
would suggest that the prevalence of resistant 
isolates among the treatment group would 
return to baseline after cessation of antibiotic 
treatment. How much spread of resistant 
strains to the community would occur is 
unknown. However, it would be less of a risk 
for developing resistant strains than the 
indiscriminate use of short-term antibiotic 
treatment for coronary artery disease (CAD) 
now going on in the absence of any proven 
benefit. 
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Design of trials 
In choosing the subjects, one consideration is 
the expected rate of endpoint events. Selection 
of subjects at high risk of outcome events 
would allow for a smaller sample size and 
shorter duration of follow-up. The results will 
be applicable only to the higher risk patient. 
Evaluation of antibiotic treatment of patients 
with stable CHD will have wider applicability, 
if the treatment is successful. 
Many but not all studies used subjects that had 
been shown to have C. pneumoniae antibody. 
The endpoint events for most of the studies 
were coronary heart disease death, myocardial 
infarction, coronary bypass surgery, a 
percutaneous revascularization procedure, and 
hospitalization for unstable angina. 
An estimate of the expected rate of events was 
based on experience in previous clinical trials 
and epidemiological studies. For stable 
patients event rate estimates were 6 to 7% per 
year. For patients with acute disease annual 
estimated event rates were 11 -13%. 
These estimates allowed developement of 
power calculations. The targeted reduction in 
events for a positive result was usually 20 to 
25%. To meet these goals for studies of stable 
patients about 4000 subject observed for 4 
years would be required. For acutely ill 
patients the length of observation could be 
reduced by almost half or fewer subjects could 
be used. 
All of the studies used antibiotics that were 
effective against C. pneumoniae. These 
included azithromycin (an azalide), 
roxithromycin, clarithromycin and the only 
non-macrolide, gatifloxacin, a new 
fluoroquinoline. 
The choice of the antibiotic and the dose, 
schedule, and length of treatment to be used 
are critical decisions. These decisions must be 
made in the face of insufficient data regarding 
factors such as the antibiotic concentrations 
reached in CV tissues, such as coronary 
plaque, the metabolic status of the infecting 
organism, and whether there will be an effect 
with suppression versus eradication of the 
organism. 
Knowledge of the biology of chronic 
Chlamydia infection suggests that short 
treatment periods will be inadequate for lasting 
benefit. The elementary body form of the 
organism is the infectious non-replicating form 
and it is not susceptible to the action of 
antibiotics. Elementary bodies may exist in the 
body for many weeks and then cause new 
cellular infection. While short-term treatment 
might kill replicating organisms in atheroma 
and temporarily reduce inflammation, it would 
be unlikely to eliminate the organism from the 
lesion. 
Treatment of chronic Chlamydia infections has 
been difficult and has required carefully 
controlled long-term courses of antibiotic. 
Examples are trachoma, a chronic C. 
trachomatis eye infection and efforts to 
eliminate C. psittaci from imported psittacine 
birds. 
Retrospective studies of antibiotics and 
cardiovascular disease 
We have recently reviewed 7 retrospective 
studies of the effect of taking routinely 
prescribed antibiotics on subsequent 
17 
expressions of CVD . 
Retrospective studies can be performed 
relatively quickly and at low cost using 
existing data sources. The method used to 
assess the association of past antibiotic use and 
risk of the outcome varied by study. 
The results of the seven studies are not 
consistent. The study that evaluated the 
relationship of antibiotic use following acute 
myocardial infarction with one-year survival 
found a higher risk of death among patients 
that did not use antibiotics compared with 
patients who received anti-chlamydial agents. 
Of the remaining six studies that evaluated 
antibiotic use in relationship to the occurrence 
of acute CVD events, one study did not find an 
effect of any of the antibiotics evaluated 
against the outcome of first MI. Among the 
four studies that included an evaluation of 
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quinolone agents, two documented an effect. 
Although all six studies included macrolides, 
an effect of that class was documented in only 
one study, which compared macrolide users 
with penicillin users. 
Therefore, in aggregate, these studies do not 
provide strong support for an effect of 
treatment with antibiotics effect against C. 
pneumoniae on CVD outcomes. However, they 
were all limited by the relatively short courses 
of antibiotics prescribed to patients in the 
context of usual clinical practice and most 
were also limited by the relatively low 
prevalence of any past antibiotic • use among 
the subjects. Therefore, while retrospective 
antibiotic studies do not provide a basis for 
routine use of antibiotics in humans for 
prevention of CVD outcomes they also do not 
provide conclusive evidence that appropriate 
antibiotics given at sufficient dose for an 
adequate duration would not have an effect on 
risk of primary or secondary CVD outcomes. 
Prospective clinical trials are needed to address 
those questions. 
Prospective clinical trials 
There have been 11 clinical trials of antibiotic 
therapy for secondary prevention of coronary 
heart disease 1 1 ' . The only two with long term 
treatment (ACES & PROVE IT) will been 
presented in Munich at the European Society 
of Cardiology on August 30, 2004. Their 
results will be available for discussion at the 
European Society for Clinical Research 
meeting. 
The two parameters important in power 
calculations: number of subjects and length of 
observation, varied greatly among the studies. 
Eight of the studies failed to come even close 
to having adequate statistical power to provide 
a convincing negative result. They can be 
considered 'pilot' studies. These 8 small 
studies are presented in table 1. 
The number of subjects varied from 60 to 
1400. All but two had 325 or fewer subjects. 
The length of observation varied from 6 
months to 2 years. In most of the trials the 
subjects were recruited during or just after a 
CHD illness. 
There was a large diversity in the length of 
treatment in these trials. Most had very limited 
courses of antibiotic treatment. Three trials, 
each that used azithromycin, treated for only 3, 
6, or 7 days. While such a course of antibiotic 
might be adequate for a susceptible acute 
infection, it is entirely inadequate for chronic 
infection. The other small trials treated for 1 to 
3 months. 
Four of the 8 trials were reported as having 
positive results and 4 were considered 
negative. These 'pilot' studies gave no clear 
direction as to what could be expected from 
adequately powered trials. 
The first trial from London in which subjects 
were given either one or two 3-day courses of 
azithromycin was reported as positive1. This 
trial suffered from faulty design with very few 
subjects as well as inadequate treatment 18. A 
surprising finding was the high rate of events 
observed in the 40 untreated subjects (only half 
of whom were randomized controls). The 28% 
events in 18 months is almost 3 times what 
would be expected in stable patients with a 
prior MI. Unfortunately this first trial 
influenced the treatment course in a number of 
subsequent studies. This was despite efforts in 
cardiology journals in 1998-9 to educate 
cardiologists about treatment requirements for 
chronic Chlamydia infection 18~19. 
Prior to undertaking these trials it was not 
known whether 3 months of treatment would 
influence chronic C. pneumoniae infection. 
Results are mixed for the two trials in table 1 
with 3-month treatment courses. 
Additional information on the effect of a 3-
month treatment course is available from the 
WIZARD trial9. Table 2 shows that the 
WIZARD trial is the only one of three large, 
adequately powered, trials that has been 
published. Overall the trial was considered 
negative because the 7% reduction in events 
was not statistically significant. There was in 
the treated group a significant 33% reduction 
in death and MI during the first six months of 
the trial (p=0.02). While the results at all time 
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periods favored the azithromycin group, there 
was a consistent loss of treatment effect by 
time, with a trend that was significant. This 
fall-off of treatment effect after the cessation 
of three months of antibiotic raises the 
question of whether a longer course of 
antibiotic might be more effective. 
The ACES trial 10, which has many protocol 
similarities with the WIZARD trial but with 
much longer treatment, may answer this 
question. 
The PROVE IT trial n , which used patients 
with unstable disease, also had long-term 
treatment. A new fluoroquinolone, 
Gatifloxacin, was given for the first 10 days of 
each month for the 2Vi years of the trial. 
Treatment trials with Atherosclerotic 
Vascular Diseases 
Table 3 shows antibiotic treatment trials 
utilizing non-invasive measurements of aortic 
aneurysm growth and carotid artery thickness, 
peripheral vascular disease symptoms and 
restenosis after stent placement in coronary 
arteries. While these trials were small, the end 
points were available in all subjects, not just 
those with events. This allowed statistically 
significant results (although the power was 
low). All of these trials showed a positive 
effect of the antibiotic (usually roxithromycin, 
a macrolide). In the study of restenosis an 
effect was seen only in subjects with high titer 
(=>512) C. pneumoniae antibody. While 
atherosclerosis plays a role in each of the 
arterial diseases in table 3, the pathogenesis of 
aortic aneurysm and of restenosis have 
differences from the occlusive diseases. 
Discussion 
The reported trials of antibiotic treatment of 
CHD events suffer from two major 
shortcomings. The courses of treatment were 
too short to be effective against a chronic 
Chlamydia infection and the size of the trials, 
with one exception, were too small to offer 
convincing evidence for either negative or 
positive results. Because of these shortcomings 
it is not yet known whether antibiotics have a 
place in treatment of CHD. 
When the results of the ACES and PROVE IT 
trials are available it is likely that a more 
definite result will be available. 
The reaction to the results of the large clinical 
trials, either positive or negative, will probably 
be in excess of what is justified. If positive, a 
new therapeutic option will be available for 
treating CHD. However, the results will prove 
little about what causes atherosclerosis and 
much about C. pneumoniae being involved in 
the cascade of events leading to acute 
complications of atherosclerosis. An unlikely 
possibility will exist that the antibiotic effect is 
due to inhibition of an unidentified organism 
other than C. pneumoniae. 
If the results are negative, treatment of CHD 
with antibiotics should cease. There is a 
remote possibility that the relatively small 
doses of antibiotic used in the trials (for safety 
purposes) were inadequate to effect the C. 
pneumoniae organism in the chronic arterial 
lesions. The negative result will say little about 
C. pneumoniae in the initiation or acceleration 
of atherosclerosis. There are differences 
between the pathogenesis of coronary events 
and atherosclerosis. Plaque instability and 
rupture are thought to play a larger role in 
coronary events than occlusive disease. 
If the positive results of the trials of arterial 
disease can be repeated with larger numbers, 
they will offer evidence suggesting that C. 
pneumoniae is involved in the pathogenesis of 
atherosclerotic occlusive disease. 
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TABLE 1. SMALL CLINICAL TRIALS - ANTIBIOTICS & C H D 
Place Population No. Antibiotic Course Observe Results 
London 1 Post-MI 60 Azithromycin 3or 6 da l"yr positive 
Buenos Aires-ROXIS2 Acute CS 202 Roxithromycin 30 da 6 mo + / -
Utah-ACADEMIC 3 Stable CAD 302 Azithromycin 3 mo 2 yr negative 
Finland-CLARIFY 4 Acute CS 148 Clarithromycin 85 da l"yr positive 
Bangkok5 Acute CS 84 Roxithromycin 30 da 3 mo negative 
London-STAMINA6 Acute CS 325 Azithromycin 7 da 1 yr. positive 
Germany-ANTIBIO 7 Acute MI 872 Roxithromycin 6 wk 1 yr negative 
Los Angles-AZACS 8 Acute CS 1400 Azithromycin 3 da 6 mo negative 
Notes - Acute CS = acute coronary syndrome; +/- = pos result at 1 mo decreasing to neg at 6 mos 
TABLE 2 . LARGE CLINICAL TRIALS - ANTIBIOTICS & C H D 
Name Population No. Antibiotic Observe Results Refs 
WIZARD Stable post MI 7000 Azith 3 mo 1 to 4 yr 7% reduction (9) 
PROVEIT Acute CS 4000 Gati 2yrs inter 2"yr Aug 30, 2004 (11) 
ACES Stable CHD 4000 Azith 1 yr. 4 yr Aug 30, 2004 (10) 
Gati= Gatifloxacin given 10 days a month for 2 Vi years 
TABLE 3. CLINICAL TRIALS - ANTIBIOTICS & VASCULAR DISEASE 
Place Population No. Antibiotic Observe Results Refs 
Finland AAA growth 32 Doxy 3 mo l"yr Pos p>0.05 (12) 
Denmark AAA growth 92 Roxi 28 da l"yr Pos p=0.02 (13) 
Zurich Peripheral VD 40 Roxi 28 da 2 "yr Pos p>0.05 (14) 
Munich Carotid thickness 272 Roxi 30 da 2 yr Pos* (15) 
Munich Restenosis 1010 Roxi 28 da l y r Pos** (16) 
* All patients tested had C. pneumoniae antibody titer >= 128; 
** Positive only in subjects with C. pneumoniae antibody titer >= 512 
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PREVALENCE OF CHLAMYDIA PNEUMONIAE IN VASCULAR INFECTIONS 
R. Sessa, M. Di Pietro*, G. Schiavoni, S. Fallucca, C. Zagaglia, S. Romano1, F. 
Benedetti-Valentini2 , C.R. Noval3, M. del Piano 
Department of Public Health Sciences, "La Sapienza" University, Rome, 'Department of Internal 
Medicine, Cardiology, University of L'Aquila, department of Vascular Surgery, "La Sapienza" 
University, Rome, Italy; 3Hospital de Madrid, Spain 
Chlamydia pneumoniae infection has 
been implicated in coronary heart disease and 
atherosclerosis by seroepidemiological studies 
and direct detection of the organism in 
atherosclerotic plaques. 
We investigated the prevalence of C. 
pneumoniae DNA in peripheral blood 
mononuclear cells (PBMC) and atherosclerotic 
carotid plaques of patients with atherosclerotic 
cardiovascular disease. 
Serological study also was performed to 
determine whether circulating anti-chlamydial 
antibodies are correlated with the presence of 
C. pneumoniae DNA. 
A total of 334 clinical specimens, 174 
PBMC and 160 atherosclerotic carotid plaques, 
were obtained from patients with 
atherosclerotic cardiovascular disease. 
The first group (Group A) included 174 PBMC 
specimens obtained from 93 patients with 
acute ischaemic heart disease and 81 patients 
with atherosclerotic carotid disease. 
The second group (Group B) included 160 
atherosclerotic carotid plaques obtained from 
patients undergoing carotid endarterectomy. 
A serum sample was obtained from all patients 
(Groups A and B) enrolled. 
DNA was extracted from PBMC and 
atherosclerotic carotid plaques using phenol-
chloroform extraction. 
Detection of C. pneumoniae DNA in PBMC 
and atherosclerotic carotid plaques was 
performed using a semi-nested PCR 
(HL1/HR1 and HM1/HR1) previously 
described. 
IgG and IgA antibodies to C. pneumoniae were 
measured by microimmunofluorescence test. 
Group A. Overall prevalence of C. 
pneumoniae DNA in PBMC was 35% 
(61/174). In particular C. pneumoniae DNA 
was detected in 25.8% of the patients with 
acute ischaemic heart disease and in 45.7% of 
patients examined with atherosclerotic carotid 
disease (p= 0.01). 
A statistically significant association was 
found between the presence of C. pneumoniae 
DNA in PBMC and serological status. 
Group B. C. pneumoniae DNA was in 35.9 % 
of patients undergoing carotid endarterectomy. 
A statistically significant association was 
found between C. pneumoniae DNA in 
atherosclerotic carotid plaques and serological 
status. 
C. pneumoniae DNA was significantly 
higher in PBMC of patients with 
atherosclerotic carotid disease compared with 
those with acute ischaemic heart disease. 
A statistically significant association was 
found between the presence of C. pneumoniae 
DNA and anti-chlamydial antibodies. 
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RESULTS OF THE AZITHROMYCIN AND CORONARY EVENTS STUDY 
(ACES) 
J. Thomas Grayston*, Richard Kronmal, Lisa A. Jackson, J. Brent Muhlestein, J.R. 
Crouse, Albert F. Parisi, Jerome D. Cohen, William Rogers, Sandra Borrowdale, Elbe 
Schron, Charles Knirsch and other members of the ACES study group** 
*Department of Epidemiology, University of Washington, Seattle WA, USA 
There are multiple lines of evidence 
supporting the hypothesis that infection with 
Chlamydia pneumoniae plays a role in the 
pathogenesis of atherosclerotic cardiovascular 
disease. This evidence raises the question of 
whether a causal effect of C. pneumoniae 
infection, if present, may be influenced by 
antibiotic treatment, resulting in a decreased 
risk of coronary heart disease outcomes. 
To evaluate the effectiveness of one 
year of weekly azithromycin treatment for the 
secondary prevention of coronary heart disease 
outcomes in persons with stable coronary 
artery disease. 
ACES is a randomized, placebo-
controlled trial of 4012 adults in the United 
States with stable coronary artery disease, as 
evidenced by prior myocardial infarction 
documented by enzyme criteria, angiographic 
evidence of > 50% stenosis of at least one 
coronary artery, or past coronary 
revascularization. Exclusion criteria included 
severe cardiac disease; recent (within 3 
months) myocardial infarction, coronary 
revascularization, or hospitalization for 
unstable angina; allergy to macrolide 
antibiotics; significant renal or hepatic 
dysfunction; malignancy; ongoing antibiotic 
therapy; or immunosuppression. 
Intervention: Azithromycin 600 mg orally per 
week for 52 weeks or placebo. 
Main Outcome Measures: The primary event 
was the first occurrence of coronary heart 
disease death, nonfatal myocardial infarction, 
coronary revascularization, or hospitalization 
for unstable angina. Patients were followed for 
a mean of 4.5 years after enrollment. 
Enrollment was initiated in May 1999 
and follow up was completed for all subjects in 
December 2003. The results of the preliminary 
analyses of the relationship of the intervention 
with the primary outcome will be presented at 
this meeting. 
** E. G. V. Giardina, J. B. Kostis, R. Krone, 
M. B. Elam, J.Varghese, M. Alam, J. R. 
Crouse, G. A. Ewy, S. Ghaffari, P. F. Cohn, 
E. Caracciolo, M. Gheorghiade, R. O'Rourke, 
S. C. Smith, M. Corson,D. Vorchheimer, 
H. Valantine, R. M. Benitez, 
D. B. Hunninghake, W. Kussmaul, C. R. Conti, 
J. P. O'Bryan, G. Albin, M. Lauer 
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CHLAMYDIA PNEUMONIAE INDUCES CASPASE-3 INDEPENDENT 
APOPTOSIS LIKE CELL DEATH OF VASCULAR CELLS 
Dumrese Claudia1*, Maurus Christine F2, Gygi Daniel1, Schneider Marten K.J.2, Walch 
Michael1, Groscurth Peter1, Ziegler Urs1 
1 1 Institute of Anatomy, Division of Cell Biology, University Zurich, Laboratory for 
Transplantation Immunology, University Hospital Zurich, Zurich, Switzerland 
The intracellular bacterium Chlamydia 
pneumoniae is suspected to play a role in 
formation and progression of atherosclerosis. 
In order to investigate a possible pathogenic 
link, cultivated human aortic smooth muscle 
cells and endothelial cells were infected with 
Chlamydia pneumoniae and analyzed 
concerning type of cell death. 
Cell death was measured by lactate 
dehydrogenase release. Apoptotic and necrotic 
events were discriminated by annexin-
V/propidium iodide staining analyzed using 
flow cytometry and by ultrastructural 
morphology using transmission electron 
microscopy. Chlamydial infection morphology 
was correlated to markers of apoptosis 
(TUNEL) and necrosis (NHS-Biotin) using 
confocal microscopy. Caspsase 3 activity was 
analyzed measuring DEVD-pNa cleavage. 
Chlamydiae were found to be localized 
in infected cells mainly as single bacteria but 
also inside of large inclusions or rarely in 
aggregates. Quantification of host cell death 
revealed strictly dose and time dependent lysis 
by Chlamydia pneumoniae. Early apoptotic 
events were detected by revealing 
phosphatidylserine exposure in Chlamydia 
pneumoniae infected vascular cells. 
Ultrastructure of cell death in Chlamydia 
pneumoniae infected smooth muscle- and 
• endothelial cells differed from that of classical 
apoptosis concerning chromatin condensation, 
nuclear fragmentation and membrane damage. 
DNA fragmentation as well as cell membrane 
permeability occurred exclusively in cells 
carrying Chlamydia pneumoniae spots or 
aggregates but not in vascular cells with 
chlamydial inclusions. Caspase-3 activity was 
never found in Chlamydia pneumoniae 
infected cells. 
This study provides evidence that 
Chlamydia pneumoniae induces apoptosis-like 
cell death in primary isolates of human aortic 
smooth muscle- and endothelial cells which is 
triggered by an alternative, caspase-3 
independent pathway. 
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CHLAMYDIA PNEUMONIAE INFECTION OF SMOOTH MUSCLE CELLS 
STIMULATES THE RELEASE OF MATRIX METALLOPROTEINASES AND 
FACTORS INHIBITING SMOOTH MUSCLE CELL PROLIFERATION 
J. Rödel1*, D. Prochnau2, K. Prager J. Baumert1, K.-H. Schmidt1, E. Straube1 
institute of Medical Microbiology and 2Clinic of Internal Medicine, Department of Cardiology, 
Friedrich Schiller University of Jena, Jena, Germany 
The activation of smooth muscle cells 
(SMC) essentially contributes to the 
pathogenesis of atherosclerosis. During 
atherogenesis, SMC migrate from the media to 
the intima. Neointimal SMC proliferation and 
production of extracellular matrix proteins 
result in the formation of a fibrous cap 
overlying the lipid-rich core of the 
atherosclerotic plaque. Acute ischemic 
syndromes are usually due to the rupture of 
instable plaques and subsequent thrombosis 
(1). In symptomatic lesions the fibrous cap can 
rupture as a result of matrix degradation 
caused by matrix metalloproteinases (MMP) 
and through the reduction in the number of 
SMC (1,2, 3). Chlamydia pneumoniae infects 
SMC in atherosclerotic plaques (4). The aim of 
the study was to investigate the effect of C. 
pneumoniae infection on the production of 
MMPs by SMC and to examine whether 
soluble factors released by infected cells 
modulate SMC proliferation. 
Human vascular SMC (PromoCell, 
Heidelberg) were infected with C. pneumoniae 
TW-183. The expression of MMP and tissue 
inhibitors of MMP (TIMPs) was analyzed by 
RT-PCR. MMPs in culture supernatants were 
measured by ELISA and enzyme activity 
assays. Conditioned medium from infected cell 
cultures was examined for the ability to 
stimulate the proliferation of uninfected SMC. 
Proliferation was analyzed by a DNA synthesis 
assay measuring the incorporation of BrdU and 
by direct cell counting. In some experiments, 
infected cells were treated with the 
cycloxygenase-2 inhibitor NS-398. 
C. pneumoniae infection of SMC up-
regulated the mRNA levels of MMP-1 
(interstitial collagenase) and MMP-3 
(stromelysin) but did not affect the expression 
of MMP-2 and -9 (gelatinases). Additionally, 
the levels of TIMP-1 and -2 mRNA remained 
unchanged upon infection, chlamydia-infected 
cells secreted increased quantities of MMP-1 
and -3 proteins (5). When uninfected SMC 
were incubated with conditioned medium from 
infected cells, SMC DNA synthesis was 
decreased by 70 % compared to the incubation 
with conditioned medium from uninfected 
cells. Impaired SMC DNA synthesis after 
exposure to conditioned medium from C. 
pneumoniae-infected SMC was accompanied 
by decreased cell proliferation. Treatment of 
infected cells with NS-398 abolished the 
capacity of conditioned medium to inhibit 
SMC proliferation, suggesting that the 
antiproliferative factor induced by C. 
pneumoniae was a prostanoid metabolite. In 
accordance, chlamydial infection of SMC 
significantly stimulated the production of 
prostaglandin E2 (PGE2) which was suppressed 
by NS-398. 
The finding that C. pneumoniae 
stimulates the production of MMPs by SMC 
and inhibits SMC proliferation through 
induction of prostanoid metabolites provides a 
hypothesis how this pathogen may contribute 
to the déstabilisation of atherosclerotic 
plaques. 
References 
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99:2503 
4.Yamashita, K. et al. 1998. Stroke 29 :773 
5. Rôdel, J. et al. 2003. FEMS Immunol. Med. 
Microbiol. 38 :159 
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C. PNEUMONIAE SEROLOGY IN PATIENTS WITH CORONARY ARTERY 
DISEASE 
Jan Kaehler1, Ralf Koester1, Marion Carstensen1, Sabine Dettlaff 2* and Thomas 
Meinertz1 
department of Cardiology, Department of Microbiology, University Hospital Hamburg, 
diagnostic Division, medac GmbH, Hamburg, Germany 
Elevated antibody titers against C. 
pneumoniae have been associated with 
coronary artery disease, but few data are 
available regarding titers in patients with stable 
or unstable angina and under treatment with 
roxithromycin. 
196 consecutive patients undergoing 
coronary angioplasty were evaluated regardless 
of antibody titers at inclusion in the context of 
a study investigating the effect of 
roxithromycin on restenosis. Indication for 
angioplasty was stable angina in 49% of 
patients and acute coronary syndrome in 44% 
of patients. Antibodies against C. pneumoniae, 
chlamydial LPS and chlamydia heat shock 
protein 60 (cHSP60) were detected by 
C. pneumoniae-sELlSA, Chlamydia-rELISA 
and cHSP-ELISA (medac, Hamburg, 
Germany). 
The prevalences for both C. 
pneumoniae-IgG antibodies and anti-LPS-IgG 
were very high: 82-93% and 53-73% 
respectively, while IgA antibodies were 
detected in up to 79% of patients. In all 
patients groups, cHSP60-IgG antibody titers 
were positive in only 18-20%. Age, body mass 
index and coronary risk factors were only 
marginal associated with the prevalence of 
antibodies investigated. 
Treatment with roxithromycin had no effect on 
any of the titers. 
All antibody titers determined increased during 
the first 6 weeks of the follow-up. With 
comparable titers at inclusion, patients with a 
history of myocardial infarction (MI) and acute 
coronary syndrome had the most pronounced 
increase in titers, while patients without 
previous MI and stable angina had the least 
pronounced increase in titers. 
Patients undergoing coronary 
angioplasty have high antibody titers against C. 
pneumoniae. Coronary angioplasty itself 
induces a small but long-lasting increase of 
antibody titers against C. pneumoniae, while 
treatment with roxithro-mycin has no effect on 
any of the titers determined. 
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ASSOCIATION BETWEEN THE DEVELOPMENT OF RESTENOSIS AFTER 
PTCA AND THE CHANGES AFTER PTCA IN THE ANTIBODY TITERS TO 
MICROBES INCRIMINATED IN THE PATHOMECHANISM OF 
ATHEROSCLEROSIS 
Krisztina Heltai1, Fruzsina Petrovay2' Zoltán Kis2, Valéria Endresz3, Endre Ludwig4, 
Róbert Kiss5, Eva Gonczol2, István Préda5, István Valyi-Nagy5 
'Department of Cardiology, Railway Hospital, Budapest, 2Division of Virology and Bacteriology, 
Bela Johan National Center for Epidemiology, Budapest, department of Microbiology and 
Immunobiology, University of Szeged, Szeged, 4St. Laszlo Hospital, Budapest, 5National Center of 
Medicine, Budapest, Hungary 
Aim of the study: To establish whether 
PTCA results in the reactivation of certain 
pathogens in coronary plaques and, if so, 
whether the reactivation has a pathogenic role 
in the development of restenosis. 
Blood samples were withdrawn from 
31 patients immediately before and 4 and 14 
days after PTCA. IgG and IgA antibody titers 
against Chlamydia pneumoniae, 
cytomegalovirus (CMV), Epstein-Barr virus 
and herpes simplex virus type 1 were 
determined by ELISA and 
microimmunofluorescence methods in 
dilutions of 1/16 to 1/2048. C. pneumoniae and 
CMV DNA detections were performed by 
PCR. The clinical courses of the patients were 
followed for 8 months. Symptoms of 
respiratory infections were not detected in the 
patients between the first and last samplings. 
PTCA may reactivate chronic C. 
pneumoniae and CMV infections, resulting in 
an increased risk of restenosis. 
1. Increases in the C. pneumoniae IgG 
and IgA titers were observed in 3 patients, and 
similar increases in the CMV antibodies in 3 
other patients. There were no changes in the 
Epstein-Barr virus and herpes simplex virus 
type 1 titers. 2. As concerns the 6 patients with 
restenosis, the antibody titers were increased in 
3, while the antibody titers were also increased 
in 3 of the 25 patients without restenosis. The 
difference is statistically significant (p=0.01), 
though the number of patients is small. 3. The 
DNA detection tests are in progress. 
CARDIOVASCULAR DISEASES - 115 
CHLAMYDOPHILA PNEUMONIAE- SPECIFIC MRNA IS PRESENT IN 
AORTIC WALL BIOPSIES OF PATIENTS SUFFERING FROM STABLE OR 
UNSTABLE ANGINA PECTORIS 
Marie Edvinsson, Eva Hjelm, Stefan Thelin, Goran Friman and Christina Nystrôm-
Rosander 
Infectious Diseases and Clinical Bacteriology, 
University Hospital, Uppsala, Sweden 
Chlamydophila pneumoniae (Cp) might 
somehow be involved in the pathogenesis of 
atherosclerosis. Several studies have 
demonstrated a serological association 
between Cp and coronary artery disease and 
DNA from the bacteria has been found in 
various atheromatous vessels. However, only a 
few investigators have managed to culture Cp 
from atheromatous plaques. Instead of 
culturing, viable bacteria could be 
demonstrated by reverse transcriptase PCR 
(RT-PCR) against bacterial mRNA. We 
investigated the presence of Cp DNA and 
mRNA in aortic wall biopsies, obtained at 
surgery, from 24 patients with stable angina 
pectoris (SAP) and 20 patients with unstable 
angina pectoris (UAP). 
DNA and RNA were extracted from the 
same biopsy using the RNA/DNA mini kit 
(Qiagen). cDNA was made using the 
SuperScript First-Strand Synthesis System for 
RT-PCR (Invitrogen). Real time PCR directed 
against the MOMP gene was used to detect the 
presence of Cp DNA and mRNA in the 
biopsies. Patient sera were tested for Cp-
specific IgM, IgG and IgA antibodies by the 
microimmunofluorescence technique. 
13 (28%) of the biopsies (6 SAP; 7 
UAP) were positive for Cp DNA, 8 (17%) 
were positive for Cp mRNA (5 SAP; 3 UAP) 
and 6 (12%) were positive for both DNA and 
mRNA (4JSAP; 2 UAP). All biopsies but one 
were positive for human cDNA encoding the 
GAPDH gene. 
Department of Medical Sciences, Uppsala 
That biopsy was negative also for Cp DNA and 
Cp mRNA. Results from the serology will be 
presented on the poster. 
We have demonstrated the presence of 
Cp in the aortic wall of patients suffering from 
stable (SAP) or unstable (UAP) angina 
pectoris. Also, we have demonstrated Cp 
mRNA in 17% of these patients indicating that 
the bacteria were metabolically active. There 
were no significant differences in the 
frequencies of positivity for Cp DNA or Cp 
mRNA between the SAP and UAP groups. 
The results support the hypothesis of an active 
role for jCp in. the pathogenesis of 
atherosclerosis. 
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COMPARISON OF CHLAMYDIA PNEUMONIA/:-SPECIFIC DNA DETECTION 
METHODS BY PCR AND TWO DIFFERENT RT-PCR METHODS 
Judith Deák1, Judith Tóth1, F. Somogyvári1, Beatrix Kele1, Elisabeth Nagy1, R. Sipka2, 
B.A. Szabó2 
'Department of Clinical Microbiology, department of Surgery, University of Szeged, Szeged, 
Hungary 
The first evidence of C. pneumoniae in 
atherosclerotic plaques was reported in 1992 
by Shor et al. The pathogenesis of 
artherosclerosis was described by Ross. In the 
various studies, C. pneumoniae has been 
detected in atherosclerotic lesions of different 
major arteries in very different distributions. 
Our aim in this study was to detect 
C. pneumoniae-specific nucleic acid in 
atherosclerosis patients. 
Internal carotid samples were collected 
from patients with significant internal carotid 
stenosis after eversion endarterectomy. The 
aortic aneurysm samples originated from the 
infrarenal region (>5 cm in diameter) after 
resection. Aortic samples were collected from 
the infrarenal region because of aortoiliacal 
occlusion or multiple stenosis between 1998 
and 2003. Carotid and aortic samples were 
graded macroscopically on a scale of 1-4. 
1. DNA was extracted with phenol-
chloroform-isoamyl alcohol (Sigma) and then 
precipitated with ethanol after proteinase K 
(Sigma) incubation. Nested PCR was carried 
out as described by Cunningham et al. 2. The 
same nucleic acid isolation method was used 
for RT-PCR (SybrGreen) method as described 
by Apfalter et al. 3. The QIAmp nucleic acid 
isolation method as described by Apfalter et al. 
was used for the TaqMan PCR assay. 
The sensitivity of RT-PCR (SybrGreen) 
proved to be higher than that of conventional 
nested PCR. The QIAmp nucleic acid isolation 
method combined with the TaqMan PCR assay 
furnished not only higher sensitivity, but also 
quantitative results. 
References 
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episodes of asthma in children. In: Chlamydial 
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Results of different PCR methods in different patient groups 
N Nested Nested RT-PCR RT-PCR RT-PCR RT-PCR 
PCR- PCR- SybrGreen- SybrGreen- TaqMan- TaqMan-
positive negative positive negative positive negative 
Carotid 58 4 54 6 52 10 48 
stenosis 
Aortic 10 0 10 0 10 0 10 
aneurysm 
Aortic 10 0 10 0 10 0 10 
occlusion 
or stenosis 
Total 78 4 74 6 72 10 68 
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CHLAMYDIA PNEUMONIAE AND CORONARY ATHEROSCLEROSIS: AN 
ASSOCIATION STUDY USING PCR ASSAY, ANTIGEN DETECTION AND 
SEROLOGY 
Gita Satpathy, Anil Bhan, Anjana Sharma, U Kar and SK Panda 
All India Institute of Medical Sciences, New Delhi, INDIA 
To determine the association of C. 
pneumoniae with coronary atherosclerosis 
using agent detection by PCR and antigen 
detection assays and antibody detection by 
microimmunofluorescence assay. 
Specimens of seventy two 
atherosclerotic plaques from coronary arteries 
from patients of coronary heart disease, 
collected during coronary artery bypass 
grafting were tested for presence of C. 
pneumoniae genome using a nested PCR assay 
and antigen detection by monoclonal based 
immunofluorescence assay. Presence of 
species specific C. pneumoniae antibodies 
were also tested in these patients using 
microimmunofluorescence assay using a kit 
from Prof. Darougar, UK. Seventy two age and 
sex matched controls were also tested for C. 
pneumoniae species specific antibodies. 
In none of these 72 atherosclerosis 
plaque specimens C. pneumoniae could be 
detected by PCR assay or by 
immunofluorescence assay. C. pneumoniae 
antibodies at a titre of >1:16 were detected in 
65% of these 72 CHD patients. However 63% 
of the controls also had C. pneumoniae 
antibodies. 
We failed to get any positive 
association of C. pneumoniae with coronary 
artery disease in these groups of patients. 
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CHLAMYDIA PNEUMONIAE INFECTION DOES NOT INCREASE 
ATHEROSCLEROTIC LESIONS IN THE ASCENDING AORTA OF APOE-
DEFICIENT MICE 
Christian Wahl*, Philipp Duerr, Sonja Maier, Ulrike Simnacher, Reinhard Marre, and 
Andreas Essig 
Department of Medical Microbiology and Hygiene, University of Ulm, Germany 
Chlamydia pneumoniae (C. 
pneumoniae) has been associated with 
arteriosclerosis. In this study we investigated 
the influence of repeated C. pneumoniae-
infection of the respiratory tract for the 
progression of arteriosclerotic lesion in the 
ascending aorta of apolipoprotein E (apoE) 
deficient mice. 
For experiments eight-weeks old male 
apoE-deficient mice on C57BL/6J background 
were used. The mice were infected intranasally 
with lxlO6 inclusion-forming units (IFU) 3 
times at 2-weeks intervals and killed 6 weeks 
later. After Elastica van Gieson's staining of 
sections from the ascending aorta, the lesion 
areas in the histological cross-sections were 
measured morphometrically. To detect 
chlamydial DNA, MOMP-PCR and 
LightCycler-PCR were performed. 
Immunohistochemistry stainings were also 
performed to detect macrophages and 
chlamydial antigen in atherosclerotic lesions. 
The serum levels of C. pneumoniae-specific 
antibody titers were determined by 
microimmunofluorescence test using C. 
pneumoniae elementary bodies as antigen. 
C. pneumoniae has no influence in the 
progression of arteriosclerotic lesions in the 
ascending aorta of apoE-deficient mice. As 
demonstrated by determination of the P-value 
(P=0,892), there is no significance in the lesion 
size between C. pneumoniae and mock-
infected mice. Each group contains 23 mice. 
To detect chlamydial antigen in aortic 
atherosclerotic lesions, a mouse anti-
chlamydial lipopolysaccharide (LPS) antibody 
was used on paraffin sections. Neither in C. 
pneumoniae-infected nor in mock-infected 
mice was chlamydial LPS antigen detected 
within atherosclerotic lesions. 
To examine the degree of vascular 
inflammation and changes in the composition 
of subpopulations of infiltrated macrophages, 
paraffin sections were stained for CD59 and 
MoMa. CD59 is a foam cell marker, whereas 
MoMa is a monocyte and macrophage marker. 
There were no significant differences of 
CD59+ (P=0,412) and MoMa+ (P=0,886) cell 
infiltration in lesions of C. pneumoniae-
infected versus mock-infected apoE-deficient 
mice. 
To examine, if C. pneumoniae can generate a 
systemic dissemination in apoE-deficient mice 
two different PCR methods were used. In only 
one mice could we detect chlamydial DNA by 
PCR. This LightCycler-PCR positive result 
could not be verified by nested MOMP-PCR, 
indicating that this probe must be handled as 
unclear. 
Only infected mice developed an IgG-titer 
between 1:256 and 1:4096 as quantified 10 
weeks after first infection, whereas all mock 
infected mice have a titer of <1:32 . 
In our study we could demonstrate, that 
C. pneumoniae has no influence in the 
progression of arteriosclerotic lesions in the 
ascending aorta of apoE-deficient mice. 
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RELATIONSHIP BETWEEN CHLAMYDIA PNEUMONIAE SEROPOSITIVITY 
AND AGE-RELATED MACULAR DEGENERATION, IN PATIENTS WITH 
CORONARY ARTERY DISEASE 
Annamária Nagy*, Andrea Facskó*, Judith Deák**, István Édes***, András Berta* 
Department of Ophthalmology*, University of Debrecen, Department of Clinical Microbiology**, 
University of Szeged, Department of Cardiology***, University of Debrecen, Hungary 
Age-related macular degeneration 
(AMD) is a leading cause of blindness in the 
well-developed countries. Many risk factors 
have been established, but the etiopathological 
background is still not completely clear. 
Among the potential risk factors, 
atherosclerosis is one of the proven causes of 
AMD. There is increasing evidence in support 
of the role of chronic Chlamydia pneumoniae 
(C. pneumoniae) infection in the pathogenesis 
of general atherosclerosis and coronary artery 
disease (CAD). The aim of the present study 
was to obtain evidence on the possible role of 
chronic C. pneumoniae infection in AMD. 
C. pneumoniae titers were determined 
with a microimmunofluorescence (MIF) 
method (Focus Technologies, Cypress, USA) 
in the serum of 30 patients with 
coronarographically-proven CAD, and also in 
24 cataract patients with no clinical signs of 
CAD (controls). The patients in both groups 
were examined clinically for the presence of 
AMD. Statistical analysis was carried out by 
means of Chi-square analysis: a level of 
p<0.05 was regarded as statistically significant. 
AMD was detected in 12 patients in the 
CAD group, and in 6 patients in the control 
group. There was no statistically significant 
difference in C. pneumoniae seropositivity 
between the CAD and control groups. 
The results of the study do not support 
the assumption that chronic C. pneumoniae 
infection plays a role in the development of 
AMD. However, these limited observations 
and the results of others justify further studies 
on the role of C. pneumoniae infection in 
AMD, and the authors plan to extend this 
examination to a larger number of subjects, 
with the use of additional laboratory 
techniques. 
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CHLAMYDIAL LPS, CIRCULATING LPS BINDING PROTEINS AND C-
REACTIVE PROTEIN IN HEALTHY BLOOD DONORS 
Korhonen T1'2*, Jounio U2, Tiirola T2, Jauhiainen M2, Silvennoinen-Kassinen S1, 
Leinonen M2 and Saikku P1 
1 Dept. of Medical Microbiology, University of Oulu, 2National Public Health Institute, Oulu and 
Helsinki, Finland 
Chlamydia pneumoniae is capable to 
multiply and survive in e.g. macrophages, 
endothelial and smooth-muscle cells, that have 
important role in the generation and progression of 
atherosclerosis. Chlamydial LPS (cLPS) induces 
macrophage foam cell formation and production of 
cytokines and growth factors. In this work, we 
studied the association between circulating cLPS, 
circulating LPS binding proteins - soluble CD 14 
(sCD14) and LPS binding protein (LBP) - and C-
reactive protein (CRP), a marker of systemic 
inflammation. cLPS levels were also compared to 
C. pneumoniae IgA antibody titres. Because the 
genetic background of a host is likely to modify 
immune response, we also studied gene 
polymorphisms that might affect LPS recognition. 
The polymorphisms tested were LBP 1341T—>C 
(Phe436—>Leu), Toll Jike receptor 4 (TLR4) 
896A-4G (Asp299-)Gly), CD14 -260C->T, and 
apolipoprotein E (ApoE) alleles E 2, 3 and 4. 
Sera and buffy coats of 387 healthy blood 
donors (265 men and 122 women) were obtained 
from Finnish Red Cross Blood Service. Serum 
levels of CRP, sCD14 and LBP were measured by 
commercial ELISA methods (Medix Biochemica, 
HyCult). Quantitation of cLPS (OD values) was 
performed by an LBP-based ELISA and C. 
pneumoniae IgA antibody titres by 
microimmunofluorescence test. DNA was 
extracted from buffy coats by a commercial kit 
(Qiagen). Polymorphisms were genotyped either 
by Light Cycler Real Time or conventional PCR. 
For statistical analysis X2 and Mann-Whitney U 
tests, Spearman's correlaton and binary logistic 
regression were used. The ApoE polymorphism 
was cathegorized as either having an ApoE4 allele 
or not. TLR 4 polymorphism genotype GG and 
LBP polymorphism genotype CC were so rare that 
they were omitted from the final analysis. 
High C. pneumoniae IgA titres were 
associated with hig levels of cLPS (Md = 0.05 OD, 
interquartile range 0.05 for IgA > 20, and Md = 
0.03 OD, interquartile range 0.07 IgA < 20) in M-
W test Z=-2.185 and p=0,029. In a binary logistic 
regression analysis for LBP, risk factors for having 
LBP levels higher than median (10.6 mg/1) were 
OR=8.8 (95 % CI 2.3-6.0) for CRP > median (0.6 
mg/1), OR=2.1 (95 % CI 1.3-3.4) for sCD14 > 
median (1.6 mg/1), OR=2.0 (95 % CI 1.3-3.3) for 
cLPS > median (OD =0.03), OR=2.6 (95 % CI 1.2-
3.3) for LBP polymorphism genotype CT and 
OR=2.3 (95% CI 1.2-4.3) for TLR4 polymorphism 
genotype AA. In a corresponding analysis for 
sCD14, risk factors for having levels higher than 
median were OR=2.2 (95 % CI 1.4-3.5) for LBP, 
OR=2.3 (95 % CI 1.4-3.7) for ApoE polymorphic 
isoform E4, OR=1.9 (95 % CI 1.2-2.9) for CD14 
polymorphism genotype TT/CT, OR=2.2 (95 % CI 
1.1-4.5) for LBP polymorphism genotype CT, and 
OR=1.8 (95 % CI 1.1-3.0) for male sex. cLPS over 
median was associated with sCD14 levels under 
median with OR=0.5 (95 % CI 0.3-0.8). 
Higher C. pneumoniae IgA antibody titres 
and higher cLPS levels were associated, 
suggesting that cLPS likely originated from C. 
pneumoniae. LBP levels were in direct relation to 
CRP ja sCD14 levels suggesting that the 
production of these proteins is somehow 
synchronized on their expression/secretion levels. 
All these molecules are acute phase proteins and, 
moreover, LPB and sCD14 are specific LPS 
binding proteins. Interestingly cLPS levels were in 
direct relation to LBP levels but inversely related 
to sCD14 levels. cLPS levels were low in these 
healthy subjects, so infrequency of positive (OD 
>0,15) values may have affected analysis. 
However, it is also possible that when cLPS level 
is high, more LPS is capable to interact with 
sCD14 directing sCD14-cLPS complexes to the 
cell surface, thus reducing free sCD14 levels in the 
serum. LBP and sCD14 levels also seem to be 
affected by polymorphisms of LBP, TLR4, CD 14 
and ApoE genes. 
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NEW INSIGHTS IN CHLAMYDIAL IMMUNOLOGY AND PATHOGENESIS 
Harlan D. Caldwell1, David Nelson1, Dezso Virok1, Heidi Wood2, Grant McClarty2 
laboratory of Intracellular Parasites, National Institutes of Health, National Institute of Allergy 
and Infectious Disease, Rocky Mountain Laboratories, Department of Medical Microbiology, 
University of Manitoba, Winnipeg, Manitoba, Canada 
Chlamydial infection is characterized by a 
plethora of strains that exhibit remarkable 
diversity in their host species, cellular infection 
tropism, and pathogenicity (1). The genetic 
basis of this host-pathogen diversity is poorly 
understood. The sequencing of several 
chlamydial genomes (2-3), together with 
comprehensive descriptions of immunity in in 
vivo and in vitro models of infection, has 
begun to provide a coherent picture of this 
intriguing host-pathogen relationship. The 
murine model of chlamydial female genital 
tract infection (4) closely mimics infection and 
disease of humans. It is therefore considered to 
be a particularly relevant model for 
understanding host immunity to chlamydial 
infection. Gene knock out mice, adoptive 
transfer of lymphocytes, and in vivo depletion 
of lymphocytes have been employed in the 
model to define parameters of innate and 
adaptive protective mucosal immunity using 
both murine and human chlamydial strains. 
This body of work, that has been recently 
reviewed (5), provides unequivocal evidence 
for a MHC class H, IL-12, CD4+ Tcell 
dependent immunity in the eradication of 
chlamydial infection from urogenital mucosal 
epithelial cells. Here we will summarize 
findings which expand on seemingly 
diminutive, yet critical, differences in IFN-
ymediated host immune mechanisms against 
murine and human strains that have transpired 
from these studies. In response to these 
differences, mouse and human strains have 
evolved unique pathogenic mechanisms 
allowing for immune evasion in their specific 
host. Together these findings provide an 
illuminating example of host and pathogen 
coevolution. It is expected that this 
information will lead to novel targets of 
antigen discovery and the development of 
genetically modified mice with enhanced 
susceptibility to infection by human strains. 
These advances could generate superior hosts 
for the study of chlamydial pathogenesis and 
vaccine development. 
The effect of IFN-y on chlamydial growth in 
vivo 
Several independent studies have shown that 
the murine strain C. muridarum (MoPn) and 
the human strain C. trachomatis (serovar D) 
exhibit remarkable differences in their 
susceptibility to eradication from the genital 
track in IFN-y(6-8) and IFN-y R_/"receptor KO 
mice (9). Clearance of MoPn from the genital 
mucosa occurs largely independently of IFN-y 
or its cognate receptor, whereas clearance of 
the human strain is distinctly IFN-y dependent. 
Infection kinetics of both strains are not 
significantly different in iNOS^KO mice 
compared to iNOS+/+ controls (10-12), 
indicating that nitric oxide (NO) is not the 
prominent IFN-y effector mechanism that 
functions in eradication of chlamydial 
urogenital epithelial infection. This difference 
between mouse and human strains in 
susceptibility to the in vivo effector function(s) 
of IFN-yis consistent with the idea that 
resistance is not static, but has evolved in a 
species-specific manner. Thus, the murine 
strain appears to have evolved a strategy for 
avoiding this effector function whereas the 
human strain(s) lack this capability; a contrast 
in pathogenesis that is incredible considering 
that the genomes of the organisms are 
remarkably similar in gene structure and 
organization (3). We have recently undertaken 
functional genomic studies to better 
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understand this unique host-pathogen 
relationship by studying chlamydial growth in 
IFN-y treated human (HeLa) and murine 
epithelial cells (MEC). 
The effect of IFN-y on chlamydial growth in 
vitro 
(i) Human strains. In HeLa cells, IFN-y 
induces the expression of indolamine-2,3-
dioxygenase (DDO), an enzyme that catalyzes 
the breakdown of L-tryptophan to L-
kynurenine, resulting in the depletion of 
intracellular tryptophan pools (13). Because 
chlamydiae are auxotrophic for tryptophan, 
IFN-y treatment is inhibitory to growth and, 
under limiting conditions, induces persistent 
chlamydial forms that can be reactivated by the 
removal of IFN-y or addition of excess 
tryptophan (14). Genome sequencing projects 
lead to the finding that all human C. 
trachomatis strains encode a tryptophan 
repressor and tryptophan synthase. 
Intriguingly, functional studies have indicated 
that the tryptophan synthase complex is active 
in genital, but not ocular, strains (15-17). trpA 
and trpB encode the a and P?subunits of 
tryptophan synthase that catalyzes the 
conversion of indole 3-glycerol phosphate 
(IGP); a substrate that is lacking in 
chlamydiae, to tryptophan (18). Why would 
human genital strains maintain the ability to 
regulate tryptophan synthesis in the absence of 
a complete biosynthetic tryptophan pathway? 
Interestingly, exogenous indole can rescue the 
growth of genital serovars following exposure 
to IFN-y (16). Moreover, missense mutations 
in the chlamydial trpA gene map to the IGP, 
suggesting that there is a selective advantage to 
utilizing indole as a substrate in chlamydiae 
(16). Mammalian cells do not produce indole 
and C. trachomatis does not encode the 
enzymes required for de novo indole 
biosynthesis (2). It is thought that the micro 
flora of the female genital tract provide a 
source of indole capable of rescuing 
chlamydial growth (17). This pathogenic 
strategy would allow genital strains to persist 
in vivo by avoidance of host EFN-y mediated 
immunity. Taken together, these findings 
suggest that human genital strains have co-
evolved in a highly specific manner to take 
advantage of the unique microenvironment of 
the human genital tract. Interestingly, this 
adaptation appears to have been influenced by 
an environmental selection that includes 
polymicrobial host pathogen interactions. 
(ii) Murine strains. MoPn growth is markedly 
inhibited in IFN-y treated HeLa 229 cells (19). 
Like human strains, infectivity is rescued by 
adding excess tryptophan but, unlike human 
strains, infectivity cannot be rescued by 
exogenous indole. Again, genomic sequencing 
has provided the reason for this biological 
difference; MoPn lacks any genetic capacity to 
synthesize tryptophan (3). Clearly, there has 
been no selective pressure on the mouse strain 
to maintain tryptophan biosynthetic capacity. 
Why? We have begun to unravel the answers 
to this question in an in vitro infection model 
using primary MEC. Both MoPn and human 
strains grow prolifically in cultured MEC. 
Growth of MoPn is unaffected in IFN-y treated 
MEC, whereas human strains are inhibited; 
findings in accordance with in vivo infection 
model results (see above). IFN-y does not 
induce EDO expression in MEC and 
intracellular tryptophan pools are unchanged; 
providing a reasonable explanation why the 
mouse strain has not retained tryptophan 
biosynthesis genes. While chlamydial infected 
IFN-y treated MEC produce nitric oxide, 
specific inhibitors of iNOS do not rescue the 
growth of human strains. Again, as with the 
human strains, these findings support the 
conclusion that the murine strain has evolved 
pathogen-specific mechanisms to avoid the 
innate immune response of its natural host. 
Understandably, human strains are exquisitely 
sensitive to this host-specific defense 
mechanism. These results pose several 
important questions. What is the murine 
species-specific host factor(s) and how does it 
function? What is the MoPn specific virulence 
factor(s) that so effectively eludes this potent 
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innate immune mechanism(s)? How can 
answers to these questions accelerate advances 
in the control of human chlamydial infection 
and disease? 
Mouse-specific regulators of innate 
immunity 
DNA microarray was used to identify IFN-y 
regulated genes that might function in 
controlling infection of human strains by 
MEC. We analyzed" and correlated 
transcriptional changes of MEC under several 
experimental conditions; (i) infection alone, 
(ii) IFN-y treatment alone, and (iii) infection 
plus IFN-y treatment. Amplified cRNA from 
the different groups was hybridized to 
Affymetrix 430A mouse chips. The array 
contains -20.000 probes covering the majority 
of known mouse genes. IFN-y treatment, 
chlamydial infection, and the combination of 
each had a significant impact on the 
transcriptome of MEC altering the expression 
-800-1200 genes. Most remarkable was the 
lack of IDO expression coupled with the 
marked up-regulation of the large family of 
pleotrophic IFN-y inducible GTP binding 
proteins in IFN-y treated chlamydial infected 
MEC. Among these, members of the p47 
GTPase family (Lrg47, IGTP, TGTP, and 
HGP) were most strongly up regulated. 
Interestingly, the P47 GTPases have recently 
emerged as a novel NOS2 independent 
regulators of murine innate immunity that 
control host resistance to a number of 
intracellular pathogens such as Toxoplasma 
gondii, Listeria monocytogenes, and 
Mycobacteria spp (20). Together, these 
findings suggest that one or more of these p47 
GTPases might be the immune regulators that 
so effectively control the intracellular growth 
of human chlamydial strains in mouse 
epithelial cells. 
A functional role for p47 GTPases in the 
resistance of MEC to infection by human 
strains is being investigated by siRNA gene 
silencing experiments. We have found that 
siRNAs specific to IGTP rescues the 
infectivity of human strains in IFN-y treated 
MEC, implicating a specific function for IGTP 
in murine host defense against infection by 
human chlamydial strains. It is noteworthy that 
IGTP has also been shown to be the primary 
GTPase that regulates intracellular defense 
against T. gondii (21) a protozoan parasite that 
resides in a parasitophorous vacuole with 
biological properties similar to the chlamydial 
vacuole (22, 23). 
Plasticity zone and pathogenesis 
The different tissue tropisms displayed by, and 
disease conditions caused by, chlamydiae are 
belied by remarkable genetic synteny among 
these organisms. The murine MoPn strain 
shares the vast majority of its genes with the 
human C. trachomatis strain (3). Therefore, 
the few genotypic differences that exist 
between chlamydiae are likely to factor 
prominently in observed variability in tissue 
tropism and disease. Genomic variability 
among C. trachomatis strains maps largely to a 
region of hyper-variability near the 
chromosomal origin of replication termed the 
plasticity zone (PZ) (3). Phenotypic divergence 
amongst C. trachomatis strains has been linked 
to two families of enzymes in the PZ. First, as 
described above, human but not murine strains 
of C. trachomatis encode a truncated 
tryptophan biosynthesis operon that allows 
these organisms to utilize indole. Interestingly, 
human epithelial cells but not mouse epithelial 
cells, express IDO, the tryptophan-degrading 
enzyme in response to IFN-y pathogen 
challenge. Therefore, it appears that human 
strains of chlamydiae have retained these 
tryptophan metabolic capabilities as a result of 
co-evolving with their natural host for the 
specific purpose of immune evasion. In 
contrast, the MoPn adapted murine strain, has 
not retained the PZ tryptophan biosynthesis 
genes, but instead has maintained three large 
intact orfs within the PZ that encode proteins 
with strong homology to the large clostridial 
cytotoxins. Although the exact role of these 
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proteins in MoPn infection is unknown, the 
proteins have highly conserved functional 
domains at their N-terminus that target and 
inactivate small GTPases. Thus, the toxin(s) 
might block G protein mediated signaling that 
is important to murine innate immune 
responses. This possibility would be consistent 
with the findings described above; murine 
epithelial cells respond to IFN-y and infection 
by a strong up-regulation of the P47 GTPases 
gene family; proteins that have intracellular 
pathogen inhibiting activities (20). 
Interestingly, human cells do not express this 
family of GTPases in response to IFN-y or 
infection. Thus, like the tryptophan operon in 
human strains, the cytotoxin(s) appear to have 
co-evolved with the murine strain in a host 
species-specific manner for the purpose of 
immune evasion. 
Conclusions 
IFN-y is a pro-inflammatory cytokine that 
plays a central role in innate and adaptive 
immune resistance to infection in mice and 
humans. This report describes findings that 
implicate a strong evolutionary pressure for 
chlamydiae to co-evolve with their natural 
host. Specifically, it is evident that human and 
mouse epithelial cells respond uniquely to 
IFN-y by producing IDO and p47 GTPases, 
respectively, and these effector molecules have 
a distinct function(s) for inhibiting intracellular 
chlamydial growth. Remarkably, human and 
murine strains have evolved specific 
mechanisms for evading these host responses. 
The role of the trpRBA operon in human 
genital strains in circumventing IDO mediated 
tryptophan deprivation is now well 
characterized. How the MoPn murine strain 
evades the potent inhibitory action of p47 
GTPases in not understood and is the subject 
of current investigation. The large cytotoxin(s) 
genes located in the PZ that possess putative 
GTPase inactivating domains are logical 
candidates. 
How can the findings discussed herein help 
improve control of human chlamydial 
infection? A major drawback in making 
significant advances in the prevention of 
human chlamydial infections disease is the 
lack of a small animal model suitable for both 
pathogenesis and vaccine studies. A possible 
consequence of the work summarized here 
would be the development of a humanized 
mouse strain, which would more closely mimic 
the human immune response to infection. This 
strain could serve as a small animal model for 
relevant pathogenesis and vaccine work on 
human chlamydial strains, something that is 
now restricted to non-human primates. 
Hypothetically, this could be achieved by 
knocking out the relevant GTPase gene(s) and 
introducing the human IDO gene whose 
expression is both targeted to epithelial cells 
and inducible by IFN-y? 
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REGULATION OF TRYPTOPHAN SYNTHASE GENE EXPRESSION BY THE 
TRYPTOPHAN REPRESSOR IN C. TRACHOMATIS 
Heidi Wood*, Christine Roshick, and Grant McClarty 
Health Canada and University of Manitoba, Winnipeg, Manitoba, Canada 
C. trachomatis encodes three genes 
involved in tryptophan biosynthesis in the 
plasticity zone: trpR, encoding the tryptophan 
repressor, and trpA and trpB, encoding the a 
and (3 subunits of tryptophan synthase. Under 
conditions of tryptophan sufficiency in E. coli, 
TrpR is complexed with tryptophan and 
represses transcription of the trp operon. When 
tryptophan levels decrease, the expression of 
these genes is induced due to the inability of 
the aporepressor to bind its cognate operator 
sequence in the absence of tryptophan. The 
purpose of this study was to examine the 
ability of different tryptophan analogues to 
bind to the tryptophan repressor (TrpR) and 
regulate expression of tryptophan synthase 
(TrpBA) and the growth of C. trachomatis 
serovar L2. 
C. trachomatis serovar L2 was cultured 
in HeLa cells in MEM lacking tryptophan (-
Trp) but supplemented with either tryptophan 
or one of the following tryptophan analogues: 
D-tryptophan, 5-fluorotryptophan, 5-
hydroxytryptophan, 5-methyl-D-tryptophan, or 
5-methyl-L-tryptophan. Infected cells were 
also incubated in media containing the 
tryptophan analogues and further 
supplemented with indole. Cultures were 
harvested at 48 h post-infection for 
enumeration of recoverable IFUs. RNA was 
extracted from parallel cultures for quantitative 
RT-PCR using the LightCycler for 
determination of trpBA transcripts levels. 
Growth of serovar L2 in the absence of 
tryptophan but in the presence of the various 
tryptophan analogues is inhibited, as 
demonstrated by a 2.5-3.5 logio decrease in 
recoverable IFUs compared to control cultures 
incubated in media containing tryptophan. 
Indole rescued the growth of serovar L2 
cultured in -Trp media. However, indole was 
incapable of rescuing the growth of serovar L2 
in the presence of 5-fluorotryptophan. This is 
consistent with the RT-PCR results indicating 
that expression of trpBA (required for the 
utilization of indole as a substrate for 
tryptophan biosynthesis) is highly repressed in 
the presence of 5-fluorotryptophan compared 
to expression in -Trp media alone. Growth of 
serovar L2 was partially rescued by 
supplementation of the media with indole in 
the presence of the remaining tryptophan 
analogues, again consistent with the finding 
that expression of trpBA is partially repressed 
in the presence of D-tryptophan, 5-
hydroxytryptophan, 5-methyl-D-tryptophan, or 
5-methyl-L-tryptophan compared to expression 
in -Trp media alone. 
Our results indicate that different 
tryptophan analogues differentially regulate the 
expression of trpBA and the growth of serovar 
L2. Therefore, culture of C. trachomatis 
serovar L2 in the presence of the tryptophan 
analogues, in particular 5-fluorotryptophan, 
will allow for the isolation of mutants with 
mutations in the tryptophan repressor gene or 
in the trp operator sequence. We have used 
this selection protocol to isolate mutants with 
the ability to express tryptophan synthase even 
in the presence of tryptophan or 5-
fluorotryptophan. We are currently in the 
process of further passing this mutant in the 
presence of 5-fluoroindole, which is converted 
to 5-flurotryptophan by TrpBA and is toxic 
once incorporated into pr-oteifis. This sélection 
protocol should allow for the isolation of 
mutants with mutations in trp A and/or trpB. 
The isolation and characterization of mutants 
with alterations in tryptophan metabolism will 
provide a better understanding of the 
relationship between IFN-y, tryptophan 
metabolism and persistence. 
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EVIDENCE FOR A SHIFT IN THE SURFACE CHARACTERISTICS OF CHLAMYDIA 
TRACHOMATIS IN PERSISTENT VS. ACTIVE INFECTION 
Hervé C. Gérard, Judith A. Whittum-Hudson, and Alan P. Hudson* 
Department of Immunology and Microbiology, Wayne State University School of Medicine, Gordon H. 
Scott Hall, Detroit, MI, USA 
Our aim was to determine whether the 
pattern of expression for genes encoding the 9 
polymorphic membrane proteins of C. trachomatis 
is different during persistent vs. active infection, 
and to define the kinetics of changing mRNA 
production from each gene during the transition 
from active to persistent infection. 
Studies from this group and others have 
demonstrated that expression of ompl, encoding 
the major outer membrane protein of C. 
trachomatis, as well as that of two other genes 
encoding surface proteins, is highly attenuated 
during persistent infection. The chlamydial 
genome project identified 9 genes encoding 
polymorphic membrane proteins (pmp's) on the 
chlamydia] chromosome, all of which may be 
expressed differently during persistent infection 
than they are during active infection. 
For active infection, HEp-2 cells were 
infected with serovar K at MOI 1:1; cells were 
harvested at various times from t=0-48 hr post-
infection (p.i.); RNA was prepared from each cell 
pellet. Normal human peripheral monocytes were 
prepared and infected at MOI 1:1 with the same 
serovar; cultures were harvested, and RNA was 
prepared from each cell pellet, at 0, 1, 2, 3, 4, 5 d 
p.i.. cDNA was made from each RNA preparation 
by standard reverse transcription. Primers for real 
time RT-PCR analyses were designed to target 
pmps A, B, C, D, E/F, G/H, I (Ct412, Ct413, 
Q414, Ct812, Ct870, Ct871, Q874). CT869 and 
Ct870 are expressed in a polycistronic transcript, 
as are Ct871 and Ct872. Real time analyses of 
cDNA were done by the SYBR green method in a 
PE Biosystems Model 7700 sequence detector. 
Data were normalized to 16S rRNA and compared 
to those of elementary bodies. 
During active infection of HEp-2 cells, all 
pmp genes were expressed throughout the 48 hr 
developmental cycle, except those encoding pmpB 
and pmpE/F. Transcription of these latter began at 
about 18 hr p.i. and continued through 48 hr. 
Genes encoding pmpA, pmpD, pmpG/H, and pmpl 
generally showed the highest levels of expression 
in infected HEp-2 cells. In the monocyte model of 
persistence, C. trachomatis transits from active 
infection to the persistent state between d 2-3 p.i.. 
At 1-2 d p.i. in the monocyte system, expression of 
all pmp-encoding genes was roughly similar to that 
at 24-36 p.i. during active infection of HEp-2 cells. 
By d 3 p.i. in infected monocytes, expression of 
genes encoding pmpC, pmpD, pmpG/H, and to a 
lesser extent pmpl, increased up to several 
hundred-fold; among these pmpD and pmpG/H 
showed the highest expression. Transcripts from 
all pmp-encoding genes decreased between d 3 and 
d 5 p.i., the terminal point in our analysis. Because 
C. trachomatis has been shown to reside in 
synovial tissue in the persistent state in patients 
with Chlamydia-induced arthritis, we assessed 
pmp transcripts in synovial biopsy samples from 6 
arthritis patients PCR-positive for the organism in 
that tissue. As in the monocyte model, expression 
of pmpD and pmpG/H was high in most patient 
samples, although some variation was found 
among the samples. Interestingly, pmpB was 
highly expressed in one patient sample. 
The MOMP is a major surface constituent 
of C. trachomatis during normal passage through 
the developmental cycle. That expression of this 
gene and others encoding surface proteins is highly 
attenuated in persistent infection explains in large 
part the well-described aberrant morphology of 
persistently-infecting Chlamydia. We reasoned 
that if ompl transcription is altered during 
persistence, then expression of genes encoding 
other surface components also might be altered. 
Data presented here show that this is indeed the 
case, at least for genes encoding pmp's. While the 
functions of the pmp gene products have not yet 
been clearly defined, the observations presented 
indicate that the surface of C. trachomatis, as well 
as various aspects of its biochemistry, is 
significantly different during persistent infection 
compared to that of active infection. We are now 
assessing expression of several other genes on the 
C. trachomatis chromosome to define their 
expression during persistent infection. 
(Supported by grant AR-42541 from the US NIH) 
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GENOMEWIDE IDENTIFICATION OF PROTEINS SECRETED BY A TYPE 
III MECHANISM DURING CHLAMYDIA INFECTION 
Agathe Subtil*, Cédric Delevoye, María Eugenia Balañá, Laurence Tastevin, Stéphanie 
Perrinet, Alice Dautry-Varsat 
Unité de Biologie des Interactions Cellulaires Institut Pasteur, Paris, France 
Chlamydia spp. are strictly intracellular 
pathogens that grow inside a compartment 
called an inclusion. The inclusion membrane 
forms a barrier between developing bacteria 
and the host cell cytosol. Evidence for passage 
of chlamydial proteins through this membrane 
first came from the observation that a family of 
chlamydial proteins, the Inc proteins, are 
associated with this membrane and are 
exposed to the cytosol. 
Using a heterologous secretion assay 
we have shown that Inc proteins are secreted 
by Chlamydia type Id secretion apparatus 
{Mol. Microbiol. 2001 39 792). In other 
pathogens, this type of secretion pathway is 
used to secrete effector molecules into the host 
cell cytosol, where they play a key role in the 
infection. The goal of this study was to 
identifiy effector proteins secreted by 
Chlamydiae during infection. We have 
developped an assay using Shigella type IH 
secretion system to screen for secreted proteins 
among C. pneumoniae and C. trachomatis 
hypothetical proteins. A genomewide approach 
allowed to identify several new candidate 
substrates for type EH secretion in Chlamydia. 
Using specific antibodies we 
demonstrate the secretion of two of them, 
which we design as CopE (Chlamydia outer 
protein) and CopF. CopE and CopF are 
conserved in all Chlamydia species, and do not 
belong to the Inc family. 
CopE is soluble and is localised to the 
host cell cytosol, while CopF associates with 
the inclusion membrane. 
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INDUCTION OF PROLIFERATION BY HUMAN MONOCYTES INFECTED 
WITH CHLAMYDOPHILA PNEUMONIAE - A PARACRINE EFFECT CAUSED 
BY THE SECRETION OF EUKARYOTIC GROWTH FACTORS 
Marion Rother*, Thomas F. Meyer, Agnes J. Szczepek 
Max-Planck Institute for Infection Biology, Department of Molecular Biology, Berlin, Germany 
Apart from acute infections, the human 
respiratory pathogen Chlamydophila pneumoniae 
(C. pneumoniae) was shown to be associated with 
complex, slowly progressing diseases such as 
atherosclerosis and lung cancer, based on 
seroepidemiological studies and detection of the 
organism in the affected tissues (1, 2). Circulating 
monocytes as well as tissue macrophages were 
found to be infected with C. pneumoniae. The 
outstanding question in the field is if and how the 
infected human monocytes contribute to the 
initiation and/or progression of above diseases on 
a cellular and molecular level. Stimulation of 
proliferation and production of specific growth 
factors like PDGF are known to play an important 
role in the etiology and progression of these 
diseases (3). Here, we investigated the influence of 
the chlamydial infection on the proliferation of the 
human monocytic cell line THP-1. Additionally, 
we determined the proliferative response of 
uninfected epithelial and monocytic cells treated 
with the conditioned supernatant from the infected 
THP-1 cells. Next, we attempted to elucidate the 
mechanisms behind the proliferative effect seen. 
Human monocytic THP-1 cells were 
infected with C. pneumoniae using live and 
inactivated organisms at different multiplicities of 
infection. Proliferation capacity of host cells and 
of cells treated with the supernatant of infected 
monocytes was measured using the WST-1 test 
and direct cell counting 24 h post infection. 
Transcript expression levels of eukaryotic growth 
and transcription factors were measured using real 
time RT-PCR. Immunoblot analyses were 
performed to detect the growth factors PDGF-A 
and PDGF-B in cell lysates and culture medium. 
Infection of human monocytes with C. 
pneumoniae led to an increase in the proliferative 
capacity of the infected cells in a dose-dependent 
manner. Monocytic and epithelial cells treated 
with the supernatant of C. pneumoniae infected 
monocytes showed a significant induction of 
proliferation compared to non-treated cells and to 
cells that were treated with the supernatant of C. 
trachomatis infected monocytes. This effect was 
seen with live, UV-inactivated and CAM-treated 
bacteria but not with heat-inactivated organisms, 
suggesting that a heat-labile bacterial component 
but not de novo bacterial protein synthesis is 
needed to induce proliferation. Based on these 
observations, we investigated the production of 
eukaryotic factors that are capable of promoting 
proliferation. Real time RT-PCR analysis of 
eukaryotic mRNA expression showed an increase 
in levels of PDGF-a, PDGF-(3, VEGF and HB-
EGF in the infected monocytes peaking at 24 h 
post infection. Furthermore, using immunoblotting 
we found a pronounced increase in PDGF-A and -
B protein levels. In addition, we determined that 
Egr-1, the transcription factor responsible for 
transcriptional activation of PDGF-A chain, is 
upregulated on mRNA level. 
Infection of monocytes with C. 
pneumoniae stimulates proliferation of monocytes 
and epithelial cells in a dose-dependent and 
paracrine manner. This effect is specific to C. 
pneumoniae, since it is not seen in C. trachomatis 
infected monocytes. Growth factors like PDGF-A 
and -B that are responsible for the induction of 
proliferation are upregulated on mRNA and 
protein level. 
Taken together, the observations from our in vitro 
studies support the hypothesis that C. pneumoniae-
infected monocytes could play an important role in 
the initiation and/or progression of associated 
diseases like atherosclerosis and lung cancer. 
Growth factors that we found to be induced during 
chlamydial infection of the monocytic host cells 
act in a paracrine fashion and could promote 
plaque thickening and tumor or tumor stroma 
growth. 
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CHARACTERIZATION OF THE IMMUNE STIMULATORY PRINCIPLE OF 
CHLAMYDOPHILA PNEUMONIAE 
Katja Gueinzius*, Siegfried Morath, 'Jens Kuipers, 2Matthias Maass, Corinna Hermann 
Biochemical Pharmacology, University of Konstanz, 1 Rheumatology, Medical University of 
Hannover, Hannover, Medical Microbiology, Medical University of Lübeck, Germany 
Persistent infections with 
Chlamydophila pneumoniae have been 
associated with inflammatory diseases. Only 
little is known about recognition of C. 
pneumoniae by the immune system and the 
role of its lipopolysaccharide (LPS). The aim 
of our study was to isolate and chemically 
characterize the immunostimulatory principle 
of C. pneumoniae. 
Human whole blood incubations were 
perfromed to investigate the activation of 
blood leucocytes by enterococcal LPS versus 
whole Escherichia coli, C. pneumoniae and C. 
trachomatis (all 5xl06/ml). The release of 
cytokines was determined by ELISA. To 
characterize the nature of the 
immunstimulatory principle, a neutralizing 
anti-CD 14-antibody, soluble CD 14, polymyxin 
B and the specific LPS-neutralizing LALF-
protein, which is isolated from horseshoe 
crabs, were emplyoed (all 10 pg/ml). 
Furthermore, the role of Toll-like receptors 
was investigated using bone marrow 
macrophages from TLR2 wild-type, TLR2 
knock out, C3H/HeN and CeH/HeJ mice. For 
the isolation of the immunestimulatory 
principle, 108 C. pneumoniae were sonified 
and butanol extraction was performed. C. 
pneumoniae extracts were subjected to 
hydrophobic interaction chromatography and 
the eluted fractions were tested as to their 
cytokine-inducing properties. The investigation 
of the chemical structure is ongoing using 
NMR and MS. 
We found that C. pneumoniae are 
capable of inducing the whole spectrum of 
inflammatory mediators in human whole blood 
(TNF, IL-16, EL-6, IL-8, IL-10) but are weak 
inducers of cytokine release compared to E. 
coli (e.g. C. pneumoniae induce 10-fold less 
TNF and IL-10). Cytokine release was not 
attenuated by UV-inactivation of C. 
pneumoniae, indicating that active infection is 
not important for activation of leucocytes. 
Furthermore, C. pneumoniae-induced cytokine 
release was significantly inhibited by the anti-
CD 14-antibody, soluble CD 14, polymyxin B 
and LALF protein. Similar results were found 
for C. trachomatis-induced cytokines. This 
argues in favor of LPS as the immune 
stimulatory principle of Chlamydia. However, 
comparison of the cytokine profiles induced by 
C. pneumoniae or C. trachomatis, revealed 
pronounced differences. While C. trachomatis 
induced much more pro-inflammatory 
cytokines, C. pneumoniae led to strong IL-10 
release, although both germs are supposed to 
possess the same family-specific LPS. 
Experiments with TLR2-deficient and TLR4-
mutated mice showed that C. pneumoniae-
induced cytokine release mainly depended on 
TLR2 but TLR4 was also involved. To clarify 
the nature of the immune stimulatory principle, 
the butanol extracts of C. pneumoniae were 
fractionated and their cytokine-inducing 
capacity was characterized. Indeed, a pool of 
fractions was obtained which showed similar 
biological activity as C. pneumoniae, e.g. a 
comparable cytokine-profile, the same CD 14-, 
LALF- and TLR2/4-dependence. The chemical 
analysis so far suggest a lipopetide, which is 
currently further defined. 
Immune stimulation by C. pneumoniae 
is different to the one by C. trachomatis. 
Lipopeptides appear to play a major role. 
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CELLULAR IMMUNITY TO CHLAMYDIAL INFECTIONS 
Svend Birkelund, Brian Vandahl, and Gunna Christiansen 
Institute of Medical Microbiology and Immunology, University of Aarhus, Aarhus, Denmark 
The objective of this paper is to review current 
knowledge on cellular immunity to chlamydial 
infections. 
The biphasic developmental cycle and 
intracellular localization provide the 
Chlamydiae with a possibility of hiding for the 
immune system and an ability to produce 
persistent infections. 
The proteins present in elementary bodies (EB) 
are only a subset of the proteins expressed in 
the intracellular replicating phase. In reticulate 
bodies (RB) proteins are synthesized that are 
degraded before the reorganization to EB 
(Shaw et al. 2002). Under the infection 
Chlamydia secrets proteins to the inclusion 
membrane and to the cytoplasm of the host 
cell, but no Chlamydia proteins have been 
identified in the cell nucleus, in the inclusion 
cytosol or secreted from the host cell into the 
chlamydial inclusion. 
The specific cellular immuneresponse is 
mainly composed of T-helper cells (CD4+) 
and cytotoxic T-cells (CD8+). Antigen 
presenting cells (macrophages or dendrite 
cells) can take up extracellular EB or 
chlamydial debris from ruptured infected host 
cells. Peptide fragments are presented on 
antigen presenting cells in the major 
histocompability complex (MHC) class II 
molecule on the surface of the cell, and antigen 
specific T-helper cells are stimulated and 
proliferate. Secreted Chlamydia proteins and 
RB specific proteins are not well presented for 
T-helper cells. A good antibody response will 
not easily be elicited to such antigens either, 
due to the missing T-helper cell epitopes. An 
exception is IncA from C. caviae (Rockey and 
Rosquist 1994). 
In an infected host cell proteins present in the 
cytoplasm can be degraded by the proteasome 
and the peptide fragments transported to the 
endoplasmic reticulum (ER) by the TAP 
complex (Transporter associated with antigen 
processing). Here the peptides are assembled 
with the MHC class I molecule and presented 
on the cell surface together with [32-
microglobulin. This complex is recognized by 
the cytotoxic T-cell and infected cells can be 
lyzed. This is the well-known type of antigen 
presentation to CD8+ cells which is restricted 
by the polymorphism in HLA-class I molecule 
(HLA-class la). Peptides can also be presented 
to CD8+ T-cells by non-HLA-class la 
molecules as HLA E, F and G or CD la, b, and 
c, and these molecules are not polymorphic. 
This family of molecules is named HLA class 
lb (Gervassi et al. 2003). 
This review will manly describe the immunity 
to C. trachomatis and make parallels to C. 
pneumoniae when there is knowledge about it. 
CD4+ and CD8+ T-cell in elimination of the 
Chlamydia infection 
Genital C. muridarum (C. trachomatis MoPn) 
infection can be cured by adoptive transfer of 
C. muridarum specific T-cell clones to 
infected mice. The T-helper cell clones have a 
Thl interleukin profile (IL-10, tumor necrosis 
factor-alpha, and y-interferon) (Igietseme et al. 
1993). In a similar experiment C. muridarum 
specific Th2 clone could not protect against 
genital infection (Hawkins et al. 2002). 
Dendritic cells pulsed with C. muridarum 
recombinant major outer membrane protein 
(MOMP) could stimulate infection-sensitized 
CD4+ cells to y-interferon production (Thl). 
However, when the in vitro MOMP-pulsed 
dendritic cell were given to a naive mice the 
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MOMP response was of the Th2 type (Shaw 
et. al. 2002), indicating that it is the 
intracellular infection in combination with the 
immune status of the host that determine the 
Thl/Th2 direction of the immune response. 
SCID mice infected intraperitoneally with C. 
muridarum develop polyserositis, and the 
infection can be cured by adoptive transfer of 
immune cells form immunocompetent mice. 
But transfer of CD8+ or CD4+ alone could not 
cure the infection (Thoma-Uszynski et al. 
1998). Therefore, when adoptive transfer of T-
helper Thl cells can protect against the 
infection in the immunocompetent host it is 
likely due to stimulation of functional CD8+ 
T-cells. 
Proteins with CD8+ T-cell epitopes 
To identify proteins containing CD8+ epitopes 
different methods can be used. Cells infected 
with Chlamydia can be mixed with autologous 
CD8+ T-cells from infected individuals 
whereby CD8+ T-cell clones can be obtained, 
but the epitope-containing protein is not easily 
identified. Another possibility is to make an 
expression library of Chlamydia proteins in 
autologous cells and use this library for 
stimulation of CD8+ T-cells. Finally, to 
identify the 8-9 amino acid residues of a CD8+ 
T-cell epitopes it is necessary to predict likely 
epitopes in the protein that fits the HLA class I 
molecule, synthesize the peptides and use them 
in ELISspot, cytotoxity - or proliferation 
assays. 
Proteins containing CD8+ eptiopes have been 
identified in the structural protein MOMP and 
in secreted proteins. 
MOMP is the single most expressed protein in 
all Chlamydia investigated. MOMP has four 
variable domains (VD1-4) that are surface 
exposed and 5 constant segments (CS1-5). 
MOMP has been extensively investigated for 
CD8+ T cell epitopes by Kim and co-workers 
(For review see Kim and DeMars 2001). The 
CD8+ T cell epitopes were primarily found in 
CS4 and one in VS2. Thereby most of the 
epitopes had the possibility of giving cross 
serotype protection. To determine the 
frequencies of MOMP specific CD8+ T-cells 
in peripheral blood from patients HLA A2 
tetramers were made with A2 epitopes of 
MOMP. CD8+ MOMP specific cells could be 
detected with a frequency of 0.01-0.20% in 
peripheral blood samples from infected 
patients, whereas none could be detected in 
uninfected controls (Kim et al. 2000). 
By screening of a C. trachomatis DNA library 
expressed eukaryotically for stimulation of 
CD8+ T-cells from mice two proteins were 
found Capl and CrpA (Stambach et al. 2003, 
Fling et al 2001). By making antibodies to 
Capl it was shown by immunofluorescence 
microscopy that Capl was localizied in the 
chlamydial inclusion membrane, and since 
CrpA has a stretch of hydrophobic amino acids 
forming a possible beta-sheet as found in the 
inclusion membrane proteins (Inc), CrpA 
might also be localized in the inclusion 
membrane as Capl. 
Inc proteins are exposed to the host cell 
cytoplasma and might therefore be degraded by 
proteases transported to the ER for assembly 
into the HLA class I complex. Chlamydia also 
secretes proteins to host cell cytoplasm. The 
secreted protein CPAF that is present in all 
Chlamydia species, reduces expression of 
HLA class I molecules of the host cell by 
degrading the host transcription factors that 
regulates HLA expression (Zhong et al. 2001). 
No CD8+ T-cell epitope has yet been 
identified on CPAF even though CPAF is 
abundant in the host cell cytoplasm. This can 
be due to the stability of CPAF itself having a 
half-life of more then 48 hrs. (Shaw et al. 
2002). 
Peptides from intracellular infection can also 
be presented at the cell surface by other 
molecules than the HLA class la. Gervassi et 
al. (2003) has investigated this by setting up 
the following experiment: First CD8+ T cell 
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clones were generated by cultivation with C. 
trachomatis infected autologous dendritic 
cells. After that the clones were mixed with 
either autologous or allogeneic C. trachomatis 
infected dendritic cells. If the clone responded 
to both autologous and allogeneic cells it was 
considered as non-class la-restricted. It was 
shown that non-class la-restricted cells were 
present and they were even lytic for the target 
cells. Therefore these epitopes, when 
identified, are good vaccine candidates because 
they can function independent of HLA class-I 
restriction. 
T-helper cell epitopes 
Antigen presenting cells (APC) takes up 
extracellular complexes as protein aggregates 
in phagosoms which fuses with lyzosomes and 
the up-taken proteins are fragmented by 
proteases and eventually presented in the MHC 
class II molecule at the cell surface for T-
helper cells. In blood samples APC are present 
so that exogenous antigens can be presented 
for T-helper cells. Therefore full-length 
protein, recombinant fragments and synthetic 
peptides of proteins can be used for narrowing 
down T-helper cell epitopes. 
This has been done for human T-helper cell 
epitopes on C. trachomatis serovar E MOMP. 
All epitopes were localized to constant 
regions, except for one that was localized to 
VS2 (Ortiz et al. 1996). The epitope localized 
to VS2 was only recognized by persons that 
had had an infection with C. trachomatis 
serotype E, and corresponding peptides to VS2 
form serovar F, I and J were not responding 
showing that the epitope was serovar specific 
(Ortiz et al. 2000). 
Omp2 which is also an outer membrane 
protein was found to have a proliferative 
response on CD4+ cells from patients with C. 
trachomatis induced reactive arthritis. A 
peptide of 15 amino acids (aa400-414) was 
identified byjuse of deletion mutants of Omp2 
and overlapping peptides. This peptide was 
conserved in all C. trachomatis sequences but 
not in C. pneumoniae Omp2, so the peptide 
was specific for C. trachomatis infections 
(Goodall et al. 2001a). 
By screening a C. trachomatis library with 
three human C. trachomatis reactive T cell 
clones of unknown specificity PmpD was 
identified as the target for one of the clones, 
enolase and CT580 for the two others (Goodall 
et al. 2001b). In the outer membrane beside 
MOMP, Omp2 and Omp3 a family of 
polymorphic membrane proteins (Pmp) is 
present. In C. trachomatis the genome encodes 
9 proteins and in C. pneumoniae the family is 
expanded to 21 genes. These proteins have the 
C-terminal ß-barrel embedded in the outer 
membrane and the N-terminal part, probably in 
the form of a parallel ß-tube protruding on the 
surface of the Chlamydia. 
CD4+ and CD8+ T-cell epitopes to C. 
pneumoniae. 
The cellular immunity to C. pneumoniae is not 
so extensively investigated as to C. 
trachomatis. 
Halme et al. (1997) analyzed T-cell clones 
obtained by stimulation with C. pneumoniae, 
by separating C. pneumoniae antigens with 
SDS-PAGE and transferring the antigens to 
nitrocellulose and used the size fractions 
antigens for stimulation of the clones. 
Antigens with sizes of 92-98, 51-55, 43-46 and 
31.5-33 kDa were found to be C. pneumoniae 
specific (Halme et al. 1997). Several of the 
Pmps in C. pneumoniae has a size of 
approximately 98 kDa. Therefore all of the 21 
Pmp genes from C. pneumoniae were cloned, 
expressed in E. coli and purified. Spleen cells 
from mice intranasally infected with C. 
pneumoniae were investigated with ELISpot 
assay for reaction to the Pmps. A significant 
response was found to Pmp8, Pmp20 and 
Pmp21, but no response was found to MOMP, 
which in C. pneumoniae is invariant (Mygind 
et al. 2004). There thus seems to be a 
difference in the response to homologous 
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proteins. The direction of the immune response 
was also investigated; it was evident that the 
mice reacted with a Thl response. 
Conclusion 
New knowledge concerning the specific 
cellular immune response to chlamydial 
infections has the potential of defining 
protective subcomponents, which may be used 
for vaccines. 
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GENOMICS SEARCH FOR HOST CELL GENES THAT CAN INHIBIT 
CHLAMYDIA GROWTH IN PRIMARY EPITHELIAL CELLS 
David E. Nelson1, Dezso Peter Virok1, Heidi Wood2, Grant McClarty2, Harlan D. 
Caldwell1 
laboratory of Intracellular Parasites, National Institutes of Health, National Institute of Allergy 
and Infectious Disease, Rocky Mountain Laboratories, Hamilton, department of Medical 
Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada 
IFN-gamma plays critical roles in 
orchestrating the innate and acquired immune 
responses to bacterial pathogens. Studies of 
animal models of chlamydial infection have 
demonstrated that resistance of mice to genital 
tract infection with human adapted strains of 
C. trachomatis is IFN-gamma dependent. 
Recently, we determined that primary mouse 
urogenital epithelial cells (MEC) resist 
infection with human serovars in an IFN-
gamma dependent fashion, and with a pattern 
similar to that seen in mouse models of 
experimental chlamydial infection. Therefore, 
the goal of this work was to use comparative 
transcriptome analysis of MEC cells to identify 
the IFN-gamma mediated factor(s) responsible 
for control of chlamydial growth in vivo. 
DNA microrarray analysis was used to 
identify IFN-gamma regulated genes that 
might function in controlling infection of 
human strains by MEC. We analyzed and 
correlated transcriptional changes of MEC 
under several experimental conditions; (i) 
infection alone, (ii) IFN-gamma treatment 
alone, and (iii) infection plus IFN-gamma 
treatment. Amplified cRNA from the different 
groups was hybridized to Affymetrix 430A 
mouse chips. The array contains -20.000 
probes covering the majority of known mouse 
genes. Array results for specific genes and 
timepoints were validated and expanded upon 
using Taqman RT-PCR. 
IFN-gamma treatment, chlamydial 
infection, and the combination of each had a 
significant impact on the transcriptome of 
MEC altering the expression -800-1200 genes. 
Although similarities between the 
transcriptional responses of MEC and the 
previously reported response of human 
epithelial cells to chlamydial infection and 
interferon were identified, a number of 
important distinctions between the mouse and 
human responses were evident. Unlike human 
epithelial cells, MEC failed to significantly 
alter tryptophan metabolism in response to 
IFN-gamma or infection, suggesting that this 
critical mechanism of chlamydial control in 
human epithelium may not be as relevant to 
murine infection. Further, MEC responded to 
IFN-gamma and chlamydial infection by 
highly up-regulating expression of a murine 
specifc family of innate immune effectors (p47 
GTPases); members of which have been 
implicated as predominate players in the IFN-
gamma mediated control of multiple 
intracellular bacterial pathogens. 
Comparative transcriptome analysis in 
MEC suggests that early innate immune 
control of chlamydial infection in mouse and 
human epithelial cells by IFN-gamma may be 
mediated by distinct mechanisms. The 
transcriptome results suggest that IFN-gamma 
mediated control of human adapted chlamydial 
strains in mouse epithelium is potentially 
regulated by a mouse specific family of innate 
immune effectors, and likely does not depend 
upon heightened tryptophan metabolism, as 
occurs in human epithelium. The findings have 
important implications for rational design of 
murine models of human chlamydial infection. 
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CHLAMYDIA PNEUMONIAE INDUCES EXPRESSION OF SUPPRESSOR OF 
CYTOKINE SIGNALING-3 (SOCS-3) IN HUMAN LUNG EPITHELIAL CELLS 
Vjera Magdalenic1'2, Sean Wattegedera2, Gwen Wathne1'2, Sarah E.M. Howie1 and Gary 
Entrican2* 
1 Department of Pathology, University of Edinburgh Medical School, Edinburgh, & 2 Moredun 
Research Institute, Pentlands Science Park, Bush Loan, Edinburgh, UK 
Interferon-gamma (IFN-y) is an 
important effector cytokine for host control of 
Chlamydia pneumoniae infection. However, 
human lung-derived epithelial cell lines differ 
in their ability to control C. pneumoniae in 
response to IFN-y treatment. HEp-2 cells 
restrict C. pneumoniae growth whereas A459 
cells do not. The objective of this work was to 
identify the factors that influence IFN-y 
responsiveness in epithelial cells with a view 
to understanding host immunity and disease 
control. 
Hep-2 and A459 cells were treated with 
recombinant human IFN-y then infected with 
C. pneumoniae (AR39). Cells were collected at 
various time points after infection and either 
lysed for analysis of mRNA expression or 
fixed for immunocytochemical studies. 
Expression of cell-surface molecules was 
performed by flow cytometry. 
Both HEp-2 and A549 cells were found 
to express CD119, the a chain of the IFN-y 
receptor. This suggested that intracellular 
events downstream of receptor ligation were 
responsible for the differences in 
responsiveness to IFN-y and prompted 
investigation of molecules associated with 
regulation of IFN-y signaling. Both suppressor 
of cytokine signaling-1 (SOCS-1) and SOCS-3 
are known to modulate IFN-y signaling. 
Immunocytochemical analysis of unstimulated 
Hep-2 and A549 cells failed to detect SOCS-1 
expression, but SOCS-3 was found in both cell 
lines. However, A549 cells expressed higher 
levels of SOCS-3, which may account for the 
difference observed between the cells. To 
ascertain if IFN-y treatment could alter the 
expression of SOCS-3, levels of mRNA 
encoding SOCS-3 were measured by real-time 
RT-PCR. There was a marked, significant 
increase in expression of mRNA encoding 
SOCS-3 in Hep-2 following IFN-y treatment, 
but not in A549 cells. This may be a normal 
counter-inflammatory mechanism of epithelial 
cells to regulate IFN-y-mediated cell 
activation. Interestingly, C. pneumoniae 
infection resulted in upregulation of mRNA 
encoding SOCS-3 in both cell lines 
irrespective of IFN-y treatment. This increase 
was confirmed by confocal microscopy, which 
revealed that SOCS-3 protein was concentrated 
in the vicinity of the chlamydial inclusion. As 
a first step to elucidating the chlamydial 
components responsible for this, uninfected 
cells were treated with lipopolysaccharide 
(LPS) derived from Salmonella minnesota 
(rough chemotype similar to chlamydial LPS) 
and LPS from Escherichia coli. S. minnesota 
LPS did not affect SOCS-3 expression whereas 
E. coli LPS induced SOCS-3 expression, 
suggesting that chlamydial LPS on its own is 
solely responsible for the upregulation in 
SOCS-3 expression following C. pneumoniae 
infection. 
Chlamydiae form complex 
relationships with their hosts that include the 
establishment of persistent infections and 
chronic disease. The data presented here 
demonstrate that C. pneumoniae can induce 
the expression, of molecules that interfere with 
responsiveness of host cells to IFN-y. This 
adds another dimension to the relationship of 
C. pneumoniae with human lung epithelial 
cells. 
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DENDRITIC CELLS AND MACROPHAGES PULSED WITH CHLAMYDIA 
PNEUMONIAE ELICIT DISTINCT IMMUNE RESPONSES IN VITRO 
Anne Tammiruusu* and Jenni M. Vuola 
National Public Health Institute, Departments of Vaccines, Helsinki, Finland 
Experimental studies have indicated an 
important cooperative role for both CD4+ and 
CD8+ T cells in adaptive immunity against 
Chlamydia pneumoniae. Clearance seems to be 
dependent on Thl-biased response 
characterized with the secretion of high levels 
of gamma interferon (IFN-y). An important 
factor contributing to T cell polarization is the 
type of antigen-presenting cell (APC). 
Macrophages (Mtj)) are mononuclear 
leukocytes distributed throughout the body and 
are an important part of the first level defence 
mechanisms during infection. Macrophages 
serve as professional APCs by processing and 
presenting antigens and secreting chemokines 
and cytokines that result in boosting or limiting 
other immune functions. All chlamydial 
species are capable of infecting and surviving 
inside mononuclear cells. Ability of 
chlamydiae to infect and survive in 
macrophages may provide a mechanism by 
which chlamydiae establish a chronic infection 
and disseminate to various tissues. Dendritic 
cells (DCs) represent specialized migratory 
derivatives of mononuclear APCs that 
efficiently uptake and process antigen for 
presentation. Dendritic cells unlike the other 
APCs are able to prime naive T cells, initiating 
the T cell response. A central importance of 
DCs is their role in linking innate immunity 
and antigen-specific adaptive immunity. 
To understand better the interaction 
between APCs and C. pneumoniae, we isolated 
and pulsed mouse DCs and macrophages with 
live or UV-inactivated C. pneumoniae and 
assessed their phenotypic changes and cytokine 
production patterns in vitro. In addition, we 
examined the capacities of DCs and M<() to 
prime syngeneic naive CD4+ T cells. DCs 
(CDllc+) and CD4+ T cells were isolated 
from spleen using cell sorting magnetic beads. 
Mouse peritoneal macrophages were isolated 
on the basis of adherence to plastic. The cell 
surface markers were detected by flow 
cytometry. Compared with naive DCs, many 
phenotypic changes of DCs pulsed with UV-
inactivated or live C. pneumoniae were 
observed. These changes included upregulation 
of MHC class H, CD8, CD80 and CD86 
expression. Similar results were obtained from 
DCs isolated from murine lungs after 
intranasal challenge in vivo. Preliminary 
studies showed that DCs pulsed with live or 
dead bacteria were able to prime naive CD4+ 
T cells very efficiently. Pulsed macrophages 
instead, were not able to prime naive CD4+ 
cells. However, primed CD4+ T cells isolated 
from mice after C. pneumoniae challenge were 
activated by macrophages pulsed with dead C. 
pneumoniae but not macrophages pulsed with 
live bacteria. Cytokine profiles of pulsed DC 
and M<|> will be analysed next. 
Our results indicate that live as well as 
UV-inactivated C. pneumoniae can stimulate 
the maturation process of DCs. Furthermore, 
the mature DCs serve as efficient APCs to both 
naive and primed CD4+ cells. Macrophages on 
the other hand were severely defective in their 
ability to serve as APCs. 
144 - IMMUNOLOGY 
CLASS IB RESTRICTED CD8+ T CELL RESPONSES IN MICE INFECTED 
WITH CHLAMYDIA PNEUMONIAE 
Amy R. Tvinnereim* and Benjamin Wizel 
University of Texas Health Center at Tyler, Tyler, Texas, USA 
Previous studies have demonstrated 
that class lb restricted CD8+ T cells are 
important for control of infection with several 
intracellular pathogens prior to expansion of 
class la restricted CD8+ T cells. Therefore, we 
wished to determine if class lb restricted CD8+ 
T cells were generated in response to 
Chlamydia pneumoniae (Cpn) infection. 
The well characterized class lb 
molecule H2-M3 has been demonstrated to 
preferentially bind 5-6 amino acid peptides 
containing a formylated methionine at residue 
1. Therefore, the Cpn genome was studied to 
find the 6 amino acids residues that initiated 
each protein. Of the initial 48 sequences which 
fit the predicted binding motif of fM (Y, F, W, 
I, L)(Y, F, I, L, V)ZXX (Z, amino acids with a 
non-polar side chain; X any amino acid), 18 
were selected for peptide synthesis. The 18 
peptides were used to stabilize H2-M3 on the 
surface of P388-M3 transfected cell lines as 
detected by an H2-M3-specific monoclonal 
antibody. These peptides were also tested for 
the ability to stimulate IFN-y production from 
splenocytes and lung mononuclear cells from 
Cpn-infected mice. In addition, short term T 
cell cultures were tested for the ability to lyse 
target cells coated with H2-M3 peptides. 
Of the 18 H2-M3 peptides studied, 5 
did not increase cell surface expression of H2-
M3. Of the remaining 13 peptides, 7 increased 
mean fluorescent intensity of an H2-M3 
expressing cell line by at least 2 fold. All 18 
peptides were then tested for the ability to 
stimulate IFN-y production in lung 
mononuclear cells and splenocytes from 
infected mice. At least 4 of the H2-M3-binding 
peptides were able to stimulate IFN-y 
production from lung mononuclear cells and at 
least 2 peptides did so from splenocytes. To 
determine if the H2-M3 restricted cells that 
produce IFN-y following Cpn infection were 
lytic, short term CTL lines were generated and 
tested in a 51Cr-release assay. CD8+ T cell 
cultures for one peptide (peptide 4) were able 
to lyse peptide coated P388-M3 and TR8.4A 
targets but were unable to lyse the same targets 
in the absence of peptide. It is unlikely that this 
lysis is due to class la restricted responses 
since the CD8+ T cells were generated from 
C57B1/6 mice that are H-2b and the P388-M3 
and TR8.4A cells are derived from H-2d and 
H-2wl? parental cell lines, respectively. Not all 
peptides which stimulated IFN-y production 
were able to lyse peptide coated target cells as 
short term cultures for 2 peptides (peptide 1 
and peptide 5) did not lyse targets coated with 
the corresponding peptides. 
H2-M3 responsive cells are present in 
the spleen and lungs of Cpn-infected mice. 
These cells produce IFN-y in response to 
stimulation with individual H2-M3 peptide 
coated cells. Furthermore, lytic cells recognize 
some of these H2-M3 peptides since short term 
cultures developed from H2-M3 stimulated 
1 splenocytes are able to lyse H2-M3 coated 
target cells. These results demonstrate that the 
H2-M3-restricted CD8+ T cell response is 
generated during Cpn infection and may be 
important to control bacteria numbers early in 
primary infection as demonstrated for Listeria 
monocytogenes. Since class lb molecules are 
non-polymorphic, including H2-M3 epitopes 
in a vaccine would result in a construct with 
subunits that are universally recognized. 
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RECOGNITION OF CHLAMYDIA TRACHOMATIS BY CD8+ CYTOTOXIC T 
CELLS 
Malgosia K. Matyszak and J. S. Hill Gaston 
University of Cambridge Clinical School, Dept of Medicine, Addenbrooke's Hospital, Cambridge 
T cell mediated immune responses and 
IFN-y production are essential for the clearance 
of Chlamydia trachomatis (CT) infection. 
However, although the importance of CT 
specific CD4+ T cells has been clearly 
demonstrated, the importance of chlamydia 
specific CD8+ T cells in anti-CT responses is 
still poorly understood. Here we have 
investigated CD8+ T cell responses to CT in 
patients with previous episodes of chlamydia 
infection. 
We used dendritic cells (DC) infected 
with live CT to generate CT specific CD8+ T 
cell lines and clones. DC were generated in 
vitro from CD 14+ monocytes obtained from 
patients' PBMC. After seven days of culture in 
the presence of GM-CSF and IL-4, DC were 
fully differentiated. DC were infected with live 
CT and co-cultured with autologous highly 
purified CD8+ T cells to generate CT specific 
CD8+ T cell lines. These lines were then used 
to generate CT specific CD8+ T cell clones. 
The clones were tested for their ability to 
produce IFN-y in response to CT by ELISA. 
They were also tested for their ability to lyse 
infected target cells in a cytotoxicity assay. 
Anti-HLA class I antibodies were used to 
block both IFN-g production and lysis. IL-12 
production was detected by ELISA. The 
surface phenotype of the CD8+ T cell clones 
was analysed by FACS using a wide range of 
monoclonal antibodies. Intracellular CT 
staining was also analysed by FACS. 
Using CT specific CD8+ T cell lines 
we showed that they can produce a high level 
of IFN-y when co-cultured with CT infected 
autologous DC or PBMC. However, 
experiments in which blocking antibodies to 
HLA class I were used revealed that IFN-y 
production can only be partially inhibited, 
suggesting the existence of HLA class I 
unrestricted responses. The two patterns of 
recognition of CT-infected cells were further 
confirmed at the clonal level: 1. CD8+ clones 
recognised CT antigens in association with 
classical class I HLA antigens and responses 
were inhibited by class I HLA-specific 
monoclonal antibodies; 2. the recognition of 
CT by CD8+ clones was unrestricted by 
classical HLA class I. Further characterisation 
of a number of HLA class I unrestricted clones 
showed that these clones were also not 
restricted by CD1 molecules. CD8+ clones 
produced high levels of IFN-y in response to 
CT and were able to lyse CT-infected target 
cells. All of these clones were CD8+/RCRa(3+ 
and contained perforin granules. The clones 
were negative for NKT receptor (CD161) but 
positive for some NK receptors, CD56, 
NKG2D. Interestingly, recognition of CT 
infected target cells by these clones was rapid 
(the lysis was detected within 6 hour post 
infection) when compared with CT specific 
HLA class I restricted clones. The latter 
required at least 20 hours of CT processing by 
DC. In addition, co-culture of CT-infected DC 
with the CT-specific clones induced DC 
activation and a rapid enhancement of IL-12 
production. 
CT specific CD8+ T cells can facilitate 
clearance of bacteria through production of 
IFN-y and by direct lysis of infected cells. In 
addition, early production of IL-12 during CT 
infection, facilitated by unrestricted CD8+ T 
cell clones, may be important in ensuring a 
subsequent Thl T cell mediated response by 
classical MHC restricted CD4+ and CD8+ T 
cells. 
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CYTOKINE RESPONSE IN CULTURED GENITAL EPITHELIAL CELLS 
WITH CO-INFECTIONS BY CHLAMYDIA TRACHOMATIS AND HSV-2 
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Clinical reports have indicated that co-
infections between sexually transmitted agents 
such as Chlamydia trachomatis and herpes 
simplex virus-2 (HSV-2) increased the 
pathogenesis and resulting sequelae produced 
by these microorganisms. The laboratory 
confirmation of these events has been elusive. 
The following studies were designed to 
evaluate the cytokine responses of 
reproductive tract cells to co-infection by these 
agents. 
Immortalized primary vaginal, 
endocervical, and ectocervical cells, primary 
human fallopian tube epithelial cells (HFTEC), 
as well as cervical carcinoma CaSki cells were 
subjected to infection by C. trachomatis 
serovar E and/or HSV-2. Following 24 and 48 
hours of infection, supernatants were collected 
and IL-la, IL-lp, IL-6, IL-10, and TNF-a 
cytokine levels were quantitated by ELISA. 
Vaginal, endocervical, and ectocervical 
cells all showed pronounced cytokine response 
to chlamydial challenge. IL-10 was down-
regulated while the other cytokines were up-
regulated 24 hours post-chlamydial infection. 
IL-6 was significantly up-regulated in all three 
cell lines. CaSki and HFTEC cells also showed 
marked cytokine responses to HSV-2, C. 
trachomatis and co-infections 24 hours post 
infection. Preliminary results indicate IL-6 and 
IL-ip up-regulation in CaSki cells by 
chlamydia, HSV-2 and co-infected cells, but 
IL-la up-regulation only by chlamydia and co-
infected cells. Primary HFTEC cells indicated 
IL-6, IL-ip, and TNF-a cytokine up-regulation 
in HSV-2 and chlamydia, chlamydia, HSV-2 
and co-infected cells, and HSV-2 and co-
infected cells, respectively. 
Infection of reproductive tract cells by 
chlamydia and/or HSV-2 up-regulate the 
production of several cytokines important in 
inflammatory responses. Infection with these 
agents down-regulated the production of IL-10 
and up-regulated the other four cytokines 
tested, notably IL-6. These data have 
implications in increased infectivity by other 
STD agents such as HIV. 
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CYTOKINE PROFILE AND TH-RESPONSE TO CHLAMYDIA PNEUMONIAE 
INFECTION IN PERIPHERAL BLOOD MONOCYTIC CELLS IN PATIENTS 
WITH ASTHMA 
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Margaret R Hammerschlag1 
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Infection with C. pneumoniae (Cpn) has 
been associated with respiratory tract illnesses and 
may also be associated with exacerbations of 
asthma. Cpn has been found to induce a potent 
pro-inflammatory response in different cell lines, 
including respiratory epithelial cells and 
monocytes. Previous studies suggest that clearance 
of infection appears to require a Thl response, 
while a predominant Th2 response may lead to 
persistent infection in Chlamydia. There is limited 
data on differences in cytokine production in 
response to infection of human peripheral blood 
monocytic cells (PBMC) between asthmatics and 
nonasthmatics. The objective of this study is to 
compare the cytokine profiles of PBMC obtained 
from asthmatic and nonasthmatic subjects 
challenged with Cpn in vitro. 
We recruited 5 patients with asthma, who 
had no acute symptoms, and 13 nonasthmatic 
controls. PBMC were isolated by centrifugation of 
whole blood in heparinized VACUTAINER CPT 
tubes (BectonDickinson), washed and plated in 
fibronectin-coated (2 pg/cm2) 96 well plates at a 
cell concentration of 5 x 105/well in RPMI media 
(10% FCS, lOmM L-glutamine). PBMC from the 
same patient were infected with Cpn at an MOI of 
1:1 or mock-infected with equal volumes of 
medium. Following centrifugation for 1 h at 3500g 
at 35°C, medium was replaced with fresh medium. 
The supernatants were sampled at different time 
points and stored at -70°C. The cells were stained 
with monoclonal genus specific antibodies 
(BioRad) after 3 days of incubation to document 
infection. Cytokines were assayed by sandwich 
ELISA (Biosource International) according to the 
manufacturer's instructions. Paired samples 
statistical analysis was performed with SPSS 
software. 
Asthmatic patients. Cytokine levels in 
supernatants of Cpn-infected PBMC were 
decreased compared to mock-infected PBMC from 
the same patients for the following cytokines: IL-
1(3 at 3h (mean 4.7 vs. 5.3 pg/ml, p<0.05), IL-12 at 
24h (mean 8 vs. 10.9 pg/ml, p<0.05), IL-10 at 3h 
(mean 0.3 vs. 3.7 pg/ml, p<0.05). Cytokine levels 
in the supernatants of Cpn-infected PBMC were 
increased compared to mock-infected PBMC from 
the same patients for the following cytokines: IL-2 
at 24h (mean 158 vs. 80 pg/ml, p<0.05) and IL-lp 
at 24h (mean 25 vs. 22 pg/ml, p<0.05). 
Control patients (nonasthmatic). Cytokine 
levels were increased in supernatants of Cpn-
infected PBMC compared to mock-infected PBMC 
from the same patients for the following cytokines: 
IL-6 at 24h (mean 26 vs. 5.5 ng/ml, p<0.05), IL-lp 
at 24h (mean 2157 vs. 99 pg/ml, p<0.05), TNF-oc 
at 24h (mean 69 vs. 0 pg/ml, p<0.05) and IL-2 at 
24h (mean 818 vs. 358, p<0.05). There was a trend 
towards an increase in IL-10 levels in supernatants 
of Cpn-infected PBMC (mean 1316 vs. 27, 
p=0.058). 
No significant changes in levels of cytokines 
following infection/mock-infection in either 
subjects or controls were found for IL-4, IFN-y and 
IL-8. 
We found a marked variation in the 
differential cytokine response to infection of 
PBMC with Cpn between asthmatics and controls. 
Surprisingly, we found decreased levels of pro-
inflammatory cytokines IL-6, IL-ip, IL-12 and 
TNF-a in asthmatics compared to controls. This 
may seem counterintuitive because Cpn is thought 
to be an inflammatory trigger causing 
exacerbations in asthma. However, the decrease in 
levels of the anti-inflammatory cytokine IL-10 in 
asthmatics compared to controls may indicate a 
Th2 response that could promote inflammation. A 
complex balance of pro- and anti-inflammatory 
response may play a role in regulating asthma as 
well as the pathogenesis of persistent infection. 
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IL-6 PRODUCTION BY UROEPITHELIAL CELLS AFTER INFECTION WITH 
CHLAMYDIA TRACHOMATIS 
J.A. Severin*, H.F.M. Willemse and J.M. O'ssewaarde 
Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, 
Rotterdam, The Netherlands 
After the initial interaction between 
Chlamydia trachomatis (CT) and the host the 
production of cytokines by epithelial cells may 
play an important role in directing the immune 
response. The objective of this study was to 
determine the secretion of interleukine 6 (IL-6) 
by uroepithelial cells of various origin after CT 
infection. 
An ureter SV40 transformed cell line 
(SV-HUC-1), two bladder carcinoma epithelial 
cell lines (SD48 and JON) and HeLa 229 cells 
were used in the infection experiments. Cells 
and chlamydia strains were free of 
mycoplasma as determined by an in-house 
PCR. Cells were seeded into 24-well microtiter 
plates. One-day-old monolayers were infected 
with CT serovar L2 at a MOI of 10. 
Supernatants from wells were harvested at 
time 0, 1,2, 3, 4, 5, 6, 7, 8, 24 and 48 h post 
infection (hpi). The cytokine IL-6 in the 
supernatants was measured using an ELISA 
assay (U-CyTech, Utrecht, the Netherlands) 
which has a lower detection limit of 5 pg/mL. 
A control well of each cell line was stained 
with monoclonal antibodies to ensure that 
>95% infectivity was achieved. 
The pattern of IL-6 release was similar 
for JON cells and for SV-HUC-1 cells. In both 
cell lines IL-6 was detectable in low levels 
(<220 pg/rnL) until 7 hpi. At that point a sharp 
increase was observed to approximately 500 
pg/mL, further increasing to 1363-2194 pg/mL 
at 24 hpi and 2509-3200 at 48 hpi. Prior to 8 
hours, however, the cell line SD48 and the 
HeLa 229 cell line did not produce detectable 
levels. IL-6 levels were detectable at 24 hpi 
and 48 hpi, but remained low (<170 pg/mL). 
Numerous studies have reported IL-6 
production by a variety of epithelial cell lines 
(1). To our knowledge studies of cytokine 
production by ureter and bladder cells in 
response to CT infection have not been 
reported before. In this study we have shown 
that some uroepithelial cells are able to 
produce IL-6, but others not. The ureter cell 
line SV-HUC-1 and the bladder cell line JON 
produced much higher levels of IL-6 than the 
HeLa 229 cells (included as a well known 
control in chlamydia research, but of cervical 
origin) and the bladder cell line SD48. It has 
been postulated that cytokine secretion may be 
related to the spontaneous release of IL-1 alpha 
after cell lysis. However, this does not explain 
the differences we have observed, because the 
increase in IL-6 levels produced by SV-HUC-1 
and JON cells was observed at 8 hpi when 
lysis by chlamydial infection had not occurred 
yet. Deregulation of IL-6 production has been 
implicated in the pathogenesis of inflammatory 
diseases (2). Further studies should be 
undertaken to assess the function of IL-6 in the 
context of infection with CT. 
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Interactions between host cells and an 
infectious pathogen usually induce the release 
of various early inflammatory mediators, such 
as chemokines. The profile of chemokines as 
produced by the host plays a significant role in 
the orchestration of the immune response as it 
controls the recruitment of specific leukocytes 
to the site of inflammation. The purpose of this 
preliminary study was to investigate the release 
of various chemokines from HeLa 229 cells in 
response to an infection with Chlamydia 
trachomatis (CT). 
The non-invasive serovar E and the 
invasive serovar L2 of CT were used to infect 
HeLa 229 cells at a MOI of 100 to ensure 
>95% infected cells. The medium of one-day-
old monolayers of polarized HeLa 229 cells in 
24-well microtiter plates was removed and 
gently replaced by the inoculum. After 1 h 
incubation at 4 °C the inoculum was replaced 
by fresh medium and the cultures were 
incubated at 37 °C. Supernatants were 
harvested at various time points after infection 
(at 0, 2, 4, 6, 8, 10, 12, 24, 48 and 72 h). 
Supernatants of two mock infected series were 
collected simultaneously as a control. By using 
a Cytometric Bead Array (BD Biosciences), 
which allows simultaneous detection of 
multiple soluble proteins in a particle-based 
immunoassay, we quantified CXCL8/IL-8, 
CCL5/RANTES, CXCL9/MIG and 
CCL2/MCP-1 levels in the supernatants. The 
assay has a lower detection limit of 10 pg/mL. 
Up until 24 h post-infection (hpi) 
CXCL8 levels were all less than 25 pg/mL. At 
48 and 72 hpi increasing concentrations of this 
chemokine were detected when HeLa 229 cells 
were infected with CT. Serovar L2 induced 
slightly higher levels than serovar E (163,1 
versus 138,4 pg/mL at 48 hpi and 427,1 versus 
259,7 pg/mL at 72 hpi). These findings are 
consistent with previous observations (1). 
For CXCL9 we observed a reversed pattern: 
CXCL9 was released in higher amounts when 
cells were infected with serovar E than serovar 
L2 (345,2 versus 126,8 pg/mL at 72 hpi). 
CXCL9 was also detected in the samples from 
the mock infected cells, but mainly during the 
first hours after infection. 
There was no difference in CCL2 levels 
between CT infected and mock infected cells: 
both increased to high levels at 24-48 hpi. At 
72 hpi we observed a moderate suppression of 
this chemokine in the CT infected cells: 1067,1 
pg/mL for serovar L2 and 4082,3 pg/mL for 
serovar E, compared to >5000 pg/mL in the 
supernatants of the mock infected cells. 
A similar concentration of CCL5 was found at 
24 hpi for both infected and mock infected 
cells (540-1720 pg/mL). After this time point 
the CCL5 concentration increased in mock 
infected cells, but decreased in serovar E and 
L2 infected cells to undetectable levels at 72 
hpi. 
These preliminary data suggest that the 
induction of a specific pattern of chemokines 
may be associated with the invasiveness of the 
infecting CT. These results are in agreement 
with differences in clinical findings. Further 
studies to unravel the complex chemokine 
patterns in response to CT infection are 
warranted. 
References 
1. Dessus-Babus S. et al. Infect. Immun. 
2002;70(6):3234-3248. 
150 - IMMUNOLOGY 
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Objective: To investigate the 
production of cytokines by T cells in patients 
with Chlamydia induced reactive arthritis 
(CIRA). 
Secretion of tumor necrosis factor 
alpha (TNF-a), interferon-gamma (IFN-y), 
interleukin (IL)-lp, -4, -6 by peripheral blood 
mononuclear cells (PBMC) and synovial fluid 
(SF) in parallel samples from 21 patients with 
CIRA were measured by immunoassays. The 
disease duration in 9 patients was < 6 months 
and in 12 patients - more than 6 months. 
Although PBMC from 15 healthy controls and 
SF from 3 patients after meniscectomy was 
investigated. 
In all cases, the enhanced activity in 
blood compared to synovial fluid was found. In 
patients with disease duration < 6 months the 
level of TNF-a was on 28,2 thimes higher in 
PBMC and on 9,8 thimes higher in SF, the 
level of IL-ip was higher on 18,3 thimes in 
PBMC and on 10,3 in SF, IL-6 - on 176,3 
thimes higher in PBMC and on 23,8 in SF, IL-
4 - on 44,4 thimes higher in PBMC and on 
11,9 - in SF, IFN-y - on 12 thimes higher in 
PBMC and on 2 - in SF (all compared to 
control, for all cases P < 0,05). In patients with 
disease duration > 6 months the level of TNF-
a was on 23,8 thimes higher in PBMC and on 
1,2 thimes higher in SF (P > 0,05), the level of 
IL-ip was higher on 12,8 thimes in PBMC and 
on 1,5 thimes in SF, IL-6 - on 236,8 thimes 
higher in PBMC and on 42 - in SF, IL-4 - on 
36,5 thimes higher in PBMC and on 13 - in SF, 
IFN-y - on 5,5 thimes higher in PBMC and on 
5,6 - in SF (P < 0,05). In early arthritis, the 
level of TNF-a and IL-ip correlated with 
disease activity as estimated by erythrocyte 
sedimentation rate. Comparative studies 
between PBMC and SF showed Th2 
dominance (IL-4) in both PBMC and SF and 
inadequate Thl type response (IFN-y) to 
pathogen, which could lead to persistence of 
chlamydiae in the joint in patients with CIRA. 
These data demonstrate production of 
cytokines by T cells in patients with 
Chlamydia induced reactive arthritis, 
indicating that activated T cells play a role in 
pathophysiological events of CIRA. 
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Chlamydia trachomatis (CTR) induced 
tubal factor infertility (TFT) is associated with 
IL-10 -1082 AA genotype that is related to 
production of IL-10 cytokine. To further 
investigate a possible impact of this divergent 
genotype distribution in TFT, we studied CTR 
induced immune responses including IL-10 
and IFN-y secretion in subjects with different 
IL-10 -1082 genotypes. 
The study population consisted of 75 
women (range of age 23-40 yrs) with TFI and 
175 blood donors as controls (age 18-59 yrs). 
IL-10 -1082 (A/G) genotyping was performed 
from isolated DNA by PCR technique. CTR 
specific cell mediated immunity was analysed 
by measuring lymphocyte proliferative (LP) 
responses against CTR EB antigen. CTR 
specific humoral immunity was analysed by 
measuring CTR spesific IgG antibodies 
(Medac). Antigen induced cytokine production 
was measured from cell culture supernatants 
using Human Thl/Th2 Cytokine Cytometric 
Bead Array kit (CBA, BD Biosciences). 
In harmony with our previous studies, 
the IL-10 -1082 A A genotype was more 
common in TFI cases (37%) than in controls 
(20%, p<0,01). CTR EB specific IgG antibody 
prevalences did not differ between genotypes 
(32% of AA types, 33% of AG types and 23% 
of GG types) suggesting that the IL-10 
polymorphism as such is not a risk factor for 
CTR infection. However, subjects with 
different IL-10 -1082 genotypes differed in 
terms of CTR induced cell mediated responses. 
Median LP responses to CTR EB antigen were 
clearly higher in subjects with IL-10-1082 AA 
genotype (27; range 0,4-310,0) than in AG 
genotype (8; 0,1-293) or GG genotype (3; 0,4-
116). IL-10 -1082 AA genotype was 
associated with higher IFN-y production 
(median 356 pg/106 CD3+ cells; range 0-1512 
pg) than GG genotype (0 pg; 0-344 pg) 
(p<0,05) when stimulated with CTR antigen. 
On the other hand, EL-10 -1082 GG genotype 
was associated with higher IL-10 production 
(12703 pg/106 monocytes; 8039-14464 pg) 
than IL10 AA genotype (4438 pg; 0-7610 pg) 
(p<0,001). 
IL-10 -1082 AA genotype as such is 
not a risk factor for CTR infection, but 
prominent IFN-y responses in these subjects 
during chronic CTR infection may be linked 
with the inflammatory reaction that provokes 
tissue injury leading to TFI. 
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THE CHLAMYDIA PNEUMONIAE OMCB PROTEIN IS AN IMPORTANT 
ADHESIN RELEVANT FOR EB ATTACHMENT TO EUKARYOTIC CELLS 
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Adhesion and subsequent internali-
sation are critical steps in the chlamydial 
infection process. Host cell glycoaminoglycans 
(GAG) have been shown to play an important 
role in the adhesion process. Recently we have 
identified heparan sulfate-like GAGs as a 
eukaryotic receptor for C. pneumoniae (1). The 
goal of this study was the identification of the 
chlamydial GAG-binding adhesin. 
We established a novel test system 
displaying C. pneumoniae proteins on the cell 
surface of the yeast Saccharomyces cerevisiae. 
Immunofluorescence microscopy verified the 
presence of bacterial proteins on yeast cell 
surface. The interaction of yeast cells 
presenting chlamydial proteins with epithelial 
(HEp-2) cells was studied in adhesion assays. 
Chlamydial adhesins identified in this assay 
were recombinantly expressed in E. coli. Latex 
beads coated with the purified proteins were 
used in adhesion assays using HEp-2 cells. 
Recombinant proteins were also used in 
competitive neutralisation / infection experi-
ments. 
A number of potential chlamydial cell 
wall proteins was displayed on the yeast cell 
surface and tested for their adhesive properties. 
One protein showing strong adhesive activities 
was the OmcB protein. OmcB-presenting yeast 
cells exhibited a dose-dependent binding to 
HEp-2 cells. This adhesion was dependent on 
the presence of GAG structures on the 
eukaryotic cell surface and CHO mutant cells 
carrying no heparan sufate showed strongly 
reduced binding. Deletion analysis revealed 
that the GAG binding activity is localised in 
the OmcB N-terminus. Site directed 
mutagenesis of single residues of a heparin 
binding motif located in this domain resulted 
in a strong reduction in adhesion. Latex beads 
coated with the recombinantly expressed 
OmcB protein exhibited strong binding to 
HEp-2 cells. Finally addition of recombinant 
OmcB protein to the infection process reduced 
the infectivity in a dose-dependent way. 
This study identified the OmcB protein 
as the chlamydial adhesin for heparan sulfate-
like GAGs on the eukaryotic cell surface. The 
neutralisation experiments indicate that OmcB 
plays an important role in the adhesion 
process. 
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There is increasing evidence that 
natural killer (NK) cells play an important role 
in infection defence at the interface between 
innate and adaptive immune response. In view 
of the association between arteriosclerosis and 
Chlamydia pneumoniae-infcction, we 
investigated whether the alloreactivity of NK 
cells against in vitro infected EC was enhanced 
with special regard to NK-adhesion and 
cytotoxicity. 
Human aortic EC (HAEC) were 
infected with the C. pneumoniae isolate 
Kajaani 6 by sonification for 24h as confirmed 
by anti-chlamydia-lipopolysaccharide 
immunofluorescence. Surface expression of 
MHC class m and adhesion molecules as well 
as binding of polyclonal anti-C. pneumoniae-
antibodies, using a pooled serum with a high 
anti- C. pneumoniae titer (1:512), to infected 
HAEC was determined by flow cytometry and 
laser scanning miscroscopy. NK cell-adhesion 
on HAEC was tested under dynamic 
conditions, and perforin reorganization was 
studied by immunofluorescence. NK-mediated 
lysis of infected and non-infected HAEC was 
analyzed in 51Cr-release assays in the presence 
or absence of anti-C. pneumoniae-antibodies. 
HAEC were infected with C. 
pneumoniae with an efficiency of > 90%. The 
expression of MHC I was increased by 55%. 
ICAM-1 (90%), VCAM-1 (127%) and E-/P-
selectin (36%) expression were also increased, 
whereas CD31 was unaffected and MHC II not 
present. The mean adhesion of NK cells from 
different individuals on infected HAEC 
increased 8.4-fold, strongly depending on the 
MHC mismatch (range 2.2 to 7.4-fold 
increase). Blocking of ICAM-1, VCAM-1 or 
E-/P-selectin on infected HAEC with specific 
antibodies reversed the observed increase of 
adhesion. Moreover, adherent NK cells on 
infected but not on non-infected HAEC 
showed a reorganization of perforin granules 
towards the site of cell-cell contact. Finally, 
direct NK cell-mediated lysis of C. 
pneumoniae-infected HAEC was 2-5 times 
higher than that of non-infected HAEC, also 
depending on the MHC mismatch, whereas 
antibody dependent cell-mediated cytotoxicity 
(ADCC) in the presence of anti-C. pneumoniae 
antibodies was not detected. 
C. pneumoniae-iniection increased the 
susceptibility of HAEC to direct NK cell-
mediated lysis. This may be due to the 
enhanced adhesion molecule expression 
leading to a strongly increased NK cell-
adhesion on infected HAEC. Thereby, NK 
cell-mediated damage of C. pneumoniae-
infected HAEC may contribute to the vascular 
damage leading to arteriosclerotic plaque 
formation at an early stage in vivo. 
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The objective of the investigation is to 
study the effect of purified monoclonal 
antibodies on the infectivity of Chlamydophila 
pneumoniae (Chlamydia pneumoniae) in in 
vitro models of chlamydial infection in cell 
monolayers. 
Monoclonal antibodies were produced 
after intranasal immunization of BALB/c mice 
with C. pneumoniae. Three anti-C. 
pneumoniae and one anti- C. psittaci purified 
monoclonal antibodies (208C3 - IgG2b, anti-
LPS C. pn.\ 209F7 - IgG2a, anti-60kDa 
protein C. pn.; 211A7 - IgM, anti-LPS C. pn.\ 
202D7 - IgG3; anti-LPS C. ps.) and one 
control monoclonal antibody with irrelevant 
specificity (8aC10 - IgG3, 0:5 S. 
typhimurium) were used in the experiments. 
The experiments were based on in vitro 
infectivity models, counting the inclusion 
forming units (IFU) in immunofluorescence, in 
different cell monolayers (L-929 - murine 
fibroblasts, HEp-2 - human epithelial cells, P-
742 - human fibroblasts from embryonic 
lungs). The chlamydial strain used in the 
infectivity studies was C. pneumoniae TWAR 
(AR-39). 
The intranasal immunization with C. 
pneumoniae gave rise to 14 hybridoma clones, 
4 of which were propagated and maintained. 
Three anti-C. pnumoniae MAbs with different 
specificity and isotype and one anti-C. psittaci 
MAb were used in the infectivity studies. In 
the used models of chlamydial infection, no 
protection was found with any of the 
monoclonal antibodies. The monoclonal 
antibody of IgM isotype was neutral and 
showed results near to the controls. There was 
significant enhancement of C. pneumoniae 
infectivity (in IFU) in different cells (32% to 
6,4-fold) in the presence of monoclonal 
antibodies of IgG3, IgG2a and IgG2b isotypes. 
The enhanced infectivity was detected in the 
presence of cross-reacting anti-LPS 
monoclonal antibody (202D7), as well as in 
the presence of specific only for the 
chlamydiae monoclonal antibodies (208C3, 
anti-LPS; 209F7, anti-60kDa protein). 
The infectivity seemed to be dependent 
mainly on the antibody isotype. The results 
suggest the existence of receptor-mediated 
antibody-dependent mechanism of chlamydial 
entry and survival. The data present in vitro 
evidence that IgG antibodies may enhance C. 
pneumoniae infectivity in different eukaryotic 
cells. 
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Sterile immunity against C. 
trachomatis depends on the induction of Thl-
mediated IFN-y production in infected tissue. 
Innate cell subsets also contribute IFN-y early 
in the course of infection and play an 
important effector role in limiting chlamydia 
burden. We previously demonstrated early 
induction of chemokines induced by IFN-y, 
CXCL10/IP-10 and CXCL9/MIG, in murine 
genital tract tissues following infection with C. 
muridarum. These chemokines are ligands for 
CXCR3, which is expressed on Thl cells and 
other immune subsets. Here, we determined 
whether endogenous CXCL10 and CXCL9 
function in recruitment of anti-chlamydial 
effector cells and the extent to which CXCR3 
mediates infiltration of Thl, as well as other 
anti-chlamydial adaptive and innate cell 
populations, to the genital mucosa, and 
subsequently chlamydia eradication. 
CXCR3 deficient (CXCR3 -/-) and 
wild type Balb/c mice were infected intra-
vaginally with C. muridarum and sacrificed 3, 
7, and 14 days later for harvest and detection 
of leukocyte subsets in the cervical-vaginal and 
oviduct regions of genital tract tissues by flow 
cytometry. Course of infection was determined 
by counting inclusion-forming units in McCoy 
cell monolayers from vaginal swabs collected 
every 3 days post-inoculation. 
CXCR3 -/- mice had significantly 
fewer CD4+CD69+IFN-y+IL-4- Thl cells in 
genital tract tissues than wild type controls as 
well as decreased numbers of CD3+, CD4+, 
and CD8+ cells. Recovery of effector 
responses in CXCR3 -/- mice occurred within 
14 days of infection and correlated with the 
onset of chlamydiae clearance, as determined 
by vaginal shedding of viable chlamydiae 
organisms, which was significantly delayed in 
comparison to wild type animals. Interestingly, 
a previously unidentified population of anti-
chlamydial cells in cervical-vaginal tissue was 
CXCR3-dependent and arrived within the first 
3 days of infection. These cells co-expressed 
the dendritic cell and granulocyte/monocytes 
markers CD 11c and LY6G/LY6C (Gr-1) but 
not T cell (CD3), B cell (CD 19), or 
macrophage (F4/80) markers. 
These data demonstrate a partial 
dependence of both adaptive and innate 
immune cells on CXCR3 for recruitment to the 
genital mucosa during infection and 
importantly point to early recruitment of a 
previously unidentified population of innate 
immune cells with immediate anti-chlamydia 
effector function. 
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EVIDENCE FOR A TYPE III SECRETION SYSTEM IN CHLAMYDOPHILA 
PSITTACI 
T. Geens* & D. Vanrompay 
Department of Molecular Biotechnology, Faculty of Applied Biological Sciences, Ghent 
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Proving that a functional type in 
secretion system (TTSS) is present in 
Chlamydophila psittaci and localizing it. 
C. trachomatis, C. muridarum, Cp. 
pneumoniae, Cp. caviae and Cp. abortus 
genome sequences were used to develop 
primers for amplification of Cp. psittaci SctW 
(YopN, CopN, a TTSS regulator in Cp. 
caviae), SctN (YscN, ATPase of the TTSS), 
SctC (YscC, translocase) and IncA (an 
inclusion membrane protein, exported via the 
TTSS). Purified PCR-products were cloned 
into pET30EkLIC (novagen), plasmids grown 
in NovaBlue singles and after purification 
introduced into E. coli BL21(DE3) for 
expression. IPTG induced and non-induced 
cultures were tested in SDS-PAGE and 
western blot. Blotting with an His monoclonal 
identified the recombinant proteins which were 
purified on BD Talon-spin colums. New 
Zealand white rabbits were immunized with 
the recombinant proteins using conventional 
protocols and resulted in four batches of 
polyclonal antibodies. 
Buffalo green monkey (BGM) monolayers 
were inoculated with the Cp. psittaci strain 
(92/1293) from which the genes were 
amplified and stained in an indirect 
immunofluorescence 15, 20, 25, 30 and 35 
hours post inoculation (second incubation with' 
Fl'fC labeled anti-rabbit) in order to determine 
the moment of expression of the protein. 
BGM monolayers were then grown onto 
cytodexl microcarriers and inoculated with the 
same strain in order to be able to examine the 
expression in electronmicroscopy with 
immunogold labeling for localization of the 
components. 
Western Blotting of Cp. psittaci 
92/1293 whole organisms with the different 
polyclonals showed that the SctW, SctN, SctC 
and IncA genes were expressed into proteins of 
43, 48, 80 and 42 kDa respectively. All 
proteins could be clearly detected using 
confocal laser scanning microscopy starting at 
20 to 25 hours post inoculation and beyond. 
The SctW, SctN and SctC staining revealed a 
uniform pattern, staining the whole chlamydial 
inclusion, while the IncA staining showed a 
rim like pattern clearly surrounding the 
inclusion. Electronmicroscopy is in progress. 
We therefore can conclude that a TTSS is 
present in Cp. psittaci. 
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Parachlamydia acanthamoebae is an 
amoebae-resisting microorganism able to enter 
and replicate within human macrophages, 
inducing their death by apoptosis. How does 
Parachlamydia escape the microbicidal 
effectors of macrophages remains unknown. 
Thus, we tested whether Parachlamydia 
downregulates the production of pro-
inflammatory cytokines or, like Coxiella 
burnetii, upregulates the production of ant-
inflammatory cytokines such as IL-10. We also 
defined the effect of Parachlamydia on the 
oxydative burst, on the production of nitric 
oxide and on the transcription of antioxydant 
such as glutaredoxin. 
We measured the oxydative activity of 
infected macrophages using a fluorogenic 
probe (H2DCFDA). Using commercial enzyme 
immunoassays, we measured in culture 
supernatants the cytokines secretion (IL-10, 
IFN-y, TNF-a, IL-lp, IL-6) of monocyte-
derived macrophages infected with living and 
heat-inactivated Parachlamydia. By real-time 
RT-PCR, we also compared the impact of 
Parachlamydia on the transcription of 
glutaredoxin, TNF-a, and indoleamine 2,3-
dioxygenase (IDO). Cells activated with LPS 
or PMA were used as positive controls. 
Living Parachlamydia did not induce: 
an oxydative burst 
the secretion of cytokines such as IL-
6, IL-10 and TNF-a, and 
the transcription of TNF-a. 
However, living Parachlamydia led to 
increased transcription of glutaredoxin, an 
anti-oxydant, and more importantly to the 
secretion of IL-ip. They slightly activated the 
transcription of IDO, an enzyme, which 
catalyzes decyclization of L-tryptophan. Heat-
inactivated Parachlamydia also did not induce 
production of pro-inflammatory cytokines such 
as IL-6. Contrarily to living Parachlamydia, 
heat-inactivated bacteria induced the 
production of IL-10, and had no effect on the 
secretion of IL-lp. 
Parachlamydia may resist destruction 
by human macrophages at least partially by 
down-regulating the production of several 
proinflammatory cytokines such as IL-6 and 
TNF-a, by not inducing an oxydative burst, 
and indirectly by inducing the transcription of 
glutaredoxin. The effect of living 
Parachlamydia on the secretion of IL-
1P suggest that the Parachlamydia-induced 
apoptosis might take place through a caspase-
dependant pathway. 
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Parachlamydia acanthamoebae is an 
obligate intracellular bacterium naturally 
infecting free-living amoebae. It is a potential 
agent of pneumonia that resists destruction by 
human macrophages. However, the strategy 
used by Parachlamydia to resist to 
macrophages is unknown. It may escape the 
endocytic pathway and replicate in a vacuole in 
close contact with the trans-Golgi network like 
Chlamydia or multiply within endoplasmic 
reticulum-associated vacuoles like Legionella. 
Thus, we analyzed the intracellular trafficking 
of this Chlamydia-like, organism and defined 
its compartment of replication within 
monocyte-derived macrophages. 
Infected cells were immunolabelled for 
the bacteria and for various intracellular 
compartments using antibodies raised against 
specific markers. We measured the rate of co-
localization of the bacteria with the different 
subcellular compartments by epifluorescence 
and confocal microscopy. 
With the infection procedure used, 
bacterial replication took place 4 to 6 hours 
post-infection within acidic vacuoles. At that 
time, Parachlamydia did not co-localized 
neither with markers of the endoplasmic 
reticulum nor with markers of the Golgi, but it 
co-localized with Lamp-1, a membrane marker 
of late endosomal and lysosomal 
compartments. A transient accumulation of 
EEA1 15 minutes post-infection, and of Rab7 
and the mannose 6-phosphate receptor 30 
minutes post-infection confirmed that 
Parachlamydia traffic through the endocytic 
pathway. The acquisition of Lamp-1 was not 
different after infection with living and heat-
inactivated bacteria. However, 24.5% and 
79.5% of living and heat-inactivated 
Parachlamydia, respectively, co-localized with 
the vacuolar proton ATPase. Moreover, 
Parachlamydia did not co-localized with 
cathepsin D, a lysosomal hydrolase, suggesting 
that Parachlamydia interferes with the 
maturation of its vacuole. 
The survival of Parachlamydia to 
destruction by human macrophages probably 
results from the control of the biogenesis of the 
vacuole by the internalized bacteria. 
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THE INFECTING DOSE OF CHLAMYDIA MURIDARUM MODULATES THE 
BALANCE BETWEEN THE INNATE AND ACQUIRED IMMUNE RESPONSE 
AND ASCENDING INFECTION 
K.A. Kelly,* W. Liu, M-H. Chang, and H.K. Maxion K.A. 
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, 
Los Angeles, California, USA 
Development of a IFNy-producing T 
lymphocyte response is critical for resolving 
genital infection caused by Chlamydia. 
However, many factors have been shown to 
modify the amplitude and cytokine profile of 
the immune response. In this report, we 
investigated the influence of inoculating dose 
of C. muridarum on the tissue distribution of 
innate and adaptive cellular immunity within 
the cervical-vaginal and oviduct regions of the 
genital tract and subsequent outcome of 
infection. 
Balb/c mice were genitally infected 
with various doses of C. muridarum ranging 
from lxlO7 to lxlO4 IFU. At various time 
points, the number of innate (Ly6G+, CDllc+) 
adaptive (CD4 CD8, CD 19) and CD4 
cytokine-producing lymphocytes (IFNy, IL-4) 
were determined locally in the oviduct and 
cervical-vaginal regions of genital tract (GT) 
using flow cytometry. The number of 
infectious organisms was determined 
regionally in tissue homogenates and the 
course of infection and oviduct histopathology 
were monitored using standard techniques. 
We found that after infection, an influx 
of both innate and adaptive immune cells 
occurred equally to various inoculating doses 
in the oviduct and cervical-vaginal regions of 
the GT. However, cells expressing the innate 
markers (Ly6G, CD 11c) were affected to a 
greater degree than lymphocytes of the 
adaptive immune response (CD4, CD8, 
CD 19). This is exceptionally obvious at all 
three infecting doses when comparing the peak 
expression of innate cells in the oviduct: 
Innate cells: 588±73.7; 504+72.5; 300+61.2; 
[Ly6G+CD 11 c+( 103)/106GTcells+SEM( 103)] 
with that of IFNy-producing CD4 cells: 
[Thl cells: 40±0.7, 36±13.3, 37±16.2] 
[Thl cells ( 103)/l 06GTcells+SEM( 103)] and 
the cervical-vaginal region: 
Innate cells: 392+82.6; 399+23.4; 230+38.4 
[Ly6G+CDl lc+(103)/106GT cells±SEM (103)] 
compared to: 
Thl cells: 20+16.1; 38±10.3; 18±18.2 
[Thl cells ( 103)/l 06GTcells+SEM( 103)]. Here 
the ratios of innate: adaptive immune cells in 
both the oviduct and cervical-vaginal regions 
increased approximately. 2-fold from the 
lowest inoculating dose of 1X104IFU to the 
highest dose of 1X107IFU. In contrast, high 
inoculating doses of C. muridarum 
corresponded to diminished numbers of viable 
chlamydiae recovered in the oviduct region of 
GT tissues. (3.50+0.27; 4.50+0.65; 5.91+0.91 
IFU; mean+SEM) and increased the oviduct 
diameter. 
The inoculating dose of C. muridarum 
does not alter the distribution of leukocytes 
recruited the oviduct or cervical-vaginal 
regions of the GT during infection. However, 
the inoculating dose changes the balance of the 
innate and adaptive immune cells recruited 
after infection to favor innate immune cells at 
higher infecting doses and modifying the 
outcome of genital infection. These findings 
suggest and important role of innate cells in 
clearing chlamydiae from the cervical-vaginal 
region and restricting ascending infection. 
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CHLAMYDIA TRACHOMATIS INFECTION IN ESTROGEN-RESPONSIVE 
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Previous studies in our laboratory have 
shown that infections induced by C. 
trachomatis serovar E and C. suis (S-45) in 
primary human and swine genital tract 
epithelial cells, respectively, are more severe in 
the estrogen-dominant phase of the 
reproductive cycle. These results reflect both 
an increase in chlamydial EB attachment as 
well as changes in the cell physiology induced 
by higher concentrations of free estrogen. In 
addition, protein disulfide isomerase, a 
component of the estrogen receptor (ER), was 
identified by association with EB attached to 
the apical membrane of polarized HEC- IB 
cells. Since ERs are documented to be found in 
the plasma membrane of hormone-sensitive 
mammalian cells, as well as in cytoplasmic 
and nuclear fractions, we hypothesize either a 
direct or indirect involvement of ER in 
chlamydial infection. 
Four epithelial adenocarcinoma cell lines, 
with designated ER sensitivity, were obtained 
commercially and compared for C. 
trachomatis serovar E infectivity with our 
standard human endometrial epithelial cell line 
HEC-IB = ER?: from breast, MCF-7 = ER+ 
and subclone HCC1806 = ER-; and from the 
endometrium, Ishikawa = ER+ and an ER-
subclone. 
All cell lines were susceptible to 
chlamydial infection. At the same level of 
MOI, the percentage of infected cells was 
consistently higher in HEC - IB cells (90%), 
than in Ishikawa ER + (51%), Ishikawa ER -
(44%), MCF-7 (57%) and HCC-1806 (20%). 
By Western blot and qPCR analyses for the ER 
isoforms, we were able to recharacterize the 
cell lines as follows: MCF-7 = ER alpha + and 
a trace of ER beta +; HCC1806 = ER beta +; 
Ishikawa ER+ and ER- = both ER alpha + and 
beta +. By FACS analysis, the amount of 
membrane ER varied from 3-12%, depending 
on the cell line. Triton X-114 extraction of the 
plasma membranes indicated that the majority 
of the membrane ERs is hydrophilic and only a 
small fraction is hydrophobic. Otherwise the 
majority of the ER alpha isoform is located in 
the nucleus and the majority of the ER beta 
isoform is located in the cytoplasm. 
Estrogen binding and EB attachment 
studies are in progress as is siRNA technology 
to obtain an ER- cell line for a more complete 
comparative study of the influence of estrogen 
on chlamydial adherence and infectivity. Such 
studies will be necessary in order to determine 
if the ER is involved in Chlamidya 
trachomatis serovar E attachment to human 
endometrial epithelial cells or, alternatively, if 
the estrogen-induced physiological effect on 
the host cells results in display of another 
receptor (s) for EB attachment/entry. 
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Chlamydia trachomatis (C. 
trachomatis) specific antibodies, especially 
those to chlamydial heat shock protein 60 
(CHSP60) predict C. trachomatis induced 
tubal factor infertility (TFI). However, 
immunopathogenesis of TFI also involves T 
cell response, and CHSP60 has been found as 
an important antigen in this process. This study 
was conducted to evaluate the role of C. 
trachomatis induced antibody responses and C. 
trachomatis induced T cell responses in 
predicting TFI. 
The study population consisted of 93 
women (range of age 23-40 yrs) with 
laparoscopically verified TFI, and 163 controls 
(age 18-59 yrs) consisting of healthy blood 
donors. Immune markers of C. trachomatis 
infection included IgG antibody determination 
using pELISA of C. trachomatis and CHSP60 
ELISA (Medac). Also included were 
lymphocyte proliferation (LP) tests induced by 
C. trachomatis EB antigen (serotypes E and F) 
or CHSP60 antigen. Statistical analyses were 
performed using SPSS program. 
Comparing to controls, TFI cases had 
more often positive antibody levels to C. 
trachomatis (41% vs. 13%) or CHSP60 (58% 
vs. 22%) (OD 0.4 was used as a cut-off level 
for IgG). In addition, positive LP responses to 
C. trachomatis EB (stimulation index SI>5) or 
to CHSP60 (SI>2.5) were found more often 
among TFI cases than among controls (82% 
vs. 59% to C. trachomatis EB; 44% vs. 31% to 
CHSP60). 
All four immunologic markers were negative 
in 6 (6%) of 93 TFI cases and in 51 (31%) of 
163 controls, while three or four of the markers 
were positive in 42 (45%) TFI cases and in 21 
(13%) controls (p<0.001). 
Although CHSP60 antibody test was the best 
test in predicting TFI (area under curve, AUC 
0.75; 95% CI 0.69-0.81), our data show that 
the predictive value can be remarkable 
improved when several immunologic markers 
are used. Comparing to subjects with all four 
markers negative, the risk for TFI was 3.6 
(95% CI 1.3-9.8) among those with one 
positive marker, 4.8 (95% CI 1.8-12.8) among 
those with two positive markers, and 17.0 (CI 
6.3-46.0) among those with three or four 
positive markers. 
Our results show that TFI prediction 
model is remarkably improved by combining 
tests for humoral and cell mediated immune 
response to C. trachomatis. 
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THE INFLUENCE OF CHLAMYDIA TRACHOMATIS ANTIBODIES AND 
HEAT-SHOCK PROTEIN 60 (HSP60) ANTIBODIES ON THE OUTCOME OF 
IN VITRO FERTILIZATION (IVF) 
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Some studies have suggested that 
previous C. trachomatis (Ct) infection may 
influence the outcome of in vitro fertilization 
(IVF). Osser et al. previously reported no 
association between antibodies to Ct 
demonstrated by microimmunofluorescence 
(MIF) and the success-rate of IVF. In this 
study we have related the IVF outcome in 
terms of take-home-babies to chlamydial 
antibodies by MIF and to antibodies to the 
chlamydial heat shock protein 60 (hsp60) in 
serum and cervical secretions. 
In an IVF programme 281 consecutive 
women were enrolled in the present study. Sera 
and/or cervical secretions were obtained at the 
first visit to the clinic. 
Chlamydial antibodies were measured by an 
in-house MIF. A recombinant chlamydial 
hsp60 antigen was used in an Elisa test. 
IVF resulted in 103 pregnancies (37%) 
and in 85 take-home babies (30%) and in 18 
(6%) miscarriages. Tubal factor infertility was 
disclosed in 17% of the cases. In a logistic 
regression model the rate of take-home babies 
was shown to be related to the age of the 
mother but not to Ct MIF antibodies in serum 
or hsp60 antibodies in serum or cervical 
secretion. Tubal factor infertility was also not 
related to the IVF outcome. Both MIF and 
hsp60 antibodies in serum, however, was 
independently associated with tubal factor 
infertility but not infertility of other types. IgA 
antibodies to hsp60 in cervical secretion was 
not related to tubal factor infertility or to hsp60 
IgG antibodies in serum. 
The only factor which influenced the 
rate of take-home babies after IVF was the age 
of the woman. Antibodies to Ct demonstrated 
by MIF or Ct hsp60 antibodies were not 
associated with such an effect. Our results 
suggest that Ct antibodies are markers of 
previous exposure to Ct but do not seem to 
influence the result of IVF. 
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IL-6 plays an important role in 
mediating inflammation and it is a central 
stimulus for the acute-phase response. IL-6 
induces the hepatic synthesis of CRP. Previous 
studies suggest that the transcriptional activity 
of the IL-6 gene and the plasma IL-6 protein 
levels might be associated with a single G/C 
exchange polymorphism sited at the -174 
promoter region of the gene1. This promoter 
polymorphism has also been shown to be 
associated with antibody levels to human heat 
shock protein 60 (hHsp60)2. We have shown 
earlier that elevated antibodies to C. 
pneumoniae and hHsp60 when present 
together with elevated CRP are a significant 
risk factor for cardiac events3. Now, our aim 
was to study the association of IL-6 gene 
polymorphism with antibodies to C. 
pneumoniae and hHsp60 and serum CRP. 
Genomic DNA was isolated from buffy 
coat specimens of 113 male blood donors, 
obtained from Finnish Red Cross Blood 
Service. IL-6 genotyping was done by real-
time PCR, antibodies to hHsp60 were 
measured by EIA, CRP and IL-6 
concentrations by commercial ELISA kits (Oy 
Medix Biochemica AB, Kauniainen, Finland 
and CLB, Amsterdam, The Netherlands, 
respectively). C. pneumoniae IgG and IgA 
antibodies were analysed by MIF method. 
Statistical analyses were performed using Chi-
squared test, Kruskal-Wallis test, Mann-
Whitney U-test and Spearman's correlation 
test. All tests were done by using SPSS 11.5. 
The genotype frequencies for IL-6 
polymorphism were 32.8% CC, 50.4% CG, 
16.8% GG. Carriers of the genotype CC had 
higher CRP levels: for CC median (md)=0.73 
mg/1 (range 0.02-4.33), for CG md=0.53 mg/1 
(0.004-3.97), for GG md=0.45 mg/1 (0.004-
0.90., and statistically significant difference 
was found between genotypes CC and GG 
(p=0.006). No association was seen between 
IL-6 gene polymorphism and antibody levels to 
C. pneumoniae and hHsp60. Subjects with 
high (>3pg/ml) IL-6 plasma levels had also 
high plasma CRP levels (Spearman's 
correlation 0.34, p<0.001). There was 
significant association neither between IL-6 
concentration and C. pneumoniae antibodies 
nor between IL-6 concentration and antibodies 
against hHsp60. IL-6 plasma levels were not 
associated with different IL-6 genotypes. 
Serum CRP levels were associated with 
polymorphism of the IL-6 gene. Neither IL-6 
levels nor antibodies to hHsp60 and to C. 
pneumoniae had such association. The CC 
genotype may cause higher production of CRP 
through higher levels of IL-6. We did not find 
any significant correlation between IL-6 
genotypes and IL-6 concentration, probably 
because of diurnal variation of IL-6 levels - the 
collection of sera in same time point of the day 
would have given better results. The lack of 
correlation between IL-6 genotype and C. 
pneumoniae and hHsp60 antibodies may be 
explained in part by the small sample size and 
low levels of antibodies against C. pneumoniae 
and hHsp60 in healthy blood donors. 
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Chlamydia pneumoniae (CP) is 
frequently found in atherosclerotic lesions and 
elevated antibody (Ab) titers as well as high 
antibody frequency of anti-CP-antibodies 
(CPAbs) have been associated with coronary 
heart disease (CHD). Since some years, 
antibodies to chlamydial heat shock protein 
(cHSP60) and human heat shock protein 
(hHSP60) have been dicussed as predictive 
serological markers for chronic chlamydial 
infection and autoimmune-mediated 
pathology. The aim of this study was to 
investigate the association between CPAbs, 
including anti-cHSP60-IgG and anti-hHSP60-
IgG, and CHD. 
0.0021). The frequency of CP-IgA-Abs was 
higher (p = 0.0247) in controls than in patients. 
This study confirms the high frequency 
of CPAbs in patients as well as in controls. 
The results of this study neither demonstrate an 
association between CHD and cHSP60-IgG or 
hHSP60-IgG nor CPAbs. Therefore, the results 
of this study do not support a value of CP 
serology including the HSP60 serology as an 
useful diagnostic marker for determination of 
high risk patients with CHD. 
348 persons were enrolled, 184 patients 
(mean age, 61.6 years) with angiographically 
proven CHD and 164 controls (mean age, 64 
years). The Abs were detected by the cHSP60-
IgG-ELISA medac, the hHSP60-IgG-ELISA 
medac and the Chlamydia pneumoniae-lgG-, 
IgA- and IgM-ELISA medac (medac, 
Hamburg, Germany). 
Anti-cHSP60-IgG and anti-hHSP60-
IgG were detected in 21.2 % and 7.1 % of 
CHD patients vs. 22.6 % and 17.1 % of the 
controls, respectively. The frequencies of anti-
CP- IgG, anti-CP-IgA and anti-CP-IgM were 
78.8, 39.3 and 5.4 % vs. 81.7, 47.6 and 2.4 %, 
respectively. There were no significant 
differences between patients and controls 
concerning frequency. No significant 
difference was detected of anti-CP-IgG and 
anti-CP-IgM as well as for anti-cHSP60-IgG. 
Compared with that, patients showed 
significant lower anti-hHSP60-IgG-Abs (p = 
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HEAT SHOCK PROTEINS (GROEL) OF THE ENVIRONMENTAL 
CHLAMYDIA UWE25 
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Heat shock proteins 60 (GroEL) are 
highly conserved among bacteria and play an 
essential role in ensuring that proteins are 
expressed as fully functional molecules. 
Elevated GroEL expression is considered a 
heat shock as well as a general stress response 
mechanism stabilizing cellular proteins. In 
contrast to most other bacteria, Chlamydiaceae 
possess three homologues of groEL (groELl, 
groEL2 and groEL3). GroEL proteins of 
Chlamydiaceae, primarily GroELl, have been 
suggested to play a central role in 
immunopathology. Expression of all three 
groEL homologues is constitutively 
throughout the chlamydial developmental 
cycle. In Chlamydia trachomatis groELl, 
groEL2 and groEL3 show subtle differences in 
expression levels and probably have different 
biological functions (Karunakaran et al., 
2003). 
biological functions than their Chlamydiaceae 
counterparts. Future detailed biochemical 
analyses will allow further insights into the 
function and evolutionary history of 
chlamydial heat shock proteins GroEL. 
Here we demonstrate that the 
Parachlamydia-related environmental 
chlamydia UWE25, which thrives as symbiont 
in free-living amoebae, also encodes three 
groEL homologues as revealed by whole 
genome sequencing. Comparative and 
phylogenetic sequence analysis as well as 
structural predictions indicated that - in 
contrast to pathogenic chlamydiae - all three 
groEL homologues are highly conserved and 
similar to E. coli GroEL. Transcription 
analysis showed the expression of all three 
groEL genes during the developmental cycle 
of environmental chlamydiae. 
The presented data suggests that 
GroELl of UWE25 functions as a homologue 
of E. coli GroEL. Interestingly, GroEL2 and 
GroEL3 of UWE25 might have different 
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APOPTOSIS OF HUMAN SPERMATOZOA BY CO-INCUBATION WITH 
CHLAMYDIA TRACHOMATIS LIPOPOLYSACCHARIDE 
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We have shown that co-incubation of 
human spermatozoa with C. trachomatis 
causes a significant decline in the percentage 
of motile sperm and results in premature sperm 
death and that this C. trachomatis - induced 
death of human spermatozoa is primarily 
caused by lipopolysaccharide (LPS). As 
apoptosis in human spermatozoa is considered 
to be controversial, this study compared three 
different methods for demonstrating apoptosis 
in human spermatozoa exposed to C. 
trachomatis LPS. 
These methods included flow 
cytometry, measurement of ADP: ATP ratios 
and measurement of oligonucleosomal DNA. 
In comparison with staurosporine-
treated spermatozoa (apoptosis control) and 
heat-shocked spermatozoa (necrosis control), 
all methods showed that a large proportion of 
C. trachomatis LPS-exposed spermatozoa 
became apoptotic within 6 h of co-incubation. 
Moreover, significant inhibition of C. 
trachomatis LPS-induced apoptosis with the 
pan-caspase inhibitor (Z-VAD-FMK) 
suggested that apoptosis was caspase-
mediated. 
The principal mode of death in human 
spermatozoa exposed to C. trachomatis LPS is 
due to apoptosis. 
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Chlamydia pneumoniae is an obligate 
intracellular bacterial pathogen known to be 
the etiological agent responsible for respiratory 
tract infection. 
The ability of pathogenic bacteria to induce 
apoptosis may play a role in the initiation of 
the infection, the survival of the pathogens, 
and their escape from the host immune 
response. 
Recently C. pneumoniae has been implicated 
as an etiological agent of chronic diseases such 
as atherosclerotic cardiovascular disease. 
Several authors have demonstrated that C. 
pneumoniae persist in viable abnormal form in 
macrophages, which contribute to local 
inflammation and development of 
atherosclerosis. 
Therefore we investigated whether C. 
pneumoniae infection of macrophages can 
induce T-cell apoptosis. 
Peripheral blood mononuclear cells 
(PBMC) were isolated from heparinized buffy 
coats obtained from blood donors by Ficoll-
Hypaque density gradient centrifugation. 
Adherent monocytes, isolated from PBMC, 
were cultured 6 days in RPMI 1640 
supplemented with Macrophages Colony 
Stimulating Factor (50 ng/ml) at 1% (v/v) fetal 
calf serum. The proportion of macrophages 
was determined by fluorescence-activated cell 
sorter (FACS) analysis with FTTC-coniugated 
anti-CD68 monoclonal antibody. 
T cells were purified from PBMC by 
RosetteSep kit according to the manufacturer's 
instructions. The proportion of T cells was 
determined by FACS with FTTC-coniugated 
anti CD-3 monoclonal antibody. T cells were 
stimulated with phytohemagglutinin (PHA; 10 
jig/ml) for 6 days in the presence of 
recombinant interleukin-2 (rIL-2) 60 IU/ml. 
Macrophages were infected with C. 
pneumoniae at multiplicities of infection 
(MOIs) of 1 and 5 in antibiotic-free RPMI 
medium containing 10% FCS. 
PHA-activated T cells PBMC were added to 
the infected macrophages at a ratio of 1:1. 
Coculture assays were performed in antibiotic-
free RPMI medium containing 10% FCS and 
60 IU of rIL-2/ml. 
In control experiments, PHA stimulated T cells 
were incubated with noninfected macrophages. 
After 4 days of coculture, the number of 
apoptotic cells was quantified by flow 
cytometric analysis of TUNEL assay and 
Tumor Necrosis Factor alpha (TNF-a) 
concentrations were measured in the 
supernatants using a commercially available 
TNF-a enzyme-linked immunosorbent assay. 
The percentage of apoptotic cells after 
4 days of coculture with C. pneumoniae 
infected macrophages at MOI 5 was higher 
than the frequency of apoptotic cells after 
coculture with noninfected macrophages. 
Infection of macrophages at an MOI of 5 led to 
an increase of TNF-a concentration compared 
with noninfected macrophage. 
Our preliminary results suggested that 
C. pneumoniae infection of macrophages 
might induce T-cell apoptosis; however, to 
support this contention further studies would 
be necessary. 
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Persistent infections with 
Chlamydophila pneumoniae have been 
associated with multiple chronic clinical and 
subclinical conditions. Variety of reports show 
that the cells acutely infected with C. 
pneumoniae are resistant to apoptosis induced 
by different stimuli. However, little is known 
about the apoptotic behaviour of host cells 
during persistent infections with C. 
pneumoniae. 
To address this issue, we induced 
persistent infection in the epithelial cell line 
HEp-2 by removing iron with deferoxamine. 
Seventy two hours after infection, we induced 
apoptosis using TNFa or staurosporine. The 
apoptosis was monitored by 
immunofluorescence (chromatin 
condensation), cytochrome c release and 
caspase 3 cleavage and by immunoblotting to 
detect PARP-cleavage and caspase 3 activity. 
Using these multiple methods, we show 
that epithelial cells persistently infected with 
C. pneumoniae resist the receptor-mediated 
apoptosis and also the apoptosis induced by an 
endogenous stimulus such as staurosporine 
treatment. 
Our findings may have serious 
implications for the clinical outcome of the in 
vivo persistent infections. 
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CHLAMYDIA INHIBIT HOST CELL-APOPTOSIS BY SPECIFIC 
DEGRADATION OF THE PRO-APOPTOTIC BH3-ONLY PROTEIN BIM 
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Cell death by apoptosis occurs as a 
consequence of the activation of an 
intracellular signal transduction pathway. 
Recent research lends increasing support to the 
notion that apoptosis plays a role in the 
defence against infectious microorganisms. 
Consistent with this concept, modulation of the 
cell's apoptosis system by the microbial agent 
is frequently observed in infections with 
intracellular pathogens. Infection of human 
cells with obligate intracellular bacteria of the 
genera Chlamydia was found to convey the 
infected cells a strongly increased resistance 
against apoptosis induced by external stimuli. 
This protection required bacterial protein 
synthesis. This is judged to be important for 
the ability of chlamydia to reproduce in human 
cells. 
Here we show that resistance to 
apoptosis is conveyed by the destruction of the 
pro-apoptotic BH3-only protein Bim/Bod 
during infection. Apoptotic stimuli that cause 
cell death by activating Bim were 
blocked upstream of the mitochondrial 
activation of Bax. 
During infection with both species, C. 
trachomatis and C. pneumoniae, Bim protein 
gradually disappeared, although no changes in 
Bim mRNA were detectable. The 
disappearance was blocked by inhibitors of the 
proteasome. Infected cells retained sensitivity 
to Bim expressed by transfection indicating 
functional relevance of the Bim disappearance. 
Furthermore, fusion to Bim targeted the green 
fluorescent protein for destruction during 
infection. Analysis of truncation mutants 
showed that a short region of Bim containing 
the BH3-domain was sufficient for recognition 
and destruction during chlamydial infection. 
These results reveal a novel way by 
which microbes can interfere with the host 
cell's apoptotic machinery and provide a 
molecular explanation of the cellular resistance 
to apoptosis during infection with chlamydia. 
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EFFECT OF NF-KAPPA-B INHIBITION ON ULTRASTRUCTURE OF 
CHLAMYDIA PNEUMONIAE IN CELL CULTURE 
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C. pneumoniae infection has been 
linked to atherogenesis. Activation of the 
transcription factor NF-kappa-B is a common 
finding in atherosclerotic lesions. The 
transcription factor family NF-kappa-B plays a 
central role in cellular defense mechanisms as 
it is involved in the inducible expression of a 
variety of cellular genes that regulate the 
immune and inflammatory response. 
Indeed NF-kappa-B is activated in C. 
pneumoniae infected cells and Aspirin inhibits 
C. pneumoniae growth by inhibition of host 
NF-kappa-B activation. 
In the present study we investigated the 
ultrastructural changes of C. pneumonaie 
development during host NF-kappa-B 
inhibition. 
The endothelial cell line EVLC2 was 
obtained from Dr. E. van Leeuwen (AZG, 
Groningen, The Netherlands). C. pneumoniae 
strain 2023 was propagated in HEp-2 cell 
monolayers. Growth was monitored 72 hours 
post infection (hpi) using a genus-specific 
fluorescein labeled monoclonal antibody 
(PathoDX, DPC, Los Angeles). Transmission 
electron microscopy was performed by a 
standard procedure in EVLC2 cells 72 hpi. 
Long term C. pneumoniae cultivation was 
achieved in EVLC2 cells. After infection, 
medium was replaced only once a week. To 
monitor the cyclic changes of infection and 
cytopathic effects, cells were stained every 4 to 
5 days, using a genus-specific fluorescein 
labeled monoclonal antibody. After a cycle of 
about three weeks good infection was present, 
with obvious large, pale inclusions. At this 
time, transmission electron microscopy was 
performed and cells were splitted and further 
propagated. 
Aspirin (2,5 and 5 mM) and specific decoy 
oligodeoxynucleotides (ODN) were used for 
NF-kappa-B inhibition. 
NF-Kappa-B inhibition by Aspirin 
treatment showed distinct effects on the 
morphology of C. pneumoniae in cultured 
EVLC2 cells. The results indicate a 
concentration dependent reduction of 
chlamydial infectious elementary bodies, 
whereas the vegetative forms of chlamydiae, 
the reticulate bodies, were not affected. At 
highest doses of Aspirin [5mM] infectious 
progeny was completely abolished. Essentially 
the same results were observed by inhibition of 
NF-kappa B by transfection with NF-kappa-B 
decoy ODNs, whereas a mutated decoy ODN 
did not effect chlamydial growth. Interestingly, 
no induction of chlamydial aberrant bodies, 
indicative for cell cycle arrest, could be 
observed. 
In the long term cultivation of C. pneumoniae 
there was also a clear reduction of elementary 
bodies, and an increase in aberrant bodies. 
NF-kappaB activation is a crucial 
precondition in the C. pneumoniae 
developmental cycle. Transmission electron 
microscopy shows that infectious elementary 
bodies decrease with increasing NF-Kappa-B 
inhibition, an effect that might also occur in 
the infected vessel wall in vivo. Part of the 
known cardioprotective effects of Aspirin 
might be explained by this bacteriostatic effect. 
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Chlamydiae are obligate intracellular 
bacteria, causing acute and chronic infections 
of the respiratory or urogenital tract. 
Furthermore, chronic or recurrent infections 
with intracellularly persistent C. pneumoniae 
have been associated with development of 
vascular lesions and coronary heart disease. 
Little is known about intracellular recognition 
of chlamydiae. While the transmembranous 
family of Toll-like receptors (TLRs) are 
suggested to mediate host responses against 
extracellular pathogens, the recently identified 
group of cytosolic Nod proteins are candidates 
for intracellular recognition of bacteria. 
In our study we transiently transfected 
HEK293 cells with plasmids encoding Nods, 
TLRs or dominant-negative mutants of 
different signalling molecules; next day cells 
were infected with C. pneumoniae, strain TW-
183 and C. trachomatis, serovar K. As a 
readout we assessed activation of a NF-KB-
dependent reporter gene, IL-8 production was 
quantified by ELISA. 
Nodi and Nod2 mediate 
responsiveness to both chlamydia strains. 
Viable bacteria were not necessary for this 
process, since intracellular transfection of UV-
killed or heat-inactivated bacteria induced 
similar results. In contrast to the Nod proteins, 
TLR2 served as a receptor most notably for 
extracellular bacteria. Thus, UV-inactivated 
chlamydiae stimulate HEK293 cells 
overexpressing TLR2 when provided from the 
extracellular side, but only marginally activate 
NF-KB in these cells when challenged from the 
intracellular side. Nod-protein-associated 
signal transduction pathway might include 
Rip2, IRAKI, IRAK2 and TRAF6, but not 
MyD88. 
Nodi and Nod2 mediate NF-KB 
activation induced by two chlamydia species. 
Heat- and UV-resistant bacterial components, 
might be responsible for the demonstrated 
results. 
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Chlamydophila pneumoniae, first 
isolated in 1965, is a wide-spread obligate 
intracellular bacteria causing acute respiratory 
tract infections including pneumonia, 
bronchitis, sinusitis, and pharyngitis. Recently, 
chronic C. pneumoniae infection has been 
associated with atherosclerosis and coronary 
heart disease. The purpose of this study was to 
investigate the importance of mitogen-
activated protein kinases and Rho-proteins for 
C. pneumoniae-mediated activation of 
HUVEC. 
target cells via small GTP-binding proteins and 
the p38 MAPK pathway. This could lead to 
endothelial activation, inflammation and 
thrombosis, which may promote 
atherosclerosis. 
Human umbilican vein endothelial cells 
(HUVEC), transiently transfected HEK293, 
Western Blot, reportergene assay, IL-8 ELISA 
Western blot analysis demonstrated an 
enhanced phosphorylation of endothelial 
mitogen-activated protein kinase (MAPK) 
family members extracellular receptor kinase 
(ERK1/2) and p38-MAPK. 
Preincubation of HUVEC with Simvastatin, a 
HMG-CoA-Reductase-Inhibitor, inhibited all 
small GTP- binding proteins and reduced 
endothelial interleukin 8- (IL-8) expression to 
almost baseline level. Using specific inhibitors 
of p38 MAPK (SB202190) or ERK1/2 (u0126) 
we identified the importance of these 
MAPKinases for the C. pneumoniae-induced 
activation of endothelial cells. 
Importance of small GTP-binding proteins and 
the p38MAPK for activation of nuclear factor-
KB (NF-KB) in target cells was confirmed 
using dominant negative plasmides in 
transiently transfected HEK293 cells. 
We demonstrated that C. pneumoniae 
triggers an early signal transduction cascade in 
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SIGNAL TRANSDUCTION PATHWAYS ACTIVATED IN ENDOTHELIAL 
CELLS FOLLOWING STIMULATION WITH THE 60-KDA HEAT-SHOCK 
PROTEIN OF CHLAMYDOPHILA PNEUMONIAE GROEL-1 
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Chlamydophila pneumoniae has been 
linked to several severe illnesses and is 
discussed in context with numerous acute and 
chronic pulmonal, neurological and 
cardiovascular diseases. However, the 
importance of different chlamydial virulence 
factors still remains uncertain. The 60-kDa 
heat-shock protein GroEL-1 has been 
suggested to be important for target cell 
activation. The purpose of our study was to 
investigate signal transduction pathways 
activated in GroEL-1-stimulated endothelial 
cells. 
activation/translocation. Increased expression 
of neutrophil chemotactic factor IL-8 was 
noted within hours. 
Stimulation with GroEL-1 induced a strong 
activation of different signal transduction 
pathways in endothelial cells. GroEL-1 triggers 
a cascade of events, which in turn may result in 
or may promote inflammation and 
atherosclerosis. 
Methods: Human umbilical vein 
endothelial cells (HUVEC); recombinant heat-
shock-protein 60 (GroEL-1, chsp60 from C. 
pneumoniae); C. pneumoniae strain TW183; 
Western Blotting, reportergene-Assay; IL-8-
ELISA. 
Results: GroEL-1 induces a time- and dose 
dependent phosphorylation of the endothelial 
mitogen-activated protein kinases (MAPK) 
p38, ERK1/2 and JNK, maximum effects were 
seen after 15 minutes using 20 pg/ml, followed 
by a subsequently activation and translocation 
of NF-kB into the cell nucleus as well as a 
time- and dose dependent expression of 
endothelial IL-8. Kinetics and efficiency of the 
activation of endothelial cells were comparable 
to a stimulation with living C. pneumoniae. 
Activation of different signal 
transduction pathways in GroEL-1 -
stimmulated endothelial cells has been 
demonstrated: phosphorylation of MAPK p38, 
ERK1/2 and JNK, and NF-kappaB 
174 - IMMUNOLOGY 
CHLAMYDIA MEDIATE ACTIVATION OF SIGNAL TRANSDUCTION 
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Chlamydiae are widespread gram-
negative obligate intracellular pathogens, 
causing respiratory and urogenital infections. 
In addition, chronic or persistent infection with 
Chlamydophila pneumoniae has been 
suggested as a trigger/promoter of 
inflammation that may result in vascular 
lesions and coronary heart disease (CHD). 
Although the genome of C. pneumoniae and C. 
trachomatis has been sequenced completely in 
1999 and several potential virulence factors 
have been identified, this information has not 
yet led to a profound understanding of the 
mechanisms of infection and target cell 
activation. In addition little is know about the 
contribution of host cell factors that promote 
infection, intracellular growth and survival of 
chlamydia. 
We could demonstrate that C. 
pneumoniae is able to infect endothelial cells 
and activate different signal transduction 
pathways, resulting in a proinflammatory and 
proatherogenic phenotype in these cells. 
Chlamydial heat shock protein 60 (cHsp60, 
GroEL-1) could be identified as a major 
virulence factor for target cell activation. C. 
trachomatis is also able to infect humane 
endothelial cells, infection, however, was not 
followed by subsequent endothelial cell 
activation. 
Our data demonstrate that target cell 
infection by chlamydia is not sufficient to 
induce a profound alteration, species-specific 
(virulence-) factors seem to play a central role 
for target cell activation. 
Supported by the Deutsche Forschungs-
gemeinschaft SPP1130 (Kr 2197/1-1). 
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Persistent C. pneumoniae infection has 
been implicated in the etiology of atherosclerosis, 
however, a direct causal role remains to be 
elucidated. We have used a combined 
transcriptome/proteome approach to identify genes 
that are differentially expressed under an 
interferon-y (IFN) induced model of persistence. A 
number of these differentially expressed C. 
pneumoniae genes were selected for production of 
antisera to allow probing infected monolayers for 
visualisation by confocal microscopy. It is the 
ultimate aim to use these antisera to screen human 
atherosclerotic tissue to try to identify a link 
between C. pneumoniae infection and 
atherosclerosis. 
C. pneumoniae A03-infected HEp2 cells 
were cultured in the presence or absence of IFN 
until 24 and 48 h post-infection. The protein 
expression profiles of infected monolayers were 
generated by 2D-gel electrophoresis and protein 
spots identified by matrix-assisted laser desorption 
ionization time-of-flight (MALDI-TOF) mass 
spectrometry. Differentially expressed proteins 
were selected for analysis by quantitative RT-PCR 
using the ABI Prism 7000 Real time PCR machine. 
Several of the differentially expressed targets were 
selected for production of antisera. Peptides were 
generated to predicted B-cell epitopes in the target 
genes and used to generate antisera in New 
Zealand white rabbits. These antisera were used to 
probe C. pneumoniae A03-infected monolayers at 
24, 48, 72 and 96 h post-infection to test the 
expression levels and cellular distribution of the 
proteins at different stages of the developmental 
cycle with and without IFN. 
38 C. pneumoniae genes were studied at 
both the mRNA and protein levels, by comparing 
the changes in expression from 24 to 48 h post-
infection and in the presence and absence of IFN. 
These 38 targets were selected based on 
differential expression patterns seen in the 
proteomic analysis. 
The cultures without IFN treatment showed varied 
correlation between RNA and protein level 
changes from 24 to 48 h post-infection. A number 
of these genes, including cell wall proteins, Map, 
CpxR, Cpn0710 and Cpn0216, were up-regulated 
at both the mRNA and protein levels. However, 
the majority (21 genes) showed no significant 
mRNA increase but did show a significant protein 
change (usually up-regulated). Cultures grown in 
the presence of IFN showed fewer genes 
correlating between mRNA and protein levels. The 
majority of genes showed a decrease in mRNA 
levels, from 24 to 48 h post-infection, but either an 
unchanged or increased protein level. 
From the 38 genes analysed we selected 16 targets 
for the production of antisera and staining of C. 
pneumoniae A03-infected HEp2 cells. Selection of 
the targets was based on differential RNA and 
protein expression profiles under IFN induced 
persistent conditions. The targets are (a) CrpA, 
YhbZ, LytB, MurA, IncA, NlpD, GroEL (up-
regulated), (b) PorB, FtsK, GlmU, Pkn5, Ndk 
(down-regulated) and (c) Ptsl, Pyk, GroES, GspD 
(unchanged). Antibody staining for confocal 
microscopy is currently being carried out on these 
targets at 24, 48, 72 and 96 hours post-infection. 
The combination of transcriptomics and 
proteomics has identified a number of 
differentially expression genes in an IFN induced 
model of persistence. While many genes show no 
correlation between mRNA and protein levels, 
patterns are starting to emerge that may be of 
interest. It is hoped that antibody staining over 
different time points with and without IFN will 
show us the pattern and location of expression of a 
number of these differentially expressed genes. 
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PRODUCTION OF EXTRACELLULAR MATRIX PROTEINS BY HUMAN 
SMOOTH MUSCLE CELLS AND FIBROBLASTS INFECTED WITH 
CHLAMYDIA PNEUMONIAE 
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Persistent and recurrent infections with 
Chlamydia pneumoniae have been associated 
with chronic obstructive airway diseases, such 
as COPD, intrinsic asthma and extrapulmonary 
diseases, i. e. atherosclerosis [1,2]. 
Chronic progressive inflammatory processes 
can result in heterogeneous forms of fibrosis. 
Fibroblasts and smooth muscle cells (SMC) 
can be activated involving alterations of the 
functional cell phenotype. Chronic 
inflammation in asthma promotes fibrosis and 
airway remodeling. 
Obstructive airway disease tissues are 
characterized by an accumulation of 
extracellular matrix proteins, such as collagen 
types I, HI and V, whereas the deposition of 
collagen IV is decreased [3, 4], 
The pathogenesis of atherosclerosis also shows 
an increased matrix production by arterial wall 
cells resulting in formation of fibrous plaques. 
To evaluate the influence of C. pneumoniae we 
examined the production of matrix proteins in 
infected SMC and fibroblasts compared to 
uninfected cells. 
Bronchial SMC and fibroblasts were 
infected with C. pneumoniae strain TW-183 at 
rising multiplicities of infection (MOI). The 
time dependent protein synthesis of infected 
cells cultures were investigated up to 72 h. 
Matrix protein syntheses were investigated by 
immunoblotting and RT-PCR. 
In Chlamydia infected cells the 
syntheses of collagens was influenced both 
time and dose dependent. SMC and fibroblasts 
showed a similar pattern in matrix protein 
syntheses. Collagen I and III proteins were 
decreased in infected cells as shown by 
immunoblotting. The mRNA expression was 
also down-regulated. Collagen IV synthesis 
and mRNA levels were increased and collagen 
V seems to be unaffected following infection. 
The infection of cell cultures with 
Chlamydia pneumoniae alters their collagen 
production. In contrast to the observations in 
asthmatic airways a different pattern in matrix 
protein production could be shown with 
decrease of collagen I and m as well as 
increased collagen IV syntheses. 
However the results support the hypothesis 
that C. pneumoniae may promote the 
déstabilisation of atherosclerotic plaques 
caused by degrading extracellular matrix 
proteins of the fibrous cap [5], 
Further experiments are needed to evaluate if 
infection of cells directly mediates the 
synthesis of extracellular matrix proteins or via 
induction of several cytokines released by 
infected cells. 
References 
[1] Cook, P. J.; Davies, P.; Tunnicliffe, W.; 
Ayres, J. G.; Honeyboume, D. and R. Wise 
(1998) Chlamydia pneumoniae and asthma. 
Thorax 53: 254-259. 
[2] Ngeh, J.; Anand, V. and S. Gupta (2002) 
Chlamydia pneumoniae and atherosclerosis -
what we know and what we don't. Clin. 
Microbiol. Infect. 8: 2-13. 
[3] Johnson, P. R. (2001) Role of human 
airway smooth muscle in altered extracellular 
matrix production in asthma. Clin. Exp. 
Pharmacol. Physiol. 28 (3): 233-236. 
[4] Roberts, C. R. (1995) Is asthma a fibrotic 
disease? Chest 107 (3) Suppl.: 111-117. 
[5] Shah, P. K. (2000) Plaque disruption and 
thrombosis: potential role of inflammation and 
infection. Cardiol. Rev. 8: 31-39. 
IMMUNOLOGY - 177 
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RECEPTOR IN HUMAN LUNG EPITHELIAL CELLS 
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The underlying molecular events 
triggered by Chlamydia pneumonia in the host 
cell that lead to chronic infection are not well 
understood. In addition to macrophages and 
lymphocytes, Chlamydia pneumoniae 
preferably attaches to and infects epithelial 
cells. Our earlier findings suggest that 
Chlamydia pneumoniae infection is capable of 
inducing several transcription factors including 
AP-1, NF-IL6 and NFkB, and the 
glucocorticoid receptor (GR) in human 
epithelial cell lines. Here we confirm that in 
vitro infection with Chlamydia pneumoniae 
activates the hosts' GR. 
Translocation/activation of the GR was 
demonstrated by Western-blotting and 
confirmed by DNA mobility shift assay using 
the glucocorticoid responsive element (GRE). 
The kinetics of the cytosol-nucleus 
translocation of the GR was identical in both 
assays and occurred 3 - 6 hours after infection 
with Chlamydia pneumoniae. Interestingly, 
different cell lines showed specific kinetics of 
the GR activation. To confirm the functionality 
of the activated GR used a GR driven 
luciferase reporter gene construct containing 
the promoter of the human p21Waf/Cip"' gene. 
Two human lung epithelial cell lines were 
transiently transfected with the reporter gene 
construct and infected with Chlamydia 
pneumoniae 6 hrs later. After an additional 
incubation time of 24 at standart conditions a 8 
- 1 2 fold increase in luciferase activity was 
observed in infected cells. 
Our data suggests that Chlamydia 
pneumoniae is capable of activating the hosts' 
GR. Further studies are needed to investigate 
the possible role of the GR in the biology of 
Chlamydia pneumoniae and its possible role in 
chronic infection. 
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C. pneumoniae is able to survive and 
multiply in several cell types including 
monocyte-macrophages. To get information on 
possible individual differences in the 
susceptibility to C. pneumoniae infection, we 
infected macrophages from healthy blood 
donors in vitro and compared these findings to 
the presence of IgA and IgG anti-chlamydial 
antibodies in serum. 
Adherent human mononuclear cells 
were isolated from buffy coats of 281 healthy 
blood donors (210 men, 71 women, aged 45.2 
± 11.4 and 44.1 + 14.9 years, respectively, 
kindly provided by Finnish Red Cross Blood 
Service permission no 48). After growing for 
two weeks, the cell cultures were infected with 
0.25 inclusion forming unites/macrophage of 
C. pneumoniae K7 strain and further incubated 
for 76 h at 35 °C in 5% C02 . The inclusions 
were counted after staining with fluorescein-
labelled monoclonal antibody against 
chlamydial LPS using UV-microscope. C. 
pneumoniae antibodies were determined with 
microimmunofluorescence. 
The production of C. pneumoniae 
inclusions in infected macrophages was highly 
variable from 0 to 3000 inclusions per culture. 
The study group was subdivided into quartiles 
according to the inclusion production (ranges 
of each quartile (Q) being QI: 0-9, QH: 10-55, 
QHI: 56-198 and QIV: 199-3000 inclusions). 
The presence of either high anti-chlamydial 
IgA (=40) or IgG (=128) or both of them 
associated positively with the inclusion 
production (QI vs. QH, p=0.181, QI vs. QHI, 
p=0.014, QI vs. QIV, p=0.014 and QI vs. QH-
QIV, p=0.014, Fisher's exact test). The p-value 
for this trend was 0.009 (linear by linear 
association test). In the QIV men produced 
more inclusions than women ( mean ± S.E., 
744+73 vs. 524+62 inclucions, respectively, 
p=0.025). The age did not associate with the 
production of inclusions. 
The individual susceptibility of 
macrophages to C. pneumoniae infection was 
highly variable. High infectivity was 
associated with high serum IgG and/or IgA 
antibody levels to C. pneumoniae. The results 
suggest that the persons, whose macrophages 
cannot restrict chlamydial growth, are more 
susceptible to C. pneumoniae infection. 
Further studies are needed to elucidate genetic 
factors affecting these individual differences in 
the susceptibility to C. pneumoniae infection. 
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CLINICAL DISEASES 

CHLAMYDIA AND RESPIRATORY INFECTIONS; SOME RECENT 
OBSERVATIONS 
Pekka Saikku 
Department of Medical Microbiology, University of Oulu, Finland 
I am presenting in this review some 
controversies and new observations on 
chlamydial respiratory tract infections. 
Diagnosis 
Since the discovery of psittacosis, the 
diagnosis of chlamydial pneumonia has been 
based on serology, which in the beginning 
was complement fixation test. Isolation of C. 
psittaci is difficult and with an air-borne 
pathogen there is always a danger of 
laboratory infections and contaminations. 
After the advent of miro-
immunofluorescence (MIF) test by Wang and 
Grayston, it became possible to demonstrate 
that vast majority of so-called psittacosis 
cases were actually caused by C. 
pneumoniae. Moreover, quite recently, it has 
been shown serologically that some C. 
psittaci cases are in fact caused by C. felis 
(Marrie et al., 2003), and this finding has also 
been confirmed with PCR (Corsaro et al. 
2002). In suspected C. psittaci cases, other 
sick pets in addition to cagebirds should also 
be sought for. 
Several laboratories have noticed that the 
isolation of C. pneumoniae is difficult to 
perform especificially from throat samples. In 
the beginning, there were claims that 
analogously to urethritis or cervicitis caused 
by C. trachomatis, the diagnosis of C. 
pneumoniae pneumonia should be based on 
isolation. Confusion due to the published 
reports on the discrepancies between 
isolations and serology delayed the 
acceptance of the agent as a true respiratory 
pathogen (Grayston et al., 1993). In 2002, 
recommendation for the diagnosis of C. 
pneumoniae pneumonia was given and it was 
based on the seroconversion in MIF test 
between paired serum samples (Dowell et al, 
2001) and nowadays C. pneumoniae is 
generally accepted as an important pathogen 
in pneumonia cases (ATS 2001, Bartlett et al. 
2000, Huchon & Woodhead 1998, BTS 
2001), although different opinions have also 
been presented (Ewig S & Torres A, 2003). 
The MIF test demands technical skills and 
several commercial EIA kits have appeared 
on the market and they seem to be applicaple 
for testing of paired sera in acute infections 
(Persson & Boman, 2000). 
Nucleic acid amplification tests have 
confirmed the earlier seroepidemiological 
findings that majority of C. pneumoniae 
infections are asymptomatic (Hyman et al. 
1995, Schmidt et al. 2002). Transient carriage 
especially during winter months and without 
serological response seems to be common 
phenomenon in small children (Schmidt et al. 
2003). In addition to the carriage problem, 
the lack of sputum specimens in pneumonia 
cases since the cough is often dry in 
chlamydial pneumonia, makes the diagnosis 
by nucleic acid amplification tests 
problematic. 
The tests for the detection of urinary antigens 
are nowadays commonly used in the 
diagnosis of legionellosis and also 
pneumococcal pneumonia. So far no studies 
on the possible antigen excretion into urine in 
chlamydial pneumonia have been published. 
Treatment 
Mixed infections are common in pneumonia 
caused by C. pneumoniae. In these cases, it is 
uncertain, if the ciliostatic action of 
chlamydia (Shemer-Avni & Lieberman, 
1995, Mogilevski et al. 2002) has only aided 
the accompanying agent into the pulmonary 
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tissue and chlamydiae does not participate in 
the actual process. Lack of circulating 
chlamydial immune complexes in some 
mixed infection cases points to this 
possibility (Leinonen & Saikku, unpublished 
observations). Although macrolides, 
tetracyclines and newer fluoroquinolones are 
recommended in the treatment of chlamydial 
pneumonias, beta-lactame antibiotics have 
also been used with some success. In these 
cases, it is possible that chlamydiae have not 
invaded into lungs. On the other hand, 
complete chlamydial cycle includes steps 
sensitive for penicillin (Brown WJ, Rockey 
DD, 2000)., and amoxicillin has even been 
suggested for the treatment of C. trachomatis 
infection during pregnancy (Crombleholme et 
al. 1990). Lack of rapid inexpensive 
diagnostic methods has hampered overall 
targeted treatment of pneumonias. 
C. trachomatis pneumonitis 
No new observations on C. trachomatis 
pneumonitis has been published, but there are 
two recent reviews on the well-characterized 
infant pneumonitis caused by C. trachomatis 
(Numazaki 2004, Hammerschlag 2004). 
Other respiratory tract infections 
There are a few reports of chlamydia-
associated sinuitis, otitis, and pharyngitis, and 
the rarity of these reports suggest that C. 
pneumoniae is not a very important 
etiological agent in these diseases (Cultrara et 
al. 2003). Recently, C. pneumoniae was 
demonstrated in gingival pouches (Mantyla et 
al. 2003) and it seems to be associated to a 
chronic inflammation of parodontal tissue 
(Worm et al. 2004). The possible presence of 
this pathogen in saliva has not been studied. 
Pathogenesis of chlamydial pneumonias 
Pathogenesis of chlamydial pneumonias has 
been studied recently in new animal models 
e.g. in pigs and rabbits (Sachse et al., 2004, 
Gieffers et al.2004). After initial period of 
neutrophil infiltration, mononuclear cells 
start to dominate. The agent is able to 
multiply in alveolar macrophages, and it has 
been reported that C. pneumoniae can be 
found in alveolar macrophages of 44% 
accidentally died young persons (Wu et al. 
2000). Macrophages transmit the agent to the 
lymphnodes and infect monocytes, which 
then can transmit the agent all over the body 
(Gieffers et al. 2004). In mice, genetic 
background and infectious dose effect the 
outcome (Huang et al. 2002). The studies on 
the genetic susceptibility for cahlamydial 
pulmonary infections in humans have just 
been started (Wu et al. 2004) 
C. pneumoniae in asthma 
C. pneumoniae and Mycoplasma pneumoniae 
have both been associated to asthma even so 
strongly that macrolide treatment has been 
recommended in this disease (Cazzola et al. 
2004). However, large intervention trials are 
lacking and in the report published so far 
(Black et al, 2001) results were inconclusive. 
New markers in chlamydia-associated asthma 
include chlamydial Hsp60 (Huittinen et al. 
2001) and slightly elevated C-reactive protein 
levels (Savykoski et al., 2004). 
Since the immunosuppressive drugs used in 
severe asthma could in long term affect 
unfavourably on chronic chlamydial 
infection, the role of chlamydia in asthma 
should be thoroughly studied. 
Chlamydia and COPD 
COPD is nowdays one of the leading causes 
of death, but has remained relatively 
unstudied. Patients are usually smokers but 
not all smokers develop the disease. Chronic 
C. pneumoniae infection can be one 
component in this disease process and there 
is a report that in COPD, immune defence 
against this pathogen is altered (Rupp et al., 
2003). During COPD exacerbations, the 
agent is repeatedly found in sputa and this 
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offers a possibility to differentiate between 
reinfection or reactivation. Recently, there 
have been claims that after fluoroquinolone 
treatment, COPD exacerbations are less 
frequent and the time interval between 
episodes prolonged, although there is no 
difference in bacterial clearance when 
compared to other antibiotics. Whether this is 
due to the sensitivity of chronic chlamydial 
infections to fluoroquinolone treatment 
suggested in a few studies (Meier et al. 1999, 
Erkens et al. 2002) is not known at present. 
New chlamydial species 
Nucleic acid analysis has revealed numerous 
environmental chlamydia around us. There 
are already some reports on their association 
with clinically manifest diseases. (Greub & 
Raoult 2002, Friedman et al. 2003). 
Multiplication inside amoebae may increase 
resistance for alveolar macrophages (Greub 
& Raoult, 2004), a well described 
phenomenon in legionellosis. The new 
chlamydia-like agents have thus a high 
pathogenic potential and they should be 
studied further. 
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STIMULATION OF LOX-1 EXPRESSION IN SMOOTH MUSCLE CELLS 
FOLLOWING CHLAMYDIA PNEUMONIAE-INFECTION AND ITS DOWN-
REGULATION BY FLUVASTATIN 
Dirk Prochnau1 , Jürgen Rödel2, Katrin Prager2, Dana Kuersten3, Eberhard Straube2, 
Hans-Reiner Figulla1 
1 2 
Clinic of Internal Medicine, Department of Cardiology, Institute of Medical Microbiology, and 
Institute of Molecular Cellbiology, Friedrich Schiller University, Jena, Germany 
Chlamydia pneumoniae infection is 
associated with atherosclerotic plaque 
development. Atherosclerotic lesions are 
characterised by accumulation of lipids and foam 
cells that arise from macrophages and smooth 
muscle cells (SMC). Oxidized low-density 
lipoprotein (oxLDL) is believed to be a key 
atherogenic component in this process. 
Accumulation of oxLDL plays a central role in the 
progression of atherosclerosis and may also 
promote plaque instability. oxLDL can enter cells 
by alternative scavenger receptors. A number of 
these cell membrane proteins that can bind oxLDL 
with high affinity have been identified on the 
surface of macrophages, endothelial and smooth 
muscle cells. Among them, the new lectin-like 
oxLDL receptor (LOX-1) was found in human 
endothelial cells and more recently in SMC. LOX-
1, a type II membrane protein with a C-type-lectin-
structure at the C-terminus, is induced by 
proinflammatory stimuli, such as shear stress, 
TNF-a, LPS and oxLDL. Recently, C. pneumoniae 
has been shown to induce human macrophage 
foam cell formation in the presence of LDL and to 
accelerate atherosclerotic plaque development in 
hyperlipidemic rabbits and mice. However, the 
mechanism of lipid uptake has not been specified. 
Our study was designed to examine whether LOX-
1 expression is stimulated by C. pneumoniae and 
whether its expression can be modified by statins. 
Human vascular SMC (VSMC) were 
subcultured in SMC growth medium 2 with 
supplements (PromoCell). Before infection, 
confluent SMC were maintained in basal medium 
containing 1 % FCS but no antibiotics for 72 h. 
SMC were infected with C. pneumoniae TW-183 
by centrifugation at 4,000 x g at 37°C for 45 min 
(MOI 0-10) and further incubated with basal 
medium containing 1 % FCS but no antibiotics. 
For heat inactivation, chlamydial suspensions were 
held at 75°C for 10 min prior inoculation onto cell 
monolayers. For UV inactivation, chlamydial 
suspensions were placed under a UV lamp (15 W 
at 30 cm) for 15 min. mRNAs were analysed by 
reverse transcription (RT)-PCR analysis. cDNA 
was amplified for pyruvate dehydrogenase (PDH) 
as reference. For immunoblotting lysates were 
separated by SDS-PAGE and transferred to 
nitrocellulose membranes. LOX-1 was detected by 
a purified goat polyclonal antibody oxLDL R-l 
(Santa Cruz Biotechnology, Inc.). For inhibition 
experiments cells were incubated with fluvastatin 
(Novartis) following infection. 
RNA levels were measured 6, 24 and 48 h 
after infection. Using RT-PCR we found low 
levels of L O X t I mRNA in mock-infected cells 
over a 48-hour period. After infection with C. 
pneumoniae LOX-1 mRNA expression was 
stimulated in a dose and time dependent manner, 
whereas the amount of PDH remained unchanged. 
After heat and UV light treatment of the 
chlamydial inoculum the level of LOX-1 mRNA 
was reduced to that of mock-infected cultures. 
LOX-1 protein (48 kDa) expression was also 
increased in response to chlamydial infection at 24 
h after infection. 
After pre-treatment of VSMC with 10 pM 
Fluvastatin LOX-1 mRNA expression was 
decreased below the baseline level of LOX-1 
mRNA in mock infected cells. 
C. pneumoniae infection stimulates the 
expression of LOX-1 in VSMC. This stimulation 
requires viability of bacterial organisms. C. 
pneumoniae may contribute to continued lipid 
accumulation in atherosclerotic lesions by up-
regulating the expression of LOX-1 in infected 
cells. Together with the widespread expression of 
LOX-1, this might contribute to the epidemiologic 
link between C. pneumoniae infection and 
atherosclerosis. The effect of lowering the LOX-1 
expression by Fluvastatin may provide a 
pharmacological option of limiting oxLDL uptake 
via this scavenger receptor. 
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IS IT POSSIBLE TO DISTINGUISH BETWEEN CHLAMYDIA PNEUMONIAE 
PNEUMONIA AND BACTERIAL PNEUMONIA? 
Naoyuki Miyashita, Hiroshi Fukano, Koichiro Yoshida, Yoshihito Niki 
Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, Kurashiki, 
Japan 
The Japanese Respiratory Society 
(JRS) published its guidelines for the 
management of community-acquired 
pneumonia (CAP) in 2000 (1). A recent study 
found that the frequency of drug-resistant 
Streptococcus pneumoniae has been increasing 
gradually in Japan. Further, the JRS 
recommends the restriction of quinolone usage 
to prevent an increase in quinolone-resistant 
strains. Based on these facts, the JRS proposed 
a differential diagnosis between bacterial 
pneumonia and atypical pneumonia for the 
selection of an appropriate antibiotic for the 
management of mild-to-moderately severe 
pneumonia. In this study, we assessed the 
Japanese CAP guidelines with regard to 
whether we could distinguish pneumonia with 
atypical pathogens from pneumonia with 
bacteria. 
Five hundred ninety-eight adults 
patients with CAP were enrolled in this study. 
Among all CAP cases, 91 cases of Chlamydia 
pneumoniae (53 cases were pure- and 38 cases 
were mixed-C. pneumoniae), 103 cases of 
Mycoplasma pneumoniae (86 cases were pure-
and 17 cases were mixed-M pneumoniae) and 
144 cases of bacterial (5. pneumoniae and/or 
Haemophilus influenzae) pneumonia were 
analyzed. 
The guidelines set up nine parameters 
and criteria for the differential diagnosis. In 
both atypical pneumonias, high prevalence 
rates were observed in the nine of six 
parameters. The accordance rate for a 
suspected atypical pneumonia with the 
guideline criteria was 84.8% in pure-M. 
pneumoniae pneumonia and 60.3% in pure-C. 
pneumoniae pneumonia, but only 9.0% in 
bacterial pneumonia, 12.1% in mixed-C. 
pneumoniae pneumonia and 16.6% in mixed-
M. pneumoniae pneumonia. 
It is well known that differentiation 
between atypical and bacterial pneumonias is 
not always possible in the initial diagnosis. In 
this study, we assessed the JRS guidelines with 
regard to whether we could distinguish 
between atypical pneumonia and bacterial 
pneumonia and confirmed that about 85% of 
pure-M. pneumoniae and more than 90% of 
bacterial pneumonia could be distinguished 
using the guideline criteria. On the other hand, 
the accordance rate in patients with pure-C. 
pneumoniae pneumonia was 60% and lower 
than that of pure-M pneumoniae pneumonia. 
The different accordance rates between C. 
pneumoniae and M. pneumoniae were based 
on underlying conditions such as age and 
underlying diseases. 
In conclusion, our results indicated that the 
differentiation of pneumonia in the JRS 
guidelines is useful for the diagnosis of M. 
pneumoniae pneumonia as a single etiological 
agent, but difficult to apply to the diagnosis of 
C. pneumoniae pneumonia. 
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DETECTION OF CHLAMYDIA PNEUMONIAE AMONG ELDERLY PATIENTS 
WITH COMMUNITY-ACQUIRED PNEUMONIA 
M. Angélica Martínez*, Ely Jover, Luis Fidel Avendaño, Vivian Luchsinger, Claudia 
Caroca, M.Angélica Espinoza 
Suecia, Santiago, Instituto de Ciencias Biomédicas, Facultad de Medicina and Hospital Clínico, 
Universidad de Chile 
To compare the use of PCR in throat 
washes with serology in paired sera, to 
diagnose C. pneumoniae among elderly 
patients with community-acquired pneumonia 
(CAP). 
From September 2002 to April 2004, 
42 adults >65 years old with a clinical 
diagnosis radiologically confirmed of 
pneumonia were enrolled at the University 
Hospital. Sputum, a throat wash and a serum 
specimen were obtained at the enrollment 
time; a second serum specimen was collected 4 
weeks later. Routine procedures, which 
included Gram staining and culture, were 
performed with sputum specimens. The throat 
wash specimens were processed by PCR for 
bacteria (C. pneumoniae, Mycoplasma 
pneumoniae, Simkania negevensis) and also 
for viral respiratory pathogens (RSV, 
adenovirus, influenza A and B, and 
parainfluenza). DNA for bacterial PCR was 
extracted with QIAamp DNA kit (QIAGEN). 
Sera were tested for IgM and IgG antibodies to 
C. pneumoniae, M. pneumoniae and IgG to 
Legionella pneumophila serogroups 1-4) by 
indirect immunofluorescence (IFI) by using 
commercial available kits. 
The mean age of patients was 75.8 
years (range 63 to 93), and 15(36%) were 
male. Underlying diseases were present in 75% 
patients, being hypertension and diabetes the 
most frequent. An etiologic agent was 
identified in 25 (59.5%) patients. The most 
common pathogens were C. pneumoniae 
(n=ll) , M. pneumoniae (n=8), Streptococcus 
pneumoniae (n=5) and Respiratory syncytial 
virus (n=8), either single or in mixed infection. 
C. pneumoniae was diagnosed in 11 patients, 
including 3 mixed infection cases (2 with M. 
pneumoniae and 1 with RSV). C. pneumoniae 
was diagnosed by serology in 10 cases, 8 of 
them showing seroconversion. A positive PCR 
resulted in only three patients, two of them 
being also positive by serology. Taking in 
account only the acute phase serum, only four 
patients could be considered positives: 2 with 
IgM positive, and 2 with high IgG titer 
(>1:512).) 
Atypical bacterial, as well as RSV, are 
frequent respiratory pathogens in the elderly 
population. C. pneumoniae seems to be an 
important cause of CAP among elderly 
patients in Chile and so far the diagnosis by 
paired serology is better than detection by IgM 
or PCR. 
Grant: 
AMAYOR 02/1-2, Universidad de Chile 
190 - CLINICAL DISEASES 
IS CHLAMYDIA PNEUMONIAE A MISSING LINK IN THE "DUTCH 
HYPOTHESIS" AND CHRONIC NON-SPECIFIC LUNG DISEASE (CNSLD)? 
D.L. Hahn*,1'2 M.B. Plane1 
Dept. Family Medicine, U. Wisconsin Medical School, Madison, WI USA, 2Dean Medical 
Center, Madison, USA 
The "Dutch Hypothesis" states that 
bronchitis, asthma and COPD are a disease 
continuum (chronic non-specific lung disease -
CNSLD) defined by a common host response 
to environmental factors.1 Research has 
traditionally focused on adaptive immunity and 
atopy as a key host characteristic. More 
recently, Chlamydia pneumoniae (Cpn) 
chronic infection has been associated with 
asthma and COPD.2 On this basis it has been 
suggested that Cpn may contribute to the 
pathogenesis of CNSLD and that innate 
immune response to Cpn may be an important 
factor in causation.3 Most published 
associations of Cpn and airways disease have 
focused on asthma and COPD, with less 
known about the relationship of chronic Cpn 
infection and uncomplicated acute bronchitis 
(UAB). Nevertheless, UAB has been 
implicated as a risk factor for the development 
of asthma,4 raising the question whether a 
common etiologic factor is present for 
CNSLD. We therefore studied whether Cpn 
chronic infection is also associated with UAB 
in patients with acute respiratory illnesses 
(ARI). 
We studied 402 outpatients (mean age 
34.2 years) with ARI diagnosed as upper 
respiratory illness (URI, n=115), UAB (n=l 89) 
or acute exacerbations of reactive airways 
disease (RAD, n=98) and obtained acute and 
convalescent serum specimens for Cpn, 
Chlamydia trachomatis (Ct) and Mycoplasma 
pneumoniae (Mpn) antibodies, and throat 
swabs for Cpn culture. Subjects with evidence 
for an acute infection by Cpn, Ct or Mpn were 
excluded. 
Cpn seropositivity (polyvalent MIF titer 
> 1:16) was 47% in URI, 57% in UAB and 
76% in RAD (P-trend <.01 after controlling for 
age, sex, smoking, allergy, Ct and Mpn titers). 
The results are consistent with a 
previous report linking Cpn-specific antibodies 
with the spectrum of respiratory illnesses 
including bronchitis, asthma and COPD 
(CNSLD).5 Defects in innate immunity have 
recently been reported in association with Cpn 
infection in asthma.6 Cpn-specific IgA 
antibodies suggesting chronic infection have 
been associated with both UAB and asthma 
but Cpn-specific hsp60 antibodies were 
associated only with asthma.7 Thus, 
development of asthma instead of just UAB 
after acute Cpn infection may depend on, in 
addition to chronic infection, a pathogenic host 
response involving chlamydial heat shock 
protein-60 (hsp60) that has been implicated in 
the pathogenesis of other chronic chlamydial 
o 
diseases. Taken together, these results suggest 
that research focusing on host innate immune 
response to infectious agents such as Cpn may 
be important to understand the 
etiopathogenesis of CNSLD. 
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CHLAMYDIA PNE UMONIAE-S PEC I FI C IGA ANTIBODIES PREDICT 
WORSENING ASTHMA SYMPTOMS IN ADULTS 
D.L. Hahn*,1'2 M.B. Plane,1 O.S. Mahdi,3 G.I. Byrne3 
Dept. Family Medicine, U. Wisconsin Medical School, Madison, WI, Dean Medical Center, 
Madison; Dept . Mol. Sciences, U. Tennessee Health Science Center, Memphis, TN, USA 
Chlamydia pneumoniae (Cpn)-specific 
IgA antibodies have been suggested as 
seroepidemiological markers for chronic lung 
infection in asthma. We sought to determine 
whether, in patients with persistent asthma, 
baseline IgA would predict future asthma 
symptoms and whether 6 weeks treatment with 
the azalide macrolide, azithromycin, would 
decrease levels of post-treatment IgA. 
We performed a pilot community-
based, multi-site, randomized, allocation-
concealed, triple blinded (patient, physician, 
data analyst), placebo-controlled trial of 6 
weeks adjunctive treatment with azithromycin 
in 45 adults (18 years of age and older) with 
stable, persistent asthma. Treatment was 
azithromycin, one 600 milligram tablet daily 
for 3 consecutive days, followed by 600 
milligrams weekly for an additional 5 weeks 
(total dose 4800 milligrams) or identical 
placebo (1:1 allocation). Outcomes were 
assessed 3 months after completion of 
treatment, Cpn-specific IgG and IgA 
antibodies against whole EBs were measured 
by ELISA as described previously.1 Antibody 
data (as OD units) were analyzed using 
Pearson correlation and linear regression to 
examine variation between repeat 
measurements on the same sample and within 
patient changes over time. 
IgA measurements on the same samples 
tested on different days were highly correlated 
(R=0.993, P<0.0001). Among all baseline 
variables, only treatment allocation and IgA 
antibody were significantly associated with 
overall asthma symptom changes. Baseline 
IgA: After controlling for treatment allocation, 
higher baseline serum IgA ELISA OD values 
were associated with overall asthma symptom 
worsening (P=0.03). Baseline IgG was not 
associated with symptom changes (P=0.63). 
Post-treatment IgA: The correlation between 
patient baseline and follow up levels was 0.967 
(P<0.0001) and there was no significant 
difference between azithromycin and placebo 
groups (P=0.62). Azithromycin: After 
controlling for antibody level, age, sex, 
smoking, skin test status, infectious onset, age 
of asthma onset, asthma severity, and change 
in controller medication use, azithromycin 
significantly (P<0.01) improved overall asthma 
symptoms. This improvement attributable to 
azithromycin was 14% in patients with low 
levels of baseline IgA antibodies, compared to 
28% in patients with high levels (P=ns). No 
comparable differences were present for IgG. 
Cpn-specific antibodies have been 
associated with asthma severity in cross-
sectional studies.2 In our prospective study, 
IgA also predicted worse asthma symptoms at 
follow up, raising the possibility that treatment 
of chronic infection might improve asthma. 
Indeed, azithromycin significantly improved 
symptoms, but larger trials must be performed 
to provide conclusive results. We were unable 
to demonstrate any significant decrease in 
C/w-specific IgA after 6 weeks treatment with 
azithromycin. In acute, uncomplicated 
genitourinary infection, loss of organism-
specific IgA can correlate with microbiologic 
eradication of Chlamydia trachomatis.3 
Eradication of chronic chlamydial infections 
are more problematic and we suggest 
measuring IgA antibodies after longer 
treatment courses. 
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THE JOINT EFFECT OF CHLAMYDIA PNEUMONIAE INFECTION AND 
MANNOSE BINDING LECTIN MUTATION IN DEVELOPMENT OF 
BRONCHIAL ASTHMA IN CHILDHOOD 
Adrienne Nagy MD1*, Gergely T Kozma MSc2, Márton Keszei MSc2, András Treszl 
PhD3, András Falus DSc2,4, Irén Budai MD5, Csaba Szalai PhD4'6 
'Budai Children's Hospital ; department of Genetics, Cell- and Immunobiology, Semmelweis 
University; 31st Department of Pediatrics, Semmelweis University; 4Section of Molecular 
Immunology, Hungarian Academy of Sciences; 5Institute of Medical Microbiology, Semmelweis 
University; 6Heim Pál Pediatric Hospital 
Although several studies found 
associations between infection with Chlamydia 
pneumoniae (C. pneumoniae) and asthma, 
these were mainly restricted to the 
exacerbation of the symptoms in adults with 
known asthma. Data about the role of C. 
pneumoniae in the initiation and development 
of asthma in children are controversial. 
We investigated the role of C. 
pneumoniae infection in 139 children with 
asthma comparing them with 174 healthy 
controls. Furthermore, we studied the 
modifying effect of mannose-binding lectin 
(MBL) variant alleles on the susceptibility to 
asthma in children infected with C 
pneumoniae. C. pneumoniae-specific 
antibodies were measured by ELISA, MBL 
genotypes were determined by PCR-RFLP. 
There were no significant differences in 
the percentage of children positive for C. 
pneumoniae-specific antibodies between cases 
and controls. Among asthmatic children 
carrying variant MBL alleles there were 
significantly more patients positive for C. 
pneumoniae-specific IgG, than among control 
children with variant MBL genotypes, 
respectively. Infected children with variant 
MBL alleles were found to have a higher risk 
of developing asthma than infected children 
with normal MBL genotype. This risk was 
especially high in children with chronic or 
recurrent infection (positive for both IgA and 
IgG), but no increased risk was seen in 
children with current C. pneumoniae infection 
(positive for IgM). 
This study indicates the important role 
of variant MBL alleles in the susceptibility to 
asthma in children infected with C. 
pneumoniae. Our result represents a non-linear 
gene-environment interaction in the 
pathomechanism of asthma. 
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CHLAMYDIA PNEUMONIAE RESPIRATORY TRACT INFECTION IS NOT 
ASSOCIATED WITH INITIATION OF ASTHMA, ALLERGIC RHINITIS OR 
ATOPIC ECZEMA IN CHILDREN 
Sebastian M. Schmidt*, Cornelia E. Müller, Siegfried K.W. Wiersbitzky 
Children's and Youth Hospital, Department of Infectious, Bronchopulmonary and Allergic 
Diseases, Ernst-Moritz-Arndt University, Greifswald, Federal Republic of Germany 
Objective: To evaluate the role of 
chlamydia (C. pneumoniae) respiratory tract 
infection on initiation of pediatric asthma, 
allergic rhinitis or atopic eczema. 
Children of three age-groups (n=1211) 
were prospectively studied for C. pneumoniae 
infection using throat swabs and polymerase-
chain reaction with enzyme immunoassay 
detection. Infected children (= study group, 
SG) were monthly examined until the agent 
could not be detected, quantifying persistent 
infection. Randomly selected, noninfected 
children matched for age, gender and origin 
served as control group (CG) regarding lung 
function and inflammatory parameters as well 
as initiation of allergic diseases judged by 
family doctor diagnosis after, in median, 22 
month. 
At the first follow-up examination, CG-
children revealed a higher frequency of 
obstructive disturbance in lung function tests 
(18/65 versus 6/49, p=0.04). Leucotriene B4 
(median 36 pg/ml vs. 21, p=0.04) and 8-
isoprostane (median 15 pg/ml vs. 12, p=0.04) 
in breath condensate characterizing neutrophil, 
agent related inflammation and oxidative stress 
in the lower airways of C. pneumoniae infected 
children, were elevated in the SG. Cysteinyl 
leucotrienes (acute allergic inflammation) were 
without difference. Immunoglobulin A 
antibodies in throat swabs were higher in 
children after C. pneumoniae infection (optical 
density median 0.7 vs. 0.4, p=0.001) 
confirming PCR-EIA results. At the final 
examination, there was no difference in 
pathological lung function tests, parameters of 
exhaled breath condensate or eosinophilia of 
the nasal mucosa. Incidence of asthma (0/55 
vs. 5/54, p = 0.03) and allergic rhinitis (3/53 
vs. 10/52, p = 0.04, Odds ratio and 95% 
confidence interval-OR 0.25 [0.06;0.98]) as 
well as prevalence of asthma (1/56 vs. 9/58, p= 
0.01, OR 0.1 [0.01;0.81]) and allergic rhinitis 
(6/56 vs. 16/58, p= 0.02, OR 0.32 [0.11;0.88]), 
however, were lower in the S G children. There 
was no association in atopic eczema. Three 
children with persistent infection revealed a 
higher incidence in allergic rhinitis compared 
to those with single C. pneumoniae detection 
(1/3 vs. 2/53, p = 0.03), however, not to the 
CG. 
A C. pneumoniae infection requires for 
eradication of the intracellular growing agent a 
strong Th 1 stimulation. Th 2 immune 
response, typical in asthma, suppresses the Th 
1 response, which might hinder the C. 
pneumoniae eradication. In consequence, one 
would expect a prolonged or persistent C. 
pneumoniae infection. Persistent infection 
would not be the cause but the consequence of 
asthma and other allergic conditions. C. 
pneumoniae might be important in 
exacerbation and prolongation of asthma. 
Nevertheless, individual factors may interfere 
with these results. However, these factors are 
important for single individuals only. 
A C. pneumoniae upper respiratory 
tract infection may not be regarded as a major 
initiator for childhood asthma or allergic 
rhinitis in the population studied. 
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CHLAMYDOPHILA PNEUMONIAE DNA DETECTION IN PERIPHERAL 
BLOOD MONONUCLEAR CELLS IN COPD PATIENTS WITH SYSTEMIC 
GLUCOCORTICOSTEROID TREATMENT. 
M.A. Zuzewicz, A.D.Barela *, M. Przybylski, R. Chazan*, M. Luczak 
Chair and Department of Medical Microbiology, Medical University of Warsaw 
* Chair and Department of Internal Diseases, Pneumonology and Allergology, Medical University 
of Warsaw, Poland 
There are published data indicating that 
COPD patients are infected with 
C. pneumoniae and some scientists consider 
the possibility of C. pneumoniae involvement 
in chronic pulmonologic and cardiovascular 
diseases. Corticosteroid therapy is not well 
defined in COPD, but acording to literature 
data it can improve patients status. The aim of 
the study was to compare the frequency of 
C. pneumoniae DNA detection in peripheral 
blood mononuclear cells (PBMC). Two groups 
were taken into consideration: systemic and 
non-systemic steroid treated subjects. 
Total number of 42 hospitalized patients with 
diagnosed COPD (according to GOLD 
standards) underwent investigation. The data 
about smoking history, cardiovascular disease 
and steroid therapy was collected. Spirometry 
was done within 72 hours before or after blood 
collection. AmpMiniKIT (Qiagen) was used to 
process PBMC semples and PCR was 
performed using method described by Tong 
and Sillis (J.Clin.Pathol.1993: 46; 313). 
In a group of the patients not taking 
systemic steroids, C. pneumoniae DNA was 
detected in 10 (32 %) of the 31 PMBC 
samples. Among 11 systemic steroid treated 
COPD subjects 6 (55 %) were PCR positive. 
These results indicated that systemic 
corticosteroid therapy could be considered as a 
possible agent, which has an influence on 
C. pneumoniae infection in the COPD 
subjects. 
CLINICAL DISEASES - 195 
CHLAMYDOPHILA PNEUMONIAE IN CHRONIC RHINOSINUSITIS 
Marie Edvinsson*, Monica Stenqvist, Eva Hjelm, Christina Nyström-Rosander 
Department of Medical Sciences, Sections for Infectious Diseases and Clinical Bacteriology, 
Deptartment of Surgical Sciences, section for Otolaryngology, Uppsala University Hospital, 
Sweden 
Chlamydophila pneumoniae (Cp) is a 
well-known pathogen in lower respiratory tract 
infections. It has been reported in patients with 
acute sinusitis and otitis media but has been 
less studied in other upper respiratory tract 
infections. Cp has been suggested as an 
immunopathogen in various chronic 
inflammatory diseases. The aim of this study 
was to investigate if an association between 
this pathogen and chronic rhinosinusitis could 
be established. 
Twenty-five consecutive patients with 
X-ray verified chronic rhinosinusitis and 10 
age-matched controls were included in the 
study. Samples for C. pneumoniae PCR were 
collected from throat and nasopharynx and 
biopsies were taken from the concha media. 
DNA was extracted from these specimens and 
analyzed with two different PCR-methods; 
touch-down PCR and real-time PCR both 
being directed against the chlamydial ompA 
gene. Serum samples were taken and tested for 
C/?-specific IgM, IgG and IgA antibodies by 
the microimmunofluorescence technique 
(MIF). Throat and nasopharyngeal samples 
were examined for growth of other respiratory 
pathogens by conventional methods. Patients 
or controls that tested positive for Cp by PCR 
in any sample and/or had high antibodies titres, 
were treated with 200mg Doxycycline daily for 
2 weeks. New throat, nasopharyngeal and 
serum samples were taken from these patients 
a minimum of four weeks post antibiotic 
treatment. 
DNA from Cp was found by both PCR 
methods from two of the patients and none of 
the controls. The bacteria were found in 
samples from the nasopharynx but could not be 
detected in throat samples or tissue biopsies 
from any of the patients or controls. Cp-
specific IgM, IgG and IgA antibodies were 
present in 1/25, 17/25 and 16/25 patients, 
respectively, and in 0/10, 2/10 and 1/10 
controls. Cp-specific IgM antibodies were 
found in one of the PCR-positive patients. 
Results from the bacterial cultures will be 
presented on the poster. 
In this study, using PCR detection in 
tissue biopsies, we were not able to establish a 
patho-etiological role for Cp in chronic 
rhinosinusitis. However, serological data 
showed an increased seropositivity rate to Cp 
in the patient group. In one of the patients, IgM 
antibodies to Cp and PCR-positivity in the 
nasophayngeal sample indicated an ongoing 
acute rhinosinusitis; in that patient Cp could 
not be found by PCR in the tissue biopsy. 
Further studies on the possible relation of Cp 
to chronic sinusitis are warranted. 
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FAILURE TO DETECT CHLAMYDOPHILA (CHLAMYDIA) PNEUMONIAE IN 
CHRONIC PHARYNGITIS 
Kenneth Persson*1, Jens Boman2, Lucyna Schalen3 and Rolf Uddman4 
Department of 1 Clinical Microbiology, 4Otorhinolaryngology, Malmö University Hospital, Malmö, 
Department of Clinical Virology, Umeä University Hospital, Umeä, Department of 
Otorhinolaryngology, Lund University Hospital, Lund, Sweden 
Chlamydophila pneumoniae (Cpn) has 
been associated with acute respiratory tract 
infections including sore throat. The organism 
has also been found by PCR and cell culture by 
pharyngeal swabs from patients with chronic 
pharyngitis (1). We have examined a group of 
patients with this condition with cell culture 
and PCR. 
Cell culture was performed on HEp2 
cells with one blind passage. The acetone-fixed 
cells were examined by immunofluorescence 
microscopy using a monoclonal antibody 
specific for Cpn. 
PCR was performed in two different 
laboratories with two different PCR protocols 
both targeting the MOMP gene. 
Pharyngeal swabs were obtained from 
29 adult patients with pharyngitis of long 
duration. All these samples were examined by 
cell culture. Cpn could not be demonstrated in 
any of these samples after one blind passage. 
Nested PCR was performed on 25 of these 
samples in one laboratory and on 23 of these 
samples in a second laboratory. No positive 
sample could be demonstrated in any of the 
two laboratories. 
Cpn could not be detected in any of our 
patients with chronic pharyngitis by cell 
culture or nested PCR performed in two 
different laboratories using two different 
protocols for DNA extraction and PCR. 
Positive findings previously reported could not 
be confirmed in this study. 
Reference 
Falck G, Heyman L, Gnarpe J, Gnarpe H. 
Chlamydia pneumoniae and chronic 
pharyngitis. Scand J Infect Dis. 1995; 
27:179-82. 
CLINICAL DISEASES - 197 
ANTIBODIES TO CHLAMYDOPHILA (CHLAMYDIA) PNEUMONIAE IN LUNG 
CANCER PATIENTS 
Persson K1*, Nilsson J1 and Lindgärde F2 
Department of 'Clinical Microbiology and Department of 2Vascular and Renal diseases, Malmö 
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Chlamydophila pneumoniae has been 
associated with lung cancer in six previous 
reports. In two of the studies the sera were 
obtained several years before cancer was 
diagnosed and in four other studies a case-
control design was used. Patients generally had 
more IgG or IgA antibodies to C. pneumoniae 
than controls. In some studies this pattern was 
observed only among patients younger than 56 
or 60 years of age. In this study patients with 
lung cancer were identified from a health-
screening programme where sera collected 
several years before detection of the disease 
were available. 
From a group of middle-aged men 
attending a health-screening programme from 
1974 through 1982 patients who had 
developed cancer were identified at a follow-
up of the group in 1988. From these patients a 
subgroup of 68 cases with lung cancer was 
identified. Two age-matched controls to each 
index case were included. 
Serum had been saved from the original visit 
and was thus available for serological study. 
Antibodies to C. pneumoniae (Cpn) were 
measured by microimmunofluorescence (MIF). 
For comparison we also tested for antibodies 
to rubella virus by a commercial Elisa kit, 
Enzygnost® Anti-Rubella-virus/IgG (Dade 
Behring, Marbug GmbH, Marburg, Germany). 
IgG and IgA antibodies to Cpn were 
analysed among 68 male patients with lung 
cancer and in 136 controls matched for age and 
gender. In a logistic regression analysis 
smoking, Cpn IgG and IgA were associated 
with lung cancer. After adjustment for 
smoking Cpn IgG antibodies were still an 
independent predictor of lung cancer while 
Cpn IgA antibodies were not. Antibodies to 
rubella virus were also measured as an 
independent control. These antibodies were not 
associated with lung cancer. 
Cpn antibodies at moderate to high 
titres were independently associated with lung 
cancer long before the cancer diagnosis was 
established. Cpn antibodies were specifically 
associated with lung cancer as the rate of 
rubella antibodies was similar in patients and 
controls. 
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CHLAMYDIA PNEUMONIAE INFECTION IS ASSOCIATED WITH SUBTYPES 
OF NON-SMALL CELL LUNG CARCINOMA 
*M. Gencay, M.P. Bihl, U. Egermann, M. Roth, M. Tamm 
University Hospital, Basel, Switzerland 
Infection with Chlamydia pneumoniae 
is discussed as a co-factor for COPD and 
asthma. An association of Chlamydia 
pneumoniae infection with lung carcinoma has 
been suggested. Here we report an association 
of chronic Chlamydia pneumoniae infection 
with squamous and large cell carcinoma of the 
lung. 
Serum samples were collected from 46 
patients (16 adeno-carcinoma, 19 squamous 
cell carcinoma, 11 large cell carcinoma) and 46 
age, sex, and locality matched controls.A 
commercially available MIF test (Orgenium, 
Finland) was used for the detection of IgG, 
IgM and IgA class antibodies. Serial sections 
of the tumour tissue of serology positive 
patients were prepared for 
immunohistochemistry (IHC) staining and 
nested-PCR. 
Anti-C. pneumoniae IgG antibodies 
were found in 80.4% of NSCLC patients 
versus 67.4% in controls. 56.5% of NSCLC 
patients had anti-Chlamydia pneumoniae IgA-
antibody titres 1:40, compared to 19.5% in 
controls. Patients with squamous cell 
carcinoma or large cell carcinoma, except one, 
had either IgG 1:256 or IgA 1:80. Combined 
high IgA and IgG titres were observed in 
81.8% of large cell and in 63.2% of squamous 
cell carcinoma compared to 12.3% in adeno-
carcinoma and in 6.5% of controls. Chlamydia 
pneumoniae infections were confirmed by IHC 
in tissue sections of 29 patients, and in 4 of 
these by nested PCR. 
This study provides evidence of 
association of chronic Chlamydia pneumoniae 
infection with squamous and large cell lung 
carcinoma by serology, IHC, and nested PCR. 
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PULMONARY CHLAMYDIA PNEUMONIAE INFECTION FOLLOWING 
LUNG TRANSPLANTATION 
*M. Gencay, M. Tamm, Ch. Aboyoun, M. Malouf, S. Rainer, M. Roth, A. Glanville 
Cardiopulmonary Transplant Unit, St. Vincent's Hospital and Department of Pharmacology, 
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Chlamydia pneumoniae is one of the 
most common respiratory pathogens and has 
been associated with bronchial and vascular 
inflammatory processes. To our knowledge, 
the role of acute or chronic C. pneumoniae. 
infection following lung transplantation has 
not yet been studied in detail. Aim of this 
study was to determine the incidence of C. 
pneumoniae infection after lung 
transplantation. 
We studied 50 lung transplant 
recipients who were undergoing bronchoscopy 
with bronchoalveolar lavage (BAL) either as a 
diagnostic procedure in symptomatic patients 
or as a surveillance or follow-up procedure. A 
total of 130 BAL samples from the 50 lung 
transplant patients were analysed. In 22 out of 
50 patients serial BAL were available from the 
immediate postoperative period. 
Antibodies to C. pneumoniae 
A commercially available MIF test (Orgenium, 
Finland) for the detection of C. pneumoniae 
specific IgG, IgM and IgA antibodies was used 
according to the manufacturers instructions. 
C. pneumoniae specific DNA 
C. pneumoniae-specific DNA using PCR was 
detected in BAL samples of 36% (8/22) of the 
patients tested within the first 4 weeks of 
surgery. BAL samples of all these 8 patients 
became negative after 1 month. In another 11 
patients C. pneumoniae PCR was positive in 
the BAL later than one month after 
transplantation and associated with symptoms 
or recurrent rejection. 
Antibodies to C. pneumoniae 
Serum samples were not available from all 
transplant patients at the time that the 
serological part of this study was performed. 
Serum samples of five PCR positive lung 
transplant patients contained high titers of IgA 
antibodies against C. pneumoniae. One of 
these patients had a high titer of IgG antibodies 
together with a high titer of IgA antibodies 
against C. pneumoniae which may indicate 
chronic C. pneumoniae infection. Acute 
infection with IgM positivity was seen in one 
of the PCR positive patients 
Our results suggest that pulmonary C. 
pneumoniae infection is frequent following 
lung transplantation. The clinical importance 
and the type of C. pneumoniae infection 
(reactivation or de novo infection) is yet to be 
determined but our preliminary analysis 
suggests that ongoing infection is deleterious 
to graft function and may be associated with 
both acute rejection and inflammatory airway 
disease after lung transplantation. 
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METABOLIC SYNDROME, CRP, AND C. PNEUMONIAE IN A FINNISH 
BIRTH COHORT 
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Markku Savolainen, Liisa Karinen, Marjo-Riitta Järvelin, Maija Leinonen 
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Obesity is nowadays a major health 
problem in industrialized countries. The 
metabolic syndrome associated with obesity is 
considered as a risk factor of cardiovascular 
diseases and type II diabetes. There are recent 
reports that chronic inflammation is associated 
with these conditions1. We studied the 
association of inflammation using serum CRP 
levels measured by high-sensitive assay 
(hsCRP) as a marker and C. pneumoniae 
antibodies in a population of young adults in 
Northern Finland. 
The Northern Finland Birth Cohort 
1966 consists of all children born in 1966 in 
Northern Finland (12058 live births, 6094 
males, 5964 females)2. In 1997, 2740 males 
and 2834 females at age 31 participated in a 
follow-up including postal questionnare, 
clinical examination and blood sampling. 
Morphometric data and serum samples were 
collected from 2740 males and 2834 females. 
Markers of metabolic syndrome (body mass 
index (BMI), systolic (sBP) and diastolic blood 
pressure (dBP), blood leukocytes, fasting total-
, LDL- , and HDL-cholesterol, triglycerides, 
glucose and insulin levels) were measured and 
correlated to CRP levels measured in a high-
sensitive EIA test (IEMA, Medix, Kauniainen) 
and C. pneumoniae IgG and IgA antibodies 
measured by micro-immunofluorescence test. 
Statistical analysis was done by Spearman's 
rank correlation. 
C. pneumoniae antibody levels in males 
were significantly higher than in females (IgG 
GMT 34.3 vs. 23.1, IgA GMT 9.3 vs. 8.7, 
respectively, p < 0.001). In males, all elevated 
markers of metabolic syndrome and lowered 
HDL levels were correlated with elevated CRP 
levels (all p <0.001). Also in females, all the 
markers excluding glucose were correlated 
with elevated CRP levels (all p-values <0.001). 
In males, C. pneumoniae IgG levels were 
positively correlated with hsCRP (p=0.014), 
BMI (p=0.002), dBP (p=0.013), triglycerides 
(p=0.015) insulin (p=0.039), and inversely 
with HDL cholesterol (p=0.022). In males, IgA 
levels were positively correlated with BMI 
(p=0.010), and inversely with LDL (p=0.025) 
and total cholesterol (p=0.043). In females, C. 
pneumoniae IgG antibodies correlated 
positively with BMI (0.004) and systolic blood 
pressure (0.032). In females, IgA levels 
correlated with BMI (0.048) and inversely with 
dBP (0.034) 
In this large population-based cohort of 
unselected young adults, all markers of the 
metabolic syndrome (BMI, sBP, dBP, various 
cholesterol and triglyceride levels and blood 
glucose and insulin levels) were correlated 
with a marker of systemic inflammation, 
hsCRP. Moreover, in both sexes C. 
pneumoniae IgG and IgA antibody levels were 
positively correlated with BMI, and in males, 
IgG levels with hsCRP, dBP, triglycerides, 
insulin and inversely with HDL levels. 
Adulthood risk markers for metabolic 
syndrome can be present already at a relative 
early age and, in some cases, they may be 
associated with a chronic C. pneumoniae 
infection. 
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A POSSIBLE ASSOCIATION OF CHLAMYDOPHILA PNEUMONIAE WITH 
JUVENILE ARTHRITIS 
Martyinova V.R., Kolkova N.I., Zigangirova N.A.*,Golobova E.S., Chistyakova E.G., 
Valieva S.I. 
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Acute and chronic reactive arthritis 
(ReA) in children (juvenile arthritis) are 
triggered by different factors and one of them 
is an extra-articular infection with the so-called 
arthritogenic bacteria, such as, Yersinia, 
Salmonella, Shigella, Campylobacter or 
Chlamydia trachomatis. Within the last 10 
years Chlamydophila pneumoniae has been 
discussed as a possible triggering factor in 
some patients with ReA. In most cases at the 
time of the diagnosis of arthritis the detection 
of resent chlamydial infection is achievable 
only by serological evidence. But to confirm 
the infectious aetiology of ReA detection of 
the chlamydial antigen at the site of primary 
infection or in the synovium is optimal. 
Objective to detect the chlamydial 
infection markers in children with ReA. 
275 patients with juvenile arthritis (4 -
16 years old) were screened for the evidence of 
chlamydial infection. This study has been held 
during 1993-2004 years. Antichlamydial 
antibodies were measured by species specific 
microimmunofluorescence (MIF) test in sera 
and synovium. Antibodies titers of > 1:64 for 
IgG in combination with IgM or IgA (>1:16) 
were considered indicative of chlamydial 
infection. Genus specific chlamydial antigen 
was detected in synovial fluid, speciemens 
from urethra and conjunctiva by direct 
immunofluorescence. 
74% of children enrolled in this study 
had chlamydial infection evidenced due to the 
positive serology or antigen detection. 34 % of 
the patients with juvenile arthritis associated 
with chlamydial infection had high antibody 
titres for C. pneumoniae. 12 % of patients had 
diagnostic antibody titres for C. trachomatis 
and 2 % - for C. psittaci. Chlamydial antigen 
has been demonstrated in synovial fluid of 72 
% of tested patients. 49 % of children had 
antigen in urogenital tract and 36 % - in 
conjunctiva. 
It has been demonstrated that children 
with ReA had high rate of chlamydial infection 
(74%). In most cases anti-C. pneumoniae 
antibodies had been detected. Synovial 
presence of chlamydial antigen in significant 
number of tested patients can indicate that 
these bacteria are responsible for initiation or 
maintenance of juvenile arthritis in some 
patients. 
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THE ROLE OF CHLAMYDIA PNEUMONIAE IN THE PATHOGENESIS OF 
ATHEROSCLEROSIS 
Éva Gönczöl 
Bela Johan National Center for Epidemiology, Budapest, Hungary 
It is commonly accepted that Chlamydia 
pneumoniae (Cpn) is frequently present in the 
form of DNA or antigens in atherosclerotic 
(AT) plaques, but it only rarely detectable in 
healthy areas of the arteries. In addition, the 
results of Cpn seroprevalence studies, 
experimental animal models, and the 
demonstration of some pathological features of 
an AT plaque by the Cpn infection of relevant 
cells in vitro have led to the suggestion that 
AT diseases are associated with Cpn infection. 
Certain aspects of Cpn infections and their 
interactions with various other factors might 
explain how Cpn is involved in the 
pathogenesis of AT. These include: (1) chronic 
infections with Cpn, (2) the host cell gene 
expression after Cpn infection, (3) the 
interaction of Cpn infection with hHSP60, a 
proposed component of autoimmunity in AT, 
and with infections by other pathogens, such as 
cytomegalovirus, (4) the interaction of Cpn 
infection with the genetic background of the 
host, including the mannose-binding lectin 
(MBL) gene allele variabilities, or the genetic 
alterations of lipid metabolism, (5) the 
production of histamine via an increased 
expression of histidine decarboxylase (HDC) 
following Cpn infection, and (6) the genotypic 
differences in the Cpn genome, possibly 
related to vascular tropism and pathogenicity. 
1. Chronic infections. 
The Chlamydiae are associated with many 
chronic human diseases, including trachoma, 
infertility and arthritis. A strong link has also 
been established between Cpn and chronic 
respiratory diseases such as adult-onset asthma 
and the inflammatory process of AT. Many 
lines of evidence point to an altered chlamydial 
state during chronic diseases in humans, 
animal models, and in vitro persistence 
cultures induced by the depletion of essential 
nutrients from cell culture medium, or by the 
exposure of in vitro chlamydial infections to 
cytokines or antibiotics, or by monocyte 
infections, or by continuous culture systems in 
HEp2 cells. These alterations include the 
presence of chlamydial RNA and DNA during 
a culture-negative state, the observation of 
aberrant chlamydial bodies, increased 
resistance to antimicrobials, altered RNA and 
protein levels and potential reactivation to an 
acute infection following immunosuppression. 
These results show that a species-specific 
persistence for the Chlamydiae exists, with a 
unique transcriptional and translational profile 
(8,9). 
2. Human gene expression after Cpn 
expression in endothelial cells and 
monocytes, key in vivo targets of Cpn 
infection and components of AT plaques. 
The upregulation of 20 of the studied 268 
human genes, including the upregulation of 
genes coding for certain cytokines, 
chemokines, growth factors, intracellular 
kinases and cell surface receptors in Cpn-
infected human endothelial cells, was 
demonstrated by a cDNA microarray (5). An 
analysis of more than 2000 unique genes in the 
human monocytic cell line U937 with cDNA 
arrays showed that Cpn significantly influences 
the expression of 128 host cell genes. The 
results demonstrated the the down-regulation 
of cellular genes associated with RNA and 
DNA metabolism, chromosomal stability and 
cell-cycle regulation, such as the Myb 
oncogene and the mini-chromosome 
maintenance protein 7. Genes rapidly 
upregulated after infection include NF-KB, I-
icBa, junB, CEBPB and TNF-a. Genes 
upregulated at later times include NF-KB-
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regulated IL-1, IL-6, MCP-1, MMP-3, 
HBEGF, MIP-ip, G-CSF and MCP-1. Cpn 
infection of U-937 cells also induced the 
expression of chemokine receptors and other 
cell surface molecules, i.e. CD44 and 
TNFAIP6, suggesting that a long-term effect of 
Cpn infection of monocytes could be the 
expression of chemokines that facilitate 
mononuclear cell infiltration. Most 
interestingly, Cpn infection induced the 
expression of genes that have been shown to 
have a considerable impact on the initiation 
and progression of AT, including genes 
associated with lipid accumulation (FABP-4), 
vasoconstriction (ET-1), tissue remodeling 
(MMPs, HBEGF and (3-thromboglobin) and 
coagulation (coagulation factor V and 
plasminogen activator urokinase) (15). 
3-4. Increased levels of serum antibodies to 
hHSP60 and Cpn, independent and joint 
effects, and association of Cpn with 
coronary artery disease (CAD) and with 
MBL variant alleles. 
The association between Cpn infection and 
CAD was first indicated by the study of P. 
Saikku et al. (13). An autoimmune component 
of AT disease has also been proposed, and 
hHSP60 has been postulated to be a putative 
autoimmune antigen (16). The combination of 
the effects of infection and autoimmune 
mechanisms, and the combination of these 
factors with certain host genetic variations, 
might be associated with the development of 
severe AT. Significantly elevated levels of 
antibodies to hHSP60 and Cpn have been seen 
in patients with CAD. Multiple logistic 
regression analysis and subanalyses of selected 
subjects showed that these associations were 
independent of age, sex, smoking and serum 
lipid levels. The antibodies to hHSP60 and 
Cpn did not correlate quantitatively; however, 
the relative risk of disease development was 
substantially increased in subjects with high 
antibody levels to both hHSP60 and Cpn. (1). 
Further, it has been reported that MBL variant 
alleles are associated with the accelerated 
development of severe AT (10). Moreover, 
MBL inhibits the infection of HeLa cells by 
different Chlamydia species, including Cpn 
(14). We reported that a higher percentage of 
patients with CAD were anti-Cpn-positive as 
compared with the control group, but on 
logistic regression analysis adjusted to age, 
sex, and serum levels, this difference was 
found to be confined to subjects carrying MBL 
variant alleles. In contrast, no significant 
difference was seen in those homozygous for 
the normal MBL allele, indicating that 
infection with Cpn leads mainly to the 
development and progression of severe CAD 
in patients with variation in the MBL gene 
(12). An additional example of the association 
of certain genetic variations of the host was 
shown by the demonstration of a persistent 
Cpn infection in the AT lesions in the aorta of 
the apoA-deficient knockout mouse model (4). 
As an environmental component, previous 
cytomegalovirus infection might be a 
predisposing factor for the progression of early 
lesions in the aorta following Cpn infection 
(3). 
5. Increased HDC production in the mouse 
lung following Cpn infection. 
A few studies indicate that histamine 
synthesized in the arterial wall participates in 
the initiation and progression of AT, and that 
IL-4 can act as an important inhibitory and/or 
stimulatory factor in the function of 
monocytes/macrophages modulated by 
histamine in relation to the process of AT. 
Histamine is produced by HDC, which 
generates histamine from L-histidine and has 
been localized in the human coronary artery 
(7). We have demonstrated an increased HDC 
production in Cpn-infected Balb/c mice, 
predominantly in the bronchial epithelial cells 
of the lung, and a higher survival rate of HDC 
knockout mice after Cpn infection. The 
production of cytokines IL-3, EL-6, IL-4 and 
IFN-y in the Qw-infected mouse lung was also 
increased. Although the co-existence of HDC 
and Cpn in the vascular tissue has not been 
documented, these results point to a role of 
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histamine in the pathomechanism of Cpn 2. 
infection (2). 
6. The genotypic differences in the Cpn 
genome. 
A Cpn isolate from the human coronary 
arteries, A-03, was characterized by sequence 
analysis of the MOMP gene (ompl) and 3. 
compared with respiratory strains. The 
sequence analysis of the ompl gene revealed 5 
nucleotide changes. The in vitro production of 
IL-8, MCP-1 and sICAM-1 of A-03 was lower 
in human endothelial cells as compared with 
respiratory strains of Cpn (11). Interestingly, 4. 
respiratory and cardiovascular isolates were 
compared to find genetic differences 
associated with pathogenicity. A polymorphic 
region encoding a tyrosine/tryptophan 
permease (tyrP) was found to differ between 
these isolates; the respiratory strains contained 5. 
multiple copies of the tyrP gene, while the 
vascular strains contained a single copy. It was 
hypothesized that the difference between the 
strains of vascular and respiratory origin may 
be responsible for the increased tendency of 
vascular strains to exhibit persistent infection 6. 
(6). 
Conclusions 
Although proof of a causal relationship 
between Cpn and AT awaits further 7. 
investigations, the increasing volume of 
knowledge available on the complex 
interactions of chronic Cpn infections with 
various host and environmental factors, and on 
the genotypic variations of Cpn strains 
possibly related to pathogenicity, suggests a 
role of Cpn in the pathology of AT. 8. 
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THE EFFECTS OF CHLAMYDIA PNEUMONIAE INFECTION ON HUMAN 
MONOCYTE-DERIVED DENDRITIC CELLS 
Kis, Zia1 Pallinger, E3, Endresz, V2, Huszti Z1, Bunan, K2, Falus, A4, Gonczol, E1 
1 2 
Division of Virology, National Center for Epidemiology, Budapest, Department of Medical 
Microbiology and Immunobiology, University of Szeged, Szeged, 3Molecular Immunology 
Research Group, Semmelweis University, Budapest, department of Genetics, Cell-and 
Immunobiology, Semmelweis University, Budapest, Hungary 
Atherosclerosis is a multifactorial, 
imflammatory disease/Traditional risk factors, 
autoimmune mechanisms and infectious 
agents, especially Chlamydia pneumoniae, 
may contribute to its development. Dendritic 
cells are the most potent antigen-presenting 
cells that play a central and unique role in the 
immune responses. It has been shown that 
dendritic cells are predominantly present at the 
sites of the predilection of atherosclerosis 
plaques in the intima of the arterial vessel wall 
of young children. 
We isolated monocyte populations 
from peripheral blood mononuclear cells of 
healthy blood donors by an adherence method, 
and treated them with granulocyte-monocyte 
colony stimulatory factor and IL-4 in order to 
obtain immature dendritic cells. These cells 
were infected for 3 days with a C. pneumoniae 
(strain TWAR 183) inoculum (MOI=5) or with 
a mock medium prepared from McCoy cells. 
Immunofluorescence staining and flow 
cytometry were applied to detect the 
expression of C. pneumoniae major outer 
membrane protein and cell surface molecules 
in the dendritic cells. The lymphoproliferative 
responses were measured by determining the 
incorporation of bromodeoxyuridine into 
dendritic cell-stimulated autologous 
lymphocytes. 
The expressions of important 
maturation markers, such as CD83, CD86, 
HLA-DR, were increased on dendritic cells 
infected with C. pneumoniae as compared with 
those of mock- infected cultures. Some of the 
CD83+ cells and CD86+ cells expressed 
C. pneumoniae major outer membrane protein 
antigen. Dendritic cells infected with the 
bacteria induced C. pneumoniae-specific 
lymphoproliferative responses of autologous 
CD4+ and CD8+ lymphocytes. 
Immature dendritic cells take up, 
process and present the C. pneumoniae 
bacteria, and the infection changes the process 
of differentiation of myeloid dendritic cells. 
CLINICAL DISEASES - 207 
NO EVIDENCE OF INVOLVEMENT OF CHLAMYDIA PNEUMONIAE IN 
SEVERE CEREBROVASCULAR ATHEROSCLEROSIS BY MEANS OF 
QUANTITATIVE REAL-TIME PCR 
Petra Apfalter*, Wolfgang Barousch, Marion Nehr, and Alexander M. Hirschl 
Department of Clinical Microbiology, Institute of Hygiene and Medical Microbiology, Medical 
University of Vienna, Austria 
All studies reporting high numbers of 
C. pneumoniae-DNA positives in stroke 
patients published to date have used PCR 
techniques highly prone to generate false 
positive results. The aim of this study was to 
analyze the prevalence of C. pneumoniae-DNA 
in plaques of the carotid artery as well as in 
peripheral blood by means of a new, closed, 
real-time PCR system. 
Carotid endarterectomy specimens and 
pre-operative peripheral blood mononuclear 
cells (PBMC) of 75 individuals suffering from 
severe cerebrovascular atherosclerosis were 
analyzed by means of a C. pneumoniae 
specific quantitative om/?A-based real-time 
PCR TaqMan system. Before the surgical 
intervention C. pneumoniae specific IgM, IgG 
and IgA as well as C-reactive protein levels 
were determined. All tissue specimens were 
also cultured for C. pneumoniae (8 passages in 
HEp-2 cells). 
We were not able to isolate 
C. pneumoniae by means of cell culture from 
any carotid endarterectomy sample. 89 % of all 
patients studied had C. pneumoniae specific 
antibodies but the pathogens' DNA was not 
detected in a single carotid atheroma. 
However, C. pneumoniae-DNA was detected 
in 4 PBMC samples (5.3%) at very low levels 
(< 1 inclusion body / 6 ml EDTA blood). No 
statistical significance was found between 
symptomatic and asymptomatic patients, 
C. pneumoniae PCR results and CRP-values 
after correction for multiplicity-of-test 
adjustment. 
By means of a closed, highly sensitive 
and specific real-time PCR, C. pneumoniae-
DNA was not detected in cerebrovascular 
atherosclerosis. PCR on PBMC was not 
predictive for endovascular chlamydial 
infection and most likely stem from prior C. 
pneumoniae respiratory tract infection in 
individual cases. 
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CULTURE OF CHLAMYDIA PNEUMONIAE FROM THE BRAINS OF LATE-ONSET 
ALZHEIMERS DISEASE PATIENTS AND SEQUENCE VARIATIONS IN THE OMP1 
GENE 
Ute Dreses-Werringloer, Yinghao Zhao, Judith A. Whittum-Hudson, Alan P. Hudson* 
Department of Immunology and Microbiology, Wayne State University School of Medicine, Gordon H. 
Scott Hall, Detroit, MI, USA 
Our aim was to culture C. pneumoniae 
from Alzheimers Disease (AD) brain tissue 
samples, and to characterize the ompl gene and 
other genetic aspects of those isolates in relation to 
the respiratory strain AR-39. 
Studies from this laboratory have 
implicated C. pneumoniae as a potential risk factor 
or causative agent in late-onset AD. We showed 
that this organism can be detected in 90% of brain 
samples from AD patients, but not those from 
controls, using a variety of standard laboratory 
methods. Our goal was to provide molecular 
analyses of brain-derived C. pneumoniae to initiate 
investigation of the strains involved in infection of 
the central nervous system. 
C. pneumoniae-PCR-positive brain 
samples from brain banks in Canada and the US 
were chosen for culture, which was performed by 
standard methods in HEp-2 cells. Briefly, cell 
monolayers were incubated with homogenized 
tissue from hippocampus or temporal cortex for at 
least 3 d. Later, either the cell lysates and/or 
supernatants were passaged to fresh monolayers 
several times. To monitor development of 
inclusions, samples were regularly taken and 
stained with a genus-specific FITC-conjugated 
monoclonal antibody targeting the chlamydial 
LPS. Stocks of C. pneumoniae elementary bodies 
so derived were prepared from highly infected 
cells. 
The ompl gene from the culture isolates was 
amplified by PCR using a high-fidelity DNA 
polymerase, then cloned into the pGEM-TEaSy 
vector. Six cloned inserts of each isolate and the 
reference strain AR-39 were sequenced. In 
addition, we amplified and performed the same 
ompl sequence determination using DNA isolated 
directly from five different AD brain tissue 
samples. 
We successfully cultured C. pneumoniae 
from two different AD brain samples, one 
originating from Toronto and the second from 
Philadelphia. The Toronto sample was culture 
positive after only one passage, indicating a high 
bacterial load in this sample. To gain a reasonable 
amount of highly infected cells, 4 more passages to 
fresh monolayers were done before making a 
preparation of elementary bodies for DNA 
analysis. For the Philadelphia sample, HEp-2-cells 
were incubated for 13 d with homogenized brain 
tissue to achieve clear culture positivity. Two more 
passages were done to enable preparation of DNA. 
DNA sequence data revealed a range of single 
nucleotide variations in the ompl gene in both 
culture isolates, as well in the index strain AR-39. 
7/12 sequenced inserts amplified from the brain 
isolates contained nucleotide changes, 4/7 of 
which caused amino acid changes. 4/6 AR-39 
inserts carried nucleotide changes, with two 
changes leading to an amino acid substitution. All 
but one of these variations were unique and were 
located in the conserved domains of MOMP. One 
change was identified in the leader sequence to the 
gene. Sequencing of the ompl gene inserts 
amplified from DNA isolated directly from brain 
samples showed single nucleotide variations as 
well. 10/20 carried deviations, 8 of those 10 
engendered amino acid changes. Variations found 
were located both in the conserved and the 
variable domains of the protein, plus one in the 
leader sequence. None of these changes matched 
those found in the culture isolates or AR-39. We 
detected two amino acid variations present in both 
the Philadelphia and Toronto patient samples. 
The ease of culturing C. pneumoniae from 
brain samples of AD patients indicates an active 
chlamydial infection in those tissues. Importantly, 
the presence of cultivatable organism in AD brains 
is not restricted to one specific region in North 
America. DNA sequence data revealed that the 
isolates, as well as the reference strain, comprise a 
non-homogeneous population. Some identical 
variations, found only in DNA directly isolated 
from two brain samples, suggest a possible shift of 
the original chlamydial populations present in the 
brains during culture in HEp-2 cells. Analyses of 
the tyrP gene and other loci are underway to 
investigate whether a neurotropic strain of C. 
pneumoniae exists. 
(Supported by grant AI-44055 from the US NIH) 
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CHLAMYDIA PNEUMONIAE AND STROKE: THE CRITICAL IMPACT OF 
PCR TECHNOLOGY OR SEEING BEHIND THE CURTAIN OF A 
DIAGNOSTIC DILEMMA 
Petra Apfalter1* and Eduard Diabl 2 
Department of Clinical Microbiology, Institute of Hygiene and Medical Microbiology, Medical 
University Vienna & Department of Neurology, General Hospital Linz; Austria 
A possible link between the respiratory 
pathogen Chlamydia pneumoniae and the 
development of atherosclerosis has led a 
sizable influx of new investigators of diverse 
medical specialities to become involved in 
Chlamydia-related research. Using polymerase 
chain reaction (PCR) numerous investigators 
postulated a strong association between C. 
pneumoniae and stroke. However, test results 
are often contradictory and thus difficult to 
interpret. We reviewed the literature in the 
field of C. pneumoniae and stroke with special 
focus on direct diagnostic attempts, especially 
PCR techniques, as well as the implication of 
methodological details on data drawn from 
clinical and prevalence studies in this field. 
Diagnosing C. pneumoniae infection 
remains fastidious, non-standardized and non-
validated. This is true for all detection methods 
available inclusive PCR. Summarized in here 
are 28 peer-reviewed studies published in 
Medline as of December 2003 that in particular 
have been addressing the question of whether 
or not C. pneumoniae is present in stroke due 
to detection of the microorganism directly in 
the affected tissue. In summary, 1444 
atherosclerotic carotid arteries and 449 
peripheral blood mononuclear cells from 992 
stroke-patients were analyzed and positivity -
ratios varied between 0 and 100%. 
Not even two studies turned out to be 
comparable in context with PCR-methodology 
applied. Nearly all investigators used outdated 
PCR technology highly prone to produce false 
positive results and did not confirm their 
positive findings. Conclusions of studies 
focusing on clinical questions were probably 
drawn from data obtained by poor 
methodology. Unless a standardized, validated 
test is available, the true prevalence of C. 
pneumoniae-DNA in cerebrovascular 
atherosclerosis can only be presumed. 
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CHLAMYDIA PNEUMONIAE INFECTION IN RELATION TO CAROTID 
ATHEROSCLEROSIS 
Hock-Liew Eng1*, Chih-Hung Chen2, Tsun-Mei Lin3 
'Department of Pathology, Chang Gung University and Memorial Hospital, Kaohsiung Medical 
Center, Kaohsiung, Taiwan, Republic of China; Departments of 2Neurology, and 3Medical 
Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, 
Tainan, Taiwan. Republic of China 
Recent studies have suggested that 
Chlamydia pneumoniae infection is an 
important factor in the development of 
atherosclerosis. However, the relationship 
between C. pneumoniae infection and carotid 
atherosclerosis is not clearly clarified. 
This study aimed to determine the association 
of C. pneumoniae infection and carotid 
atherosclerosis in patients with ischemic 
stroke. 
We recruited 307 patients (age 67.25 
+/- 11.01 years, M/F = 174/133) with ischemic 
stroke. Intima-media thickness (IMT) of 
common carotid artery was assessed by duplex 
ultrasonography. The serum levels of the C. 
pneumoniae IgG antibody were measured by 
microimmunofluorescence. An IgG titer 1:16 
was considered to be seropositive, and a titer 
1:64 was defined as persistent C. pneumoniae 
infection. 
The carotid IMT was not different in 
patients with C. pneumoniae seropositivity 
(0.99 +/- 0.15 mm; n = 221) or negativity (0.96 
+/- 0.16 mm; n = 86). In patients with 
persistent C. pneumoniae infection (n = 87), 
the IMT was significantly higher than those 
without persistent infection (1.03 +/- 0.15 vs. 
0.96 +/- 0.15 mm, respectively; p < 0.001). 
After adjustment for other risk factors, 
persistent C. pneumoniae infection was still a 
significant factor for the IMT (P = 0.161; p = 
0.003). 
Our findings support the role of C. 
pneumoniae infection for the development of 
atherosclerosis. 
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SEXUALLY TRASNMITTED CHLAMYDIAL INFECTIONS - SEQUELAE IN 
WOMEN 
Jorma Paavonen 
Department of Obstetrics and Gynecology, University of Helsinki 
Introduction 
While it is healthy for individuals to enjoy 
active sex lives, it is important to realize that 
there are over 25 sexually transmitted 
infections (STIs) some which, if left untreated 
may cause serious and permanent health 
problems. STIs are among the most common 
causes of illness and a major public health 
problem. Many STIs favour the spread of HIV 
infection and can cause serious health 
problems in newborns, or may cause infertility. 
The past decade has seen a continuing and 
considerable deterioration in sexual health 
particularly among young people. Risk taking 
sexual behavior is increasing, STIs have 
increased alarmingly, and teenage pregnancies 
are increasing. We are now facing a public 
health crisis in sexual health. 
CT is the major threat of reproductive health in 
women (1). The chlamydia epidemic during 
recent decades has led to a secondary 
epidemics of subfertility and adverse 
pregnancy outcome (APO). In Finland, 
between 1995-2002, the incidence of 
Chlamydia trachomatis (CT) infections has 
been steadily increasing although there have 
been no major changes in public STI services 
or screening practices (2). National sentinel 
clinic surveillance network based on laboratory 
notification system documented rapidly 
increasing incidence rates especially among 
adolescents and young people, from 23.4 per 
10,000 to 29.2 per 10,000. In the age group of 
less than 29 years, 19% reported 5 or more 
annual sex partners in 2000, compared to 8% 
in 1995. 
Chlamydia trachomatis: The Ultimate 
Intracellular Pathogen 
CT is an intracellular bacterial pathogen. 
Chlamydial serovars D-K cause nearly 4 
million new STI cases annually in the United 
States and 90 million cases worldwide. Other 
serovars (A, B, Ba, and C) are responsible for 
trachoma, the leading cause of preventable 
blindness, afflicting some 500 million people 
worldwide. In part of because chlamydiae are 
true obligate intracellular pathogens, 
chlamydial diseases tend to be chronic in 
nature (3). These bacteria survive and grow 
only after they invade mucosal epithelial cells. 
During this growth, or developmental cycle, 
the bacteria alternate between two structurally 
and physiologically distinct forms. In one, the 
elementary body (EB), the bacteria are 
infectious and make initial contact with 
susceptible target epithelial cells. Following 
attachment to such cells, endocytosis, the EB 
containing endosome travels on microtubules, 
moving away from the endocytic pathway and 
toward the exocytic pathway. The EB envelope 
changes, transforming the metabolically inert 
EB, which is about 0.2 pm in diameter, into 
the metabolically active reticulate body (RB), 
which is 0.8 pm in diameter. DNA, RNA, and 
protein are synthesized within the RB, leading 
to successive rounds of binary fission and 
increased numbers of progeny. To 
accommodate this growing RB population, the 
endosomal vacuole membrane expands, and 
this entity is called an inclusion. Metabolically 
active RBs associate with the interior side of 
the inclusion membrane, acquiring nutrients. 
Next, RBs dissociate from the inclusion 
membrane, apparently signaling that the 
intracellular, osmotically fragile, noninfectious 
RBs are ready to complete the cycle by 
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becoming infectious EBs. Following escape or 
release from the host cell, the compact, rigid 
EB can survive extracellularly for limited 
periods before finding new susceptible 
epithelial cells to invade and begin another 
infectious round of growth and amplification. 
Soon after chlamydiae infect a host cell, they 
induce anti-apoptotic signals and thus gain 
time to move through this developmental 
cycle. Late during each cycle host cells 
degrade liberating infectious EB. Under some 
circumstances intracellular environment may 
not be favorable for this cycle. For instance, 
treating cells with interferon-gamma (IFN-y) 
blocks the RB-EB cycle, Similarly, adding 
penicillin or subinhibitory concentrations of 
macrolides induces an aberrant, slowly 
metabolizing form of RB, which can persist for 
extended periods. This slowly metabolizing 
RB form may well be the predominant 
chlamydial form in vivo, and its behavior may 
explain the chronic nature of chlamydial 
diseases and the long-term sequelae (3). 
Clinical Manifestations of Chlamydial 
Infection 
Mucopurulent cervicitis (MPC), endometritis, 
and PID are the major clinical manifestations 
of genital chlamydial infection in women. 
MPC represents the ignored counterpart of 
urethritis in male (4). Clinical diagnosis of 
MPC is difficult, and no uniform or accurate 
criteria for the diagnosis of MPC exist. 
Endometritis as a clinical-pathologic syndrome 
represents the first step of a lower genital tract 
infection ascending to the upper genital tract 
(5). Clinical and laboratory correlates suggest 
that endometritis is a distinct clinical entity. 
However, the natural history and long-term 
prognosis of endometritis alone (in the absence 
of laparoscopic signs of salpingitis) remain 
undefined. In particular, the frequency with 
which endometritis remains limited to the 
uterus or progresses into salpingitis has not 
been well understood. Risk factors for 
endometritis include chlamydial and 
gonococcal infetion, current IUD use, recent 
douching, and being in days 1 to 7 of the 
menstrual cycle. The clinical spectrum of 
endometritis alone probably encompasses 
mostly asymptomatic women who may in fact 
outnumber women with symptomas and signs 
suggestive of acute PID. The potential for the 
progression to salpingitis associated with long-
term risk for subfertility warrants prompt 
antimicrobial therapy (6). The effects of 
endometritis on implantation and pregnancy 
outcome are similarly not well known. 
However, subclinical endometritis as such may 
not increase the risk for subfertility (7). The 
term PID refers to infection of the uterus, 
fallopian tubes, and adjacent pelvic structures 
not associated with surgery or pregnancy. PID 
comprises a spectrum of inflammatory 
disorders of the upper female genital tract, 
including any combination of endometritis, 
salpingitis, tubo-ovarian abscess, and pelvic 
peritonitis (8). Bilateral lower abdominal pain 
is the most common presenting symptom of 
PID. Perihepatitis causes right quadrant upper 
abdominal pain mimicking acute cholecystitis. 
Other common symptoms are abnormal 
vaginal discharge, metrorrhagia, postcoital 
bleeding, dysuria and fever. However, 
symptomatic PID only represents the tip of the 
iceberg. Minimally symptomatic patients 
usually seek medical care late which increases 
the risk for tubal damage and long-term 
sequelae. After a single episode of PID, the 
risk for TFI is approximately 11%. Each repeat 
episode of PID doubles or triples the risk. TFI 
remains the leading cause of IVF in developed 
countries. Women with a history of PID have 
approximately 6 to 10-fold increased risk of 
tubal pregnancy compared to women with no 
history of PID. Chronic pelvic pain occurs in a 
large proportion of women crippled with past 
PID. Women with a history of PID are 
approximately 10 times more likely to be 
admitted for pelvic pain, and hysterectomy 
rates are eight times higher than in other 
women. Thus, women with PID suffer 
substantial long-term gynecological morbidity 
in later lives. 
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C. trachomatis infection as a risk factor for 
cervical cancer 
Human papillomavirus (HPV) infection is the 
leading cause of cervical neoplasia. Additional 
risk factors include other STIs and smoking. 
The evidence linking oncogenic HPV types 
and cervical carcinoma is strong and 
consistent. Longitudinal seroepidemiologic 
studies have provided evidence that CT 
infection is an independent risk factor for the 
development of cervical carcinoma. Past 
infection with CT as demonstrated by the 
presence of species specific 
microimmunofluorecense test antibodies 
confers an increased risk for developing 
cervical squamous cell carcinoma but not 
cervical adenocarcinoma (9). This risk 
estimate remained significant after adjustment 
for HPV exposure and smoking. CT serotype 
G was most strongly associated with 
subsequent development of cervical cancer 
(10). Increasing numbers of exposures to 
different CT serotypes also increased the risk. 
Thus, these longitudinal studies support earlier 
descriptive or cross sectional studies linking 
CT and cervical cancer (11). Use of serum 
banks and cancer registries provides an ideal 
setting for etiological studies with true cancer 
as the end point. It is tempting to speculate on 
the potential molecular mechanisms explaining 
the association between CT or specific CT 
serotypes and cervical neoplasia. 
Immunopathogenesis of Chlamydial 
Infection 
Given the intracellular developmental cycle of 
Chlamydia, there is strong evidence for the 
involvement of host immune response such as 
IFN-y, in the natural history of chlamydial 
infection. Host response to chlamydial 
infection can result either in a protective or 
pathological immune response (12). Tissue 
damage results more from immune recognition 
of specific antigens expressed by the organism. 
Given the primary protective role effected by 
the cell-mediated Th-1 response in resolving 
infection, inflammatory damage within the 
upper reproductive tract may be the result of a 
failed or weak Th-1 action resulting in chronic 
infection or as a result of an exaggerated or 
overstimulated Th-1 response. A balance, 
therefore, exists between the protective and 
deleterious effects of cell-mediated immunity. 
Carefully regulated cytokine production is 
central to successful immune responses to 
intracellular pathogens. Deficiencies in the 
production or activity of these 
proinflammatory cytokines can be associated 
with failure of protective immunity or harmful 
persistent inflammation. The model of 
pathogenesis by which CT progresses from 
acute to chronic infection remains yet to be 
fully understood. The pathways by which acute 
chlamydial infection achieves resolution or 
alternatively progresses to chronic infection 
appears to depend on a close interplay between 
host and pathogen. A number of 
interconnected factors appear to play a 
significant roles - human genetics and 
endocrinology, cytokine profile, previous 
infections, pathogen load, chlamydial strain, 
the presence of other genital infections, and 
others. 
The Role of Chlamydial Heat Shock Protein 
60 in Tubal Factor Infertility 
The major chlamydial component associated 
with permanent tubal damage and other long-
term sequelae is chlamydial heat shock protein 
60 (CHSP60) which has the unique capability 
to modulate host immune responses (13). The 
mechanism by which exposure to CHSP60 
clicits pathology has been explained in many 
ways. CT may enter a persistent state within 
human host cells during which expression of 
CHSP60 is enhanced whereas levels of the 
major outer membrane protein (MOMP) are 
minimized. This provides a continued source 
of antigenic stimulation. Evidence implicating 
CHSP60 as the critical antigen is extensive 
through studies reporting the increasing 
prevalence of CHSP60 antibodies among 
women with increasing severity of chlamydial 
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disease. A number of studies investigating 
serological responses of infertile women to 
CHSP60 have demonstrated a correlation 
between antibodies and TFI. CHSP60 antigen 
is recognized by T cells present in the 
peripheral blood and in the inflamed fallopian 
tube tissue of TFI patients (14, 15). Most 
CHSP60 specific T cell clones produce 
predominantly IL-10 (16). CHSP60 seems to 
induce Th2-type cytokine response in 
chlamydia-specific T cells and may thereby 
downregulate or replace an initial Thl 
mediated immune response needed to 
eliminate Chlamydia. CHSP60 specific 
immune response is associated with specific 
HLA-DQ alleles and IL10 polymorphism in 
TFI patients (17). Thus, in genetically 
predisposed individuals the induction of 
deleterious cytokine response can lead to a 
cycle of persistent infection associated with 
continuous antigenic stimulation and chronic 
inflammation the end result of which would 
then be scarring and structural damage of the 
fallopian tube. It is possible that CHSP60 
associated genetic markers can be used as 
surrogate markers to identify individuals at 
risk for developing TFI. 
Chlamydia trachomatis Antibody Testing in 
Subfertility Evaluation 
CT is the leading cause of permanent tubal 
damage worldwide. Detecting evidence of past 
chlamydial infection using serology is non-
invasive, simple, and quick to perform (18). 
Chlamydial antibodies persist years as a 
serologic scar consistent with past infection. 
Thus, chlamydial antibody titers (CAT) can be 
used as a screening test for distal tubal damage 
among subfertile women. A linear trend has 
been observed between serum CAT and the 
likelihood of tubal damage (18). Thus, CATs 
are of predictive value in the detection of tubal 
damage and are quantitatively related to the 
severity of damage. Chlamydia serology is 
useful as a screening test for tubal damage in 
subfertile women and can be used for tailoring 
further management of such women (19). 
However, the choice of cut-off level used for 
screening depends on the prevalence of 
chlamydial infection in the population and the 
antibody test used. In many infertility clinics 
CAT screening has already been introduced in 
the initial work-up of subfertile couples. 
Control Strategies 
Disease prevention can be primary, secondary, 
or tertiary. Clinicians and other health care 
providers have an important role in the primary 
prevention of STIs through lifestyle counseling 
and health education, and by asking questions 
about risk taking sexual behavior, by 
encouraging screening tests for those at risk, 
by ensuring that sex partners are properly 
managed, and by counseling about safe sex 
practices. Unfortunately, primary STI 
prevention by health education has not proven 
very effective (20, 21). Health care 
professionals dealing with sexual health must 
be non-judgemental, reassuring and maintain 
confidentiality. Early diagnosis and treatment 
will prevent long-term health implications 
posed by bacterial STIs, such as CT. Partner 
notification, expedited partner care, and patient 
initiated partner treatment are important but 
often ignored steps in preventing the spread of 
STIs (22). 
Secondary prevention by screening for CT is 
likely to have the most critical role in the 
prevention of subfertility. Because CT is the 
major cause of upper genital tract infection and 
tubal damage in, it is logical to focus 
prevention efforts on chlamydia. Thus, 
screening for CT is of paramount importance 
in the prevention of upper genital tract 
infection. Chlamydial infection fills the 
prerequisites for disease prevention by 
screening because chlamydial infections are 
highly prevalent, are associated with 
significant morbidity, can be readily 
diagnosed, and are treatable. Use of the first 
void urine (FVU) specimens (or vulvar or 
vaginal swabs) and NAA tests for diagnosis, 
and single dose of azithromycin for treatment 
should enhance these efforts. One recent 
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randomized trial showed that intervention with 
selective screening effectively reduced the 
incidence of symptomatic PID by 64% during 
one year of follow-up (23). High CT screening 
activity in Sweden resulted in a dramatic 
decrease of CT rates (which unfortunately has 
been recently increasing again), followed by a 
rapid decrease in the rates of hospitalizations 
for PID (24). Even more important, 5-10 years 
later this was followed by a significant fall in 
the rate of ectopic pregnancies, especially in 
young age groups (25). These examples show 
that CT screening is effective in a real-life 
situation. However, it is not yet known 
whether CT screening produces a 
corresponding fall in the incidence of TFI. 
Cost-effectiveness analyses heavily advocate 
CT screening (26). A recent critical review of 
such studies concluded that screening is cost 
effective because future sequelae of untreated 
infection can be prevented. However, we do 
not know whether the natural history of nucleic 
acid amplification test (NAAT) detected 
infections is the same as culture detected 
infections. NAATs are at least 30-40% more 
sensitive than culture for detecting chlamydia. 
It is unknown whether NAAT positive (culture 
negative) infections are as likely to progress 
into upper genital tract infection and cause 
irreversible tubal damage. The probability of 
upper genital tract infection subsequent to 
untreated infection is central to the cost-
effectiveness of screening programmes. 
Tertiary prevention includes treatment that 
prevents upper-genital tract infection from 
leading to tubal obstruction. However, the 
damage may already be there. There is really 
no evidence that improved or more effective 
antimicrobial therapy could lead to better 
outcome. However, partner notification and 
appropriate counseling are of paramount 
importance in order to prevent recurrent 
infections. Recurrent chlamydial infection 
doubles or triples the risk for permanent tubal 
damage. 
C. trachomatis vaccine development 
CT is a huge challenge for vaccine 
development (27). An efficacious vaccine is 
the best approach to deliver long-lasting 
protection against CT to the greatest number of 
people worldwide. Using the whole organism 
for vaccination has proved unattractive. On the 
other hand, no single subunit vaccine has yet 
produced sterilizing long-term immunity. Most 
of the chlamydia vaccines developed and 
tested so far in animal models only give 
temporary or partial protection. The potential 
CT vaccine will probably contain a cocktail of 
recombinant proteins to be able to deliver 
enough T cell epitopes. A partially protective 
vaccine effective against PID and tubal 
damage would be an acceptable goal of the 
first generation chlamydia vaccine. 
References 
1. Paavonen J, Eggert-Kruse W. Chlamydia 
trachomatis: impact on human 
reproduction. Hum Reprod Update 
1999;5:433-447. 
2. Hiltunen-Back E, Haikala O, Kautiainen 
H, Ruutu P, Paavonen J, Reunala T. 
Nationwide increase of Chlamydia 
trachomatis infection in Finland. Sex 
Transm Dis 2003;30:737-741. 
3. Wyrick PB. C. trachomatis', infection 
strategies of the ultimate intracellular 
pathogen. ASM News 2002;68:70-76. 
4. Brunham RC, Paavonen J, Stevens CE, 
Kiviat N, Kuo CC, Critchlow CV, Holmes 
KK. Mucopurulent cervicitis- The ignored 
counterpart in women of urethritis in men. 
N Engl J Med 1984;311:1-6. 
216 - CLINICAL DISEASES 
5. Eckert LO, Hawes SE, Wölner-Hanssen P, 
Kiviat NB, Wasserheit JN, Paavonen JA, 
Eschenbach DA, Holmes KK. 
Endometritis: The clinical-pathologic 
syndrome. Am J Obstet Gynecol 
2002;186:690-695. 
6. Eckert LO, Thwin SS, Hillier SL, Kiviat 
NB, Eschenbach DA. The antimicrobial 
treatment of subacute endometritis: A 
proof of concept study. Am J Obstet 
Gynecol 2004;190:305-313. 
7. Haggerty CL, Ness RB, Amortegui A, 
Hendrix SL, Hillier SL, Holley RL et al. 
Endometritis does not predict reproductive 
morbidity after pelvic inflammatory 
disease. Am J Obstet Gynecol 
2003;188:141-148. 
Pelvic 
rd 
8. Paavonen J, Molander P 
Inflammatory Disease. In: Gynecology, 3 
edition. Shaw et al. (eds), Churchill 
Livingstone, 2003 pp. 891-900. 
9. Koskela P, Anttila T, Björge T, Brunsvig 
A, Dillner J, Hakama M, et al. Chlamydia 
trachomatis infection and invasive 
cervical cancer. Int J Cancer 2000;85:35-
39. 
10. Anttila T, Saikku P, Koskela P, Bloigu A, 
Dillner J, Ikäheimo I, et al. Serotypes of 
Chlamydia trachomatis and risk for 
development of cervical squamous cell 
carcinoma. JAMA 2001;205:47-83. 
11. Smith JS, Munoz N, Herrero R, Eluf-Neto 
J, Ngelangel C, Franceschi S, et al. 
Evidence for Chlamdyia trachomatis as a 
human papillomavirus cofactor in the 
etiology of invasive cervical cancer in 
Brazil and the Philippines. J Infect Dis 
2002;185:324-331. 
12. Debattista J, Timms P, Allan J, Allan J. 
Immunopathogenesis of Chlamydia 
trachomatis infections in women. Fertil 
Steril 2003;79:1273-1287. 
13. Kinnunen A, Paavonen J, Surcel H-M. 
heat shock protein 60 specific T-cell 
response in chlamydial infections. Scand J 
Immunol 2001;54:2001. 
14. Kinnunen A, Molander P, Laurila A, 
Rantala I, Morrison R, Lehtinen M, 
Karttunen R, Tiitinen A, Paavonen J and 
Surcel HM. Chlamydia trachomatis 
reactive T lymphocytes from upper genital 
tract tissue specimens. Human Reprod 
2000;15:1484-1489. 
15. Kinnunen A, Molander P, Morrison RP, 
Lehtinen M, Karttunen R, Tiitinen A, 
Paavonen J, Surcel HM. Chlamydial heat 
shock protein 60 specific T cells in 
inflamed salpingeal tissue. Fertil Steril 
2002;77:162-166. 
16. Kinnunen A, Surcel H-M, Halttunen M, 
Tiitinen A, Morrison RP, Morrison SG, 
Koskela P, Lehtinen M, Paavonen J. 
Chlamydia trachomatis heat shock 
protein-60 induced interferon-y and 
interleukin-10 production by peripheral 
blood lymphocytes in infertile women. 
Clin Exp Immunol 2003;131:299-303. 
17. Kinnunen A, Surcel HM, Lehtinen M, 
Karhukorpi J, Tiitinen A, Halttunen M, 
Bloigu A, Morrison RP, karttunen R, 
Paavonen J. HLA DQ alleles and 
interleukin-10 polymorphism associated 
with Chlamydia trachomatis-related tubal 
factor infertility: A case-control study. 
Hum Reprod 2002;17:2073-2078. 
18. Akande VA, Hunt LP, Cahill DJ, Caul 
EO, Ford WCL, Jenkins JM. Tubal 
damage in infertile women: prediction 
using chlamydia serology. Hum Reprod 
2003;18:1841-1847. 
CLINICAL DISEASES - 217 
19. Land JA, Evers JLH, Goossens V. How to 
use Chlamydia antibody testing 
subfertility patients. Hum Reprod 
1998;13:1094-1098. 
20. Aral SO. Determinants of STD epidemics: 
implications for phase appropriate 
intervention strategies. Sex Transm Inf 
2002;78 (Suppl I): i3-il3. 
21. Wight D, Raab GM, Henderson M, 
Abraham C, Buston K, Hart G, Scott S. 
Limits of teacher delivered sex education: 
interim behavioural outcomes from 
randomized trial. BMJ 2002;324:1430-
1433. 
26. Honey E, Augood C, Templeton A, 
Russell I, Paavonen J, Märdh P-A, et al. 
Cost effectiveness of screening for 
Chlamydia trachomatis: a review of 
published studies. Sex Transm Inf 
2002;78:406-412. 
27. Igietseme JU, Eko FO, Black CM. 
Contemporary approaches to designing 
and evaluating vaccines against 
Chlamydia. Expert Rev Vaccines 
2003;2:129-146. 
22. Golden MR, Whittington WLH, 
Handsfield HH, Malinsky C, Clark A, 
Hughes JP, Gorbach P, Holmes KK. 
Partner management for gonococcal and 
chlamydial infection. Sex Transm Dis 
2001;28:658-665. 
23. Scholes D, Stergachis A, Heidrich FE, 
Andrilla H, Holmes KK, Stamm WE. 
Prevention of pelvic inflammatory disease 
by screening for cervical chlamydial 
infection. N Engl J Med 1996;334:1362-
1366. 
24. Kamwendo F, Forslin L, Bodin L, 
Danielsson D. Decreasing incidences of 
gonorrhoea- and chlamydia-associated 
acute pelvic inflammatory disease. A 25-
year study from an urban area of central 
Sweden. Sex Transm Dis 1996;23:384-
391. 
25. Egger M, Low N, Smith GD, Lindblom B, 
Herrman B. Screening for chlamydial 
infections and the risk of ectopic 
pregnancy in a county of Sweden: 
ecological analysis. BMJ 1998;316:1776-
1780. 
218 - CLINICAL DISEASES 
COMPLICATIONS OF CHLAMYDIA TRACHOMATIS INFECTION - CAN 
THEY BE REVERSED BY SCREENING? 
Herrmann, B1*, Harbord, R2, Egger, M2, Lindblom, B3, Low, N2 
'Section of Sexually Transmitted Infections, Swedish Institute for Infectious Disease Control, Uppsala, 
Sweden, 2Dept of Social Medicine, University of Bristol, Bristol, U.K., 3Dept of Women 's and Children's 
Health, Uppsala University, Uppsala, Sweden 
Due to methodological and ethical 
problems in studying the natural history of 
chlamydia the information about the incidence of 
sequelae is scarce. This study aimed to determine 
the incidence of chlamydia associated reproductive 
complications in women. A second objective was 
to examine the uptake of chlamydia screening and 
relate it to the risk of reproductive sequelae. 
Record linkage study. We constructed a 
retrospective cohort of all women in Uppsala, 
Sweden aged 15 to 39 years in the period 1985-
1989. Using a unique personal identifier we linked 
data f rom a register of all chlamydia tests 
performed in women in Uppsala f rom 1985 to 
1996, in-patient and outpatient hospital records up 
to 2000 and demographic and social data from the 
Census. After linkage the unique identifier was 
dropped from the record. We examined 
associations between chlamydia and adverse 
reproductive outcomes by Cox proportional hazard 
models and calculated the incidence of hospital-
treated pelvic inflammatory disease (PID), ectopic 
pregnancy (EP) and infertility using survival 
methods. 
There were 93,284 women in the study 
population with over 1 million woman years of 
follow up. 36,683 (39.3%) women had at least one 
chlamydia test and 4,004 (4.3%) had at least one 
positive result. Chlamydia infection was associated 
with education level and household income: 14.3% 
of women with <11 years of education had a 
positive test compared to 7.8% in women with >14 
years of education; and in women f rom the lowest 
quartile of household income chlamydia was 
detected in 12.3% of tests, compared with 9.8% 
among women from the highest quartile. Women 
who were never tested for chlamydia were more 
likely to have reached a high educational level and 
to come f rom better off households. 
There were 2,688 episodes of PID, 1,504 of 
ectopic pregnancy and 2,628 of infertility recorded 
during follow up. Amongst women under 25 years 
at study entry 5.6% had been diagnosed with PID 
after 15 years of follow up, 2.2% with EP and 
7.0% with infertility. Women with a positive 
chlamydia test were more likely than those with 
negative tests to develop an outcome. After 
adjustment for education, housing, income and 
number of births the hazard ratios were 1.3 (95% 
CI 1.0-1.5) for PID, 1.3 (0.9-1.1) for ectopic 
pregnancy and 1.3 (1.1-1.6) for infertility. Women 
who were never screened for chlamydia had the 
lowest level of complications and were only 60 to 
80% as likely to experience a complication 
outcome as those who tested negative. 
The prevalence of chlamydia decreased f rom 10.5 
(95%CI 9.8-11.3) per 1000 woman years during 
the study period, similarily the rates of 
complications per 1000 woman years also 
declined: PID frm 1.7 (1.4-2.0) to 0.2 (0.1-0.3), 
ectopic pregnancy f rom 1.7 (1.5-2.1) to 0.3 (0.2-
0.4) and infertility f rom 1.5 (1.2-1.8) to 0.2 (0.1-
0.4) 
Widespread chlamydia screening was 
temporally associated with reductions in the 
incidence of reproductive complications during the 
study period. This study is the first to estimate 
population-based risks of reproductive tract 
complications of genital chlamydial infection in a 
population exposed to nationwide opportunistic 
screening. The incidence of reproductive 
complications was found to be lower than those of 
widely cited older studies, probably due to the 
effects of antibiotic treatment. Lower complication 
risks among women not tested for chlamydia 
indicate that self-selection takes place. 
Low educational attainment and household income 
were socioeconomic markers for increased risk of 
chlamydia infection and reproductive tract 
damage. 
In the light of the increasing incidence of 
chlamydia in recent years screening programmes 
should be evaluated. Economic evaluations of the 
cost-effectiveness of chlamydia screening should 
be based on current estimates of complication risks 
and take into account the health seeking behaviour 
of women. 
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INFECTION HISTORY AND IN VITRO NEUTRALIZING ANTIBODIES AGAINST 
CHLAMYDIA TRACHOMATIS 
Van Der Pol, B.1*, Williams, J.A.1, Batteiger, B.E.1, Orr, D.P.2 & Fortenberry, J.D.2 
'Division of Infectious Diseases, Department of Medicine and 2Division of Adolescent Medicine, 
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA 
The objective of this study was to assess the 
titre of neutralizing serum antibodies to Chlamydia 
trachomatis in samples obtained from young 
women. Titre results were compared with infection 
history in order to better understand the clinical 
significance of the assay. 
Vaginal swab and serum samples were 
obtained from young women, aged 14-17 at 
enrollment, who were participating in a 
longitudinal study of sexual behaviors. Participants 
were seen in a primary health-care clinic every 3 
months for up to 27 months. Serum and vaginal 
swabs were collected during these visits. Vaginal 
swabs were also collected on a weekly basis during 
3 month periods. 
For this sub-analysis, sera from 4 women 
were selected. These 4 participants were chosen 
based on 1) having an infection, identified from 
weekly swabs, that lasted at least 7 weeks, and 2) 
having at least one subsequent infection. 
The neutralization assay was performed using 
a hamster kidney cell line with laboratory strains 
of C. trachomatis titred to give 0.6-2.0 x 102 ifu 
per microtitre well in the presence of a non-
neutralizing serum control. Sera were diluted 2-
fold in chlamydia transport medium and tested in a 
range from 1:8 to 1:256. 
Neutralizing antibodies (NA) were defined as 
the titre that gave a reduction in the number of ifu 
of at least 50% compared to wells with control 
serum. The data are reported as the highest 
dilution that resulted in >50% reduction. 
Participant 14 was infected with serovar D at 
enrollment and B after her 7th quarterly visit; each 
infection lasted > 9 weeks. Her NA titre to D was 
1:8 when the infection was identified and never 
rose above that level. No NA against serovar B (all 
titres <1:8) was detected from any serum sample 
from this participant. 
Participant 41 was infected with serovar B for 
7 weeks prior to her 5th clinic visit and D at both 
her 7th & 8th visits. She had no detectable NA 
against B in vitro. Her NA titre to D was 1:16 at 
enrollment and rose to 1:128 immediately 
following her B infection (3 months prior to her 
first documented infection with D). In the serum 
collected during the 7th visit at which the D 
infection was diagnosed, her NA titre had fallen to 
1:8. At her 8th visit, her NA titre had increased to 
1:64, but she was again infected with D. By her 9th 
quarterly visit, her NA titre against D was > 1:256. 
Participant 94 had infections with serovar F, 3 
weeks prior to her 3rd clinic visit; D, identified at 
the 4th visit; E, 10 weeks prior to her 6th visit; and 
B at her 7th visit. Her NA titre against F was 1:128 
at enrollment and rose to > 1:256 following the F 
infection. Her NA titre to D was at > 1:256 at all 
time points measured. Her NA to E was > 1:256 
from enrollment until it fell to 1:128 at her 6th visit, 
at which the E infection was diagnosed. Her NA 
titre to E subsequently fell to 1:64. Her NA titre 
against B rose from undetectable to 1:8 at the time 
of her infection with B and then fell below the 
detectable level at later visits. 
At enrollment, participant 99 had no 
detectable NA to serovars F, K, or E. The young 
woman was infected with F for 10 weeks prior to 
visit 2, but no serum was obtained. Her next serum 
sample was from visit 4 and she had antibodies to 
all F, K and E. Her NA to F rose to > 1:256 by the 
4th visit and remained at that level for the 
remaining 12 months of her follow-up. Also at her 
4th visit, a K infection was identified. Her NA titre 
to K was 1:128 and remained within 1 dilution of 
this level. 9 weeks prior to her 6th visit, the 
participant had another F infection despite the 
continued high level NA to F. The participant's E 
NA titre decreased from 1:64 to 1:8 at the visit 
prior to an E infection. Her NA titre against E was 
1:16 at the end of this 8 week infection and 
increased to 1:128 by the end of the study period. 
NA titres to serovar B were consistently lower 
than titres to serovars D, E, F, and K. The pattern 
seen in the participant who had no NA titre to any 
of the 4 serovars tested at enrollment suggests that 
the NA response is broadly reactive, but may have 
a type-specific component resulting in higher titres 
to the infecting serovar. However, high NA titres 
were not protective in this study. This assay may 
not be appropriate for use in vaccine development. 
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ASSOCIATION OF INTERPERSONAL VIOLENCE, GENITOURINARY 
SYMPTOMS AND HEALTH SEEKING BEHAVIOR IN MINORITY 
ADOLESCENT WOMEN WITH CHLAMYDIA 
JD Champion, JM Piper, AEC Holden, RN Shain, JE Korte, S Perdue 
Departments of Family Nursing Care, OB/GYN and Microbiology, The University of Texas Health 
Science Center at San Antonio, San Antonio, Texas. USA 
Chlamydia trachomatis (CT) continues 
to be the most common sexually transmitted 
pathogen in humans. This organism may also 
be the most common cause of acute pelvic 
inflammatory disease (PID). Despite the 
availability of effective treatment, chlamydial 
infection has remained common in adolescent 
women partly because the majority do not 
realize that they are infected. Prior studies have 
attempted to identify symptoms associated 
with chlamydial infection in adolescent women 
to improve sexually transmitted infections 
(STI) detection. Identifying chlamydial 
infections based on symptoms, however, has 
proven difficult. The World Health 
Organization algorithm for treatment of 
vaginal discharge has proved to be the least 
effective algorithm for identifying and treating 
STI. Up to 68% of women with chlamydial 
infection have been reported to be 
asymptomatic. Because of this, the Center for 
Disease Control and Prevention (CDC) has 
recommended screening sexually active 
women below 25 years of age at least annually, 
regardless of symptoms. Unfortunately, in 
many parts of the world, routine annual 
screening is not possible. Improved 
understanding of symptoms of chlamydial 
infection could be of benefit in resource poor 
settings. Negative outcomes associated with a 
history of sexual or physical abuse including a 
variety of chronic somatic and physical health 
complaints and disproportionate use of primary 
health care services have been documented. 
This study focuses on Mexican-and African-
American adolescent women with current CT 
infection. It addresses the relationship of 
sexual or physical abuse to health seeking 
behavior and the pathology of genitourinary 
symptoms that impact on diagnoses of CT and 
PID. These findings have relevance to 
clinicians who work with abused adolescent 
women. 
Mexican- and African-American 
adolescent women (n=332) with current 
cervical CT, underwent a targeted physical 
exam and questioning regarding sexual or 
physical abuse, current genitourinary 
symptomatology, and pelvic inflammatory 
disease (PID) risk behaviors to determine the 
relationship of sexual or physical abuse to the 
pathology of genitourinary symptoms that 
impact on diagnoses of CT and risk for PID. 
Bivariate comparisons found abused 
adolescent women reported more PID risk 
behaviors including earlier coitus, more sex 
partners, higher STD recurrence, and delayed 
health-seeking behavior. Multivariate 
comparisons found abused adolescent women 
more likely to report pathologic genitourinary 
symptomatology than nonabused. Clinicians 
made more presumptive diagnoses of PID for 
abused than nonabused adolescent women on 
physical exam. 
These findings differentiate abused 
women to be at high risk for PID. Due to its 
considerable impact on genitourinary 
symptomatology and risk for PID, assessment 
for abuse is essential in clinical management of 
adolescent women with CT and diagnosis of 
PID. 
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ADOLESCENT WOMAN ABUSE AND SEXUALLY TRANSMITTED 
INFECTIONS: A FRAMEWORK FOR ANALYSIS OF CLINICAL DILEMMAS 
Jane Dimmitt Champion, Katherine Artnak 
Department of Family Nursing Care, The University of Texas Health Science Center at San 
Antonio, San Antonio, Texas, USA 
A high prevalence of sexual and 
physical abuse has been identified among 
adolescent women who have sexually 
transmitted infections including Chlamydia. 
The need for health care practitioners to 
incorporate ethical analysis into the case 
management of sexually transmitted diseases 
in situations in which sexual or physical abuse 
exists is becoming more apparent - particularly 
within independent practice settings. The 
literature contains many articles dealing with 
the more abstract treatment of clinical ethics, 
but for the practitioner there is unfortunately 
little information available that utilizes ethical 
principles in a useable framework addressing 
the concrete reality of daily, difficult, clinical 
decision making. This presentation applies a 
model of reasoned analysis to actual' case 
studies concerning adolescent woman abuse 
and sexually transmitted infection including 
Chlamydia, utilizing the concepts of casuistry 
or case-based reasoning, and offers this 
method as a framework for ethical analysis. 
Clinical cases involving adolescent 
woman abuse and sexually transmitted 
infections including Chlamydia were identified 
within medical practices in metropolitan and 
rural communities. 
These cases, complicated by the co-
existence of adolescent woman abuse and 
sexually transmitted infection form a 
taxonomy of cases from which to examine the 
unique ethical issues of patient privacy and 
legitimate breaches of confidentiality within 
these communities. 
The concepts of casuistry or case-based 
reasoning, offer a legitimate method of ethical 
analysis for practitioners working with woman 
abuse and sexually transmitted infections 
within diverse communities. 
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FREQUENCY AND DISTRIBUTION OF CHLAMYDIA TRACHOMATIS 
GENOTYPES CAUSING CERVICAL INFECTION AMONG GYNAECOLOGIC 
PATIENTS 
M.Angélica Martínez*, M.Eugenia Pinto, Victoria Paredes, Jorge Sandoval, Ivan Reid, 
Enrique Napolitano, Raúl Aguirre and Ramiro Molina 
Universidad de Chile, Facultad de Medicina, Universidad de Chile Hospital José Joaquín Aguirre, 
Gynecology Center General Science, Gynecology Service Hospital San José Suecia, Santiago, 
Chile 
Objective: To estimate the prevalence 
of Chlamydia trachomatis in cervical 
infections in gynecological patients in Santiago 
of Chile, and to determine their serovar 
distribution. 
A total of 273 non-pregnant women 
attending four gynecological outpatient 
settings from April 2003 to April 2004, were 
enrolled in this study. Endocervical specimens 
were obtained, placed in 1.5-ml of sucrose 
phosphate buffer (2SP), and transported to the 
laboratory in ice. Specimens were centrifuged, 
suspended in PBS, and the DNA extracted 
with the QIAamp DNA Kit (QIAGEN, USA). 
Specimens were screened by PCR 
amplification of a 517-bp fragment of the 
cryptic plasmid of C. trachomatis. The 
chlamydial ompl gene was amplified in a 
primary PCR with primers SEROIA and 
SER02A, and then by a nested PCR with two 
pairs of primers: OMP1-OMP6AS, and 
OMP6S-VD42, to include the four variable 
domains. PCR products were purified with the 
QIAquick PCR purification Kit (QIAGEN, 
USA) and then sequenced in both strands by 
the Big Dye Terminator Technology with an 
Applied Biosystem (USA) sequencer. 
Sequences were analyzed by BLAST similarity 
search. 
The mean age of women was 31.9 years 
(range 15 to 56 years). The presence of signs 
and symptoms of lower genital tract infection 
was recorded in 257 (94%) women, being 
positive in 112 (43.6%) of them; 90% in 
adolescent female and 35.02% in women > 20 
years. The overall frequency of C. trachomatis 
cervical infection was 3.3 % (9/273). The 
positivity rate by age of patients was 10% 
(4/40) in adolescent female 15-19 years, 3.7% 
(3/82) in women 20-29 years, and 2.1% (2/95) 
for women 30-39 years. C. trachomatis was 
not found in the 56 women >40 years. 
Screening of women < 31 years could be 
detected 7 out of 9 infections (77.8%). The 
identified serovars were Da, 1 strain, E, 4 
strains, F, 3 strains and G, one strain. 
The prevalence of C. trachomatis in 
this study varies between 0 and 10% among 
different age groups, with the highest 
prevalence among adolescent females. Despite 
the scarce number of strains sequenced 
serovars E and F seem to be the most prevalent 
serovars in cervical infections in Chile. 
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MOLECULAR TYPING OF THE CHLAMYDIA TRACHOMATIS BY RFLP 
ANALYSIS AND SEQUENCING OF THE PCR-AMPLIFIED MAJOR OUTER 
MEMBRANE PROTEIN GENE 
D Kese*, Kek B, Petrovec M, Zore A 
Institute of Microbiology and Immunology, Medical Faculty, Ljubljana, Slovenia 
The aim of the study was to establish 
the procedure for genetic characterization of 
clinical Chlamydia trachomatis isolates by the 
restriction fragment length polymorphism 
(RFLP) analysis and complete sequencing of 
the ompl gene and to define the prevalence of 
particular C. trachomatis genotypes among 
infected patients in Slovenia. 
C. trachomatis was isolated in the 
tissue culture from conjunctiva swab 
specimens of 10 patients with acute 
conjunctivitis and from urethral swab 
specimens of 12 patients. All isolates were 
further grown for two passages on 
cycloheximide-treated HeLa 229 cells. DNA 
was extracted from clinical isolates and from 
C. trachomatis D-K reference strains. PCR 
amplification was performed by using the 
specific primers CT-1 and CT-5 designed from 
the first and the fifth conserved domain of 
omp\ gene. According to the computer 
analysis of the restriction map of each C. 
trachomatis omp 1 gene sequences, the 
amplified DNA products of 1141 bp were 
separately digested in two steps by RFLP 
typing. First digestion with the Alul restriction 
enzyme allowed to differentiate serovars A, B, 
Ba, D, E, F, G, K and the C complex (C, J, H, I 
and L3). Serovars belonging to the C complex 
were further typed by digestion with Hinfl. The 
fragments of digested DNA were resolved by 
electrophoresis on an 8 % polyacrylamide gel 
and visualized by ethidium bromide staining. 
Later on, for comparing and proving the RFLP 
results, sequencing of the omp 1 gene of 
clinical isolates was done. For the sequencing 
of the omp\ gene, DNA was purified using the 
Wizard PCR Preps DNA Purification System 
(Promega). The sequencing was carried out on 
the ABI PRISM 310 genetic analyzer (PE 
Biosystems) using BigDye DNA sequencing 
kit according to the manufacturer's 
instructions. The omp 1 sequences were edited, 
aligned, and analyzed using the software 
Lasergene 5.0 Package Dnastar, Wisconsin. 
The ompl gene was successfully 
amplified and genotyped from all 22 C. 
trachomatis positive clinical isolates and from 
eight C. trachomatis reference strains. Thus, 
on the basis of two enzymatic digestions, five 
different genotypes of C. trachomatis in 
clinical isolates were recognized: in 12 isolates 
genotype E, in five genotype F, in three 
genotype K, in one isolate genotype G and in 
another one genotype D were determined. 
These results were entirely confirmed by 
sequence analysis. 
The prevalence of C. trachomatis 
genotypes in Slovenia is similar like in other 
European countries, where genotype E is the 
dominant genotype, followed by genotypes F, 
K, G, and D. The results obtained by 
genotyping of the ompl by RFLP analysis 
showed a high correlation with sequencing 
results. Furthermore, this study also indicated 
that genotyping of clinical C. trachomatis 
isolates by the PCR- RFLP analysis is 
relatively simple method and it could be useful 
for studying C. trachomatis epidemiology. 
Sequencing is a highly reliable 
epidemiological tool, but it is laborious and 
expensive. 
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CHLAMYDIAL INFECTION IN NON-PREGNANT WOMEN WITH 
ENDOCERVICITIS IN ST.-PETERSBURG 
Shirshova N., Shipitsyna E., Savicheva A., Polyanin A., Domeika M.* 
The D.O. Ott Research Institute of Obstetrics and Gynecology, St.-Petersburg, Russia *Swedish 
Institute for Infectious Diseases Control, Uppsala, Sweden 
Objective: Investigation of the 
frequency of Chlamydia trachomatis detection 
in non-pregnant women with endocervicitis. 
Diagnosis of cervicitis was based on 
results of clinical examination, "Bed-side" 
microscopy and microscopic investigation of 
cervical specimens Gram stained. For 
detection of C. trachomatis, Ureaplasma 
urealyticum, Mycoplasma hominis, 
Mycoplasma genitalium, herpes simplex virus 
(HSV) and human papillomavirus (HPV) 
polymerase chain reaction was used. 
A total of 70 non-pregnant women 
(aged 18 to 43) with endocervicitis were 
examined. C. trachomatis were detected in 26 
women (37.1%). In 24 women (34.2%) were 
found U. urealyticum, in 13 (18.5%) - M. 
hominis, in 3 (4.2%) - M. genitalium. 
The frequency of detection of HSV and HPV 
was 10% (7 of 70) and 22.8% (16 of 70), 
respectively. In 6 women of 26 (24%) there 
were the cases of C. trachomatis 
monoinfection, whereas in 20 women (76%) 
chlamydiae were detected in association with 
other microorganisms: in 20% of cases C. 
trachomatis were found along with U. 
urealyticum, 6% - mycoplasmas, 6% - HSV, 
and 44% - HPV. 
C. trachomatis is the leading cause of 
endocervicitis in non-pregnant women in St.-
Peterburg. 
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CHLAMYDIAL INFECTION MAY EXPLAIN SPOTTING 
Per-Anders Märdh, Bo Sikström*, Elisabeth Nagy** 
Department of Obstetrics and Gynecology, Lund University, Lund, *Carolina Clinic, Uppsala, 
Sweden, **Department of Clinical Microbiology, University of Szeged, Szeged, Hungary 
Chlamydia trachomatis is known as a 
causative agent of endometritis. One result of 
starting oral contraceptive use is spot 
bleedings, which has generally been believed 
to be due to hormonal imbalance. Women 
starting to take the pill either start sexual life 
or have changed sexual partner. 
Forty-five women, 18-29 years with 
spotting and 47 age-matched women without 
such bleeding disturbances were investigated 
after they had started to take oral 
contraceptives. They were all checked for 
vaginal flora changes by studying wet and 
stained vaginal smears and they were tested for 
Amsel's criteria. Furthermore, all were tested 
for C. trachomatis by performing cultures on 
cycloheximide-treated McCoy cells of cervical 
specimens and of endometrial aspirates on 
those who developed spotting. The 
endometrial aspirates were tested for bacteria, 
including anaerobes. Those with chlamydial 
infection were given 300 mg lymecycline 
twice daily for 10 days and those with vaginal 
flora changes were prescribed 400 mg 
metronidazole twice daily for 7 days. The 
number of spotting in the groups given and not 
given antibiotic therapy before starting the next 
pill chart were noted. 
The number of women with and 
without spotting who were chlamydia-positive 
were 10 (22.2%) and 5 (10.6%), respectively 
(p<0.05). In three women with spotting only 
the endometrial aspirate was chlamydia-
positive. Vaginal flora changes occurred in 18 
(40.1%). In those in whom lactobacilli 
predominated in the vagina, the corresponding 
figure was 6 (12.8%) (p<0.01). In those with 
flora changes, 8 (17.8%) had a positive 
bacterial culture (but chlamydia-negative) from 
the endometrium. In the group with a positive 
microbiological finding, the number of 
spotting per 28 days was reduced from 5.2 to 
1.7 after antibiotic treatment (p<0.01). In 
those, who were not infected by Chlamydia 
trachomatis and who had no flora change and 
who not received an antibiotic drug, the 
episodes of spotting decreased from 7.3 to 3.9 
(p<0.05). 
In a woman who starts on the pill and 
who get spottings, search for an infectious 
cause should be made (and not only change 
branch of contraceptive as in generally made 
today). Search for a genital chlamydial 
infection in these women may prevent the 
infection from becoming chronic and causing 
serious complications and sequelae. 
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CHLAMYDIA TRACHOMATIS HEAT-SHOCK-PROTEIN 60 (CHSP60) ANTIBODIES 
IN WOMEN WITHOUT AND WITH TUBAL PATHOLOGY USING A NEW 
COMMERCIALLY AVAILABLE ASSAY 
J. Spaargaren1, C.J. Bax2,3, P.M. Oostvogel4, J.B. Trimbos2, P.J. Dörr3, A.S. Peña5, S.A. Morré5 
'Public Health Laboratory, Municipal Health Service, Amsterdam department of Gynecology, Leiden 
University Medical Center, Leiden, department of Obstetrics and Gynecology, MCH Westeinde Hospital, 
The Hague, department of Medical Microbiology, MCH Westeinde Hospital, The Hague. 5Laboratory of 
Immunogenetics, Section Immunogenetics of Infectious Diseases, VU University Medical Center, 
Amsterdam. The Netherlands 
Chlamydial heat shock protein 60 
(cHSP60) assays are extensively used in assessing 
serological responses to urogenital C. trachomatis 
infection. Although comparison of the different 
"in-house" assays is difficult due to a lack of 
standardization, there is a consensus among the 
users of these assays that the anti-cHSP60 
responses in women increase with the severity of 
C. trachomatis associated disease, leading to the 
suggestion that the high amino acid sequence 
homology between chlamydial and human HSP60 
results in autoimmune-mediated fallopian tube 
damage. Due to the significance of the possible 
association of the response to cHSP60 and 
progressive disease, a commercially produced 
assay that employs defined recombinant cHSP60 
should allow for the comparison of results 
obtained in different laboratories, as well as 
forward the use of cHSP60 as a diagnostic tool if 
the assay proves to be relevant in predicting 
pathology or clinical outcome of a urogenital 
chlamydial infection. This study evaluated a 
recently introduced commercially available 
cHSP60 serologic assay and determined the anti-
cHSP60 responses in three gynaecologically well-
defined groups of women. 
Group 1 consisted of women without tubal 
pathology as assessed by either hystero-
salpingography or laparoscopy (n=21), Group 2 
consisted of pregnant women (unknown tubal 
status, proven fertility; n=86), and Group 3 
consisted of women with confirmed (based on 
hysterosalpingography or laparoscopy) tubal 
pathology (n=ll). C. trachomatis positivity was 
assessed previously using one of the following 
serologic assays: MIF (BioMerieux's 
Hertogenbosch, The Netherlands), BAG 
Chlamydia EIA (Biologische Analysensystem 
GmbH, Lich, Germany) and the CT-pELISA 
(Medac, Wedel, Germany). The study groups and 
techniques described previously. The cHSP60 
assay (Medac, Wedel, Germany) was performed 
according to the manufacturers instructions. 
C. trachomatis IgG positivity was 
previously determined to be 19% for Group 1, 
40% for Group 2, and 64% for Group 3, showing 
the expected clear difference in IgG sero-
prevalence between women with and without 
procedure-confirmed tubal pathology, while an 
intermediate prevalence was observed in pregnant 
women. The same pattern but with lesser incidence 
was observed in the anti-cHSP60 responses being 
4.8, 16 and 27%, for Groups 1-3, respectively (Chi 
squared test for trend: Chi=3.1, p=0.079, group 1 
vs group 3: p=0.096, OR 10.6). The incidences of 
anti-cHSP60 were increased in the CT IgG positive 
subgroups to 25, 35 and 43%, for Groups 1-3, 
respectively (see panel 2 in figure 1), while only 
3.8% anti-cHSP60 titers were observed in the C. 
trachomatis IgG negative subgroups, all in 
subgroup 2 (unknown tubal status, proven 
fertility). This indicates that the concordance 
between CT IgG and cHSP60 positivity is high, 
almost 90%, however, clearly a different subgroup 
of women is identified by the cHSP60 assay since 
only 40% of the C. trachomatis IgG positive 
women has a cHSP60 response (measurement of 
agreement: kappa 0.371). Finally, the median 
cHSP60 titers increased from group 1 to 3: 50, 100 
and 200, respectively, suggesting an association 
between the level of cHSP60 response and tubal 
pathology. 
The standardization cHSP60 serology 
provided through this new commercially available 
assay will potentially enhance the comparability of 
cHSP60 results between laboratories. The results 
presented here, although obtained in small but 
well-defined groups, look suggestively promising. 
Indeed, power calculations (alpha =0.5, beta=0.1) 
show that doubling (1.7 times) the size of the 
(sub)groups would results in significant p-values 
instead of clear trends. However, further studies 
are needed in larger groups with different degrees 
of pathology due to C. trachomatis infections to 
further determine the diagnostic, prognostic and 
clinical relevance of this new assay. 
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CHLAMYDIA TRACHOMATIS IN FRESH TISSUE FROM THE FALLOPIAN 
TUBES OF PATIENTS WITH ECTOPIC PREGNANCY 
1 1 2 Carina Bjartling , Stellan Osser and Kenneth Persson * 
Departments of 'Obstetrics and Gynecology and 2Clinical Microbiology, Malmö University 
Hospital, Malmö, Sweden 
Ectopic pregnancy (EP) has been 
associated with previous infection by 
Chlamydia trachomatis in serological studies. 
It is assumed that damage of the Fallopian 
tubes is the result of prior salpingitis. The 
presence of C. trachomatis (Ct) in tubal tissue 
from patients with EP has been reported by 
some groups but other studies have failed to 
demonstrate organisms or DNA from Ct in 
such tissue. We have previously examined 
archival material of tubal tissue from patients 
with ectopic pregnancy but failed to detect Ct 
DNA (1). In this study we have examined fresh 
tubal tissue samples from patients with EP. 
Fresh frozen tubal tissue from 55 
patients with EP was collected and then 
examined for the presence of Ct DNA by 
polymerase chain reaction (Cobas Amplicor™, 
Roche Molecular Systems Inc. Branchburg 
N.J. USA). Blood samples were obtained from 
each patient and analysed for antibodies to c-
hsp60, h-hsp60 by Elisa (Medac GmbH, 
Wedel Germany) and antibodies to Ct by an in-
house microimmunofluorescence method 
(MIF). 
Ct DNA was not detected in any of the 
55 tissue specimens from the Fallopian tubes 
of patients with ectopic pregnancy. The tissue 
extraction procedure was checked by spiked 
samples. 
Chlamydial antibodies by MIF and antibodies 
to chlamydial heat shock protein 60 were more 
common in a subgroup of patients with ectopic 
pregnancy who had a history of prior salpingits 
or who at operation had signs suggesting 
previous salpingitis. Antibodies to human heat 
shock protein 60 were not associated with 
ectopic pregnancy. 
DNA of C. trachomatis was not 
detected in this study of fresh frozen tissue of 
the Fallopian tubes from patients with ectopic 
pregnancies. Both MIF antibodies and 
antibodies to chlamydial hsp60 were 
associated with ectopic pregnancy in a 
subgroup of women with a history or signs of 
previous salpingitis. Thus persistent infection 
of C. trachomatis could not be demonstrated in 
our patients with EP although a subgroup had 
serological markers of previous Ct infection. 
Reference 
Osser S, Persson K. Chlamydial antibodies and 
deoxyribonucleic acid in patients with ectopic 
pregnancy. Fertil Steril 1992; 57:578-82. 
228 - CLINICAL DISEASES 
INFLUENCE OF CHLAMYDIA TRACHOMATIS INFECTION IN COUPLES 
CONSULTING IN AN IVF CENTER: PROSPECTIVE STUDY 
B. de Barbeyrac1*, A. Papaxanthos2, C. Mathieu3, C. Germain4, J.L. Brun3, G. Chçne4, 
G. Mayer2, C. Bébéar1, C. Hocké3 
'Laboratoire de bactériologie, 2Laboratoire de biologie de la reproduction,3 Service de gynécologie 
4Unité de soutien méthodologique à la recherche clinique et épidémiologique, Hôpital Pellegrin, 
Hôpital Saint-André, CHU Bordeaux, France 
C. trachomatis infection is the most 
common bacterial STI throughout the world. The 
role of C. trachomatis as an etiologic agent of 
female infertility is well established but its role in 
male infertility is controversial. The aims of this 
prospective study were 1) to investigate the 
prevalence of C. trachomatis infection in subfertile 
couples 2) to study the possible relationship 
between markers of C. trachomatis infection and 
male infertility 3) to determine whether a 
relationship exists between previous exposure to 
C. trachomatis and the pregnancy rate in vitro 
fertilization (IVF). 
A total of 277 consecutive couples 
consulting for infertility and IVF in Pellegrin 
Hospital, without symptoms of genital tract 
infection, were included. Couples were screened 
for C. trachomatis by using PCR test (Cobas 
amplicor, Roche) in biological specimens: first 
void urine of the female and male partners, semen 
specimen, and endocervical material. In men, the 
ejaculates were also used for microscopical semen 
analysis according to the WHO criteria. Serologic 
testing was performed in both partners for anti-
chlamydial IgG and IgA antibody by using Elisa 
(seroCT, BMD, France). Pregnancy rate was 
defined as positive PhCG > 1000UI/L or an 
echographic gestational sac. 
The characteristics of the studied 
population was as following: mean age 34.6 y for 
male and 32.1 y for female, duration of infertility 
3.9 y for both. The principal indication of IVF was 
tubal factor 32.5%, endometriosis 6.5%, 
dysovarian function 12.3%, male infertility 35.7% 
and others 13%. Genital C. trachomatis was 
identified (positive PCR) in 1.15% (IC 0.24%-
3.33%)(3/260) of males and 2.68 % (IC 1.09%-
5.45%) (7/261) of females. In men, results of 
serologic testing were positive in 28/267 sera 
(10.5%) and in 16/245 semens (6.5%). When 
combining all chlamydial markers, 17.31% 
(40/231) have at least one positive marker. In 
female, results of serologic testing were positive in 
49/268 sera (18.3%). When combining all 
chlamydial markers, 20.39% (52/255) have at least 
one positive marker. Both, male and female, were 
positive in 17 cases. No relationship was observed 
between presence of chlamydial infection markers 
in men and altered semen characteristics. Out of 
209 undergoing IVF, 43 women (20.6%) became 
pregnant and 30 (14.4%) had term deliveries. 
Fifty-two couples with at least one positive marker 
were compared to 119 couples without positive 
marker for IVF outcome. Couples with positive 
markers had a pregnancy rate of 23.1% (12/52) as 
compared to 20.2% (24/119) with negative marker. 
The incidence of early pregnancy loss was 9.6% 
(5/52) and 4.2% (5/119) respectively in the 
positive and negative groups (p = 0.42). 
In our population, the prevalence of C. 
trachomatis infection is low and the C. 
trachomatis infection, present or passed, do not 
seem to have a negative influence on semen 
characteristics and on outcome of IVF in subfertile 
couples. Our results are in accordance with other 
studies in comparable groups of subfertile couples. 
In this subfertile population, chlamydial serology 
can be a good predictor of tubal disease in infertile 
women, however there is no relationship between 
the presence of any positive marker of C. 
trachomatis infection and the quality of semen and 
the pregnancy rate in IVF. 
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SEROLOGY COMPARISON BETWEEN PATIENTS WITH ECTOPIC 
PREGNANCY AND PATIENTS WHO UNDERWENT SURGICAL 
STERILIZATION 
Victoria Paredes, M. Angélica Martinez*, Hugo Salinas 
Department of Gynaecology Hospital Universidad de Chile José Joaquín Aguirre and Instituto de 
Ciencias Biomédicas, Facultad de Medicina Universidad de Chile, Suecia, Santiago, Chile 
Objective: To perform a case control 
study for correlating the serological response 
to Chlamydia trachomatis and ectopic 
pregnancy. 
One hundred and four subjects were 
enrolled in this study. Among them, 16 were 
enrolled from women with ectopic pregnancy 
and 88 from women who underwent surgical 
sterilization. Serum samples were obtained at 
the enrollment time and tested for IgM and IgG 
antibodies to C. trachomatis by the indirect 
fluorescent antibody (IFA) technique 
(BioMerieux, France), according to the 
manufacturer's instructions. Doubling 
dilutions of test sera from 1:16 to 1:64 in PBS 
were incubated at 35° for 30 min with slides 
and then washed twice for 5 min with PBS. 
Fluorescein isothiocyanate conjugated 
antiserum (Zeus, USA) was then applied to 
slides. The slides were again incubated and 
washed as above. Positive and negative control 
sera were included in each run. The endpoint 
title was the highest dilution of sera showing a 
strong and uniform apple green fluorescence 
staining. The presence of an IgM title >1:16 or 
an IgG title >1:32 were taken as evidence of 
current or past infection respectively. Positive 
samples were assayed for antibodies to C. 
pneumoniae by IFA. A statistical analytical 
comparison between the proportions was 
performed. 
31.2% of the patients diagnosed with 
ectopic pregnancy had a title of IgG > 1/32, 
whereas 4.5% of control patients had a positive 
C. trachomatis serology. This difference was 
statistically significant. IgM was present in 
12.5% patients, and in no patients of the 
control group. 
The results obtained in the study 
suggest a correlation between a positive 
serology to Chlamydia trachomatis and the 
occurrence of ectopic pregnancy. IgM was 
detected in a few patients, which suggest that 
the acute infection wasn't related directly to 
the occurrence of ectopic pregnancy. 
Grant: Hospital Universidad de Chile José 
Joaquín Aguirre 
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MANAGEMENT OF PERISITENT INFECTION CAUSED BY CHLAMYDIA 
TRACHOMATIS 
M.A.Gomberg, I.N.Aniskova, A.A.Kubanova 
Central Research Institute for Skin and Venereal Diseases, Moscow, Russsia 
To eliminate persistent chlamydial 
infection in patients in whom standard 
antibiotic treatment was ineffective. 
We modified a standard cell culture 
technique by hybridizing donor cells (i.e. 
swabs from patients) and recipient cells (L-929 
in which isolation of chlamydia was 
performed) to reveal persistent forms of C. 
trachomatis in patients after ineffective 
antibiotic treatment of chlamydial infection. 
Interferon a2b (two courses of 1 mln IU per 
day for 5 consecutive days with a 2 week 
intetval; 10 mln IU per course) was used in 
patients with deteriorated immune status 
before the new prolonged course of antibiotic 
treatment (azithromycin 1.0 g 3 times with 7 
days interval) was indicated. 
In 47 patients with a history of 
ineffective antichlamydial treatment certain 
significant disturbances of immune system 
were found, such as a decrease in CD4+ cell 
count, HLA-DR+ cell count, and increased 
serum level of IgA. All these parameters 
became normal after IFN was used. 
Azithromycin when used after IFN course 
eliminated C. trachomatis in 96% of patients 
treated. 
By modifying a standard cell culture 
technique, persistent forms of chlamydia may 
be isolated. Elimination of persistent infection 
caused by C. trachomatis in patients with 
insufficient immune system is achieved when 
IFN-a2b is used before a prolonged course of 
antibiotic treatment. 
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CLINICAL RELEVANCE OF SYSTEMIC AND LOCAL IGA RESPONSES IN 
WOMEN SUSPECTED OF HAVING A UROGENITAL CHLAMYDIA TRACHOMATIS 
(CD INFECTION BUT WITHOUT THE PRESENCE OF CT-DNA 
S.A. Morré1, K. Dreesbach2, J. Merks3, R.A. Coutinho4, A.S. Peña1, J. Spaargaren3 
laboratory of Immunogenetics, Section Immunogenetics of Infectious Diseases, VU University Medical 
Center, Amsterdam. 2Medac, Diagnostic Division, Wedel, Germany. 3Public Health Laboratory, Municipal 
Health Service, Amsterdam. 4Municipal Health Service, Amsterdam, The Netherlands 
Chlamydia trachomatis infections are 
generally diagnosed by the presence of CT-DNA in 
the lower genital tract (LGT). Without CT-DNA 
presence no treatment will occur. In women with 
aberrant forms of CT infection (persistence) or: 
upper genital tract infection without LGT the 
infection can spread and they are at risk for late 
complication of a CT infection. 
Secretory IgA is the predominant immunoglobulin 
present in mucous secretions, where it plays an 
important role in the host defence against 
infection. IgA can neutralize toxin activity and 
disrupt adherence of pathogens to mucosal cellular 
receptors. 
The aim of this study was to assess the 
clinical relevance of IgA responses (local and 
systemic) in subgroups of women with regard to 
the following variables: the presence of CT-DNA, 
CT IgG responses, and symptom presentation. 
Women of Dutch Caucasian origin 
(n=150) attending the STD outpatient clinic in 
Amsterdam, The Netherlands, were included in 
this study. A standardized questionnaire was used 
to assess self reported symptom presentation at the 
moment of consultation. Cervical swabs were 
taken for the detection of CT-DNA (Roche; 
Hoffman-LaRoche, Basel, Switzerland) and the 
local IgA immune response. Venous blood was 
collected for the analysis of IgG and IgA 
antibodies against C. trachomatis. In serum, the 
CT-IgG pELISA and the CT-IgA pELISA (Medac, 
Wedel, Germany) were performed according to the 
manufacturers instructions and modified for 
detection of local IgA antibodies. Finally, co-
infection status was determined for C. albicans, N. 
gonorrhoeae, T. vaginalis, HSV 1 and 2 in order to 
correct for symptomatology. 
Four groups of women were studied: 
I: CT-DNA positive, IgG positive (n= 36) 
II: CT-DNA positive, IgG negative (n=38) 
EI: CT-DNA negative, IgG positive (n= 38) 
IV: CT-DNA negative, IgG negative (n= 38) 
Summary of the responses (%) 
Systemic IgA; local IgA; systemic & local IgA for 
the four groups. Group I: 44;42;19. Group II: 
0;13;0. Group ffl: 29;26;13. Group IV: 3;5;0. 
Systemic and local IgA responses 
The incidence between systemic and local IgA 
responses is quite similar in the four groups except 
for group D (0% vs 13%, p=0.05, OR 12). This 
group represents most likely women with their first 
CT infection as based on CT-DNA presence, who 
have no IgG response and no systemic CT-IgA, 
and whose immune responses are restricted to the 
local lower genital tract side of infection. 
Concordance between IgA responses 
Both in group I and in group HI one third of the 
samples positive for systemic or local IgA 
antibodies were actually positive for both. As 
expected, concordance between systemic and local 
IgA responses was exclusively observed in the 
people with systemic IgG responses. 
Relation between symptoms and IgA responses 
With regard to the relation between 
symptomatology in a CT infection and an IgA 
responses a relation was only observed in group 
HI: systemic and local IgA responses were 15% in 
women without symptoms and 36% in women 
with symptoms (p=0.2, OR 3.1) Women with co-
infections were excluded in this study since these 
co-infections could be confounding for the 
symptom presentation. 
Although clearly further studies are needed 
including follow-up investigations, IgA antibodies 
might be indicators for peripheral infections and 
assessment might be clinically relevant in women 
where CT-DNA cannot be detected in the lower 
genital tract. Both spread of CT in the population 
and late complications in the individual patient 
might potentially be prevented if these CT-DNA 
negative women with IgA responses are treated 
with antibiotics. 
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CHLAMYDIA TRACHOMATIS AND ITS EFFECT ON MALE FERTILITY 
J. Rezacova 1, J. Masata 2, M. Pribylova 3, M. Drazdakova 3 
'Gynecology and Obstetrics - ÜPMD, 3rd Medical Faculty of Charles University, Department of 
Gynecology and Obstetrics of the General University Hospital, 1st Medical Faculty of Charles 
University, Department of Dermatology of the General University Hospital, 1st Medical Faculty of 
Charles University, Prague, Czech Republic 
Chlamydia trachomatis is one of the most 
frequent causes of uro-genital infection. For 
women, chronic inflammation provoked by this 
bacteria causes occlusion of tubes, and occurrence 
of chlamydial uro-genital infection is linked to 
male fertility defects, too. It is characteristic for 
chlamydial infection, that it is often asymptomatic, 
or with very mild clinical symptoms. Thus, 
laboratory methods are particularly important for 
its timely detection and treatment. In our study, we 
attempted to compare results of laboratory tests 
(detection presence of Chlamydia trachomatis in 
ejaculate using DNA amplification method, 
detection of IgA and IgG anti-chlamydial 
antibodies in blood serum and ejaculate), with 
results of spermiograms of the males examined, 
and with total number of their sexual partners. We 
assumed, that with increasing number of sexual 
partners, probability of chlamydial uro-genital 
infection grows, which may be a cause of 
deterioration of spermiologic parameters. All 
patients where laboratory tests suggested present 
infection were treated and their spermiograms 
were checked 8 weeks later. 
266 males of infertile married couples 
were examined. For all males, spermiograms were 
evaluated according to WHO criteria. Specific 
anti- Chlamydia trachomatis IgA and IgG 
antibodies in blood serum and ejaculate were 
tested using ELISA method. DNA of Chlamydia 
trachomatis amplification was performed by LCR 
using MEIA method. Total number of sexual 
partners of the males was ascertained by a targeted 
questionnaire. For statistical evaluation, %2 was 
used. 
Of the entire group of 266 males 
examined, abnormal spermiograms were detected 
for 129 (48%) males. Due to the number of sexual 
partner, males were divided into 3 groups: a) 1 
partner, b) 2-5, c) 6 and more partners. 50 males 
had one partner (the 1st group), 110 belonged to the 
2"d group and 106 to the 3rd group. In each group, 
a number of males with normal and abnormal 
spermiograms were compared. Results were 
statistically significant - with increasing number 
of sexual partners, occurrence of pathospermia 
increased. For only two (1%) of males examined, 
the presence of Chlamydia trachomatis in 
ejaculate was proved through tested using LCR. 
However, anti-chlamydial IgA and IgG antibodies 
were detected in blood serum or ejaculate, or in the 
blood serum and at the same time also in the 
ejaculate. For 38 males with IgA antibodies in 
ejaculate, pathospermia was ascertained as well. 
One of them had only one sexual partner, 12 males 
had 2-5 partners and 25 males with presence of 
IgA antibodies in ejaculate had 6 and more 
partners. All males with IgA positive ejaculate was 
treated by lg of Azitromycin, and their 
spermiograms were checked in 8 weeks after the 
treatment. For 20 (61%) out of 33 (5 did not 
appear for the check-up) males with pathospermia, 
spermiograms improved to the norm. 
266 male partners of infertile couples were 
examined. For 129 (48%) of them, abnormal 
spermiograms were ascertained. With increasing 
number of sexual partners, the number of males 
with pathospermia was increasing, with statistical 
significance. Only for two of the males examined 
(1%) was Chlamydia trachomatis detected in 
ejaculate. For all 38 males with positive anti-
chlamydial IgA antibodies in ejaculate, abnormal 
spermiograms were detected, and 25 (56%) of 
them had 6 and more sexual partners. After the 
treatment, spermiograms improved to 
normospermia for 20 of 33 (61%) males originally 
with pathospermia (5 did not appear for the check-
up). In these cases, detection of IgA anti-
chlamydia antibodies in ejaculate proved to be an 
indicator of the presence of infection which had 
not been detected by LCR test. 
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THE ROLE OF CHLAMYDIA TRACHOMATIS IN PROSTATITIS SYNDROME 
Visnja Skerk1, Ivan Krhen2, Slavko Schonwald11, Vjeran Cajic, Leo Markovinovic1, 
Srdan Roglic1*, Sime Zekan1, Aijana Tambic Andrasevic1, Vladimira Kruzic3 
1 9 
University Hospital for Infectious Diseases "Dr. Fran Mihaljevic", Clinic for Urology, Clinical 
Hospital Centre Rebro, 3Croatian Institute of Public Health, Zagreb, Croatia 
A total of 1442 patients with symptoms 
of chronic prostatitis were examined over a 4 
year period at the Outpatient Department for 
Urogenital Infections, University Hospital for 
Infectious Diseases "Dr. Fran Mihaljeviae", 
Zagreb, Croatia. An infectious aetiology was 
determined in 1070 (74,21%) patients. In 561 
(52,4%) of 1070 patients the inflammatory 
finding (>10 WBCs/hpf) was found in EPS or 
VB3. 
Normal, <10 WBCs/hpf was found in 
362 (67,54%) of 536 patients with symptoms .. .„•••'• 
of chronic prostatitis in whom C. trachomatis 
was detected in EPS or VB3, in 51 (33,77%) 
out of 151 patients with isolated Trichomonas 
vaginalis and in 40 (55,56%) out of 72 patients 
with isolated Ureaplasma urealyticum. 
Escherichia coli was the causative pathogen in 
95, Enterococcus in 68, Proteus mirabilis in 
37, Klebsiella pneumoniae in 16, 
Streptococcus agalactiae in 19, and 
Pseudomonas aeruginosa in 3 patients with 
chronic prostatitis. Other patients had a mixed 
infection. In patients with chronic bacterial 
prostatitis caused by E. coli, P. mirabilis, Kl. 
pneumoniae, Enterococcus or Streptococcus 
agalactiae, an inflammatory finding was 
regularly found in EPS or VB3. 
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ANTIBODIES AGAINST THE CHLAMYDIAL HEAT SHOCK PROTEIN IN 
BLOOD SERA AND SEMINAL PLASMA OF MEN (MALE PARTNERS OF 
SUB FERTILE COUPLES, DONORS OF SEMEN AND BLOOD DONORS) 
Zuzana Medkova1, Leopold Pospisil2, Jiri Canderle2, Hana Stroblova3 
'Department of Immunology, Laboratories BIO-PLUS, Brno, Veterinary Research Institute, Brno, 
department of Microbiology University Hospital Bmo, Brno, Czech Republic 
The aim of the study was the evaluation 
of the presence of DNA C. trachomatis in 
urine and semen, species specific antibodies 
against major outer membrane protein 
(cMOMP) and antibodies against 60 kD heat 
shock protein (cHsp60) C. trachomatis in 
seminal plasma and/or blood of three different 
fertility-related groups of men (male partners 
of subfertile couples, donors of semen, blood 
donors). 
The DNA C. trachomatis in semen 
(PCR, Cobas Amplicor, Roche), IgG 
antibodies against the cHsp60 (ELISA medac) 
and species specific IgA and IgG antibodies 
against the cMOMP (ELISA medac) in the 
blood serum and seminal plasma in 46 men 
from couples with fertility disorders and in 15 
of semen donors were estimated. The third 
examined group was represented by 49 blood 
donors; in the last group the antibodies of the 
blood serum only were evaluated. 
The anti-cHsp60 antibodies in the 
seminal plasma of men from couples with 
fertility disorders were detected in 3 cases 
(6.5%), in the serum in 16 cases (34.8%). The 
anti-cMOMP antibodies in the ejaculates were 
detected as IgA isotype in 9 cases (19.6%) and 
in 2 cases IgG (4.3%). The anti-cMOMP 
antibodies in the serum were detected as IgA 
isotype in 2 cases (4.3%) and in 6 cases IgG 
(13.0%). The anti-cHsp60 antibodies in the 
seminal plasma of the sperm donors were not 
found but in the serum they were detected in 3 
cases (20.0%). The anti-cMOMP antibodies in 
their ejaculates were detected as IgA isotype in 
4 cases (26.7%) but not a single case in the 
IgG. The anti-cMOMP antibodies in the serum 
were not detected as IgA isotype, but in the 
IgG they occurred in 3 cases (20.0%). The 
anti-cHsp60 antibodies in the blood serum of 
the blood donors were detected in 11 cases 
(22.4%), in two of them only the specific anti-
cMOMP antibodies were proved. No specific 
DNA of C. trachomatis was found in the 
ejaculates and urine in the groups of infertile 
men and donors of semen. 
There are strong signs of contact to 
C. trachomatis infection in all tested groups of 
men. However, the evaluation of the stage of 
infection based on serology is problematic 
(probably except the presence of anti-cHsp60 
antibodies in samples from infertile men as the 
marker of the possibility of the 
immunopatological stage). The results indicate 
the urgent need for screening high-risk groups 
of young people. 
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COST EFFECTIVENESS ANALYSIS OF SCREENING UNITED STATES 
ARMY MALE BASIC TRAINING RECRUITS FOR CHLAMYDIA 
TRACHOMATIS 
Eric E. Shuping, LTC, MC1, Joel C. Gaydos MD, MPH2, Charlotte A. Gaydos MS, 
MPH, DrPH3 
'General Preventive Medicine Residency, The Walter Reed Army Institute of Research (WRAIR), 
Silver Spring, MD, 2United States Department of Defense Global Emerging Infections 
Surveillance and Response System (GEIS), WRAIR, Silver Spring, MD, The Johns Hopkins 
University School of Medicine, Baltimore, MD, USA 
To determine the cost effectiveness of 
screening active duty United States Army male 
recruits for Chlamydia trachomatis when they 
first report for military duty. 
A decision analytical model was 
applied to three screening strategies using a 
urine nucleic acid amplification test (NAAT): 
no screening, screening all male recruits, and 
screening only male recruits age 24 years or 
less. A two-year analytical horizon with a 
societal perspective was used. The main 
outcome was cases of pelvic inflammatory 
disease (PID) prevented. Secondary outcomes 
included chronic pelvic pain and Chlamydia 
induced male urethritis. Probability and cost 
estimates were obtained from prior studies, 
literature review and discussions with subject 
matter experts. Male probability estimates 
included Chlamydia prevalence, treatment side 
effects, symptomatic Chlamydia infection 
treatment and male to female transmission. 
Female probabilities included partner 
notification, female community screening, PID 
development and treatment, and chronic pelvic 
pain. The model included screening costs, 
costs for treatment of people with positive 
screening tests, to include costs of notified 
partner treatment, costs of side effects after 
treatment, outpatient and inpatient PID costs, 
and the cost of chronic pelvic pain. Screening 
test sensitivity was considered to be 91.3%, 
with 99.1% specificity. Sensitivity analyses 
were performed on the probabilities used. All 
costs were discounted at 3.0% per year. 
A theoretical cohort of 10,000 
unscreened male recruits of all ages, with a 
Chlamydia prevalence of 5.3%, resulted in 197 
cases of PID, with a cost of $ 302,184 (1st 
strategy). This same cohort of all ages was 
tested using a NAAT costing $15 per person 
(2nd strategy). The probability of partner 
notification was set at 25.0% and the 
probability of a new partner of an untreated 
male was estimated to be 28.0%. This strategy 
resulted in a cost of $450,506 and prevention 
of 59 cases of PID, 12 cases of chronic pelvic 
pain and 68 male urethritis cases, compared to 
no screening. Similarly, screening cohort 
members age 24 years or less (N=8,900, 
Chlamydia prevalence of 5.6%) (3rd strategy) 
resulted in a cost of $ 429,007, with prevention 
of 56 cases of PID, 12 cases of chronic pain 
and 58 male urethritis cases, compared to no 
screening. The incremental cost effectiveness 
ratio (ICER) of screening all recruits compared 
to no screening was $2,514 per case of PID 
prevented. The ICER ratio of screening 
recruits age 24 years and younger, compared to 
no screening, was $2,265 per case of PID 
prevented. Sensitivity analyses were done for 
cost of the test, partner notification and new 
partners of untreated males. When the cost of 
the NAAT was reduced to $10 per test, partner 
notification was increased to 50% and future 
partners of untreated males was increased to 
50%, the ICER of screening males age 24 
years and younger was $ 709 per case of PID 
prevented, compared to no screening. 
Screening for Chlamydia trachomatis 
in United States Army male recruits reporting 
for military duty was not cost effective in this 
decision model. However, the military may 
benefit from the early prevention of male and 
female disease. Cost-effectiveness might be 
achieved through the integration of both male 
and female screening programs. 
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CHLAMYDIA TRACHOMATIS AND NEONATAL CONJUNCTIVITIS IN A 
DUTCH INNER CITY 
Rours G.IJ.G*1, de Groot R1, de Faber T2, Verbrugh H3, Verkooyen R3 
department of Paediatrics, Erasmus Medical Center, Rotterdam, department of Ophthalmology, 
Eye Hospital, Rotterdam, department of Medical Microbiology, Erasmus Medical Center, 
Rotterdam, The Netherlands 
C. trachomatis is the most common 
sexually transmitted infection in The Netherlands 
these days, but no data are available concerning 
the impact of chlamydial infection for newborns 
and infants. The purpose of this study was to 
evaluate the role of C. trachomatis as causative 
pathogen for neonatal conjunctivitis with a focus 
on diagnostic testing, clinical presentation and 
empiric treatment while comparing chlamydial 
conjunctivitis to conjunctivitis due to other 
pathogens. 
A prospective and retrospective study was 
done in 2 next-door inner city clinics in Rotterdam. 
Retrospectively bacterial conjunctivitis in infants 
less 3 months of age presenting between July 1996 
and 2001 was analyzed using data from medical 
records and a Problem Orientated Classification 
System in the Sophia Pediatric Hospital, and from 
medical records in the Eye Hospital. Prospectively 
bacterial conjunctivitis according to the same 
criteria presenting between September 2001 and 
2002 was analyzed. Patients with clinically viral 
conjunctivitis or dacryostenosis, who were not 
tested and not treated with antibiotics but 
improved, were excluded from the study. 
Eligible were for the study were 87 infants 
with 64 infants retrospectively, who had a median 
age of 2 weeks and 23 infants prospectively with a 
median age of one week. Microbiological testing 
was done for 59 infants in the retrospective study 
of whom 42 infants also had a chlamydial PCR 
done. Overall, 85% had a positive test result if 
chlamydial PCR was included in testing and 39% 
without chlamydial PCR. Prospectively all infants 
had a regular cell culture and chlamydial PCR 
done of whom 83% had a positive test result with 
inclusion of a chlamydial PCR, but 22% without 
chlamydial PCR testing. C. trachomatis was the 
most common pathogen occurring in 64% of 
patients retrospectively and 61% prospectively. All 
patients with chlamydial conjunctivitis were under 
8 weeks of age. Retrospectively and prospectively 
the number of presenting symptoms varied from 
one to three symptoms, but most patients with 
chlamydial conjunctivitis presented with 
mucopurulent discharge followed by swelling of 
the eyes and redness. Retrospectively more than 
two third of chlamydia positive patients had all 3 
symptoms suggesting a more severe clinical 
expression, but this was not found prospectively. 
In both parts of the study respiratory complications 
were found in just over a third of chlamydia 
positive infants of whom a third also had feeding 
problems. The clinical presentation was similar in 
patients with conjunctivitis due to other pathogens. 
Before microbiological diagnosis less than half the 
patients received antibiotics effective for C. 
trachomatis with a better cover up to three quarter 
of patients in the chlamydia positive group. 
General practitioners used in less than 20% an 
antibiotic effective for chlamydia opposed to more 
than half the ophthalmologists. Very little systemic 
treatment was given. 
C. trachomatis is the major cause of 
bacterial conjunctivitis in infants consulting these 
clinics. Clinically no distinction can be made 
between conjunctivitis due to chlamydia or other 
pathogens and untreated chlamydial conjunctivitis 
can lead to respiratory complications with 
subsequent feeding problems. The majority of 
empiric treatment did not cover chlamydial 
conjunctivitis. 
This knowledge should impact the 
choice of diagnostic testing as well as the 
choice of antimicrobials and route for 
(empiric) treatment of neonatal conjunctivitis 
in this population. 
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SENSITIVITY AND SPECIFICITY OF A DUAL AMPLIFICATION 
CHLAMYDIA TRACHOMATIS IMMUNE-ASSAY IN CONJUNCTIVAL 
SPECIMENS COMPARED TO THE POLYMERASE CHAIN REACTION 
Iren Budai1, Csaba L. Marodi1, Jeannette Toth2 
'institute of Medical Microbiology and 21st Department of Ophthalmology, Faculty of General 
Medicine Semmelweis University, Budapest, Hungary 
Culture or direct immune fluorescent 
assay (DFA) is not widely accessible methods 
for Chlamydia trachomatis detection. Nucleic 
acid amplification tests (NAATs) are too 
expensive for extended application. Enzyme 
immune assays (EIAs) are cheap and easy to 
use, but their sensitivity varies in range 48-
91% depending on the individual test used and 
the comparative methods. Only few tests are 
approved for use with conjunctival specimens. 
Aim of this work was to determine the 
sensitivity of a dual amplification EIA 
compared to PCR in conjunctival specimens of 
symptomatic patients. 
In the period between June 2002-
March 2004, 101 conjunctival swab samples 
were collected by ophthalmologists from 
patients (age: 1 week-80 years, male/female: 
53/48) with the symptoms of acute or chronic 
conjunctivitis. Swabs were placed into special 
transport tube of DAKO IDEIA™ PCE test 
system. Samples were stored after collection at 
- 20 °C until testing. Prior to the analysis, 
samples were thawed at room temperature, 
whirly-mixed and heat-treated at 95 °C for 30 
minutes using water-bath. A volume of 100 
microlitre of re-cooled sample from each tube 
was transferred to Roche Amplicor™ 
Specimen Transport Medium swab test system 
tube and stored at - 20 °C until testing. EIA 
and PCR were performed according to the 
manufacturers' instructions. 
From the 101 samples, 18 were positive 
and 12 were borderline as tested by EIA. After 
the confirmatory PCR analysis, 27 out of 101 
appeared to be positive. All the 18 EIA 
positives were PCR positive respectively. 
Eight of the 12 borderline results were 
confirmed by PCR, 4 of the 12 however turned 
out to be negative. Only one of the EIA 
negative sample was PCR positive. The 
sensitivity of EIA proved to be 96.4% (27/28), 
furthermore the specificity 94.8% (74/78). The 
positive predictive value (PPV) is at 87.1% 
(27/31), and the negative predictive value 
(NPV) appeared to be 98.6% (74/75). 
The data obtained by this comparative 
study on conjunctival samples using dual 
amplification EIA and PCR demonstrates that 
this EIA test has high sensitivity (96.4%) and 
NPV (98.6%), therefore it may be suitable as a 
cost-effective method for the diagnosis for 
chlamydial conjunctivitis. Its lower specificity 
(94.8%) and PPV (87.1%) indicate the need for 
a confirmatory test for borderline results. 
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OCULAR CHLAMYDIAL INFECTIONS: CLINICAL PICTURE, DIAGNOSIS, 
AND THERAPY 
Eva-Maria Haller-Schober*, Helga Lechner 
Hospital of the Medical University Graz, Austria, Department of Ophthalmology, Graz, Austria 
Chlamydiae are among the most 
common human pathogens being responsible 
for various diseases, especially in the 
urogenital (C. trachomatis D - K) and 
respiratory (C. pneumoniae) tract. 
Ocular chlamydial infections are caused by C. 
trachomatis A-C (Trachoma) or D-K 
(inclusion conjunctivitis). 
In adults C. trachomatis is commonly 
transferred from the urogenital tract to the eye 
by auto-inoculation. Especially in young 
women, where chlamydial cervicitis is often 
asymptomatic, the ophthalmologist might be 
the first physician to see a symptomatic 
chlamydial disease. Chlamydial conjunctivitis 
is rarely seen and therefore often 
misdiagnosed. The clinical picture - follicular 
conjunctivitis - is commonly caused by viruses 
or bacteria and therefore, local antiviral or 
antiinflammatory therapy or broad-spectrum 
antibiotics are prescribed. As chlamydial 
conjunctivitis does not respond to the common 
local therapy with broad-spectrum antibiotic 
eyedrops it tends to become chronic, but heals 
without complications when systemic 
macrolids or tetracyclines are given. 
In newbornes, infected by the mother during 
birth, a papillary conjunctivitis develops with 
onset of symptoms around the 5 th day after 
birth. If not diagnosed and systemically treated 
a chlamydia-associated pneumonia may 
develop. 
quick "non-culture techniques" might be a 
good alternative. One of these, a direct 
immunofluorescence assay on conjunctival 
scrapings, has proven to be sufficiently 
sensitive and specific when compared to cell 
culture and PCR. This is in accordance to our 
own observations, since we perform this 
method since 1987. 
The incidence of ocular chlamydial 
infections as observed in the Department of 
Ophthalmology in Graz from 1987 to 2003 
was 7% in adults and 0.08% in newbornes. 
Follicular conjunctivitis, especially in 
young adults, might be chlamydia-associated. 
It is commonly associated with asymptomatic 
colonization of the urogenital tract or active 
urogenital disease. Therefore, chlamydial 
conjunctivitis should be treated with both, 
local and systemic antibiotics. Oral 
azithromycin or doxycyline and locally applied 
0,3% povidone-iodine eyedrops are an 
effective combination for treatment. 
As the clinical picture is not 
pathognomonic, and C. trachomatis is 
causative in about 5 - 19% of ocular diseases, 
an exact laboratory diagnosis is important. 
Nucleic amplification methods such as PCR or 
LCR, are the most sensitive and specific 
methods, but costy and not suitable for bed-
side testing. Well established inexpensive and 
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PATHOGENIC ROLE OF CHLAMYDIA TRACHOMATIS IN PSORIATIC 
ARTHRITIS 
Iván Péter and Beatrix Farkas 
Department of Dermatology and Oncodermatology, University of Pécs, Pécs, Hungary 
Psoriatic arthritis has been defined as 
an inflammatory arthritis associated with 
psoriasis that may affect as many as 30% of 
psoriasis patients. Epidemiological study 
reported strong familial clustering of psoriatic 
arthritis although the precise etiology of the 
disease is poorly understood. Reactive arthritis 
is a common and important form of acute 
arthritis at least has a strong association with 
the presence of Chlamydia trachomatis 
infection as the most frequent sexually 
transmitted disease in the developed countries. 
patients with psoriatic arthritis can be the 
triggering microorganisms related to disease 
pathogenesis. 
To test the - hypothesis that psoriatic 
arthritis could be triggered by Chlamydia 
trachomatis infection of the urogenital tract. 
25 patents with psoriasis (psoriatic 
arthritis and psoriasis without arthritis), 25 
patients suffering from reactive arthritis 
without psoriasis and 25 healthy volunteers 
were investigated for chlamydia infection by 
detecting DNA of Chlamydia trachomatis in 
urine or cervical specimens. 
Chlamydia trachomatis infection was more 
frequent in groups of patients with psoriasis 
and reactive arthritis than in the controls 
(p<0,05). 
1. Especially evident was the high prevalence 
of Chlamydia trachomatis infection among 
patients with psoriatic arthritis compared 
with psoriasis (p<0,05). 
2. No significant differences were found in 
the rate of urogenital chlamydia infection 
between the groups of patients suffering 
from reactive arthritis and psoriatic arthritis 
(p>0,05). 
This report indicates that the presence of 
Chlamydia trachomatis in specimens from 
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THE VAGINAL COINFECTIONS OF CHLAMYDIA TRACHOMATIS 
CERVICITIS 
András Ujházy 
Semmelweis University 1st Department of Obstetrics and Gynecology, Budapest, Hungary 
The authors investigated the association 
between cervical Chlamydia trachomatis 
infection and vaginal infections among female 
adolescents and young women. Purpose of the 
study was to determine the most frequent 
vaginal coinfection with chlamydial cervicitis. 
298 volunteers participated in the study 
between the age of 16 and 24. The presence of 
C. trachomatis in the endocervix was 
evaluated using PCR test. The vaginal flora 
was examined by microscopy. The results of 
the study were evaluated in three groups of 
patients: asymptomatic women, women with 
signs and symptoms of lower genital tract 
infection, and those who were seeking legal 
abortion. 
Bacterial vaginosis was the most 
prevalent vaginal coinfection with C. 
trachomatis infection in all the three groups. 
The frequency of bacterial vaginosis was 11% 
(27/245) among patients without C. 
trachomatis infection and 29.4% (5/17) among 
those with chlamydial cervicitis. The 
prevalence of normal vaginal flora was 69.4% 
(170/245) in the group of patients without 
C. trachomatis infection compared to 29.4% 
(5/17) among women with chlamydial 
cervicitis. 
The prevalence of normal vaginal flora 
(69.4%) was significantly more common 
among patients not infected with C. 
trachomatis in the cervix compared with those 
who had cervical chlamydial infection 
(29.4%). 
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STRATEGIES FOR EXTENDED CHLAMYDIA TRACHOMATIS SEROLOGY 
IN INFERTILE PATIENTS: A CLINICAL EVALUATION OF CHLAMYDIA 
TRACHOMATIS MOMP-, CHLAMYDIAL 60KD HEAT SHOCK PROTEIN 
AND HUMAN HSP60 SEROLOGY 
Andreas Neuer*, Ying Gao**, Istvan Sziller*** and Stefan Dieterle* 
*University of Witten/Herdecke, Germany, **University of Wuhan, China, ***Semmelweis 
University Budapest, Hungary 
Tubal infertility is an important cause 
of female infertility and a frequent reason for 
IVF treatment. Several studies have shown that 
tubal infertility is mainly caused by Chlamydia 
trachomatis (C. t.) and triggered by immune 
pathologies. Chlamydial heat shock proteins, 
mainly the 60kD chlamydial heat shock protein 
(chsp60) represent important immunogenic 
antigens. It has been shown that the severity of 
a chlamydial infection and the resulting 
sequelae are associated with this antigen. The 
aim of this study was to correlate well 
established serological markers of chlamydial 
serology (C. i.-MOMP) with only recently 
available parameters of chlamydial infection 
(chsp60 and human hsp60). An evaluation of a 
possible clinical applicability was performed. 
Both chlamydial MOMP- and chsp60 
antibodies were most prevalent in patients with 
tubal factor infertility (p< 0.001). The 
combined presence of chlamydial MOMP and 
chsp60 correlated with the occurrence of 
miscarriage and ectopic pregnancy. 
The detection of chlamydial MOMP 
IgG antibodies in IVF patients reflects the 
already established high predictive value of 
this antibody with tubal occlusion. Additional 
risk factors following IVF treatment like 
miscarriage and ectopic pregnancy can be 
characterized by the combined measurement of 
chsp60 and MOMP antibodies. 
Sera samples of female patients 
undergoing IVF treatment were assayed by 
ELISA for the presence of chlamydial MOMP 
IgG and IgA, chsp60 IgG and human hsp60 
IgG antibodies (medac, Hamburg Germany). 
All patients were symptom free. No acute 
chlamydial or other infection was present. The 
following groups were investigated: 
99 patients with occluded tubes undergoing 
IVF treatment 
99 patients with male factor infertility and 
open tubes undergoing ICSI treatment 
50 patients with miscarriage after IVF 
treatment 
44 patients with miscarriage after ICSI 
treatment 
19 patients with ectopic pregnancy after IVF 
treatment 
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INFECTION WITH CHLAMYDOPHILA PSITTACI MIMICKING SIDS 
Walder G.1, Hotzel H.2, Brennsteiner G.1, Berndt A.2, Pavlik M.3, 
Dierich M.P.1 Stoiber H.1 
'institute of Hygiene and Social Medicine, Med. University of Innsbruck, Innsbruck, Austria, 
2Federal Institute of Consumer Protection and Veterinary Medicine, Jena, Germany, 3Institute of 
Forensic Medicine, Med. University of Innsbruck, Innsbruck, Austria 
We report the case of a 3 month old 
boy, who was unexpectedly found dead in his 
bed by his parents after a three day course of 
slight rhinitis. The child had been afebrile all 
the time and there were no obvious signs of 
systemic infection. Resuscitation attempts by 
the father were unsuccessful. 
Postmortem examination showed 
punctual hemorrhage of thymus, pleura and 
endocardium, slightly enlarged cervical lymph 
nodes and signs of bronchiolitis. Kidneys, 
liver, brain, spleen and adrenals appeared 
normal. Samples of the myocardium, brain, 
lung and kidneys were tested for viral and 
chlamydial infection by PCR. Tests for 
Chlamydiales were carried out using two sets 
of primers targeting the 16s-rRNA gene and 
the ompA gene. 
Chlamydial DNA was detected in the 
myocardium, CNS and lungs, only the renal 
tissue gave a negative result. Positive samples 
were subjected to sequence analysis of the 
ompA gene, which yielded >99.9% identity 
with Chlamydophilsa psittaci. The agent was 
further visualized by microscopy using anti-
LPS antibodies. 
We conclude, that the child died of 
disseminated infection with Ch.lamydoph.ila 
psittaci. Given the potentially severe course of 
illness, this agent should be considered in 
respiratory infections of children and 
investigated with suitable diagnostic methods. 
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EVIDENCE FOR CHLAMYDOPHILA PSITTACI INFECTION IN PULMONARY 
EMPHYSEMA 
D. Theegarten*1, O. Anhenn*1, H. Hotzel2, M. Wagner1, A. Marra3, G. Stamatis3, G. 
Mogilevski1, K. Sachse2 
'Department of Pathology, Ruhr-University, Bochum, department of Thoracic Surgery, 
Ruhrlandklinik, Essen, 3Institute of Bacterial Infections and Zoonoses, Federal Research Centre for 
Virus Diseases of Animals (BFAV), Jena, Germany 
Objective: Previous investigations 
suggested involvement of chlamydial infection 
in pulmonary emphysema. 
A panel of tissue samples from patients 
having undergone lung volume reduction 
surgery for advanced alpha-1 antitrypsin 
deficiency (AATD) or non-alpha-1 antitrypsin 
deficiency emphysema or wedge resection for 
hamartochondroma (n=14) was examined by 
transmission electron microscopy (n=39) and 
PCR (n=37). 
In all five cases of AATD and 27 cases 
of non-AATD (79.4%), persistent chlamydial 
infection was detected by ultrastructural 
examination. Bronchiolitis and intra-alveolar 
accumulation of macrophages were seen in all 
positive cases. The presence of Chlamydia 
psittaci was demonstrated by PCR in lung 
tissue of four AATD (66.7%) vs. nine non-
AATD emphysema patients (29.0%). Partial 
DNA sequencing of four positive samples 
confirmed the identity of the agent as 
Chlamydophila psittaci. In contrast, 
Chlamydophila pneumoniae was detected only 
in one AATD patient. Lung tissue of a control 
group of non-smokers with hamartochondroma 
was completely negative for chlamydial DNA 
by PCR or chlamydial bodies by TEM. 
These data indicate a role of 
Chlamydophila psittaci in pulmonary 
emphysema and raise interesting questions on 
pathogenesis and source of infection. 
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DETECTION OF CHLAMYDOPHILA PSITTACI AND CHLAMYDOPHILA 
ABORTUS IN INDUCED SPUTUM OF PATIENTS WITH EXACERBATED OR 
STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
O. Anhenn*1, D. Theegarten1, H. Hotzel2, K. Sachse2, G. Rohde3 
'Department of Pathology, Ruhr University, Bochum, 2Institute of Bacterial Infections and 
Zoonoses, Federal Research Centre for Virus Diseases of Animals (BFAV), Jena, department of 
Pneumology, Allergology and Sleep Medicine, University Hospital, Bergmannsheil, Bochum, 
Germany 
Previous investigations suggested 
involvement of chlamydial infection in chronic 
obstructive pulmonary disease (COPD), 
especially in advanced emphysema. The 
question was whether Chlamydophila spp. 
could be detected in induced sputum of 
patients with exacerbated versus stable COPD. 
Induced sputum from patients with an 
acute exacerbated (AE-COPD) or stable COPD 
admitted to hospital for other reasons (S-
COPD) was investigated by immuno-
fluorescence and PCR. 
Immunofluorescence revealed 16 
chlamydia-positive cases (69.6%) in AE-
COPD and ten (50%) in S-COPD. In PCR 14 
samples were positive (42.4%) in AE-COPD 
and one (4.5%) in S-COPD for Chlamydophila 
psittaci. This difference was significant 
(p<0.01). Partial DNA sequencing of six 
positive samples confirmed the identity of the 
agent as Chlamydophila psittaci in four and 
Chlamydophila abortus in two patients. 
Chlamydophila pneumoniae was not detected. 
Induced sputum is an easy and non-
invasive method for detection of Chlamydiae 
in COPD patients. Higher detection rates in 
AE-COPD indicate a role of Chlamydophila 
psittaci arid Chlamydophila abortus in 
exacerbations. 
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AN OUTBREAK OF LYMPHOGRANULOMA VENEREUM PROCTITIS 
AMONG MEN HAVING SEX WITH MEN IN ROTTERDAM, THE 
NETHERLANDS 
J.M. Ossewaarde1*, R.F. Nieuwenhuis1, J. Dees1, H.B. Thio1, M. Thomeer1, H.A.M. 
Neumann1, H.M. Götz2, MJW van de Laar3, W.I. van der Meijden1 
Erasmus Medical Center, Rotterdam, 2Municipal Health Service, Rotterdam, 3National Institute 
for Public Health and the Environment, Bilthoven, The Netherlands 
In February 2003 we encountered a 
solitary case of classical inguinal LGV presenting 
with buboes (1). A few weeks later, a patient 
presented with acute severe proctitis, but without 
the classical inguinal syndrome, which 
nevertheless was shown to be caused by C. 
trachomatis serovar L2. Contact tracing revealed 
that many more cases could be expected. The ob-
jective of this study was to determine the size of 
the outbreak and to investigate clinical and labo-
ratory findings. 
The Cobas Amplicor (Roche Diagnostics) 
was used for routine diagnosis. Antibodies to C. 
trachomatis were determined using a peptide ELA 
(SeroCT; Savyon Diagnostics Ltd.). C. trachoma-
tis PCR-positive specimens were genotyped by 
PCR-RFLP of the MOMP gene (2). The index 
patient and all first ring contacts were asked to 
inform as many contacts as possible. Active con-
tact tracing was carried out. Fifteen patients in-
cluded in the study were examined by the 
venereologist, 12 by the gastroenterologist and two 
by the radiologist. After the initial investigations 
national, European and world wide alerts were 
issued (3). 
High IgG and IgA titers to C. trachomatis 
were found in 13 patients. PCR was positive in 
rectal specimens of 12 patients, eight were 
confirmed by RFLP to be serovar L2 and one 
appeared to be serovar LI. The gastro-intestinal 
symptoms included mucous or purulent discharge 
in 11, constipation in 10 and blood loss in eight 
patients. Twelve men were HIV positive, five 
received HAART. Proctoscopy revealed mucous 
or purulent exudates in nine, ulcers in three, blood 
in two, and erythematous mucosa in two patients. 
In nine patients, sigmoidoscopy showed proctitis 
with well-demarkated ulceration and a very friable 
mucosa with easy bleeding. Biopsies demonstrated 
a chronic and non-specific inflammation, 
characterized by a granulocytic _ and 
lymphohistiocytic infiltrate in the lamina propria, 
consisting of granulocytes, lymphocytes, plasma 
cells, and histiocytes. Staining with monoclonal 
antibodies showed positive cells in the infiltrate. 
Diffuse mucosal wall thickening with submucosal 
edema, perirectal infiltration and adenopathy was 
identified on MRI images of 2 patients. All pa-
tients were treated with a three week course of 
doxycycline. During this study, one patient also 
seroconverted for HCV. Contacts were reported 
from The Netherlands (36), Germany (11), Bel-
gium (4), United Kingdom (2), and France (1). 
Most encounters were at gay parties and gay clubs. 
Most men reported unprotected anal sexual contact 
and fisting. As a result of the extended sur-
veillance initiated by the Public Health Depart-
ments many more patients were traced from other 
cities throughout The Netherlands and in Antwerp, 
Belgium. The total number of reported cases sus-
pected for LGV proctitis was 57 in March 2004. 
We have revealed a sexual network among 
men having sex with men with a high prevalence 
of LGV proctitis. In many cases large ulcers were 
present. Considering these ulcers and thé sexual 
techniques practiced, the risk of transmission of 
other STIs like HIV and blood borne infections 
like HCV appears to be increased. Recognition of 
this clinical entity is important to advise the ap-
propriate antibiotic therapy (21 days doxycycline 
twice daily 100 mg). The outbreak is not confined 
to Rotterdam, but probably extends throughout the 
western world. 
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CHLAMYDIA TRACHOMATIS AND MYCOPLASMA GENITALIUM CO-
INFECTION IN THE YOUNG WOMEN 'S PROJECT COHORT 
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Mycoplasma genitalium (MG) has been 
strongly implicated in the etiology of non-
gonococcal urethritis (NGU) in men. Although 
infection with Chlamydia trachomatis (CT) is 
responsible for a large proportion of NGU, many 
cases of undefined etiology still remain. Many of 
the studies that demonstrated this association 
concentrated on identifying the causative agents in 
men with non-chlamydial NGU. Therefore, few 
studies have evaluated the occurrence of both MG 
and CT in men. 
Only recently have studies focused on MG 
infection in women and these have either excluded 
patients with CT infection or concluded that CT 
and MG occur independently in women. The 
purpose of this analysis was to determine if there 
is an association between infections with CT and 
MG in adolescent women. 
Samples were obtained from adolescent 
women participating in a longitudinal study of 
sexual behaviors. Women were aged 14-17 at 
enrollment and attended clinic on a quarterly basis 
for up to 27 months. During the clinic visits, 
interviews were conducted to collect data 
regarding sexual behaviors and a physical 
examination was conducted during which vaginal 
swabs were collected for PCR testing. 
Swabs were tested for CT and MG as well 
as gonorrhea and trichomonas. CT testing was 
performed using the AMPLICOR® assay. MG 
testing was performed using the PCR assay 
developed by Totten et. al. with samples in 
AMPLICOR® specimen processing reagents. 
ModMgPal & ModMgPa3 primers and MgprobeP 
probe sequences for the MG PCR were 5' TGA 
AAC CTT AAC CCC TTG G, 5' AGG GGT TTT 
CCA TTT TTG C, and GAA GGT ATG ATA 
ACA ACG GTA GAG CT, respectively. Primers 
were labeled with biotin and probes were labeled 
with digoxigenin to enable detection in a 96-well 
ELISA format. Samples were considered positive 
if the ELISA OD was >.25 with samples giving 
OD between .10-.25 being repeated. Samples with 
at least 2 results >.10 were called positive. 
Statistical analysis was performed using 
logistic regression. To account for correlation 
within subjects as a result of repeated testing, the 
generalized estimation equation (GEE) approach 
was used to estimate the variance of the 
parameters. All tests were performed with a-level 
at .05. 
Data for this analysis were collected from 
April 1999 to November 2003. Samples from 232 
women collected during 1367 clinic visits were 
tested for CT and MG. CT results were positive for 
129 samples from 80 women. The cumulative 
prevalence of CT was 34.5% (80/232). The MG 
assay was positive for 45 samples from 28 women. 
The cumulative MG prevalence was 12.1% 
(28/232). Of the 45 samples from which MG was 
identified, 9 (20.1%) were also positive for CT. In 
the remainder of the samples, CT was present in 
9.1% (120/1322). The difference in CT rates 
between subjects with and without MG was 
significant (GEE p-value=.018). The odds ratio for 
CT in women with MG is 1.26 [95% CI 1.04, 1.53] 
compared to women without MG 
In this adolescent population with high CT 
prevalence, women with MG infection were 26% 
more likely to have a CT infection than women 
negative for MG. These data suggest that future 
studies of MG should take into account the CT 
infection status of study participants. 
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PREVALENCE OF CHLAMYDIA TRACHOMATIS OMPA GENOTYPE 
VARIANTS AMONG UROGENITAL CLINICAL ISOLATES 
Gomes JP*, Azevedo J, Santo I, Ferreira A, Paulino A, Florindo C, Correia H, Borrego 
MJ 
Bacteriology Department, National Institute of Health, Lisboa, Portugal 
To determine the prevalence of 
Chlamydia trachomatis (Ct) ompA genotype 
D, I and J variants among Portuguese 
urogenital isolates. 
PCR-Amplicor (Roche™) has been 
used by the Chlamydia laboratory of the 
National Institute of Health in Lisbon to 
diagnose Ct urogenital infections since 1993. 
Positive samples (urines and endocervical 
swabs) are routinely kept at -80°C. We used 
the High Pure PCR Template Preparation kit 
(Roche™) to extract chlamydial DNA from 
3ml of urine or 200pl of Amplicor transport 
medium. C. trachomatis serovar determination 
was achieved by amplification and sequencing 
of the ompA gene. Each DNA sample was 
subjected to PCR and nested-PCR using 
previously described primers Nlo/Nro and 
Pctm3/Sero2A, respectively, and the amplified 
products were purified using QIAquick PCR 
Purification Kit (Qiagen). Primers OmpA-3 
and OmpA-4 were used for sequencing the 
-1000 bp amplified fragment of the ompA 
gene using BigDye terminator chemistry and 
capillary sequencing (Applied Biosystems). 
Sequences were aligned with currently 
available chlamydial sequences from GenBank 
using LaserGene99 software (DNASTAR) to 
determine the corresponding serovar of each 
clinical strain and to check for mutations in the 
ompA sequence that identify genovariants. 
From the total C. trachomatis positive 
samples, up to 25 % were lost during the 
genotyping method. In fact, we can expect a 
lower sensitivity of the single copy ompA PCR 
when compared to the highly sensitive 
diagnostic method (PCR-Amplicor) targeted 
against a 10 copies plasmid. A total of 234 
clinical isolates were genotyped. ompA 
genotype E was present in 91 (38.9%) samples 
followed by F with 42 (17.9%) samples and G 
with 29 (12.4%) samples. Genotypes described 
in literature as presenting variants were 
commonly found in this study. J-like strains 
were present in 11 (4.7%) cases; 4 (36.4%) of 
these were typed as Ja and 7 (63.6%) as J. I-
like strains were present in 11 (4.7%) cases; 2 
of these showed non-conclusive sequencing 
data, 4 (36.4%) revealed an ompA sequence 
closer to la except for 1 nucleotide change that 
was specific of I, and 5 (45.5%) matched 
perfectly with la. Curiously, all these 
similarities refer to strain Ia-IU4168 but not to 
Ia-UW202 which is considered the la 
prototype strain and shows 5 nucleotide 
changes to the former. D-like strains were 
found in 26 (11.1%) clinical isolates from 
which 8 (30.8%) typed as D and 18 (69,2%) 
typed as D variants. From these, 12 (66.7%) 
were further identified as Da and 6 (33.3%) 
presented nucleotide changes specific to D 
and/or to Da and thus were classified as D/Da. 
This large proportion of D variants was also 
observed in a previous larger study involving 
464 Ct strains typed by RFLP: 50 (10.8%) D-
like isolates, from which 33 (66%) were D 
variants. 
A high prevalence of variants of 
genotypes D, I and J was observed among 
Portuguese Ct isolates. Worldwide, previous 
Ct typing studies involved mostly monoclonal 
antibodies and RFLP that can't elucidate about 
genovariants. On the other hand, it's difficult 
to determine if strain variation is related with 
host immunological pressure. Nowadays, the 
use of discriminative methods like sequencing 
may evidence trends on ompA gene evolution. 
Future studies considering ompA gene 
mutation, will certainly elucidate on its 
consequences over the MOMP antigenic 
structure. Hopefully, this will clarify the 
consequences of gene variability on the Ct / 
host interaction phenomena. 
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PUBLIC HEALTH MEASURES THAT LEAD TO A SHARP DECREASE OF 
COMPLICATIONS AND SEQUEL OF GENITAL CHLAMYDIAL 
INFECTIONS IN THE FEMALE 
Per-Anders Märdh 
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To be able to successfully combat the spread of 
sexually transmitted infections (STsI), such as 
infections by Chlamydia trachomatis, a number of 
prerequisites must be fulfilled. One is the 
development of laboratory methods so the infections 
can be diagnosed. The method should not be too 
complicated to perform. Thereby it can be widely 
applied, which is important, if the aim is to use it for 
a more general attempt to decrease the number of 
affected in a region. It must also exist a diagnostic 
service open to any health provider that intends to 
make use of it. This is of particular importance as 
persons with genital chlamydial infections are, to a 
large extent, more or less asymptomatic and that 
screening therefore constitutes a fundamental 
measure in detection of such cases. Thus, a 
syndrome-based approach to decrease the prevalence 
of genital chlamydial infections is not a 
recommendable approach. Another reason is that 
partner notification must be based on confirmation of 
the infection in the index case by a laboratory test, 
not at least because symptoms and signs are rather 
unspecific and shared by those caused by other 
infections, such as gonorrhoea. A constellation that 
fulfilled the prerequisites mentioned, was the 
diagnostic service made use of cycloheximide-treated 
McCoy cell cultures that was made available in Lund, 
Sweden, already in year 1976. It took approximately 
10 years before all counties in Sweden had 
laboratories offering services for diagnosing genital 
chlamydial infections. The involvement of a large 
number of health care units where potentially infected 
persons are seen is a demand to effectively be able to 
decrease transmission of C. trachomatis in a society. 
An obstacle has been and is still to some extent the 
need of having access to a gynaecological 
examination chair, as the most sensitive specimen to 
test is not voided urine but a vaginal introital sample. 
In Sweden, the gynaecological discipline took part in 
a nationwide screening activity where samples were 
collected at youth clinics and as an integrated part of 
cytological screening programmes and in women 
attending for legal abortion. - Another prerequisite 
for being successful is the access of an effective 
therapy that infected persons will accept without too 
much of compliance problems. Different tetracycline 
and erythromycin drugs have so far been effective, 
although azithromycin would have eliminated any 
compliance problem, particular if given to a patient 
already before leaving the clinic after having returned 
for receiving the message of being infected by C. 
trachomatis. In Sweden, the society offers free 
therapy to all infected, at least when the infection is 
diagnosed at certain unita. This is particular 
important in the teenage population which often has 
no own economy. - A revisit constitutes another 
essential factor in decreasing the prevalence of 
genital chlamydial infections. Information to the 
patient about the character of the infection is 
important and even legally requested in Sweden to be 
performed by any health provider that had diagnosed 
a case. Another reason for a revisit is to initiate 
partner notification, which is also an obligatory 
request by legal regulations in Sweden. - One way to 
evaluate the effect of any widely adapted community 
effort to combat the chlamydial epidemic, of course, 
be to study any change in the prevalence of infected 
persons. Another way would be to register the 
number of cases of complications, i.e. the rate of 
pelvic inflammatory disease (PID). In Sweden, an 
intensive screening activity took place during the 
1980-ties, where more than half a mill, samples were 
tested annually (the entire Swedish population was 
appr. 8.5 mill, at that time). The number of PID cases 
dropped sharply after these screening efforts to even 
become an uncommon condition. A sequel of genital 
chlamydial infection is extrauterine pregnancies (that 
is generally routinely monitored in national diagnosis 
registers). This condition also dropped sharply in 
Sweden, but first after a lag period of up to 7-8 years 
after start of the nation-wide screening programmes. 
There will generally pass such a period after women 
who often have contracted the chlamydial infection as 
a teenager intend to get pregnant. A similar pattern 
was also seen some years later in Norway, which 
made similar community efforts but with a later start. 
The mentioned measures taken, that all were aimed to 
decrease the number of persons infected by C. 
trachomatis, strongly indicate that they had been very 
effective. 
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TESTING OF URINE AND CERVIX SAMPLES FROM PREGNANT PATIENTS 
(IN THE THIRD TRIMESTER) FOR THE PRESENCE OF INFECTION BY C. 
TRACHOMATIS USING PCR AND LCR METHODS 
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Chlamydia trachomatis (CT) infection 
has a negative impact on pregnancy and on the 
new-born. The consequences of CT infections 
in pregnancy include neonatal infection and 
premature labour. The risk for the new-born of 
acquiring the infection after perinatal exposure 
is 60-70%. The role of CT in premature labour 
is not yet clear. Our objective was therefore to 
ascertain the occurrence of C. trachomatis 
infection from cervix and urine samples taken 
from pregnant women before delivery, and to 
compare it against data obtained 10 years ago. 
Between April 2002 and July 2003, 207 
women in the third trimester of pregnancy 
were examined (consented with co-operation) 
at the Department of Obstetric and 
Gynaecology. For all these patients, a cervix 
smear was taken, and for 166 a urine sample as 
well. Cervix samples were tested for presence 
of C. trachomatis using PCR method (Roche) 
and urine samples using LCR method 
(Abbott). The women were also asked to fill in 
a questionnaire covering the risk factors of the 
infection. 
ascertained in our study was significantly 
lower than in a similar study performed by 
Natl. Inst, of Public Health, Prague and the 
General Teaching Hospital, Prague 8 years 
ago, when the occurrence for pregnant women 
was 15%, but the median age then was 25 
compared to the current 30 years of age. 
Although we ascertained a significant 
decrease in the occurrence of infection by CT, 
it still remains high for pregnant women below 
25 years of age. The result of the study was 
influenced by the change of the average age of 
pregnant women (by 5 years). Urine is a 
suitable, non-invasive biological material for 
testing the infection by C. trachomatis for 
pregnant women, while the highest results are 
achieved by testing women below 24 years of 
age. 
Of 166 women tested from both urine 
and cervix, 4 were positive (2.1%): in 2 cases 
only urine, in 2 cases both urine and cervix 
samples were positive. In this group, 31 
women in the age category below 24 years 
(where the risk of infection by C. trachomatis 
is the highest) were tested: 3 of them (9.7%) 
had a positive result (for all 3 the urine was 
positive, only in 1 case both urine and cervix 
were positive). For 207 samples, PCR 
inhibitors were detected only 3 times; no 
inhibition of LCR test against the PCR test was 
ascertained. The occurrence of C. trachomatis 
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CHLAMYDIA TRACHOMATIS INFECTION AND THE RISK OF PERINATAL 
MORTALITY IN HUNGARY 
László Kalmár1, Judith Deák2, Tibor Nyári3 
'Department of Obstetrics and Gynaecology, department of Clinical Microbiology, department 
of Medical Informatics, University of Szeged, Hungary 
Chlamydial infections of the genital 
tract are thought to often lead to preterm birth, 
which is the most important perinatal problem 
in Hungary. A multicentre study was carried 
out, in Hungary, to determine the prevalence of 
Chlamydia trachomatis infection, risk factors 
for the infection and to relate the infection to 
perinatal mortality, accounting for potential 
confounding effects. 
Logistic regression analysis was used to 
assess risk factors and a Bayesian approach 
was taken to assessing the prevalence of 
Chlamydia trachomatis 
C. trachomatis infection 
A total of 6156 pregnant women were 
examined for the occurrence of C. trachomatis. 
The overall average C. trachomatis infection 
rate was 5.9%, the data varying in the range 
1.3-9.8%. The assessed overall average C. 
trachomatis infection rate was 7.1%, the 
estimated infection rates for the centres 
varying in the range 1.9-14.1 %. 
Certain potential risk factors for C. 
trachomatis infection were examined: age, 
unemployment rate and family status. Young 
age (less than 24 years old) (OR and 95% 
CI: 1.6 (1.3-2.0)), unmarried status (1.5 (1.2-
1.9)) and the high unemployment rate (2.1 
(1.6-2.7)) were statistically significant 
predictors of the infection (p<0.05). 
Furthermore, the age group between 15-24 
years displayed a high rate of infection (7.9%). 
The infection rate was significantly (p=0.0002) 
higher in single than in married patients. 5.3% 
of the married women were C. trachomatis-
positive. 
There was a significant difference (p=0.001) 
between the rate of premature uterine activity 
that occurred in the infected group (8.1%), and 
the non-infected group (5.3%). Premature 
rupture of the membranes (PROM) occurred in 
20.0%. Differentiation of the C. trachomatis-
positive and negative groups revealed that the 
rate of PROM was 21.0% in the infected 
group, whereas it was 19.9% in the non-
infected group. This difference was not 
significant (p>0.05). 
The average perinatal mortality rate was 2.4% 
(148/6156) in the seven centres combined. 
There was a significantly higher (p=0.042) 
mortality rate (4.1%) in the group of C. 
trachomatis-positive patients than in the group 
of negative patients (2.3%). In the group of 
148 perinatal deaths, the maternal C. 
trachomatis infection rate was 10.1%. 
With regard to the C. trachomatis infection 
and perinatal mortality rates in the normal and 
low birth weight groups, among the 28 infants 
under 2500 g the maternal C. trachomatis 
infection rate was 21.4%, whereas in the group 
of 120 infants above 2500 g the maternal 
infection rate was only 7.5%. This difference 
was significant (p=0.044). 
C. trachomatis infection (OR and 95% CI: 1.9 
(1.1-3.3)), low birth weight (1.7 (1.1-2.7), no 
previous delivery (1.9 (1.3-2.7) and the high 
unemployment rate (1.5 (1.2-2.2)) were all 
significant predictors of the neonatal mortality 
(p<0.05) in the multiple regression analysis. 
Testing pregnant women for diseases 
that can be transmitted transplacental^ or 
perinatally is an important part of obstetric 
care. Screening for C. trachomatis of 
unmarried women under 24 years of age is 
suggested and need increased observation 
during labour. 
Reference 
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J, Kovács L. Chlamydia trachomatis infection 
and the risk of perinatal mortality in Hungary. 
J Perinat Med 2001; 29(l):55-9. 
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THE PREVALENCE OF CHLAMYDIA TRACHOMATIS INFECTION IN 
DIFFERENT POPULATIONS OF ST.-PETERSBURG 
I. Makhinenko1, E. Sokolovsky1, A. Savicheva2, E. Shipitsyna2, M. Domeika3 
'The I.P. Pavlov Medical University, St.-Petersburg, Russia, 2The D.O. Ott Research Institute of 
Obstetrics and Gynecology, St.-Petersburg, Russia, 3Swedish Institute for Infectious Diseases 
Control, Uppsala, Sweden 
The prevalence of STIs in St.-
Petersburg is still very high, with Chlamydia 
trachomatis infection being the most prevalent. 
The study was aimed to investigate the 
frequency of detection of genital chlamydial 
infection in different populations of St.-
Petersburg. 
The following populations were 
examined: patients of STI clinics, adolescents, 
pregnant women planning to carry pregnancy 
up to the term and those who wanted to 
terminate pregnancy. For diagnosing C. 
trachomatis in urethral swabs from men and 
cervical swabs from women polymerase chain 
reaction was used. 
Results: A total of 907 patients were 
examined. The overall prevalence of C. 
trachomatis was 6.7% (61 of 907). Among 300 
patients of STI clinics C. trachomatis was 
detected in 16 (5.3%) cases. In the youth 
population (n=300) the prevalence of C. 
trachomatis was shown to be 10% (30 cases). 
Among 254 pregnant women intending to 
carry pregnancy chlamydial infection was 
diagnosed in 11 women (4.3%). Of 53 
pregnant women who decided to terminate 
pregnancy 4 (7.5%) were infected with C. 
trachomatis. 
The highest rate of C. trachomatis 
detection was found in the youth population. 
The high prevalence of chlamydial infection 
among pregnant women intending to terminate 
pregnancy also draws attention. 
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PREVALENCE OF CHLAMYDIA TRACHOMATIS AND NEISSERIA 
GONORRHOEAE INFECTIONS AND SEXUAL BEHAVIOR AMONG FEMALE 
POPULATION IN NOVOSIBIRSK, RUSSIA 
A.A. Khryanin*, O.V. Reshetnikov, N.A. Krivenchuk, V.A. Aleksenzev, T.R. Teinina, 
A.D. Anpilogova, P. McMullin, M. Dubucq 
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Epidemiology of sexually transmitted 
diseases (STDs) is largely based on 
surveillance data. The aim of the present study 
was to examine the prevalence of Chlamydia 
trachomatis and Neisseria gonorrhoeae 
infections and risk factors for these infections 
among various groups of female population in 
Novosibirsk, Western Siberia. 
RNA/DNA-probe hybridization 
methods (PACE 2C for Chlamydia 
trachomatis and Neisseria gonorrhoeae; 
PACE 2 System for Chlamydia trachomatis-, 
PACE 2 System for Neisseria gonorrhoeae', 
Gen-Probe Incorporated, San Diego, CA, 
USA) was used for N. gonorrhoeae and C. 
trachomatis testing in 339 female subjects. 
Pregnant women (1 group, n=107, mean age 
25.9 years), gynecological outpatients (2 
group, n=104, mean age 25.8 years), and 
asymptomatic women who underwent regular 
check up (3 group, n=128, mean age 26.3 
years) voluntarily participated in the study. 
After a confidential interview, a gynecologic 
examination was performed with collection of 
endocervical specimens. 
2.8, 95% CI = 1.0-8.9, p = 0.04), alcohol or 
drug intoxication during first intercourse (OR 
= 10.6, 95% CI = 2.2-50.7, p = 0.003), daily 
sexual intercourse (OR = 3.2, 95% CI = 1.1-
9.5, p = 0.02), migration from rural regions 
(OR = 7.0, 95% CI = 2.1-22.7, p = 0.001), 
lower educational attainment (OR = 5.0, 95% 
CI = 0.9-29.1, p = 0.037). Marital status, 
family income, previous STDs, history of 
vaginal discharge, and condom use were not 
significantly different between infected and 
non-infected women. 
The prevalence of C. trachomatis 
infection in our female population is moderate 
(5.3%), N. gonorrhoeae was detected in 2.4%. 
As in other populations, risk factors for STDs 
are younger age, lower socioeconomic status, 
and risky sexual behavior. 
Overall prevalence of C. trachomatis 
infection was 5.3% (4.7%, 6.7%, and 4,7% in 
1, 2 and 3 groups, respectively). N. 
gonorrhoeae was detected in 2.4% (0%, 5.8% 
and 1.6% in 1, 2 and 3 groups). Out of eight N. 
gonorrhoeae-positive females, three have both 
infections. In univariate analysis, STDs were 
significantly associated with age under 25 
years (odds ratio [OR] = 3.4, 95% confidence 
interval [CI] = 1.1-11.3, p = 0.02), age at first 
sexual intercourse less than 18 years (OR = 
256 - EPIDEMIOLOG Y 
SCREENING FOR CHLAMYDIA TRACHOMATIS IN ASYMPTOMATIC 
WOMEN IN HUNGARY. AN EPIDEMIOLOGICAL AND COST-
EFFECTIVENESS ANALYSIS 
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A multicentre survey was carried out in 
order to determine the prevalence and risk 
factors for Chlamydia trachomatis infection in 
the population of asymptomatic women in 
Hungary. Results were used to carry out a cost-
effectiveness analysis of screening for 
chlamydial infection in women with 
asymptomatic genital infections. 
Independent predictors of chlamydial 
infection were assessed by using multiple 
logistic regression analysis. The model 
included age, marital status, social 
background, number of previous pregnancies, 
number of deliveries, number of abortion, type 
of contraceptive method, type of previous 
STD. Odds ratios, together with their 
corresponding 95% confidence intervals (CI), 
were computed. 
An incremental cost-effectiveness analysis was 
performed to compare the strategies of 
screening with the ELISA method (the 
sensitivity and specificity of this test are 70% 
and 99%, respectively) for the detection of C. 
trachomatis (strategy B), screening with use of 
the amplified Gen-Probe method (the 
sensitivity and specificity of this test are 92% 
and 99%, respectively) for the detection of C. 
trachomatis (strategy C), and no application of 
screening methods (strategy A). Costs were 
based on local charges. 
Decision analysis was used to assess the 
potential outcome of chlamydial infection. 
Sensitivity analysis was performed for 
outcomes in the model in order to determine 
how changes in estimated values affected the 
results and to identify "break-even" prevalence 
points. 
According to the test, the prevalence of 
Chlamydia trachomatis among 1300 pregnant 
women was 4.5%. After Bayes' correction, the 
overall estimated prevalence of chlamydial 
infection was 5.1%. There were significant 
differences in proportions of chlamydial 
infection in different regions, and also in 
different age groups and different family status 
groups. The group aged under 20 years 
displayed a very high rate of infection: 12.6%. 
However, with the correction for an inadequate 
procedure from Bayes' theorem, the overall 
estimated prevalence of chlamydial infection 
was estimated to be 16.9%. 
Cost-effectiveness analysis, with associated 
sensitivity analysis was carried out for women 
aged below 20 years. The Gen-Probe method 
was best provided the infection prevalence 
exceeded 16.7%, the PID rate exceeded 24% 
and the probability of tubal infertility in 
untreated women exceeded 25%. 
According to the infection rate of 
12.6%, the most cost-effective strategy was 
strategy B (screening for C. trachomatis by 
using the ELISA method). Strategy C 
(screening for C. trachomatis by using the 
amplified Gen-Probe method) was slightly less 
cost-effective than neither testing, nor treating 
(strategy A). When the estimated rate of 
infection of 16.9% in the age group under 20 
years was taken into consideration, the 
established rate proved higher than that 
calculated in sensitivity analysis, strategy C is 
more cost-effective than strategy A. 
We conclude that screening with amplified 
Gen-Probe assays (followed by treatment of 
positive patients) is the preferred screening 
strategy for young women in Hungary. 
Reference 
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Apr; 80(4):300-6. 
EPIDEMIOLOGY - 257 
PREVALENCE OF CHLAMYDIA TRACHOMATIS AND ONCOGENIC HUMAN 
PAPILLOMAVIRUS TYPES IN CYTOLOGIC ATYPIA OF THE UTERINE 
CERVIX 
József Kónya*, Krisztina Szőke, Enikő Fehér, Anita Szalmás 
Department of Medical Microbiology, Medical and Health Science Center, University of 
Debrecen, Hungary 
As a consequence of long-lasting or the 
repeating exposure to C. trachomatis, systemic 
antibody responses develop, which are readily 
detected from peripheral blood. A history of 
having substantial C. trachomatis exposure as 
detected by serum antibodies is a cofactor of 
human papillomavirus (HPV) mediated 
cervical carcinogenesis. 
In this study, we examined the 
concurrent C. trachomatis infections in 
cytologic atypia of the uterine cervix in order 
to evaluate the impact of C. trachomatis 
infection in patients with high risk for cervical 
intraepithelial neoplasia. Cervical scrapes form 
351 patients were subjected to PCR 
amplification with primer sets for HPV, C. 
trachomatis. 
Based on negative beta-globin results, 8 
specimens were not eligible for further 
analysis. Oncogenic HPV types were detected 
in 125 specimens (36.4%). C. trachomatis was 
found only in three specimens (0.9%). 
In conclusion, concurrent C. 
trachomatis infection was uncommon and 
hence it was an improbable risk factor in 
cytologic atypia. 
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THE PREVALENCE OF CHLAMYDIA TRACHOMATIS IN ASYMPTOMATIC 
AND SYMPTOMATIC MALE POPULATION IN CROATIA - A 
PROSPECTIVE PILOT STUDY 
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Objective: To determine prevalence of 
Chlamydia trachomatis (C. trachomatis) in 
aymptomatic and symptomatic men with 
genitourinary infection. 
Sample, included 300 male participants 
(age ranged from 20-69) who approached 
CNIPH Laboratory for testing on C. 
trachomatis infection in period from October 
2003 to March 2004. Based on clinical data 
patients were divided in 4 categories: 
I. Symptomatic patients (nonspecific 
urethritis), N=109 
n. Asymptomatic participants (test was a 
part of extended periodical general 
medical examination), N=90 
HI. Asymptomatic participants (came 
because their partner has some 
symptoms in genital or urethral area), 
N=83 
IV. Asymptomatic participants (came due 
to infertility problems), N=18. 
Urethral swabs were tested by enzyme 
immunoassay - EIA for detection of 
chlamydial antigen (MicroTrak II Chlamydia 
EIA-Trinity Biotech). Positive results were 
confirmed by direct fluorescent-antibody test -
DFA (MicroTrak II Chlamydia trachomatis 
Direct Specimen Test). 
Overall prevalence of C. trachomatis 
was 8%. Average age of positive patients was 
30.2 years. The prevalence of symptomatic C. 
trachomatis infections was 18.3%, while the 
prevalence of asymptomatic C. trachomatis 
infections was 2.1% (in the group II the 
prevalence was 1/90, in the group III - 2/83, 
and in the group IV - 1/18). 
Since reporting of C. trachomatis 
positive cases is known to be underestimated, 
it is valuable to continue the study in order to 
obtain more objective data about prevalence of 
symptomatic and asymptomatic C. trachomatis 
infections in men in Croatia. 
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In the past decade the incidence rates of 
STDs rose sharply in Russia and other 
countries of the former Soviet Union. 
Gonorrhea and chlamydia infections are 
common in among adolescents. However, 
whether this is a result of unsufficient sexual 
education in youth, is not clear. The purpose of 
this study was to evaluate sexual behavior, 
condom use, and prevalence of Chlamydia 
trachomatis infection among male university 
students in Novosibirsk, Russia. 
Overall 321 male students in three 
universities were examined (mean age 
19.6+0.1 years, range 17-26 years). 
Information on sexual behavior was obtained 
through structured questionnaire. First void 
urine samples were tested for C. trachomatis 
infection with «Gen-Probe AMPLIFIED™ 
Chlamydia Trachomatis Assay» (Gen-Probe 
Incorporated, San Diego, CA, USA). 
Almost all (99%) students know that 
HIV may be acquired through vaginal 
intercourse and drug injection, however, only 
51% suggest risk of acquisition via oral sex. 
Eighty- seven percent knows that the use of 
condoms can prevent HIV and other STDs. 
The age of the first sexual intercourse was 
15.9+0.1 years (range 12-20 years). Sixty-nine 
percent reported that they were sexually active 
over last 3 months. Among them, 62% always 
or most of the time use condoms during sexual 
intercourse. STDs had been found previously 
in 13% of those examined. C. trachomatis 
infection was detected in 10 subjects (3.1%). 
There was no difference between infected and 
non-infected students in relation to age, age at 
the first intercourse, number of sexual partners, 
condom use pattern, and knowledge about 
STDs. 
The data show that the prevalence rate 
of C. trachomatis infection among Russian 
male university students is similar to those 
found in Western European populations. This 
may be due to sufficient knowledge about 
STDs prevention and low-risk sexual behavior 
in this group of the population. 
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The aim of the study was to evaluate 
sexual behaviour and occurrence of Chlamydia 
trachomatis and Neisseria gonorrhoeae among 
males attending STI clinic. 
One hundred thirty-six participants 
aged 17-49 (28,3±0,6) years completed a 
structured questionnaire concerning their 
knowledge about STI and their sexual 
behaviour. Diagnosis was defined by using 
RNA/DNA hybridization in urethral swabs 
(PACE 2C® for Chlamydia trachomatis and 
Neisseria gonorrhoeae; PACE 2 System for 
Chlamydia trachomatis; PACE 2 System for 
Neisseria gonorrhoeae', Gen-Probe 
Incorporated, San Diego, CA, USA). 
Occurrence of C. trachomatis and N. 
gonorrhoeae infections were 11.7% and 5.0%, 
respectively. Males with diagnosed infections 
reported urethral discharge more frequently 
than persons without these infections (68.2% 
and 42.9%, respectively, p = 0.03). 
There were no differences between 
infected and non-infected males in educational 
level, age at first sexual intercourse, previous 
STI, presence of constant sexual partner, 
frequency of sexual contacts, condom usage. 
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Contact tracing aims to break the chain 
of transmission of infection, by identifying 
partners of an individual with a STI (index 
partner) and offering counselling, screening 
and treatment, if appropriate. This is 
particularly important in the management of 
genital infection with Chlamydia trachomatis 
(CT). 
Objective: To evaluate the 
effectiveness of partner notification for 
patients with CT infection during the four-year 
period of 2000-2003, at the STD Clinic of 
Lisbon. 
Every male and female patient 
diagnosed with genital CT infection (index 
partner) was encouraged to contact his or her 
sexual partners and advise them to attend the 
STD Clinic for counselling, screening and 
treatment. CT positivity and negativity was 
determined in urine samples using PCR-
Amplicor (Roche™). C. trachomatis serovar 
determination was achieved by amplification 
and sequencing of the ompA gene, in the 
Chlamydia laboratory of the National Institute 
of Health, Lisbon. 
244 (129 female and 115 male) patients 
were diagnosed with CT infection, of whom 
33.6% (34 men and 48 women) had no 
symptoms. 83 (34%) sexual contacts attended 
the STD Clinic, and 29 (34.9%) out of these 
tested CT positive: 8/16 female partners were 
asymptomatic, 6 had mucopurulent cervicitis 
and 2 had cervicitis; 8/13 male partners had no 
symptoms and 5 had urethral discharge. 
7 index patients and their sexual partners had 
100% identical CT serovars by amplification 
and sequencing of the ompA gene. 
Patient referral contact tracing was 
satisfactory, in a country where there are no 
national guidelines and routine contact tracing 
is not undertaken: 34% sexual contacts of CT 
diagnosed patients attended for screening and 
treatment. 
CT positivity among partners of infected 
persons was 34.9% (29/83). All of them were 
treated. 
55.2% (16/29) out of these CT positive 
contacts had no symptoms. 
Asymptomatic genital Chlamydia 
trachomatis (CT) infection is very common, so 
contact tracing is particularly important in 
order to prevent complications and squeal. 
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TRACHOMATIS IN FEMALE PATIENTS WITH CLINICALLY MANIFESTED 
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Chlamydial endocervicitis is acnowledged 
"by many investigators as the most common clinical 
manifestation of genital chlamydial infection. It 
has a crucial role in the epidemiology of 
chlamydial infection. Considerig previous studies 
genital chlamydial infection is the most common 
sexually transmitted infection. 
The present study was carried out in a four 
year period. 242 patients were examined with 
clinically manifested endocervicitis in whom 
chlamydial antigen was defined in the endocervix. 
According to age the patients were divided into 
three groups: first group under 20 years, second -
from 20 to 30 years and the third above 30 years. 
Direct immunofluorescence was used for detecting 
antigen for C. trachomatis in the endocervix. 
Conventional microbiology for the other most 
common microorganisms in the vaginal microflora 
such as T. vaginalis, Bacterial vaginosis or 
Candida ect. Cytology for Pappanicolau smears 
was examined in the same patients as well. 
Colposcopy was performed to exclude some other 
lesions namely HPV infection. The patients in 
whom C. trachomatis was found in the endocervix 
were treated with Azythromycin. The same 
treatment received the sexual partners of these 
patients 
C. trachomatis was found in 102 (41.9%) 
of the examined patients with clinically manifested 
cervicitis. According to age they were distributed 
as follows: under 20 years 26 patients (10.78); 
from 20 to 30 years 70 patients (29.04%) and 
above 30 years 6 patients (4.95%). 
The patients in whom C. trachomatis was detected 
according to their marial status were as follows: in 
the group under 20 years all the 26 patients were 
single; in the group from 20 to 30 years 39 patients 
were single, 26 patients were married and in the 
group above 30 years - 3 patients were married 
and 3 single As a total according to the marital 
status 69 women were single v/s 29 married. 
Acoording to the use of contraception (oral 
contraceptive pills and IUD) 30 patients (29.7%) 
used such methods. 
C. tachomatis was detected in 17 pregnant women 
with cervicitis (16,83%). 
Accordint to parity and pregnancies terminated 
and age the distribution was as follows: 
- Under 20 years no parity in 24 patients 
(20 - no abortions, with 1 abortion - 2 women 
with two abortions 2 women and one with a 
stillbirth. 
- From 20 to 30 years - no deliveries - 54 
patients (no previous abortions - 43, with 1 
induced abortion - 4, with 1 spontaneous aborton -
3 women, with 2 spontaneous abortions - 4; 
According to the preceding deliveries 14 women 
had one previous delivery (no previous abortions -
11, with 1 abortion - 1, with 2 abortions - 2); with 
2 deliveries - 3 (no abortions - 2, with 2 abortions -
1) 
- Above 30 years - no deliveries - 2 (no 
abortions); with 1 delivery and 1 abortion - 1; with 
two deliveries - 3 (two had no abortions and one of 
these had 1 abortion). 
More than half of the women examined 
who had chlamydial cervicitis were between 20 
and 30. One third of the patients wer eunder 20 
years. This age goups represents the most sexually 
active part of the cohort examined and sexual 
activity may contribute for this high prevalence. 
Contraception in the patients with chlamydial 
cervicitis was as follows 22 women (22,55%) used 
hormonal contraception and 7 women (6,86%) 
were using IUD, so. 30 women (29,4%) - almost 
1/3 of all used some method of contraception. 
17 women (16,2%) were pregnant. The diagnosis 
and treatment of chlamydial infection especially in 
pregnant women is important to avoid 
complications of the mother and the newborn. 
Chlamydial infection was found most commonly in 
women under 20 years and in women between the 
age of 20 and 30 years who still have not 
accomplished their reproductive capacity. The risk 
of infertility after untreated chlamydial infection is 
great. Our study shows that most of the women 
infected were in their active reproductive age with 
still not accomplished reproductive capacity. The 
financial costs for the treatment of infertility are 
high and this increases the significance for timely 
diagnosis and treatment of chlamydial infection. 
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CTSG - A NOVEL SCIENTIFIC SOCIETY FOR STUDYING THE 
EPIDEMIOLOGY OF GENITAL CHLAMYDIAL INFECTIONS IN CENTRAL 
AND EASTERN EUROPE 
Mihael Skerlev 
Department of Dermatology and Venereology of Zagreb, University Hospital and Medical School 
of Zagreb University, Zagreb, Croatia 
Since there has not been any organized 
and consistent network regarding the genital 
Chlamydia trachomatis (C. trachomatis) 
infections in the region so far, the initiative of 
networking has been started in Croatia, in May 
2002, in order to increase the awareness of the 
necessity for more exact epidemiological data, 
the effective management, and prevention of 
chlamydial genital infection. With the help of 
Pliva, as the leading Croatian pharmaceutical 
company, the network of researchers in seven 
Central & Eastern European countries (Russia, 
Poland, Hungary, Czech Republic, Slovakia, 
Slovenia, and Croatia) has been established 
and gradually improved. Thus, as an example 
of the activity, the pilot study has been 
performed in order to assess the prevalence 
rate and risk factors for Chlamydia 
trachomatis genital infection in adolescents 
under surveillance of the international group of 
researchers named Chlamydia Trachomatis 
Study Group - (CTSG). 
The results of the study have been for 
the first time presented in the integral form 
during the 8th World STI-AIDS Congress, 
Punta del Este, Uruguay December 2-5, 2003. 
According to the preliminary results of the 
prospective, multicentric study regarding the 
C. trachomatis screening of sexually active 
young women between 16 and 24 years old in 
Central & Eastern Europe (Hungary, 
Poland, Russia, Czech Republic, Slovakia, 
Slovenia and Croatia; 1408 patients included, 
1101 of them meeting the protocol criteria) 
6.9% of young females, aged less than 24 
years, were positive for C. trachomatis. The 
PCR positive female patients (and their sexual 
partners) were treated in accordance with the 
CDC guidelines for the treatment of genital C. 
trachomatis infection (azithromycin lg single 
dose). As far as the male population is 
concerned, the total number of included 
patients was 185 (Croatia, Slovenia, Slovakia, 
Russia) and out of 96 evaluable patients -
14.6% were found to be positive for C. 
trachomatis. 
It should be certainly pointed out that 
the Foundation Assembly of CTSG association 
has been taken place on December 1, 2003, 
during the above mentioned World Congress. 
For the beginning, the activities have been 
directed to the legal and administrative aspects 
of the CTSG. However, the discussion related 
to the results of screening pilot study, 
publication of study results, and project plan 
for larger screening study - application for 
financial support for national/international 
project should be definitely in our focus in 
order to continue such an international project 
with more successful performance and more 
comprehensive results. 
264 - EPIDEMIOLOGY 
THE PREVALENCE OF CHLAMYDIA TRACHOMATIS INFECTIONS IN 
SOUTH HUNGARY 
Zoltán Fekete1, Zoltán Pál1, György Bártfai1 and Judith Deák2 
'Department of Obstetrics and Gynaecology, department of Clinical Microbiology, University of 
Szeged, Szeged, Hungary 
Chlamydia trachomatis (C. 
trachomatis) is one of the most common 
sexually transmitted bacterial pathogens. The 
diagnosis of C. trachomatis infection is 
difficult as approximately 85% of the infected 
females have no symptoms. Without adequate 
treatment, pelvic inflammatory disease, ectopic 
pregnancy and frequently infertility may 
develop. Prevention and early diagnosis 
followed by proper treatment are therefore of 
paramount importance. The aim of our study 
was to evaluate the prevalence of the infection 
among young females in South Hungary and to 
specify the factors predisposing to infection. 
188 healthy, sexually active, non-
pregnant volunteers between 16 and 24 years 
of age took part in the study between August 
2003 and March 2004. None of the participants 
used any antibiotics for 4 weeks before 
cervical sampling. During the gynaecological 
examination specimens were taken for cervical 
cytology, vaginal bacterial culture and C. 
trachomatis screening by a PCR method 
(Roche, Cobas Amplicor). A questionnaire too 
was completed. 
Only 5 (2.65%) of these women were 
found to be infected by C. trachomatis. The 
average education level was fairly high: 78.6% 
of the subjects had completed secondary 
school and 15.4% were university students. 
Around 35% of them lived in small villages. 
Condom use was around 30%. 
In the surveyed population the 
prevalence of C. trachomatis was rather low. 
We assume that the reasons for the favourable 
results were the relatively high educational 
level and the 30% condom use. Further studies 
on larger numbers of subjects are needed in 
order to obtain a more accurate picture of the 
prevalence of C. trachomatis, and we must 
also focus on the high-risk population. 
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PREVALENCE OF GENITAL CHLAMYDIAL INFECTIONS AMONG YOUNG 
FEMALES IN PRAGUE 
Masata, J., Drazdakovä, M., Hruba, D., Rezacova, J. 
Department of Obstetric and Gynecology, Charles University Prague 
The aim of the study was to evaluate 
changes in the prevalence of Chlamydia 
trachomatis infection in women in the Czech 
Republic over a 10-year period. 
1031 women were included in this 
prospective study. The first subgroup of 648 
was monitored at the 1st Department of 
Gynecology - Obstetrics from September 1993 
to June 1997, and second group of 383 women 
from January 2002 to February 2004. The first 
group was divided into five subgroups: 
infertile women, patients before artificial 
termination of pregnancy, pregnant women 
approx. 4 week before delivery, women with 
cervicitis and pelvic pain. The group of 
infertile patients was further divided into 
subgroups, according to their diagnosis. All 
patients were clinically examined, and all 
clinical and epidemiological data were 
recorded in special form. For all women 
examined, two smears from the cervix were 
taken for antigen detection using a direct 
immunofluorescence method (DIF - DFA, 
Chlamyset Orion), and using an immuno-
enzymatic method (ELISA - Wellcozyme set, 
Murex). 
The second large group of 2002-2004 was 
examined by DNA testing using LCx reagent 
set (Abbott, USA) and PCR (Roche). This 
group was subdivided into infertile women, 
pregnant women 4 week before delivery, and 
patients before artificial termination of 
pregnancy. Same data were recorded in the 
similar special form. We determined a 
prevalence of antigens; for statistical 
evaluation chi square and ANOVA was used. 
A high prevalence of active chlamydia 
infection (12 %) was ascertained in the total 
group of women examined between 1993 and 
1997, while the highest prevalence was in the 
youngest women, up to 25 years of age. The 
lowest prevalence was in the group of infertile 
women (10%), and the highest in the group of 
women before artificial termination of 
pregnancy (18%). 81% of women were aged 
between 21-35 years. The lowest age median 
was in the group of women 4 weeks before 
delivery (25 years). 
There was an evident decrease of prevalence in 
the group of women tested in 2002; in the total 
group prevalence was 4.7 %. The age of the 
women was similar to that of the previous 
group; the only increase was in the median age 
in pregnant women before delivery (to 29). 
The lowest prevalence was in the group of 
women before delivery (2.1% - we provide 
further detailed evaluation of this subgroup), 
and in the age category to 24 the prevalence of 
Chlamydia trachomatis infection was 9.3%. 
Prevalence in infertile women is 6.4%. 
We were able to conclude from the 
results of our study during 1993-1997 that 
Chlamydia trachomatis infection had high 
prevalence in the groups examined. Thus we 
recommended a screening program to provide 
early recognition, treatment and prevention of 
complications related to chlamydial infection. 
The results from 2002-2004 confirm a 
significant decrease in the prevalence of the 
infection. The decrease of the prevalence may 
be due to the opportunity of using modern 
DNA testing virtually throughout the Czech 
Republic. The second reason for the decrease 
is the wide use of macrolides antibiotics in our 
country. The majority (80 %) of women with 
positive chlamydia test were younger than 25 
years of age. Screening should thus be targeted 
to these younger women. 
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PREVALENCE OF GENITAL CHLAMYDIA TRACHOMATIS INFECTIONS 
AMONG YOUNG FEMALES IN ZAGREB 
Vlasta Hirsl-Hecej 
Children's Hospital Zagreb, University of Zagreb Medical School, Zagreb, Croatia 
Genital Chlamydia trachomatis 
infections in women have important medical, 
social and economic consequences. Routine or 
selective screening and treatment of those 
found positive is an effective measure against 
the serious consequences of chlamydial 
infections, including tubal infertility and 
ectopic pregnancy. Objectives of the study 
were to determine the prevalence of 
chlamydial genital infection among young 
females up to 24 years of age, to identify 
demographic, behavioral, and clinical factors 
associated with chlamydial infection, and to 
develop the criteria for potential screening 
strategies. 
Sexually active females who were 
attending two gynecological outpatient clinics 
and youth counseling center in Zagreb for 
various reasons, were enrolled consecutively. 
A standardized questionnaire, gynecological 
exam, and detection of Chlamydia trachomatis 
by the PCR of cervical sample was performed 
in all cases. 
388 patients were included, and 353 
met criteria. Prevalence of Chlamydia 
trachomatis infection among young females 
was 4.9% and 5.4% respectively, which seems 
to be the lowest prevalence in the region. 
Comparing the Chlamydia trachomatis 
infected group to the noninfected, with regard 
to demographic facts, behavior, symptoms, and 
clinical signs, the statistically significant 
associated factors of the genital chlamydial 
infection were determined (p<0.05): the earlier 
age of menarche, multiple lifetime sexual 
partners, sexual partners with multiple 
previous partners, ectopy of the cervix, and 
cervical friability (bleeding by sampling). 
Our analysis support the 
recommendation for testing of all sexually 
active young females at each pelvic 
examination immediately followed by 
treatment of those found positive. Screening 
tests are important given the asymptomatic 
nature of the disease and chronicity of the 
chlamydial infection, and criteria to guide the 
use of screening tests are needed. 
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CHLAMYDIA TRACHOMATIS IN OUR ROUTINE WORK- 2 YEARS 
OVERVIEW 
Tatjana Grdanoska*, Gordana Jankoska, Ivanka Hadzi, Petruseva Meloska, Danica 
Cvetkovic, Gordana Mircevska, Milena Petrovska, Nikola Panovski 
Institute of Microbiology and Parasitology, Medical Faculty, University "Sv. Kiril i Metodij", 
Skopje, Macedonia 
Data concerning routinely used 
diagnostic methods for diagnosis of urogenital 
chlamydial infections nor the percentage of 
positivity of examined patients at the Institute 
for Microbiology, Medical Faculty, Skopje, 
have not been presented out of Macedonia. 
Therefore the aim of this work is a 2 years 
overview of our routine diagnosis of 
chlamydial infections detected by the presence 
of specific antigen or antibodies. 
C. trachomatis antigen in endocervical 
and urethral swabs was detected by DIF 
method - IMAGEN™Chlamydia, DAKO. The 
specific immune response was detected using 
ImmunoComb Chlamydia Bivalent IgG, 
ImmunoComb Chlamydia Monovalent II IgA 
(Orgenics). The presence of other cultivable 
pathogenic bacteria, Mycoplasma/Ureaplasma 
and Candida spp. were detected using standard 
laboratory methods. 
Out of a total of 46 786 outpatient's 
specimens 8050 (17.2%) patients were 
examined for detection of C. trachomatis with 
predominance of females (2386 or 85.6% of 
them). The most common diagnose in 
examined females were PID, Colpitis, 
Cervicitis, Infertilitas and other different 
diagnoses (36.7%, 17.5%, 16.0%, 11.5%, 
18.3% respectively). A total of 2788 (34.6%) 
patients were positive for Chlamydia 
trachomatis antigen and in 724 (38%) of them 
C. trachomatis was detected as monobacterial 
isolation. The most common associations of 
Chlamydia tachomatis were Uraplasma 
uralyticum, Candida spp., Streptococcus ß 
haemolyticus, Gardnerella vaginalis (32.2%, 
21.4%, 19%, 14.3%, respectively). A total of 
3.7% of these patients had C. trachomatis 
antigen in eye swabs as a genitoocular 
transmission. Out of 2568 examined patients 
for specific anti-Chlamydial antibodies 528 
(20.5%) were positive, 385 (73%) of them for 
IgG and 143 (27%) for both IgG and IgA 
antibodies. According to these results we could 
not determine the prevalence or incidence of 
chlamydial infections, but our results are 
presenting the presence of Chlamydial antigen 
and antibodies in a respectable number of 
individuals from allover Macedonia. 
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ASSOCIATION BETWEEN CIRCULATING C. PNE UM ON I A E D N A AND 
HERPESVIRIDAE-DNA, INFLAMMATORY BIOMARKERS, AND 
RESPIRATORY FUNCTION AMONG COPD SUBJECTS 
1 1 O 1 1 1 
Smieja M , Petrich A , Blankenberg S , Carruthers S , Mahony JB , Luinstra K , 
Chong S1, Leigh R3, Pugsley S1, Cox G1 
McMaster University St. Joseph's Healthcare, Hamilton, Ontario, Canada1, Johannes Guttenberg 
Universitat-Mainz, Mainz, Germany2, and University of Calgary, Calgary, Alberta, Canada3 
Sero-epidemiologic studies have 
inconsistently associated C. pneumoniae and 
various Herpesviridae with chronic 
cardiorespiratory diseases. By measuring DNA 
detection of C. pneumonaie and Herpesviridae 
in circulating mononuclear cells, we studied 
the association between DNA detection, 
respiratory function and plasma inflammatory 
biomarker concentrations. 
Chronic obstructive pulmonary disease 
(COPD) subjects from an ongoing prospective 
study were sampled at baseline to obtain 
peripheral blood mononuclear cells (PBMC). 
Subjects were attending routine respirology 
outpatient clinics, and had smoking-associated 
moderate to severe COPD diagnosed as the 
primary respiratory diagnosis by a staff 
respirologist. Clinical characteristics and 
spirometry were recorded. DNA from PBMC 
was extracted with a Qiagen QIAamp DNA 
mini-kit, and amplified in triplicate by a nested 
PCR targeting the ompA gene. Herpesviridae 
were amplified by two consensus PCRs 
targeting the polymerase gene. Plasma C-
reactive protein (CRP) was assayed by a high-
sensitivity automated assay (Dade Behring), 
and matrix metalloproteinase (MMP)-9 by 
enzyme immunoassay (R&D Systems). 
Eighty-two COPD subjects were 
studied, with a mean forced expiratory volume 
in 1 second (FEVi) of 1.45 L (SD 0.53), 
percent of age, gender and height-predicted 
FEVi of 49.8% (SD 12.8%), and mean age of 
64.0 (SD 8.9) years. 51/82 (62.2%) were men, 
and 27/82 (32.9%) were current smokers. Five 
of 82 (6%) had detectable circulating C. 
pneumoniae DNA, and 47/82 (57%) had 
detectable Herpesviridae (1 or more of human 
herpesviruses 1 to 8). C. pneumoniae or 
Herpesviridae detection was associated with 
worse respiratory function, independently of 
age, gender, height, smoking and chronic 
sputum production. C. pneumoniae detection, 
but not Herpesviridae, were associated with 
higher MMP-9 concentrations. CRP levels 
were not associated with either infection. 
Among four C. pneumoniae DNA-positive 
subjects, 6-month follow-up blood samples 
were DNA negative and had lower MMP-9 
concentrations (P=0.01), whereas CRP levels 
were comparable. A inflammatory-infection 
risk score based on the detection of C. 
pneumoniae, Herpesviridae, CRP>median, or 
MMP-9>median was strongly (beta= -5.7 per 
cent predicted FEVi per factor) and 
significantly (P<0.001) associated with worse 
respiratory function. 
Our cross-sectional study results show 
an association with worse lung function, 
C. pneumoniae or Herpesviridae, and 
inflammatory biomarkers. The role of C. 
pneumoniae in COPD, and in particular its 
interaction with Herpesviridae and 
inflammatory responses, requires careful 
investigation in prospective studies. 
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EVIDENCE FOR THE INVOLVEMENT OF SIMKANIA NEGEVENSIS IN 
RESPIRATORY ILLNESS IN CORNWALL, UK 
M. G. Friedman1, S. Kahane1, B. Dvoskin1, J. W. Hartley2* 
'Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel, department 
of Clinical Microbiology, Royal Cornwall Hospital, Treliske, Truro, Cornwall, UK 
Simkania negevensis is a recently 
discovered chlamydia-like intracellular 
microorganism, which has been associated 
with bronchiolitis in infants in Israel and in 
Canada and with community-acquired 
pneumonia in adults in Israel; a high 
seroprevalence of antibodies to the 
microorganism has been found in various 
population groups. Our objectives were to 
determine the seroprevalence of antibodies to 
S. negevensis in healthy adults in Cornwall, 
UK, and in a group of patients with respiratory 
tract infection, and to determine whether the 
organism could be detected by PCR in 
nasopharyngeal aspirates of such patients and 
be isolated from such aspirates. 
Clinical samples: Serum samples from 
200 presumably healthy pregnant women (aged 
16-42) and from 120 patients with evidence of 
respiratory tract infection (aged 1-55 years); 
nasopharyngeal aspirates (NPA) from 222 
infants/children with respiratory tract infection 
(up to 2 years of age). Serology: Detection of 
IgG and IgA antibodies to S. negevensis was 
carried out by the ELISA technique previously 
described (1). PCR primer sets: Nested PCR 
primers specific for S. negevensis were used to 
amplify a 405 bp 16S rDNA sequence of S. 
negevensis. Isolation: Protocols for isolation of 
Simkania and Simkania-like microorganisms 
from nasopharyngeal aspirates were performed 
as described previously (2). 
The prevalence of IgG antibodies 
specific for S. negevensis was 46% in the 
healthy women. IgA antibodies were found in 
3%. In the patients with respiratory tract 
infection, IgG antibodies were increasingly 
prevalent with increasing age, starting from 
15% in children aged 1-4 to 62% in adults 
aged 16-55 years. IgA antibodies were detected 
in 16% of the ill adults aged 16-55. 
In NPA, S. negevensis was detected by 
both PCR and isolation in 27% of the samples, 
by one or the other in 23% of the samples, and 
by neither in 50% of the samples. Eight 
isolates were grown in quantity for further 
characterization. 
Infection with S. negevensis or closely 
related microorganisms is prevalent in the 
general population in Cornwall, UK, the 
prevalence increasing with age, and may be 
associated with respiratory tract infection. 
More extensive studies are needed to confirm 
this association, and molecular studies are 
needed to determine the degree of similarity of 
the UK clinical isolates to isolates obtained in 
Israel and other parts of the world. 
References 
(1) Friedman et al., (1999) Epidemiol. Infect. 
122: 117-123. 
(2) Kahane et al., (1998) J. Infect. Dis. 177: 
1425-1429. 
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IDENTIFICATION OF SIMKANIA NEGEVENSIS AND ITS ISOLATION FROM 
DRINKING WATER AND WASTE WATER IN ISRAEL 
S. Kahane1*, B. Dvoskin1, N. Platzner2, A. Itzhaki3, M.G. Friedman1 
faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, 2Public Health 
Regional Laboratory and 3Southern Regional Health Office, Israel Ministry of Health, Beer Sheva, 
Israel 
Simkania negevensis is a recently 
discovered chlamydia-like intracellular 
microorganism, which has been associated 
with bronchiolitis in infants and with 
community-acquired pneumonia in adults; a 
high seroprevalence of antibodies to the 
microorganism has been found in various 
population groups. S. negevensis can be grown 
in various cell lines, as well as in free-living 
amoebae such as Acanthamoeba polyphaga. 
Our objectives were to develop assay systems 
for detection of the organism in water samples, 
to determine whether the organism can be 
detected in drinking water and in reclaimed 
waste water in Israel, and if so, to attempt to 
isolate the organism from drinking water. 
Water samples: Waste-water samples 
were obtained from the public health 
laboratory involved in routine evaluation of 
water quality. Drinking water samples were 
obtained from several neighborhoods in Beer 
Sheva and its satellite communities, as well as 
from deep underground water reserves. 
DNA preparation: Biologic material 
present in water was concentrated by filtration 
(cellulose acetate), and DNA was prepared by 
the QIAamp kit (Qiagen). 
PCR primer sets: Two sets of nested 
PCR primers specific for S. negevensis were 
used to amplify either a 405 bp 16S rDNA 
sequence or an intron located in the 23S rDNA 
of some S. negevensis strains. 
Isolation: Protocols for isolation of 
Simkania and Simkania-like microorganisms 
from drinking water were developed using 
filtration and selective growth 
conditions/techniques. 
We present here evidence for the 
existence of Simkania or Simkania-like 
microorganisms in drinking water and in 
reclaimed waste-water. Detection of the 
microorganism was made possible by the 
development of a specific and sensitive filter 
membrane immunoassay (MELA) and was 
confirmed by PCR detection of microbial 
DNA in the water samples. A number of 
isolates were identified by Simkania-specific 
PCR assays. Electron microscopy as well as 
immunoperoxidase assays furnished 
confirmatory evidence that these isolates were, 
indeed S. negevensis or closely related 
organisms. 
The common presence of S. negevensis 
in water sources together with the high 
seroprevalence of antibodies to it and early age 
of acquisition of infection may implicate water 
as a source of infection. The possible 
significance of this finding for public health 
and for municipal water testing and treatment 
needs to be further examined. 
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SURVEILLANCE - WHAT WE KNOW AND DO NOT KNOW ABOUT THE 
SPREAD OF INFECTIONS BY CHLAMYDIA TRACHOMATIS 
Per-Anders Märdh 
Department of Obstetrics and Gynecology, Lund University, Lund, Sweden 
Why a surveillance system for Chlamydia 
trachomatis? 
By collecting information from multiple 
sources, one may have a chance to better 
understand the current epidemiological 
situation and to better foresee trends of 
changes in prevalence of infection by 
Chlamydia trachomatis. Monitored data, if 
containing a number of relevant items, may not 
only be used for descriptive epidemiological 
surveys, but also be used to feed back 
suggestions to data providers for optimisation 
of patient care and recommendations for 
relevant screening programmes. That is, 
development of a surveillance system may be 
used in the combat of this sexually transmitted 
infection. National or regional data may also 
be used as an argument for decision makers in 
requests to allocate resources to the health care 
system to reduce the burden of these infections 
in a community on a more long-term 
perspective. For example, to reduce the 
number of extrauterine pregnancies requiring 
gynaecological surgery, cases which develop 
tubal factor infertility resulting in a demand for 
in vitro fertilisation and of cases with chronic 
abdominal pain (women who will be high 
consumers of health care for many years) (1,2). 
Which data do we have? 
Most of the data we have so far collected are 
mostly derived from limited strata of the 
population. There are almost no data based on 
population-based surveys (3-5). The groups 
that have been most frequently investigated for 
C. trachomatis are those attending where the 
health care system is equipped and trained to 
sample for other sexually transmitted agents, 
such as at venereal disease and gynecological 
clinics (where access to a gynaecological 
examination chair have until more recently 
been a demand to sampling women). Other 
groups where the society have offered or 
required tests for the organism are military 
recruits, military staff, prisoners, sex workers, 
teenagers in correction schools etc. Where 
screening has been performed is has almost 
always not been screening in the original 
definition of the concept, but in fact been so 
called selective screening. The criteria for 
selective screening have generally been age 
and factors associated with contraction of other 
sexually transmitted infections (STIs). 
A number of essential microbiological data 
are often lacking in publications and 
surveillance systems (if they do at all exist) 
However, to be able to more exact understand 
the epidemiological picture, monitored data 
should include, for example, the type of 
sample analysed, the collection (and even the 
transport) device employed as well as the 
laboratory method used (6,7). Extreme 
examples when it is obvious to know the 
circumstances when voided urine has been 
analysed by culture. Such a combination would 
have resulted in a sensitivity of perhaps only 
40%. If culture of cervical or urethral samples 
collected with toxic calcium-alginate tipped 
swabs, there could have been a three hundred 
percent difference in the recovery rate as 
compared to the use of non-toxic swabs. The 
sampling device may also be essential for the 
specificity and sensitivity of NAAT assays. 
There may be a great difference in the chance 
to detect a genital infection by C. trachomatis, 
if the activity of Taq-polymerase inhibitors is 
not hindered by anti-inhibitors. The sensitivity 
may be profoundly, if the sampling device is 
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not closed to avoid contamination and where 
chemical sterilisation is not provided. 
Although some of these obstacles are often 
avoided in current products on the market, data 
from less recent studies must be considered by 
caution. Also if in-house tests developed by 
research laboratories have been used. It is also 
to remember the low sensitivity of the ELISA 
test provided by Abbott and sold all over the 
world for a long period of time, which had a 
sensitivity of 40-60% as compared with culture 
and also a low specificity if not "positive" tests 
were confirmed by the so called "confirmatory 
test". Reporting the test conditions in more 
detail is essential to be able to calculate 
correction factors for more exact determine of 
the prevalence. As some of the chlamydia tests 
have been subjective, it is essential to know 
the experience of the laboratory workers that 
have performed the tests. However, this 
knowledge is difficult to obtain if not 
acquainted with local conditions. The former 
current use of the subjective 
immunofluorescence tests in certain European 
countries resulted in a marked overdiagnosis of 
C. trachomatis infections. 
Selective screening? 
If data is provided to a surveillance system, it 
is essential to know whether or not they 
represent data from screening or not. Gender 
and age are the most frequent data provided 
and often the only data provided in 
surveillance systems for C. trachomatis. When 
screening is performed it is essential to know 
which selective criteria that have been used to 
include persons in the screening programme. 
Otherwise, the data reported may be 
misleading if mixed with data from case 
detection. If screening data is used to estimate 
the prevalence of genital chlamydia, it is 
important to know what percentage of persons 
that denied participation among those 
approached with the offer. 
Determination of prevalence in low-
prevalence populations 
There is a difficulty to determine the 
prevalence of genital chlamydial infections in 
low prevalence populations with the currently 
commonly used diagnostic tests. It is relevant 
to stress to physicians performing chlamydia 
testing in such a patient clientele that a positive 
test does not necessarily means a positive 
patients. The positive predictive value for the 
chlamydia test may be even lower than 50% in 
such a population (6). To know the number of 
samples tested in relation to those being 
positive in a given clinical setting, is therefore 
important. A positive chlamydia test in a low 
prevalence population may require retest of the 
patient, preferably with another technique 
before informing and treating the patients as 
Chlamydia-infected. 
Surveillance based on clinical or laboratory 
data? 
Monitoring of clinical data of patients positive 
for C. trachomatis may mean access to some 
parameters that would not be available if a 
surveillance system is only based on laboratory 
reports. The opposite is true if only the latter 
type of data is known. Thereby follows that 
double reporting is to prefer. Any discrepancy 
may highlight reluctance of any part to 
contribute to the surveillance system. 
Sentinel surveillance system? 
A common view is that sentinel surveillance is 
more "safe" than other forms of monitoring 
and reporting. However, over time the attitudes 
and values of clients to attend when experience 
symptoms or just for cheek-ups before and 
after intercourse with a new consort have 
certainly differed over time. Furthermore, 
motivation and knowledge among staff and 
access to manpower and economic resources 
for screening and even for conformation of 
presumed clinical diagnoses by laboratory 
testing also change over time. Obviously, 
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introduction of new methods to detect 
chlamydial infections that have occurred 
repeatedly over the years interfere with any 
view that static conditions characterise any 
sentinel surveillance system. 
Important not only to present regional or 
national data, but also data broken down to 
clinic or even subunits of a clinic 
Access to data from a given health unit, may 
highlight any change in its power to detect new 
cases of genital chlamydial infection (8). A 
drop of positive cases may represent lost 
interest to diagnose such cases, lack of 
resources for performing tests in potential 
carriers or to undertake screening programmes. 
Furthermore, the contact surface of the unit 
may more or less be restricted to retests of an 
earlier detected and treated cohort of carriers. 
Such detailed analyses of data from single data 
providers can also be used to motivate efforts 
or to find reasons to allocate manpower or 
economic contributions to make the unit 
effective to detect infected individuals. 
Monitor outcome of therapy 
As a markedly high percentage of at least girls 
are positive for C. trachomatis some month 
after therapy, there seems to be a reason to 
recommend retest of treated cases after some 
months. To what extent these positive cases 
after therapy represent reinfection or 
therapeutic failure, is poorly documented. Are 
recommended therapies not adequate or it is 
only compliance problems, or do resistant 
strains or strains with reduced susceptibility to 
recommended drugs circulate, explain these 
"failures" (9)? A surveillance system 
containing data from therapeutic failures may 
add to the chance to explore if there are any 
not yet recognised problems with current 
therapy practice. 
To request monitoring of data by a busy 
clinic may require allocation of extra 
resources 
If an authority ask for any more extensive 
monitoring of data, they should realise the 
manpower required to fulfil the task and 
possible contribute to allocate adequate 
resources. 
Feed back of data 
To motivate persons to collect data, it is 
important to make them feel that they are 
continuously a part of a system that will give 
them a chance to see where they do stand in 
relation to other units. In the past, this aspect 
has often been overseen. The time lag between 
when data have been provided and when all 
the collected data are available to any of the 
data providers must be as short as possible to 
keep up the interest for them to coo-operate. 
The development of methods to communicate 
by computer has open up possibilities to rapid 
exchange of information. 
Plea for a pan-European surveillance 
system for genital chlamydial infections 
There is an obvious need for development of a 
pan-European surveillance system for genital 
and allied infections caused by C. trachomatis. 
Such a system does not yet exist. In those 
countries where some type of surveillance 
system has been developed, it is generally not 
congruent with that in any other European 
country. First of all there is a need to create an 
optimal list of data that ought to be collected 
and that can be applied at least in the majority 
of the European countries. 
What percentage of all persons infected by 
C. trachomatis will be registered? 
Even with a working surveillance system, a 
small percentage of all chlamydia-infected will 
be monitored in such a means. Thus, of all 
infected, maybe only as few as 40% will 
experience symptoms that may make them to 
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at leat to consider to attend for testing. Of 
these persons may only half attend and maybe 
only half of them in turn will got their 
infection diagnosed as no etiological tests will 
be undertaken. If no laboratory report of 
positive persons are requested, one could 
speculated that just half of the positive cases 
will be reported. Thereto one may add some 
percentage of infected cases that will be 
missed by the fact that there are no tests with 
an overall sensitivity among any of the 
laboratory methods in current use. 
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EPIDEMIOLOGY OF GENITAL CHLAMYDIA TRACHOMATIS INFECTIONS 
IN THE UNITED STATES 
Debra J. Mosure 
Centers for Disease Control and Prevention, Division of STD Prevention, Atlanta, GA, USA 
. Genital Chlamydia trachomatis 
infections are the most commonly reported 
notifiable disease in the U.S., and are the most 
prevalent bacterial sexually transmitted disease 
(STD). Over 70% of infections are 
asymptomatic and are a major cause of 
reproductive health consequences in women, 
including PID, ectopic pregnancy, and chronic 
pelvic pain. Because of the asymptomatic 
nature of the disease, widespread screening 
and treatment programs for young sexually 
active women were established in public 
programs across the U.S. in the late 1980s. 
Surveillance systems are a fundamental 
component of STD prevention and control 
(The Hidden Epidemic, Institute of Medicine, 
1997). The purpose of this abstract is 1) to 
describe surveillance systems currently used to 
monitor trends in genital chlamydial 
infections, and 2) to summarize trends in 
chlamydial infections and chlamydia screening 
coverage in the U.S. 
Data from multiple sources, including 
case reports and assessments of chlamydia 
prevalence, are used to monitor disease burden 
and guide chlamydia screening programs. 
Case-reporting is the process of reporting cases 
of notifiable infectious diseases from providers 
or laboratories to health departments and is 
influenced by reporting and screening 
practices. Prevalence monitoring data are 
obtained from selected populations, usually 
systematically collected from routine 
screening; positivity (number of positive tests, 
divided by the number positive and negative 
tests) is used to estimate prevalence. 
Rates of chlamydial infections have 
increased from 50.8 to 296.5 cases per 100,000 
persons from 1987 to 2002, with signficantly 
higher rates in women than in men. The 
highest age-specific rates and prevalence are in 
15- to 19-year-old women and 20- to 24-year-
old men. Although chlamydia is widely 
distributed among all racial and ethnic groups, 
positivity is consistently highest in minorities. 
Data from prevalence monitoring indicates that 
the 2002 state-specific median chlamydia 
positivity among 15- to 24-year old women 
seen in family planning clinics was .5.6%, and 
in prenatal clinics, 7.4%. Since widespread 
chlamydia screening was implemented in 
1988, there has been a 55% decline in 
chlamydia positivity in the Northwest region of 
the U.S. In 2000, the estimated chlamydia 
screening coverage for adolescent women in 
the U.S. was 60% (90% Credibility Interval, 
55%-66%). 
Chlamydia case rates may not be a 
good indicator of actual morbidity. While case 
rates have increased in both women and men 
since the late 1980s, in areas where large-scale 
screening programs have been implemented, 
prevalence monitoring data show that 
chlamydia prevalence has declined in women. 
Despite the success of chlamydia screening 
programs, screening coverage remains 
inadequate, and chlamydia remains 
unacceptably high in young women. 
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CHLAMYDIA TRACHOMATIS INFECTIONS - SURVEILLANCE IN 
SOUTHERN-HUNGARY 
György Bártfai* and Judith Deák** 
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Chlamydia trachomatis (C. trachomatis) 
infection is not a notifiable sexually transmitted 
disease in Hungary. It is therefore rather difficult 
to get a valid picture of magnitude of the infected 
population. Efforts have been made in Hungary to 
collect information via numerous epidemiological 
studies among young women (1), teenage girls (2, 
3), pregnant women (4-6) and women with 
cervicitis or ectopic pregnancies (7). In spite of the 
convincing results, adequate regular screening is 
still an unmet demand. 
Our objective to obtain information on the 
prevalence of C. trachomatis infection among a 
young (16-24 years) female population through a 
temporary surveillance project in Southern 
Hungary, to work out proposals for a screening 
policy and up-to-date treatment, and to specify the 
factors predisposing to infection. 
206 sexually active, non-pregnant women 
aged between 16 and 24 years took part voluntarily 
in the study between August 2003 and May 2004. 
None of them had used any antibiotics for 4 weeks 
before cervical sampling. At the gynaecological 
examination, specimens were taken for cervical 
cytology, vaginal bacterial culturing and C. 
trachomatis screening by using Cobas Amplicor 
PCR method (8). A questionnaire was completed. 
Only 6 (2.91%) of these women proved to 
be infected by C. trachomatis. Condom use was 
around 30%. The education level of the surveyed 
population: 78% of the subjects had completed 
secondary school and 15% were university 
students. More than 60% of them lived in urban 
areas. 
C. trachomatis is a sneaking disease: 
approximately 85% of C. trachomatis-infected 
females have no symptoms, and without adequate 
treatment, pelvic inflammatory disease, ectopic 
pregnancy and frequently infertility may develop. 
Prevention and early diagnosis followed by 
appropriate treatment are therefore essential. In 
this region of Hungary, the prevalence of C. 
trachomatis infection in the surveyed population 
was quite low. We assume that the reasons for the 
favourable results were the relatively high 
educational level and the 30% condom use. 
Because of the long-term sequelae of C. 
trachomatis infection, the regular and adequate 
treatment of the young female and male (!) 
population is advised. However, multicentre 
nationwide studies are needed in order to obtain a 
more accurate picture of the prevalence of C. 
trachomatis. 
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SURVEILLANCE OF CHLAMYDIA TRACHOMATIS IN THE (NOT YET 
EXPANDED) EUROPEAN UNION 
Ian Simms, Catherine M Lowndes and Kevin A Fenton 
Health Protection Agency Communicable Disease Surveillance Centre, London, United Kingdom 
Recent increases in sexually 
transmitted infection (STI) incidence in Europe 
have highlighted the need for systems that 
effectively monitor STI trends and distribution 
in a timely and efficient manner to inform 
public health action. The consistency of STI 
trends across Europe points to common 
causative factors, common priorities and a 
need for shared solutions. Prior to EU 
expansion, a cross-sectional survey of STI 
surveillance systems in the 14 EU countries 
and Norway was undertaken in 2002 as part of 
a European Commission-funded project on 
methods of STI surveillance in Europe (the 
European Surveillance of STIs, or ESSTI 
network). The study characterised the range, 
content and performance of existing national 
STI surveillance systems in order to inform 
future collection of comparable surveillance 
data across Europe. 
There is considerable variation in the 
surveillance of STIs in Europe. Whilst case 
reporting from clinicians and/or laboratories is 
the mainstay of general STI surveillance, 
laboratory reporting is the focus for 
surveillance of Chlamydia trachomatis. There 
is considerable variation in the coverage, 
timeliness, specificity and representativeness 
of STI surveillance systems. In addition, the 
relative sensitivity of systems for detecting the 
true population burden of STIs is affected by 
variations in types of laboratory diagnostic 
tests used, and by differences in screening and 
contact tracing practices. 
Chlamydial infection is only notifiable 
by clinicians in Sweden, Ireland and the UK: 
laboratory reporting or sentinel case reporting 
is more often relied upon for surveillance in 
other countries. For example, in Finland, 
laboratory notification of chlamydia has been 
in operation since 1994, and compulsory 
clinical notification was discontinued in 1998. 
Policies and practices for screening for 
chlamydial infection vary widely, from testing 
in some STI clinics only, through screening of 
pregnant women, to screening of attendees at 
primary care sites including general practice. 
In Sweden, screening is carried out in STI 
clinics and youth clinics. In the UK, a national 
screening programme has recently been 
established, and studies are underway to 
inform future screening policy in other 
countries such as the Netherlands and Ireland. 
In the absence of screening programmes the 
detected burden of chlamydial infection is 
likely to be much lower than the actual 
prevalence due to the large proportion of 
asymptomatic infections 
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THE EMERGENCE OF LGV DETECTED IN FRANCE THROUGH A 
ROUTINE LABORATORY-BASED SURVEILLANCE NETWORK OF 
CHLAMYDIA TRACHOMATIS INFECTIONS IN FRANCE 
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'institut de Veille Sanitaire, Saint-Maurice, 2Centre National de Référence des chlamydiae, 
Université de Bordeaux 2,3Institut Alfred Fournier, Paris, France 
A laboratory-based surveillance 
(Renachla) was established in 1990 in France 
to monitor trends of Chlamydia trachomatis 
(Ct) infection. 
About 90 laboratories report monthly to 
the Institut ; de ' Veille Sanitaire (InVS) the 
numbers of positive Ct samples and associated 
epidemiological data as well as the total 
number of samples processed. 99% of the 
samples are genito-urinary samples. Tests 
available for detection of Ct are culture, 
ELISA, DIF, and increasingly since 1997 
hybridization and NA amplification methods. 
Because the number of laboratories varied 
every year, the average number of Ct identified 
per laboratory per year is computed to monitor 
annual trends in Ct infection incidence. For 
each positive sample, the following data are 
collected: age, sex, symptoms, lab method and 
since 1999, anatomical site. Since 2000, the 
national reference laboratory for Chlamydia 
performs molecular typing of a selection of 
samples. Genotyping of the gene encoding the 
major outer membrane protein (MOMP) was 
performed by nested-polymerase chain 
reaction (PCR) and restriction fragment length 
polymorphism (RFLP), using DNA extracted 
from positive clinical specimens. 
The average number of Ct identified 
per laboratory per year, stable form 1990 to 
1991, decreased steadily from 1992 to 1996, 
increased in 1997 and 1998 and was stable 
since 1999 to 2002. 
312 urogenital samples collected from 1999 to 
2001 were typed: 
- 179 B-complex (genovar D:35, Da: 14, E:127, 
B:l, Ll : l , L2:l), 
- 42 genovar F, 37 genovar G, 
- 50 C-complex (genovar H:16, 1:11, Ia:l, J:6, 
K:16) and 4 mixed infections. 
No anorectal positive samples were reported 
from 1999 to 2001. In 2002, 10 anorectal 
positive samples were reported and 18 in 2003. 
23 out of the 28 anorectal specimens were 
sampled from males and 17 were reported by a 
laboratory located in Paris. 
16 male anarectal samples were typed: 
- 11 genovar L2, 1 genovar Da 
- 2 genovar J, 1 genovar G, 1 genovar K 
Incidence of chlamydial infection with 
microbiological diagnosis seems stable in 
France since 1999. The predominance of 
genovar E (40.7%) and F/G (25.3 %) is similar 
than in other countries. 
Since 2002, male cases with anorectal samples 
positive for chlamydia have been reported, a 
majority of them of genovar L2, suggesting 
that an outbreak of lymphogranuloma 
venereum (LGV) seems to occur in the homo-
bisexual group. 
Laboratory-based surveillance, less costly than 
clinic-based surveillance, is able to monitor 
temporal trends. Even if sexual orientation is 
not reported, the increased ano-rectal Ct 
positive samples -a surrogate marker for male 
homosexual intercourse- in laboratories 
located in Paris combined with specific typing, 
allowed RENACHLA to suspect an outbreak 
of LGV in the homo-bisexual group of Paris 
area. 
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CHLAMYDIA OF VETERINARY 
INTEREST 

ANIMAL CHLAMYDIOSIS 
Andreas Pospischil 
Institute of Veterinary Pathology, University of Zurich, Switzerland 
Epidemiology and zoonotic potential 
Chlamydiae are widely distributed throughout 
the world, causing various forms of disease in 
animals and humans. Several species, 
particularly Chlamydophila (Cp.) psittaci and 
Chlamydophila abortus, are known to be 
transmissible from animals to humans, causing 
significant zoonotic infections (Table 1) 
(Buxton, 1986; Hedberg et al„ 1989; 
Vanrompay et al., 1995; Brewis & McFerran, 
1997; Goupil et al., 1998; Bennedsen & 
Filskov, 2000; Entrican et al., 2001, Pospischil 
et al. 2002). 
The unique biphasic lifestyle of these obligate 
intracellular bacteria, which includes an 
infective extracellular and a parasitic 
intracellular phase, renders the respective 
diseases difficult to control. This is 
compounded by the specialist growth 
conditions for the organisms and the lack of a 
genetic based system for the transformation of 
chlamydiae, both of which have hampered 
research on these pathogens. To escape the 
host immune response these bacteria are 
capable of transforming into persistent stages 
of development characterized by a distinct 
antigenic profile. 
Chlamydioses in poultry and other avian 
species 
The most important animal chlamydiosis of 
zoonotic character is psittacosis, a systemic 
disease in psittacine birds of acute, protracted, 
chronic or subclinical manifestation (Kaleta, 
1997; Andersen & Vanrompay, 2000). It is a 
notifiable disease in Belgium, Germany, 
Ireland, Switzerland," the UK and other 
countries. In Italy, cases of transmission to 
humans are notifiable. The economic damage 
in connection with outbreaks in poultry flocks 
can be considerable (Grimes & Wyrick, 1991; 
Vanrompay et al., 1993). Although the 
causative agent, Chlamydophila psittaci, is 
known to be very wide spread in many avian 
species, not all carrier birds actually show 
symptoms of disease (Barr et al., 1986). 
Chlamydioses in sheep and goats 
Enzootic abortion of ewes or ovine enzootic 
abortion (OEA) caused by Chlamydophila 
abortus has become recognised as a major 
cause of loss in sheep (and goats) in Europe 
(Gut-Zangger et al., 1999), North America and 
Africa. It is the most common infectious cause 
of lamb loss in several countries of Western, 
Central and Northern Europe (Aitken, 2000), 
e.g. accounting for around 50% of all 
diagnosed abortions in the UK. OEA is a 
notifiable disease in Ireland, where its 
incidence has increased dramatically in recent 
years (Markey et al., 1996). In the UK, cases of 
transmissions to humans are notifiable. 
Chlamydophila abortus from sheep and goats 
is transmitted to humans and can cause 
abortion in pregnant women in the last 
trimester of pregnancy (Pospischil et al., 
2002). 
Chlamydioses in cattle, pigs, cats, horses, 
and reptiles 
Over the last few years, endometritis and 
hypofertility in dairy cattle have sometimes 
been attributed to chlamydial infections, with 
clinical manifestations often recurrent in spite 
of treatment (Wittenbrink et al., 1993; 
Magnino et al., 1999). In a regional survey in 
Germany, Chlamydophila psittaci / 
Chlamydophila abortus were detected at a rate 
of up to 100% in affected herds. Economic 
losses as a consequence of a drop in milk 
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production and milk quality, as well as 
abortions and reduced fertility rates were 
estimated to be 40,000 Euros per year at an 
average farm of 60 dairy cows and 20 heifers. 
Investigations carried out in Italy (Magnino et 
al., 1999, 2000a) have shown that the 
chlamydial organisms involved in these 
outbreaks belong to the so-called "non-
invasive" strains classified as Chlamydophila 
pecorum. The same agent was also detected in 
cases of encephalomyelitis in water buffaloes 
used for milk production (Galiero et al., 1998, 
Magnino et al., 2000b). 
Chlamydioses in pigs are associated with three 
different species, i.e. Chlamydia (C.) suis 
(formerly C. trachomatis), Chlamydophila 
pecorum and Chlamydophila 
psittaci/Chlamydophila abortus (Wittenbrink 
et al., 1991; Hoelzle et al., 2000). A widely 
held view is that chlamydiae may act in 
concert with other agents in multifactorial 
infectious diseases, such as abortions in sows, 
polyarthritis in piglets, diarrhoea in pigs and 
genital disorders in boars (Zahn et al., 1995, 
Szeredi et al., 1996, Schiller et al., 1997, 
Thoma et al., 1997, Busch et al. 2000). 
According to veterinary practitioners, clinical 
manifestations of conjunctivitis in cats are 
often suggestive of chlamydial infections 
caused by Chlamydophila felis (Bart et al., 
2000). Based on an investigation of 462 cats 
with upper respiratory infections, Sykes et al. 
(1999) observed a prevalence of this agent of 
14.3%. In a recent study of feline 
conjunctivitis Chlamydophila felis and 
Neochlamydia hartmanellae were detected 
using 16S and 23S gene PCR (von Bomhard et 
al., 2003). Occasional evidence of 
Chlamydophila psittaci/Chlamydophila 
abortus detected from aborted horse fetuses 
and Chlamydophila pneumoniae associated 
with respiratory disorders indicates a role of 
these species in various equine diseases 
(Henning et al., 2000). Although the former 
appears to be a commensal germ in many 
instances, the importance of chlamydial 
infection in horses is probably underestimated. 
In the last few years, several strains of 
Chlamydophila pneumoniae were isolated 
from reptiles, some which are kept as pet 
animals (Berger et al., 1999; Hotzel et al., 
2001, Bodetti et al., 2002a, b). 
Current taxonomy - a new veterinary 
perspective 
Dramatic changes have occurred in the 
taxonomy of bacteria known as Chlamydia. 
The traditional taxonomic classification of 
Chlamydia is based on limited phenotypic, 
morphologic and genetic criteria. This 
classification does not take into account recent 
analyses of the ribosomal operon or recently 
identified obligate intracellular organisms that 
have a chlamydia-like developmental cycle of 
replication. Neither does it provide a 
systematic rationale for identifying new 
strains. Everett et al., 1999 used phylogenetic 
analyses of the 16S and 23S rRNA genes to 
show that the order Chlamydiales contains at 
least four distinct groups at the family level 
and that within the Chlamydiaceae are two 
distinct lineages, which branch into nine 
separate clusters. This results in a 
reclassification of the order Chlamydiales. 
This retains currently known strains with > 
90% 16S rRNA identity in the family 
Chlamydiaceae and separates other chlamydia-
like organisms that have 80-90% 16S rRNA 
relatedness to the Chlamydiaceae into new 
families. The Chlamydiaceae, which had only 
the genus Chlamydia, is divided into two 
genera, Chlamydia and Chlamydophila. Two 
new species, Chlamydia muridarum and 
Chlamydia suis join Chlamydia trachomatis in 
the emended genus Chlamydia. 
Chlamydophila assimilates the current species, 
Chlamydia pecorum, Chlamydia pneumoniae 
and Chlamydia psittaci, to form 
Chlamydophila pecorum, Chlamydophila 
pneumoniae and Chlamydophila psittaci. 
Three new Chlamydophila species are derived 
from Chlamydia psittaci: Chlamydophila 
abortus, Chlamydophila caviae and 
Chlamydophila felis. These families, genera 
and species are readily distinguished by 
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analysis of signature sequences in the 16S and 
23 S ribosomal genes (Everett and Andersen 
1999). This is of special relevance to animal 
chlamydiosis since Chlamydophila psittaci, 
Chlamydophila abortus, Chlamydophila 
caviae and Chlamydophila felis cause 
distinctly separate diseases in different animal 
species. The use of advanced PCR detection 
systems (16S, 23S, intergenic spacer 16S-23S) 
has shown that other intracellular Chlamydia-
like pathogens including Simkania negevensis 
(Kahane et al. 1993), Waddlia chondrophila 
(Rurangirwa et al., 1999) and Parachlamydia 
acanthamoebae (Fritsche et al., 1999) exist in 
mammalian host cells and can be etiologic 
agents in a number of diseases. The perception 
of novel Chlamydia has changed quite 
dramatically in recent years as a result of three 
main findings: 
• the isolation of a 'chlamydia-
like' organism from an aborted bovine foetus 
(Dilbeck et al., 1990; Kocan et al, 1990); 
• the discovery and ultra-
structural analysis of several endosymbionts of 
free-living amoebae (Fritsche, 1993); 
• the description of a conspicuous bacterium 
growing as contaminant in a cell culture within 
"cytoplasmic phagosomes" (Kahane, 1993). 
It seems likely that within the Chlamydiales a 
wide range of environmental chlamydiae 
occur, forming a large, environmental reservoir 
of undefined potential for animal and human 
disease. In a survey of bacterial endosymbionts 
of Acanthamoeba spp., Fritsche et al., 2000 
identified four chlamydia-like organisms 
involving 5% of the amoebae examined. One 
of these endosymbionts was found stably 
infecting an amoeba from a case of amoebic 
keratitis in North America. The other three 
were recovered in acanthamoebae from 
environmental sources. Analyses of nearly full-
length 16S rRNA gene sequences of these 
isolates showed that they clustered with other 
members of the order Chlamydiales but in a 
lineage separate from those of the genera 
Chlamydia, Chlamydophila, Simkania, and 
Waddlia (16S rRNA sequence similarities 
<88%). While the 16S rRNA sequence 
similarity of all four isolates to Parachlamydia 
acanthamoebae was fairly low (91.2 to 
93.1%), two of the investigated chlamydia-like 
symbionts were more closely related to 
Neochlamydia acanthamoebae (96.5% and 
97.1%). With sequence similarities to each 
other of 91.4 to 99.4%, it was postulated these 
four isolates might represent three distinct 
species and, perhaps, new genera within the 
Parachlamydiacea. Nucleotide probes targeted 
to 16S rRNA genes suggested there were two 
separate phylogenetic lineages among these 
isolates. In summary there is strong molecular 
evidence for a huge, previously underestimated 
diversity of chlamydiae. In the light of these 
data, classification of all novel non-
Chlamydiaceae within the order Chlamydiales 
should be regarded as tentative until further 
isolates of (environmental) chlamydiae have 
been characterised both biologically and 
genetically. 
Phylogenetic analysis 
Phylogenetic analyses of surface antigens and 
other chlamydial proteins were used to 
reconstruct the evolution of the 
Chlamydiaceae (Bush and Everett, 2001). 
Trees for all five coding genes (the major 
outer-membrane protein (MOMP), GroEL 
chaperonin, KDO-transferase, small cysteine-
rich lipoprotein and 60 kDa cysteine-rich 
protein) supported the reclassification of the 
family Chlamydiaceae, which is based on 
ribosomal, biochemical, serological, ecological 
and DNA-DNA hybridization data. Genetic 
distances between some species were quite 
large. All nine species were clearly 
differentiated. The distribution of virulence 
traits such as host and tissue tropism is 
mapped onto the consensus phylogeny. Closely 
related species are no more likely to share 
virulence characters than were more distantly 
related species. Lateral transfer of the genes 
cannot explain this phylogenetically disjunct 
distribution of virulence traits. One 
interpretation of this observation is that when 
chlamydiae gain access to a new niche, such as 
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a new host or tissue, significant adaptation 
ensues and the virulence phenotype of the new 
species reflects adaptation to its environment 
more strongly than it reflects its ancestry. 
Within the Chlamydiaceae, genomic 
sequences for Chlamydophila abortus and C. 
felis have been completed but their annotation 
is on the way. A genomic sequence for 
Chlamydophila psittaci is needed to 
understanding the pathology of these agents. 
There is also an absolute need for the genomic 
sequences of fresh isolates to explore the 
differences of these organisms (Table 2). 
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Table 1: Chlamydial species their animal host species, disease and known zoonotic aspect 
Chlamydiales Host species Disease Zoonotic aspect 
Chlamydia muridarum mouse pneumonitis, lower & upper 
genital tract infection 
Chlamydia suis Pig intestinal & genital infections 
Chlamydophila 
psittaci 
feral & domesticated 
birds 
respiratory, gastrointestinal 
signs 
Zoonosis 
Chlamydophila 
abortus 
small ruminants, cattle abortion Zoonosis 
Chlamydophila felis cats conjunctivitis Zoonosis 
Chlamydophila caviae Guinea pigs conjunctivitis, keratitis 
Chlamydophila 
pecorum 
cattle sheep, goats, 
koala, pig 
pneumonia, polyarthritis, 
conjunctivitis, abortion, 
encepahlomyelitis, 
gastrointestinal disease, genital 
signs 
Chlamydophila 
pneumoniae 
horse, koala respiratory disease, urogenital 
disease 
Zoonosis ? 
Table 2. General features of chlamydial genomes, bp, base pairs; seq., sequence 
Environmental 
chlamydia 
UWE25 
Chlamydophila 
caviae GPIC 
Chlamydophila 
pneumoniae 
CWL029 
Chlamydia 
trachomatis 
s v D 
Chlamydia 
muridarum 
MoPn 
Chlamydophila 
abortus 
S26/3 
Chromosome 
(bp) 
2,414,465* 1,173,390 1,230,230 1,042,519 1,072,950 1,144,377 
Plasmid (bp) - 7,966 - 7,493 7,501 -
G + C content 
(%) 
35,8 39,2 40,6 41,3 40,3 39,9 
Total CDSs 2,031 1,009 1,073 894 921 -
With 
functional 
assignment 
784 (38%) 605 (60%) 636 (59%) 604 (67%) 563 (61%) 
(Conserved) 
hypothetical 
623 (31%) 320 (32%) 251 (23%) 35 (4%) 281 (31%) -
Unknown (no 
seq. 
homology) 
624 (31%) 84 (8%) 186 (17%) 255 (29%) 77 (8%) 
Coding 
density (%) 
83 88 88 90 90 -
Average gene 
length (bp) 
962 1,030 1,031 1,049 1,064 -
rRNA 
operons 
3 1 1 2 2 -
tRNAs 35 38 38 37 37 -
Mofdified from Horn et al„ Science, Vol 304, Issue 5671, 728-730, 30 April 2004 
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GENOMIC ANALYSIS OF THE ORDER CHLAMYDIALES 
G. S. A. Myers1*, P. Bavoil2, R. Brunham3, T.D. Read4, S. R. Gill1 and C. M. Fraser1 
^IGR, Rockville MD USA; 2U. Maryland, Baltimore MD USA; 3University of British Columbia 
CDC, Vancouver BC, Canada; 4NMRC, Rockville MD USA 
We are continuing the momentum of 
discovery generated by the first chlamydial 
genome sequences by extending the breadth of 
genomics to include the entire order 
Chlamydiales. We will create two important 
new resources for chlamydial research: a non-
redundant microarray of chlamydial genes 
(named here the "Taxochip") and a database of 
chlamydial gene distribution from a large 
number of isolates gathered from around the 
globe. These tools will enable the investigation 
of fundamental questions about chlamydial 
pathogenicity and virulence and the evolution 
of the chlamydiae themselves, as well as 
broader evolutionary questions about 
host/parasite relationships and the continuum 
of obligate intracellular life to pathogenicity. 
difficulties, particularly the lack of genetic 
tools with which to manipulate chlamydiae. 
The need to grow these obligate intracellular 
parasites within eukaryotic cells, with the 
resulting, significant problems of inactivation, 
alteration and contamination of the organisms 
on purification, also remains a major limiting 
factor. In the face of these difficulties, genome 
sequencing has been central to progress in this 
field. Moreover, the wealth of chlamydial 
genome data generated to date has enabled the 
members of the Chlamydiaceae to be used as a 
major model of reductive evolutionary 
processes. The work presented here moves 
genomic analysis beyond the single genome to 
meta-analysis of a higher taxonomic grouping. 
We are sequencing seven Chlamydiales 
genomes to closure using the random shotgun 
strategy pioneered at TIGR. These are the three 
American Type Culture Collection (ATCC) 
type strains of the unsequenced species of the 
family Chlamydiaceae (C. suis, C. pecorum 
and C. psittaci) plus the koala C. pneumoniae 
strain and more evolutionarily distant members 
of the order, Waddlia chondrophila, Simkania 
negevensis and Parachlamydia PL-9. 
Four of the seven genomes have 
completed the random sequencing phase at the 
time of abstract submission - C. suis, C. 
pecorum, C. psittaci and S. negevensis. 
Assembly of these genomes is in progress. We 
will present the preliminary analysis of these 
genomes and the status of the remaining three 
genomes. 
Efforts to understand most aspects of 
chlamydial infection and disease have been 
hampered by systematic experimental 
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SEQUENCING, ANNOTATION AND COMPARATIVE ANALYSIS OF THE 
CHLAMYDOPHILA ABORTUS GENOME 
D. Longbottom*1, N. R. Thomson2, C. Yeats3, M. Holdén2, S. Bentley2, M. 
Livingstone1, R.S. Yaga1, F.A. Lainson1, A. Cerdeno-Tarraga2, E. Feil4, K. Bell5 and J. 
Parkhill2 
'Moredun Research Institute, Edinburgh, UK; 2Pathogen Sequencing Unit & 3PFAM Group, 
Sanger Institute, Cambridge, UK; 4Dept. of Biology & Biochemistry, University of Bath, UK; 
5Scottish Crop Research Institute, Dundee, UK 
To sequence the genome of the animal 
pathogen Chlamydophila abortus for 
comparative analysis with the published 
genomes of the other chlamydial species, and 
also to provide a functional genomics platform 
for the identification of novel putative 
pathogenicity determinants. 
C. abortus (strain S26/3) was grown in 
McCoy cells and genomic DNA prepared 
according to standard methods. Small insert 
genomic DNA libraries were generated in 
pUC18 (1-2.5 kb) and large insert plasmid 
(pSP64) and lambda (k-FIX-II) libraries were 
used as scaffold. The genome sequence was 
assembled, finished and annotated, as 
previously described1. The program Artemis2 
was used to collate data and facilitate 
annotation. The annotated C. abortus genome 
was compared to published chlamydial 
genomes using the Artemis Comparison Tool 
(ACT2). 
The genome was determined to be 
1.144 Mb in size, with a G+C content of 
39.9%. Genome analysis revealed the presence 
of 963 predicted coding sequences (CDS), and 
a single copy of the 5S, 23S and 16S rRNA 
operon. 700 of the predicted CDS have been 
given functional assignments, based on 
database similarity and identification of motifs. 
Of particular interest was the identification of a 
further 12 polymorphic membrane proteins 
(pmps), in addition to the 6 originally 
identified3, as well as the absence of genes 
involved in tryptophan biosynthesis. The C. 
abortus genome was also found to contain 19 
genes that show no similarity to genes in the 
published Chlamydophila genomes. Whole 
genome comparisons revealed a high level of 
conservation in gene order, particularly with C. 
caviae, where there are only four regions 
showing variation or significant differences. 
The first is at the terminus of replication, in the 
region termed the plasticity zone or replication 
termination region. The other regions include 
genes coding for a large cluster of pmps, genes 
involved in biotin synthesis and genes, which 
share similar N-terminal transmembrane 
helices and coiled-coil regions of varying 
length. 
The C. abortus genome is the fifth 
chlamydial species to be sequenced. This also 
represents the first sequence of an 
economically significant animal pathogen, and 
zoonotic pathogen, of the Chlamydiaceae 
family to be sequenced. Genomic sequencing 
will assist in the identification of antigens 
involved in pathogenesis and in the 
development of rational vaccine control 
strategies. Comparative analysis will also help 
in identifying potential niche-specific genes 
that will help in understanding the diverse host 
and disease range of this important group of 
bacterial pathogens. 
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CHLAMYDIA ARE HIGHLY ADAPTED PARASITES IN MAN AND ANIMAL 
Eberhard Straube, Jürgen Rödel 
Department of Medical Microbiology, Friedrich-Schiller-University of Jena, Jena, Germany 
Chlamydiae are obligate intracellular bacteria 
with a fine regulated pathogenicity for man 
and animal. There are at least three fields of 
interest in the parasitic capacity of these 
bacteria: 
i. Escape the nonspecific as well as specific 
defense of the host: 
The first step of this escape mechanism is 
the intracellular multiplication of metabolic 
active bacteria within a separated 
compartiment. Secondly, the expression of 
IFN-y, TNF-a, and other effectors of cell 
regulation in Chlamydia infection prevents 
a lytic infection and promotes an 
intracellular persistence. Thirdly, 
Chlamydia infected cells are impaired in 
HLA antigen presentation by secretion of C-
PAF by chlamydial inclusions which 
degrades transcription factors involved in 
the expression of HLA I as well as HLA II 
antigen. Additionally, persistent reticulate 
bodies obviously have a reduced cross talk 
throuhg the membrane of the inclusion 
bodies, which leads to a reduced 
presentation of Chlamydia specific antigens 
by the host cell. 
ii. Modulation of the proliferation of infected 
host cells by Chlamydia: 
C. pneumoniae infection of human smooth 
muscle cells as well as endothelial cells 
leads to the expression of basic fibroblast 
growth factor and interleukin 6. 
Additionally, Chlamydia infected 
monocytes showed expression of PDGF. In 
the same time, the Chlamydia infected cells 
express several antiproliferative effectors as 
prostaglandins. This mechanism may be 
involved in the déstabilisation of 
atherosclerotic plaque. As shown in several 
experiments, Chlamydial HSP may be 
involved in the regulation of cell 
proliferation. 
iii. Surviving within the host cell: 
Beside the formation of metabolic inactive 
reticulate bodies under the influence of 
interferons secreted by the infected cell 
itself, the modulation of apoptosis seems to 
be an important surviving mechanism for 
intracellular Chlamydia. As shown by 
several experiments, the induction of 
apoptosis by staurosporin fails in 
Chlamydia infected cells. Very recent 
experiments with fibroblasts and 
endothelial cells reveals a Chlamydia 
specific protein which binds the activated 
caspase 8 and block the following steps of 
apoptosis. 
The recent knowledge of Chlamydia 
pathogenicity is full of gaps. Experimental 
experience mainly is concentrated on human 
pathogen species, whereas animal pathogen 
species and especially enviromental Chlamydia 
are fairly unknown creatures in this respect. 
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CHLAMYDIAL IN WILD BOAR - PATHOGENS OR NATURAL RESERVOIR? 
Helmut Hotzel1, Angela Berndt2, Falk Melzer1, and Konrad Sachse1* 
Federal Research Centre for Virus Diseases of Animals (BFAV), Jena, Germany, 'institute of 
Bacterial Infections and Zoonoses, 2Institute of Molecular Pathogenesis 
It was the aim of the present study to 
examine a wild boar population for the 
presence of chlamydiae and discuss the 
implications of positive findings. 
A total of 46 organ tissue samples from 
14 wild boar (7m, 6f, 1 unknown gender) 
bagged at a seasonal hunt in Thuringia 
(Germany) were examined for the presence of 
chlamydiae by nested PCR and 
immunohistology. The specimens of lungs, 
pulmonary lymph nodes, large intestine, and 
uterus (from females) were collected on the 
day of the hunt and stored at -20°C. DNA was 
extracted from tissue using the High Pure PCR 
Template Preparation Kit (Roche Diagnostics). 
The nested PCR assay using primer pairs 
191CHOMP/CHOMP371 and 201CHOMP/ 
CHOMP336s, which amplifies a 437 to 455-bp 
segment of the ompA gene of all species of the 
genera Chlamydia and Chlamydophila, was 
described previously (Sachse and Hotzel, 
2002). For nucleotide sequencing, positive 
bands were cut out of the agarose gel, DNA 
extracted using the QIAquick Gel Extraction 
Kit (QIAGEN), subjected to cycle sequencing 
using the BigDye™ Terminator Cycle 
Sequencing Ready Reaction Kit (Applied 
Biosystems), and processed by the ABI PRISM 
310 Genetic Analyzer (Applied Biosystems). 
Species identity was established through 
BLAST search. Sequence alignments and 
analysis were conducted using the Vector NTI 
Suite 8.0 software package (Informax Inc.). 
Samples from two PCR-positive animals were 
examined by immunohistochemistry to 
determine the localisation of chlamydial bodies 
in tissue. Cryostat sections of lungs and uteri 
of 7 pm thickness were prepared, and detection 
of chlamydiae was done using a primary 
monoclonal antibody against chlamydial LPS 
(Chemicon) and a commercially available 
staining kit (APAAP, ChemMate Detection 
Kit, alkaline phosphatase/red, rabbit/mouse, 
DakoCytomation). For negative control, slides 
were incubated with pre-immune mouse serum 
(dilution 1:500) instead of the anti-Chlamydia 
antibody. Sections were counterstained with 
haematoxylin and mounted with Canada 
balsam (Riedel de Haen). 
Chlamydial DNA was detected in 8 
animals (57.1%), i.e. 5 females (rate of 83.3% 
among females) and 3 males (rate of 42.9%). 
Sequencing of the amplified ompA segments 
revealed three different chlamydial species: 
Cp. psittaci (10 positive samples/4 animals), 
Cp. abortus (4/2), and Chlamydia (C.) suis 
(3/2). Among all organs, the lung was most 
frequently found to be infected, i.e. in 7 of the 
8 chlamydia-positive animals. In 3 females, the 
uterus samples tested positive. Another 
affected organ was the pulmonary lymph node 
with 5 positives. The detection rate in the large 
intestine was remarkably low (2/13 positives). 
Immunohistochemical staining of tissue 
sections confirmed the presence of typical host 
cell damage caused by chlamydial inclusions 
in lungs and uteri. Macroscopically, neither 
carcasses nor accessible organs had signs of 
pathological changes. PCR tests for 
mycoplasmas and mycobacteria were negative 
in all cases. 
While the role of chlamydiae as 
pathogens in wild boar has yet to be 
established, the present findings revealed a 
possible wildlife reservoir of these bacteria. 
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A PCR-RFLP ASSAY TARGETING THE 16S RIBOSOMAL GENE FOR THE 
DIAGNOSIS OF ANIMAL CHLAMYDIOSES 
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We describe the field application of a 
PCR-RFLP assay targeting the 16S ribosomal 
gene of Chlamydiaceae. The assay allows the 
selective amplification of a portion of the 
genome of the organisms and its subsequent 
species identification directly from clinical 
samples. 
A Polymerase Chain Reaction (PCR) 
assay targeting the 16S ribosomal chlamydial 
gene was developed, employing a modified 
procedure slightly different from the one 
proposed by Ossewaarde and Meijer (1999). 
Genomic DNA was purified from animal 
tissues and swabs by using a commercial kit 
which is based on the silica 
particles/guanidium thiocyanate method. For 
PCR, oligonucleotide primers 16SFOR2 (5'-
CGTGG ATG AGGC ATGC AAGTCGA-3') 
and 16SREVmod (5'-ATCTCTCAATCCG 
CCTAGACGTCA-3') were used. 
The amplified products were digested with 
different endonucleases (MseI, Mboll, Hhal, 
HinfI) in a Restriction Fragment Length 
Polymorphism (RFLP) assay. PCR and RFLP 
products were detected by agarose gel or 
polyacrylamide gel electrophoresis. 
Our PCR-RFLP assay allows the 
detection and differentiation of 6 chlamydial 
species whose denominations have been 
recently proposed by Everett et al. (1999) and 
which are of major interest in veterinary 
laboratories (Chlamydophila psittaci, C. 
abortus, C. pecorum, C. suis, C. felis, C. 
pneumoniae). 
The amplicons size ranges from 265 bp to 270 
bp depending on the chlamydial species. Three 
different RFLP patterns are obtained when 
digesting the amplicons with Mse I, and the 
fragments sizes are respectively: as to C. 
abortus: 159+81+29 bp; as to C. psittaci, 
C. felis and C. pneumoniae: 159+110 bp; as to 
C. pecorum and C. suis: 88+81+70+29 bp. 
In order to differentiate C. suis from C. 
pecorum, the restriction enzymes M boll and 
Hhal can be used. Mb oil digests only the C. 
pecorum amplicon (175+92 bp), while Hhal 
digests only C. suis (133+133 bp). In order to 
distinguish among C. felis, C. psittaci and C. 
pneumoniae, the enzyme Hinfl can be used. 
The restriction patterns of their amplicons are 
as follows: 196+73 bp for C. psittaci, and 
145+73+51 bp for C. felis, while no restriction 
fragments are obtained for C. pneumoniae. All 
observed restriction patterns are in accordance 
with nucleotide sequences available in the 
NCBI GenBank. 
Chlamydial infections are widespread 
in intensively-reared animals (cattle, sheep, 
goats, swine) as well as in wildlife and in 
companion animals (pet birds, cats). The 
detection of these organisms directly in clinical 
samples is usually possible either by 
immunoenzymatic/immunochromatographic 
commercial tests, which are often easy to 
perform but lack specificity and sensitivity, or 
in cell culture, which is still considered the 
gold standard procedure but is time-consuming 
and cumbersome. Molecular techniques such 
as our PCR-RFLP assay offer a faster and 
easier alternative, and allow also to identify the 
species of chlamydiae involved in animal 
disease. This identification is required for 
monitoring and controlling the disease in 
animal populations and for the assessment of 
the zoonotic implications of animal chlamydial 
infections. 
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The range of animals infected by 
Chlamydiales has been expanding. Recent 
studies using PCR have identified several 
Chlamydia species infecting a wide range of 
Australian marsupials, including koalas and 
Western Barred Bandicoots (Perameles bou-
gainville). Bandicoots are an endangered 
species, now found in the wild on only 2 
islands off the coast of Western Australia. 
Chlamydia infection has been associated with 
serious eye disease with significant morbidity. 
The purpose of this study was to attempt to 
isolate Chlamydia spp. from specimens from 
these animals in tissue culture to determine the 
species, growth characteristics, and in vitro 
antibiotic susceptibilities. 
Chlamydia isolation was performed in 
cycloheximide-treated HEp-2 cells grown in 
96-well microtiter plates. Each specimen was 
passaged up to 6 times. Culture confirmation 
was performed with fluorescent antibody 
staining with genus specific (anti-LPS) and C. 
pneumoniae species specific (anti-MOMP) 
monoclonal antibodies. Susceptibility testing 
was also performed in HEp-2 cells grown in 
microti ter plates. 
Thirty-nine ocular, throat, cloacal 
specimens were obtained from 37 wild 
bandicoots. One additional throat specimen 
was obtained from a koala. A total of 11 
(28.2%) specimens from 9 (24.3%) bandicoots 
were positive for Chlamydia spp after 3-6 
passages. The single koala specimen was also 
positive and confirmed as C. pneumoniae by 
staining with a species specific monocloncal 
antibodies and genotyping. Ten of 11 bandi-
coot specimens were confirmed as 
Chlamydiales by FA staining with genus speci-
Medical Center, Brooklyn, USA, Queensland 
fic antibodies, one specimen was typed as C. 
pneumoniae with species-specific antibodies. 
Inclusions varied in size and granularity. Eight 
of the 11 culture positive specimens were 
previously found to be positive by 16 S RNA 
PCR. One animal was culture positive at QUT. 
In vitro testing of the koala C. pneumoniae 
isolate found the MICs/MBCs for levoflox-
acin, erythromycin, clarithromycin and azithro-
mycin of 0.5, 0.015, 0.06, and 0.015 pg/ml, 
respectively. Further genotyping and 
susceptibility testing of these isolates is 
ongoing. 
We were able to isolate in tissue culture 
Chlamydia spp. from multiple anatomic sites 
from 24% of bandicoots. Three of the 11 
culture positive specimens were previously 
negative by 16 S RNA PCR. Tissue culture 
using cycloheximide-treated HEp-2 cells ap-
pears to be an effective system for isolation 
and growth of these organisms. Ninety-one 
percent of the bandicoot isolates were 
definitely Chlamydiales, one specimen was 
typed as C. pneumoniae. Further studies are 
needed to define the exact species of the other 
isolates. In vitro susceptibility testing of a C. 
pneumoniae isolate obtained from a koala 
demonstrated similar antibiotic susceptibilities 
as human isolates. Although molecular 
techniques offer the opportunity for rapid 
screening of specimens, there is still the need 
to actually isolate the organism for in vitro 
susceptibility testing. Several of the animals in 
this study were initially treated with beta-
lactam antibiotics without response but 
subsequently responded to intramuscular tetra-
cycline. Results of susceptibility testing will 
provide alternative modes of treatment, which 
will be important for the conservation of this 
endangered species. 
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The authors report a field application of a 
PCR-RFLP assay targeting the Chlamydiaceae 16S 
rRNA gene. It allows the detection and typing of 
the chlamydial species which are of major interest 
in veterinary laboratories (Chlamydophila (Cp.) 
psittaci, Cp. abortus, Cp. pecorum, Cp. felis, Cp. 
pneumoniae and Chlamydia (C.) suis, according to 
the revised classification proposed by Everett et 
al., 1999). In the present study, 74 clinical 
specimens (organ tissues and swabs) from pigs 
were investigated for chlamydial infection by 
PCR-RFLP: 21 samples (28%) were found PCR 
positive and typed as Chlamydia suis. 
Genomic DNAs were purified from a total 
of 74 porcine clinical specimens (organ tissues and 
swabs) by using a commercial kit based on the 
silica particles/guanidium thiocyanate method. A 
Polymerase Chain Reaction (PCR) assay targeting 
a portion of the Chlamydiaceae 16S rRNA gene 
was developed, employing a modified procedure 
slightly different from the one proposed by 
Ossewaarde and Meijer (1999). PCR primers 
16SFOR2 (5' -CGTGGATGAGGCATGCAAGTC 
GA-3') and 16SREVmod (5'-ATCTCTCAATCC 
GCCTA GACGTCA-3') were used. The PCR 
amplicons were digested with different restriction 
endonucleases (Msel, Hhal, Mboll) in a 
Restriction Fragment Length Polymorphism 
(RFLP) assay. PCR and RFLP products were 
detected, respectively, by agarose gel and 
polyacrylamide gel electrophoresis both stained 
with ethidium bromide. 
21 samples out of 74 resulted PCR positive 
with an amplicon of 265-266 bp that was digested 
with the restriction endonuclease Msel (RFLP 
assay). Two distinct RFLP patterns were obtained: 
pattern I (85, 81, 71, 29 bp) and pattern B (81, 71, 
48, 36, 29 bp). Pattern II can be observed only in 
C. suis, while pattern I can be observed both in C. 
suis and Cp. pecorum. In order to differentiate 
these two chlamydial species, other two 
endonucleases were used: Hhal and MboW. Hhal 
digests C. suis amplicons yielding two fragments 
of 133 bp each, while Cp. pecorum amplicons are 
not digested; Mboll digests only Cp. pecorum 
amplicons (175, 92 bp). The two restriction 
patterns obtained are in accordance with 
nucleotide sequences available in the NCBI 
GenBank. 
Pigs can be infected by different 
chlamydial species, namely C. suis, Cp. pecorum, 
and Cp. abortus. Diseases associated with 
chlamydiae in swine include encephalitis, 
conjunctivitis, enteritis, pneumonia, polyarthritis, 
and reproductive disorders (abortion, hypofertility, 
neonatal death); clinically inapparent infections 
have been reported as well (Daniels et al., 1994; 
Nietfeld et al., 1997; Rogers et al., 1993; Sarma et 
al., 1983). In our survey, all positive samples were 
typed as C. suis and no other chlamydial species 
was detected. 
Molecular methods offer a convenient tool 
for the routinary diagnosis of animal chlamydial 
infections. In particular, our PCR-RFLP analysis 
of a portion of the chlamydial 16S rRNA gene 
showed a high discriminatory power to 
differentiate chlamydial PCR amplification 
products to the species level. The detection and 
subsequent identification of chlamydial species, in 
both animal farms and pets, is required for 
monitoring and controlling these infections and for 
assessing their zoonotic potential. 
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Genomic analysis of Chlamydia caviae (C. 
psittaci GPIC) has revealed a 3877-bp ORF 
predicted to encode a member of the 
invasin/intimin family of virulence factors. 
Invasin/intimin orthologs have been extensively 
characterized in Yersinia, EPEC and EHEC, and 
are also found in Salmonella and Bordetella. 
Comparative genomics within the Chlamydiaceae 
indicate that the invasin ortholog is so far unique 
to C. caviae although a 360-bp segment of the 
gene is found at the same site in C. muridarum (C. 
trachomatis MoPn). Surprisingly, the C. caviae 
invasin ortholog is inactivated by virtue of two 
frame-shift mutations early in the gene. 
Concurrent to these findings, Rockey and 
collaborators have identified invasin sequence as 
the insertion site for a novel transposable element 
carrying tetracycline resistance genes (tetR) in a C. 
suis isolate (swine C. trachomatis) (personal 
communication). Hence, in all chlamydiae where 
invasin sequence has been identified to date, the 
gene is either degenerate or inactivated by 
mutation. 
These observations led us to search for the 
presence of invasin-related sequence across the 
genus Chlamydia in veterinary and human isolates. 
A panel of specific and degenerate primers was 
designed to amplify invasin fragments or the entire 
locus using sequence from the flanking conserved 
rRNA and nqrF genes. Genomic DNAs used for 
this analysis were from C. trachomatis (5 human 
genital isolates), C. pecorum (22 
ovine/bovine/swine isolates), tets C. suis (1 
isolate), C. psittaci (11 avian isolates), C. felis (3 
isolates) and C. abortus (9 ovine/bovine isolates). 
In addition amplicons were obtained from early 
yolk sac passages of C. caviae and from C. caviae 
recovered after 5 sequential ocular passages in 
guinea pigs. 
In all cases except C. suis, amplified 
fragments were significantly smaller than for C. 
caviae, suggesting that full-length invasin would 
not be found. Nucleotide sequence analysis 
subsequently confirmed the absence of invasin-
related sequence in C. trachomatis. Invasin is also 
absent from C. abortus, C. felis, C. psittaci and C. 
pecorum. In C. psittaci, ORF70 encoding a 
hypothetical protein of 70-kDa unrelated to invasin 
is present at the same site. Fragments of ORF70 
are found in C. pneumoniae, C. felis and C. 
abortus strains. All C. pecorum strains tested 
harbor a unique 8-mer oligonucleotide sequentially 
repeated 11 to 44 times at the same site. The 
nucleotide sequence of C. caviae invasin from 
early passages or reisolated from guinea pigs 
confirmed the presence of the frame-shift 
mutations. This indicates that these mutations are 
likely not the result of the expansion of an invasin-
negative clone over many years of in vitro culture. 
Nucleotide sequence analysis of the C. suis 
amplicon however has revealed the presence of a 
full-length invasin ortholog, which - uniquely in 
Chlamydia - is uninterrupted by mutation. 
Globally, our results indicate that the 5S 
rRNA-nqrF intergenic segment displays unusually 
high genetic variation across the Chlamydia 
virotypes. The observation of multiple repeats in 
C. pecorum suggests that this site is unstable 
relative to the rest of the genome. On the 
evolutionary scale, such instability may have 
promoted both the frequent acquisition of 
heterologous DNA at that site (eg invasin, tetR 
genes, ORF70) and, paradoxically, their rapid 
degeneration. The biological significance of these 
observations remains to be elucidated. 
Significantly however, the isolation of an 
uninterrupted invasin gene from C. suis will now 
allow to evaluate its possible role in chlamydial 
pathogenesis. 
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Chlamydophila pneumoniae is the main 
agent of human respiratory infections. Previous 
investigations suggested also involvement in 
chronic obstructive lung disease (COPD). 
Other Chlamydiaceae and possible zoonotic 
implications had not been considered so far. 
Tissue of patients with advanced alpha-
1 antitrypsin deficiency (AATD) and non-
AATD emphysema having undergone lung 
volume reduction surgery or with giant bullous 
emphysema having undergone bullectomy as 
well as sputum samples from patients with 
stable and exacerbated COPD were 
investigated with light microscopy, 
transmission electron microscopy (TEM), 
immunohistochemistry (IHC) and immuno-
fluorescence (IF) as well as PCR. 
Bronchiolitis, interstitial inflammation 
and intra-alveolar accumulation of 
macrophages were seen histologically in a 
variable extent in all cases. In 100% (n=5) of 
AATD emphysema, 79.4% (n=27) of non-
AATD and 73.3% (n=15) of giant bullous 
emphysema, persistent chlamydial infection 
was detected by ultrastructural examination 
(TEM). Chlamydial infection was seen in 
83.3% (n=12) of AATD emphysema, 100% 
(n=50) of non-AATD and 93.75% (n=16) of 
giant bullous emphysema by IHC and IF. 
Detection rates in macrophages, type 2 
pneumocytes, bronchiolar epithelial cells, and 
lymphocytes revealed some differences 
between the three forms of emphysema. The 
presence of Chlamydia psittaci was 
demonstrated by PCR in lung tissue of four 
AATD (66.7%) vs. nine non-AATD 
emphysema patients (29.0%). Partial DNA 
sequencing of four positive samples confirmed 
the identity of the agent as Chlamydophila 
psittaci. In contrast, Chlamydophila 
pneumoniae was detected only in one AATD 
patient. 
In samples of induced sputum IF 
revealed 69.6% Chlamydia spp. positive cases 
in acute exacerbated (AE) COPD and 50% in 
stable (S) COPD. In PCR 42.4% of the 
samples were positive for Chlamydophila 
psittaci in AE-COPD and 4.5% in S-COPD 
(p<0.01). Partial DNA sequencing of six 
positive samples confirmed the identity of the 
agent as Chlamydophila psittaci in four and 
Chlamydophila abortus in two patients. 
Chlamydophila pneumoniae was not detected. 
These data indicate a role of 
Chlamydophila psittaci and Chlamydophila 
abortus in COPD and pulmonary emphysema. 
Zoonotic transmission of Chlamydophila spp. 
is well known and especially important for 
Chlamydophila psittaci und abortus. These 
can be found in avians, cattle, swines, sheep 
goats and horses. Further investigations on 
human and animal strains are necessary. 
Chlamydophila pneumoniae seems not to play 
a relevant role in these diseases according to 
our results. 
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Characterization of 21 European 
Chlamydophila psittaci isolates using serovar-
specific monoclonal antibodies (MAbs) in an 
indirect immunofluorescence staining, OmpA 
RFLP analysis and OmpA sequencing. 
21 Cp. psittaci field isolates from 
various avian species and countries including 
Belgium (n = 7), Germany (n = 6), Italy (n = 7) 
and The Netherlands (n = 1) were used as well 
as serovar A to F reference strains VS1, CP3, 
GD, NJ1, CPMN and VS225. Strains were 
grown in BGM cells. OmpA was PCR 
amplified, cloned into pGemT (promega) and 
sequenced using vector associated SP6 and T7 
priming sites. Alignments (ClustalX) were 
imported into TreeconW using the Jukes and 
Cantor algorithm and the Neighbour-Joining 
method to design the Cp. psittaci ompA 
phylogenetic tree. OmpA sequences of the 
reference strains were digested in silico 
(Webcutter 2.0) using AM. The obtained 
reference restriction patterns were used for 
typing the field strains following gel-based 
analyses (Magellan) of Alul digested OmpA 
genes. Serotyping was performed using 
serovar-specific MAbs (VS1/7A7/E8, 
CP3/4C6/G2, GD/2H9, NJ1/2GB/C2, 
MN/4A10/A4 and VS225/D6/36) and the 
family-specific control MAb (7B6III) in an 
indirect immunofluorescence staining on Cp. 
psittaci infected BGM monolayers. Slides 
were examined using confocal laser scanning 
microscopy (Radiance 2000, Bio-Rad). 
The ompA genes present in 21 isolates 
were successfully sequenced resulting in the 
detection of 8 genotype A, 5 genotype B and 2 
genotype D sequences as well as 1 genotype E 
and F sequence. Genotype C was not present. 
Five out of 21 birds (3 pigeons, 1 parrot and 1 
turkey) were simultaneously infected with 2 
different genotypes. Interestingly, sequencing 
indicated the presence of the E/B ompA 
sequence being discovered in 9 birds 
originating from different geographical areas 
and hosts in Italy as well as in Germany. 
Phylogenetic analysis supported the creation of 
a new genotype E/B, closely related to the 
genotypes A, B and E. Only 19 out of 21 
isolates could be serotyped revealing 1 mixed 
infection. The two remaining isolates only 
reacted with the family-specific MAb. OmpA 
RFLP analysis was successful in all cases, 
revealing 5 mixed infections. The new 
genotype E/B, determined by OmpA 
sequencing could not be distinguished from 
genotype E and reacted with both the serovar E 
and B-specific MAb. A certain degree of host-
specificity was observed as genotype A, B, and 
E/B was most often isolated from psittacines, 
pigeons and ducks respectively. 
Serotyping was historically important 
for the characterization of avian Cp. psittaci 
strains but has often been replaced by ompA 
RFLP analysis. However, the present study 
emphasises the need for a sensitive, rapid and 
especially more discriminatory genotyping 
technique than RFLP as genotype E/B was 
only identified by ompA sequencing. 
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Members of the genus Chlamydia are 
obligate intracellular parasites that play an 
important role in both human and animal diseases. 
Plasmids were initially described in both C. 
trachomatis and C. psittaci. Following theese 
reports, a lot of studies have described the 
molecular characterization of chlamydial plasmids. 
pCT is a plasmid of 7.5 kb commonly found in 
almost all isolates of C. trachomatis. ORF3 of C. 
trachomatis has been shown to encode an 
antigenic protein of 28 kDa, pgp3, which has been 
expressed in E. coli. This protein is a marker of 
current C. trachomatis infection in humans and 
can be clearly identified by staining inclusions in 
C. trachomatis infected cells. As far as the C. 
psittaci plasmid is concerned, all avian isolates of 
C. psittaci contain a plasmid which varies in size, 
being either 6.2 kb or 7.2-7.3 kb, whereas ovine 
abortion isolates do not. The genomic organization 
of C. psittaci plasmid (pCp) accounts for the 
presence of eight major ORFs, as observed in C. 
trachomatis strains. In this study, we performed a 
preliminary analysis of the ORF3 gene of 11 C. 
psittaci strains of various animal origin, by PCR-
based RFLP. 
Chlamydia isolates and cell culture. The 
avian C. psittaci isolates were from parrots (n° 4), 
f rom pigeons (n° 5) and from parakeet (6BC 
strain). An additional C.psittaci strain (Scalorbi) 
recently isolated in our laboratory f rom the sputum 
of a patient with pneumonia likely contracted f rom 
a parrot with psittacosis was also studied. All the 
Chlamydia strains were grown in LLC-MK2 cells. 
DNA extraction. Infected cells were centrifuged 
and total DNA was purified from the pellet, by 
using the tissue protocol of the QIAamp DNA 
Mini Kit (Qiagen, Düsseldorf, Germany). 
RFLP analysis of chlamydial pgp3 gene amplified 
by PCR. The extracted DNA was used to perform 
the PCRs for the Chlamydia cryptic plasmid, The 
primers used to generate 1 kb fragment of the orf-3 
gene were ORF3DX (5' -GAAAGTTACTTTTTCC 
TTG-3 ' ) and ORF3SN (5 'ATGGGAAATTCTGG 
TTTTT) (10). Positive amplicons for the orf-3 
gene were digested with Bfa I (New England 
Biolabs, Beverly NA). 
Orf-3 DNA sequencing. The orf-3 nucleotide 
sequence of two C. psittaci strains: i.e. Scalorbi 
and PV1867 strain respectively, was determined 
by automated sequencing. The DNA sequencing 
was performed in both orientations. Data were 
analyzed with the Chromas shareware program and 
contig were assembled by the Contig Assembly 
Program Based on Sensitive Detection of 
Fragment overlaps (www.infobiogen.com). 
Sequence homology study was performed by 
BLAST similarity search and multiple alignment 
with CLUSTALW. 
Immunofluorescence (IF) Indirect IF assay was 
performed on the monolayers of LLC-MK2 cell 
cultures infected with C. psittaci strains to detect 
the expression of pgp3 protein. 
From the restriction enzyme digestion with 
Bfa I and agarose gel electrophoresis of the 
products of amplification of the pgp3 gene of the 
1 1 C . psittaci strains we found that the digestion 
resulted in a profile characterized by the presence 
of 3 bands of 447 bp, 274 bp, and 241 bp. 
Sequencing analysis of the orf3 gene f rom two C. 
psittaci strains (one f rom pigeon and Scalorbi, a 
human isolate) revealed only two differences in the 
nucleotide sequence. The deduced peptides 
sequences showed 1 amino acid change between 
the two C. psittaci strains. In order to verify the 
antigenicity of pgp3 gene products in C. psittaci 
strains, all the strains were grown in LLC-MK2 
cells, fixed 48 hours after infection and probed 
with rabbit serum anti-recombinant pgp3. As 
second antibodies, fluorescein-conjugated goat 
anti-rabbit immunoglobulins were used. All the 
strains gave rise to inclusions clearly identified by 
IF. 
In conclusion, sequence analysis of 0 R F 3 
of two C. psittaci strains demonstrated that the 
homogeneous profile detected by RFLP was 
related to the very low variability in nucleotide 
sequences (2 bp) and that 0 R F 3 f rom C. psittaci 
strains is immunogenic as previously demonstrated 
for C. trachomatis ORF3. 
CHLAMYDIA OF VETERINARY INTEREST - 301 
HIGH PREVALENCE OF CHLAMYDIAL (CHLAMYDOPHILA PSITTACI - C. 
PSITTACI) INFECTION IN FETAL MEMBRANES OF ABORTED EQUINE FETUSES 
SHOWN BY IMMUNOHISTOCHEMISTRY AND PCR 
Levente Szeredi1*, Helmut Hotzel2 and Konrad Sachse2 
'Central Veterinary Institute, Budapest, Hungary; 2Federal Research Centre for Virus Diseases of Animals, 
Jena, Germany 
The aim of the study was to examine the 
occurrence of chlamydial infection in equine fetuses 
and fetal membranes and assess the importance of 
this infection in equine abortions. 
77 cases of equine abortion from 43 herds 
and from different parts of Hungary were investigated 
between 1998 and 2000. After gross pathological 
examinations, one to three pieces of the 
allantochorion from each case and a total of 431 
tissue samples from different fetal organs (lungs, 
heart, liver, spleen, kidney, brain, adrenal gland, 
lymph node, small intestine, thymus) were fixed in 10 
% formalin and embedded in paraffin wax. The 
sections were stained with haematoxilin and eosin, 
and several special staining methods were used for 
the detection of pathogens (Giemsa, PAS, Warthin-
Starry, Brown-Brenn, Gomori methenamin-silver 
stain). All tissue samples were examined by 
immunohistochemistry for the presence of chlamydial 
LPS. The positive tissue samples were also examined 
with polyclonal antibody detecting C. trachomatis 
and C. suis, but not C. psittaci, C. pecorum or C. 
abortus. Additionally, PCR was used to detect 
chlamydial DNA in the fetal membranes in 60 cases. 
PCR products were sequenced in a few cases to 
identify the chlamydial species involved. Smears 
made from the allantochorion were investigated for 
the occurrence of Chlamydiae by Stamp stain and 
immunocytochemistry in 77 and 63 cases, 
respectively. In 47 cases, complement fixation test 
(CFT) was used to detect chlamydia-specific 
antibodies in sera of aborted mares. Bacteriological 
examination to detect aerobic bacteria and 
immunohistochemical tests to demonstrate equine 
arteritis virus (EAV), equine herpesvirus type 1 
(EHV-1), Leptospira, Toxoplasma gondii, or 
Neospora caninum were also conducted in each case. 
Chlamydia was evident in 64 cases (83%). 
Chlamydial LPS antigen was found in 54 (70%) cases 
in the allantochorion only, but not in any of the fetal 
tissues. Chlamydial antigen appeared as small dots or 
inclusion bodies in the cytoplasm of the 
chorionepithelial cells. Three different patterns of 
cellular infection were observed: a) sporadic infection 
of a few cells (30 cases), b) infection in foci in 
several cells (16 cases), and c) large number of 
infected cells in multiple areas (8 cases). Only three 
cases were positive with both Stamp stain and 
immunocytochemistry, and only two (4.3%) sera 
reacted positively in CFT. Immunohistochemistry 
with polyclonal antibody specific for C. trachomatis 
and C. suis gave negative results. PCR examination 
of paraffin-embedded tissue was positive for 
Chlamydiaceae in 51/60 (85%) cases. The findings of 
PCR and immunohistochemistry were concordant in 
47 (78.3%) cases, whereas 10 PCR-positive samples 
proved negative in immunohistochemistry and only 3 
PCR-negatives were immunohistologically positive. 
Partial sequencing in the ompA gene region revealed 
that the agent was C. psittaci. 
In 36 (56.2%) of the 64 positive cases, non-
chlamydial agents could be identified as the most 
likely cause of infection: 22 cases were due to 
different infections (EAV: 1, EHV-1: 10, Leptospira: 
2, Str. equinus: 1, Str. equi subsp. zooepidemicus: 2, 
E. coli: 2, Pseudomonas aeruginosa: 1, Gram-
negative coliform: 1, Encephalitozoon cuniculi: 1, 
Fungi: 1) and 14 abortion cases had a non-infectious 
cause (placental insufficiency: 5, trauma: 1, twins: 2, 
umbilical cord torsion: 2, disturbance of the lipid 
metabolism in the mare: 1, severe calcium deposition 
in the fetus and fetal membranes: 2, congenital 
malformation of the fetus: 1). In 17 (26.6%) cases, no 
lesions were found and the cause of abortion could be 
not identified. In the remaining 11 cases (17.2 %), 
Chlamydiae as the only agents were found in 
association with mild or moderate placentitis. 
However, the severity of infections showed only a 
weak correlation with the severity of histological 
lesions in the fetal membranes. 
An unexpectedly high prevalence of 
chlamydial (C. psittaci) infection was found in the 
aborted fetal membranes. However this infection 
seemed to be inapparent in most of the cases (82.8%) 
and the role of Chlamydiae in inducing placentitis 
(17.2%), although likely, could not be unambiguously 
demonstrated. Further studies are needed to explain 
the role of chlamydial infection of allantochorion in 
cases of equine abortion. 
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USE OF ANTIGEN ELISA AND REAL-TIME PCR FOR THE DETECTION OF 
CHLAMYDIACEAE IN SWEDISH ANIMALS 
Stina Englund*, Stefan Jernstedt, Göran Bölske 
National Veterinary Institute, Department of Bacteriology, Uppsala, Sweden 
Antigen detecting ELISA tests are often 
used for detection of Chlamydiae in routine 
diagnostic work instead of culture, because the 
latter is rather expensive and demands long 
time for incubation and expertise skills. The 
commonly used IDEIA Chlamydia test is not 
intended for the detection of Chlamydiae in 
animal samples and has not been evaluated for 
these kinds of specimens. Furthermore, the 
type and quality of the specimen is crucial to 
the success of this diagnostic test. Fast and 
sensitive detection of Chlamydiae can also be 
accomplished by PCR, where real-time PCR 
has become a promising alternative to standard 
PCR, and especially to nested PCR, because of 
enhanced sensitivity and specificity as well as 
the lowered risk for cross-contamination by 
amplicons. We are currently evaluating the 
utility of antigen ELISA and real-time PCR for 
the detection of Chlamydiaceae in a variety of 
animal specimens. 
We have used the IDEIA™ Chlamydia 
test, which utilises an antibody against the 
chlamydial LPS, and the real-time PCR 
developed by Everett et al. (1), which targets 
the 23 S ribosomal DNA and rapidly and 
specifically detects all members of the family 
Chlamydiaceae. The samples analysed were 
conjuctival and nasal cotton swabs from cats; 
liver, lung and spleen specimens from birds 
with suspected Chlamydophila psittaci 
infection; sheep placentas, and liver and lung 
samples from sheep fetus. Preparations of 
swabs and tissue specimens for PCR analysis 
were preformed according to the protocols by 
Sachse and Hotzel (2). 
Real-time PCR analysis of conjuctival 
and nasal cotton swabs from cats was shown to 
be more sensitive than the antigen ELISA. The 
PCR and ELISA test results for the tissue 
specimens from birds and sheep were in 
accordance with each other, except for the 
analysed sheep placentas. These samples were 
heavily decayed and yielded positive ELISA 
results but negative PCR results. 
Further analyses of the placentas revealed the 
presence of bacteria, which gave positive 
signals in the antigen ELISA. Inhibition of the 
amplification reaction was observed in about 
one third of the tissue samples and could be 
due to excess DNA and/or impurities still 
present in the sample preparation. 
In this study the real-time PCR was 
more sensitive and specific compared to the 
antigen ELISA. To further improve the 
sensitivity of the PCR a more efficient sample 
preparation method is required for some types 
of specimens. When using the antigen ELISA 
the interpretation of the test results should be 
cautious as there is a risk for false negatives 
due to low sensitivity or a risk for false 
positives due to cross-reactions. 
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DETECTION OF CHLAMYDOPHILA PSITTACI IN HORSES WITH 
RECURRENT AIRWAY OBSTRUCTION 
D. Theegarten*1, B. Mentrup1, H. Hotzel2, G. Mogilevski2, K. Sachse2, O. Anhenn1 
department of Pathology, Ruhr-University, Bochum, 2Institute of Bacterial Infections and 
Zoonoses, Federal Research Centre for Virus Diseases of Animals (BFAV), Jena, Germany 
Previous investigations suggested 
involvement of chlamydial infection in human 
chronic obstructive pulmonary disease 
(COPD). Recurrent airway obstruction (RAO) 
in horses is considered as a chronic disease of 
the bronchioles with some similarities to 
human COPD. It was questioned, whether 
Chlamydophila spp. could be detected in lung 
tissue of horses with RAO. 
Lung tissue of seven horses with RAO 
and seven healthy controls was investigated by 
immunohistochemistry, PCR and transmission 
electron microscopy (TEM). 
Chlamydia psittaci could be detected in 
all cases of RAO by immunohistochemistry. 
Inclusion bodies could be seen in 
macrophages, type II pneumocytes and 
bronchiolar epithelial cells. Two of seven cases 
were positive for Chlamydophila psittaci in 
PCR. In three cases, additionally investigated 
by TEM, a typical chlamydial infection with 
perinuclear inclusions was seen as well. 
Controls were Chlamydia-negative by all 
methods. 
Chlamydophila psittaci was found to be 
occuring in horses with RAO. Further 
investigations concerning differences and 
similarities of equine and human strains in 
RAO versus COPD are necessary. 
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EVALUATION OF AN OMP A NESTED PCR / ENZYME IMMUNOASSAY FOR 
DIAGNOSING CHLAMYDIOSIS IN TURKEYS 
M. Van Loock1, K. Verminnen2*, T. Messmer3, B. M. Goddeeris1, G. Volckaert1 and D. 
Vanrompay2 
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Chlamydia psittaci, recently 
reclassified as Chlamydophila psittaci (Everett 
et al., 1999), is an important turkey pathogen 
(reviewed in Andersen and Vanrompay, 2003). 
Despite the fact that basic diagnostic principles 
are applicable to Cp. psittaci, diagnosis 
remains very difficult. C. psittaci is an obligate 
intracellular bacterium and handling this 
zoonotic agent requires special biohazard 
laboratory facilities. Detection of viable 
bacteria requires a 'demanding' isolation 
method. However, there is an increasing 
request for more rapid, convenient, highly 
specific and sensitive diagnostic tests. In the 
present study we developed a nested PCR/EIA 
for detecting the Cp. psittaci outer membrane 
protein A (ompA) gene. The specificity and 
sensitivity of the test was compared to 
isolation as well as to a nested 16S rRNA 
PCR. 
Pharyngeal swabs from 200 turkeys, 
originating from 10 different farms (Belgium 
N=8, France N=2), were collected at slaughter 
using cotton-tipped aluminium shafted swabs 
(Fiers) containing 2 ml Cp. psittaci transport 
medium. Swabs were examined for the 
presence of viable Cp. psittaci by isolation in 
Buffalo Green Monkey cells followed by 
identification using the IMAGEN™ 
immunofluorescence staining 
(Dakocytomation), (Vanrompay et al., 1992). 
For PCR, two different DNA extraction 
methods were used: the QiaAmp DNA blood 
mini kit (QIAGEN) and the SET method, as 
described by Messmer et al. (1997) and 
Wilson et al. (1996), respectively. DNA 
extracted with the QiaAmp DNA blood mini 
kit was tested in the nested 16S rRNA PCR as 
described by Messmer et al. (1997) and the 
nested omp A PCR/EIA. The latter was 
developed using external and internal primers 
designed in the conserved regions of the ompA 
gene generating a biotin- fluorescein dual 
labelled internal PCR product of 450 bp. A 
tenfold dilution of the PCR product was 
incubated on streptavidin coated microtitre 
plates and detected with a peroxidase labelled 
anti-fluorescein antibody. Both PCR assays 
were designed to increase sensitivity and 
circumvent inhibitors present in clinical 
samples. 
Using the nested 16S rRNA PCR, 6.5% 
(13/200) of the turkeys were still shedding Cp. 
psittaci at slaughter resulting in 50% positive 
farms. Isolation and the nested omp A PCR/EIA 
are currently being performed. Full results will 
be presented. 
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EPIDEMIOLOGICAL INVESTIGATION OF CHLAMYDOPHILA PSITTACI IN 
PIGEONS AND WILD BIRDS IN CROATIA 
Estella Prukner-Radovcic*, Danijela Horvatek, Z. Gottstein, Irena Ciglar Grozdanic, H. 
Mazija 
Faculty of Veterinary Medicine, University of Zagreb, Department of Avian Diseases, Zagreb, 
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Previously investigations showed that 
pigeons and other wild birds, because of their 
specific migrations route, represent potential 
source of infections for humans and poultry in 
suburban area. Seroepidemiological surveys 
indicated that especially pigeon's chlamydiosis 
is widely spread. During 2003 occurrence of 
the Chlamydophila psittaci (C. psittaci) 
infection in pigeons and other free-living wild 
birds in the city of Zagreb (Croatia) was 
examined. 
In present study altogether 242 adult 
pigeons (Columba livia) and 54 birds of 11 
wild bird species: 27 blackcap (Sylvia 
atricapilla), 15 robin (Erithacus rubecula), 4 
blackbird (Turdus merula), 1 nightingale 
(.Erithacus megarhynchos), 1 song thrush 
(Turdus philomelos), 1 goldcrest (Regulus 
regulus), 1 willow warbler (Phylloscopus 
trochilus), 1 chiffchaff (Phylloscopus 
collybita), 1 greenfinch (Carduelis chloris), 1 
wren (Troglodytes troglodytes), and 1 sparrow 
hawk (Accipiter nisus), were caught in the 
various location in city of Zagreb. Pigeons 
were, after taking samples, kept in cages until 
achieving the preliminary results, and wild 
birds were, after weighting, measuring of wing 
length, and taking samples, marked with the 
leg ring and released again into the wildness. 
Altogether 182 blood sera from pigeons 
were tested for the presence of antibodies 
against C. psittaci using ELISA test 
(RfDASCREEN® Chlamydia psittaci, R-
Biopharm, Darmstadt, Germany). Blood sera 
from 174 (95.6 %) pigeons contained specific 
antibodies against C. psittaci. According to 
results of investigation of Gerbermann et al. 
(1994), who graded the significance of blood 
serum antibodies level, we found sera from 36 
pigeons to be low positive (20.69 %), 81 
medium positive (46.55 %) and 57 very 
positive (32.76 %). 
Because ELISA tests revealed 
significant number of pigeons positive to 
antibodies against C. psittaci, 182 with 
additional 96 pigeons cloacal swabs (altogether 
278 pigeons) as well as 54 wild-bird cloacal 
swabs were tested for presence of C. psittaci 
antigen using IDEIA™ PCE Chlamydia kit 
(DAKO Cytomation Ltd., United Kingdom). 
Out of that, 44 pigeons (15.83 %) were 
positive to antigen and 234 (84.17 %) were 
negative. None of 54 wild birds were positive 
to C. psittaci antigen. Pigeons positive to 
antigen were examined cytologically by Stamp 
staining method and intracellular inclusion 
bodies were found. Pathomorphological 
examination of birds with clinical signs of 
chlamydiosis revealed enlarged liver and 
spleen as well as exudates in air sacs. 
Findings of specific antibodies and 
antigen of C. psittaci confirms the high rate of 
infection among urban pigeons in Zagreb. 
Although, the pigeon serovars of C. psittaci are 
of medium pathogenicity for human, findings 
of 15.83 % positive birds to antigen represents 
the possible source of infection for humans, 
especially for older people and 
immunodeficient patients, as well as for the 
poultry production near city of Zagreb. 
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IDENTIFICATION OF CHLAMYDOPHILA PSITTACI SUBCLINICAL 
INFECTIONS FROM ORNATE BIRDS IN MEXICO 
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Objective: To determine the presence 
of Chlamydophila psittaci in apparently 
healthy ornate birds kept under conditions of 
captivity and semicaptivity in Mexico. 
Faecal (2) and conjunctival (2) samples 
from 40 birds of the genus Amazona, 
Agapornis, Ara, Pionus and Ramphastos were 
taken. 20 birds belong to three recreative parks 
of Mexico city, being under semicaptivity 
conditions. 20 birds belong to private families, 
being kept under captivity conditions. 
For the identification of Chlamydophila 
psittaci, one group of samples (1 faecal + 1 
conjunctival) was run by means of bacteria 
isolation in cell culture (L929 mouse 
fibroblasts) followed by detection of 
Chlamydophila inclusions through indirect 
immunofluorescence test. As positive control 
cell monolayers were infected with 
Chlamydophila pecorum T23 strain. As 
negative control uninfected monolayers were 
used. Both controls were processed under the 
same conditions than the clinical samples. 
Number of positive samples and percentage of 
infectivity were determined for each group of 
birds. 
For the identification of aerobe mesophile 
bacteria, the other group of samples (1 faecal + 
1 conjunctival) was run by means of bacteria 
isolation on blood and McConkey agars 
followed by biochemical identification. 
Chlamydophila psittaci was detected in 
all samples of the 40 birds. Nevertheless, the 
percentage of infectivity within the type of 
sample varied between 20 and 90%. 
Evenmore, concerning the faecal samples there 
was no significant difference among the 
different rate of infection found. As for the 
conjunctival samples, however, a significant 
difference was found in such rate where 65% 
of the samples showed a percentage of 
infectivity of 90%. 
Regarding other bacteria, from the faecal 
samples microorganisms of the genus 
Corynebacterium, Klebsiella, Erysipelothrix, 
Flavobacterium, Kurthia, Staphylococcus, 
Actinomyces and Escherichia were isolated in 
percentages between 5 and 25%, whereas from 
the conjunctival samples Klebsiella, Neisseria 
and Staphylococcus were isolated in 
percentages of 5 and 20%. No significant 
difference was found between bird groups. No 
apparent relationship was observed between 
the presence of Chlamydophila psittaci and the 
other isolated prokaryotes. 
Chlamydophila psittaci is present 
within bird populations in Mexico, which are 
in close contact with human beings. The role 
of these bacteria in clinical infections of birds 
and humans needs to be explored. 
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COMPARISON OF TWO COMMERCIAL ANTIBODY DETECTION KITS 
FOR DIAGNOSIS OF INFECTIONS DUE TO CHLAMYDOPHILA SPECIES IN 
SWEDISH CATTLE 
Ann-Charlotte Godin*, Camilla Bjorkman, Stefan Alenius 
Dept. of Ruminant Medicine and Veterinary Epidemiology, Faculty of Veterinary Science, 
Swedish University of Agricultural Sciences, Uppsala, Sweden 
Chlamydial infection in cattle has been 
described worldwide to cause disease e.g. 
pneumonia, enteritis, conjunctivitis, 
polyarthritis, encephalomyelitis, fertility and 
reproductive disorders such as abortion and 
endometritis. In some countries, chlamydial 
infection is considered as ubiquitous. The 
prevalence of chlamydial infections in Swedish 
cattle is not known and in 2002, a project 
started to evaluate diagnostic methods, 
occurrence and importance in Swedish cattle. 
I order to identify infected 
animals/cattle herds to sample for investigation 
of the Chlamydophila species present in 
Swedish cattle by polymerase chain reaction 
(PCR) reliable serological screening methods 
would be desirable. Two commercially 
available antibody detection kits were selected 
and compared: Chekit (Dr. Bommeli AG) and 
Panclabort (YabA Ltd.). Both kits were used 
according to the manufacturers instructions. 
Briefly: The Chekit Chlamydia enzyme 
immunoassay (EIA) detects antibodies against 
Chlamydia psittaci (old taxonomy) in serum 
and plasma samples of ruminants. Microtiter 
plates are pre-coated with inactivated antigen. 
Antibodies to C. psittaci bind to the antigen 
and form a complex. A peroxidase labelled 
anti-ruminant IgG conjugate is added and 
binds to this complex. After washing a 
chromogen solution is added. The optical 
density is measured and is proportional to 
amount of antibody to C. psittaci present in the 
sample. The Panclabort enzyme-linked 
immunosorbent assay (ELISA) detects 
antibodies against Chlamydophila abortus in 
sheep, goats, cattle, pigs or women and 
according to the manufacturer, achieve virtual 
100 % specificity. Microtiter plates are pre-
coated with a patent applied "highly specific 
antigen" (as said by the manufacturer). 
Positive sera are defined as those, which show 
an optical density (OD) higher than the "Cut 
off ' standard serum. 
Sera from 181 cows from 13 dairy 
herds and one beef cattle herd with 
reproductive problems such as late abortions, 
weak neonates and repeat breeding were 
analysed with both Chekit and Panclabort. Of 
the 14 herds, two were negative in both tests, 
four were positive in both tests and eight were 
positive only in the Chekit. The seroprevalence 
in aborted/reproductive problem cows (n = 81) 
was higher than in the control group (n = 100) 
with the Panclabort (8.6 %, 2 %, respectively), 
but not with the Chekit (27,2 %, 31 %, 
respectively). Surprisingly none of the 
Panclabort positive cows was positive in the 
Chekit test. 
Further studies to evaluate these tests 
are obviously needed and in progress. In 
addition, more investigations of the 
significance of chlamydial infections in 
Swedish cattle herds with reproductive 
problems are required. 
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EVALUATION OF AN AUTOMATED COMPLEMENT FIXATION TEST 
(SERAMAT) FOR THE DETECTION OF CHLAMYDIAL ANTIBODIES IN 
SHEEP AND GOATS SERA 
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The authors report the results of a 
preliminary survey for the application of an 
automated complement fixation test (CFT) for the 
detection of chlamydial antibodies in sheep and 
goats sera. Ninety sera (64 from goats and 26 from 
sheep) were examined with a commercial CFT kit 
for chlamydial antibodies and subsequently with 
an automated CFT (Seramat). The agreement 
between the two tests is good (K= 0.65). The 
advantages of the automated test versus the manual 
CFT would include a greater reproducibility of 
results and lower demands on the time of skilled 
technical and professional staff. 
Ninety sera (64 from goats and 26 from 
sheep) were chosen from a collection of samples 
that had already been tested with a complement 
fixation test (CFT) employing a commercial kit 
(Dade Behring, Marburg, Germany). A cut-off 
value of 1/32 was considered, according to the OIE 
recommendations (3). Overall, the chlamydial 
antibody titres with the manual test had been found 
< 1/32 for 69 sera, and > 1/32 for 21 sera. All 
samples had been kept stored at -20°C after the 
first test. After thawing, they were heat-inactivated 
at 60°C for 30 minutes and processed in an 
automated system (Seramat). 
Sixty-one out of 69 samples that had been found < 
1/32 by the manual CFT were also found < 1/32 in 
the automated test, while four were found 1/32, 
one 1/64 and three 1/128. 17 out of 21 samples 
ranging from 1/32 to 1/256 in the manual test gave 
titres > 1/32 in the automated test. Differences in 
their titres between the tests were null for 5 
samples, limited to one dilution for 8 samples, and 
to two dilutions for 4 samples. The remaining four 
sera that had titres > 1/32 in the manual CFT (three 
samples at 1/64, one sample at 1/32) were found < 
1/32 in the automated test. The agreement between 
the manual CFT and the Seramat system is good 
(K=0.65; 95% CI: 0.46-0.83). 
The complement fixation test is the most 
widely used procedure for the diagnosis of 
chlamydiosis in small ruminants (3) and it has 
been widely employed for decades as a stand-alone 
method (5) or in comparison with other tests, 
mostly ELISA tests that have been proposed as an 
alternative through the years (1,2,4). Although the 
CFT lacks specificity (beside Chlamydophila 
abortus, the agent of ovine enzootic abortion, the 
test detects antibodies to C. pecorum and other 
bacteria too) and does not allow to distinguish 
between responses to vaccination and to infection, 
nevertheless its use has been reported also recently 
in surveys in sheep and goats (7) due to its cost 
effectiveness and usefulness as a flock diagnosis. 
Our purpose has been to investigate the 
feasibility of the wide-scale application of the CFT 
for mass screenings for chlamydial antibodies with 
an automated system by comparing its results with 
those obtained with a manual CFT. The use of 
automated systems in veterinary medicine has been 
already described for the serological diagnosis of 
infectious diseases (6,8). The advantages of such 
an automation over the manual method would be 
those of greater reproducibility of results and 
lower demands on the time of skilled technical and 
professional staff, as the instrument allows to 
perform around 50 determinations in an hour's 
session. Given the preliminary results, the Seramat 
system seems suited to the purpose. Sources of 
variation between the manual and automated tests 
may include the different preparations of the 
antigen, an issue that will be addressed in further 
trials. 
References 1) Anderson I.E. et al., Vet Microbiol 
43, 1-12, 1995. 2) Jones G.E. et al., Vet Rec 141, 
164-168, 1997. 3) Office International des 
Epizooties. Enzootic abortion of ewes. Chapter 
2.4.7. In: Manual of Standards for Diagnostic 
Tests and Vaccines, 4th Ed., Paris, France, 2000 
(web format). 4) Salti-Montesanto V. et al., Am J 
Vet Res 58, 228-235, 1997. 5) Stamp J.T. et al., J 
Comp Pathol 62, 93-101, 1952. 6) Timbs D.V. et 
al., N Zeal Vet J 26, 52-56, 1978. 7) Travnicek M. 
et al., Vet Med Czech 46, 281-285, 2001. 8) 
Weddell W„ N Zeal Vet J 22, 1-4, 1974. 
CHLAMYDIA OF VETERINARY INTEREST - 293 
CHLAMYDOPHILA ABORTUS - THE RISK TO PREGNANCY 
David Buxton, David Longbottom, Ian E. Anderson, Morag Livingstone, Sean 
Wattegedera, Stephen Maley and Gary Entrican 
Moredun Research Institute, Pentlands Science Park, by Edinburgh, Scotland, UK 
Fetal mortality in sheep, caused by infection 
with C. abortus (syn. ovine chlamydial 
abortion; enzootic abortion of ewes; EAE), 
was first defined in 1950 (Stamp et al., 1950). 
Abortion occurs close to the expected time of 
lambing when the only clinical sign might be a 
sanguineous vaginal discharge, sometimes 
with mild malaise. Characteristic macroscopic 
lesions are restricted to the placenta with 
aborted and stillborn lambs generally 
appearing normal. The placental membranes 
appear thickened and reddish-yellow and a 
dirty pink vaginal exudate may be noted for a 
further seven to ten days (Aitken, 2000); both 
are a source of infection for susceptible female 
sheep as well as humans. 
Infection appears to most commonly establish 
in non-pregnant sheep with a subclinical 
primary infection that persists without clinical 
signs of illness. The tonsil is infected early on 
and latency may establish here and in other 
lymphoid tissues (Entrican et al., 2001). In 
latently infected ewes the organism is 
undetectable but during a subsequent 
pregnancy it is suggested that alterations in 
host immune function related to pregnancy 
allows chlamydial multiplication and an 
intermittent, low-grade chlamydaemia. The 
first evidence of infection is in the hilar 
chorionic epithelial cells (trophoblast cells) of 
the placen tome (Entrican et al., 2001) and 
thereafter the bacterium spreads out into the 
surrounding chorion. The associated fetal 
inflammatory response comprises neutrophil 
polymorphs, macrophages and lesser numbers 
of lymphoid cells. Deeper in the mesenchyme 
there is oedema, less intense inflammation and 
vasculitis, sometimes with thrombosis. Cells 
expressing the macrophage-associated 
molecule CD 14 are numerous as are cells 
expressing mRNA encoding for TNF-a but 
evidence of expression of IFN-y is minimal 
(Buxton et al 2002). In associated lesions in 
the maternal caruncular septa, lymphocytes 
predominate with CD8+ being more numerous 
than CD4+ and with B cells and y-8 T cells also 
present in the margins of septal necrotic foci 
(Sammin, 2003). 
Abortion therefore appears to be associated 
with a fetal cell-mediated immune response to 
C. abortus, provoked by the predilection of the 
organism for chorionic epithelial cells, which 
it destroys with the release of LPS. The toxic 
sequelae include placental thrombosis and 
infarction, and the destruction of chorionic 
epithelial cells leads to disruption of the 
hormonal control of pregnancy. It would seem 
likely that the maternal inflammatory response 
may also have a role in terminating pregnancy. 
This subacute ovine infection, fatal to the lamb 
but less commonly causing illness in the ewe, 
is in contrast to the acute infection that may 
occur in pregnant women following exposure 
to C. abortus, when both fetus and mother may 
be severely affected. 
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RECHALLENGE OF PREVIOUSLY-INFECTED PREGNANT EWES WITH 
CHLAMYDOPHILA ABORTUS 
Sammin, D.J.1*, Markey, B.K.2, Bassett, H.F.2 and McElroy, M.C.1 
Central Veterinary Research Laboratory, Department of Agriculture and Food, Abbotstown, 
Castleknock, Dublin, 2Faculty of Veterinary Medicine, University College, Belfield, Dublin, 
Ireland 
Elucidation of the maternal and foetal 
immune responses following experimental 
rechallenge with Chlamydophila abortus. 
Ten pregnant ewes which aborted 
following challenge with Cp. abortus were 
intravenously rechallenged with Cp. abortus 
one year later when again 91-98 days pregnant. 
Five rechallenged ewes were killed on each of 
days 21 and 35 post-rechallenge. 
Morphological changes in the placentas and 
foetal organs and foetal systemic responses to 
chlamydial infection were characterised at each 
time point. The pattern of development and 
distribution of lesions and the nature of the 
foetal response to Cp. abortus following 
rechallenge infection is described. 
None of the ewes aborted after 
rechallenge. At 21 days post-rechallenge, 
chorioallantoic pathology was observed in 
three of the five ewes. Chlamydial inclusion 
bodies were present in trophoblasts in the hilar 
zone. In addition, focal areas where the 
trophoblast layer was lost were heavily 
infiltrated by neutrophils and the underlying 
stroma was infiltrated by macrophages and 
very occasional lymphocytes. Periplacentomal 
endometritis was apparent in one of the ewes. 
Chlamydial LPS-positive inclusion bodies 
were present in the endometrial epithelium at 
the placentomal limbus. Associated changes 
included focal ulceration of the endometrium 
and sparse infiltration of the subendothelial 
stroma with neutrophils, macrophages and 
lymphocytes. Multifocal necrosis was evident 
in the livers of some of the foetuses and 
foetuses exhibited moderate leucocytosis. 
At 35 days post-rechallenge, 
pathological changes were observed in the 
chorioallantois of the five ewes. 
Immunolabelled chlamydial LPS was present 
at the chorionic surface and there was 
moderate to severe inflammatory infiltration in 
the underlying chorioallantoic stroma. Marked 
neutrophil infiltration of the chorionic surface 
was observed where primary villi and the 
periplacentomal chorioallantoic membrane 
were denuded of trophoblasts. Perivascular 
aggregates of macrophages and lymphocytes 
were apparent but lymphocytes constituted 
only a small proportion of the cellular infiltrate 
in the chorioallantois. Focal endometritis was 
evident at the placentomal limbus. Ulceration 
of the luminal epithelium was accompanied by 
intense subepithelial infiltration of neutrophils, 
macrophages and lymphocytes. Pathological 
changes in the foetus included hepato-
splenomegaly, lymphadenopathy and the 
presence of occasional hepatic granulomas. 
The foetal systemic response to Cp. abortus 
infection featured marked leucocytosis with 
pronounced neutrophilia, elevated plasma 
fibrinogen and detectable serum antibody to 
chlamydial lipopolysaccharide. 
In natural circumstances, ewes, which 
develop chlamydial placentitis are usually 
protected against chlamydial abortion in 
subsequent pregnancies. The absence of 
abortion in the rechallenged ewes suggests the 
development of a protective immunity. 
Maternal immunity would appear to protect 
against abortion by preventing Cp. abortus 
from reaching the foetal side of the placenta. 
The patterns of change in placentas and 
foetuses following intravenous rechallenge of 
previously-infected ewes closely resembled 
those observed following intravenous 
challenge of naïve ewes. It seems that if 
chlamydiae succeed in reaching the susceptible 
trophoblast layer, the same pattern of lesion 
development occurs in the placenta and the 
foetal response to infection is qualitatively 
similar regardless of the dam's immune status. 
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DETECTION OF CHLAMYDIA SPECIES IN MALE GENITAL TRACTS AND 
SEMEN OF RUMINANTS AND PIGS: PRELIMINARY RESULTS 
K. Teankum'*, N. Borel1, F. Janett2, L. Vaughan1, E. Brugnera1, E. Bürgi2, L. Corboz3, 
R. Weilenmann1, C. Kaiser1, A. Pospischil1 
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It is well known that chlamydial 
infection can lead to abortion in ruminants and 
pigs. In male animals, Chlamydophila (C.) 
abortus can cause orchitis, epididymitis, and 
seminal vesiculitis, resulting in shedding of the 
pathogen in semen. Nevertheless, the 
importance of venereal transmission is not 
clear and the carrier state of male animals is an 
open question. Therefore, it is of interest to 
investigate the prevalence and distribution of 
chlamydial infection in male genital organs 
and semen of ruminants and pigs. 
Testes, epididymis, accessory glands 
and urethra were collected from 13 boars and 3 
bulls with infertility problems. Macroscopic 
inspections of the male genital tract samples 
was complemented by histopathology, routine 
bacteriology and immunohistochemistry on 
formalin-fixed and paraffin-embedded material 
using a Chlamydiaceae family-specific mouse 
monoclonal antibody directed against the 
chlamydial lipopolysaccharide. The ejaculates 
were examined by routine bacteriology and 
polymerase chain reaction (PCR) for the 16S 
rRNA gene specific for the order 
Chlamydiales. To validate PCR technique for 
detection of Chlamydia in semen, chlamydia-
free ejaculates were chosen from 2 boars: one 
with azoospermia and another one with normal 
sperm count, The sensitivity of PCR and 
inhibitory effects of the semen were assessed 
by spiking these two selected semen samples 
with C. abortus DNA in 10-fold dilutions 
(10,000 to 1 templates). The spiked semen 
samples were extracted directly using the 
QIAamp DNA kit (Qiagen) by the body fluid 
protocol. 
Histopathologically, sperm granulomas 
in epididymis and testicular degeneration were 
detected in 4 out of 13 boars. Examination of 3 
bulls revealed testicular degeneration (2/3), 
severe testicular hypoplasia (1/3) and severe 
chronic orchitis with calcification (1/3). 
Immunohistochemistry for chlamydial antigen 
as well as routine bacteriology were negative 
in all animals (13 boars and 3 bulls). In DNA-
spiked semen, PCR assay was able to detect as 
few as approximately 10 templates per 
microliter. Both types of semen (azoospermic 
and normal sperm-count semen) gave the same 
results in the 16S rRNA PCR. 
Various pathological lesions were 
found to be causes of infertility in boars and 
bulls. Testicular degeneration and spermatic 
granulomas were often observed in boars, but 
also congenital anomalies such as testicular 
hypoplasia have to be considered as possible 
causes of infertility in male animals. No 
specific etiologic agent could be elucidated by 
routine bacteriology. Immunohistochemistry 
for chlamydial antigen was also negative. The 
16S rRNA PCR on the formalin-fixed and 
paraffin-embedded male genital tract samples 
as well as the investigation of an adequate 
number of animals is in progress. PCR for C. 
abortus in azoospermic semen and normal 
semen gave the same results of sensitivity. 
This finding indicates that spermatozoa have 
no strong effect on our PCR assay. The same 
validation procedure for the PCR assay on 
semen samples of bulls, rams, and bucks is 
currently in progress. 
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SEROLOGICAL DETECTION OF CHLAMYDOPHILA ABORTUS INFECTION 
IN SHEEP 
M. Livingstone*, G. Entrican, S. Wattegedera, D. Buxton and D. Longbottom 
Moredun Research Institute, International Research Centre, Pentlands Science Park, Penicuik, UK 
Chlamydophila abortus is the causative 
agent of enzootic abortion of ewes (EAE) in 
many sheep-rearing countries throughout the 
world. Goats also suffer significant losses due 
to C. abortus infection, and to a lesser degree, 
cattle, swine and deer may also be affected. 
The organism also has zoonotic potential by 
presenting a serious health risk to pregnant 
women thus highlighting the importance of 
detection, control, and prevention of 
transmission of disease. 
Diagnosis and screening of sheep for C. 
abortus infection relies heavily on antibody 
detection in serum samples. The most 
commonly applied serological assay is the 
complement fixation test (CFT), which is 
based on chlamydial lipopolysaccharide. 
However, there are inherent difficulties 
associated with such genus-specific antigens 
resulting in lack of specificity and sensitivity. 
A recently developed test, shown to be more 
specific and sensitive them the CFT, based on a 
recombinant fragment of the polymorphic 
outer membrane protein POMP90 (romp90-4 
iELISA) (1), and another based on the VS2 
region of the major outer membrane protein 
MOMP (MOMP VS2 iELISA) (2) were used 
to examine the humoral responses of C. 
abortus-infected ewes throughout the course of 
pregnancy (3). This study compared antibody 
responses to both MOMP and POMP antigens 
and established their potential as diagnostic 
antigens for EAE. 
Serological analysis showed that the POMP 
iELISA was able to detect antibody as early as 
one week post infection, this being in contrast 
to the MOMP iELISA, and indeed the CFT, 
where antibodies could only be detected 
around the time of lambing or abortion. The 
MOMP iELISA failed to detect an antibody 
response in three of seven experimentally 
infected animals, a result, which was 
corroborated by Western Blotting against 
whole C. abortus EBs, and therefore shows 
that not all animals seroconvert to native 
MOMP. The sensitivity of the POMP iELISA 
is further highlighted by its ability to detect 
antibodies in an animal, which seroconverted 
during the course of the experiment, again, no 
such response was detected by the MOMP 
iELISA. 
The study showed that inconsistent 
MOMP antibody responses observed in 
individual animals could indicate that POMP 
antigens may be more appropriate than MOMP 
antigens for the detection of EAE. The 
POMP90-4 iELISA is significantly more 
sensitive than the MOMP VS2 iELISA for 
detecting C. abortus-infected sheep. Early 
identification of infected sheep is hugely 
beneficial in the control of a disease such as 
EAE, and so allows appropriate measures to be 
put in place in order to prevent environmental 
contamination and the spread of infection to 
other susceptible animals and humans. 
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DIAGNOSIS OF OVINE CHLAMYDOPHILOSIS ABORTIONS BY PCR-RFLP 
PERFORMED ON VAGINAL SWABS 
Marsilio F.*, Di Martino B., Di Francesco C., Meridiani I. 
Department of Comparative Biomedical Sciences, University of Teramo, Teramo, Italy 
Chlamydophila abortus is the causative agent 
of the Ovine Enzootic Abortion in sheep and goats. It is 
considered one of the most common pathogen of small 
ruminants with significant economic implications. The 
diagnosis of C. abortus infections is usually performed 
by several antigen detection techniques such as ELISA 
test or by immunological and histochemical stainings of 
chlamydial inclusions following isolation in cell 
cultures®. In human medicine, polymerase chain 
reaction (PCR) assay from tissue submitted from 
abortions or from vaginal swabs is considered the most 
sensitive method available for diagnosis of chlamydial 
infections. Several genomic regions have been used for 
identification of chlamydial species. The omp2 gene of 
the Chlamydiaceae has two conserved regions at the 5' 
end bordering a variable segment, and primers designed 
to be complementary to these conserved regions have 
been used to amplify the omp2 gene from many 
Chlamydiaceae. The sequence variations have been used 
to perform species identification tests as heminested 
PCR or PCR-restriction fragment length polymorphism 
(PCR-RFLP) analysis®. In the present note we report 
the development and use of PCR-RFLP specific for 
identification of omp2 gene of C. abortus on vaginal 
swab samples from sheep flocks suffering from 
abortions. 
C. abortus (strain 1188/22 - H574) egg yolk 
sac preparations were kindly provided by Prof. E. 
Andreani (Faculty of Veterinary Medicine, University of 
Pisa, Italy). DNA was extracted by using DNeasy tissue 
kit (Qiagen). A total of 117 vaginal swabs were obtained 
from 14 herds. The swabs were placed into D-MEM, 
kept at 4°C during the transport to the laboratory and 
then stored at -80°C until use. DNA extractions were 
carried out using the QIAamp Ultrasense Virus kit 
(Qiagen), which is specific for nucleic acid extraction 
from liquids containing few cells. The target sequence 
for molecular identification of Chlamydiaceae is a 587-
bp fragment of the omp2 gene. The PCR was performed 
in a total reaction volume of 50 pi containing 5 pi of 
template, buffer 10 X, 200 pM of each dNTPs, 1,25 U 
of HotMaster Taq DNA Polymerase (Eppendorf), 10 
pmol of each primers Chla AF 5'-atg tcc aaa ctc ate aga 
cga g-3' (522-541 nucleotides) and Chla AR 5'-cct tct 
tta aga ggt ttt acc ca-3'. Amplifications were carried out 
under the following PCR conditions: 40 cycles of 
denaturing at 94°C for 1 min, annealing at 56°C for 1 
min and extension at 72°C for 1 min. The species 
identification of C. abortus was performed by RFLP 
analysis using the Alul enzyme. Restriction with Alul 
(motif AjGCT) were predicted to give species-specific 
bands lengths of 352 bp and 235 bp, discriminating C. 
abortus from other species. Digestions were performed 
in 20 pi reaction volume by incubating 2000 ng of PCR 
product with 1 U of Alu I (Biolabs, New England) and 2 
pi of 1 OX buffer for 2 h at 37°C. The products were 
analysed by electrophoresis on a 3% agarose gel stained 
with ethidium bromide. To evaluate the amplification 
sensitivity, ten-fold dilutions of C. abortus DNA (stock 
concentration 48 ng/pl) were quantified by 
Biophotometer 6131 (Eppendorf). The limit of detection 
was determined by the final dilution at which PCR 
products were still visible. The method was applied on 
117 vaginal swabs. In each test positive and negative 
controls were used; positive controls were retrived from 
C. ahortni-infected McCoy cells and negative controls 
were retrieved from mock infected McCoy cells. The 
negative samples obtained from positive herds were then 
subjected to a further PCR assay by using universal 
primers (Pomod 5'-aga gtt tga tcm tgg-3' and PC3mod 
5'-gga eta hag ggt ate taa t-3')(3) directed against 
bacterial 16S ribosomal DNA useful to demonstrate the 
presence of aspecific bacterial DNAs after the extraction 
procedures. 
Chlamydophila spp. DNAs were detected in n° 
6 vaginal swabs from five (5/13) herds. The additional 
RFLP analysis performed using Alul enzyme 
demonstrated that all PCR products belong to C. 
abortus. Bacterial 16S ribosomal DNAs were detected 
in all vaginal swabs examined. The serial dilution 
experiments showed that RFLP-PCR method can detect 
> 69 copies of bacterial genome. 
The assay performed at our laboratory has the 
potential to provide a simple method for the detection 
and identification of C. abortus from vaginal swabs 
using a rapid DNA extraction procedure combined with 
a PCR-RFLP analysis and it is useful to perform the 
diagnosis of chlamydial infections and to start up 
researches on pathogenesis. 
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CHLAMYDIAL CONJUNCTIVITIS IN DOMESTICATED ANIMALS: 
PRELIMINARY RESULTS IN GUINEA PIGS, PIGS AND SHEEP 
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Ocular surface diseases such as 
conjunctivitis and keratitis make up the majority of 
clinical cases admitted to the ophthalmology unit 
of the Vetsuisse Faculty University of Zurich. 
Since Chlamydia and Chlamydia-like organisms 
have been associated with ocular surface infections 
in cats, the aim of the present study was to 
investigate the potential importance of Chlamydia 
in other species such as guinea pigs, pigs and 
sheep. A particular aim was to determine the 
pathogenecity of all Chlamydiaceae including 
recently discovered Chlamydia-like organisms in 
these species. Additionally, we wanted to 
determine whether co-infections exist in pigs from 
intensively kept populations in the EU that may 
also be infected with PRRSV (Porcine Respiratory 
and Reproductive Syndrome Vims) and compare 
them to PRRSV-free populations in Switzerland. 
Clinical information with special emphasis 
of ocular manifestations was recorded in 95 guinea 
pigs, 147 pigs and 136 sheep. All animals of the 
diseased groups showed clinical symptoms of 
ocular surface disease or lived in close contact 
with such animals. Results were compared with 
healthy animals which were asymptomatic and had 
no contact with affected groups. Conjunctival 
smears were Romanowsky-type stained. The 
smears were grouped according to the 
inflammatory pattern and screened for chlamydial 
inclusion bodies. Four adult guinea pigs with 
ocular manifestations were examined 
macroscopically and by histopathology of the eye, 
heart, liver, spleen and kidneys. The organs were 
stained immunohistochemically and with HE. 
Immunohistochemical staining used a specific 
monoclonal antibody directed against chlamydial 
LPS of the Chlamydiaceae family. A 16S rRNA 
gene PCR specific for the Chlamydiales order was 
performed and a new IGS rRNA gene PCR 
specific for Chlamydiaceae was established in 
order to differentiate between different 
Chlamydiaceae strains. Positive 16S rRNA gene 
PCR results were sequenced while positive IGS 
rRNA gene PCR were sequenced or digested with 
various restriction endonucleases to give 
Chlamydiaceae strain-specific patterns. 
Guinea pigs: 21 of 40 diseased animals tested 
positive with IGS PCR for C. caviae GPIC while 
only 3 of 20 healthy animals showed a positive 
reaction. With the 16S PCR Chlamydia-like 
organisms were found more often in the diseased 
group (14/40) than in the healthy group (3/20). 
Histopathologically, a moderate-severe, subacute 
conjunctivitis was found in the sacrificed animals. 
Diagnoses of cytology (diseased group) with the 
Romanowsky-type staining were neutrophilic 
(14/27), chronic-active (6/27) and chronic (7/27) 
conjunctivitis. 22 of 27 showed basophilic 
inclusion bodies. The healthy group instead 
showed a neutrophilic (3/32), chronic-active (1/32) 
and chronic (2/32) conjunctivitis. 
Pigs: Using IGS PCR, intensively kept pigs in the 
EU tested positive for C. suis (61/72) more often 
than Swiss PRRSV-free pigs (7/34). On the other 
hand, Chlamydia-like organisms were only 
detected in Swiss pigs (13/34) using 16S PCR. 
Sheep: C. abortus (3/31), C. pecorum (2/31) and 
C. suis (4/31) were found with IGS PCR in two 
different flocks in which chlamydial abortions 
occurred. Chlamydia-like organisms were also 
detected with the 16S PCR (12/31) in the eye. 
Our preliminary results show that 
Chlamydia and Chlamydia-like organisms can be 
found in patients with ocular surface 
manifestations as well as in clinically healthy 
animals. Investigations will be completed e.g. with 
immunohistochemical staining of conjunctival 
smears. Up to now Chlamydophila abortus has not 
been detected in conjunctival smears of sheep. Our 
results open the possibility of Chlamydia being 
transmitted via ocular discharge between species. 
The pathological relevance of the Chlamydia-like 
organisms in different domesticated animals will 
be investigated further. 
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ROLE IN ABORTION OF CHLAMYDOPHILA ABORTUS IN SHEEP AND 
GOATS IN SARDINIA, ITALY 
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In this work, we have estimated the 
seroprevalence of Chlamydophila abortus in 
naturally exposed sheep and goats, and 
detected the bacterial DNA directly from 
foetal-derived placental tissue and tissues from 
aborted lambs. The aim of work was to 
establish the occurrence, distribution and role 
in abortion of C. abortus in sheep and goats. 
During the period 1999-2002, we have 
analysed 9349 serum samples and 517 aborted 
samples (422 foetuses and 95 placenta) from 
675 sheep and 82 goats farms distributed over 
all the island of Sardinia. After abortion 
notification, about 10% of animals from each 
farm was randomly selected. For every farm a 
schedule was compiled providing information 
regarding number of animals, abortion/flock, 
and breeding conditions (wild, semi-wild, 
intensive state). 
Sera collected from adult animals were 
examined to detect antibodies specific to C. 
abortus by a commercial ELISA ( "screen" and 
"controlled" plates, PanClabort, Yaba). 
Of a total of 7194 sheep serum samples, 440 
(6%) were positive in the ELISA test, with the 
following distribution: 186/1972 (9%) during 
the two lambing seasons of 1999, 90/1437 
(6%) during 2000, 48/1689 (3%) in 2001, and 
116/2096 (5%) in 2002. The arithmetic mean 
of the percentage of doubtful ovine sera during 
the 1999-2002 was 2%. 
Regarding the caprine serum samples, 
of a total of 2155 goats, 299 (14%) were found 
positive, with the following distribution in 
1999, 2000, 2001 and 2002, respectively 
being: 44/463 (9%), 62/554 (11%), 24/365 
(6%) and 169/773 (21%). The arithmetic mean 
of the percentage of doubtful caprine sera 
during the 1999-2002 was 2%. 
The second aim was to detect C. 
abortus in abortion products and to compare 
the presence of C. abortus in different ovine 
and caprine foetal tissues. 
DNA was extracted from the digested-
tissue samples of brain, skeletal muscle, 
spleen, abomasums and placenta using the 
High Pure Template Kit (Roche). Detection of 
the presence of Chlamydophila abortus DNA 
was carried out using a PCR assay targeting 
the pmp genes (Laroucau K et al., 2001 Vet 
Microbiol 82:155-164). The expected size of 
the amplified DNA fragment was 300 bp. 
From a total of 1076 ovine and 108 
caprine fetal samples including muscle, liver, 
abomasum, spleen, brain and placenta, 25 (2 
%) ovine and 1 (0.9%) caprine sample was C. 
abortus PCR-positive. Among the ovine 
samples, the placenta was the tissue with the 
highest frequency of positive results: 5/62 
corresponding to 8%. 
Seroprevalence analysis and PCR 
results indicate that, in Sardinia, C. abortus 
has a relatively low role in ovine and caprine 
abortion. 
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Chamydophila abortus, an intracellular 
bacterium, is the aethiological agent of enzootic 
abortion in small ruminants, infecting the placenta 
and causing abortion during the last trimester of 
gestation. A Thl immune response involving IFN-
y production and CD8+ T cells response has been 
reported as necessary to resolve the infection in a 
mouse model. Several reports in these models have 
demonstrated that the induction of a Th2 response 
elicited by helminth parasites infections influence 
the course of the infection by other intracellular 
microorganisms. The authors demonstrated 
(Buendia et al., 2002) that the previous infection 
with Nippostrongylus brasiliensis, a rodent 
gastrointestinal nematode extensively used in 
experimental models of parasite induced Th2 
responses, alters the immune specific response 
against C. abortus infection showing that mice co-
infected with N. brasiliensis and C. abortus 
increased bacterial multiplication in spleen and 
liver and also reduced IFN-y production. With 
these previous findings, the objective in this study 
is to determine if different vaccines against C. 
abortus are capable to induce the stablishement of 
an immune response (experience 1) and to effect a 
good protection (experience 2) avoiding the 
possible deleterious effects of a co-infection stage. 
In the two experiences performed, two 
inactivated experimental vaccines, one adjuvated 
with aluminium hydroxide (A10H3), another with 
QS21, a semi purified saponin, and the live 
attenuated vaccine (strain IB) were employed for 
vaccination as described by Caro et al. (2003). 
C57BL/6J mice were used to establish the 
folio wings groups: N. brasiliensis- infected-
vaccinated mice with their N. brasiliensis non-
infected counterparts, and non-vaccinated mice as 
infection controls. All groups (5 mice per group) 
were infected with C abortus. The course of 
parasite infection and the Th2 immune response 
produced was determined as described by Buendia 
et al. (2002). The mice were inoculated 
subcutaneously with 1000 viable third stage N. 
brasiliensis larvae and intraperitoneally with 106 
inclusion-forming units (IFUs) of C. abortus strain 
AB7. In the experience 1 was determined the 
influence of the parasite on the inductory immune 
response stablished by vaccination. Mice were 
inoculated with N. brasiliensis 7 days before 
vaccination. In the experience 2 was determined 
the influence of the parasite on the effectiveness of 
the immune response produced by vaccination. 
Mice were inoculated with N. brasiliensis 20 days 
after vaccination and 7 days before C. abortus 
infection. All mice were infected with C. abortus 
four weeks after vaccination. At day 4 post-
infection mice were killed and samples were 
collected to carry out bacteriological analysis. 
With the stablishment of a Th2 immune 
response induced by the parasite demonstrated, in 
the experience 1 no significant differences were 
found between mice inoculated with N. 
brasiliensis-v accinated and their counterparts. 
However, in the experience 2 significant 
differences were found between mice vaccinated 
with A10H3 inoculated with N. brasiliensis and 
their counterparts, not inoculated with the parasite, 
showing major presence of C. abortus in the first 
one. 
The Th2 immune response established by 
N. brasiliensis before vaccination had not 
influence on the induced protection. However, if 
the Th2 immune response is established after 
vaccination and just before infection, the 
effectiveness of the vaccines could be altered. Our 
results indicated that the experimental inactivated 
QS21 and the attenuated IB vaccines produced a 
degree of protection that avoids the deleterious 
consequences of co-infection stages. 
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COMPARISON OF CELL CULTURE METHODOLOGIES FOR THE 
DEVELOPMENT OF CHLAMYDOPHILA ABORTUS AND CHLAMYDOPHILA 
PECORUM 
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Objective: To determine the best cell 
culture methodology for the isolation and 
development of Chlamydophila abortus and 
Chlamydophila pecorum between chicken 
fibroblast primary cultures and mouse 
fibroblast cell line L929, while using three 
different cell culture media. 
C. abortus strain A22 (1.6 x 107 
IFU/ml), and C. pecorum strain T23 (0.8 x 107 
IFU/ml), were used to infect cell monolayers 
of chicken (primary culture) and mouse (cell 
line L929) fibroblasts. Every cell monolayer 
type was grown using three different cell 
culture media, Dulbecco Iscove's modification 
(Iscove's), Ham Nutrient Mixture F12 
Kaighn's modification (F12K), and Nutrient 
Mixture F12 Coon's modification (F12). 
Chlamydophila development was evaluated by 
determining the number of intracellular 
inclusions by indirect immunofluorescence test 
at 48, 72 and 96 h p.i. for C. abortus, and at 
24, 48 and 72 hs for C. pecorum. Five 
replicates per antigen-cell culture combination 
were used, and 300 cells per replicate were 
analysed by immunofluorescence. Uninfected 
monolayers treated on the same way were used 
as negative controls. The data obtained were 
analysed using the fixed effect model by the 
minimal square method of Steel and Torrie 
under the Statystical Analysis System for PC 
modality PROC GLM. Afterwards, the Turkey 
test was used to determine any significative 
result 
F12K medium was the cell culture 
medium that faster growth of both eukaryotic 
cell types, infected and uninfected, induced. 
Iscove's medium promoted a moderate growth 
of the host cells allowing an easy detection of 
Chlamydophila inclusions. F12, in 
comparison, led to the slowest multiplication 
rate of the eukaryotic cells making the 
identification of the prokaryotic inclusions 
even easier. 
The best cell culture medium for the 
development of C. abortus in both host cell 
types, and of C. pecorum in chicken fibroblasts 
was found to be the F12, whereas the 
development of C. pecorum in L929 cells was 
most favoured by the F12K medium. 
There was no significant difference in the 
growth rate of C. abortus A22 within the L929 
cells and the chicken fibroblasts primary cell 
culture. C. pecorum T23, however, showed a 
significant better growth in the mice 
fibroblasts than in the chicken fibroblasts cells. 
The incubation time at which the highest 
number of Chlamydophila inclusions was 
found was 72 h for the C. abortus strain and 24 
h for the C. pecorum strain used. 
F12K cell culture medium might be of 
great utility to start up a cell culture from 
frozen cells. Iscove's cell culture medium 
seems to be a good election to start up primary 
cell cultures, recovery of frozen cells, cell 
culture propagation, and for the isolation of 
Chlamydophila spp when using cell cultures. 
Finally, F12 represents a good alternative for 
the preparation of cell monolayers used for the 
isolation of Chlamydophila spp from clinical 
samples as well as for the bacteria propagation 
in the laboratory. 
The mouse fibroblasts represent a better 
option than the chicken fibroblasts for the 
growth and development of C. abortus and C. 
pecorum 
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This study compared foetal and 
maternal immunopathological responses in 
placentae of Chlamydophila abortus-
challenged sheep. 
Forty one pregnant ewes were intra-
venously challenged with Cp. abortus. 
Twenty-one ewes aborted. The remaining 20 
challenged ewes and nine control ewes were 
sequentially killed at either 14, 21, or 28 days 
post infection (p.i.). Morphological changes at 
the placental interface were correlated with the 
distribution pattern of chlamydial antigen and 
the different numbers of lymphocyte subsets 
(CD4+, CD8+, CD45R+, WC1+) present in 
foetal and maternal components of the 
placenta. 
14 Days Post Challenge 
Small foci of contiguous trophoblasts in the 
hilar zone contained chlamydial LPS-positive 
inclusion bodies. An increased number of 
chorioallantoic macrophages was apparent 
beneath these inclusion-bearing trophoblasts. 
Chlamydial inclusions were infrequent in 
syncytia lining caruncular septae. Occasional 
small foci of coagulative necrosis in septae 
were infiltrated by neutrophils. 
21 Days Post Challenge 
Inclusion bodies were common and widely 
distributed in trophoblasts. In addition, focal 
areas where the trophoblast layer was lost were 
heavily infiltrated by neutrophils and the 
underlying stroma was infiltrated by 
macrophages and very occasional 
lymphocytes. 
Very occasional chlamydial LPS-positive 
inclusion bodies were present in the 
endometrial epithelium at the placentomal 
limbus. Associated changes included focal 
ulceration of the endometrium and sparse 
infiltration of the subendothelial stroma with 
neutrophils, macrophages and lymphocytes. 
Occasional foci of septal necrosis were 
infiltrated by neutrophils and small numbers of 
macrophages and lymphocytes. 
28 Days Post Challenge 
Immunolabelled chlamydial LPS was widely 
distributed at the chorionic surface and the 
trophoblast layer was replaced over large areas 
by fragmenting neutrophils. Oedema and 
necrosis of the chorioallantois was particularly 
severe surrounding placentomes, a notable 
feature of which was arteritis and thrombosis. 
Perivascular aggregates of macrophages and 
lymphocytes were apparent but lymphocytes 
constituted only a small proportion of the 
cellular infiltrate in the chorioallantois. 
Immunolabelled chlamydial antigen was 
occasionally evident in the endometrial 
epithelium. Focal endometritis was evident at 
the placentomal limbus whilst occasional 
placentomal infarcts involved septae (and 
adjoining villi). Intralesional lymphocytes were 
numerous and consistently featured more 
CD8+ than CD4+ cells. 
The foetal response to chlamydia-
induced loss of the trophoblast layer was 
innate in nature. In contrast, the numerous T-
lymphocytes within focal inflammatory 
infiltrates on the maternal side of the placenta, 
suggested an acquired, chlamydia-specific, 
local immune response. This study emphasised 
the significance of chorioallantoic pathology in 
the pathogenesis of enzootic abortion of ewes, 
in particular the extensive loss of the 
trophoblast layer and involvement of 
chorioallantoic arteries in the inflammatory 
process. 
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Role of specific cellular immune 
response has been well stablished in the 
infections induced by the family 
Chlamydiaceae members. However, the 
importance of each T cell subset seems to 
depend on species, since CD4+ cells are the 
main subset involved in the response to 
Chlamydia trachomatis (Morrison and 
Caldwell, 2002), while CD8+ cells have a 
crucial role in the resolution of Chlamydophila 
pneumoniae infection (Penttila et al., 1999). 
The aim of this study is to clarify the role of T 
cell subsets in the response to Chlamydophila 
abortus primary infection. 
Female C57BL/6 mice were depleted of 
CD4+ or CD8+ cells by monoclonal antibody 
inoculation and infected with the AB7 strain of 
C. abortus. At different post-infection days, 
mice were killed and samples were collected to 
carry out bacteriological, and histopathological 
analysis. In addition, spleen cell culture and 
IFN-y quantification, immunohistochemical C. 
abortus antigen location and a TUNEL assay 
for apoptosis detection were performed. 
T cell subset depletion displayed very 
different results: CD8-depleted mice showed a 
very high mortality after C. abortus infection 
(90% at day 8 post-infection) while CD4-
depleted mice showed a decreased morbidity, 
expressed as weight loss. In relation with the 
chlamydial burden, CD8-depleted mice 
showed a significant increase compared with 
CD4-depleted and non-depleted mice. 
Additional analysis showed that CD8-depIeted 
mice had a higher number of apoptotic cells in 
the inflammatory foci of the liver, an increase 
in the dissemination of the C. abortus infection 
in the lung and an exacerbated IFN-y 
production by spleen cells after specific 
stimulation. 
All these data lead to the conclusion 
that CD8 T cells have a very important role in 
the control of primary C. abortus infection. 
This role could involve both a regulatory 
control of the CD4 T cell response and a direct 
cytotoxic or IFN-y-mediated action on infected 
cells. 
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Infection with Chlamydophila abortus 
in sheep affects pregnancy outcome with late 
abortion or birth of weak lambs. After 
abortion, sheep mount protective but not 
necessarily sterile immunity. The aim of this 
work was to identify differences in the cellular 
population(s) responsible for recall responses 
in animals that aborted after experimental 
infection. We also investigated cytokine 
production in the same cellular population(s), 
with specific reference to IFN-y and IL-4. 
PBMCs from 2 naive and 4 post 
abortion animals (1 year post-abortion) were 
stimulated in vitro in a lymphocyte 
proliferation assay with elementary bodies 
(either heat killed [HK] or triton-X treated 
LPS-depleted). Proliferating cells were 
identified by flow cytometry after CFSE 
(carboxyfluorescein diacetate succinimidyl 
ester) staining combined with surface staining. 
Cells were phenotyped using markers that 
identified the following subpopulations: 
CD4+, CD8+, y/5 TCR+, B cells and 
monocytes. Cytokine flow cytometry (CFC) 
for IFN-y and IL-4 producing cells was 
performed on mitogen-stimulated PBMCs 
from control animals. Surface phenotyping in 
association with intracellular cytokine 
detection allowed the identification of the cell 
type producing each specific cytokine. 
There were no qualitative or 
quantitative differences in the response to HK 
EBs between the two groups. Proliferative 
responses to Triton X-treated EBs were 
consistently higher in the post-abortion group 
compared to the naive sheep (average SI of > 
20 and < 2 respectively). CFSE analysis 
revealed a limited proliferation of CD4+ve and 
CD8+ve cells, with no noticeable difference 
between groups. However, we observed 
differences in the proportion of proliferating 
y/5 T cells and B cells between then two 
groups, with both cell types responding 
vigorously in the post-abortion animals 
compared to the control sheep. CFC analysis 
of normal PBMCs demonstrated that a small 
proportion of y/5 T cells were capable of 
producing IFN-y or IL-4 after mitogenic 
stimulation (between 2 to 5% and 0.4-0.8% 
respectively). 
y/5 T cells are important components of 
the mucosal immune system. In ruminants they 
can account for up to 30% of the circulating 
lymphocytes and are also found in normal 
pregnant uterine epithelium. Little is currently 
known on role of y/6 T cells during chlamydial 
infections. We hypothesize the development of 
a higher precursor frequency of y/5 ?T cells 
specific for chlamydial antigens (because of 
the limited TCR variability characteristic of 
this population) as consequence of infection 
and abortion. Otherwise, y/5 T cells 
proliferation could be due to a bystander effect 
in response to IL-2 production by other cells, 
since ruminant y/5 T cells constitutively 
express CD25. 
Based on cytokine profiles it is also possible to 
hypothesize a modulatory role for these cells. 
A rapid localized production of IFN-y in the 
uterine microenvironment could control C. 
abortus growth in immune animals, whereas 
secretion of IL-4 could diminish cell mediated 
responses. The balance between these two 
responses could contribute to dictating the 
outcome of C. abortus infection in sheep. 
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Chlamydophila abortus is a 
Gramnegative bacteria, which causes Ovine 
Enzootic Abortion (OEA) in small ruminants. 
It has important implications in veterinary 
medicine and Public Health, it causes serious 
economic loss in countries where it has been 
reported, in addition, infection with strains of 
this microorganism has also been associated 
with abortion and other clinical symptoms in 
humans. The studies related to the OEA in 
Mexico are few, reason why a real dimension 
of the problem does not exist. 
The objective of the present study was 
to describe the prevalence in high ovine 
production farms from the Highlands in the 
State of Mexico. 
Highlands with high ovine production in the 
State of Mexico and to reduce the risk factors 
against human population. 
Acknowledgements 
This work was partially supported by 
CONACYT, Mexico, grant 136109-B and 
40504-Z, UAEM grant 1540/2001 and 
1671/2003 and ICAMEX. 
386 sera were taken from ewes in 
between 1 and 4 years age during the lambing 
season in 30 different farms. An rELISA test 
was used, in which the a recombinant antigen 
(fraction rOMP91B), has a high sensitivity and 
specificity, avoiding cross reactions with other 
Chlamydophilas and other gramnegative 
bacteria. 
Our results are: 11.82% sera were 
positive for prevalence, and a prevalence of 
25% for farms. 
The presence of ewes that have titles of 
antibodies against C. abortus in Mexico 
demonstrates that OEA is not an exotic 
disease, as has been considered by the Mexican 
sanitary authorities. These results will allow 
the establishment of zoo-sanitary measures, 
that will help diminish and control the 
presence of OEA in ovine flocks of the 
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Since 1999, all abortion cases at Paris 
Zoo are routinely screened for abortive 
diseases such as Brucellosis or Chlamydiosis. 
Then, from 1999 to 2003, several abortions 
related to Chlamydiosis were reported among 
hoofstock, including Springbok, Beisa Oryx 
and Sable Antelopes. They were diagnosed 
using both serology and immunofluorescence 
detection tests. In February 2003, an abortion 
case was reported within a springbok 
(Antidorcas marsupialis) herd. PCR assay 
using primers targeting the pmp gene family 
was performed on both vaginal swab and 
placenta samples revealing the presence of 
Chlamydophila. 
The inoculation into chicken embryos 
of infected placenta extract led to successful 
isolation of C. abortus strain. The ompl gene 
coding the major outer membrane protein 
(momp) and the 16S-23S rRNA spacer region 
of the springbok isolate were compared to 
those of various strains by restriction fragment 
length polymorphism (RFLP). The RFLP 
analysis showed that this isolate belonged to 
Chlamydophila abortus species and was highly 
related to known ruminant's abortion strains. 
In an outbreak of C. abortus abortion, 
the first goal is to limit spread of infection as 
much as possible. In sheep and goats, 
treatment of clinically affected and pregnant 
animals with a long-acting oxytetracycline is 
the most commonly used method to decrease 
the abortions but the bacterial shedding was 
not suppressed. Vaccination with inactivated 
bacteria emulsified in adjuvant is often 
disappointing because, even if the incidence of 
abortion can be reduced, the infection persists 
as well as the bacterial shedding. In contrast, 
the temperature-sensitive live C. abortus 
vaccine IB gives strong, long-lasting 
protection, significantly reduces shedding and 
it is commercially available. As the chlamydial 
strain of Paris Zoo was isolated, the efficacy of 
this live vaccine against this strain was tested 
using a mouse model, and then a vaccination 
program set up for some Zoo animals. 
But beyond prophylactic topics, the 
occurrence of this disease in Paris Zoo raises 
two different questions: first, considering 
epidemiology of chlamydiosis and the wild 
hoofstock swapping within Europe, the zoo of 
Paris is probably not the only institution facing 
C. abortus infection. Then, what about the 
opportunity of vaccination of all animals as it 
is not possible to predict the risk of chlamydial 
shedding of seropositive animals? 
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Ovine enzootic abortion, which is 
caused by C. abortus, is an important disease 
in many countries. It is known that in a 
primary infection, the establishment of a 
specific cellular immune response is necessary 
for the clearance of the bacteria. The CD8 T 
cells are crucial to resolve the infection at 
difference other infections produced by others 
members of the family Chlamydaceae in 
which CD4 are the main subset involved in the 
response. The commercially available 
inactivated vaccines used for prevention have 
shown an inadequate degree of protection. An 
alternative approach has been the development 
of a live temperature-sensitive attenuated 
vaccine offering good protection. However, the 
potential dangers of attenuated vaccines, and 
the identification of new strains of C. abortus 
may influence on the use of this vaccine. The 
authors have designed new inactivated 
vaccines, using several adjuvants, which 
conferred a good protection, avoiding abortion 
and the persistence of C. abortus in uterus. 
Thus, the aim of this study is to know, in a 
mouse model, the role of the different 
lymphocyte subsets on the conferred protection 
induced by our experimental inactivated 
vaccines and the live attenuated vaccine. 
To determine the role of CD4 and CD8 
T cells, female C57BL/6 mice were used and 
depletion was developed using GK1.5 and 
GK2.43 monoclonal antibodies respectively. 
For the study of B cells, knockout pMT mice 
were used. Two inactivated experimental 
vaccines-one adjuvated with QS21 (purified 
saponin) and another with aluminium 
hydroxide-, and the live attenuated vaccine 
(strain IB) were employed for vaccination of 
mice. 
Four weeks after vaccination, CD4-
depleted, CD8-depleted and KO B mice were 
infected with a sublethal dose of AB7 strain of 
C. abortus. Wild type vaccinated mice were 
used as control groups. Additional groups of 
non-vaccinated wild type mice served as 
control of the vaccine effect on the C. abortus 
infection. The morbidity caused by infection 
was measured as weigh loss in each one of the 
groups. At day 4 post-infection, mice were 
killed and samples were collected to carry out 
bacteriological and histopathological analysis. 
In addition, spleen cell culture for cytokine 
production quantification was performed. 
The morbidity and isolation of the 
microorganism was significantly higher in 
depleted CD4 and CD8 vaccinated mice than 
in non-depleted counterparts, although always 
all groups displayed lower values than non-
vaccinated control groups. The IFN-y 
production was markedly reduced in the CD4 
depleted vaccinated mice in relation to non-
depleted control groups. In relation to the B 
cells, the morbidity and the isolation of C 
abortus was significantly higher in KOB 
vaccinated mice than in controls counterparts, 
excepting for the AIOH3 vaccinated mice. 
CD4 and CD8 T cells play a role, but 
not essential, for the conferred protection by 
both inactivated and attenuated vaccines. CD4 
T cells are associated with the main production 
of IFN-y in the secondary immune response. In 
contrast, the B cells showed to play a major 
role in the adequate establishment of a 
secondary immune response induced by the 
tested vaccines but the AIOH3 vaccine. 
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BACTERIOPHAGE INFECTING CHLAMYDOPHILA ABORTUS 
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To date, five bacteriophages have been 
described in association with the 
Chlamydiacaeae species, specifically members 
of the genus Chlamydophila. Recently, a novel 
antigen was observed in an outer membrane 
protein (OMP) preparation of C. abortus strain 
S26/3. MALDI-TOF mass spectroscopic 
analysis identified the protein as similar to the 
VP1 structural protein of chlamydiaphages 
Chp2 (associated with C. abortus) and 
CPAR39 (associated with C. pneumoniae). 
The aim of this study was to isolate the phage 
genomic DNA for sequencing and molecular 
characterization. 
Phage-infected C. abortus S26/3 was 
grown in McCoy cells. Insoluble OMPs were 
prepared by extraction of the cell pellet with 
sarkosyl, followed by sarkosyl/DTT. OMPs 
were analysed by SDS-PAGE and MALDI-
TOF analysis. Chlamydiaphage single stranded 
genomic DNA was isolated and purified from 
harvested tissue culture material at 72 hours 
post infection using a QIAprep Spin Miniprep 
Kit (Qiagen). Phage gDNA was initially 
amplified by PCR using primers based on 
conserved regions of the known 
chlamydiaphage genomes and using the proof-
reading enzyme Pfu DNA polymerase 
(Promega). PCR fragments were sequenced on 
a Megabace 500 Automated Capilliary 
Sequencer (Amersham Biosciences). Double 
stranded replicate form phage DNA was 
isolated from phage infected reticulate bodies 
at 50 hours post infection, as described above. 
Purified phage genomic DNA was digested 
with BamHl and cloned into pBluescript II SK. 
Plasmid DNA was purified and sequenced, as 
described above. Sequence contig assembly 
and analysis was performed using Lasergene 
sequence analysis software (DNASTAR). 
SDS-PAGE analysis of the insoluble 
sarkosy/DTT OMP preparation revealed the 
presence of a dominant protein band of 
approximately 60 kDa. MALDI-TOF analysis 
confirmed the identity of the protein as 
chlamydiaphage structural protein VP1. Phage 
DNA was successfully amplified by PCR and 
the complete genomic sequence determined. 
Following assembly, the genome was 
determined to be 4.5 kb in size, and organized 
into five major open reading frames (ORFs). 
These ORFs are positioned in the same relative 
genomic locations as occurs in the other 
chlamdiaphages. 
Sequencing of the phage DNA 
confirmed this to be a new chlamydiaphage, 
the second one to be associated with C. 
abortus. The discovery of another phage 
infecting the Chlamydiacaeae is indicative of 
the widespread nature of these bacteriophages. 
The fact that the phage co-purified with the 
OMP fraction could be indicative of the 
presence of the phage receptor in this fraction. 
Chlamydial molecular research has been 
hindered due to the intracellular nature of the 
chlamydiae and the lack of a functional system 
for the transfer of genetic material. These 
chlamydiaphages could provide a natural gene 
transfer system for the manipulation of the 
chlamydial genome. 
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THE TISSUE AND CELL CULTURE MICROARRAY: A DIAGNOSTIC TOOL FOR 
EVALUATION OF ANTI-CHLAMYDIAL-ANTIBODIES 
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A. Pospischil1 
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The tissue microarray (TMA) technology 
represents one of the most promising approaches 
in the fields of proteomics for analysis in situ. 
TMAs are constructed by obtaining cylindrical 
tissue specimens from regular paraffin blocks, 
assembling them into a single block, and preparing 
sections containing multiple tissue specimens. 
TMA sections can be analyzed using standard 
pathology methods, such as hematoxylin and eosin 
(HE) staining, immunhistochemistry (IHC) or in 
situ hybridization (ISH). The TMA system is 
already widely used in human cancer research on 
formalin-fixed and paraffin-embedded biopsy 
specimens. Our aim was to adapt the TMA 
technology for evaluation of commercially 
available and experimentally produced anti-
chlamydial-antibodies (Abs) tested on Chlamydia 
infected animal and human tissues as well as on 
cell pellets infected with different Chlamydia 
strains. 
The tissue array block was created with the 
Tissue Arrayer from Beecher Instruments. 
Different animal tissues with naturally acquired or 
experimentally induced chlamydial infections were 
included: placentas from sheep, goat and cattle 
(necropsy material, chlamydial abortion due to 
Chlamydophila (C.) abortus), human placenta 
(necropsy material, zoonotic infection due to C. 
abortus from goat abortion), liver from birds 
(necropsy material, chlamydial infection due to C. 
psittaci), kidney and pericardium from reptiles 
(necropsy material, granulomatous inflammations 
caused by C. pneumoniae) and intestine from 
gnotobiotic piglets (experimentally infected with 
Chlamydia suis and C. pecorum). Uninfected 
tissues served as negative controls (placentas from 
sheep, goat and cattle, human placenta, liver from 
birds, kidney and pericardium from reptiles and 
intestine from gnotobiotic piglets). 
The cell culture array block was created with the 
Tissue MicroArray Builder from Histopathology 
Ltd, Hungary (P.H. Stehelin & Cie AG). Vero, 
Caco-2 and Hep-2 cells were infected with 
different chlamydial strains: 1710S (C. pecorum), 
S26/3 (C. abortus), S45/6 (Chlamydia suis), 
T49/90 (C. psittaci) and Kajaani 6 (C. 
pneumoniae). After various stages of infection, 
cells were scraped from the cell culture flasks and 
the resulting cell pellets were embedded in 
paraffin. Uninfected cell cultures served as 
negative controls. 
The tissue and the cell culture array blocks 
were cut using a special adhesive-coated tape 
sectioning aid system. The sections were stained 
with HE and IHC was performed using a 
Chlamydiaceae family-specific mouse monoclonal 
antibody (Ab) directed against the chlamydial 
lipopolysaccharide (cLPS; Clone ACI-P, Progen, 
Heidelberg, Germany) or a monoclonal Ab 
directed against the chlamydial heat shock protein 
60. Detection was performed with the Detection 
Kit (Dako ChemMate™, Glostrup, Denmark). 
Additionally, 19 monoclonal antibodies 
derived from mice intravenously infected with C. 
pneumoniae strain AR-39 were tested on the tissue 
and cell culture array blocks. 
The tissue and cell culture array system is 
obviously not only a tool for high-throughput 
microscopic studies on tumor specimens but also a 
technology for testing commercially available or 
newly produced anti-chlamydial Abs on different 
animals tissues or cell cultures on a single 
microscope slide. The various animal tissues in our 
study needed different IHC protocols (i.g. 
microwave pretreatment for tissues of reptiles and 
birds) and therefore drawbacks can arise. The anti-
LPS-chlamydial Ab as well as to a lesser extent the 
chlamydial anti-hsp 60 Ab gave positive results in 
all naturally and experimentally infected animal 
tissues and cell pellets. From the 19 monoclonal 
antibodies, two showed crossreactivity to C. 
pecorum, C. abortus, Chlamydia suis and C. 
psittaci. 
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THE 40-KDA RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN 
(MOMP) OF VETERINARY SIGNIFICANT CHLAMYDIAE AS A TOOL TO 
IMPROVE SERODIAGNOSIS OF ANIMAL CHLAMYDIAL INFECTIONS 
Ludwig E. Hoelzle*, Katharina Hoelzle, Diana Sieber, Max M. Wittenbrink 
Institute of Veterinary Bacteriology, Vetsuisse Faculty University Zurich, Zurich, Switzerland 
OmpA genes encoding the 40-kDa 
MOMP of Chlamydophila (Ch.) abortus, Ch. 
pecorum, and Chlamydia (C.) suis were cloned 
into the arabinose-inducible plasmid vector 
pBADMycHis. Full-length recombinant 
MOMPs (rMOMP) were expressed in 
Escherichia (E.) coli and assessed for their 
sérodiagnostic potential to distinguish 
chlamydial species-specific antibodies in 
animal sera. 
Immune sera were raised in rabbits and 
pigs against native purified elementary bodies 
of the three chlamydial species. In addition, 
serum samples taken from 25 sows prior to and 
in the 7th week after vaccination with 
Ch. abortus as well as serum samples taken 
from four heifers prior to and after 
experimental intra-uterine infection with 
Ch. abortus were included in the study. 
Quantification of IgG serum antibodies against 
the chlamydial lipopolysaccharide (LPS) and 
against the three rMOMPs was performed for 
all sera by indirect enzyme-linked 
immunosorbent assay (ELISA). Pre-exposition 
sera served as a reference to establish cut-off 
levels. All post-exposition sera exhibited 
strong seroreactivities against the chlamydial 
LPS. For the rMOMP ELISA mean IgG 
antibody levels were at least 5.8-fold higher 
with the particular rMOMP homologous to the 
chlamydial species used for immunisation or 
infection than with heterologous rMOMPs 
(P<0.001). These preferential ELISA 
reactivities with the homologous rMOMP were 
also confirmed by Western blotting. 
The results suggest that the entire 
chlamydial rMOMP could provide a useful 
species-specific sérodiagnostic antigen. Our 
expression system also allowed the production 
of full-length rMOMP of other chlamydial 
species, such as C. trachomatis, Ch. 
pneumoniae, and Ch. psittaci. Currently, 
subfragments of the ompA gene of different 
chlamydial species are expressed in E. coli for 
detailed epitope mapping. 
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GROUP SIZE AND A N T I - C H L A M Y D O P H I L A IGM ANTIBODIES PREDICT 
THE RATE OF NATURAL CHLAMYDOPHILA SPP. INFECTION IN CALVES 
JunBae Jee, Fred J. DeGraves, TeaYoun Kim, and Bernhard Kaltenboeck* 
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Chlamydophila spp. infection of the 
vaginal mucosa is highly prevalent in heifers 
that had not had sexual intercourse. To 
analyze the rates and mechanisms of 
acquisition of such infections in cattle at an 
early age, we conducted a one-year 
prospective cohort study in a dairy farm. 
Specimens were collected in weekly 
intervals from birth to week 12 post-partum 
from 40 female Holstein calf-dam pairs in a 
dairy herd. Real-time PCR detected, 
quantified, and differentiated Chlamydophila 
23S rRNA gene DNA in nasal, vaginal, and 
rectal cytobrush and milk samples. 
Chemiluminescent ELISA with lysed 
Chlamydophila abortus or C. pecorum 
elementary body antigens quantified 
antibodies against Chlamydophila spp. in sera. 
Data were analyzed by polynomial and logistic 
regression, and by repeated measures analysis 
of variance. 
Chlamydophila spp. DNA was found 
in 61% of calves and 20% of dams in at least 
one positive qPCR. In calves, clinically 
inapparent C. pecorum infection with low 
organism loads was 5-fold more prevalent 
than C. abortus infection, and most frequently 
detected in the vagina compared to rectal or 
nasal swabs. In dams, C. abortus dominated in 
milk and C. pecorum in the vagina. 
The square of weekly group size of calves 
correlated positively with frequency and 
intensity of Chlamydophila infection (Figure 
1). Per one calf increase in group size, the 
odds ratio for infection (Wald 95% confidence 
interval) of individual calves is 1.18 (1.13-
1.24, p < 0.01). The group size with a 50% 
probability of infection of any given calf in 
this group is approximately 28. Per one calf 
increase in group size, the odds ratio for 
infection of the group (infection of a calf of 
the group) is 2.68 (1.95-3.69, p < 0.01). The 
group size with a 50% probability of group 
infection is approximately 14. 
Anti-Chlamydophila IgM antibodies in 
infected calves and dams were higher than in 
non-infected ones (p < 0.02). Logistic 
regression models predicted (p < 0.02) that at 
50% Chlamydophila herd prevalence an 
animal with half the population mean of anti-
Chlamydophila serum IgM has a 13-22% 
probability of PCR detectable Chlamydophila 
infection, and an animal with twice the IgM 
level has a 78-87% probability. 
Figure 1. Influence of group size on rate and 
level of weekly Chlamydophila infection in 
calves. Percentage infected calves (A) and the 
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amount of Chlamydophila genomes detected 
per qPCR of infected calves (B) plotted for 
each week and group size observed in the 
study. Melting curve analysis in the qPCR 
identified Chlamydophila spp.; (•), C. 
pecorum infected calves; (•), both C. pecorum 
and C. abortus infection detected in calves; 
and (o), qPCR negative calves in a study 
week. The Logio of the mean of 
Chlamydophila genomes (± 95% confidence 
interval) indicates genomes detected only per 
positive qPCR in each sampling week. Logio = 
0 indicates negative groups with zero 
Chlamydophila genomes detected by qPCR. 
Polynomial regression equations composed of 
intercept and the square of group size, but not 
group size, highly significantly (p < 0.01) 
describe (A) the relationship between group 
size and percentage infected calves; and (B) 
and group size and the level of Chlamydophila 
infection per infected calf. These results 
indicate that frequency and intensity of 
Chlamydophila infection in calves increases 
with the square of group size. Logistic 
regression analyses highly significantly (p < 
0.01) indicate that group size predicts 
infection of individual calves (C) and the 
group as whole (D). 
The results of this investigation 
confirm the high seroprevalence of 
Chlamydophila infection in cattle. 
Furthermore, they establish a pivotal 
importance of herd size and anti-
Chlamydophila immune status on prevalence 
of infection with Chlamydophila spp. in cattle. 
CHLAMYDOPHILA ABORTUS ANTIBODY PREVALENCE USING A 
RECOMBINANT ELISA (ELISAR) TEST IN SHEEP FARMS IN MEXICO 
Beltrán, L.T1*., Jiménez, E.J.M1., Escalante, O.C2. and Montes de Oca, J.R1. 
'Animal Health, Veterinary Faculty, UAEM, 2Departament of Microbiology and Immunology, 
Veterinay Facuty, UNAM, Mexico 
C. abortus is the ethiologic agent 
involved in the small ruminants enzootic 
abortion (OEA) which has a worldwide 
prevalence and distribution. The disease is 
important for the economic loss it represents 
in animal farms, because during the last third 
of estation it infects the placenta and causes 
abortion. It also represents a potential 
zoonosis risk especially for women. There are 
few research studies regarding OEA in 
Mexico. This research study was made to find 
out the C. abortus antibody prevalence in 
sheep farms in central Mexico. 
1873 sera were taken from sheep in 
reproductive age in 77 different farms. The 
antibody presence was made by using a 
recombinant ELISA kit (ELISAr), following 
the kit instructions. There was a 9.71% total 
prevalence. 49.4% of the sampled farms were 
positive. Regarding the sampled 
municipalities, there were statistical 
differences (p<0.05), with Jocotitlân 
municipality showing the highest percentage 
of positive samples (13%), followed by 
Acambay (6.5%) and Xalatlaco (5.2%). The 
highest percentage was found in native sheep 
(28.6%); in imported sheep a 3.9% prevalence 
was found. Nevertheless, there was no 
statistical difference (p>0.05). 
Our results show a lower prevalence 
than those reported in Mexico, because we 
used a more specific and sensitive diagnostic 
test to C. abortus, because the antigen has no 
cross reaction with other gramnegative 
bacteria or other Chlamydophila species such 
as C. pecorum which is frequently isolated 
from faeces in clinically healthy animals or 
from animals showing a non apparent 
infection. These results give us a more certain 
seroprevalence in Mexico, with which we can 
say that C. abortus is not an enzootic disease 
as it has acutally been considered in Mexico 
by the sanitary authorities. Taking into 
consideration these results, important 
prevention and control measures can be taken 
to diminish the OEA in high production sheep 
areas in Mexico. 
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MONITORING THE RESPONSE OF OCULAR CHLAMYDOPHILA FELIS 
INFECTION TO DOXYCYCLINE THERAPY USING QUANTITATIVE REAL-
TIME PCR 
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Chlamydophila felis (C. felis) is a 
common cause of ocular disease in the cat. 
Real-time PCR is a sensitive technique that 
can be used to quantify C. felis DNA from 
ocular swabs. The objective of this study was 
to assess if doxycycline therapy for 7 or 14 
days could eliminate C. felis and resolve 
clinical signs. Real time PCR was used to track 
infection and monitor the effect of treatment 
on C. felis bacterial load. 
Fifteen specific-pathogen-free derived 
cats were inoculated with 3x10 infectious 
units of a field isolate of C. felis onto the 
conjunctiva (day 0). The cats were assigned to 
3 groups (A-C). By day 7, signs of clinical 
disease were present in all cats and treatment 
was commenced. Group (4 cats) received no 
treatment. Groups B (6 cats), and C (5 cats) 
were given lOmg/kg doxycycline once daily 
for 7 days and 14 days respectively. Ocular 
swabs were taken from each cat at regular 
intervals for the identification of C. felis. A 
clinical scoring system was used to assess the 
severity of the disease. 
Following extraction of DNA from the swabs, 
a multiplex, quantitative real-time taqman 
PCR was performed to identify C. felis DNA 
and feline 28S ribosomal DNA (rDNA). C. 
felis DNA was quantified relative to 28 S 
rDNA, and each swab was assigned a C. felis 
relative copy number. 
All swabs were positive for 28S DNA. 
All swabs were negative for C. felis DNA on 
day - 7 and 0. Swabs from all cats were 
positive for C. felis DNA by day 4. 
Subsequently in group A (untreated group), C. 
felis DNA was recovered from all swabs 
throughout the trial. Relative copy numbers 
peaked at days 7 to l l and gradually 
diminished thereafter. The clinical scores 
peaked in severity between days 7 and 14, then 
diminished gradually to a plateau 1-2 weeks 
later. 
Treatment with doxycycline reduced the 
relative copy number of C. felis within 24hours 
in all cats. 
In group B, C. felis DNA was detected from all 
swabs except for on day 14 when swabs from 3 
cats were negative (1 day post cessation of 
treatment). However all swabs were positive 4 
days later. Clinical scores decreased markedly 
after day 11, however by day 21 (8 days post 
cessation of treatment) there was recurrence of 
clinical signs, similar to those seen during the 
initial acute phase of infection. 
All the cats in group C became negative for C. 
felis DNA between days 14 to 28. However all 
became positive again by day 32 - 46 of the 
trial (12-26 days post cessation of treatment). 
Clinical scores had markedly decreased by day 
14. By day 35 (15 days post cessation of 
treatment) the clinical signs returned and in 
some cats were as severe as those seen during 
the initial acute phase of infection. 
Seven and fourteen days of 10mg/kg 
doxycycline failed to eliminate C. felis 
infection. However both treatment protocols 
were effective in reducing clinical signs and 
relative copy numbers of C. felis. Quantitative 
real-time PCR is a useful technique for 
monitoring the effect of treatment on ocular C. 
felis bacterial load. 
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CHARACTERISATION OF CHLAMYDIAL ISOLATES FROM CONJUNCTIVAL 
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In Italy, the prevalence of feline 
chlamydiosis was evaluated through 
seroepidemiological surveys and PCR assays, but 
only recently has the isolation of Chlamydophila 
felis been reported (2). This study describes the 
characterisation of four feline chlamydial isolates 
and their comparison with known feline 
chlamydial strains. 
During the implementation of a 
surveillance programme of the health status of 
feline colonies in the Emilia-Romagna region 
(October 2002-December 2003), conjunctival 
swabs were taken from the eyes of four stray cats 
with signs of conjunctivitis. C. felis was isolated 
by LLC-MK2 cells (a continuous cell line derived 
from rhesus monkey kidney tissue) monolayers 
inoculation (3) and was identified by PCR. DNA 
was extracted from the cultures using a 
commercially available kit (Dneasy Tissue Kit, 
Qiagen) and amplified for ompA (6), omp2 (5) and 
graEL-homologue (4) genes. The ompA amplicons 
were digested with the restriction endonuclease 
Alu I. The ompA, omp2 and groEL PCR products 
were purified using a commercial kit (High Pure 
PCR Product Purification Kit, Roche) and 
sequenced. The sequences were compared with the 
same regions of known C. felis strains in GenBank 
database using ClustalW (9). The isolates were 
grown in LLC-MK2 cells seeded in plastic 
individual wells of a six-well plate. The infected 
cells were harvested 48 h after infection with 
sterile rubbers and sonically disrupted. The 
elementary bodies (EBs) were purified by 
continuous 30-60% sucrose-gradients density 
centrifugation and re-suspended in PBS (7). 
Polypeptide profiles of Ebs were analysed by 
sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) with the buffers of 
Laemmli, using 10.0% (w/v) pre-cast gel 
(Invitrogen). 
The DNA extracted from the cultures 
produced the expected PCR products. All the 
ompA amplicons showed the same Alu I restriction 
pattern, which was identical to that generated with 
other feline chlamydial strains isolated in various 
countries (8). In addition, the four isolates showed 
the same ompA, omp2 and groEL nucleotide 
sequences (GenBank accession numbers 
AY184290, AY 184289, AY184288), identical to 
those obtained previously from DNA extracted 
from conjunctival swabs of 30 cats in three 
catteries in Bologna (1). OmpA nucleotide and 
predicted amino acid sequence homologies 
between the four isolates and the known C. felis 
strains FEPN (accession number M73037), FP 
Cello (accession number AF269258) and FP Baker 
(accession number AF269257) were found to be 
100%. Comparison of the omp2 sequence of the 
four isolates with that of the FP strain (accession 
number AF367407) showed 99.8% similarity. The 
four isolates showed similar polypeptide profile. 
These results suggest the presence in the 
area surveyed of only one strain of C. felis 
showing a high degree of genomic similarity with 
other feline chlamydial strains isolated in other 
countries. In view of the limited geographical area 
surveyed so far, further investigations of C. felis 
isolates from other areas of Italy are necessary to 
confirm the strain homogeneity. 
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EVIDENCE OF INFECTION IN TORTOISES BY CHLAMYDIA-LIKE 
ORGANISMS DIFFERING FROM KNOWN SPECIES OF CHLAMYDIALES 
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The present work was undertaken to 
study the prevalence of chlamydia-like 
organisms in a tortoise population and partially 
characterise these agents. 
Nasal lavage samples from a group of 
155 tortoises belonging to at least 12 different 
species from private owners were examined. 
Lavage fluid was subjected to DNA extraction 
and amplification by diagnostic chlamydia-
specific ompA-PCR. All positive samples were 
further examined by PCR using primer pairs 
from the 16S rRNA, ompB and groESL genes. 
All specific PCR products were sequenced, 
and the sequences were compared to their 
homologs from the established chlamydial 
species. The Vector NTI Suite 8.0 software 
(Informax Inc., Oxford, UK) was used for 
sequence alignments, and phylogenetic 
analysis of the sequences was carried out using 
the PHYLIP software package, version 3.6 
(University of Washington, Seattle, WA). The 
tree was constructed according to the 
maximum likelihood method (without 
molecular clock) at standard settings. 
Chlamydial DNA was detected in 
lavage samples from 16 animals (10.3 %). The 
highest infection rates were found in the 
species Testudo marginata (5/34 = 14.7 % of 
the subgroup), Testudo horsfeldii (3/24 = 12.5 
%) and Testudo graeca (5/49 = 10.2 %). To 
identify the chlamydial species involved, the 
PCR products were sequenced. However, 
BLAST analysis revealed a lack of homology 
at the species level to the existing species of 
Chlamydiaceae. Likewise, phylogenetic trees 
constructed from partial sequences of the 
ompA, ompB, and 16S rRNA genes showed 
that the present samples clustered outside the 
nine species of Chlamydia and Chlamydophila. 
Sequences of the nearest relative, 
Chlamydophila pecorum, were still clearly 
distinct from those of the positive tortoise 
samples. All animals investigated suffered 
from nasal discharge. However, available 
pathological data are not sufficient to confirm 
any association of these symptoms with the 
presence of chlamydia-like organisms. 
The data indicate that the tortoises had 
been infected apparently by two different and 
so far unknown chlamydia-like agents. The 
taxonomic identity and the pathogenic 
importance of these agents has yet to be 
established. 
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PATHOGENICITY OF CHLAMYDIA TRACHOMATIS SEROVAR E GENITAL 
INFECTION IN SPECIFIC PATHOGEN FREE PIGLETS 
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Despite intensive research in chlamydial 
pathogenesis and host immune responses, vaccine 
development has been hampered by the incomplete 
understanding of the virulence factors and the 
critical factors governing protective immunity. It is 
still unknown why certain Chlamydia trachomatis 
serovars cause asymptomatic or symptomatic 
infection or ascend to the upper genital tract. 
Former studies have mainly used non-primate 
monkey, mice or guinea-pig models of infection. 
However pigs are genetically en physiologically 
more related to man than mice and guinea-pigs. 
Pigs are susceptible for Chlamydophila psittaci, C. 
abortus, C. pecorum and Chlamydia suis, the latter 
being phylogenetically related to human C. 
trachomatis strains. The main objective of the 
present study was the validation of the pig as an 
alternative animal model for C. trachomatis female 
genital tract infection. 
15 specific pathogen free gilts (Intervet 
Akzo Nobel, The Netherlands) were devided into 3 
groups (n=5), each reared in separate isolation 
units. Groups 1 and 2 were intra vaginally infected 
with the serovar E strains 468 and reference strain 
Bour (ATCC VR-348B), respectively. Bour has 
been isolated from a trachoma patient (Hanna, 
1959) while strain 468 was isolated from a female 
patient with complaints of abnormal vaginal 
discharge and lower abdominal pain (dysuria and 
discharge in the male partner) (Morre 2002, 
personal communication). Group 3 served as non-
infected control. Pigs were monitored every other 
day for clinical signs. Serum and genital tract 
secretions were collected immediately prior to the 
experimental infection and at days 7, 14 and 21 
PI. At the same time fever was measured. IgM, 
IgA and IgG antibody titres were determined by 
ELISA using BPL inactivated elementary bodies 
as antigen. Vaginal swabs for isolation (HeLa 
cells) were collected immediately prior to the 
experimental infection and at 4, 7, 10, 14, 18 and 
21 days PI. At euthanasia (21 days PI), pigs were 
examined for macroscopic lesions. Liver, spleen, 
ovaries, oviducts, longitudinal sections of uterine 
horns, uterine corpus, cervix, urethra and vagina 
were sampled for both immunofluorescence 
staining (IMAGEN™, Dako, Denmark) on cryostat 
tissue sections and histopathology on paraffin 
sections. 
Hyperaemia of the vulva and elevated 
body temperatures were observed in groups 1 and 
2 as well as congestion of the vagina and urethra, 
thickening of the cervix and uterus wall and 
congestion of the mesovarium. Clinical signs, 
macroscopic and histopathological lesions were 
more severe in the 468 infected group 1. Bacterial 
excretion and replication was most prominent in 
group 1. Bour and 468 could replicate in the lower 
and upper genital tract. However, Bour did not 
replicate in the urethra and upper genital tract 
replication was only observed in 1 on 5 pigs, while 
all 468 infected pigs showed bacterial replication 
in the upper genital tract. Serum (7 days PI) and 
mucosal (14 days PI) antibody titres were observed 
in all infected groups. 
Above described variables show that this 
new pig model, which demonstrated differences in 
tissue tropism and pathology observed for the two 
strains studied, is at the moment potentially the 
best model to extrapolate results obtained to the 
human situation since it mimics genetically and 
physiologically humans better than current animal 
models. 
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Immune reactivity for Chlamydophila 
psittaci in Slovenia was monitored in parrots, 
canaries, finches and nine species of recently 
captured free-living birds (house sparrows, 
Eurasian goldfinches, tree sparrows, 
chaffinches, Euopean greenfinches, European 
serines, Eurasian siskins, Eurasian linnets and 
Eurasian bullfinches) for the period 1991 to 
2001. 
In subsequent years, specific IgG 
antibodies were found using 
immunofluorescence in parrots (0.7 - 53.6%), 
canaries (0.0 - 3.5%), finches (0.0 - 5.7%) and 
in recently captured free-living birds (33.3% of 
Eurasian goldfinches in 1994). An 
experimental infection with Chlamydophila 
psittaci was performed in order to study 
clinical signs and pathological changes of 
canaries and finches after infection. 
Chlamydophila psittaci strains used for 
experimental infection were isolated from 
cockatiel (Nymphicus hollandicus) and 
genotyped. 
Chlamydial DNA was extracted from original 
material followed by RFLP-PCR analysis. 
Infection of canaries and finches was 
confirmed by direct immunofluorescence and 
modified staining method of Gimenez using 
organ smears and imprints. In addition, 
serological methods as indirect 
immunofluorescence and complement fixation 
were applied. However, in spite of positive 
immunological reaction there were no clinical 
signs of chlamydial infection three weeks after 
infection. 
The present study includes also results 
of serological survey of persons belonging to 
the most important risk groups (breeders, pet's 
shopkeepers and veterinarians) exposed to 
infection with Chlamydophila psittaci. The 
results of microimmunofluorescence 
identifying the presence of specific antibodies 
and correlation between appearance of 
infection in birds and important risk groups are 
presented. 
Among the 143 persons belonging to 
the most important risk groups we found 10 
(7%) persons who were immunologically 
reactive. Testing of two successive samples 
was used to demonstrate an increase of IgG 
and IgA. However, IgM characteristic for the 
acute infection could not be detected. 
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DEVELOPMENT OF A HAMSTER MODEL OF CHLAMYDIA PNEUMONIAE 
INFECTION 
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Chlamydia pneumoniae is a common cause 
of respiratory infections in humans and is also 
associated with outcomes other than respiratory 
disease, including coronary heart disease and 
myocardial infection. So far, experimental models 
of C. pneumoniae infection included the use of 
mice or rabbits. Here we report of a new model of 
C. pneumoniae infection in the hamster, which 
appears to be particularly useful for assessing the 
protective activity of potential vaccine candidates 
or for the study of the response to antibiotic 
treatment with new drugs. 
C. pneumoniae. C. pneumoniae FB/96 
strain, a clinical isolate from an Italian patient with 
pneumonia, was used in this study. It was grown in 
LLC-MK2 cells and EBs were purified by sucrose 
gradients. 
Model of infection 
Animals used in this study were adult 
Syrian hamsters. They were inoculated with EB 
suspension (2 x 108 IFU of EBs) or SPG buffer by 
intraperitoneal or intranasal route. At 3, 5, 7, 10, 
14, 20 and 40 days after infection, animals were 
anaesthetized, bled by cardiac puncture and 
sacrificed. Many organs (lung, spleen, liver, 
thymus and mediastinal lymph nodes) were 
removed, homogenated, inoculated in LLC-MK2 
cells and cultures were incubated for up to three 
days. Chlamydial inclusions were evidenced by 
immunofluorescence microscopy. 
Immunofluorescence 
Intracellular chlamydial inclusions were 
visualized with a UV fluorescence microscopy 
after staining the infected cells using monoclonal 
FITC-conjugated antibodies. 
Analysis of peritoneal macrophages 
Two days after intraperitoneal infection 
animals were intraperitoneally injected with 8 ml 
of thioglycollate broth. After 2 more days, 
peritoneal macrophages were collected; the 
presence of chlamydiae were detected by 
immunofluorescence both directly inside the 
collected macrophages and in LLC-MK2 cells 
infected by disrupted macrophages supernatants 
and incubated for 96 hours. 
Serology 
Specific serum IgG and IgM 
immunoglobulins were detected by both micro-
immunofluorescence test and by WB. 
The cultures of the spleens from all 
peritoneally infected hamsters were positive up to 
7 days after chlamydial injection, thereafter the 
infectivity decreased, being all the animals 
negative by 20 days after infection. C. pneumoniae 
isolation from thymus and mediastinal lymph 
nodes was positive in 70-80% of the hamsters up 
to 10 days of infection, afterwards the isolation 
rate decreased, being all the animals negative by 
20 days after infection. C. pneumoniae was 
isolated less frequently from the liver. The lungs 
were always negative. On the contrary, the cultures 
of the organs from the intranasally infected 
hamsters were less frequently positive: in 
particular spleens, thymus and mediastinal lymph 
nodes were found positive in about 20-30% of the 
animals up to 7 days of infection, thereafter 
turning negative. One lung homogenate was found 
positive at day 3 after chlamydial injection. All 
inoculated animals developed serum IgM and IgG 
antibody response against C. pneumoniae, with no 
significant differences between the intraperitoneal 
and intranasal infected group. We were able to 
detect the presence of chlamydial inclusions in 
peritoneal macrophages in animals infected by 
inoculation of EBs in the peritoneal cavity. It is, 
therefore, likely that the systemic spread of 
chlamydiae to various selected organs occurs by 
macrophage carriage. 
Since C. pneumoniae was isolated from 
the spleen of all the intraperitoneally injected 
animal, monitoring spleen infection after 
peritoneal injection of C. pneumoniae in the 
hamster is a useful model for in vivo screening of 
potential vaccine candidates, or for the study of the 
response to antibiotic treatment of C. pneumoniae 
infection. Furthermore, the availability of an 
infection model in a new animal species may also 
provide a source of useful information for the 
study of C. pneumoniae pathogenicity and in 
particular the still elusive mechanisms which link 
C. pneumoniae infection to vascular degenerative 
disease. 
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Cathelicidin-derived peptides, a family 
of antimicrobial peptides identified in 
mammalian species, exert a potent and broad 
spectrum in vitro activity against bacteria, 
fungi and protozoan parasites and they have a 
protective effect in animal models of infection. 
In addition, some of these peptides bind to LPS 
and neutralize its effects in in vivo models of 
endotoxemia. 
These features brought considerable interest to 
these peptides as lead compounds for the 
development of novel anti-infective agents. 
Although their bactericidal activity has been 
extensively tested on representative Gram-
positive and Gram-negative bacteria, 
spirochetes and fungi, Chlamydia have not 
been systematically tested. Therefore, in this 
study the in vitro activity of six synthetic 
cathelicidin-derived peptides, was investigated 
against Chlamydia strains isolated from 
animals. 
A total number of 11 chlamydial strains 
were tested. These strains included 4 C. 
psittaci isolates, 2 C. abortus strains, 1 C. 
pecorum isolate and 4 C. felis isolates. The 
strains were grown in LLC-MK2 cells. 
Six synthetic cathelicidin-derived peptides 
from diverse mammalian species were used: 
SMAP-29 from sheep, LL-37 from humans, 
Bac7, BMAP-28 and BMAP-27 from cattle, 
and PG-1 from pigs. Each peptide was 
synthesized by solid phase Fmoc chemistry. 
The peptides were purified by reversed-phase 
high pressure liquid chromatography on a 
preparative Cig Delta-Pak column with 
appropriate water-acetonitrile gradients, in the 
presence of 0.1% trifluoroacetic acid. 
The lowest concentration of peptide required 
to achieve >50% reduction of chlamydial 
inclusions compared with drug-free controls, 
was assessed in vitro: a total volume of 150 pi 
of purified chlamydial EBs suspension in SPG 
medium containing 4xl04/inclusion-forming 
units (IFU) per ml, were then added to the 
tubes containing 150 pi of the appropriate 
dilution of cathelicidin peptide. The 
suspensions were then incubated at room 
temperature (23°C) for 2 hours, unless 
otherwise indicated. Following incubation, 100 
pi of EB suspension treated with the antibiotic 
peptide or with PBS alone, were inoculated in 
triplicate onto LLC-MK2 and chlamydial 
inclusions were detected by 
immunofluorescence. 
The results reported are the mean of 
three different experiments. Chlamydial strains 
were partially sensitive only to SMAP-29 that 
reduced by >50% the inclusion count of 4 out 
of 11 strains tested, at a concentration of 100 
pg/ml. The chlamydiae sensitive to SMAP-29 
were the four isolates from cats. In particular, 
the reduction of the inclusion count was of 
85%, 76%, 72%, and 62% for the 4 C. felis 
isolates, respectively. 
On the contrary, the remaining 7 chlamydial 
strains were susceptible neither to SMAP-29 
nor to the other 5 cathelicidin peptides tested at 
a concentration of 100 pg/ml. 
Among the various cathelicidin 
peptides tested, only SMAP-29 was able to 
inhibit, to some extent, the replication of the 
chlamydial strains studied. However, the 
inhibitory activity was observed at high 
peptide concentration and was limited to C. 
felis isolates. 
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Widespread Subclincal Bovine Chlamydial 
Genital Infection 
Over several decades, evidence has 
accumulated to suggest the ubiquitous 
presence of infections with intracellular 
bacteria of the genus Chlamydophila in cattle 
and other livestock species. In a herd of 51 
virgin heifers with 100% seroprevalence of 
exposure to chlamydial agents, we analyzed 
vaginal cytobrush specimens collected for 4 
weeks in weekly intervals for the presence of 
Chlamydiaceae bacteria by a high-sensitivity, 
high-specificity quantitative PCR. A 53% 
prevalence of low-level C. abortus and 
C. pecorum genital infection was detected. 
This indicates predominantely extragenital 
transmission of Chlamydophila spp. in cattle 
and conforms to the high seroprevalence of 
anti-Chlamydia antibodies. 
Reduction of Bovine Lertility by Subclinical 
C. abortus Infection 
Since virtually all cattle are naturally 
pre-exposed to Chlamydophila abortus, we 
analyzed the effects of controlled re-infection 
on fertility of cattle. Twenty virgin heifers 
were estrus-synchronized, inseminated one 
time, and challenged immediately by intra-
uterine administration of C. abortus. Two 
weeks later, 10 additional heifers were estrus-
synchronized, inseminated, and uterine-
challenged. This second group of animals was 
also indirectly exposed to 
C. abortus infection (cohort challenged) by 
contact with the previously challenged cohorts. 
Pregnancy was determined by rectal palpation 
42 days after insemination. One hundred 
percent, 83%, 50%, 66%, and 0% of heifers 
were pregnant after uterine challenge with 0, 
104, 105, 106, or 108 IFU of C. abortus, 
respectively, without signs of clinical disease. 
Sixty five percent and 50% of heifers were 
pregnant without or with cohort challenge, 
respectively. Eighty seven percent and 33% of 
heifers were pregnant with above or below 
median anti-C. abortus IgM, respectively (p = 
0.004). Logistic regression models predicted 
that the uterine C. abortus inoculum causing 
infertility is 8.5-fold higher for heifers without 
cohort exposure and 17-fold higher for heifers 
with high IgM than for heifers with cohort 
exposure or with low IgM. Thus, uterine as 
well as indirect cohort infection with 
C. abortus significantly reduces bovine 
fertility, and high anti-C. abortus IgM 
antibodies correlate with protection from 
suppression of fertility. 
Identification of Protective C. abortus 
Antigens 
In a BALB/c mouse model of C. 
abortus-induced pneumonia, we screened for 
protective antigens of C. abortus by random 
expression library immunization, an unbiased 
functional genomics approach in which the 
entire genome of a pathogen is screened for the 
best vaccine candidates. After immunization 
with pools of genetic immunization plasmids 
with random inserts of C. abortus DNA, mice 
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were intranasally challenged with C. abortus 
and sacrificed after 12 days. Lung weight 
increase, reflecting the degree of cellular 
infiltration and chlamydial load, was measured 
to indicate disease or protection from it. 
Protective pools of plasmids were further split 
in 2 more rounds of vaccination of mice. All 
candidate plasmids of protective groups in the 
3rd round were sequenced and those encoding 
peptides longer than 50 amino acids were 
screened in a final round. Four of 5 protective 
fragments (dnaX2, gatA, gatC, pbp3) encoded 
peptides of cytosolic proteins; only one (pmp5) 
encoded a peptide of an outer membrane 
protein, traditionally considered the best 
vaccine candidates. The dnaX2 fragment, 
encoding a portion of the C. abortus DNA 
polymerase, completely protected mice from 
chlamydial disease, better than the best 
protection achieved with live vaccination by 
low-level intranasal chlamydial inoculation. 
Enhanced Fertility of Vaccinated Cattle after 
Challenge with C. abortus 
The pool of the five most protective 
C. abortus genes were evaluated as genetic and 
Alum-Quil A-based recombinant protein 
vaccines for protection against C. abortus-
induced infertility in pre-exposed cattle. A 
natural Holstein heifer infection model was 
used in which 27 
C. abortus challenged cohort animals 
transmitted C. abortus to, and induced 
infertility in, 11 vaccinated and 12 mock-
vaccinated herd mates that were indirectly 
challenged by environmental exposure to C. 
abortus during insemination and early 
pregnancy. Four of 5 heifers (80%) that 
received genetic vaccine and 5 of 6 heifers 
(83%) that received protein vaccine were 
pregnant, as opposed to 6 of 12 heifers (50%) 
that received control vaccine. The odds ratio 
for improvement of fertility with vaccination 
against C. abortus was 4.5. 
ONLY THE LIVE VACCINE IB AGAINST CHLAMYDIAL ABORTION OF EWES 
INDUCES A LOWER LEVEL OF IFN-y IN BLOOD OF PREGNANT MICE THAN IN 
NON PREGNANT MICE 
Amel Bouakane, Annie Rodolakis* 
INRA Pathologie Infectieuse et Immunologie Centre de Tours Nouzilly, Nouzilly, France 
In ruminants Chlamydophila abortus 
which can colonize different types of placenta 
causes enzootic abortions during the last third of 
gestation of ewes and goats. The abortion is due to 
multiple factors, one of them could be the capacity 
of the bacteria to infect and damage the placenta. 
However in a previous study on the virulence of 
several C. abortus strains we have demonstrated 
that there was no relationship between the number 
of bacteria in the placenta and abortion. The same 
study revealed significant differences in level of 
interferon y (IFN-y) in the blood of mice 
inoculated with these different strains (Bouakane 
et al 2003). Cytokines may play an important role 
in the mechanism of abortion, notably the IFN-y. 
Indeed inflammatory cytokines such as TNF-a and 
IFN-y can exert detrimental effects in the placenta 
and have to be present at low concentrations, 
whereas the regulatory cytokines IL-10 and TGF-(3 
are beneficial and have to be preponderate 
(Entrican 2002). This means that infections 
eliciting inflammatory responses and high levels of 
TNF-a or IFN-y in the placenta or in blood may 
cause abortion. 
It has long been known that IFN-y play a key role 
in host defense against chlamydial infections: IFN-
y alters the growth of Chlamydiaceae in cell 
culture inducing in some conditions persistent 
infections that are characterized by aberrant forms 
which are viable but non-cultivable. More in vivo 
studies in murine models have demonstrated that 
IFN-y is critical in early infection since treatment 
of nude and immunocompetent mice with 
monoclonal antibodies against IFN-y made worse 
the lesions in the lung, liver and the spleen. In 
addition other studies confirmed the role of IFN-y 
for the prevention of disseminated diseases 
following genital tract infection and it has been 
speculate that the difference in sensitivity among 
the Chlamydia trachomatis serovars to IFN-y could 
explain the tropism of ocular and genital strains 
(Morrison 2003). 
In order to explore the relationship 
between the virulence of strains and the level of 
IFN-y elicited by different Chlamydophila strains 
and its role on the outcome of pregnancy, about 
105 plaque forming units (PFU) of 2 
Chlamydophila pecorum strains AB10 and M14 
isolated from an aborted ewe and goat respectively 
and of 8 C. abortus strains, 5 of which were 
isolated from ovine abortion (AB7, AB13, AB16, 
AB17 and POS), 1 from a caprine abortion (LLG), 
I from the feces of an healthy ewe (Mo907), and 
the attenuated vaccinal IB strain which is a 
thermosensitive mutant of AB7, were 
intraperitoneally inoculated in 5 non pregnant and 
5 pregnant mice. Pregnant mice were inoculated at 
II days of pregnancy. All the mice were killed 5 
days after challenge. Their blood was collected 
and the uterine horn of pregnant mice removed in 
order to determine the levels of infection of pooled 
placentas and foetuses 
The level of IFN-y induced in blood by C. 
pecorum strains did not differ from those of 
control mice and in non pregnant mice the higher 
level of IFN-y was induced by the vaccinal IB 
strain and the parental strain AB17 which 
provoked the same level of IFN-y, according to the 
results of Buendia et al (1999). The C. abortus 
strain AB17 which caused many abortions in 
pregnant mice induced significantly higher level of 
IFN-y than for controls but lower than AB7 and IB 
strains. In pregnant mice inoculated with AB7, 
AB16 and AB17, the serums level of IFN-y was 
significantly higher in pregnant mice, than in non 
pregnant, but in contrast for the vaccinal strain IB, 
the virulence of which was attenuated, the level of 
IFN-y in blood of pregnant mice was significantly 
lower than in pregnant mice. 
This result shows that in addition to 
difference of sensitivity to IFN-y, chlamydial 
strains exhibit difference in the ability to elicit the 
release of IFN-y in blood that depends of the 
physiological condition of the mice and which 
could be related to virulence of strains. 
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ABORTION 
Rodolakis A1*, Bouakane A1, Rekiki A1'2 
'Unité de Pathologie Infectieuse et Immunologie, INRA-Centre de Tours, Nouzilly, France, 
Institut de la Recherche Vétérinaire de Tunisie, Tunis, Tunisie 
The live vaccine IB has been shown to 
offer a good protection in ewes and goats against 
all Chlamydophila abortus strains tested up to 
date.. However none of these strains presented 
antigenic polymorphism with monoclonal 
antibodies or were isolated from vaccinated flock. 
More, the efficacy of the vaccine against 
Chlamydophila pecorum is still unknown while 
some isolations of C. pecorum strains from 
abortions in sheep and goats have been reported in 
France, Tunisia, and Morocco. 
The aim of this study was to evaluate by 
using a mouse model, the efficacy of IB vaccine 
against two-C. pecorum strains isolated from a 
case of abortion in a goat (Ml4) in Morocco and a 
sheep (AB10) in France and three-C abortus 
strains, presenting antigenic variations on Pmp, 
AB16 isolated from a vaccinated ovine flock in 
France and POS and LLG isolated in Greece from 
an aborted ewe and goat, respectively. Moreover 
LLG and POS presented antigenic variations on 
MOMP. These 3 C abortus presented also 
differences in virulence for mice. 
The effectiveness of the vaccine has 
traditionally been assessed in pregnant mice by 
comparing the average number of live mouse pups 
at birth in unchallenged mice and in vaccinated 
and unvaccinated challenged mice and their 
survival during their first week of life. However, 
C. pecorum strains as AB16 and LLG were less 
abortifacient than classical C. abortus strains and 
induced too few abortions to reveal vaccine 
activity, except when using large number of mice. 
So the efficacy of the live vaccine strain IB was 
investigated by the clearance of bacteria in 
placentas of vaccinated mice challenged 
intraperitoneally at 11 days of pregnancy, a more 
accurate model which was consistent with the 
prevention of chlamydial shedding at parturition. 
For AB16, LLG and POS individual placentas and 
foetuses were taken and their infection was 
determinated by plaque assay, while for M14 and 
AB10 all the placentas of the same uterine hom 
were pooled to increase the number of bacteria to 
be counted. Although the number of PFU in 
pooled placentas was lower for C. pecorum strains 
than for C. abortus it was sufficient to evaluate the 
efficacy of the vaccine. 
Live IB vaccine provide effective protection 
against the three C abortus strains tested and 
against the field strains of C. pecorum, since it 
significantly reduced the placental Chlamydophila 
colonisation, but it more effectively reduced 
infection after inoculation of strain AB16 than 
POS or LLG strains. 
These results demonstrated that the 
antigenic variations on Pmp and MOMP of AB16, 
LLG and POS do not affect the protection confers 
by the live vaccine despite AB16 being isolated 
from a vaccinated flock. Furthermore, strain AB16 
was not inevitably isolated from a failure of 
vaccination but from an ewe latently infected at 
the time of vaccination. 
More the efficiency of the live C abortus 
vaccine was not restricted to the C abortus specie. 
However, the epidemiology and persistence of 
C. pecorum infection in sheep and goats in 
Maghreb have to be studied in order to understand 
if in these countries some factors enhance the 
ability of C pecorum to cause abortion. 
Nevertheless, until the mechanisms that control 
variations in virulence of different C pecorum 
strains are unknown it would be necessary to check 
the efficacy of the IB vaccine under local field 
conditions and in local ovine breeds such as 
Barbarine. As C pecorum is also associated with a 
severe reproductive tract disease in the koala 
population, it would be interesting to test the 
efficacy of the IB vaccine against C pecorum 
strains isolated from such disease in these 
Australian animals. 
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The areas in the trachoma field that is 
generating the greatest amount of attention is 
the implementation of programs aimed at the 
elimination of blinding trachoma as a major 
public health problem. Important operational 
research is under way to make these programs 
more efficient. 
There have been some exciting results 
in basic research on the causative agent, 
Chlamydia trachomatis, in the past several 
years. Most interesting results have come from 
mining the genome. Access to the organism's 
complete genome has allowed researchers to 
identify some properties of those organisms 
that have been typically associated with 
endemic ocular trachoma that differ from those 
chlamydiae that have been associated with 
genital tract or more invasive diseases. For 
example, the specific epidemiological 
association of serovars A, B, Ba, and C with 
ocular trachoma and serovars D-K with 
infections of the genital tract has confirmed in 
multiple studies. The LGV serovars (LI 
through L3) are sexually transmitted organisms 
that are capable of infectng and causing 
disease in a wide variety of systemic sites. The 
LGV serovars are easily differentiated from the 
A-K serovars, which have been termed the 
"trachoma biovar" to contrast with the more 
invasive LGV biovar. Previously we have been 
unable to identify biologic properties that 
differentiate the serovars associated with 
blinding trachoma from those of the trachoma 
biovar associated with genital tract disease. 
Recently, however, two sets of genes 
have been identified that do suggest such a 
differentiation. The polymorphic membrane 
protein gene designated pmpH has been shown 
to differ in ways that are consistent with each 
of these three disease-causing groups of 
Chlamydia trachomatis (1). This suggests 
distinct evolutionary divergent patterns for this 
gene. 
More exciting, because of the 
functional implication, have been the findings 
relevant to the presence of a tryptophan 
synthase (2). This enzyme converts indole into 
tryptophan. The isolates from trachoma do not 
have the enzyme, whereas isolates of genital 
tract origin do (whether they are in LGV or 
trachoma biovars). Gamma-interferon is an 
important host response to chlamydial 
infection, and is known to interfere with the 
completion of the chlamydial developmental 
cycle. Its action is thought to be due to 
tryptophan depletion. In vitro, the interferon's 
inhibitory effect in cell culture can be reversed 
by adding indole, if the chlamydiae possess a 
functional tryptophan synthase. This "indole 
rescue" was only observed with isolates of 
genital tract origin. This likely represents 
selection for a survival characteristic for the 
organism. The authors posit that presence of 
the enzyme will allow for productive infection 
in the genital tract where normal flora may 
produce indole, thus allowing the chlamydiae 
to escape the interferon effect. 
Control Efforts 
There has been a major international 
effort where WHO, governmental agencies and 
non-governmental organizations together with 
the pharmaceutical industry (specifically 
Pfizer, Inc.) formed an alliance for the control 
of blinding trachoma. The strategy being 
implemented here is the use of an integrated 
approach for trachoma control largely known 
as the SAFE strategy. This was largely due to 
the efforts of Dr. Joseph Cook, who provided 
the impetus for putting those components that 
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had been associated with preventing trachoma, 
and trachomatous blindness into a single 
integrated approach. This SAFE strategy has 
four basic components: Surgery for the re-
direction of inturned eyelashes (entropion) and 
correction of trichiasis (where the eyelashes 
actually abrade the cornea); Antibiotic 
treatment or using azithromycin for 
antichlamydial therapy; Facial cleanliness; and 
Environmental improvement (3). 
Ultimately these approaches have 
several long-term goals. The use of surgery is 
to prevent the development of blindness in 
those who already have lid damage from 
earlier chlamydial infection. Conjunctival 
scarring is clearly associated with severe 
disease and high infectious loads over a period 
of time (4). Some studies have suggested that 
the earlier surgery is done the better the likely 
outcome (5). Surgery is associated with high 
recurrence-rates of lid distortion and it is 
uncertain whether over-correction of the lids is 
a more reasonable early approach but it is clear 
that the use of surgery cannot be considered a 
single-time event and that long-term follow-up 
after surgery is required (6). 
Treatment of active disease is done 
with oral azithromycin, which has an 
extraordinary advantage for the treatment of C. 
trachomatis infections. Its single-dose therapy 
is highly effective, with cure rates in excess of 
95% for both ocular and genital tract C. 
trachomatis infections. Azithromycin is highly 
effective in treating active trachoma. Control 
programs are based on community-wide 
treatment where trachoma is highly endemic. 
In such communities many individuals have 
active infection in the absence of clinically 
active disease. 
The use of topical tetracycline can also 
be beneficial, but it is extraordinarily 
burdensome as effective treatment can require 
30 daily applications. Applying drug to the 
conjunctiva cannot be expected to have an 
effect on extra-ocular sites of infection. The 
organism can be readily recovered from the 
upper respiratory tract of individuals in 
trachoma endemic areas. 
The F and E components of the SAFE strategy 
are then aimed at creating a milieu in which 
the spread of C. trachomatis is not going to be 
efficient. It has long been clear that trachoma 
is a disease associated with poverty, 
inadequate sanitation, poor water supplies, etc. 
The disease was endemic in much of the 
industrialized world, and disappeared with 
general environmental improvement. The key 
factor in the disappearance of trachoma is not 
known. Improving personal hygiene (as in 
facial cleanliness) and environmental 
improvement (which in this context means the 
provision of adequate water supplies and 
latrines to reduce fly populations) are laudable 
goals under any circumstances. Flies have long 
been considered a likely mechanical vector for 
the spread of C. trachomatis in a many 
trachoma endemic areas. Musca sorbens is the 
fly species that has been typically associated 
with eye contact. It has been difficult to get 
objective evidence of the impact of facial 
cleanliness and environmental improvement in 
the control programs. For example, efforts at 
demonstrating chlamydia on trapped flies from 
trachoma endemic areas have met with rates of 
success that are too low to provide compelling 
evidence for their role in transmission. 
However, recently studies on spraying with 
insecticides to reduce fly populations and 
evaluation of latrines have shown that both fly 
populations and clinically active trachoma can 
be reduced by spraying with insecticides (7). 
Less compelling results (but still successful 
outcomes) were seen with the use of latrines. 
Spraying cannot be considered a long-term 
measure as it would be predicted that flies 
would develop insecticide resistance, but as 
evaluation of a potential strategy this was a 
successful experiment. 
Thus, it seems that many of the 
components are in place for the potential 
elimination of trachoma. Pfizer has continued 
with a generous program of donating drug and 
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together with other donors has supplied 
financial support to trachoma elimination 
programs. To date, well over 40,000 trichiasis 
surgeries have been performed, over 7 million 
people have been treated for trachoma and 
trachoma control programs are active in 13 
countries with sufficient azithromycin donated 
to treat approximately 20% of the worlds at-
risk population. There are still a number of 
questions and operational issues that are 
relevant to these trachoma control programs. It 
is unclear how often community-wide 
treatment should be performed and what kind 
of selective treatment might be used as a 
follow-up after the intial community-wide 
treatment in trachoma endemic areas. It has 
been clearly shown that the use of clinical 
diagnosis of trachoma is not going to be a 
useful approach to follow-up as trachoma rates 
fall in a community after mass treatment or in 
communities where initial endemicity is low 
(less than 5% or 10%)(8). What is clear is that 
there is slow resolution of disease in some 
individuals so that when the presence of 
follicular disease occurs at the roughly 5% to 
10% levels of the target populations, most of 
the individuals with the clinical signs of 
trachoma are not currently positive with C. 
trachomatis. Thus, it would seem logical to 
suggest that sensitive diagnostic tests such as 
nucleic acid amplification tests (NAAT) 
should be used on appropriate samples of the 
population to monitor the impact and long-
term effects of the treatment programs. 
This diagnostic problem was actually 
anticipated by results from initial community-
wide treatment trial of azithromycin, which 
was performed in three hyper-endemic areas in 
Africa (Egypt, Tanzania, and The Gambia)(9). 
In each of these communities the effect of 
community-wide azithromycin treatment was 
more impressive on positivity by NAATs than 
on clinical disease, which fell at a slower rate. 
That initial trial (Azithromyin in Control of 
Trachoma - or ACT) found that a large 
proportion of individuals without disease were 
NAAT positive for chlamydial genes. It was 
clear that the highest rate of positivity was 
associated with severe active trachoma and 
most of this disease was seen in young 
children. This was consistent with all of the 
earlier studies and the traditional view that the 
family unit (specifically children in the family) 
represented the major reservoir of trachoma 
infection within a community. However, the 
very high rate of infection in adults and 
individuals without clinical disease provided a 
mandate for treatment of the entire community 
in this hyper-endemic setting. While it is not 
clear how important any chlamydia-
positive/disease-negative specific individual 
(who is likely to carry a lower infectious load 
than a clinically active individual) might be in 
the overall spread of infection, the large 
number of such individuals provided a 
compelling argument to include them in the 
treatment programs. More recently, 
quantitative PCR has shown that much of the 
predicted distribution of chlamydial infection 
can be confirmed on a quantitative basis (10-
11). The highest rates of infection and 
infectious loads are found in those with the 
most active disease; and many individuals are 
NAAT-positive in the absence of clinical signs 
of active disease; and interestingly, that very 
young children (less than 1-year of age) who 
are often not included in control programs for 
practical reasons (it has long been known that 
the onset of infection is within the first couple 
of months of life) can be heavily infected. That 
suggests that every effort should be made to 
include treatment of infants in the control 
program. 
On balance, it would appear that the 
great successes of the initial efforts to 
eliminate blinding trachoma as a public health 
problem are very promising (3). Clearly there 
are logistic problems ahead. Maintaining the 
enthusiasm and recruiting the other areas 
where trachoma is a problem into the Global 
Alliance for the Elimination of Trachoma is 
still a challenge. However, the results to date 
do suggest that the elimination of blinding 
trachoma is an achievable. 
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OCULAR CHLAMYDIAL DISEASE AND INFECTION IN A COHORT OF 
GAMBIAN CHILDREN 
N. Faal1, M. Holland2,1. Sarr1, H. Joof1, M. Laye1, E. Cameron, F. Pemberton-Pigott, D 
Mabey2, R.Bailey1 
MRC Laboratories, Fajara, The Gambia and London School of Hygiene and Tropical Medicine, 
London, United Kingdom 
To describe the prevalence of trachoma 
and ocular chlamydial infection in a cohort of 
Gambian children and to investigate whether this 
is related to the number of subsequent disease and 
infection episodes. 
To investigate the relationship of infectious load, 
measured by quantitative PCR to disease duration 
and outcome. 
Three hundred and forty six children, aged 
4-15 years, from nine villages in The Gambia were 
recruited into a prospective cohort study. The 
children were sampled every two weeks over a 
period of 28 weeks. At each visit a clinical 
examination of the conjunctiva was made and a 
digital photograph of the everted eyelid was taken. 
Two swabs were used to collect cellular material 
from the conjunctiva of the right eye, a dry swab 
for DNA and a swab for RNA collected into an 
RNA preservative (RNAlater, Ambion Inc). 
The DNA was extracted from one of the swabs and 
the presence of chlamydial DNA in the 
conjunctiva was detected by Amplicor® and then 
by quantitative real-time PCR against the single 
copy gene, omp-1. RNA was extracted from the 
second swab, digested with DNAse I and the 
presence of chlamydial 16S ribosomal RNA 
(rRNA) detected using quantitative real-time RT-
PCR. Amplicor® and OMP-1 quantitation were 
done on the first sample collected from each 
individual and 16S rRNA quantitation was done on 
every RNA swab collected from each individual. 
There were 114 females (33%) and 232 
males (67%) in the cohort; the median age of 
study participants was 8 years (4-15 years). 
Seventy-four children (21%) had clinical signs of 
trachoma (TF and/or TI) at their first visit and 18 
children (5.2%) had evidence of trachomatous 
scarring (TS). 30% of children with normal 
conjunctivae at baseline (82/272) developed 
trachoma during follow-up. 
Chlamydial DNA was detected by Amplicor® in 
67/325 children (20%) and by omp-1 quantitation 
in 35/327 children (10%). The median omp-1 
copy-number was 4 (1-18218). Chlamydial RNA 
was detected in 72/331 children (22%) with a 
median copy-number of 2638 (2-2.96 xlO7). 143 
children (55% of those uninfected at baseline) 
became infected (16S rRNA positive) during the 
follow-up period. 
Chlamydial DNA was detected in 15% of children 
without disease signs at baseline, and in 46% of 
those with disease signs at baseline. Chlamydial 
16S rRNA was detected in 15% of children 
without disease signs at baseline and in 46% of 
those with disease signs at baseline. 
Being positive for 16S rRNA at baseline was 
significantly associated with the number of 
episodes of infection experienced during follow-up 
(Wilcoxon, p=0.045) but not with the number of 
disease episodes experienced during follow-up. In 
individuals with coincident infection and disease at 
baseline (n=30), there was a significant correlation 
between the infectious load and the duration of the 
disease episode (Spearman's R=0.40, p=0.026); 
however infectious load was not associated with 
disease outcome. 
The presence of clinical signs at baseline was 
significantly associated with the number of 
episodes of disease experienced during follow-up 
(p>0.0001), with the proportion of follow-up time 
the individual was diseased (p>0.0001) but not 
with the number of infections. 
Both the prevalence and incidence of 
both disease and infection was high in this 
cohort. Clinical signs of trachoma did not 
always coincide with detectable infection and 
this has implications for studying the immune 
response based on the observation of clinical 
signs when there is no detectable antigenic 
stimulus present. The data suggest that 
individuals with prevalent infections have 
higher numbers of subsequent infections and 
individuals with prevalent disease have more 
episodes of disease and when coincidentally 
infected have higher infectious loads. 
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SUSCEPTIBILITY TO TRACHOMATOUS SCARRING AND TRICHIASIS IS 
ASSOCIATED WITH INTERFERON GAMMA (IFNT) AND INTERLEUKIN 10 (IL10) 
GENE SINGLE NUCLEOTIDE POLYMORPHISM (SNP) HAPLOTYPES 
*A. Natividad1, K. Rockett2, O. Koch2, J. Wilson2, R.L. Bailey3, MJ. Holland1, N. Faal3, D. 
Kwiatkowski2, D.W. Mabey1 
'London School of Hygiene and Tropical Medicine, London, 2Welcome Trust Center for Human Genetics, 
Oxford, 3Medical Research Council Laboratories, The Gambia 
Experimental evidence implicates 
interferon gamma (IFNy) in protection from and 
resolution of chlamydial infection. Conversely 
interleukin 10 (IL-10) is associated with 
susceptibility and persistence of infection and 
pathology. However data in humans relating to 
these observations are scarce. To study the 
involvement of these cytokines in disease 
pathogenesis we have searched for association 
between polymorphisms across the IL10 and IFNy 
loci and the risk of developing the severe 
complications of human ocular Chlamydia 
trachomatis infection. 
A case-control study of 651 Gambian 
subjects with scarring trachoma and trichiasis and 
pair-matched controls with normal conjunctiva 
were screened for associations between single 
nucleotide polymorphism (SNP) haplotypes and 
disease. MassEXTEND (Sequenom) and MALDI-
TOF mass spectrometry has been used for 
detection and analysis of SNPs and the program 
PHASE has been used to infer haplotypes from 
population genetic data. 
Haplotype analysis has shown IL10 and 
IFNy SNP_haplotypes to confer susceptibility to 
sequelae of ocular C. trachomatis infection, 
namely conjunctival scarring and trichiasis. Within 
these disease-associated haplotypes, we have also 
found SNPs in IFNy and IL10 regulatory regions 
associated with these phenotypes. IFNy+874A 
allele, previously linked with lower IFNy 
production, was more common among cases than 
controls but not significantly, and lies within the 
disease-susceptibility haplotype. The promoter 
IL10-1082G allele, previously associated with high 
IL-10 expression, is in both the susceptibility and 
resistance haplotypes. By looking at the Linkage 
Disequilibrium (LD) pattern and haplotype 
structure among those genes in Gambians we argue 
that the above may be the result of a haplotype 
effect and propose to further study the influence of 
the disease-associated haplotypes on expression. 
In humans increased expression of IFNy 
and IL-10 has been found in the conjunctiva of 
individuals infected with C. trachomatis. 
Previously, we reported higher antigen-stimulated 
IFNy production by peripheral blood lymphocytes 
from matched controls compared to patients with 
trachomatous scarring. Also high ex vivo IL-10 
production by lymphocytes from patients with 
scarring trachoma has been reported. 
There is evidence that cytokine production may be 
under transcriptional regulation and variants in 
IFNy and IL10 regulatory regions have been 
demonstrated to influence gene expression. We 
have shown that common SNPs located in 
regulatory regions of both cytokine genes are 
associated with susceptibility to scarring trachoma 
and trichiasis. The putative functionality of some 
of those mutations is questionable and we suggest 
that either some of these markers may be in high 
LD with others influencing promoter activity. Or 
that extended promoter haplotypes, which include 
additional SNP sites to those already found, may 
underlie some of the variation in IL-10 and IFNy 
production levels. 
We further propose to study the functional basis of 
these associations by quantifying haplotype-
specific transcription in vivo and to investigate 
whether any of the differences found are due to 
functional SNPs within the disease-susceptibility 
haplotypes. 
It is believed that a good understanding of 
how genetic variants might influence susceptibility 
to disease might help to dissect the molecular basis 
of the pathogenesis of the disease. This may 
provide key information to overcome the major 
barrier that human chlamydia vaccine development 
faces, i.e. the poor understanding of the molecular 
aetiology of the disease. 
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ELEVATED IL-8 AND IL-1B TEAR FLUID LEVELS ARE ASSOCIATED 
WITH OCULAR INFECTION AND CLINICAL DISEASE SIGNS OF ACTIVE 
TRACHOMA 
*M. Holland1'2, N. Faal1 , E. Cameron1, F. Pemberton-Pigott1, I. Sarr1, H. Joof1, 
R.Bailey1'2 D. Mabey2 
'MRC Laboratories, Fajara, The Gambia and 2London School of Hygiene and Tropical Medicine, 
London, United Kingdom 
To quantify the levels of cytokines present 
in the tear film of children from a trachoma 
endemic population & investigate the relationship 
between children with and without clinical signs of 
disease. 
Three hundred and forty six children, aged 
4-15 years, from nine villages in The Gambia were 
recruited into a cohort study. The children were 
followed up every two weeks over a period of 28 
weeks. At each visit, a clinical examination of the 
conjunctiva was made and a digital photograph of 
the everted eyelid was taken. Two swabs were 
collected from the upper tarsal plate for laboratory 
diagnosis of infection. A dry swab for DNA and a 
swab for RNA collected into an RNA preservative 
(RNA later). Tear fluid was collected from the eye 
by placing a Merocel surgical sponge in the 
inferior conjunctival fornix until swollen. Sponges 
were then immediately placed in 500 pi of PBS 
containing a cocktail of proteinase inhibitors and 
the sample stored on frozen freezer blocks before 
transfer back to the laboratory. Samples were then 
stored at -20°C until assay. 
The DNA was extracted from the dry swab and the 
presence of chlamydial DNA in the conjunctiva 
was detected by Amplicor® and then by 
quantitative real-time PCR against the single copy 
gene, omp-1. RNA was extracted from the second 
swab, digested with DNAse I and the presence of 
chlamydial 16S ribosomal RNA (rRNA) detected 
using quantitative real-time RT-PCR. Tear fluid 
cytokine levels were then estimated using a 
Cytometric Bead Array for the cytokines IL-ip, 
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, 
TNFa and IFNy. The baseline sample from each 
subject was then tested by each of these assays. 
Cytokine data were highly skewed therefore all 
tests for significance were made by Mann-Whitney 
U test without adjustment for multiplicity. 
232 (67%) & 114 (33%) with a median age 
of 8 years (4-15 years) were recruited. The 
prevelance of disease signs (TF and/or TI) at 
baseline was 21% (74/346). 5.2% of children 
(18/346) had evidence of trachomatous scarring 
(TS). Chlamydial DNA was detected by 
Amplicor® in (20%) 67/335 children and in 10% 
(35/327) by omp-1. Chlamydial RNA was detected 
in 22% (72/331)- Chlamydial DNA was detected in 
15% of children without clinical signs at baseline, 
and in 46% of those with clinical signs at baseline. 
Chlamydial 16S rRNA was detected in 15% of 
children without clinical signs at baseline and in 
46% of those with clinical signs at baseline. 
DL-2, IL-4, IL-5, IL-6, IL-10 and IL-12p70 were 
not detected in tear fluid (<20 pg/ml) in sufficient 
numbers of samples to present a meaningful 
analysis. IFNy, TNFa, IL-ip and IL-8 were all 
detectable (>20 pg/ml) in a sufficient number of 
samples to allow tests for significance. Increased 
levels of IL-ip and IL-8 were significantly 
associated with observation of clinical disease 
(Median levels 49 vs 31 p=0.006; 166 vs 87 
p=0.001), detection of chlamydial DNA 
(Amplicor) (121 vs 70 p=0.0004; 230 vs 73 
p=0.0001) and detection of chlamydial 16S rRNA 
(54 vs 29 p=0.0004; 164 vs 80 p=0.0001). Levels 
of TNFa and IFNy were not associated with any in 
vitro tests for the presence of ocular infection. 
When IFNy was detected in tears, lower levels 
were observed in those with signs of disease (24 vs 
34 p=0.0014). All levels pg/ml. 
IL-ip and IL-8 represent the beginning of a 
cascade of inflammation and extracellular matrix 
breakdown. Therefore it may be informative to 
further understand the relationship between the 
duration of disease/infection and the continued 
production of cytokines in relation to disease 
pathogenesis. Following subjects in a cohort study 
affords us this opportunity. 
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CONJUNCTIVAL CYTOKINE AND FIBROGENIC GENE EXPRESSION IN 
THE MEMBERS OF A TRACHOMA ENDEMIC GAMBIAN COMMUNITY 
M J . Burton1'2*, R.L. Bailey1'2, D. Jeffries2, D.C.W. Mabey1 and M.J. Holland1'2 
'London School of Hygiene and Tropical Medicine, London, UK, 2Medical Research Council 
Laboratories, Fajara, The Gambia 
Blinding trachoma results from 
recurrent conjunctival infection by Chlamydia 
trachomatis. An inflammatory response is 
induced, which is believed to promote 
conjunctival scarring and ultimately blindness. 
Information is limited on the immunological 
responses in trachoma to chlamydial infection, 
some of which may promote scarring. An 
improved understanding may assist the 
development of interventions against this 
disease. 
The population of two trachoma 
endemic Gambian villages was studied. 248 
individuals of all ages were examined for the 
signs of trachoma. Conjunctival swab samples 
were collected and immediately placed in 
RNALater® for RNA stabilisation and 
isolation. Total RNA was extracted using the 
RNAeasy Mini Kit®. C. trachomatis infection 
was identified by the detection of chlamydial 
16S rRNA expression by a one-step RT-PCR 
(described in an accompanying paper). Human 
mRNA was reverse transcribed using the 
Omniscript RT Kit®. The expression of the 
following human cytokine and fibrogenic 
genes was quantitated in all 248 samples: IFN-
y, TNF-a, IL-1J3, IL-2, IL-4, IL-10, IL-12p40, 
IL-12p35, Perforin, TGF-02, MMP-1, MMP-9 
and Type 1 collagen. The results were 
normalised to the level of expression of HPRT 
in the same sample. Quantitative real-time 
PCR was performed on an ABI 5700, using the 
Quantitect SYBR Green PCR Kit®. All 
samples were tested in duplicate against a 
standard calibration curve constructed using 
serial dilutions of a known amount of the 
target cDNA being assayed. 
42 (16.0%) of subjects had active 
trachoma. C. trachomatis 16S rRNA was 
detected in 17 (6.8%). Clinically active 
trachoma (TF and or TI) was strongly 
associated with increased expression of TNF-a 
(p<0.0001), IL-lß (p<0.0001), IL-10 
(p<0.0001) and MMP-9 (p=0.0021). The 
presence C. trachomatis infection was 
associated with increased expression of IFN-y 
(p<0.0001), IL-4 (p<0.009), IL-12p40 
(p<0.0001) and Perforin (p<0.0001). The 
expression of TGF-ß2 did not vary by the 
clinical or infection state. The ratio of Type 1 
Collagen / MMP-1 was increased in disease. 
C. trachomatis infection was associated 
with expression of cytokines characteristic of 
an activated T-cell mediated immune response. 
Both Th1 and TH2 cytokine expression was 
increased in the presence of infection. 
Increased Perforin expression is consistent 
with cytotoxic T-cell activity. Clinically active 
trachoma was characterised by a pro-
inflammatory response (IL-lß and TNF-a) and 
increased expression of the anti-inflammatory 
cytokine IL-10. There was evidence of changes 
in the regulation of the extracellular matrix 
with increased expression of MMP-9, which 
may contribute to the pathogenesis of the 
scarring in trachoma. 
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EXPRESSION OF CHLAMYDIAL 16S RRNA IN SUBJECTS WITH 
TRACHOMA: CLINICAL ASSOCIATIONS AND RISK FACTORS 
MJ. Burton1, 2, MJ Holland1' 2, D Jeffries2, GJ Johnson2' 3, DCW. Mabey1 and *RL 
Bailey1'2 
1 2 
London School of Hygiene & Tropical Medicine, London, UK, Medical Research Council 
Laboratories, Fajara, The Gambia, 3Institute of Ophthalmology, London, UK 
Studies in trachoma using sensitive 
nucleic acid detection tests frequently find 
detectable C. trachomatis DNA in subjects 
without signs of active trachoma. Whether 
these individuals harbour infection of 
epidemiological significance is unknown, but 
is important for targeting of treatment. The 
high sensitivity of DNA amplification assays 
could lead to positive results from subjects 
with transient inoculations or reflect 
environmental or physical contamination. Thus 
it is unclear how far the detection or estimation 
of chlamydial DNA reflects infection at the 
conjunctival surface. Chlamydial 16S rRNA is 
one of the most prominent genes expressed as 
elementary bodies (EB) transform into actively 
replicating reticulate bodies (RB), and its 
expression could be a marker for actively 
replicating or viable organisms. We studied 
chlamydial 16S rRNA expression in subjects 
exposed to trachoma in order to report risk 
factors for 16S rRNA expression and its 
association with clinical signs of disease 
248 subjects were studied. The left eye 
of each subject was graded, and sampled for 
RNA isolation and for DNA. Total RNA was 
extracted using the RNAeasy Mini Kit and 
measured using the RiboGreen® kit. The 
expression of C. trachomatis 16S rRNA was 
quantitated by RT-PCR using forward and 
reverse primers spanning a 173 bp sequence in 
the body of the 16S rRNA gene kindly 
provided by Grant McClarty. Samples were 
tested in duplicate on an ABI 5700 against a 
standard calibration curve constructed using 
serial dilutions of target cDNA product in a 
fixed amount of herring sperm DNA, and 
sample copy numbers were estimated using the 
QuantiTect SYBR Green RT-PCR kit. DNA 
was extracted using the Amplicor CT/NG ® 
kit, purified and concentrated using the 
QIAamp® DNA Mini Kit and assayed by 
quantitative real-time PCR for ompl. 
42(16.9%) subjects had active 
trachoma. C. trachomatis 16S rRNA was 
detected in 17(6.8%) and ompl DNA in 49 
(19.8%) subjects. All but one of the 17 
individuals with 16S rRNA expression had 
detectable ompl. However, only 16/49(32.6%) 
of those with ompl had 16S rRNA expression 
detected. 16S rRNA expression was strongly 
associated with active disease, ..(particularly 
follicular disease), sharing a room with an 
active case, higher ompl levels, and was less 
likely with increasing age. In contrast, the 
finding of chlamydial DNA in the absence of 
16S rRNA was associated with low loads of 
ompl, and not significantly with either age or 
clinical state. 
Multivariate logistic regression modelling 
suggested that active disease (TF/TI)(OR 35.6: 
95% CI 6.47-195; p<0.001) and the presence 
of another active case in the same room (OR 
8.73: 95% CI 2.09-36.5; p=0.003) behaved as 
independent predictors of 16S RNA expression 
Data are consistent with the idea that 
high level chlamydial 16S rRNA expression 
indicates established, productive, or 
metabolically active C. trachomatis infection 
and that such expression is more likely to 
associate with the clinical signs of trachoma. 
Further studies may clarify this interpretation, 
assess the response to treatment and establish 
whether detecting 16S RNA (perhaps using 
NASBA or TMA based rapid tests) has utility 
for targeting treatment of trachoma or 
assessing those who may need retreating. 
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PLASMID COPY NUMBER ESTIMATION IN OCULAR SAMPLES: 
QUANTITATION OF PGP-3 AND OMP1 GENES AND THEIR RATIO IN 
GAMBIAN SUBJECTS EXPOSED TO TRACHOMA 
Esther Arye1*, Martin Holland1'2, Matthew Burton2 and Robin Bailey1'2 
1 2 
Medical Research Council Laboratories, Fajara, The Gambia; London School of Hygiene and 
Tropical Medicine, London United Kingdom 
Trachoma, caused by Chlamydia 
trachomatis is the world's leading cause of 
blindness. Blindness due to trachoma can be 
prevented when detected early. There is a 
need for a rapid and accurate diagnosis. The 
common cryptic plasmid of C. trachomatis 
has been used as a diagnostic target in a 
number of commercially available nucleic 
acid amplification assays. Based on reports 
that there are normally 7- 10 copies of the 
plasmid per chlamydial chromosome. (1) 
Tarn et al., 1992) there have been suggestions 
that tests using these targets confer increased 
sensitivity. Pickett and colleagues used a 
Taqman probe based method and estimated a 
copy number of 4 or less (ref). One plasmid 
encoded protein, pgp-3 has been found to be 
a target of the human immune response (3). If 
plasmid encoded proteins are under immune 
pressure, plasmid copy number may be 
affected by the host response, and may 
therefore be variable to a greater extent in 
samples derived from natural infection than 
in chlamydial organisms grown in tissue 
culture systems. This might affect the 
sensitivity of plasmid- based testing. We used 
real time PCR methods to estimate in parallel 
copy numbers of ompl and pgp-3 in ocular 
samples. 
74 samples positive by Amplicor 
testing were evaluated, with DNA extracted 
according to the manufacturers instructions. 
The positive samples were further processed 
to purify and concentrate sample DNA, 
because the Amplicor buffer was not 
compatible with the quantitative PCR assay. 
Real time quantitative PCR was performed 
using the ABI 5700 sample detection system. 
Subsequently a 123 base pair fragment within 
domain three of the ompl gene and a 139 base 
pair fragment within the pgp 3 gene were 
targeted for amplification. For each sample and 
target, quantification was performed twice on 
two replicate aliquots of the re-suspended DNA. 
Each assay included 6 concentrations of 
standard (ten fold dilutions of the stock solution 
from 105 to a single copy per capillary) and a 
negative control; these were used to generate a 
standard curve. 
For analysis, data were log transformed and 
cross-plotted, ratios of pgp-3/ompl both 
calculated directly and estimated by regression 
methods. 
Ompl was detected in all but 2 samples, 
with estimated copy number from 1 to 28888 
per (il. Pgp-3 was detected in all samples, but 
was not quantifiable in 6, with estimated copy 
number from 2 to 265459 per pi. Based on 69 
samples processed to date the median value of 
the pgp/ompl ratio was 5.33, with interquartile 
range from 1.67-18. The estimated regression 
coefficient of pgp 3 copy on ompl copy was 
5.75 (95% CI 4.55-6.94). 
These data suggest that a plasmid copy 
number of 5-6 may be the best estimate for 
clinical samples from subjects with trachoma. 
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EFFICACY OF AZITHROMYCIN FOR TRACHOMA CONTROL IN MALI 
USING THREE STRATEGIES 
J.F. Schémann1*, J. Orfila2, F. Hamdad-Daoudi2 
'institut d'Ophtalmologie Tropicale de l'Afrique (IOTA), Mali, Bamako, laboratoire de 
Bactériologie- Hygiène, CHU d'Amiens, France 
In the course of a national survey on 
trachoma conducted in Mali in 1996-1997, we 
diagnosed active trachoma, either follicular 
(TF) or intense (TI) among 34.9% of children 
aged under ten [1]. Azithromycin as 
demonstrated by Schachter et al [2] is able to 
decrease frequency of trachoma in at risk 
communities and a single dose has proved as 
active as local treatment with tetracycline 
ointment [3]. This antibiotic may be massively 
distributed to the whole population of endemic 
villages. For limiting the amount of drug 
distributed, other alternatives have been 
considered excluding either men or older 
children of the distribution, or the inhabitants 
of households with no active trachoma among 
children. 
Three strategies for distributing azithromycin 
have been studied: Mass treatment of all the 
inhabitants of endemic villages(i), treatment of 
all children younger than 11 and women 
between 15 and 50 years old(ii),treatment 
restricted to inhabitants of households where at 
least one child is discovered trachomateous(iii) 
[4]. 
A sample of 2100 persons was required 
to test each strategy. Three villages with a 
population of approximately 700 people, were 
selected at random for each strategy. 
Adults were given lg azithromycin (i. e four 
250mg tablets). Children were given a dose of 
20mg/kg (to a maximum of lg). 
Eyes were examined using a X2.5 loupe and an 
electric torch. Simplified trachoma grading 
was employed. 
Ocular swabs were taken for PCR Cobas 
Amplicor™ (Roche Diagnostic Systems, 
France). The PCR test was undertaken before 
treatment. A second sample was taken on day 
30 from persons who had been treated, to 
evaluate the efficacy of the treatment. 
A logistic regression was used to predict 
clinical activity at six months with the 
following covariates: strategy (women and 
children or targeted household treatment 
compared to mass treatment), age, gender, and 
risk factors such as a dirty face or the presence 
of a latrine in the household. The study, which 
started at the end of May 2000 had to be 
interrupted and was completed in January 
2001. Because of possible seasonal variations 
the analysis was adjusted on the survey period. 
Azithromycin was given to 70.2% of 
the population identified in the villages 
covered by strategy I, to 48.4% of the 
population in villages covered by strategy n, 
and to 38.3% of the population in villages 
concerned by strategy m. 
One month after the azithromycin had been 
distributed, the decline in prevalence of active 
trachoma among children aged from one to ten 
was significant for all three strategies: 
in villages covered by mass distribution, it had 
fallen from 23.7% to 13.9%, in those in which 
women and children had been treated, it had 
gone down from 20.8% to 10.2%,and in the 
villages in which distribution had been 
targeted on households, it had fallen from 
20.2% to 11.2%. 
Six months after distribution, the decline in 
prevalence of active trachoma among children 
aged from one to ten was still decreasing: to 
8.1% in mass distribution, to 4.0% in women 
and children treatment, and to 7.9% in the 
household targeted strategy. 
Before treatment, presence of chlamydia 
assessed by PCR appeared to be more frequent 
than signs of active trachoma (TF or TI) 
determined by a simple clinical examination. 
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However, one month after treatment, the 
phenomenon had been reversed and there were 
more case of clinical trachoma than people 
with chlamydia. The decline in the PCR 
positive rate after treatment was significant in 
the three villages (P = 0.04 ; 0.01 et 0.04 
respectively). 
Administration of a single dose 
produces a diminution in the prevalence of 
active trachoma after one month with all three 
strategies. The decline in prevalence increased 
at six months and the one-month period is 
probably too short to assess the efficacy of the 
molecule, as follicles may disappear long after 
the infectious agent. In all three strategies, the 
clinical cure rates on day 30 were similar. 
After six months we are authorized to affirm 
that the strategy focused on children and 
women is at least equivalent to mass 
distribution, and that it is justifiable to exclude 
men. Training and logistic means are the same 
for mass treatment and for women and child 
strategies, nevertheless it allows quite 
substantial reduction of the antibiotic pressure. 
The strategy targeted on households with 
trachoma is not inferior to the mass strategy 
and could reduce more importantly the 
quantity of drug distributed. Unfortunately it 
needs for being implemented to examine all 
children for trachoma assessment and 
consequently to train health workers to 
diagnose trachoma clinically. 
These tree strategies are acceptable for 
trachoma control programmes over a period of 
six months, but it will be important to compare 
these results one year after treatment. 
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CAN TRACHOMA BE ELIMINATED WITH MASS ANTIBIOTICS ALONE? 
T.M. Lietman1'2*, M. Melese3, W. Alemayehu3, D.C. Lee1, J.D. Chidambaram1, E. Yi1, 
V. Cevallos1, Z.X. Zhou1, J.P. Whitcher1'2, B. Gaynor1'2 
^.1. Proctor Foundation and the department of Ophthalmology, University of California, San 
Francisco, San Francisco, USA, 3Orbis International, Ethiopia 
The WHO and their partners are 
attempting to eliminate blinding trachoma, in 
large part by the use of mass azithromycin 
administrations. While annual treatments have 
had success in areas with modest disease such 
as Nepal and Morocco, preliminary results in 
more severely affected regions have been less 
encouraging. Mathematical models have 
demonstrated that it is theoretically possible to 
eliminate infection with repeat mass 
treatments, given sufficient coverage of the 
population and given a slow enough return of 
infection back into the population after 
treatment. Precise estimates of this latter 
parameter have never been reported. Here we 
determine the rate chlamydial infection returns 
into a community in Ethiopia and estimate the 
treatment frequency (i.e. biannual, annual, etc.) 
required to eliminate infection. 
24 villages in the Gurage Zone of 
Ethiopia were monitored for infection at 
baseline, 2 months after treatment, and 6 
months after treatment, using the Roche PCR 
amplicor test on conjunctival swabs from all 
children aged 1-5 years, the age-group in 
which infection is the highest and in which the 
return of infection is the most rapid. The rate 
of return of infection after mass treatment was 
calculated based on 2 and 6 month data. A 
mathematical model was used to determine 
what coverage and frequency of mass 
treatment would be necessary to eliminate 
infection given the estimated rate of return of 
infection. Essentially, infection must be 
reduced more by mass treatments than it 
returns between visits. Inter-village variance 
was estimated, and confidence intervals were 
used to express uncertainty due to sampling 
error. 
2714 children were monitored. The 
prevalence of infection was 56.3% 
pretreatment (95% CI 47.5%-65.1%), 6.7% 
two months post-treatment (4.2%-9.2%), and 
11.0% six months post-treatment (7.3%-
14.7%). Infection returned after treatment at an 
exponential rate of 12.3% per month (4.6%-
19.9% per month). The treatment frequency 
necessary for elimination was calculated to be 
once every 11.6 months (95% CI 7.2 to 30.9 
months), given a coverage level of 80%. 
Results are sensitive to both the estimate of the 
rate of return and the estimate of the coverage 
level. Inter-village variance is sufficiently high 
that multiple villages need to be monitored to 
make reasonable estimates of these parameters. 
The rate that ocular chlamydial 
infection returns into a community after mass 
treatment suggests that elimination of ocular 
chlamydial infection is feasible with periodic 
antibiotic administrations and attainable 
coverage levels, although distributions may 
need to be given more than once per year in 
severely affected areas. 
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H E R D P R O T E C T I O N F R O M T R A C H O M A W I T H P E R I O D I C M A S S 
A N T I B I O T I C T R E A T M E N T 
J.D. Chidambaram1A*, M.Melese2, W.Alemayehu2, D.C.Lee1A, V.Cevallos1A, 
C.Donnellan1A, Z.X. Zhou1A, E.H. Yi1A, J.P. Whitcher1A1B, B.D. Gaynor1A1B, T.M. 
Lietman1A,1B 
AF.I. Proctor Foundation & BDept. of Ophthalmology, 'University of California, San Francisco, 
USA; 2ORBIS International, Ethiopia 
A key component of the WHO's 
strategy to eliminate blinding trachoma is 
periodic mass antibiotic treatment. Trachoma 
programs currently achieve only 60-90% 
treatment coverage, as it is very difficult to 
reach every individual within the community. 
Here we evaluate whether the remaining 
untreated members of the community might 
receive indirect protection by living in a 
population where most others have been 
treated. We compared the prevalence of ocular 
chlamydial infection in untreated children 
residing in treated versus untreated villages. 
In a trachoma-endemic district of the 
Gurage Zone in Ethiopia, 8 villages were 
randomly chosen for mass azithromycin 
distribution in Spring 2003. A further 8 
villages were selected randomly from the same 
pool of villages for trachoma monitoring in 
Fall 2003 - these villages were not treated 
until after this study. Single dose oral 
azithromycin was offered to all individuals 
aged 12 months and older—children younger 
than 12 months were not treated due to 
approval issues in this age group. By Fall 
2003, all children under 18 months were 
untreated regardless of the village in which 
they resided. In Fall 2003 right upper tarsal 
conjunctival swabs were taken from all 
children under 18 months and tested for 
•Chlamydia trachomatis DNA (Roche 
Amplicor). Results were analyzed with a 
logistic regression model, accounting for 
clustering within villages. 
A high antibiotic coverage of 91% was 
achieved in treated villages. 4% of untreated 
children residing in treated villages had 
evidence of chlamydial infection, as opposed 
to 10% of children in untreated villages. 
Children from untreated villages had 2.9-fold 
odds of harboring infection compared to 
children in treated villages (P=0.03, adjusted 
for village clustering). 
Untreated children apparently received 
some protection from ocular chlamydial 
infection by living in a village where most 
individuals have been treated. This protection 
lasted for at least 6 months following antibiotic 
distribution. If treatments are repeated 
frequently enough, persistence of this indirect 
protective effect may be analogous to the herd 
protection seen with vaccination programs. 
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TOPICAL MICROBICIDES FOR THE PREVENTION OF CHLAMYDIA 
TRACHOMATIS INFECTION: RESULTS OF PRECLINICAL EFFICACY 
STUDIES CONDUCTED IN THE MONKEY MODEL 
Dorothy L. Patton*, Yvonne T Cosgrove Sweeney, Walter E. Stamm§ 
Departments of Obstetrics and Gynecology and §Medicine, University of Washington, Seattle, WA 
Topical microbicide products are being 
developed for the purpose of protecting 
individuals from STI acquisition. We use the 
non-human primate model of chlamydial 
infection to assess the ability of topical 
microbicide products to prevent Chlamydia 
trachomatis infection. These studies have been 
standardized and are conducted under NIH 
contract agreement. 
Macaca nemestrina monkeys are 
administered a single intravaginal application 
(1.5ml) of a topical microbicide product-in-
development. Thirty minutes after product 
application, the animal is challenged with a 
human genital isolate of C. trachomatis (105 
inclusion forming units in 1ml inoculum, 
serovar E) via cervical wash. Presence of 
chlamydial infection is documented over the 
next 5 weeks by culture and nucleic acid 
amplification test (NAAT) detection assays 
from cervical swabs, and by serologic 
response. Six test animals per product are 
compared with six positive control animals run 
in parallel, but with no intravaginal product 
application. Two four-arm experiments were 
conducted, each assessing three topical 
microbicide products compared with a no 
product arm. 
In all, six topical microbicide products 
with various mechanisms of action have 
completed these preclinical efficacy studies. 
Polystyrene Sulfonate gel and Cellulose 
Sulfate gel (both provided by the CONRAD 
organization) act as adsorption inhibitors, 
BufferGel (provided by ReProtect) acts as an 
acid buffer, PRO 2000 gel (provided by 
Indevus) is an entry and fusion inhibitor, C31G 
gel (provided by Biosyn) is a surfactant, and 
D2A21 gel (provided by Demegen) acts as a 
membrane disrupter. 
Half of the positive control animals (6 
of 12) developed chlamydial infection. Each 
remained culture and NAAT positive 
throughout the five week experiment and 
developed serologic IgG titer to C. 
trachomatis. In addition, one animal tested 
positive by NAAT assay only through week 
four. This animal did not seroconvert. The 2% 
D2A21 gel performed similarly to the positive 
controls, in that half the animals (3 of 6) were 
culture and NAAT positive on repeat visits, 
and each developed a serologic response. 
Similarly, 3 of 6 animals in the 0.5% PRO 
2000 gel test group tested positive by culture 
and NAAT assays throughout the course of the 
experiment, but only one animal developed an 
antibody response to infection. Two of six 
animals in the BufferGel group developed 
chlamydial infection with subsequent antibody 
response, while a third animal in this group 
remained NAAT positive throughout the 
experiment, tested culture positive on two 
occasions (days 7 and 35 after inoculation), yet 
did not develop an antibody response by day 
35 (end of experiment). Conversely, three 
animals in the Cellulose Sulfate gel test group 
developed chlamydial antibody, only two of 
which had sustained culture and NAAT 
positivity. The third animal in this group had a 
short-lived positive status (days 2 and 7 only) 
by culture and NAAT assays. Finally, only two 
of six animals in both the Polystyrene 
Sulfonate gel and 1.0% C31G test groups 
developed chlamydial infection and antibody 
response. 
While complete protection from C. 
trachomatis infection was not achieved with 
any of the topical microbicide products tested 
to date, partial protection may have occurred. 
Even a decrease in the transmission rate of 
chlamydial infection may ultimately result in a 
decrease in acquisition of concomitant 
infections such as HIV. 
Supported by NIAID N01-AI-95388 and WaNPRC RR-00166. 
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E V A L U A T I O N O F F O U R CHLAMYDIA 
C A N D I D A T E S I N A R A B B I T M O D E L 
PNEUMONIAE V A C C I N E 
I. W. Fong*1, B. Chiu2, E. Viira1, J. B. Mahony3, D. Jang3, B. Coombes3, P. Dunn4, 
J.Caterini4, A. Murdin4 
Departments of Medicine1, St. Michael's Hospital, University of Toronto, Department of 
Laboratory Medicine , University of Alberta , Department of Pathology and Molecular Medicine, 
McMaster University3, and Aventis Pasteur4 
Objective: 1) To determine the 
protective efficacy of C. pneumoniae DNA 
vaccines against pneumonia in a rabbit model. 
2) To determine whether DNA vaccines can 
reduce or protect against pulmonary 
inflammation. 
3)_To determine whether DNA vaccines can 
reduce the bacterial burden in the lungs. 
4) To determine whether DNA vaccine can 
reduce the prevalence of bacteremia and hence 
dissemination to the arterial wall. 
5 groups of 20 rabbits were immunized 
with 4 DNA immunization constructs 
(pCA1555, encoding the 76 kDa antigen 
homolog; pCACRMP60, encoding the 60kDa 
cysteine rich membrane protein; and 
pCA1764, encoding the ATP/ADP translocase 
(Nptlcp); and a control of empty DNA 
immunization vector pCA/MycHis. Animals 
were immunized with 200pg DNA 
intramuscularly and 200pg DNA intranasally 3 
times at 2 weeks interval, then challenged with 
107 EFU of C. pneumoniae intranasally. Lungs 
were harvested 7 days post challenge and 
assessed for severity of inflammation by a 
standardized score. Antigen burden in the 
lungs was assessed by immunohistochemical 
stain of lung sections for C. pneumoniae (foci 
of infection). C. pneumoniae DNA in lung 
homogenates/washings and peripheral blood 
mononuclear cells (PBMC) was also analyzed 
by PCR. 
The mean inflammatory-histology 
score per lung of the control group was 
significantly higher (11.75 ± SD 4.35), than all 
except one of the vaccine group: 8.2 + 4.37 for 
pCAMOMP (p=0.011), 8.6 ± 2.93 for 
pCACRMP60 (p=0.019), 7.68 ± 2.81 for 
pCA1764 (p=0.002), and 9.30 ± 1.98 for 
pCA1555 (p=0.094). 
C. pneumoniae antigen was detected in greater 
number of foci per lung sections in the control 
group (4.8 ± 1.96) than all of the vaccine 
groups: 2.95 ± 1.82 in the pCAMOMP 
(p=0.008), 2.25 ± 1.29 in the pCA CRMP60 
(p=0.0002), 2.42 ± 2.09 in the pCA1764 
(p=0.002) and 3.05 ± 2.48 in the pCA1555 
group (p=0.013). 
The detection of C. pneumoniae DNA in 
PBMC was similar between the controls (25%) 
and the combined vaccine groups (23.4%), but 
the detection in lungs was lower in the vaccine 
groups (12.7% overall, but 5.0% and 5.3% for 
pCAMOMP and pCA1764) versus 30% in the 
control group (p=0.08, trend). 
Immunization with DNA constructs is 
capable of reducing pulmonary inflammation 
by 21% to 35% and the antigen load by 37% to 
53% in the lungs following C. pneumoniae 
infection, but did not reduce the prevalence of 
C. pneumoniae DNA in peripheral blood by 
PCR. The most promising DNA construct for 
vaccine development is the 76 kDa antigen 
homolog, and MOMP vaccine appeared less 
protective. A combination of the two for 
additive effect or other genes should be 
investigated. 
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EVALUATION OF THE ROLE OF TUMOR NECROSIS FACTOR ALPHA IN 
CHLAMYDIA PNEUMONIAE ATHEROGENESIS IN MICE 
Tadayoshi Nosaka, Lee Ann Campbell*, Michael Rosenfeld, Kambiz Yaraei and Cho-
chou Kuo 
Department of Pathobiology, University of Washington, Seattle, WA, USA 
Chlamydia pneumoniae, a human 
respiratory pathogen, has been associated with 
atherosclerosis by seroepidemiological studies and 
detection of the organism in atheromatous lesions. 
Studies in animal models of atherosclerosis and C. 
pneumoniae lung infection have produced a strong 
indication that C. pneumoniae is a co-risk factor of 
hyperlipidemia for atherosclerosis [1]. It has been 
shown that C. pneumoniae can establish chronic 
infection in atheromatous lesions in 
hyperlipidemic mice. Therefore, it has been 
speculated that chronic inflammatory reactions 
induced by chlamydial infection may be one 
mechanism by which C. pneumoniae accelerates 
the progression of atherosclerosis. Tumor necrosis 
factor a (TNF- a), a pro-inflammatroy cytokine, 
elicts responses predominantly through the TNF-
R1 (p55) receptor (2,3). Therefore, p55 receptor 
knockout mice were use to determine whether 
signalling through this receptor contributes to C. 
pneumoniae accelerated atherogenesis. 
Male p55-knockout mice on C57BL/6J 
background were inoculated intranasally with 
lxlO7 inclusion forming units of C. pneumoniae 
AR-39 three time at 9, 11, 13 wks of age. Control 
animals were inoculated with buffer. Mice were 
fed a high fat/high cholesterol diet starting at the 
day of the first inoculation throughout the duration 
of the experiment. Mice were sacrificed at 21 wks 
of age (12 wks on diet) and 25 wks of age (16 wks 
on diet). Mice were sedated and blood was 
collected by exsanguination from the femoral 
artery at necropsy. The heart and aorta were 
perfusion-fixed with 10% buffered formalin and 
removed in toto. The aorta was separated from the 
heart and sections of the aortic sinus were stained 
with oil red O. The aortic sinus is the site most 
prone to develop atherosclerosis in this model [4], 
Lesion areas were measured by computer assisted 
morphometry in 15-step sections. Serum antibody 
against C. pneumoniae was measured by the 
micro-immunofluorescence test. This study had 
been approved by the institutional animal use 
committee. 
All infected mice developed antibody 
against C. pneumoniae, while all sham-inoculated 
controls were antibody negative. No differences in 
total plasma cholesterol values were observed 
between infected and sham-inoculated animals. 
Total cholesterol levels were 249 mg/dl (N=14) 
and 262 mg/dl (N=16) and 243 mg/dl (N=17) and 
253 mg/dl (N=10) at 21 and 25 wks of age, 
respectively for non-infected and infected animals. 
No differences were observed in the number of 
animals which developed foam cell lesions 
between non-infected and infected animals at both 
time points (p>0.1): 3 of 11 and 6 of 15 animals at 
21 wks of age and 8 of 11 and 8 of 18 animals at 
25 wks of age for non-infected and infected 
animals, respectively. There were also no 
differences in the mean areas of lesions in those 
mice which developed lesions: 855 + 454 um2 
(N=3) and 1054 ± 179 um2 (N=6) at 21 wks 
(p>0.2) and 3129 ± 3036 um2 (N=8) and 2755 ± 
1796 um2 (N=8) at 25 wks of age (p>0.6), 
respectively for non-infected and infected animals. 
This study shows that C. pneumoniae 
infection does not accelerate foam cell lesion 
development in the aortic sinus in hyperlipidemic 
p55 receptor knockout mice. These findings 
suggest that signalling through the p55 receptor 
may play a role in the atherogenic effects of C. 
pneumoniae in hyperlipidemic mice. 
Acknowledgement: This study was supported 
in the USPH Grant HL-56036. 
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INFECTION WITH CHLAMYDIA PNEUMONIAE STOPS DEVELOPMENT OF 
PEAK BONE DENSITY IN GROWING MALE MICE AND IS ASSOCIATED 
WITH A TH-1 TYPE IMMUNE RESPONSE 
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Infection with Chlamydia pneumoniae 
is sometimes associated with chronic 
infections in humans. It has been proposed that 
C. pneumoniae may aggravate atherosclerosis 
by activating macrophages to secrete 
cytokines, such as interleukin-1 and -6 and 
tumour necrosis factor. Interestingly, these 
cytokines are also known to increase bone 
resorption through increased expression of 
receptor activator of NF-kB (RANKL), a key 
element in osteoclast differentiation and 
activation. We investigated whether C. 
pneumoniae infection of still growing male 
mice was associated with decreased peak bone 
density. 
Nineteen C57BL/6 mice were infected 
by nasal inoculation with a C. pneumoniae 
containing suspension at ten weeks of age, for 
three consecutive weeks, and 20 mice were 
sham infected and served as control. Bone 
density (BMD, mg/mm3) of the distal femur, 
proximal tibia, and femur diaphysis was 
measured before/pre and after/post 16 days of 
infection using peripheral quantitative 
computed tomography. 
Cytokine levels were measured in serum for 
presence of IL-lp, TNF-a, IL-6 and 
osteocalcin. Isolated lymphocytes from 
infected and sham infected mice were analyzed 
for CD3+, CD3+/RANKL+ T cells, C D l l b and 
CDllb/IL-1 activated macrophages by 
flo wcytrometry. 
Compared to sham infected mice, the 
C. pneumoniae infected mice increased 
significantly less in total BMD of the distal 
femur (0.4% vs. 9.4%, p=0.01), proximal tibia 
(-1.6% vs. 9.7%, p=0.001), and cortical BMD 
of the femur diaphysis (2.7% vs. 5.4%, 
p=0.006). The levels of interleukin-6 (56 vs. 
39 pg/mL, p=0.02) and interleukin-1 p (11 vs. 0 
pg/mL, p=0.003) were increased in serum of 
infected mice. Also levels of osteocalcin (228 
vs. 50 pg/mL, p<0.001) were increased in the 
infected mice. There was no significant 
difference in weight gain (p=0.53) when 
comparing infected and sham infected mice. 
However, there was a significant difference in 
CD3+ T-cell activity when comparing infected 
mice to sham infected mice (p=0.01). Infected 
mice also demonstrated an activation of 
RANKL. 
We have here demonstrated for the first 
time that infection with the intracellular 
pathogen C. pneumoniae may decrease the 
accumulation of bone density in growing mice. 
These might caused by an activation of CD3+ 
T-cells, expressing the osteoclast activator 
RANKL on their cell surface. 
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ANALYSIS OF CYTOKINE LEVELS IN THE ACUTE PHASE OF 
CHLAMYDIA PNEUMONIAE LUNG INFECTION IN MICE 
Kambiz Yaraei, Lee Ann Campbell*, Cho-chou Kuo, Tadayoshi Nosaka, Michael E. 
Rosenfeld 
Department of Pathobiology, University of Washington, Seattle, USA 
The objective of this study was to 
analyze plasma cytokine profiles during the 
acute phase of Chlamydia pneumoniae lung 
infection in mice. Although the responses of 
specific cytokines to C. pneumoniae infection 
have been evaluated in vitro [1, 2, 3] and in 
vivo in the lung [4], plasma cytokines profiles 
have not been analyzed. Such information is 
essential for determining the role of cytokines 
in disease manifestations, immunity and 
immunopathology of C. pneumoniae infection. 
Eight week old, male C57BL/6J mice 
were housed in a modified specific pathogen 
free facility and fed normal chow and water 
ad-libitum. Mice were inoculated intranasally 
with 3xl07 inclusion forming units of linear-
gradient purified C. pneumoniae (strain AR-
39) organisms while mice were under sedation. 
Controls were sham inoculated with PBS. The 
third group received no treatment. Blood 
samples were obtained by cardiac puncture 
into a heparinized syringe at 1, 3, 6, 12, 48, 
and 72 hrs post inoculation. Blood was 
immediately centrifuged to obtain plasma, 
which was stored at -70°C until tested. All 
animal protocols for this study were approved 
by the Institutional Animal Care and Use 
Committee. The Multiplex Cytokine Assay 
(Bio-Plex™ cytokine assay, Bio-Rad 
Laboratories, Inc) was used to generate the 
plasma cytokine profile. The assays were run 
in duplicate. 
Intranasal administration of PBS likely 
irritated the mice and stimulated a transient 
increase in all of the cytokines as compared to 
non-treated controls. However, intranasal 
inoculation with live C. pneumoniae 
stimulated 4-fold or greater increases in IL-5, 
IL-10, IL-12, GM-CSF, IL2 (p<0.01) and 3-
fold increases in IL-6 and IFNy (p<0.05) as 
compared to the PBS inoculated mice. IL-ip 
was increased 4-fold and IL-4 2-fold. 
However, these increases were not statistically 
significant. Surprisingly, no increase in TNFa 
was observed. The time courses for obtaining 
peak levels of cytokine varied considerably 
and ranged from 6 to 72 hrs post inoculation. 
Whether inoculation with live organisms is 
required to stimulate cytokine response is 
being evaluated by inoculating the mice with 
heat- or UV-inactivated organisms 
A single intranasal inoculation of 
C57BL/6J mice with C. pneumoniae 
stimulated significant increases in the plasma 
levels of IL-2, IL-5, IL-6, IL-10, IL-12, GM-
CSF, and IFN-y but not INF-a, IL-lp or IL-4. 
These results indicate that both pro- and anti-
inflammatory cytokines are variably produced 
in response to acute pulmonary infection with 
C. pneumoniae. 
Acknowledgement: This study was supported 
in part by the USPH grants HL58954 and HL-
56036. 
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R E P E A T E D CHLAMYDIA PNEUMONIAE I N F E C T I O N I N M I C E 
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Acute C. pneumoniae infection often leads to a 
mild self-restricted respiratory tract infection but the 
infection may also become chronic. Chronic chlamydial 
infections are associated with several severe disease 
outcomes. Seroepidemiological studies first suggested 
an association between chronic C. pneumoniae infection 
and coronary artery disease as well as artherosclerosis, 
and human studies using immunochemistry, PCR and 
even culture of C. pneumoniae as well as several 
experimental infection models have later confirmed the 
association (reviewed by Grayston 2000). As persistent 
infection can follow the acute phase of infection, it 
suggests that the immune response developed during the 
acute infection is not optimally effective for clearance of 
infection and prevention of pathologic sequelae. Also, 
occurrence of repeated infections indicates that the 
immunity after natural infection is indeed not completely 
protecting, and repeated infections may enhance the 
development of harmful pathological features of 
chlamydial diseases. Our groups own work and work of 
others has indicated that persistent infection occurs in 
approximately 20% of immunocompetent WT mice 
(presence of C. pneumoniae DNA in the absence of 
cultivable EBs in lungs) after acute C. pneumoniae 
infection. In the current work, we characterized the role 
of repeated C. pneumoniae infections (= three 
infections) to bacterial persistence in BALB/c mice. 
Furthermore, the immunologic response was 
characterized by analysing lymphocyte responses from 
the spleen and lungs. 
6- to 8-week old female BALB/c mice were 
infected intranasally with lxlO6 IFU of C. pneumoniae 
isolate K6 in 40pl of SPG solution under Metofane 
anesthesia. Two rechallenges were given after the mice 
had cleared the previous infection (-50-60 days after 
first challenge, 30-35 days after second challenge). At 
certain timepoints (days 4, 11, 18, 28, 42, 60) a group of 
six mice were sacrificed. The lungs were dissected and 
mechanically homogenized. The right lung supernatant 
was cultured for C. pneumoniae and the left lung was 
assessed for the presence of C. pneumoniae DNA by 
Taqman quantitative PCR. Lymphocyte subsets of the 
isolated splenocytes and mononuclear cells from the 
lungs were characterized. 
In BALB/c mice a significant protection is 
acquired after primary C. pneumoniae infection, as 
during the reinfection fewer bacteria can be cultured 
from the lungs of infected mice and these mice can clear 
the infection faster (in two weeks)(Penttila et al. 2000). 
The third C. pneumoniae challenge resulted in mice a 
self-restricted infection without notable clinical 
symptoms. After third challenge as well as after second 
challenge less bacteria were cultured from the lungs and 
the kinetics of bacterial load reduction was identical to 
the kinetics observed after reinfection. However, 
although no cultivable bacteria could be detected after 
two weeks of third challenge, a part of mice still were C. 
pneumonie positive measured by quantitative PCR until 
two months after the third challenge. 
In our earlier experiments we have found that 
C. pneumoniae primary infection induces specifically a 
strong CD 19+ cell (= B cell) influx to the lungs of 
infected mice, and the dominance of B cells over the T 
cells is even stronger early after reinfection. The 
proportion of CD8+ T cells of all lymphocytes isolated 
from lungs of infected mice stays constant during both 
primary and reinfection, but the number of CD4+ T cells 
slightly increases during the early phase of reinfection. 
The proportions of the different lymphocyte subsets in 
lungs revert to the levels of uninfected animals in 
parallel with the kinetics of bacterial clearance of 
infected animals. In the spleen the proportions of 
different lymphocyte subsets are similar to those in 
uninfected animals. 
In this study, we found that a third successive 
C. pneumoniae challenge clearly augmented the 
proportions of B cells in the lungs of infected mice. 
Also, the great dominance of CD 19+ lymphocytes over 
the other investigated lymphocyte subsets lasted longer 
than after the second challenge. The proportion of CD8+ 
as well as CD4+ T cells in the lungs remained 
unchangeable after the third challenge. We found also, 
that the third C. pneumoniae infection led to a slight 
increment of CD4+ T cells in the spleens of infected 
animals at the very early phase of infection. 
Third inoculation of C. pneumoniae led to a 
self-restricted infection in BALB/c mice that resembled 
reinfection. We found that C. pneumoniae can establish 
a persistent infection in part of the mice up to two 
months after third inoculation. This is in accordance 
with data observed also after reinfection. Thus, repeated 
C. pneumoniae infections did not significantly increase 
the number of persistently infected mice. Long-term 
effects of repeated infections on the bacterial persistence 
in mice are underway. 
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Chlamydia pneumoniae is an important 
cause of respiratory infections, and has been 
suggested to be a risk factor in atherosclerosis 
and immune-reactive chronic inflammatory 
disorders. Humans commonly encounter C. 
pneumoniae, most individuals having several 
infections during their lifetime. Animal studies 
have revealed that C. pneumoniae infection in 
mice causes prolonged pneumonitis, with 
similarities to the human disease. The 
significance of the isotypes of antibodies to 
chlamydial proteins, of the induction of 
antibodies to bacterial and host heat shock 
proteins (HSPs), and of the presence of C. 
pneumoniae DNA in the circulation has not 
been fully elucidated, and may well be of 
importance as concerns an understanding of 
the pathomechanism of C. pneumoniae 
infections. 
BALB/c mice were inoculated 
intranasally with C. pneumoniae to simulate 
repeated human infections. C. pneumoniae-
specific antibodies to whole bacterium and 
antibodies reacting with HSPs were measured 
by means of ELISA tests. Nested PCR was 
used to detect C. pneumoniae DNA in the 
peripheral blood. 
After primary infection, C. 
pneumoniae-specific IgM antibodies were 
detected in all animals, and a majority of the 
mice demonstrated IgM response after 
secondary infections also. IgG antibodies were 
detected 2 weeks after the first inoculation, and 
the titre increased markedly after the second 
infection. IgA antibodies with high titre were 
detectable in the sera after repeated infections. 
Antibodies reacting with cHSP60 and mouse 
HSP60 homologues were detected in high titre 
after repeated infections in a majority of mice 
and groEL-specific antibodies were also 
measurable, but less frequently and in lower 
titre. After acute infection, C. pneumoniae 
DNA was readily detectable in the peripheral 
blood of the mice. The clearance of the DNA 
was more rapid after the second and third 
infections, but some mice gave a positive PCR 
test at later time points, even after a single 
inoculation. 
Analysis of the occurrence of 
immunoglobulin isotypes in the serum after 
multiple C. pneumoniae infection may provide 
a clue to the evaluation of diagnostic 
serological tests. The presence of C. 
pneumoniae DNA in the blood can serve as an 
additional tool for the diagnosis of acute and 
persistent infection, and for epidemiological 
studies in which the contribution of infection 
to atherosclerotic diseases is assessed. C. 
pneumoniae reinfections result in the 
production of antibodies that react with 
bacterial and endogenous HSPs with potential 
roles in protection against infection and in the 
development of autoimmune mechanisms. 
This work was supported by grants 
T037501 (V.E.) and T034954 (E.G.) from the 
National Research Fund (OTKA) and grant 
378/2003 from ETT (E.G.). 
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Dietary flavonoids, which are found in almost all 
foods of plant origin, are receiving increasing 
attention as potential protectors against variety of 
human diseases, in particular cardiovascular diseases 
and cancer. These polyphenolic compounds are 
shown to prevent lipid peroxidation and inhibit for 
example LPS induced cytokines and NO production 
both in vitro and in animal models. Some of the 
compounds are strongly chlamydiacidal in cell 
cultures. Previously, Cpn inoculation has been shown 
to cause aortic endothelial dysfunction in 
apolipoprotein E-knockout mice and coronary 
dysfunction in pigs. In this study we wanted to clarify 
if two common phenolic compounds, quercetin and 
luteolin, could have an effect on aortic endothelial 
function in Cpn inoculated C57BL/6J mice. 
Female C57BL/6J mice were given quercetin and 
luteolin intraperitoneally (in 1% DMSO) once daily 
for three days prior to inoculation, and the treatment 
was continued until the mice were sacrificed at four 
days post infection (p.i). Three groups of 8 mice 
inoculated intranasally with Cpn isolate K7 were 
treated either with 20 mg/kg quercetin, 2 mg/kg 
luteolin or given diluent (infected controls). Fourth 
group was inoculated with SPG instead of Cpn 
(uninfected controls). Lung tissue was analysed for 
the presence of viable Cpn by culture and Cpn DNA 
by quantitative PCR. The descending aorta from six 
mice per group was cut into rings and the force of 
contraction of the rings was measured with an 
isometric force-displacement transducer with 
computerised system (EMKA 2000, France). 
Endothelial function was measured as relaxation 
response to different concentrations of Methacholine 
(MC) in the rings precontracted with noradrenaline. 
In addition, the effects of NOS enzyme inhibitor (L-
NAME) and nonselective COX inhibitor (diclofenac) 
on the arterial relaxation were measured. 
Treatments had no marked effect on the number of 
Cpn genomes in lung tissue (quercetin: l ,34xl06 ; 
luteolin: l ,15xl0 6 ; control: 0,79xl06 genomes in 50 
mg of tissue), but significant decrease compared to 
infected controls was found in the numbers of 
infectious chlamydia (controls: 38863 IFUs/2 ml of 
lung tissue homogenate; quercetin: 10721, p=0.021; 
luteolin: 8471, p=0.02;). Neither Cpn nor chlamydial 
DNA was detected in the uninfected control groups. 
MC-induced relaxation of the aortic rings from 
uninfected mice was significantly reduced after L-
NAME, but not after diclofenac pretreatment. 
However, Cpn inoculation further impaired the 
relaxation response after both of these pretreatments. 
In the aortas without any pretreatments, infection 
impaired the relaxation response slightly but not 
significantly. The impairing effect of infection was 
completely abolished in the aortas of quercetin-
treated mice after L-Name pretreatment and slightly 
after diclofenac. In the aortas from luteolin-treated 
mice, this kind of improvement of the endothelial 
function was not detected. 
Although both quercetin and luteolin significantly 
decreased the presence of infectious chlamydia in the 
lungs at four days p.i., the number of genomes were 
not affected. Our preliminary results from a follow-up 
study show that similar quercetin treatment at later 
time points, especially at six and ten days p.i., more 
likely causes an increase in the Cpn counts in the 
lungs. Quercetin and luteolin were highly 
chlamydiacidal in cell cultures in vitro, but our 
studies suggest that the improvement of endothelial 
function in quercetin-treated mice is not directly due 
to decreased chlamydial load in the mice. The effect 
of L-NAME pretreatment on the aortas showed that 
infection impaired the endothelium-dependent, NO-
mediated arterial relaxation in the aortas, as reported 
in apoE-ko mice also by Liuba et al. (2000). Further 
analyses are needed to find out whether the decreased 
NO availability is a result from impaired NOS 
function or increased NO consumption. Diclofenac 
had no effect on endothelial function in uninfected 
mice but further impaired the relaxation in the aortas 
of infected mice. Thus, COX-mediated relaxation 
may also contribute to the endothelial dysfunction in 
this model. The effects of quercetin may be through 
preventing inflammation and oxidative reactions and 
thus sparing the use of available NO. 
Reference Liuba P. et al. 2000. Circulation 
102:1039-1044. 
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Atherosclerosis is considered as a 
combination of chronic inflammation and 
endothelial cholesterol accumulation, and 
chronic C. pneumoniae infection may 
contribute to its pathogenesis. The inhibitors of 
cholesterol synthesis, statins, are widely used 
in hypercholesterolemic patients to lower 
cholesterol levels, and evidently several statins 
also have antibacterial and immunomodulatory 
effects. The aim was to study, using a C. 
pneumoniae mouse model, how lipophilic 
simvastatin affects chlamydial viability, as 
well as the development of inflammatory and 
immune response during acute primary 
infection, and further, if outcome differs in the 
mice fed a fat diet. 
Eight to nine weeks-old female NIH/S 
mice were used, and they were fed either 
autoclaved regular diet or irradiated fat diet 
(21% total fat, 0.2% cholesterol and 19.5% 
casein. Simvastatin (L-644, a gift from Merck) 
was dissolved in 1 % dimethylsulfoxide 
(DMSO). Daily treatment (0.5 mg/kg) was 
given intraperitoneally in 100 pi volume for 24 
consecutive days. Separate group of mice was 
injected with the respective DMSO vehicle. 
Three days after the initiation of the statin 
treatment (day 0), the mice were intranasally 
inoculated with 5.3* 105 inclusion-forming 
units (IFU) of C. pneumoniae Kajaani 7 isolate 
in 40 pi of saccharose phosphate glutamate 
solution (SPG) during methoxyflurane 
anesthesia. Control mice in both groups were 
inoculated similarly with 40 pi of SPG. 
Samples were taken up to day 20 postinfection 
(p.i.). Chlamydias were cultured from the lung 
in HL cells in several dilutions. After 72h of 
incubation, the cells were methanol-fixed and 
stained with chlamydia LPS-specific FITC-
conjugated monoclonal antibody. IgG 
antibodies specific for C. pneumoniae were 
measured by EIA. Inflammatory changes in the 
lungs were determined from formalin-fixed 
lung sections stained with hematoxylin and 
eosin. Changes were given a histology score 
from 1 to 5, depending on the amount of 
mononuclear cells and the area affected. Serum 
total cholesterol and triglycerides were 
measured with fully enzymatic methods. 
Simvastatin treatment decreased IFU 
counts 65 to 80 % compared to untreated mice 
on a regular diet, and 55 to 82 % in the mice 
fed with a fat diet. These reductions were seen 
at the early stages of infection (days 3 and 6 
p.i.). Simvastatin treatment alone did not 
significantly affect C. pneumoniae IgG levels 
in the regular diet fed mice, but in the fat diet 
fed mice, simvastatin treatment slightly 
increased C. pneumoniae IgG levels. In regular 
diet fed mice, at each time point, there was a 
slight increase in mononuclear cell infiltrates 
due to simvastatin treatment. A temporary 
reduction in inflammatory cell infiltrates in the 
lungs was seen in simvastatin treated mice fed 
a fat diet. Fat diet feeding alone caused a 71 % 
increase in total cholesterol levels. Feeding the 
mice with fat diet increased triglyceride levels 
by 38 %. Serum lipid levels did not decrease 
due to simvastatin treatment. 
In the present study we showed that 
simvastatin treatment exhibits in vivo anti-
chlamydia and immunomodulatory effects in 
NIH/S mice. 
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The objective of this study was to 
assess inflammatory modification of the 
extracellular matrix in the female mouse 
urogenital tract as a consequence of chlamydial 
infection. 
Female C3H/HeN mice were 
inoculated intravaginally with Chlamydia, 
muridarum. Following culture confirmation of 
the infection, groups of mice were euthanized 
at intervals that represented different phases of 
acute and chronic inflammatory response. 
Upper genital tracts (uterus, oviduct, and 
ovary) were fixed in neutral buffered formalin 
or embedded in OCT and frozen at -70° C. 
Serial 5 pm sections of formalin-fixed, 
paraffin embedded tissues were cut, stained 
using Masson Trichrome stain or hematoxylin 
and eosin. Serial 5 pm sections of frozen tissue 
were also cut and stained by routine 
immunohistochemical methods for matrix 
metalloproteinase-9 or various collagen types. 
Some frozen sections were also assessed using 
in situ zymography to detect elastases and 
collagenases. At day 56, post-infection, a dye 
trace technique was used to ascertain the 
occurrence of oviduct occlusion as a post-
infection sequela in this model. Evan's blue 
(0.5% in phosphate-buffered saline, pH 7.2) 
was instilled into the uterine horn and the 
progress of the dye through the distal uterus 
and into the oviduct was monitored on a 
dissecting microscope set at 20X 
magnification. 
As has been previously reported, we 
observed acute inflammation within 4 days of 
infection. The acute response ascended with 
the infection from the uterus to the oviduct and 
associated serosa by days 7-10 and peaked 
with a vigorous infiltrate in most tissues by 10-
14 days post-infection. Denudement and 
sloughing of large portions of the epithelium, 
apparently as a result of damage to the 
underlying basal lamina, occurred only in 
regions sustaining significant acute 
inflammation (segmented neutrophils). A 
primary constituent molecule of the basal 
lamina was determined to be type IV collagen 
- a known substrate for MMP-9. The 
cytoplasm of neutrophils infiltrating the 
affected tissue stained intensely for MMP-9 
and this appeared to be discharged upon 
contact with or following migration across the 
epithelium. Acute inflammation was also 
associated with elastase and collagenase 
activity as detected by in situ zymography. 
Fibroblasts of the substantia propria in both 
infected and uninfected tissues also stained 
intensely for type IV collagen. Severe 
inflammatory damage to the oviduct 
epithelium was followed by a failure to restore 
normal oviduct architecture and a propensity to 
replace normal tissue with fibrotic tissue (as 
assessed by Masson trichrome stain) in the 
subepithelium of the isthmus and in the 
oviduct lumen as observed in sections derived 
from several mice. Fibrotic occlusion of the 
oviduct was observed in several sections that 
also displayed hydrosalpinx. The use of a dye 
trace technique indicated that all oviducts from 
previously infected mice (40 of 40) were 
occluded but only 7 of 40 of the uninfected 
controls failed to allow dye to pass into and 
through the oviduct. 
The nature and severity of the acute 
inflammatory response is likely to account for 
the damage leading to occluded oviducts in 
this model. One effector of this damage may 
be neutrophil elaborated MMP-9. 
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PREGNANT MOUSE MODEL 
K. Kerr* \ M.Livingstone1, I.E. Anderson1, G. Entrican1, D. McKeever1'2, D. Buxton1 
and D. Longbottom1 
1 2 
Moredun Research Institute, Pentlands Science Park, UK; Department of Veterinary Clinical 
Studies, Easter Bush, University of Edinburgh, UK 
Chlamydophila abortus targets the 
placenta, causing tissue damage, inflammation 
and abortion (1). Ruminants are the principal 
hosts, although humans are susceptible to 
infection. C. abortus is the main infectious 
cause of abortion in ewes in the UK and results 
in major economic losses to the agricultural 
industry. A pregnant mouse model has been 
developed to investigate immune responses 
and disease pathogenesis for comparison with 
the ovine disease. The aim of this study was to 
define the immunopathological responses in 
this model, specifically characterising immune 
cell subpopulations and cytokine expression. 
CBA (H-2k) mice were inoculated 
intraperitoneally with 106 inclusion forming 
units of C. abortus (strain S 26/3) on day 11 of 
gestation. PBS was administered to control 
mice at the same time. On days 3, 5, 6 and 7 
post-inoculation (p.i.), post-mortem 
examinations were carried out. Samples of 
liver, spleen and foetal-placental units were 
collected into 10% formalin for the detection 
of chlamydial antigen by immunoperoxidase 
labelling, into zinc-salts fixative to characterise 
immune cells by immuno-histochemistry and 
into 4% paraformaldehyde for in situ 
hybridization for the detection of cytokines. 
Liver and foetal-placental units were sampled 
in sucrose phosphate glutamate to assess 
infectivity by culturing live organisms on 
McCoy cell monolayers. Serum samples were 
collected pre- and post-infection, to 
characterize antibody isotypes and cytokine 
levels by ELISA. 
Inoculation of pregnant mice with C. 
abortus caused abortion on days 6-8 p.i.. 
Infected cells were found at the maternal-foetal 
interface on days 3 and 5 p.i.. Chlamydial 
inclusions were scattered throughout the 
trophoblastic labyrinth of the placenta between 
days 3 and 7 p.i., which immediately preceded 
abortion. Infected areas were accompanied by 
a maternal mononuclear inflammatory cellular 
infiltrate. C. abortus was cultured from both 
maternal and foetal tissues, with higher 
numbers present in placenta, the target organ. 
Antibody isotypes have been identified against 
whole EBs. The role of the inflammatory 
response in disease pathogenesis including the 
characterisation of cellular phenotypes and the 
cytokine message, both in situ and in serum are 
under investigation. 
Chlamydial antigen has been identified 
in maternal and foetal tissues and 
polymorphonuclear neutrophils are present in 
close proximity to infection sites as observed 
in the natural ovine host of C. abortus (1). The 
defining of the immune response to C. abortus 
infection will help in the identification of 
novel protective mechanisms. 
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To identify genetic correlates of a 
phenotypic shift in susceptibility to macrolide 
(MCD) antibiotics of clinical Cp isolates persisting 
despite azithromycin (AZM) therapy. 
Two patients with respiratory Cp infe-
ctions failed to eradicate the organism after AZ 
therapy. The isolates exhibited a stable, 4-X 
increase in MIC to erythromycin (ERY) and AZM, 
relative to pre-rx isolates. A comprehensive search 
of known and potential MCD resistance 
^determinants was undertaken by 1) identifying 
homologues in the Cp genome; 2) designing PCR 
primers to amplify these potential genes and their 
putative promoter regions; and 3) sequencing the 
PCR targets from pre- and post-rx isolates. DNA 
was prepared from 2 pre-rx, and 3 post-rx Cp 
isolates. PCR and sequencing of the MCD-binding 
region of the 23S rRNA of these isolates were 
previously described, as was the attempt to find an 
erm (ERY ribosomal methylase) homologue using 
degenerate PCR; these methods failed to reveal a 
mechanism of resistance. New primers were 
designed to amplify the MCD contact regions of 
ribosomal proteins L4 and L22, which have MCD 
resistance mutations in some bacteria. A compa-
rison of other proteins involved in MCD resistance 
revealed significant homologies in the Cp genome. 
Three S. aureus proteins had chlamydial 
homologues. The ermA gene, a 23S rRNA 
ribosomal methylase, has 24% identity and 42% 
similarity over its first 215aa to the Cp 
dimethyadenosine transferase gene, known as the 
kasugamycin resistance gene (ksgA). KsgA 
methylates the 16S rRNA, and KsgA mutants are 
implicated in MCD hypersusceptibility in E. coli. 
Second, the MCD efflux gene product (MefA) has 
homology to a Cp putative efflux protein (YgeD), 
with 23% identity and 41% similarity in its N-
terminal one-third. Finally, the virginiamycin 
(streptogramin) resistance gene product (VgaB), 
an ATP-binding efflux pump, shares 32% identity 
and 53% homology over its C-terminal two-thirds 
with the chlamydial yjjK gene, encoding a putative 
ATP-binding transporter. Notably, the MCD-
streptogramin resistance gene product MsrC of E. 
fecalis was homologous to both VgaB and YjjK. 
VgaB gene product also showed limited homology 
to chlamydial ATP-binding proteins (yhbC, oppB), 
exclusively in their ATP-binding domains. No no 
significant homologies could be found in the 
chlamydia genomes to MCD hydrolases (vgbA, 
vgbB), esterases (ereA, ereB), phosphorylases 
(mphA), transferases (InuA) or gram-negative 
multi-drug efflux proteins (acrAB, TolCj.PCR was 
performed using 25 pM primers, 1.5mM MgCl2, 
and denaturation at 95°C x 5min, then 30 cycles of 
94°C x 30sec, 60°C x 30sec, 72°C x 30sec, 
followed by extension at 72°C x 7 min. The 
annealing temperature was 50 °C for the yjjK PCR. 
The PCR fragments were resolved on a 1% 
agarose gel, then spin-column purified and 
sequenced in both directions utilizing the 
individual PCR primers. BLAST2 program 
http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html 
was used to compare sequencing data to the 4 
reference Cp sequences in GenBank. 
Single bands were obtained from each of 
the L4, L22, ksgA, ygeD and yjjK PCR reactions, 
and except for ksgA, each DNA sequence was 
identical to the 4 reference Cp. While ambiguous 
bases were seen at some sites in the sequence, or 
rarely in one direction of sequencing, they were 
specifically absent at the key regions of interest, 
suggesting the absence of minority populations in 
the amplicon. The ksgA gene has 2 known 
polymorphisms, with K108T and R161K 
mutations found only in the Cp TW-183. 
It is fortunately difficult to induce drug 
resistance to MCD or quinolones in Cp. Recently, 
phenotypic and genotypic MCD resistance has 
been described in C. trachomatis (Ct) clinical 
isolates, while in our study only subtle phenotypic 
resistance was demonstrated. We have developed 
PCR sequencing protocols to identify potential 
MCD resistance determinants. A broad search of 
all known MCD targets failed to define a 
genotypic change in the Cp isolates. Phenotypic 
changes in the MCD susceptibility in these isolates 
may be due to alterations in expression of these 
genes, heterogeneous expression of resistance in 
the population, or entirely new targets. 
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WHY IS CHLAMYDIA PNEUMONIAE (CP) RESISTANT TO TRIMETHOPRIM 
(TMP)? 
Paul F. Riska1, Stephan Kohlhoff2 and Margaret R. Hammerschlag1'2 
Departments of 'Medicine and Pediatrics, State University of New York Downstate Medical 
Center, Brooklyn, New York, USA 
To identify the basis for TMP 
resistance in Cp - is it due to the sequence of 
the TMP target, the dihydrofolate reductase 
enzyme (DHFR) or to ineffective drug uptake 
or drug efflux. 
We had previously shown that Cp is 
highly resistant to TMP (MIC >128 ug/ml) but 
susceptible to a novel DHFR inhibitor, 
Iclaprim (ICL, Arpida, Ltd) which has an MIC 
of 0.5 ug/ml (Kohlhoff, ICAAC, 2003). We 
reasoned that if the Cp DHFR is intrinsically 
resistant to TMP, then expressing it in E. coli 
should protect the recombinant strain from 
killing by TMP. Since overexpressed E. coli 
DHFR protein has itself been shown to 
increase TMP MIC's, we expressed an E. coli 
DHFR gene in parallel experiments. 
Specifically, primers were designed to amplify 
the entire DHFR gene, designated folA from 
both Cp (514bp) and E. coli strain K12 
(480bp). The PCR fragments were cloned into 
the PET 100 vector (Invitrogen) which was 
then used to transform E. coli BL21. Plasmid 
integrity was confirmed by restriction enzyme 
analysis. In this strain, conditional expression 
of the inserted folA gene occurs after IPTG is 
added to the media. Of note, the recombinant 
DHFR enzyme produced carries an N-terminal 
6-His peptide tag, allowing detection and 
purification. 
Protein induction was verified after 3 and 24 
hrs of induction by IPTG, by loading protein 
fractions onto a 14% SDS-PAGE, revealed by 
a 6-His specific fluorescent detection system 
(InVision, Invitrogen). 
Microplate MIC 's for TMP were performed 
for the recombinant E. coli strains using 2-fold 
dilutions of TMP (Sigma) froml28 to 0.25 
ug/ml. Each starin was either induced with 
IPTG (0.25 to 1 mM) overnight or uninduced 
in these experiments. 
Recombinant DHFR was highly 
induced at 3 h and even more at 24 hrs after 
IPTG, as new bands appeared on the protein 
gel stained to show 6-His proteins. 
The recombinant DHFR enzymes appeared to 
be fully functional in E. coli treated with TMP. 
Specifically, untransformed or vector-
transformed E. coli had a TMP MIC of 1 
ug/ml, regardless of IPTG. E. coli bearing an 
extra E. coli folA gene had an MIC increased 
to 8 ug/ml upon IPTG induction, while the Cp 
DHFR recombinant strain had an MIC of 128 
ug/ml after IPTG induction. 
A Cp DHFR gene expressed in E. coli 
can complement the host gene, which allows 
the E. coli strain to survive in the presence of 
up to 64 ug/ml of TMP. While extra copies of 
the native E. coli gene also boost the MIC, 
presumably by "soaking up" TMP, the effect 
of the Cp gene at comparable expression levels 
is far more dramatic, indicating greater 
intrinsic resistance of the Cp enzyme to TMP. 
This resistance seems sufficient to explain the 
non-susceptibility of Cp to TMP in vivo. 
Future work will aim to determine whether 
ICL can bind the Cp DHFR enzyme. The 
availability of the recombinant enzyme will 
also facilitate in vitro screening of other 
potential DHFR inhibitors which may have 
activity against the chlamydiae. 
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GENETIC VARIABILITY OF ANTIMICROBIAL RESISTANCE TO 
RIFAMPIN AND RIFALAZIL IN CHLAMYDIA PNEUMONIAE AND 
CHLAMYDIA TRACHOMATIS 
Andrei Kutlin1, Paul Riska2, Stephan Kohlhoff1, Pat Roblin1 and Margaret R. 
Hammerschlag1 
Departments of Pediatrics1 and Medicine2, State University of New York Downstate Medical 
Center, Brooklyn, New York, USA 
Data on treatment of C. pneumoniae 
infection are limited and microbiologic failure 
has been described. Although rifamycins have 
excellent activity against C. pneumoniae and 
C. trachomatis in vitro, concerns about 
development of resistance has prevented them 
from being used for treatment of chlamydial 
infections. Rifalazil (RFL), a new 
semisynthetic rifamycin with a long half-life, 
is the most potent antimicrobial against C. 
pneumoniae and C. trachomatis, thus may 
have potential for treatment of acute and 
chronic C. pneumoniae and C. trachomatis 
infections. We investigated the effect of 
passage of C. pneumoniae and C. trachomatis 
in subinhibitory concentrations of RFL and 
rifampin (RIF) on the development of 
resistance in vitro. 
HEp-2 cells were inoculated with C. 
trachomatis UW-3/Cx/D and BU-434/L2 and 
C. pneumoniae TW-183 and CWL-029, 
incubated in 1/8-1/2 MIC concentrations of 
each drug. After 6-12 passages MICs were 
performed. DNA from the original and post rx 
cultures was extracted. PCR fragments 
covering predicted rifamycin resistance region 
in the rpoB gene were sequenced for C. 
pneumoniae and C. trachomatis. Additionally, 
two PCR fragments covering the entire 3759 
bp rpoB gene of C. trachomatis 434/L2 were 
also sequenced. 
MICs for C. trachomatis increased 1.6-
3.2xl04 and 5.0xl02 X times for RIF and RFL, 
respectively. In contrast, the MICs for RIF and 
RFL for C. pneumoniae TW-183 increased 7.5 
and 4 X times after 6 passages; and 31.25 and 
16 X times after 12 passages. Cross-resistance 
was demonstrated with both species. No 
resistance was observed with C. pneumoniae 
CWL-029. 
The MIC and sequencing results are shown 
below: 
Strain Drug MIC (pg/ml) Mutation 
initial 6 pass 12 pass 
TW-183 RIF 0.008 0.06 0.25 L456I 
RFL 0.001 0.004 0.016 D461E 
CWL029 RIF 0.016 0.016 0.016 -
RFL 0.001 0.001 0.002 -
D RIF 0.008 128 ND H471Y 
RFL 0.001 0.5 N D H471Y 
L2 RIF 0.008 256 ND None 
RFL 0.002 1.0 ND V136F 
Two mutational changes were found in the 
predicted rifamycin resistance region of the 
rpoB gene in RIF and RFL resistant C. 
pneumoniae. One mutation was detected in 
RIF and RFL resistant C. trachomatis UW-
3/Cx/D. No mutations were found in the 
resistance region of the rpoB gene of resistant 
C. trachomatis 434/L2. However, sequencing 
of the entire rpoB gene showed a mutation 
upstream of that predicted resistance region in 
RFL resistant C. trachomatis 434/L2. 
Passage in subinhibitory concentrations 
of RFL and RIF induced development of 
resistance in both chlamydial species with 
higher-level resistance for C. trachomatis than 
for C. pneumoniae. One C. pneumoniae isolate 
failed to develop resistence to either drug. RFL 
appeared to induce resistance to a lesser degree 
than RIF. This is the first description of 
antibiotic resistance-associated mutations in C. 
pneumoniae and of RIF resistance in C. 
trachomatis not associated with mutations in 
the rpoB gene. Clinical significance of these 
findings is not clear and should be further 
investigated. 
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COMPARATIVE RANDOMIZED PILOT STUDY OF AZITHROMYCIN AND 
DOXYCYCLINE EFFICACY AND TOLERABILITY IN THE TREATMENT OF 
PROSTATE INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS 
Ivan Krhen1, Visnja Skerk2, Miroslav Lisic2, Josip Begovac2, Srdan Roglic2, Vedrana 
Skerk3, Suncanica Ljubin Sternak4, Artur Banaszak5, Jadranka Strugar-Suica5, Jacinta 
Vukovic5, Velimir Milosevic1* 
1 2 
Clinical Hospital Centre Rebro, Zagreb, University Hospital for Infectious Diseases "Dr. Fran 
Mihaljevic", Zagreb, 3Medical Faculty, University of Zagreb, 4Croatian National Institute of Public 
Health, Zagreb, 5Pliva d.o.o. Pharmaceutical Company, Zagreb, Croatia 
A total of 125 patients were examined, 
older than 18 years of age, with symptoms of 
chronic prostatitis and presence of Chlamydia 
trachomatis confirmed by DNA/RNA 
hybridization method and/or by isolation on 
McCoy culture and—by immunofluorescent 
typing with monoclonal antibodies in 
expressed prostatic secretion or in voided 
bladder urine collected immediately after 
prostatic massage. 
The patients were randomized in ratio 
2/1; azithromycin/doxycycline, to receive a 
total of 4,0 g azithromycin for 4 weeks, given 
as a single, 1-day therapy of 1 x 1000 mg 
weekly for 4 weeks or doxycycyline 100 mg 
b.i.d. for 28 days. Patient's sexual partners 
were treated at the same time. Clinical and 
bacteriological efficacy were evaluated 4-6 
weeks after the end of therapy. 
In the group of patients with chlamydial 
infection of prostate, the eradication rates 
(azithromycin 65/82, doxycycline 33/43; 
p=0,82) and the clinical cure rates 
(azithromycin 56/82, doxycycline 30/43; 
p=0,94) were not significantly different with 
regards to the administered drug. 
380- TREATMENT 
EFFICIENCY OF JOSAMYCIN (WILPRAFEN®) IN TREATMENT OF 
GENITAL CHLAMYDIA TRACHOMATIS INFECTION 
N.E.Vorobyova, E.V. Sokolovsky, N.K. Selimyan*, E.V. Shipitsyna*, K.V. Shalepo*, 
T.A. Khusnutdinova*, M.A. Bashmakova*, A.M. Savicheva* 
The LP. Pavlov Medical University, St.-Petersburg, *The D.O. Ott Research Institute of Obstetrics 
and Gynecology, St.-Petersburg, Russia 
Monitoring of Josamycin (Wilprafen®) 
therapy of genital C. trachomatis infection. 
C. trachomatis infection was treated in 
47 patients (32 women and 15 men) with 
Josamycin (Wilprafen®) (500 mg twice a day 
for 10 days). 
C. trachomatis were detected in 
cervical swabs from women and urethral 
swabs from men using cell culture and PCR. 
Follow-up examinations were carried out on 
the 2, 5, 7, 10 day of treatment, and 1, 2, 3 
weeks and 1, 3, 6 months post therapy. 
In 20 patients C. trachomatis were 
isolated in cell culture on 2 day of the therapy. 
In none of the patients C. trachomatis were 
found using cell culture 5 days after beginning 
of the treatment. By PCR chlamydiae were 
detected in 93% of the patients on the 2 day 
and in 51%, 36%, 19% - on the 5, 7, 10 day of 
the therapy, respectively. In none of the 
patients C. trachomatis were found 1, 2, and 3 
weeks after beginning of the treatment. 
In 4 patients chlamydiae were repeatedly 
detected after treatment both by cell culture 
and PCR: in one woman and one man - one 
month, in one woman - 3 months, and in one 
man - 6 months after completing therapy. 
Josamycin (Wilprafen®) was shown to 
be effective in the treatment of C. trachomatis 
infection. There were 4 cases of recurrent 
chlamydial infection, reinfection cannot be 
completely excluded. 
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TREATMENT OF UPPER GENITAL TRACT CHLAMYDIA TRACHOMATIS 
INFECTION BY STIMULATING SUPER OXIDE DEFENSE SYSTEM 
Mavrov G.I., Kondakova A.K. 
Institute for Dermatology and Venereology Academy of Medical Sciences of Ukraine, Kharkiv, 
Ukraine 
Objective: To study condition of 
oxidant-antioxidant system in patients with 
genital chlamydiosis as a factor of unspecific 
of host resistance to infection; 
to study the efficacy and endurance of high 
doses of josamicin (1.5 g per day, during 20 
days) in a combination with echinacin (200 
mg) and silibinin (420 mg) in treatment of 
patients with upper genital tract symptomatic 
C. trachomatis infection. 
Blood samples from 33 patients with 
upper genital tract symptomatic C. trachomatis 
infection (main group) and from 27 healthy 
donors (control group) were investigated. 
Antioxidant activity of blood plasma, level of 
general lipids in blood serum, peroxide 
hemolysis of erythrocytes, level of Malone 
aldehyde in serum and in erythrocytes were 
determined. Josamicin was used in 86 patients 
with C. trachomatis genital infection (42 males 
and 44 females). All patients had been 
suffering chronic infection (from 1 to 5 years). 
Women were with pelvic inflammatory 
disease; men - with urethroprostatitis. The 
average age of the patients was 28. 
C. trachomatis was indicated by direct 
immunofluorescence (MIF) and polymerase 
chain reaction (PCR). In cases of MIF and 
PCR discordant results the diagnostic culture 
in L-929 cells was performed. 
In the patients with complicated 
chlamydiosis the decrease of functional 
activity of antioxidant system of an organism 
was observed which is accompanied by 
activation of peroxide lipid oxidation. Serum 
level of general lipids (g/T) in donors was 
4.3+0.6, in patients - 4.6+0.8. Malone 
aldehyde level in plasma (pMol/ml) 
respectively - 0.7±0.1 and 1.2+0.4. Malone 
aldehyde level in erythrocytes (pMol/ml) -
8.5+2.3 and 15.4 +3.5. Antioxidant activity of 
plasma (%) was 42.4+6.1 and 35.7+9.2. 
Antioxidant activity of erythrocytes (%) was 
respectively 8.8±1.2 and 4.2+1.8. 
Ceruloplasmin activity in plasma (mg/l) in 
donors was 380 +75; in patients was - 320+90. 
Peroxide hemolysis of erythrocytes (%) was 
respectively 9.2+0.9 and 16.8+1.6/ and 
catalyza activity in erythrocytes (%) was 
measured as 75.3+5.5 in donors and 51.2+8.4 
in patients. 
Substantial clinical improvement was observed 
after treatment with josamicin in a 
combination with echinacin and silibinin in 83 
(96.5±1.8 %) patients. The function of a liver 
was not changed significantly during 
treatment. Two (2.3 %) patients reported side 
effects as nausea and sick feelings in a 
stomach, which, however, did not, required 
cancellation. After-treatment control tests (in 1 
and 3 months) revealed C. trachomatis in 3 
(3.6%) patients. Thus the microbiological 
effect of treatment was observed in 85 
(98.8+1.1%) patients. 
It is necessary to take into account a 
dislocation of balance between free-radical and 
antioxidant systems when treating patients 
with chronic complicated upper genital tract 
C. trachomatis infection. A conclusion was 
made about high doses of josamicin efficiency 
for treatment of upper genital tract Chlamydia 
trachomatis infection in a combination with 
echinacin and silibinin. 
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EFFICACY OF COMBINED TREATMENT OF CHRONIC GENITAL 
INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS 
A.A. Khryanin* 
Novosibirsk State Medical University, Novosibirsk, Russia 
Chlamydia trachomatis is the most 
common cause of pelvic inflammatory disease 
in industrialised countries, and is an important 
cause of female and male infertility worldwide. 
Genital infections caused by C. trachomatis 
initiate and maintain the inflammatory process 
but are usually asymptomatic. Oral enzymes 
(OE) therapy (phlogenzim) is based on 
complex therapeutic capabilities of a 
combination of plant (bromelin) and animal 
proteolytic (trypsin) enzymes and rutosid. Due 
to its pathophysiological action OE shows 
antiinflammatory, antiedematous, fibrinolytic 
efficiency and demonstrates modulating of the 
immune system by chronic inflammation. 
To investigate efficacy of combined 
therapy with doxycycline monohydrate (unidox 
solutab) and oral enzymes (phlogenzim) in 
patients with chronic Chlamydia trachomatis 
infections. 
The study involved 84 patients with 
chronic genital infections caused by C. 
trachomatis (54 males and 33 females). Male 
urethral swabs and female endocervical smears 
were examined for C. trachomatis infection 
using transcription-mediated amplification 
(PACE 2 System for Chlamydia trachomatis, 
Gen-Probe Incorporated, San Diego, CA, 
USA) initially and 1-2 months after 
completion of treatment. All patients of the 
main group (n=42) received optimal antibiotic 
therapy (doxycycline monohydrate) combined 
with OE therapy (phlogenzim): doxycycline 
monohydrate (unidox solutab) was given at a 
dosage of 1 tablet (100 mg) two times a day 
(after meal) for 10 days; OE (phlogenzim) was 
given at a dosage of 3 tablets two times a day 
(30 min. before meal) for 14 days. The control 
group (n=42) received monotherapy with 
antibiotic. 
The efficacy of combined therapy 
(doxycycline monohydrate and phlogenzim) in 
the main group of patients was 97.6%. In the 
control group of patients treated with antibiotic 
only the efficacy of treatment was 78.6% 
(OR=11.2; 95% CI 1.3-247.9; p=0.007). The 
patients of the main group reported of no side 
effects of the therapy. 6.5% of the patients in 
the control group were found to have side 
effects. 
Phlogenzim increases effectiveness of 
unidox solutab 19% and efficacy of the 
combined therapy in patients is 97.6%. OE 
appears to decrease side effects of antibiotic 
therapy. Oral proteolytic enzymes therapy is 
recommended as effective pathogenic therapy 
of chronic genital infections caused by C. 
trachomatis. 
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Chlamydia trachomatis is the most 
common sexually transmitted bacteria 
worldwide and one of the etiological 
microorganisms of chronic prostatitis (CP). 
Doxycycline and azithromycin are 
recommended as the primary but ofloxacin and 
levofloxacin as alternative drugs in the 
treatment of chlamydial infections. 
Fluoroquinolones are recommended in the 
treatment of CP because of their 
pharmacokinetic profile. The causes of 
antimicrobial resistance of chlamydia in vitro 
and clinical treatment failure associated with it 
have been reported. 
In vitro activity of fluoroquinolones against 
C. trachomatis in patients with CP being not 
treated with antibiotics earlier was compared. 
C. trachomatis survival in the presence 
of few fluoroquinolones, doxycycline and 
azithromycin in total of 304 patients was 
analysed. All men, aged 19 to 54 years with 
C. trachomatis and CP symptoms for more 
then 3 months, were investigated from 
February 1998 through to May 2002. The 
patients reported constant sexual partners for a 
minimum 6 months. 
The presence of C. trachomatis, determined 
through cultures, was found in the urethra and 
in expressed prostatic secretion. The presence 
of reticulate (RB) and elementary (EB) 
chlamydia bodies in the absence (control) and 
presence of antibiotics was detected by 
luminescence microscopy. 
The mean percent of cells with 
chlamydial RB in the control and in the 
presence of ciprofloxacin (CIPX), ofloxacin 
(OFLX), pefloxacin (PFLX), lomefloxacin 
(LOMX), azithromycin (AZM) and 
doxycycline (DOX) was found to be 4.67, 
3.76, 4.18, 4.41, 3.51 and 5.08, respectively. 
Antibiotics were considered more effective 
when fewer cells with RB were found in their 
presence. Azithromycin (3.51% cells with RB) 
and ofloxacin (3.76%) were found to be the 
most active agents, with doxycycline (5.08%) 
being least active. 
Azithromycin can still play a 
significant role in the treatment of chlamydial 
infections. The prescription of doxycycline for 
many years might have led to a higher level of 
resistance in some regions. 
Ofloxacin can be recommended as the primary 
drug in the treatment of chlamydia-infected 
patients with CP. Prescription of other 
fluoroquinolones should be made individually. 
The investigation of antibiotic susceptibility in 
patients with CP and C. trachomatis prior to 
treatment is recommended. 
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Fluoroquinolones play important role in 
the therapy of pelvic inflammatory diseases, 
caused by C. trachomatis because of their 
favorable antibacterial spectrum and 
pharmacokinetic profile. For the first time 
chlamydia survival in the presence of 
lomefloxacin (LOMX) and levofloxacin 
(LVFX) in 33 patients with chronic prostatitis 
(CP) was investigated and analyzed in this 
study. 
Chlamydia survival in the presence of 
LOMX and LVFX in 33 patients, being not 
cured with antimicrobial agents earlier, was 
evaluated and compared. All men, aged 25 to 
39 (mean 34.0) years with C. trachomatis and 
lower urinary symptoms for more then 3 
months, caused by CP, were investigated from 
July 2002 through to January 2003. 
Susceptibility was tested against 2 
fluoroquinolones: LOMX and LVFX. The 
antimicrobial agent was considered the more 
effective in individual sensibility the less cells 
(%) with chlamydial reticulate bodies were 
found in tests. Chlamydia survival was 
considered as low and antimicrobial agent as 
effective in individual sensibility when no cells 
with chlamydial reticulate bodies (RBs) were 
found in tests. Meanwhile, chlamydia survival 
was considered as intermediate (I) or high (R -
resistant) when amount of cells with 
chlamydial RBs in the presence of antibiotics 
decreased as compare with the control on more 
or less than 50%, respectively. 
Chlamydia survival in the presence of 
LOMX was found to be low (6.06% patients 
with chlamydial findings) as compared with 
LVFX (30.3% patients). In the presence of 
LOMX and LVFX no cells with chlamydial 
RBs were found in 17 (57.51%) and 10 
(30.3%) patients, respectively. 
It is the first study when chlamydia 
survival in the presence of LOMX and LVFX 
was evaluated in the chlamydia-infected 
patients with CP. Methods currently used for 
in vitro chlamydia susceptibility studies are not 
analogous to the infection as it occurs in vivo. 
Thus, although in vitro antichlamydial activity 
of LOMX in patients with C. trachomatis and 
prostatitis was found to be more effective than 
LVFX, further clinical trials of these agents are 
recommended. 
It seems to be more apt to investigate 
antichlamydial activity of antibiotics in 
chlamydia-infected patients with CP, prior to 
therapy, to minimize possible clinical failures 
as well. 
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DETERMINANTS OF CHLAMYDIA IMMUNITY AND VACCINE EFFICACY 
Joseph U. Igietseme*, Francis Eko, Qing He, Godwin Ananaba, Teresa Brown, Claudiu 
Bandea, Godwin Ifere, Deborah Lyn and Carolyn M. Black 
National Center for Infectious Diseases, CDC, Atlanta GA and Morehouse School of Medicine, 
Atlanta, GA, USA 
The study objective was to define the 
immunologic and antigenic conditions for 
inducing protective chlamydial immunity, and 
to validate these paradigms as determinants of 
the efficacy of experimental vaccines. 
C57BL/6 mice (6wk) were vaginally 
infected with C. trachomatis serovar D. After 
6 wk, chlamydia-specific T cells of CD4 and 
CD8 phenotypes were cloned from genital tract 
draining iliac lymph nodes and characterized 
as T helper (Th) type 1 or 2, as previously 
described (1). Graded doses of clones were 
adoptively transferred into naive syngeneic 
mice at various times before and after genital 
challenge. The course of infection was 
monitored by cervico-vaginal swabbing and 
culture isolation of chlamydiae (7). Also, we 
produced four experimental chlamydial 
vaccines consisting of selected membrane 
proteins (MOMP, ompA, omcA, omcB and 
PorB) delivered as single and multiple subunits 
with ISCOMS or recombinant Vibrio cholerae 
ghosts, and chlamydiae delivered with specific 
antibodies (2-4). The immunogenicity (Thl 
and IgG/IgA responses) and vaccine efficacy 
of these regimens were compared to a highly 
efficacious reference experimental vaccine 
composed of chlamydia-pulsed IL-10 knockout 
dendritic cells that induced a sterilizing long 
term protective immunity (5). 
T cell clones characterized as high IFN-
y-secreting CD4 (A-l) and CD8 (B-l) cells 
transferred significant protection (P > 0.0001 
and 0.002, respectively) against genital 
chlamydial infection, although the CD4 T cell 
clones conferred a greater level of immunity. 
Also, mice that cleared their infections had 
significant levels of IgA and IgG2a in their 
cervico-vaginal secretions two weeks after cell 
transfer, suggesting an adequate T cell help for 
a humoral immune response that complements 
the protective immunity driven by T cell 
effectors (4). However, the antibody levels in 
the recipients of the CD4 Thl clone A-l were 
~ 14-fold higher than those in the recipients of 
the CD8 clone B-2, suggesting that the 
superior protection conferred by A-l was 
associated with the robust helper function. As 
previously reported (1), the ability of a clone to 
resolve an infection was dose-dependent, 
requiring high IFN-Y secretion, and coincided 
with a timely recruitment and maintenance of a 
high frequency of T cells in the genital mucosa 
of infected animals. Furthermore, the ability of 
a vaccine construct to induce protection was 
associated with the number of chlamydial 
subunits, the delivery system that fosters rapid 
processing, an early induction of elevated IL-
12 and a high mucosal Thl response. 
The immunologic basis for the apparent 
greater contribution of CD4 than CD8 Thl 
cells to chlamydial immunity was associated 
with the enhanced helper function of CD4 Thl 
cells for specific antibody response. Potentially 
protective vaccine constructs require the 
delivery of multiple chlamydial subunits, the 
induction of an early and elevated IL-12, and 
activation of a high frequency of Thl cells. 
These studies have defined and further 
clarified the immunologic and antigenic 
requirements for designing efficacious 
chlamydial vaccines. 
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A NOVEL APPROACH TO DESIGNING MULTISUBUNIT CHLAMYDIA 
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Morehouse School of Medicine, Atlanta, GA and National Center for Infectious Diseases, CDC, 
Atlanta GA, USA 
The objective of this study was to 
investigate the ability of recombinant VCG 
(rVCG) to serve as effective vaccine delivery 
vehicles and to compare the immunogenicity 
and vaccine efficacy of rVCG expressing 
single and multiple chlamydial subunits. 
Single and multiple subunit vaccine 
vectors were constructed by cloning the entire 
coding sequences, minus the leader sequences, 
of chlamydial ompl and omp2 genes into the 
membrane targeting vector pKSEL5-2. 
Expression of the fusion proteins was 
confirmed by Western blot analysis using 
monoclonal antibodies to MOMP and OMP2. 
Vibrio cholerae cells harboring the cloned 
genes were cotransformed with the lysis 
plasmid, pDKLOl. Recombinant V. cholerae 
ghosts (rVCG) expressing MOMP (rVCG-
MOMP) or MOMP/OMP2 (rVCG-Ml-2) were 
produced by protein E-mediated lysis of the 
cells as previously described1. C57BL/6 mice 
were immunized three times at 2 weekly 
intervals, intramuscularly, with lyophilized 
rVCGs (3 mg per mouse) in PBS. The vaccine 
dose was formulated to contain 2 x 109 
CFU/mg of lyophilized rVCG. Blood and 
mucosal secretions were collected from each 
animal and the serum and vaginal washes were 
pooled for each group 2. The iliac lymph nodes 
(ILN) draining the genital tract and the spleens 
(systemic draining tissues) were harvested 
from immunized mice at two and eight weeks 
postimmunization and immune T cells were 
purified by the nylon wool enrichment 
procedure as previously described3. The 
immunogenicity (Thl frequency and 
IgA/IgG2a responses) and vaccine efficacy of 
the single and multi-subunit vaccine constructs 
were evaluated and compared. 
Overall, significantly higher levels of 
Thl cells were induced by both vaccine 
constructs eight weeks postimmunization but 
the frequency of mucosal Thl cells elicited by 
the multi-subunit vaccine was 2-3 fold higher 
than that of the single subunit construct. The 
levels of IFN-gamma secreted by mucosal and 
splenic T cells from vaccinated mice also 
demonstrated the immunogenic superiority of 
the multiple subunit vaccine construct. Also, 
significant amounts of the Thl-associated 
IgG2a and IgA antibodies were detected in the 
genital tracts and sera of immunized mice, 
indicating that these vaccine constructs induce 
an effective humoral immune response 
targeted to the genital tract. Furthermore, the 
ability of the vaccine constructs to induce 
protection correlated with the number of 
chlamydial subunits and a high frequency of 
mucosal Thl response, as previously reported4. 
The results from this study have 
verified the hypothesis that rVCG could serve 
as effective bacterial delivery vehicles for 
single or multiple-subunit chlamydial vaccines 
to induce high levels of protective immune 
responses. There was a comparative vaccine 
advantage associated with the multi-subunit 
approach. Thus, rVCG harboring both 
chlamydial MOMP and the 60 kDa cysteine-
rich OMP induced up to three-fold higher 
frequency of specific Thl cells and conferred a 
greater level of protective immunity than the 
single subunit vaccine. 
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ENHANCED PROTECTIVE IMMUNITY AGAINST CHLAMYDIA BY A 
RECOMBINANT MOMP/PorB MULTI-SUBUNIT VACCINE 
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The objective of this study was to 
evaluate the vaccine advantage of a 
heterologous multi-subunit regimen composed 
of the outer membrane proteins MOMP and 
PorB delivered as a multi-subunit vaccine 
using the recombinant Vibrio cholerae ghost 
platform technology. 
Several vaccine vectors expressing the 
chlamydial MOMP and/or the outer membrane 
protein PorB were constructe d using the 
membrane targeting vector pKSEL5-2. The 
fusion proteins were expressed from Vibrio 
cholerae cells harboring the vaccine vectors 
and confirmed by immunoblot analysis. 
Recombinant V. cholerae ghosts (rVCG) 
expressing the fusion proteins were produced 
by gene ¿¿-mediated lysis of the cells as 
described previously 1. Female C57BL/6 mice 
were immunized intramuscularly, three times 
every 2 weeks, with lyophilized rVCGs (3 mg 
per mouse) reconstituted in PBS. Pooled serum 
and vaginal wash samples from each group of 
animals were analysed by ELISA2. Also, the 
iliac lymph nodes draining the genital tract and 
the spleens were harvested from immunized 
mice on weeks two and eight following 
immunization and purified immune T cells 
were evaluated for specific T cell response as 
described previously3,4. The immunogenicity 
of the vaccine constructs was correlated to the 
ability to protect mice following challenge. 
Within 2 weeks of immunization, the 
multiple subunit vaccine construct 
(rVCGMOMP/ PorB) induced high levels of 
specific Thl response (i.e. antigen-specific 
IFN-gamma production) in the mucosal and 
systemic sites of vaccinated mice. This high 
Thl response remained high up to eight weeks 
postimmunisation. Although significant levels 
of IFN-gamma that increased from two to eight 
weeks were induced by the single vaccine 
constructs (rVCG-MOMP or rVCG-PorB) 
after immunization, the level of mucosal and 
systemic Thl response induced by the multi-
subunit vaccine was significantly higher than 
that of the single subunit constructs (p> 0.002). 
Also, significant levels of IgA and the Thl-
associated IgG2a antibodies were detected in 
the genital secretions and sera of immunized 
mice. Taken together, the results indicate that 
these vaccine constructs induced both humoral 
and cellmediated mucosal and systemic 
immune responses. In addition, the protective 
efficacy of the vaccine constructs correlated 
with the level of mucosal Thl response 
elicited, as previously reported 4. 
This study has shown that rVCG are 
effective bacterial delivery vehicles for 
heterologous multi-subunit chlamydial 
vaccines for the induction of high levels of 
protective immune responses. Immunogenicity 
studies indicated that the multi-subunit 
construct induced a greater mucosal Thl 
response than either of the single subunit 
constructs. Challenge studies revealed that 
rVCG expressing both chlamydial MOMP and 
the outer membrane protein PorB conferred a 
greater level of protective immunity compared 
to the single subunit vaccines. Thus, both 
immunogenicity and protection studies support 
the hypothesis that there is a vaccine advantage 
in the utilization of a multi-subunit versus 
single subunit approach to chlamydia vaccine 
design. 
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Objective: To use expression library 
immunization (ELI) to identify gene(s) that 
elicit protection in a mouse model of infection 
against a challenge infection with C. 
trachomatis MoPn. 
Genomic DNA, isolated from cell 
culture material of C. trachomatis MoPn, was 
fragmented and ligated into pCI30 to create a 
DNA expression library. The recombinant E. 
coli clones were screened by poly-His 
detection for clones expressing chlamydial 
genes and these clones selected for use in the 
primary library screen. DNA extracted from 
pools of these clones were used in the 
immunization of BALB/c mice by gene gun 
technology. Following the immunization 
protocol the animals were challenged with a 
dose of live C. trachomatis MoPn and vaginal 
swab samples collected for analysis of 
infection status using in vitro cell culture 
techniques. The process of screening in an 
animal model was repeated until a small 
number of recombinant clones involved in 
protection against chlamydial infection were 
identified. These genes were then identified by 
sequencing. 
A C. trachomatis genomic expression 
library comprising over 20,000 recombinant 
clones was constructed in the unique pCI30 
vector that contains a poly-His fusion partner. 
The expression library was screened by poly-
His detection for clones expressing C. 
trachomatis genes and approximately 3,000 
protein expressing clones were identified and 
selected for further investigation. These clones 
were sub-divided into eight sub-libraries, and 
used to immunize groups of mice using a gene 
gun. The animals were then challenged with 
live C. trachomatis, and recovery of infectious 
particles was monitored until the infection was 
resolved in control group animals. This 
primary in vivo library screen resulted in the 
identification of a single protective sub-library 
containing 384 recombinant clones. 150 of 
these 384 clones were randomly selected and a 
two dimensional screen was established sub-
dividing the clones into 15 pools each 
containing 20 recombinant clones, to allow 
double representation of each clone in different 
pools. These pools of clones were used to 
immunize mice in a secondary animal screen 
with subsequent challenge where the infection 
was monitored until control animals displayed 
natural clearance of the infection. This 
secondary screen enabled a small number of 
clones to be identified that are able to confer 
protection against C. trachomatis genital tract 
infection. The genes involved in protection in 
the mouse model of disease have been 
identified through sequencing and are currently 
being analyzed as potential vaccine candidates. 
This study has identified a small 
number of potential vaccine antigens from an 
initial expression library of 20,000 
recombinant clones expressing chlamydial 
gene fragments through sequential library 
screening and sequence analysis. Ultimately 
these potential vaccine candidates may provide 
a means to control the severe sequelae 
associated with C. trachomatis genital tract 
infections in humans. 
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ALTERED INFLAMMATORY MEDIATORS ARE ASSOCIATED WITH 
PROTECTION BY THE ANTI-CHLAMYDIAL ANTI-IDIOTYPIC VACCINE 
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Detroit, USA 
We have previously shown that a 
molecular mimic of chlamydial glycolipid 
exoantigen (GLXA), an anti-idiotypic antibody 
(mAb2) is protective against either ocular or 
genital challenge with human ocular or 
urogenital biovars of C. trachomatis. To better 
understand the mechanisms of protective 
vaccination, we performed experiments to 
determine the impact of the mAb2 vaccine on 
local cytokine expression in a murine genital 
infection model. Because inflammation is a 
major component of chlamydial infections, we 
tested whether cytokine transcripts were 
reduced to correlate with observed reduced 
pathology and infectious loads. 
BALB/c mice were immunized S.C. 
twice with mAb2 (12 micrograms each) at a 2 
wk interval. Control donors were 
unimmunized. Spleen cells were collected and 
pooled from each group. Half of the mAb2-
immune cells were depleted of T cells by anti-
T cell Ab + C (mAb2-T); the other half were 
C. treated only (mAb2+T). Donor cells (1 
splenic equivalent) were delivered LP. into 
BALB/c-SCID recipient mice (n=5 per group) 
and 24 hr later mice were challenged topically 
vaginally with 2000 TCID50 of C. trachomatis 
(K serovar, UW-31); 5 mice which received 
normal (NL) cells were uninfected. In addition 
to culture/DFA, genital tracts and hind knees 
were collected 3 wks after challenge for 
histopathology and molecular analyses by real 
time RT-PCR (qPCR) for IFNgamma, IL-4, 
TNFalpha, iNOS, and IL-10 transcripts. Sera 
were tested by Western blotting against 
solubilized K serovar EB. 
Consistent with previous adoptive 
transfer experiments, mAb2-immune spleen 
cells reduced vaginal shedding (p<.02-.04 vs T 
depleted or vs. normal cell recipients). 
Immunoblots showed Ab responses to several 
antigens by mAb2+T or NL recipient mice. 
qPCR for several cytokines demonstrated 
consistent decreases in pro-inflammatory 
cytokine transcripts in genital tract tissues of 
mAb2+ T recipients, and transcript levels were 
often close to those for uninfected mice. 
Generally, NL and mAb2-T recipients had 
similar transcript levels. IL-4 transcripts were 
significantly higher in upper tract of recipients 
of mAb2-immune cells compared to those for 
recipients of T-depleted or NL cells (pc.01-.04 
by ANOVA on Ranks).TNFalpha transcripts 
were significantly lower in uterine horn of 
mAb2-immune cell recipients compared to 
other infected groups (pc.02). 
Our results show that the mAb2 
vaccine led to sustained decreases in genital 
tract inflammation based on mAb2-associated 
reduction in TNFalpha and increase in IL-4 
transcripts in these tissues. T cell depletion 
caused transcriptional responses in genital tract 
tissue and serum Ab responses similar to those 
for challenged recipients of non-immune cells. 
These data support a major role of mAb2-
immune T lymphocytes in protective 
immunization by this vaccine candidate since 
genital tract inflammation and infectious loads 
were increased in the absence of T cells. 
Whether Th2 are essential protective effectors 
in this model is under continuing investigation. 
Dominant IL-4 producing Th2 cells would 
favor an anti-inflammatory environment 
important in maintaining the function of 
genital tract tissue. It will be important to 
examine the effect of the mAb2 vaccine on 
inflammatory mediators at early times for 
comparison to these results at d. 21 post-
challenge. 
Supported by USPHS grant AI-44493 
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V A C C I N A T I O N W I T H T H E CHLAMYDIA TRACHOMATIS (CT) M A J O R 
O U T E R M E M B R A N E P R O T E I N ( M O M P ) C A N I N D U C E P R O T E C T I O N 
A G A I N S T A G E N I T A L C H A L L E N G E 
S. Pal, E. M. Peterson, and L. M. de la Maza* 
University of California, Irvine, Department of Pathology, Medical Sciences, Irvine, 
USA 
CT, the most common sexually 
transmitted bacterial pathogen in the world, 
can produce severe acute and chronic 
infections. In an attempt to formulate a vaccine 
we immunized mice with a preparation of the 
MOMP that was extracted and purified from 
the CT mouse pneumonitis (MoPn) serovar. 
The CT MoPn MOMP was purified 
using two zwitterionic detergents and a 
hydroxyapatite column. Eight-week old female 
BALB/c mice were vaccinated with the 
purified preparation of the CT MoPn MOMP 
using Montanide ISA 720 (Seppic Inc; 
Fairfield, NJ) and CpG (ODN 1826; Coley 
Pharmaceutical Group; Kanata, ON) as 
adjuvants. A negative control group was sham 
immunized with ovalbumin. The animals 
received three subcutaneous and intramuscular 
immunizations at two-week intervals. A 
positive control group was immunized once 
intranasally (i.n.) with 104 inclusion forming 
units (IFU) of CT. 
Following immunization serum and vaginal 
antibodies to CT were measured using an 
ELISA. The CT-specific T-cell proliferative 
response was determined using splenocytes. 
Cytokines were measured in splenocytes 
stimulated with CT elementary bodies (EB). 
Four weeks after the last immunization mice 
were challenged in the left ovarian bursa with 
105 IFU of CT, while the right ovarian bursa 
served as a control. Vaginal cultures for CT 
were collected at weekly intervals. 
Six weeks after the genital challenge, animals 
were mated twice and the status of the 
pregnancies was followed. 
After vaccination with the MOMP the 
mice developed a strong immune response as 
shown by high IgA and IgG CT-specific 
antibody titers in serum and vaginal washes. In 
addition, levels of IgG2a were higher than 
those of IgGl. Also, a robust T-cell 
proliferative response to CT EB was observed 
in splenocytes from the MOMP-immunized 
animals. Control mice vaccinated i.n. with CT 
also developed strong humoral and cell 
mediated immune responses while the negative 
controls vaccinated with albumin did not. High 
levels of IFN-gamma and very low levels of 
IL-4 were detected in supernatants from EB-
stimulated splenocytes harvested from the 
MOMP vaccinated mice and the positive 
controls immunized i.n. 
Following the genital challenge, of the mice 
vaccinated with the MOMP, only 15% (3/20; 
p<0.05) had positive vaginal cultures while 
85% (17/20) of the animals immunized with 
ovalbumin had positive cultures over the 6 
weeks of observation. Only 14% (3/21; 
p<0.05) of the animals serving as positive 
controls, that were inoculated i.n. with CT, had 
positive vaginal cultures. 
After mating, of the mice vaccinated with 
MOMP, 75% (15/20; p<0.05) had embryos in 
both uterine homs while only 10% (2/20) of 
the mice immunized with albumin had 
embryos in both uterine horns. In the group 
vaccinated i.n. with EB, 81% (17/21; p<0.05) 
of the animals had embryos in both uterine 
horns. 
Immunization with a purified 
preparation of the MOMP is as effective as 
vaccination with viable EB at eliciting a 
protective immune response in mice against a 
genital challenge with CTMoPn. 
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Objective: To determine the 
proliferative responses of NZW rabbit's 
lymphocytes to C. pneumoniae (C. pn) 
infection, DNA vaccines before and after 
infection, and crude extracts of heat killed 
organisms. 
5 groups (gp) of rabbits were studied 
with 15 animals/gp except gp V had 8 rabbits. 
Gp I control received no vaccines or infection; 
gp II were inoculated with heat killed C. pn 
alone (3 separate times, 3 wks apart); gp IH 
were infected with C. pn intranasally x 3 (3 
wks apart); gp IV were vaccinated with 76 kDa 
DNA construct of C. pn in live vector 
(ALVAC) initially followed by 2 doses of 76 
kDa protein I.M., 2 weeks apart; gp V were 
vaccinated with combined DNA constructs of 
76 kDa & MOMP in ALVAC initially, 
followed by 76 kDa protein & MOMP protein 
x 2 I.M., 2 wks apart. Gp IV & V were 
subsequently infected intranasally with C. pn x 
3, 3 wks apart. Proliferation assays by 
thymidine incorporation were performed on 
PBMC (peripheral blood mononuclear cells) at 
4 wks after the last infection or 2 wks after the 
last vaccine (gps IV & V had tests before and 
after infections). Proliferation assays were 
expressed either as delta cpm or stimulation 
index (SI). Delta cpms of > 1000 or SI > 2.0 
compared to control antigens were considered 
significant 
Infection of C. pn (without vaccines, gp 
IH) caused increased proliferation of 
lymphocytes to the mitrogen (PHA) at day 3, 
with A cpm of 2364 and SI of 5.0 (similar to 
the control gp); but no increase proliferation to 
C. pn antigens (76 kDa or crude extract) after 6 
days. Inoculation of heat killed C. pn (gp II) 
resulted in increased proliferation of PBMC 
with PHA, and with 76 kDa antigen, but not 
significantly greater than the control gp and the 
SI was not increased to C. pn antigens. Gp IV 
(single vaccine) showed proliferation to PHA 
(no greater than control gp) before infection 
with C. pn, but no significant proliferation to 
any of C. pn antigens (76 kDa, MOMP, crude-
extract). However, after infection there was 
significant increased in A cpm to PHA 
(p<0.05) and increased A cpm to 76 kDa and 
C. pn crude-extract but not significantly 
greater than the control group, and no increase 
in SI. Gp V (combined vaccine) showed strong 
lymphocyte proliferation to PHA (before and 
after infection), increased proliferative 
response to 76 kDa antigen after infection (A 
cpm 6385 vs 260 for control gp p<0.05 
(ANOVA), with SI of 2.2 before and 2.6 after 
infection (vs 1.3 for control gp, p<0.05); gp V 
also showed increase proliferative response to 
crude-extract of C. pn after infection (A cpm 
2848 vs control 0 p<0.05) but the SI was not 
increased; there was borderline increased A 
cpm to MOMP after infection (1011 vs 40 for 
control gp, p>0.05). 
Infection of the rabbits with C. 
pneumoniae did not result in increased cellular 
immunity as measured by lymphocyte 
proliferation assay. Inoculation with heat killed 
organisms resulted in borderline response in 
lymphocyte proliferation. Vaccination with 76 
kDa construct alone gave minimal lymphocyte 
proliferation response to any antigen, but 
combined with MOMP vaccine resulted in 
significant but modest lymphoblastic 
transformation. A combination of DNA 
vaccines and protein boosts maybe necessary 
to obtain optimum cellular immunity. 
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Drug discovery with high throughput 
screening requires sophisticated equipment and 
large compound libraries. As an alternative, 
smaller targeted library can be constructed 
with the 3D structure of a valid target 
molecule, but in the case of Chlamydia 
pneumoniae, no publicly available 3D crystal 
structure exists for any protein. One way to 
deal with this would be computer-aided 
homology modeling where one creates a 3D 
model of a selected target protein, using 
structural homologies with known 3D crystal 
structure, and then virtually screens molecules 
that bind to that model. Instead of creating this 
kind of model we decided to utilize virtual 
screenings inability to reliably discriminate 
ligand binding between closely related protein 
isoforms and used the 3D structure of 
structural homolog of selected C. pneumoniae 
target protein, with active site area highly 
similar to that of C. pneumoniae target protein, 
in virtual screening. The aim was to create a 
targeted library containing molecules that bind 
to the C. pneumoniae target protein and inhibit 
C. pneumoniae growth. Inhibition potential of 
the library was evaluated with a new 96-well 
plate C. pneumoniae assay, based on time-
resolved fluorometry. 
The FlexX program and the x-ray 
structure of ErmC' rna methyltransferase, a 
close structural homolog of selected C. 
pneumoniae target protein dimethyladenosine 
transferase, were used to construct the targeted 
library by virtually screening two internet 
databases of commercially available 
compounds, containing a total of 3 x 105 
molecules. Top-ranking molecules of that 
virtual screen were purchased and formed a 
small targeted library of 33 molecules. 
The targeted library was tested in new 
96-well plate C. pneumoniae assay and active 
molecule proportion was 27.3% (9 of 33). This 
number is significantly higher than could be 
expected after a random library screen. None 
of the tested compounds showed any 
cytotoxicity against host cell in preliminary 
cytotoxicity tests. 
Stmctural homolog based virtual 
screening enables creation of a targeted library, 
which reduces significantly amount of 
molecules in the primary screening assay, 
without actually doing the time consuming and 
expensive crystallization of the target protein. 
This method can be utilized whenever an 
appropriate structural homolog of a valid target 
with known 3D structure can be found. 
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O F T H E I M M U N O M O D U L A T I N G E F F E C T O F L A , 2 5 - D I H Y D R O X Y V I T A M I N 
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Verminnen K.1, Van Loock M.2, Cox E.3 and Vanrompay D.1 
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Chlamydophila psittaci causes 
respiratory infections in turkeys leading to 
important economical losses. Vaccines are 
unavailable. The present study evaluates the 
ability of recombinant MOMP and 
pcDNAl/MOMP to protect SPF turkeys 
against challenge with the homologous C. 
psittaci serovar D strain and evaluates the 
immunomodulating effects of la , 25-
dihydroxyvitamin D3 [la,25(OH)2D3], to 
elevate mucosal and serum antibody responses 
following vaccination. 
Turkeys (CNEVA Ploufragan, France) 
were reared in negative pressure isolators and 
received 2 intramuscular immunizations, the 
first at the age of 1 day and the second 3 weeks 
later. Groups 1 and 2 received rMOMP, either 
without or with la,25(OH)2D3. Group 3 
received pcDNA/MOMP. Groups 4 and 5 were 
primed with pcDNA/MOMP and boosted with 
rMOMP without or with la,25(OH)2D3. 
Group 6 served as non-immunized, infected 
control. C. psittaci serovar D (108 TCID50 of 
strain 92/1293) challenge was administered by 
aerosol, 14 days following booster vaccination. 
Severe clinical signs and macroscopic 
lesions in the respiratory tract, pericardium, 
spleen and liver and were only observed in 
control group 6. Immunofluorescence staining 
of frozen tissue sections of control group 6 
revealed strong bacterial replication in the 
respiratory tract resulting in pharyngeal and 
cloacal shedding in all birds. The best 
protection was observed in groups 3, 4 and 5 
regarding clinical signs, lesions, replication 
and bacterial excretion. Groups 1 and 2 
showed little protection. However, at 
challenge, (2 weeks following booster 
vaccination) the highest antibody responses 
were observed in the significantly protected 
groups 4 (31ogio) and 5 (3,71ogio), primed with 
DNA and boosted with rMOMP. At that time, 
antibody titres in the best protected DNA 
vaccinated group 3 were rather low (21ogio) 
but still augmenting. Antibody titres in the less 
protected groups 1 and 2 were comparable 
(2,51ogio). Supplementation of la,25(OH)2D3 
to parenteral immunization enhanced the IgA, 
IgM and IgG serum antibody titres in the 
rMOMP vaccinated group 2 but not in the 
DNA vaccinated group 5. However, 
la,25(OH)2D3 enhances mucosal IgA antibody 
titres in both groups 2 and 5. At euthanasia, 18 
days PI, proliferative responses of peripheral 
blood lymphocytes (PBL's) in groups 3 (S.I. 
14.9), 5 (S.I. 12.4) and 4 (S.I. 10!2) were 
significantly higher than for groups 2 (S.I. 7.1), 
1 (S.I. 4.0) and 6 (S.I. 1,3). 
pcDNA/MOMP vaccinated turkeys of 
group 3 were significantly protected against 
severe clinical signs and lesions, pharyngeal 
and cloacal excretion and bacterial replication 
at the respiratory tract. pcDNA/MOMP primed 
and rMOMP boosted turkeys of groups 4 and 5 
were also significantly protected as compared 
to the non-vaccinated controls. MOMP 
priming and boosting (groups 1 and 2) was less 
effective. Supplementation of la,25(OH)2D3 
enhanced the IgA mucosal antibody titres in 
both rMOMP (group 2) and DNA (group 5) 
vaccinated birds and augmented IgM, IgA and 
IgG serum antibody titres in rMOMP 
vaccinated birds. la,25(OH)2D3 also enhanced 
proliferative responses of PBL's in both 
rMOMP and DNA vaccinated birds. 
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A N E W L G V S T R A I N O F C H L A M Y D I A T R A C H O M A T I S I D E N T I F I E D I N 
M E N H A V I N G S E X W I T H M E N I N A M S T E R D A M : A N U N R E C O G N I Z E D 
O U T B R E A K 2 0 0 2 - 2 0 0 4 
Joke Spaargaren1, Han S.A. Fennema2, Servaas A. Morré3, Henry J.C. de Vries2'4, Roel 
A. Coutinho5 
'Public Health Laboratory, Municipal Health Service, 2Sexually Transmitted Disease Outpatient 
Clinic, Municipal Health Service, Laboratory of Immunogenetics, Section: Immunogenetics of 
infectious Diseases, VU, University Medical Center, 4Department of Dermatology, Academic 
Medical Centre, University of Amsterdam, 5Municipal Health Service, Academic Medical 
Center/University of Amsterdam, Department of Human Retrovirology, Amsterdam, The 
Netherlands 
Following a recent outbreak of 
lymphogranuloma venereum (LGV) in 
Rotterdam, reported in December 2003. 
We performed a retrospective study to assess 
the occurrence of LGV proctitis among men 
having sex with men (MSM) attending the 
STD clinic in Amsterdam in 2002 and 2003. 
Both in selected symptomatic infected men 
(76.5%) and in asymptomatic infected men 
(41.9%) LGV was detected. Sequence analysis 
of the omp - 1 gene demonstrated that an up 
until now unknown LGV variant of CT is 
circulating, which we designated L2b. 
Our results stress that a strict public health 
monitoring is indicated to assess the severity of 
this apparently unrecognized epidemic 
outbreak of LGV among MSM, which can be 
traced back at least to January 2002. 
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